<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29518356</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>TREM2 Is a Receptor for &#x3b2;-Amyloid that Mediates Microglial Function.</ArticleTitle><Pagination><StartPage>1023</StartPage><EndPage>1031.e7</EndPage><MedlinePgn>1023-1031.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2018.01.031</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(18)30056-4</ELocationID><Abstract><AbstractText>Mutations in triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to increased Alzheimer's disease (AD) risk. Neurobiological functions of TREM2 and its pathophysiological ligands remain elusive. Here we found that TREM2 directly binds to &#x3b2;-amyloid (A&#x3b2;) oligomers with nanomolar affinity, whereas AD-associated TREM2 mutations reduce A&#x3b2; binding. TREM2 deficiency impairs A&#x3b2; degradation in primary microglial culture and mouse brain. A&#x3b2;-induced microglial depolarization, K<sup>+</sup> inward current induction, cytokine expression and secretion, migration, proliferation, apoptosis, and morphological changes are dependent on TREM2. In addition, TREM2 interaction with its signaling adaptor DAP12 is enhanced by A&#x3b2;, regulating downstream phosphorylation of SYK and GSK3&#x3b2;. Our data demonstrate TREM2 as a microglial A&#x3b2; receptor transducing physiological and AD-related pathological effects associated with A&#x3b2;.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yingjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xilin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Department of Neurology, Union Hospital, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, Fujian 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoguang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lu-Lin</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gui</LastName><ForeName>Xun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pi&#xf1;a-Crespo</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Muxian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ningyan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Union Hospital, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, Fujian 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Timothy Y</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China. Electronic address: xuh@sbpdiscovery.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG038710</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG048519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044420</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056114</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056130</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2018 Mar 7;97(5):991-993. doi: 10.1016/j.neuron.2018.02.018.</RefSource><PMID Version="1">29518360</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">R47H</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList><CoiStatement><b>DECLARATION OF INTERESTS</b>. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29518356</ArticleId><ArticleId IdType="mid">NIHMS952791</ArticleId><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.01.031</ArticleId><ArticleId IdType="pii">S0896-6273(18)30056-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, Tipton T, Chapman MA, Riecken K, Beccari S, et al. Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain. Cell Rep. 2017;18:391&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5263237</ArticleId><ArticleId IdType="pubmed">28076784</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) J Biol Chem. 2015;290:26043&#x2013;26050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucsein C, Kettenmann H, Nolte C. Electrophysiological properties of microglial cells in normal and pathologic rat brain slices. Eur J Neurosci. 2000;12:2049&#x2013;2058.</Citation><ArticleIdList><ArticleId IdType="pubmed">10886344</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavanaugh SE, Pippin JJ, Barnard ND. Animal models of Alzheimer disease: historical pitfalls and a path forward. ALTEX. 2014;31:279&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">24793844</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Carey K, Godowski PJ. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene. 1997;14:2033&#x2013;2039.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160883</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562&#x2013;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci. 2011;12:284&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321383</ArticleId><ArticleId IdType="pubmed">21448224</ArticleId></ArticleIdList></Reference><Reference><Citation>Doens D, Fernandez PL. Microglia receptors and their implications in the response to amyloid beta for Alzheimer's disease pathogenesis. J Neuroinflammation. 2014;11:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975152</ArticleId><ArticleId IdType="pubmed">24625061</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, Goate AM. Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Franciosi S, Ryu JK, Choi HB, Radov L, Kim SU, McLarnon JG. Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1&#x2013;42-induced cell signaling and functional responses in human microglia. J Neurosci. 2006;26:11652&#x2013;11664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674791</ArticleId><ArticleId IdType="pubmed">17093087</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Hardy J. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369:1569&#x2013;1570.</Citation><ArticleIdList><ArticleId IdType="pubmed">24143816</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang TY, Zhao Y, Li X, Wang X, Tseng IC, Thompson R, Tu S, Willnow TE, Zhang YW, Xu H. SNX27 and SORLA Interact to Reduce Amyloidogenic Subcellular Distribution and Processing of Amyloid Precursor Protein. J Neurosci. 2016;36:7996&#x2013;8011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961782</ArticleId><ArticleId IdType="pubmed">27466343</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, Landreth GE. Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease. J Neurosci. 2017a;37:637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med. 2015;212:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, von Saucken VE, Landreth GE. TREM2 in Neurodegenerative Diseases. Mol Neurodegener. 2017b;12:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541421</ArticleId><ArticleId IdType="pubmed">28768545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, et al. Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet. 2014;23:5838&#x2013;5846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer's disease: accidental encounters or partners? Neuron. 2014;81:740&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983361</ArticleId><ArticleId IdType="pubmed">24559670</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, Hyman BT, Shatz CJ. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science. 2013;341:1399&#x2013;1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra286.</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ, Brett TJ. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173322</ArticleId><ArticleId IdType="pubmed">27995897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon YT, Ciechanover A. The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy. Trends Biochem Sci. 2017;42:873&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">28947091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam D, Schlichter LC. Expression and contributions of the Kir2.1 inward-rectifier K(+) channel to proliferation, migration and chemotaxis of microglia in unstimulated and anti-inflammatory states. Front Cell Neurosci. 2015;9:185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428136</ArticleId><ArticleId IdType="pubmed">26029054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature genetics. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JE, Han PL. An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp Neurobiol. 2013;22:84&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699678</ArticleId><ArticleId IdType="pubmed">23833557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Allen M, Sakae N, Ertekin-Taner N, Graff-Radford NR, Dickson DW, Younkin SG, Sevlever D. Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains. Mol Neurodegener. 2016;11:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5124229</ArticleId><ArticleId IdType="pubmed">27887626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Trumbach D, Wurst W, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18:1186&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8:595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 2017;170:649&#x2013;663. e613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Zhang YW, Xu H, Thinakaran G. Pathological and physiological functions of presenilins. Mol Neurodegener. 2006;1:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513131</ArticleId><ArticleId IdType="pubmed">16930451</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, van Echten-Deckert G. Cross-talk of membrane lipids and Alzheimer-related proteins. Mol Neurodegener. 2013;8:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016522</ArticleId><ArticleId IdType="pubmed">24148205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HK, Park UJ, Kim SY, Lee JH, Kim SU, Gwag BJ, Lee YB. Free radical production in CA1 neurons induces MIP-1alpha expression, microglia recruitment, and delayed neuronal death after transient forebrain ischemia. J Neurosci. 2008;28:1721&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671544</ArticleId><ArticleId IdType="pubmed">18272692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Huang T, Zhao Y, Zheng Q, Thompson, Robert C, Bu G, Zhang Y-w, Hong W, Xu H. Sorting Nexin 27 Regulates A&#x3b2; Production through Modulating &#x3b3;-Secretase Activity. Cell Reports. 2014;9:1023&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4328673</ArticleId><ArticleId IdType="pubmed">25437557</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron. 2016;91:328&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 2016;90:724&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Tseng IC, Heyser CJ, Rockenstein E, Mante M, Adame A, Zheng Q, Huang T, Wang X, Arslan PE, et al. Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis. Neuron. 2015;87:963&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575284</ArticleId><ArticleId IdType="pubmed">26335643</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Chen XF, Wang T, Wang Z, Liao C, Wang Z, Huang R, Wang D, Li X, Wu L, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med. 2017;214:597&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339672</ArticleId><ArticleId IdType="pubmed">28209725</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Chen XF, Zhang ZL, Wang Z, Shi XZ, Xu K, Zhang YW, Xu H, Bu G. DAP12 Stabilizes the C-terminal Fragment of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) and Protects against LPS-induced Pro-inflammatory Response. J Biol Chem. 2015;290:15866&#x2013;15877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505493</ArticleId><ArticleId IdType="pubmed">25957402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu B, Jiang L, Huang T, Zhao Y, Liu T, Zhong Y, Li X, Campos A, Pomeroy K, Masliah E, et al. ER-associated degradation regulates Alzheimer's amyloid pathology and memory function by modulating gamma-secretase activity. Nat Commun. 2017;8(1472)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684335</ArticleId><ArticleId IdType="pubmed">29133892</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29532057</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Excessive Daytime Sleepiness With Longitudinal &#x3b2;-Amyloid Accumulation in Elderly Persons Without Dementia.</ArticleTitle><Pagination><StartPage>672</StartPage><EndPage>680</EndPage><MedlinePgn>672-680</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.0049</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Aging is associated with excessive daytime sleepiness (EDS), which has been linked to cognitive decline in the elderly. However, whether EDS is associated with the pathologic processes of Alzheimer disease remains unclear.</AbstractText><AbstractText Label="OBJECTIVE">To investigate whether EDS at baseline is associated with a longitudinal increase in regional &#x3b2;-amyloid (A&#x3b2;) accumulation in a cohort of elderly individuals without dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This prospective analysis included participants enrolled in the Mayo Clinic Study of Aging, a longitudinal population-based study in Olmsted County, Minnesota. Of 2900 participants, 2172 (74.9%) agreed to undergo carbon 11-labeled Pittsburgh compound B positron emission tomography (PiB-PET). We included 283 participants 70 years or older without dementia who completed surveys assessing sleepiness at baseline and had at least 2 consecutive PiB-PET scans from January 1, 2009, through July 31, 2016, after excluding 45 (13.7%) who had a comorbid neurologic disorder.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Excessive daytime sleepiness was defined as an Epworth Sleepiness Scale score of at least 10. The difference in A&#x3b2; levels between the 2 consecutive scans (&#x394;PiB) in A&#x3b2;-susceptible regions (prefrontal, anterior cingulate, posterior cingulate-precuneus, and parietal) was determined. Multiple linear regression models were fit to explore associations between baseline EDS and &#x394;PiB while adjusting for baseline age, sex, presence of the apolipoprotein E &#x3b5;4 allele, educational level, baseline PiB uptake, global PiB positivity (standardized uptake value ratio &#x2265;1.4), physical activity, cardiovascular comorbidities (obesity, hypertension, hyperlipidemia, and diabetes), reduced sleep duration, respiratory symptoms during sleep, depression, and interval between scans.</AbstractText><AbstractText Label="RESULTS">Of the initial 283 participants, mean (SD) age was 77.1 (4.8) years; 204 (72.1%) were men and 79 (27.9%) were women. Sixty-three participants (22.3%) had EDS. Baseline EDS was significantly associated with increased regional A&#x3b2; accumulation in the anterior cingulate (B coefficient&#x2009;=&#x2009;0.031; 95% CI, 0.001-0.061; P&#x2009;=&#x2009;.04), posterior cingulate-precuneus (B coefficient&#x2009;=&#x2009;0.038; 95% CI, 0.006-0.069; P&#x2009;=&#x2009;.02), and parietal (B coefficient&#x2009;=&#x2009;0.033; 95% CI, 0.001-0.065; P&#x2009;=&#x2009;.04) regions. Association of EDS with longitudinal A&#x3b2; accumulation was stronger in participants with baseline global PiB positivity in the anterior cingulate (B coefficient&#x2009;=&#x2009;0.065; 95% CI, 0.010-0.118; P&#x2009;=&#x2009;.02) and cingulate-precuneus (B coefficient&#x2009;=&#x2009;0.068; 95% CI, 0.009-0.126; P&#x2009;=&#x2009;.02) regions.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Baseline EDS was associated with increased longitudinal A&#x3b2; accumulation in elderly persons without dementia, suggesting that those with EDS may be more vulnerable to pathologic changes associated with Alzheimer disease. Further work is needed to elucidate whether EDS is a clinical marker of greater sleep instability, synaptic or network overload, or neurodegeneration of wakefulness-promoting centers. Early identification of patients with EDS and treatment of underlying sleep disorders could reduce A&#x3b2; accumulation in this vulnerable group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Diego Z</ForeName><Initials>DZ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St Louis</LastName><ForeName>Erik K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Val J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Rosebud O</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Przybelski</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machulda</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Psychology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097495</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG045390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018898</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2018 Jun 1;75(6):654-656. doi: 10.1001/jamaneurol.2018.0005.</RefSource><PMID Version="1">29532083</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006970" MajorTopicYN="N">Disorders of Excessive Somnolence</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077260" MajorTopicYN="N">Sleepiness</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr St Louis reports receiving research support from the Mayo Clinic Center for Clinical and Translational Science, the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH), the Michael J. Fox Foundation, and Sunovion Inc. Dr Knopman reports serving as deputy editor for <i>Neurology</i>; serving on a data safety monitoring board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer Network study; serving as an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals, and the Alzheimer&#x2019;s Disease Cooperative Study; and receiving research support from the NIH. Dr Boeve reports serving as an investigator for clinical trials sponsored by GE Healthcare, FORUM Pharmaceuticals, and C2N Diagnostics; receiving royalties from the publication of a book entitled <i>Behavioral Neurology Of Dementia</i> (Cambridge Medicine, 2009); serving on the scientific advisory board of the Tau Consortium; consulting for Isis Pharmaceuticals; and receiving funding from the Mangurian Foundation. Dr Lowe reports serving on scientific advisory boards for Bayer Schering Pharma, Piramal Life Sciences, and Merck Research and receiving research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the National Institute on Aging (NIA) and National Cancer Institute of the NIH. Dr Roberts reports receiving research funding from the NIH and Hoffman-La Roche. Dr Mielke reports consulting for Lysosomal Therapuetics Inc and Eli Lilly and Company and receiving research funding from the NIH, Biogen, and Roche. Dr Machulda reports receiving research funding from the NIH. Dr Petersen reports receiving consulting fees from Hoffman-La Roche, Merck, Genentech, Biogen, and Eli Lilly and Company and receiving research support from the NIA of the NIH. Dr Jack reports consulting for Eli Lilly and Company and receiving funding from the Alexander Family Alzheimer&#x2019;s Disease Research Professorship of the Mayo Foundation. No other disclosures reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29532057</ArticleId><ArticleId IdType="pmc">PMC5885188</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.0049</ArticleId><ArticleId IdType="pii">2674279</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Academy of Sleep Medicine The International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed Westchester, IL: American Academy of Sleep Medicine; 2005.</Citation></Reference><Reference><Citation>Young TB. Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. J Clin Psychiatry. 2004;65(suppl 16):12-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15575799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA. Prevalence of excessive daytime sleepiness in a sample of the Australian adult population. Sleep Med. 2014;15(3):348-354.</Citation><ArticleIdList><ArticleId IdType="pubmed">24513435</ArticleId></ArticleIdList></Reference><Reference><Citation>Bixler EO, Vgontzas AN, Lin HM, Calhoun SL, Vela-Bueno A, Kales A. Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. J Clin Endocrinol Metab. 2005;90(8):4510-4515.</Citation><ArticleIdList><ArticleId IdType="pubmed">15941867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooneratne NS, Weaver TE, Cater JR, et al. . Functional outcomes of excessive daytime sleepiness in older adults. J Am Geriatr Soc. 2003;51(5):642-649.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752839</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley D, Monjan A, Masaki K, et al. . Daytime sleepiness is associated with 3-year incident dementia and cognitive decline in older Japanese-American men. J Am Geriatr Soc. 2001;49(12):1628-1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">11843995</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaussent I, Bouyer J, Ancelin ML, et al. . Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep. 2012;35(9):1201-1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413797</ArticleId><ArticleId IdType="pubmed">22942498</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsapanou A, Gu Y, Manly J, et al. . Daytime sleepiness and sleep inadequacy as risk factors for dementia. Dement Geriatr Cogn Dis Extra. 2015;5(2):286-295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521063</ArticleId><ArticleId IdType="pubmed">26273244</ArticleId></ArticleIdList></Reference><Reference><Citation>Elwood PC, Bayer AJ, Fish M, Pickering J, Mitchell C, Gallacher JE. Sleep disturbance and daytime sleepiness predict vascular dementia. J Epidemiol Community Health. 2011;65(9):820-824.</Citation><ArticleIdList><ArticleId IdType="pubmed">20675705</ArticleId></ArticleIdList></Reference><Reference><Citation>Keage HA, Banks S, Yang KL, Morgan K, Brayne C, Matthews FE. What sleep characteristics predict cognitive decline in the elderly? Sleep Med. 2012;13(7):886-892.</Citation><ArticleIdList><ArticleId IdType="pubmed">22560827</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlino G, Piani A, Gigli GL, et al. . Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: a population-based study. Sleep Med. 2010;11(4):372-377.</Citation><ArticleIdList><ArticleId IdType="pubmed">20219426</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayley AC, Williams LJ, Kennedy GA, et al. . Excessive daytime sleepiness and falls among older men and women: cross-sectional examination of a population-based sample. BMC Geriatr. 2015;15:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491238</ArticleId><ArticleId IdType="pubmed">26141865</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho DZ, St Louis EK, Boeve BF, et al. . Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Med. 2017;32:236-243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5551490</ArticleId><ArticleId IdType="pubmed">28065685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology: a bidirectional relationship. Nat Rev Neurol. 2014;10(2):115-119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979317</ArticleId><ArticleId IdType="pubmed">24366271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedernaes J, Osorio RS, Varga AW, Kam K, Schi&#xf6;th HB, Benedict C. Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer&#x2019;s disease. Sleep Med Rev. 2017;31:102-111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4981560</ArticleId><ArticleId IdType="pubmed">26996255</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, et al. . Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, et al. . Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005-1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga AW, Wohlleber ME, Gim&#xe9;nez S, et al. . Reduced slow-wave sleep is associated with high cerebrospinal fluid A&#x3b2;42 levels in cognitively normal elderly. Sleep. 2016;39(11):2041-2048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070758</ArticleId><ArticleId IdType="pubmed">27568802</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Gamaldo AA, An Y, et al. . Self-reported sleep and &#x3b2;-amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013;70(12):1537-1543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918480</ArticleId><ArticleId IdType="pubmed">24145859</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher KE, Bendlin BB, Racine AM, et al. . Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging. 2015;36(9):2568-2576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4523445</ArticleId><ArticleId IdType="pubmed">26059712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, McLeland JS, Toedebusch CD, et al. . Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70(5):587-593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Huang Y, Bero AW, et al. . Disruption of the sleep-wake cycle and diurnal fluctuation of &#x3b2;-amyloid in mice with Alzheimer&#x2019;s disease pathology. Sci Transl Med. 2012;4(150):150ra122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Marks SM, Vogel JW, et al. . &#x3b2;-Amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat Neurosci. 2015;18(7):1051-1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482795</ArticleId><ArticleId IdType="pubmed">26030850</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, et al. . Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913-922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, et al. . APP processing and synaptic function. Neuron. 2003;37(6):925-937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgel M, Prince JL, Wong DF, Resnick SM, Jedynak BM. A multivariate nonlinear mixed effects model for longitudinal image analysis: application to amyloid imaging. Neuroimage. 2016;134:658-670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4912927</ArticleId><ArticleId IdType="pubmed">27095307</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. . The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, et al. ; The Mayo Clinic Study of Aging . Prevalence of mild cognitive impairment is higher in men. Neurology. 2010;75(10):889-897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. . The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology. 2012;78(5):342-351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280046</ArticleId><ArticleId IdType="pubmed">22282647</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Molano JR, Ferman TJ, et al. . Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J Clin Sleep Med. 2013;9(5):475-480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629322</ArticleId><ArticleId IdType="pubmed">23674939</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14(6):540-545.</Citation><ArticleIdList><ArticleId IdType="pubmed">1798888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sforza E, Pichot V, Martin MS, Barth&#xe9;l&#xe9;my JC, Roche F. Prevalence and determinants of subjective sleepiness in healthy elderly with unrecognized obstructive sleep apnea. Sleep Med. 2015;16(8):981-986.</Citation><ArticleIdList><ArticleId IdType="pubmed">26141008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ III. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87(12):1202-1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541925</ArticleId><ArticleId IdType="pubmed">23199802</ArticleId></ArticleIdList></Reference><Reference><Citation>St Sauver JL, Grossardt BR, Yawn BP, et al. . Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012;41(6):1614-1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535751</ArticleId><ArticleId IdType="pubmed">23159830</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. . Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol. 2012;72(5):730-738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539211</ArticleId><ArticleId IdType="pubmed">23280791</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):588-597.</Citation><ArticleIdList><ArticleId IdType="pubmed">8991972</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR Jr. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage. 2005;26(2):600-608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739382</ArticleId><ArticleId IdType="pubmed">15907317</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Lowe VJ, Senjem ML, et al. . 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131(pt 3):665-680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Vemuri P, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2010;133(11):3336-3348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Lesnick TG, et al. . Brain &#x3b2;-amyloid load approaches a plateau. Neurology. 2013;80(10):890-896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Lowe VJ, Graff-Radford NR, et al. . Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer&#x2019;s disease spectrum. Brain. 2015;138(pt 5):1370-1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407190</ArticleId><ArticleId IdType="pubmed">25805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundry R, Nunn CL. Stepwise model fitting and statistical inference: turning noise into signal pollution. Am Nat. 2009;173(1):119-123.</Citation><ArticleIdList><ArticleId IdType="pubmed">19049440</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015;16(2):109-120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312418</ArticleId><ArticleId IdType="pubmed">25588378</ArticleId></ArticleIdList></Reference><Reference><Citation>Pack AI, Dinges DF, Gehrman PR, Staley B, Pack FM, Maislin G. Risk factors for excessive sleepiness in older adults. Ann Neurol. 2006;59(6):893-904.</Citation><ArticleIdList><ArticleId IdType="pubmed">16718691</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Yager C, Brandt J, et al. . Objectively measured sleep and &#x3b2;-amyloid burden in older adults: a pilot study. SAGE Open Med. 2014;2:2050312114546520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304392</ArticleId><ArticleId IdType="pubmed">25621174</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio RS, Ayappa I, Mantua J, et al. . Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer&#x2019;s disease in cognitively normal elderly individuals. Neurobiol Aging. 2014;35(6):1318-1324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022140</ArticleId><ArticleId IdType="pubmed">24439479</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori C, Mercuri NB, Izzi F, et al. . Obstructive sleep apnea is associated with early but possibly modifiable Alzheimer&#x2019;s disease biomarkers changes. Sleep. 2017;40(5):zsx011.</Citation><ArticleIdList><ArticleId IdType="pubmed">28329084</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiota S, Takekawa H, Matsumoto SE, et al. . Chronic intermittent hypoxia/reoxygenation facilitate amyloid-&#x3b2; generation in mice. J Alzheimers Dis. 2013;37(2):325-333.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948880</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelber RP, Redline S, Ross GW, et al. . Associations of brain lesions at autopsy with polysomnography features before death. Neurology. 2015;84(3):296-303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335994</ArticleId><ArticleId IdType="pubmed">25503626</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooneratne NS, Vitiello MV. Sleep in older adults: normative changes, sleep disorders, and treatment options. Clin Geriatr Med. 2014;30(3):591-627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4656195</ArticleId><ArticleId IdType="pubmed">25037297</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilleminault C, Partinen M, Quera-Salva MA, Hayes B, Dement WC, Nino-Murcia G. Determinants of daytime sleepiness in obstructive sleep apnea. Chest. 1988;94(1):32-37.</Citation><ArticleIdList><ArticleId IdType="pubmed">3383654</ArticleId></ArticleIdList></Reference><Reference><Citation>Seneviratne U, Puvanendran K. Excessive daytime sleepiness in obstructive sleep apnea: prevalence, severity, and predictors. Sleep Med. 2004;5(4):339-343.</Citation><ArticleIdList><ArticleId IdType="pubmed">15222989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett LS, Langford BA, Stradling JR, Davies RJ. Sleep fragmentation indices as predictors of daytime sleepiness and nCPAP response in obstructive sleep apnea. Am J Respir Crit Care Med. 1998;158(3):778-786.</Citation><ArticleIdList><ArticleId IdType="pubmed">9731004</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjabi NM, Bandeen-Roche K, Marx JJ, Neubauer DN, Smith PL, Schwartz AR. The association between daytime sleepiness and sleep-disordered breathing in NREM and REM sleep. Sleep. 2002;25(3):307-314.</Citation><ArticleIdList><ArticleId IdType="pubmed">12003161</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjabi NM, O&#x2019;hearn DJ, Neubauer DN, et al. . Modeling hypersomnolence in sleep-disordered breathing: a novel approach using survival analysis. Am J Respir Crit Care Med. 1999;159(6):1703-1709.</Citation><ArticleIdList><ArticleId IdType="pubmed">10351907</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzer R, Gaudreau H, D&#xe9;cary A, et al. . Slow-wave activity in sleep apnea patients before and after continuous positive airway pressure treatment: contribution to daytime sleepiness. Chest. 2001;119(6):1807-1813.</Citation><ArticleIdList><ArticleId IdType="pubmed">11399708</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M, Riedner BA, Huber R, Massimini M, Ferrarelli F, Tononi G. Source modeling sleep slow waves. Proc Natl Acad Sci U S A. 2009;106(5):1608-1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635823</ArticleId><ArticleId IdType="pubmed">19164756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Mawuenyega KG, Patterson BW, et al. . Associations between &#x3b2;-amyloid kinetics and the &#x3b2;-amyloid diurnal pattern in the central nervous system. JAMA Neurol. 2017;74(2):207-215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305432</ArticleId><ArticleId IdType="pubmed">27992627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, et al. . Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci. 2011;14(6):750-756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, Tononi G. Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nat Neurosci. 2008;11(2):200-208.</Citation><ArticleIdList><ArticleId IdType="pubmed">18204445</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisor JP, Rempe MJ, Schmidt MA, Moore ME, Clegern WC. Sleep slow-wave activity regulates cerebral glycolytic metabolism. Cereb Cortex. 2013;23(8):1978-1987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707408</ArticleId><ArticleId IdType="pubmed">22767634</ArticleId></ArticleIdList></Reference><Reference><Citation>Donlea JM, Ramanan N, Shaw PJ. Use-dependent plasticity in clock neurons regulates sleep need in Drosophila. Science. 2009;324(5923):105-108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850598</ArticleId><ArticleId IdType="pubmed">19342592</ArticleId></ArticleIdList></Reference><Reference><Citation>Tononi G, Cirelli C. Sleep and synaptic homeostasis: a hypothesis. Brain Res Bull. 2003;62(2):143-150.</Citation><ArticleIdList><ArticleId IdType="pubmed">14638388</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabuchi M, Lone SR, Liu S, et al. . Sleep interacts with A&#x3b2; to modulate intrinsic neuronal excitability. Curr Biol. 2015;25(6):702-712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366315</ArticleId><ArticleId IdType="pubmed">25754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam K, Duffy AM, Moretto J, LaFrancois JJ, Scharfman HE. Interictal spikes during sleep are an early defect in the Tg2576 mouse model of &#x3b2;-amyloid neuropathology. Sci Rep. 2016;6:20119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730189</ArticleId><ArticleId IdType="pubmed">26818394</ArticleId></ArticleIdList></Reference><Reference><Citation>Nofzinger EA, Buysse DJ, Miewald JM, et al. . Human regional cerebral glucose metabolism during non&#x2013;rapid eye movement sleep in relation to waking. Brain. 2002;125(pt 5):1105-1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">11960899</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Vaishnavi SN, Couture L, et al. . Spatial correlation between brain aerobic glycolysis and amyloid-&#x3b2; (A&#x3b2;) deposition. Proc Natl Acad Sci U S A. 2010;107(41):17763-17767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955133</ArticleId><ArticleId IdType="pubmed">20837517</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98(2):676-682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Horovitz SG, Braun AR, Carr WS, et al. . Decoupling of the brain&#x2019;s default mode network during deep sleep. Proc Natl Acad Sci U S A. 2009;106(27):11376-11381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708777</ArticleId><ArticleId IdType="pubmed">19549821</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe4;mann PG, Wehrle R, Hoehn D, et al. . Development of the brain&#x2019;s default mode network from wakefulness to slow wave sleep. Cereb Cortex. 2011;21(9):2082-2093.</Citation><ArticleIdList><ArticleId IdType="pubmed">21330468</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen Res. 2012;7(5):376-385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350122</ArticleId><ArticleId IdType="pubmed">25774178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006;7(4):278-294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilas P, Ehrenberg AJ, Dunlop S, et al. . Locus coeruleus volume and cell population changes during Alzheimer&#x2019;s disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement. 2017;13(3):236-246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5298942</ArticleId><ArticleId IdType="pubmed">27513978</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer&#x2019;s disease. Biol Psychiatry. 2012;71(9):805-813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701122</ArticleId><ArticleId IdType="pubmed">21816388</ArticleId></ArticleIdList></Reference><Reference><Citation>Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer&#x2019;s disease: interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res. 2005;30(6-7):895-908.</Citation><ArticleIdList><ArticleId IdType="pubmed">16187224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross JA, McGonigle P, Van Bockstaele EJ. Locus coeruleus, norepinephrine and A&#x3b2; peptides in Alzheimer&#x2019;s disease. Neurobiol Stress. 2015;2:73-84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4657149</ArticleId><ArticleId IdType="pubmed">26618188</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori C, Romigi A, Nuccetelli M, et al. . Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol. 2014;71(12):1498-1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">25322206</ArticleId></ArticleIdList></Reference><Reference><Citation>Slats D, Claassen JA, Lammers GJ, Melis RJ, Verbeek MM, Overeem S. Association between hypocretin-1 and amyloid-&#x3b2;42 cerebrospinal fluid levels in Alzheimer&#x2019;s disease and healthy controls. Curr Alzheimer Res. 2012;9(10):1119-1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">22742854</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaab DF, Fliers E, Partiman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res. 1985;342(1):37-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">4041816</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilas P, Dunlop S, Heinsen H, Grinberg LT. Turning on the light within: subcortical nuclei of the isodentritic core and their role in Alzheimer&#x2019;s disease pathogenesis. J Alzheimers Dis. 2015;46(1):17-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550582</ArticleId><ArticleId IdType="pubmed">25720408</ArticleId></ArticleIdList></Reference><Reference><Citation>Karageorgiou E, Vossel KA. Brain rhythm attractor breakdown in Alzheimer&#x2019;s disease: functional and pathologic implications. Alzheimers Dement. 2017;13(9):1054-1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585024</ArticleId><ArticleId IdType="pubmed">28302453</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Fenik P, Zhan G, Xin R, Veasey SC. Degeneration in arousal neurons in chronic sleep disruption modeling sleep apnea. Front Neurol. 2015;6:109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443725</ArticleId><ArticleId IdType="pubmed">26074865</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao ZZY, Zhao X, Zhan G, Fenik P, Veasey S. Chronic short sleep initiates an amyloid cascade in locus coeruleus neurons and tau-dependent neurodegeration. Sleep (Basel). 2017;40(suppl):A100.</Citation></Reference><Reference><Citation>Kendzerska TB, Smith PM, Brignardello-Petersen R, Leung RS, Tomlinson GA. Evaluation of the measurement properties of the Epworth Sleepiness Scale: a systematic review. Sleep Med Rev. 2014;18(4):321-331.</Citation><ArticleIdList><ArticleId IdType="pubmed">24135493</ArticleId></ArticleIdList></Reference><Reference><Citation>Onen F, Moreau T, Gooneratne NS, Petit C, Falissard B, Onen SH. Limits of the Epworth Sleepiness Scale in older adults. Sleep Breath. 2013;17(1):343-350.</Citation><ArticleIdList><ArticleId IdType="pubmed">22467194</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns MW. Sleepiness in different situations measured by the Epworth Sleepiness Scale. Sleep. 1994;17(8):703-710.</Citation><ArticleIdList><ArticleId IdType="pubmed">7701181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet MH. ACNS clinical controversy: MSLT and MWT have limited clinical utility. J Clin Neurophysiol. 2006;23(1):50-58.</Citation><ArticleIdList><ArticleId IdType="pubmed">16514351</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotti LM, Staab BA, Rye DB. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med. 2013;9(8):789-795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3716670</ArticleId><ArticleId IdType="pubmed">23946709</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BM, Rainey-Smith SR, Villemagne VL, et al. ; AIBL Research Group . The relationship between sleep quality and brain amyloid burden. Sleep. 2016;39(5):1063-1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835305</ArticleId><ArticleId IdType="pubmed">27091528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29566794</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Tau Kinetics in Neurons and the Human Central Nervous System.</ArticleTitle><Pagination><StartPage>1284</StartPage><EndPage>1298.e7</EndPage><MedlinePgn>1284-1298.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2018.02.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(18)30136-3</ELocationID><Abstract><AbstractText>We developed stable isotope labeling and mass spectrometry approaches to measure the kinetics of multiple isoforms and fragments of tau in the human central nervous system (CNS) and in human induced pluripotent stem cell (iPSC)-derived neurons. Newly synthesized tau is truncated and released from human neurons in 3&#xa0;days. Although most tau proteins have similar turnover, 4R tau isoforms and phosphorylated forms of tau exhibit faster turnover rates, suggesting unique processing of these forms that may have independent biological activities. The half-life of tau in control human iPSC-derived neurons is 6.74&#xa0;&#xb1; 0.45&#xa0;days and in human CNS is 23&#xa0;&#xb1; 6.4&#xa0;days. In cognitively normal and Alzheimer's disease participants, the production rate of tau positively correlates with the amount of amyloid plaques, indicating a biological link between amyloid plaques and tau physiology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: satochihiro@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barth&#xe9;lemy</LastName><ForeName>Nicolas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jockel-Balsarotti</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crisp</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasten</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirmess</LastName><ForeName>Kristopher M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanaan</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Michigan State University, College of Human Medicine, Department of Translational Science and Molecular Medicine, Grand Rapids, MI 49503, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarasheski</LastName><ForeName>Kevin E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker-Nigh</LastName><ForeName>Alaina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: karchc@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA; Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: batemanr@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG053474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS098577</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG046374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078398</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095773</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2018 Mar 21;97(6):1202-1205. doi: 10.1016/j.neuron.2018.02.030.</RefSource><PMID Version="1">29566788</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2018 May 16;98(4):861-864. doi: 10.1016/j.neuron.2018.04.035.</RefSource><PMID Version="1">29772204</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">SILK</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cell</Keyword><Keyword MajorTopicYN="N">isoform</Keyword><Keyword MajorTopicYN="N">phosphorylation</Keyword><Keyword MajorTopicYN="N">positron emission tomography</Keyword><Keyword MajorTopicYN="N">production rate</Keyword><Keyword MajorTopicYN="N">stable isotope labeling kinetics</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>DECLARATION OF INTERESTS. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and may receive royalty income based on technology licensed by Washington University to C2N Diagnostics. R.J.B. receives income from C2N Diagnostics for serving on the Scientific Advisory Board, and B.W.P. receives consultation income from C2N Diagnostics. T.L.S.B. participates in research sponsored by Avid Radiopharmaceuticals, Eli Lilly, Roche, Johnson &amp; Johnson, and Biogen. Washington University has submitted the U.S. non-provisional patent application &#x201c;Methods for measuring the metabolism of CNS derived biomolecules in vivo,&#x201d; serial #12/267,974 (R.J.B. and K.G.M.), and &#x201c;Tau kinetics measurements,&#x201d; serial #CA 2962969 (R.J.B., T.M.M., K.G.M., and C.S.). The remaining co-authors have no conflicts to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29566794</ArticleId><ArticleId IdType="mid">NIHMS985441</ArticleId><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pii">S0896-6273(18)30136-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, and Hutton M (1999). Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet 8, 711&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban H, Nishishita N, Fusaki N, Tabata T, Saeki K, Shikamura M, Takada N, Inoue M, Hasegawa M, Kawamata S, and Nishikawa S (2011). Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. USA 108, 14234&#x2013;14239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3161531</ArticleId><ArticleId IdType="pubmed">21821793</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, Bu&#xe9;e L, Gabelle A, Junot C, Lehmann S, and Becher F (2016). Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J. Proteome Res 15, 667&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">26742856</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Bateman RJ, Marin P, Becher F, Sato C, Lehmann S, and Gabelle A (2017). Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-&#x3b2; pathology. bioRxiv. 10.1101/226977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/226977</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, and Holtzman DM (2006). Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med 12, 856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al.; Dominantly Inherited Alzheimer Network (2012). Clinical and biomarker changes in dominantly in herited Alzheimer&#x2019;s disease. N. Engl. J. Med 367, 795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Gustke N, Drewes G, Mandelkow EM, and Mandelkow E (1993). Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11, 153&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">8393323</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Gardoni F, Parnetti L, Magno L, Malinverno M, Saggese E, Calabresi P, Spillantini MG, Padovani A, and Di Luca M (2009). Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol. Aging 30, 34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17709155</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, and Braak E (1995). Staging of Alzheimer&#x2019;s disease-related neuro fibrillary changes. Neurobiol. Aging 16, 271&#x2013;278, discussion 278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, et al. (2016). Tau and Ab imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease . Sci. Transl. Med 8, 338ra66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright J, Hussain S, Dang V, Wright S, Cooper B, Byun T, Ramos C, Singh A, Parry G, Stagliano N, and Griswold-Prenner I (2015). Human secreted tau increases amyloid-beta production. Neurobiol. Aging 36, 693&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">25442111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Bussi&#xe8;re T, Bu&#xe9;e-Scherrer V, Delacourte A, and Hof PR (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev 33, 95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IRA, Neumann M, Lee VM-Y, Hatanpaa KJ, White CL 3rd, Schneider JA, Grinberg LT, Halliday G, et al.; Consortium for Frontotemporal Lobar Degeneration (2007). Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 114, 5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmel G, Mager EM, Binder LI, and Kuret J (1996). The structural basis of monoclonal antibody Alz50&#x2019;s selectivity for Alzheimer&#x2019;s disease pathology. J. Biol. Chem 271, 32789&#x2013;32795.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Dage JL, and Citron M (2012). Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis 48, 356&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">22668776</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs B, Hamel C, and Kanaan NM (2016). Pathological conformations involving the amino terminus of tau occur early in Alzheimer&#x2019;s disease and are differentially detected by monoclonal antibodies. Neurobiol. Dis 94, 18&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4983528</ArticleId><ArticleId IdType="pubmed">27260838</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp MJ, Mawuenyega KG, Patterson BW, Reddy NC, Chott R, Self WK, Weihl CC, Jockel-Balsarotti J, Varadhachary AS, Bucelli RC, et al. (2015). In vivo kinetic approach reveals slow SOD1 turnover in the CNS. J. Clin. Invest 125, 2772&#x2013;2780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4563686</ArticleId><ArticleId IdType="pubmed">26075819</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, et al. (2012). Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Derisbourg M, Leghay C, Chiappetta G, Fernandez-Gomez F-J, Laurent C, Demeyer D, Carrier S, Bu&#xe9;e-Scherrer V, Blum D, Vinh J, et al. (2015). Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci. Rep 5, 9659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431475</ArticleId><ArticleId IdType="pubmed">25974414</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, Holland D, Brewer JB, Chen C-H, Thompson WK, et al.; ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators (2015). Genetic overlap between Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease at the MAPT locus. Mol. Psychiatry 20, 1588&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539304</ArticleId><ArticleId IdType="pubmed">25687773</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, et al. (2013). Antisense reduction of tau in adult mice protects against seizures.J. Neurosci 33, 12887&#x2013;12897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728694</ArticleId><ArticleId IdType="pubmed">23904623</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, et al. (2017). Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med 9, 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792300</ArticleId><ArticleId IdType="pubmed">28123067</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Kouri N, Murray ME, and Josephs KA (2011). Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci 45, 384&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208128</ArticleId><ArticleId IdType="pubmed">21720721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrlich M, Hallmann A-L, Reinhardt P, Ara&#xfa;zo-Bravo MJ, Korr S, R&#xf6;pke A, Psathaki OE, Ehling P, Meuth SG, Oblak AL, et al. (2015). Distinct neurodegenerative changes in an induced pluripotent stem cell model of frontotemporal dementia linked to mutant TAU protein. Stem Cell Reports 5, 83&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4618448</ArticleId><ArticleId IdType="pubmed">26143746</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, Ghetti B, Martins RN, Masters CL, Mayeux R, et al.; Dominantly Inherited Alzheimer Network (2014). Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci. Transl. Med 6, 226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, and Caceres A (1991). Estrogen-enhanced neurite growth: evidence for a selective induction of Tau and stable microtubules. J. Neurosci 11, 392&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575216</ArticleId><ArticleId IdType="pubmed">1899446</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, et al. (2002). Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, and Scheres SHW (2017). Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, and Diamond MI (2009). Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem 284, 12845&#x2013;12852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk KE, Mirbaha H, Jiang H, Holtzman DM, and Diamond MI (2015). Distinct therapeutic mechanisms of Tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J. Biol. Chem 290, 21652&#x2013;21662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4571888</ArticleId><ArticleId IdType="pubmed">26126828</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ, et al. (2016). The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain 139, 2249&#x2013;2260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958902</ArticleId><ArticleId IdType="pubmed">27286736</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, Cahill ME, Bigio EH, Berry RW, and Binder LI (2005). Tau truncation during neurofibrillary tangle evolution in Alzheimer&#x2019;s disease. Neurobiol. Aging 26, 1015&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748781</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase C, Stieler JT, Arendt T, and Holzer M (2004). Pseudophosphorylation of tau protein alters its ability for self-aggregation. J. Neurochem 88, 1509&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, and Trojanowski JQ (2010). Total and phosphorylated tau protein as biological markers of Alzheimer&#x2019;s disease. Exp. Gerontol 45, 30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815003</ArticleId><ArticleId IdType="pubmed">19853650</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, Betts JC, Loviny TL, Blackstock WP, and Anderton BH (1998). New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer&#x2019;s disease brain using nanoelectrospray mass spectrometry. J. Neurochem 71, 2465&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">9832145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, and Blennow K (2001). Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett 297, 187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137759</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, and Binder LI (2004). Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer&#x2019;s disease. J. Neurosci 24, 7895&#x2013;7902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729917</ArticleId><ArticleId IdType="pubmed">15356202</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz PM, LaPointe N, Guillozet-Bongaarts AL, Berry RW, and Binder LI (2006). N-terminal fragments of tau inhibit full-length tau polymerization in vitro. Biochemistry 45, 12859&#x2013;12866.</Citation><ArticleIdList><ArticleId IdType="pubmed">17042504</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, and Lee VM-Y (2013). Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy.J. Neurosci 33, 1024&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanmert D, Cantlon A, Muratore CR, Jin M, O&#x2019;Malley TT, Lee G, Young-Pearse TL, Selkoe DJ, and Walsh DM (2015). C-terminally truncated forms of Tau, but not full-length Tau or its C-terminal fragments, are released from neurons independently of cell death. J. Neurosci 35, 10851&#x2013;10865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605107</ArticleId><ArticleId IdType="pubmed">26224867</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT, and Goate AM (2012). Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J. Biol. Chem 287, 42751&#x2013;42762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522274</ArticleId><ArticleId IdType="pubmed">23105105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, and Diamond MI (2012). Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem 287, 19440&#x2013;19451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W-K, Moore WT, Williams RT, Hall FL, and Yen S-H (1993). Application of synthetic phospho- and unphospho- peptides to identify phosphorylation sites in a subregion of the tau molecule, which is modified in Alzheimer&#x2019;s disease. J. Neurosci. Res 34, 371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">8455212</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, and Duff K (2012). Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Song X, Nisbet R, and G&#xf6;tz J (2016). Co-immunoprecipitation with Tau isoform-specific antibodies reveals distinct protein interactions and high-lights a putative role for 2N Tau in disease. J. Biol. Chem 291, 8173&#x2013;8188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825019</ArticleId><ArticleId IdType="pubmed">26861879</ArticleId></ArticleIdList></Reference><Reference><Citation>LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, and Binder LI (1995). Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc. Natl. Acad. Sci. USA 92, 10369&#x2013;10373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40798</ArticleId><ArticleId IdType="pubmed">7479786</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, Liu W, Hu X, Hanna M, Caravaca A, and Paul SM (2015). Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci. Rep 5, 11161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4460904</ArticleId><ArticleId IdType="pubmed">26057852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair W, Muntel J, Tepper K, Tang S, Biernat J, Seeley WW, Kosik KS, Mandelkow E, Steen H, and Steen JA (2016). FLEXITau: quantifying post-translational modifications of Tau protein in vitro and in human disease. Anal. Chem 88, 3704&#x2013;3714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5808556</ArticleId><ArticleId IdType="pubmed">26877193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E-M, Stamer K, Vogel R, Thies E, and Mandelkow E (2003). Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24, 1079&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643379</ArticleId></ArticleIdList></Reference><Reference><Citation>McAvoy T, Lassman ME, Spellman DS, Ke Z, Howell BJ, Wong O, Zhu L, Tanen M, Struyk A, and Laterza OF (2014). Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin. Chem 60, 683&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">24566260</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith JE Jr., Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, et al. (2013). Characterization of novel CSF Tau and ptau biomarkers for Alzheimer&#x2019;s disease. PLoS ONE 8, e76523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792042</ArticleId><ArticleId IdType="pubmed">24116116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, Gordon BA, Su Y, Christensen J, Friedrichsen K, Jackson K, Hornbeck R, Balota DA, Cairns NJ, Morris JC, et al. (2017). AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. Neuroimage 161, 171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696044</ArticleId><ArticleId IdType="pubmed">28756238</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita T, and Sobue K (2009). Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J. Biol. Chem 284, 27734&#x2013;27745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785701</ArticleId><ArticleId IdType="pubmed">19648118</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasozomenos SC, and Binder LI (1987). Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil. Cytoskeleton 8, 210&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">2446784</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, Xiong C, Chott R, Yarasheski K, Sigurdson W, et al. (2015). Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol 78, 439&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DHW, Noble W, and Hanger DP (2013). Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14, 389&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Noble W, and Hanger DP (2014). A role for tau at the synapse in Alzheimer&#x2019;s disease pathogenesis. Neuropharmacology 76 (Pt A), 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24076336</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Hansson SF, Tran AJ, Zetterberg H, Grognet P, Vanmechelen E, H&#xf6;glund K, Brinkmalm G, Westman-Brinkmalm A, Nordhoff E, et al. (2008). Characterization of tau in cerebrospinal fluid using mass spectrometry. J. Proteome Res 7, 2114&#x2013;2120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18351740</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, et al. (2013). Increased in vivo amyloid-b42 production, exchange, and loss in presenilin mutation carriers. Sci. Transl. Med 5, 189ra77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Guan S, Burlingame A, Prusiner SB, and Ghaemmaghami S (2010). Analysis of proteome dynamics in the mouse brain. Proc. Natl. Acad. Sci. USA 107, 14508&#x2013;14513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922600</ArticleId><ArticleId IdType="pubmed">20699386</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, and Evans AC (1998). Correction for partial volume effects in PET: principle and validation. J. Nucl. Med 39, 904&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, et al. (2014). Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MC, Cheng C, Mair W, Almeida S, Fong H, Biswas MHU, Zhang Z, Huang Y, Temple S, Coppola G, et al. (2016). Human iPSC-derived neuronal model of Tau-A152T frontotemporal dementia reveals Tau-mediated mechanisms of neuronal vulnerability. Stem Cell Reports 7, 325&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032560</ArticleId><ArticleId IdType="pubmed">27594585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren M, Vanderstichele H,&#xc5;gren H, Zachrisson O, Edsbagge M, Wikkels&#xf8; C, Skoog I, Wallin A, Wahlund L-O, Marcusson J, et al. (2001). Tau and Abeta42 in cerebrospinal fluid from healthy adults 21&#x2013;93 years of age: establishment of reference values. Clin. Chem 47, 1776&#x2013;1781.</Citation><ArticleIdList><ArticleId IdType="pubmed">11568086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito T, Preza E, Mahoney CJ, Set&#xf3;-Salvia N, Ryan NS, Morris HR, Arber C, Devine MJ, Houlden H, Warner TT, et al. (2015). Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Hum. Mol. Genet 24, 5260&#x2013;5269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550814</ArticleId><ArticleId IdType="pubmed">26136155</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoothoff WH, and Johnson GVW (2005). Tau phosphorylation: physiological and pathological consequences. Biochim. Biophys. Acta 1739, 280&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615646</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, D&#x2019;Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, Blazey TM, Christensen JJ, Vora S, Morris JC, et al. (2013). Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE 8, e73377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, Bateman RJ, Cairns NJ, Aldea P, Cash L, et al.; Dominantly Inherited Alzheimer Network (2015). Partial volume correction in quantitative amyloid imaging. Neuroimage 107, 55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, and Gamblin TC (2009). Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. Biochemistry 48, 6002&#x2013;6011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739831</ArticleId><ArticleId IdType="pubmed">19459590</ArticleId></ArticleIdList></Reference><Reference><Citation>Szendrei GI, Lee VM-Y, and Otvos L Jr. (1993). Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. J. Neurosci. Res 34, 243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680727</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, and Yamanaka S (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, and Shaw LM (2013). Longitudinal change in CSF Tau and Ab biomarkers for up to 48 months in ADNI. Acta Neuropathol 126, 659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D, Wray S, Vandrovcova J, Ramasamy A, Walker R, Smith C, Luk C, Gibbs JR, Dillman A, Hernandez DG, et al. (2012). MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum. Mol. Genet 21, 4094&#x2013;4103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428157</ArticleId><ArticleId IdType="pubmed">22723018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, and Mandelkow E (2016). Tau in physiology and pathology. Nat. Rev. Neurosci 17, 5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, Sanders DW, Cook C, Fu H, Boonen RACM, et al. (2016). Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci 19, 1085&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow E-M, Diamond MI, Lee VM-Y, and Holtzman DM (2011). In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci 31, 13110&#x2013;13117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgrafe K, Mandelkow E-M, and Holtzman DM (2014). Neuronal activity regulates extracellular tau in vivo. J. Exp. Med 211, 387&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Patel TK, Hochgrafe K, Mahan TE, Jiang H, Stewart FR, Mandelkow E-M, and Holtzman DM (2015). Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol. Neurodegener 10, 55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4621881</ArticleId><ArticleId IdType="pubmed">26502977</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, and Holtzman DM (2013). Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, Karch CM, Fan CC, Bonham LW, Kouri N, Ross OA, Rademakers R, Kim J, Wang Y, H&#xf6;glinger GU, et al.; International FTD-Genomics Consortium (IFGC) (2017). Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 133, 825&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429027</ArticleId><ArticleId IdType="pubmed">28271184</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Dennissen FJA, Kumar Y, Luedtke J, Biernat J, Mandelkow E-M, and Mandelkow E (2017). Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture. J. Biol. Chem 292, 12192&#x2013;12207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519369</ArticleId><ArticleId IdType="pubmed">28536263</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29572282</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>17</Issue><PubDate><Year>2018</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Memory decline accompanies subthreshold amyloid accumulation.</ArticleTitle><Pagination><StartPage>e1452</StartPage><EndPage>e1460</EndPage><MedlinePgn>e1452-e1460</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000005354</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Extensive cortical &#x3b2;-amyloid (A&#x3b2; positivity) has been linked to cognitive decline, but the clinical significance of elevations in A&#x3b2; within the negative range is unknown.</AbstractText><AbstractText Label="METHODS">We examined amyloid and cognitive trajectories (memory, executive function) in 142 cognitively normal older individuals enrolled in the Alzheimer's Disease Neuroimaging Initiative who were A&#x3b2;-negative at baseline and who had at least 2 [<sup>18</sup>F]-florbetapir PET scans over 3.9 &#xb1; 1.4 years. We determined whether A&#x3b2; accumulation was associated with longitudinal changes in memory or executive function.</AbstractText><AbstractText Label="RESULTS">Among baseline-negative individuals, florbetapir slope (mean annual increase 0.002 &#xb1; 0.008 standardized uptake value ratio units/y) was not related to age, sex, education, <i>APOE4</i> status, baseline memory or executive function, temporoparietal glucose metabolism, baseline hippocampal volume, or hippocampal volume change; but it was related to higher baseline cortical florbetapir, indicating that A&#x3b2; accumulation was ongoing at baseline in those who accumulated during the study. Over the course of follow-up, 13 individuals converted to florbetapir+ and 14 nearly nonoverlapping individuals converted to mild cognitive impairment or Alzheimer disease. Amyloid accumulation among baseline-negative individuals was associated with poorer longitudinal memory performance (<i>p</i> = 0.019), but it was not associated with changes in executive function. Reducing the sample to individuals with at least 3 timepoints to estimate the florbetapir slope strengthened the relationship further between florbetapir accumulation and memory decline (<i>p</i> = 0.007).</AbstractText><AbstractText Label="CONCLUSIONS">Memory decline accompanies A&#x3b2; accumulation in otherwise healthy, A&#x3b2;-negative older adults. Amyloid increases within the negative range may represent the earliest detectable indication of pathology with domain-specific cognitive consequences.</AbstractText><CopyrightInformation>&#xa9; 2018 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>From Helen Wills Neuroscience Institute, University of California; and Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA. slandau@berkeley.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horng</LastName><ForeName>Andy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From Helen Wills Neuroscience Institute, University of California; and Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>From Helen Wills Neuroscience Institute, University of California; and Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010104">Oxygen Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Apr 24;90(17):759-760. doi: 10.1212/WNL.0000000000005362.</RefSource><PMID Version="1">29572279</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010104" MajorTopicYN="N">Oxygen Radioisotopes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29572282</ArticleId><ArticleId IdType="pmc">PMC5921038</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000005354</ArticleId><ArticleId IdType="pii">WNL.0000000000005354</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313:1924&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. . Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. . Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014;71:1379&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun M, Joshi A, et al. . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, et al. . Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010;74:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, et al. . Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 2017;317:2305&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Lowe VJ, Weigand SD, et al. . Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, et al. . 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, et al. . Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014;6:228fs213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. . Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011;32:1207&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Breault C, Joshi AD, et al. . Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013;54:70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747730</ArticleId><ArticleId IdType="pubmed">23166389</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Fero A, Baker SL, et al. . Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 2015;56:567&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5313473</ArticleId><ArticleId IdType="pubmed">25745095</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, et al. . Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012;6:502&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons LE, Carle AC, Mackin RS, et al. . A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012;6:517&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A. l'Examen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964.</Citation></Reference><Reference><Citation>Mohs RC. The Alzheimer's Disease Assessment Scale. Int Psychogeriatr 1996;8:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994890</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale&#x2013;Revised, Manual. San Antonio: The Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale&#x2013;Revised. San Antonio: Psychological Corporation; 1981.</Citation></Reference><Reference><Citation>Reitan R, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. Tucson: Neuropsychology Press; 1985.</Citation></Reference><Reference><Citation>Morris JC, Edland S, Clark C, et al. . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part IV: rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993;43:2457&#x2013;2465.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255439</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. . Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S13&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodglass H, Kaplan D. The Assessment of Aphasia and Related Disorders. 2nd ed. Philadelphia: Lea &amp; Febiger; 1983.</Citation></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008;28:8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Backman L, Small BJ, Fratiglioni L. Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain 2001;124:96&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">11133790</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 2008;14:266&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763488</ArticleId><ArticleId IdType="pubmed">18282324</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel M, Hogenauer M, Delker A, et al. . Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage 2015;108:450&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">25482269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Roontiva A, Thiyyagura P, et al. . Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med 2015;56:560&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">25745091</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Mintun MA, Xiong C, et al. . Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011;70:857&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243969</ArticleId><ArticleId IdType="pubmed">22162065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29580670</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>869</StartPage><EndPage>879</EndPage><MedlinePgn>869-879</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2018.01.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(18)30031-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Individuals in early stages of Alzheimer's disease are a targeted population for secondary prevention trials aimed at preserving normal cognition. Understanding within-person biomarker(s) change over time is critical for trial enrollment and design.</AbstractText><AbstractText Label="METHODS">Longitudinal cerebrospinal fluid samples from the Alzheimer's Disease Neuroimaging Initiative were assayed for novel markers of neuronal/synaptic injury (visinin-like protein 1, Ng, and SNAP-25) and neuroinflammation (YKL-40) and compared with &#x3b2; amyloid 42, tau, and phospho-tau181. General linear mixed models were used to compare within-person rates of change in three clinical groups (cognitively normal, mild cognitive impairment, and Alzheimer's disease) further defined by &#x3b2; amyloid status.</AbstractText><AbstractText Label="RESULTS">Levels of injury markers were highly positively correlated. Despite elevated baseline levels as a function of clinical status and amyloid-positivity, within-person decreases in these measures were observed in the early symptomatic, amyloid-positive Alzheimer's disease group.</AbstractText><AbstractText Label="DISCUSSION">Knowledge of within-person biomarker change will impact interpretation of biomarker outcomes in clinical trials that are dependent on disease stage.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sutphen</LastName><ForeName>Courtney L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCue</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herries</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladenson</LastName><ForeName>Jack H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: fagana@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ADNI</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034119</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051596">Neurocalcin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050825">Synaptosomal-Associated Protein 25</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496688">VSNL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="Y">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051596" MajorTopicYN="N">Neurocalcin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050825" MajorTopicYN="N">Synaptosomal-Associated Protein 25</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">Longitudinal biomarkers</Keyword><Keyword MajorTopicYN="N">Neuronal injury</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29580670</ArticleId><ArticleId IdType="mid">NIHMS985439</ArticleId><ArticleId IdType="pmc">PMC6110083</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2018.01.012</ArticleId><ArticleId IdType="pii">S1552-5260(18)30031-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer&#x2019;s disease: an appraisal from 1984 to 2014. J Intern Med 2014; 275:251&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956752</ArticleId><ArticleId IdType="pubmed">24605808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature 2009;461:916&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron 2013;80:1347&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glund K, Kern S, Zettergren A, B&#xf6;rjesson-Hansson A, Zetterberg H, Skoog I, et al. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry 2017; 7:e995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5545720</ArticleId><ArticleId IdType="pubmed">28072416</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Nosheny R, Tosun D, Trojanowski JQ, Shaw LM, et al. Emerging &#x3b2;-amyloid pathology and accelerated cortical atrophy. JAMA Neurol 2014;71:725&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410966</ArticleId><ArticleId IdType="pubmed">24781145</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med 2014; 6:226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer&#x2019;s disease. Alzheimers Res Ther 2015;7:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690296</ArticleId><ArticleId IdType="pubmed">26698298</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell KH. The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer&#x2019;s disease&#x2014;old wine in new bottles. Front Mol Neurosci 2012;5:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3284765</ArticleId><ArticleId IdType="pubmed">22375104</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Hertze J, Zetterberg H, Landqvist Wald&#xf6; M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer&#x2019;s disease. Ann Clin Transl Neurol 2015; 3:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4704480</ArticleId><ArticleId IdType="pubmed">26783546</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 2015;72:1029&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4570860</ArticleId><ArticleId IdType="pubmed">26147946</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, D&#x2019;Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 2011;70:274&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154071</ArticleId><ArticleId IdType="pubmed">21823155</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Lee J-M, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 2012;78:709&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306162</ArticleId><ArticleId IdType="pubmed">22357717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer&#x2019;s disease in a memory clinic cohort. Alzheimers Res Ther 2015;7:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574487</ArticleId><ArticleId IdType="pubmed">26383836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, D&#x2019;Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol 2016; 73:561&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4861689</ArticleId><ArticleId IdType="pubmed">27018940</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Littell RC, Henry PR, Ammerman CB. Statistical analysis of repeated measures data using SAS procedures. J Anim Sci 1998;76:1216&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">9581947</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol (Berl) 2013;126:659&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson OAlzheimer&#x2019; s Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain J Neurol 2016;139:1226&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Iulita MF, Ower A, Barone C, Pentz R, Gubert P, Romano C, et al. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimers Dement 2016;12:1132&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">27452424</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson JB,Szijan I, Coulter PM. Localization of RC3 (neurogranin) in rat brain subcellular fractions. Brain Res Mol Brain Res 1994; 27:323&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7898318</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;ez-Guerra FJ. Neurogranin, alink between calcium/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life 2010; 62:597&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">20665622</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K-P, Huang FL, J&#xe4;ger T, Li J, Reymann KG, Balschun D. Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. J Neurosci 2004;24:10660&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730132</ArticleId><ArticleId IdType="pubmed">15564582</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer&#x2019;s disease. Neurology 2001;56:127&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W, et al. Differential loss of synaptic proteins in Alzheimer&#x2019;s disease: implications for synaptic dysfunction. J Alzheimers Dis 2005;7:103&#x2013;17; discussion 173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington H, Paterson RW, Portelius E, T&#xf6;rnqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology 2016;86:829&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793782</ArticleId><ArticleId IdType="pubmed">26826204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, &#xd6;hrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer&#x2019;s disease. Alzheimers Dement 2015;11:1180&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">25533203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 2015;72:1275&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694558</ArticleId><ArticleId IdType="pubmed">26366630</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Zetterberg H, Skillb&#xe4;ck T, T&#xf6;rnqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation tocognition and neurodegeneration in Alzheimer&#x2019;s disease. Brain J Neurol 2015;138:3373&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643642</ArticleId><ArticleId IdType="pubmed">26373605</ArticleId></ArticleIdList></Reference><Reference><Citation>Noor A, Zahid S. A review of the role of synaptosomal-associated protein 25 (SNAP-25) in neurological disorders. Int J Neurosci 2017; 127:805&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">27734716</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm A, Brinkmalm G, Honer WG, Fr&#xf6;lich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer&#x2019;s disease. Mol Neurodegener 2014;9:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253625</ArticleId><ArticleId IdType="pubmed">25418885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010;7:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892443</ArticleId><ArticleId IdType="pubmed">20540736</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, &#xd6;hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Lancet Neurol 2016; 15:673&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, Mart&#xed;nez-Lage P, S&#xe1;nchez-Juan P, Olazar&#xe1;n J, Ant&#xfa;nez C, Izagirre A, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology 2015; 85:626&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">26180139</ArticleId></ArticleIdList></Reference><Reference><Citation>Gispert JD, Mont&#xe9; GC, Falcon C, Tucholka A, Rojas S, S&#xe1;nchez-Valle R, et al. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol Aging 2016; 38:47&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">26827642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer&#x2019;s disease. EMBO Mol Med 2016;8:1184&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048367</ArticleId><ArticleId IdType="pubmed">27534871</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H Review: tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol 2017;43:194&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28054371</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJB, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 2016;44:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4913039</ArticleId><ArticleId IdType="pubmed">27318129</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement 2010;6:257&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867839</ArticleId><ArticleId IdType="pubmed">20451874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011;68:1257&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5604752</ArticleId><ArticleId IdType="pubmed">21670386</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29540588</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>15</Issue><PubDate><Year>2018</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Midlife cardiovascular fitness and dementia: A 44-year longitudinal population study in women.</ArticleTitle><Pagination><StartPage>e1298</StartPage><EndPage>e1305</EndPage><MedlinePgn>e1298-e1305</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000005290</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To investigate whether greater cardiovascular fitness in midlife is associated with decreased dementia risk in women followed up for 44 years.</AbstractText><AbstractText Label="METHODS">A population-based sample of 1,462 women 38 to 60 years of age was examined in 1968. Of these, a systematic subsample comprising 191 women completed a stepwise-increased maximal ergometer cycling test to evaluate cardiovascular fitness. Subsequent examinations of dementia incidence were done in 1974, 1980, 1992, 2000, 2005, and 2009. Dementia was diagnosed according to DSM-III-R criteria on the basis of information from neuropsychiatric examinations, informant interviews, hospital records, and registry data up to 2012. Cox regressions were performed with adjustment for socioeconomic, lifestyle, and medical confounders.</AbstractText><AbstractText Label="RESULTS">Compared with medium fitness, the adjusted hazard ratio for all-cause dementia during the 44-year follow-up was 0.12 (95% confidence interval [CI] 0.03-0.54) among those with high fitness and 1.41 (95% CI 0.72-2.79) among those with low fitness. High fitness delayed age at dementia onset by 9.5 years and time to dementia onset by 5 years compared to medium fitness.</AbstractText><AbstractText Label="CONCLUSIONS">Among Swedish women, a high cardiovascular fitness in midlife was associated with a decreased risk of subsequent dementia. Promotion of a high cardiovascular fitness may be included in strategies to mitigate or prevent dementia. Findings are not causal, and future research needs to focus on whether improved fitness could have positive effects on dementia risk and when during the life course a high cardiovascular fitness is most important.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H&#xf6;rder</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Neuropsychiatric Epidemiology Unit (H.H., L.J., X.G., S.K., S.&#xd6;., I.S.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health-AGECAP, and Department of Clinical Neuroscience (G.G.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden. Helena.Horder@neuro.gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansson</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Neuropsychiatric Epidemiology Unit (H.H., L.J., X.G., S.K., S.&#xd6;., I.S.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health-AGECAP, and Department of Clinical Neuroscience (G.G.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>XinXin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>From the Neuropsychiatric Epidemiology Unit (H.H., L.J., X.G., S.K., S.&#xd6;., I.S.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health-AGECAP, and Department of Clinical Neuroscience (G.G.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimby</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Neuropsychiatric Epidemiology Unit (H.H., L.J., X.G., S.K., S.&#xd6;., I.S.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health-AGECAP, and Department of Clinical Neuroscience (G.G.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Neuropsychiatric Epidemiology Unit (H.H., L.J., X.G., S.K., S.&#xd6;., I.S.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health-AGECAP, and Department of Clinical Neuroscience (G.G.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;stling</LastName><ForeName>Svante</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Neuropsychiatric Epidemiology Unit (H.H., L.J., X.G., S.K., S.&#xd6;., I.S.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health-AGECAP, and Department of Clinical Neuroscience (G.G.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skoog</LastName><ForeName>Ingmar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Neuropsychiatric Epidemiology Unit (H.H., L.J., X.G., S.K., S.&#xd6;., I.S.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health-AGECAP, and Department of Clinical Neuroscience (G.G.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Apr 10;90(15):675-676. doi: 10.1212/WNL.0000000000005282.</RefSource><PMID Version="1">29540586</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Oct 16;91(16):762-763. doi: 10.1212/WNL.0000000000006348.</RefSource><PMID Version="1">30323073</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Oct 16;91(16):763. doi: 10.1212/WNL.0000000000006350.</RefSource><PMID Version="1">30323074</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010809" MajorTopicYN="Y">Physical Fitness</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29540588</ArticleId><ArticleId IdType="pmc">PMC5894933</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000005290</ArticleId><ArticleId IdType="pii">WNL.0000000000005290</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rolland Y, Abellan van Kan G, Vellas B. Physical activity and Alzheimer's disease: from prevention to therapeutic perspectives. J Am Med Dir Assoc 2008;9:390&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">18585641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 2009;39:3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">18570697</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia? A systematic review and meta-analysis of longitudinal studies. BMC Public Health 2014;14:510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064273</ArticleId><ArticleId IdType="pubmed">24885250</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DI, Taler V, Davidson PS, Messier C. Measuring the impact of exercise on cognitive aging: methodological issues. Neurobiol Aging 2012;33:622.e29&#x2013;622.e43.</Citation><ArticleIdList><ArticleId IdType="pubmed">21514694</ArticleId></ArticleIdList></Reference><Reference><Citation>Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, Vanhees L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev 2008;2:CD005381.</Citation><ArticleIdList><ArticleId IdType="pubmed">18425918</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PJ, Blumenthal JA, Hoffman BM, et al. . Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom Med 2010;72:239&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897704</ArticleId><ArticleId IdType="pubmed">20223924</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J, Angevaren M, Rusted J, Tabet N. Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev 2015;4:Cd005381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10554155</ArticleId><ArticleId IdType="pubmed">25900537</ArticleId></ArticleIdList></Reference><Reference><Citation>Defina LF, Willis BL, Radford NB, et al. . The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study. Ann Intern Med 2013;158:162&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3926646</ArticleId><ArticleId IdType="pubmed">23381040</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg J, Aberg MA, Schioler L, et al. . Cardiovascular and cognitive fitness at age 18 and risk of early-onset dementia. Brain 2014;137:1514&#x2013;1523.</Citation><ArticleIdList><ArticleId IdType="pubmed">24604561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulmala J, Solomon A, Kareholt I, et al. . Association between mid- to late life physical fitness and dementia: evidence from the CAIDE study. J Intern Med 2014;276:296&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">24444031</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011;10:819&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: analysis of population based data. Lancet Neurol 2014;13:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">25030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson C, Blohme G, Hallberg L, et al. . The study of women in Gothenburg 1968&#x2013;1969: a population study: general design, purpose and sampling results. Acta Med Scand 1973;193:311&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">4717311</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson C, Vedin JA, Grimby G, et al. . Maximal work performance test in middle-aged women: results from a population study. Scand J Clin Lab Invest 1978;38:181&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">653306</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg G. Borg's Perceived Exertion and Pain Scales. Champaign: Human Kinetics; 1998.</Citation></Reference><Reference><Citation>Johansson L, Guo X, Waern M, et al. . Midlife psychological stress and risk of dementia: a 35-year longitudinal population study. Brain 2010;133:2217&#x2013;2224.</Citation><ArticleIdList><ArticleId IdType="pubmed">20488887</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF, Andersson E, Ekbom A, et al. . External review and validation of the Swedish National Inpatient Register. BMC Public Health 2011;11:450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142234</ArticleId><ArticleId IdType="pubmed">21658213</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Waern M, Sjogren K, et al. . Midlife respiratory function and incidence of Alzheimer's disease: a 29-year longitudinal study in women. Neurobiol Aging 2007;28:343&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">16513221</ArticleId></ArticleIdList></Reference><Reference><Citation>Saltin B, Grimby G. Physiological analysis of middle-aged and old former athletes: comparison with still active athletes of the same ages. Circulation 1968;38:1104&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">5721960</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimby G, Borjesson M, Jonsdottir IH, Schnohr P, Thelle DS, Saltin B. The &#x201c;Saltin-Grimby Physical Activity Level Scale&#x201d; and its application to health research. Scand J Med Sci Sports 2015;25(suppl 4):119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">26589125</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry VW, Baruth M, Beets MW, Durstine JL, Liu J, Blair SN. Fitness vs. fatness on all-cause mortality: a meta-analysis. Prog Cardiovasc Dis 2014;56:382&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">24438729</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFina LF, Haskell WL, Willis BL, et al. . Physical activity versus cardiorespiratory fitness: two (partly) distinct components of cardiovascular health? Prog Cardiovasc Dis 2015;57:324&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">25269066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofi F, Valecchi D, Bacci D, et al. . Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med 2011;269:107&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">20831630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard C, Dionne FT, Simoneau JA, Boulay MR. Genetics of aerobic and anaerobic performances. Exerc Sport Sci Rev 1992;20:27&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">1623888</ArticleId></ArticleIdList></Reference><Reference><Citation>Nithianantharajah J, Hannan AJ. The neurobiology of brain and cognitive reserve: mental and physical activity as modulators of brain disorders. Prog Neurobiol 2009;89:369&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">19819293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngandu T, Lehtisalo J, Solomon A, et al. . A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">25771249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Espeland MA, Castro CM, et al. . Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: the LIFE randomized trial. JAMA 2015;314:781&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698980</ArticleId><ArticleId IdType="pubmed">26305648</ArticleId></ArticleIdList></Reference><Reference><Citation>van Charante EP, Richard E, Eurelings LS, et al. . Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet 2016;388:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">27474376</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BM, Peiffer JJ, Martins RN. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease? Mol Psychiatry 2013;18:864&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164816</ArticleId></ArticleIdList></Reference><Reference><Citation>Spartano NL, Himali JJ, Beiser AS, et al. . Midlife exercise blood pressure, heart rate, and fitness relate to brain volume 2 decades later. Neurology 2016;86:1313&#x2013;1319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826343</ArticleId><ArticleId IdType="pubmed">26865519</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas AG, Dennis A, Bandettini PA, Johansen-Berg H. The effects of aerobic activity on brain structure. Front Psychol 2012;3:86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3311131</ArticleId><ArticleId IdType="pubmed">22470361</ArticleId></ArticleIdList></Reference><Reference><Citation>Loe H, Rognmo O, Saltin B, Wisloff U. Aerobic capacity reference data in 3816 healthy men and women 20&#x2013;90 years. PLoS One 2013;8:e64319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654926</ArticleId><ArticleId IdType="pubmed">23691196</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29582053</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>834</StartPage><EndPage>841</EndPage><MedlinePgn>834-841</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.0233</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Nerve growth factor (NGF) is an endogenous neurotrophic factor that prevents the death and augments the functional state of cholinergic neurons of the basal forebrain, a cell population that undergoes extensive degeneration in Alzheimer disease (AD).</AbstractText><AbstractText Label="OBJECTIVE">To determine whether stereotactically guided intracerebral injections of adeno-associated viral vector (serotype 2)-nerve growth factor (AAV2-NGF) are well tolerated and exhibit preliminary evidence of impact on cognitive decline in mild to moderate AD-associated dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In a multicenter phase 2 trial, 49 participants with mild to moderate AD were randomly assigned in a 1:1 ratio to receive stereotactically guided intracerebral injections of AAV2-NGF or sham surgery. Participants were enrolled between November 2009 and December 2012. Analyses began in February 2015. The study was conducted at 10 US academic medical centers. Eligibility required a diagnosis of mild to moderate dementia due to AD and individuals aged 55 to 80 years. A total of 39 participants did not pass screening; the most common reason was Mini-Mental State Examination scores below cutoff. Analyses were intention-to-treat.</AbstractText><AbstractText Label="INTERVENTIONS">Stereotactically guided intracerebral injections of AAV2-NGF into the nucleus basalis of Meynert of each hemisphere or sham surgery.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Change from baseline on the Alzheimer's Disease Assessment Scale-cognitive subscale at month 24.</AbstractText><AbstractText Label="RESULTS">Among 49 participants, 21 (43%) were women, 42 (86%) self-identified as white, and the mean (SD) age was 68 (6.4) years. AAV2-NGF was safe and well-tolerated through 24 months. No significant difference was noted between the treatment group and placebo on the primary outcome measure, the Alzheimer's Disease Assessment Scale-cognitive subscale (mean [SD] score, 14.52&#x2009;[4.66] vs 9.11&#x2009;[4.65], P&#x2009;=&#x2009;.17).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This multicenter randomized clinical trial demonstrated the feasibility of sham-surgery-controlled stereotactic gene delivery studies in patients with AD. AAV2-NGF delivery was well-tolerated but did not affect clinical outcomes or selected AD biomarkers. Pathological confirmation of accurate gene targeting is needed.</AbstractText><AbstractText Label="TRIAL REGISTRATION">clinicaltrials.gov Identifier NCT00876863.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rafii</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of California in San Diego, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuszynski</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California in San Diego, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California in San Diego, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barba</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of California in San Diego, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewer</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California in San Diego, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rissman</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California in San Diego, San Diego.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Affairs Medical Center, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siffert</LastName><ForeName>Joao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nestle Health Science, Florham Park, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>AAV2-NGF Study Team</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00876863</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG030048</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9061-61-4</RegistryNumber><NameOfSubstance UI="D020932">Nerve Growth Factor</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000623888">Adeno-associated virus-2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2018 Jul 1;75(7):791-793. doi: 10.1001/jamaneurol.2017.4029.</RefSource><PMID Version="1">29582049</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020532" MajorTopicYN="Y">Basal Nucleus of Meynert</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059329" MajorTopicYN="Y">Cholinergic Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="Y">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020932" MajorTopicYN="N">Nerve Growth Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019219" MajorTopicYN="N">Parvovirinae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013238" MajorTopicYN="N">Stereotaxic Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Tuszynski founded Ceregene, Inc but dissociated from the company in 2013 and had no conflict of interest subsequent to that time. Dr Siffert was an employee of Ceregene, Inc and owned stock, is a full-time employee of Nestle Health Science, and is a shareholder in Alcobra Pharma and AveXis. Dr Brewer is a consultant for Elan, Bristol-Myers Squibb, Avanir, Novartis, Genentech, and Eli Lilly and holds stock options in CorTechs Labs, Inc and Human Longevity, Inc. Dr Aisen is a consultant to NeuroPhage, Merck, Roche, Novartis, Lundbeck, Biogen, Probiodrug, Pfizer, Anavex, and Abbvie and receives grants from Eli Lilly and Company, Janssen, the Alzheimer&#x2019;s Association, and the National Institutes of Health. No other conflicts were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29582053</ArticleId><ArticleId IdType="pmc">PMC5885277</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.0233</ArticleId><ArticleId IdType="pii">2675302</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408-414.</Citation><ArticleIdList><ArticleId IdType="pubmed">7046051</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer&#x2019;s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537):1237-1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobley WC, Rutkowski JL, Tennekoon GI, Gemski J, Buchanan K, Johnston MV. Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons. Brain Res. 1986;387(1):53-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">3742234</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Holtzman DM, Kromer LF, et al. . Regulation of TrkA and ChAT expression in developing rat basal forebrain: evidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons. J Neurosci. 1995;15(4):2888-2905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577746</ArticleId><ArticleId IdType="pubmed">7536822</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol. 1999;57(4):451-484.</Citation><ArticleIdList><ArticleId IdType="pubmed">10080385</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci. 1986;6(8):2155-2162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568758</ArticleId><ArticleId IdType="pubmed">3746405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kromer LF. Nerve growth factor treatment after brain injury prevents neuronal death. Science. 1987;235(4785):214-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">3798108</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, U HS, Amaral DG, Gage FH. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci. 1990;10(11):3604-3614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570113</ArticleId><ArticleId IdType="pubmed">2230949</ArticleId></ArticleIdList></Reference><Reference><Citation>Koliatsos VE, Nauta HJ, Clatterbuck RE, Holtzman DM, Mobley WC, Price DL. Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey. J Neurosci. 1990;10(12):3801-3813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570054</ArticleId><ArticleId IdType="pubmed">2269884</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuello AC, Maysinger D, Garofalo L. Trophic factor effects on cholinergic innervation in the cerebral cortex of the adult rat brain. Mol Neurobiol. 1992;6(4):451-461.</Citation><ArticleIdList><ArticleId IdType="pubmed">1285934</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W, Wictorin K, Bj&#xf6;rklund A, Williams LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature. 1987;329(6134):65-68.</Citation><ArticleIdList><ArticleId IdType="pubmed">3627243</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Li Y, Chen K, Gage FH, Epstein CJ, Mobley WC. Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age-related neurodegeneration. Neurology. 1993;43(12):2668-2673.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Winn SR, Liu YT, et al. . The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci U S A. 1994;91(23):10898-10902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45133</ArticleId><ArticleId IdType="pubmed">7971980</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, Roberts J, Senut MC, U HS, Gage FH. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther. 1996;3(4):305-314.</Citation><ArticleIdList><ArticleId IdType="pubmed">8732162</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg MB, Friedmann T, Robertson RC, et al. . Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science. 1988;242(4885):1575-1578.</Citation><ArticleIdList><ArticleId IdType="pubmed">3201248</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, Thal L, Pay M, et al. . A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11(5):551-555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852017</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafii MS, Baumann TL, Bakay RA, et al. . A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer&#x2019;s disease. Alzheimers Dement. 2014;10(5):571-581.</Citation><ArticleIdList><ArticleId IdType="pubmed">24411134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, Yang JH, Barba D, et al. . Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol. 2015;72(10):1139-1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944824</ArticleId><ArticleId IdType="pubmed">26302439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop KM, Hofer EK, Mehta A, et al. . Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol. 2008;211(2):574-584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709503</ArticleId><ArticleId IdType="pubmed">18439998</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog CD, Bishop KM, Brown L, Wilson A, Kordower JH, Bartus RT. Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases. Drug Deliv Transl Res. 2011;1(5):361-382.</Citation><ArticleIdList><ArticleId IdType="pubmed">25788422</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski VC, Iliff LD, Zilhka E, et al. . Cerebral blood flow in dementia. Arch Neurol. 1975;32(9):632-637.</Citation><ArticleIdList><ArticleId IdType="pubmed">1164215</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984;141(11):1356-1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Raman R, Schmitt FA, et al. . Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord. 2009;23(3):260-267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762354</ArticleId><ArticleId IdType="pubmed">19812469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer&#x2019;s disease. J Am Geriatr Soc. 2004;52(7):1070-1076.</Citation><ArticleIdList><ArticleId IdType="pubmed">15209643</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer&#x2019;s disease. Lancet. 1994;344(8926):895.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916431</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer JB, Magda S, Airriess C, Smith ME. Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. AJNR Am J Neuroradiol. 2009;30(3):578-580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5947999</ArticleId><ArticleId IdType="pubmed">19112065</ArticleId></ArticleIdList></Reference><Reference><Citation>Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology. 2011;77(17):1619-1628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198979</ArticleId><ArticleId IdType="pubmed">21998317</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. . Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341-355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Dale AM; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal. 2011;15(4):489-497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115407</ArticleId><ArticleId IdType="pubmed">21388857</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, Bernot T, Moseanko R, et al. . Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol. 2009;215(1):153-159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632603</ArticleId><ArticleId IdType="pubmed">19013154</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, Mateling M, Kovacs I, et al. . Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci. 2013;33(39):15596-15602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782628</ArticleId><ArticleId IdType="pubmed">24068826</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29600961</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.</ArticleTitle><Pagination><StartPage>2144</StartPage><EndPage>2155</EndPage><MedlinePgn>2144-2155</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI96429</ELocationID><ELocationID EIdType="pii" ValidYN="Y">96429</ELocationID><Abstract><AbstractText>The apolipoprotein E E4 allele of the APOE gene is the strongest genetic factor for late-onset Alzheimer disease (LOAD). There is compelling evidence that apoE influences Alzheimer disease (AD) in large part by affecting amyloid &#x3b2; (A&#x3b2;) aggregation and clearance; however, the molecular mechanism underlying these findings remains largely unknown. Herein, we tested whether anti-human apoE antibodies can decrease A&#x3b2; pathology in mice producing both human A&#x3b2; and apoE4, and investigated the mechanism underlying these effects. We utilized APPPS1-21 mice crossed to apoE4-knockin mice expressing human apoE4 (APPPS1-21/APOE4). We discovered an anti-human apoE antibody, anti-human apoE 4 (HAE-4), that specifically recognizes human apoE4 and apoE3 and preferentially binds nonlipidated, aggregated apoE over the lipidated apoE found in circulation. HAE-4 also binds to apoE in amyloid plaques in unfixed brain sections and in living APPPS1-21/APOE4 mice. When delivered centrally or by peripheral injection, HAE-4 reduced A&#x3b2; deposition in APPPS1-21/APOE4 mice. Using adeno-associated virus to express 2 different full-length anti-apoE antibodies in the brain, we found that HAE antibodies decreased amyloid accumulation, which was dependent on Fc&#x3b3; receptor function. These data support the hypothesis that a primary mechanism for apoE-mediated plaque formation may be a result of apoE aggregation, as preferentially targeting apoE aggregates with therapeutic antibodies reduces A&#x3b2; pathology and may represent a selective approach to treat AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Aimin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bien-Ly</LastName><ForeName>Nga</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoyle</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keyser</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefton</LastName><ForeName>Katheryn B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Grace O</ForeName><Initials>GO</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Javier Remolina</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>Adam P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Getz</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henne</LastName><ForeName>Kirk</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyns</LastName><ForeName>Cheryl Eg</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerner</LastName><ForeName>Eli Paul</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudry</LastName><ForeName>Eloise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Zachary K</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG053976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG047336</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Invest. 2018 May 1;128(5):1734-1736. doi: 10.1172/JCI120414.</RefSource><PMID Version="1">29600962</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058846" MajorTopicYN="N">Antibodies, Monoclonal, Murine-Derived</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Neuroscience</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> NBL, YZ, APS, JLG, JG, KH, ZS, MSD, and RW are employees of Denali. FL, HJ, and DMH are inventors on a patent filed by Washington University on the topic of anti&#x2013;apoE antibodies that was licensed by Denali. DMH cofounded and is on the scientific advisory board of C2N Diagnostics. DMH consults for Genentech, AbbVie, Eli Lilly, Proclara, and Denali. Washington University receives research grants to the lab of DMH from C2N Diagnostics, Eli Lilly, AbbVie, and Denali.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29600961</ArticleId><ArticleId IdType="pmc">PMC5919821</ArticleId><ArticleId IdType="doi">10.1172/JCI96429</ArticleId><ArticleId IdType="pii">96429</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med. 2016;8(6):595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and &#x2018;wingmen&#x2019;. Nat Neurosci. 2015;18(6):800&#x2013;806. doi: 10.1038/nn.4018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4018</ArticleId><ArticleId IdType="pmc">PMC4445458</ArticleId><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488(7409):96&#x2013;99. doi: 10.1038/nature11283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11283</ArticleId><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180&#x2013;184. doi: 10.1038/ng0694-180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977&#x2013;1981. doi: 10.1073/pnas.90.5.1977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.5.1977</ArticleId><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer&#x2019;s disease: the influence of apolipoprotein E on amyloid-&#x3b2; and other amyloidogenic proteins. J Lipid Res. 2017;58(5):824&#x2013;836. doi: 10.1194/jlr.R075481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R075481</ArticleId><ArticleId IdType="pmc">PMC5408619</ArticleId><ArticleId IdType="pubmed">28246336</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer&#x2019;s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541(1):163&#x2013;166. doi: 10.1016/0006-8993(91)91092-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(91)91092-F</ArticleId><ArticleId IdType="pubmed">2029618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992;135(2):235&#x2013;238. doi: 10.1016/0304-3940(92)90444-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(92)90444-C</ArticleId><ArticleId IdType="pubmed">1625800</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A&#x3b2; amyloidosis. J Exp Med. 2012;209(12):2149&#x2013;2156. doi: 10.1084/jem.20121274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20121274</ArticleId><ArticleId IdType="pmc">PMC3501350</ArticleId><ArticleId IdType="pubmed">23129750</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, et al. Anti-ApoE antibody given after plaque onset decreases A&#x3b2; accumulation and improves brain function in a mouse model of A&#x3b2; amyloidosis. J Neurosci. 2014;34(21):7281&#x2013;7292. doi: 10.1523/JNEUROSCI.0646-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0646-14.2014</ArticleId><ArticleId IdType="pmc">PMC4028501</ArticleId><ArticleId IdType="pubmed">24849360</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272(29):17972&#x2013;17980. doi: 10.1074/jbc.272.29.17972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.29.17972</ArticleId><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7(9):940&#x2013;946. doi: 10.1038/sj.embor.7400784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, et al. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol Commun. 2015;3:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641345</ArticleId><ArticleId IdType="pubmed">26556230</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, et al. Rapid microglial response around amyloid pathology after systemic anti-A&#x3b2; antibody administration in PDAPP mice. J Neurosci. 2008;28(52):14156&#x2013;14164. doi: 10.1523/JNEUROSCI.4147-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4147-08.2008</ArticleId><ArticleId IdType="pmc">PMC2743894</ArticleId><ArticleId IdType="pubmed">19109498</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fc&#x3b3; receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94&#x2013;108. doi: 10.1038/nri3582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3582</ArticleId><ArticleId IdType="pubmed">24445665</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudino L, et al. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol. 2008;181(9):6664&#x2013;6669. doi: 10.4049/jimmunol.181.9.6664.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.9.6664</ArticleId><ArticleId IdType="pubmed">18941257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, et al. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature. 2016;537(7618):50&#x2013;56. doi: 10.1038/nature19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Demattos RB, et al. A plaque-specific antibody clears existing &#x3b2;-amyloid plaques in Alzheimer&#x2019;s disease mice. Neuron. 2012;76(5):908&#x2013;920. doi: 10.1016/j.neuron.2012.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.10.029</ArticleId><ArticleId IdType="pubmed">23217740</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, et al. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci Transl Med. 2011;3(89):89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63(3):287&#x2013;303. doi: 10.1016/j.neuron.2009.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.06.026</ArticleId><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Liu CC, Chen XF, Zhang YW, Xu H, Bu G. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A&#x3b2; metabolism in apoE4-targeted replacement mice. Mol Neurodegener. 2015;10:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356137</ArticleId><ArticleId IdType="pubmed">25871773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, et al. Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer&#x2019;s disease mouse models. Neurobiol Aging. 2016;44:159&#x2013;172. doi: 10.1016/j.neurobiolaging.2016.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.04.020</ArticleId><ArticleId IdType="pubmed">27318144</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med. 2013;5(212):212ra161. doi: 10.1126/scitranslmed.3007000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007000</ArticleId><ArticleId IdType="pmc">PMC4334150</ArticleId><ArticleId IdType="pubmed">24259049</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2005;102(4):1211&#x2013;1216. doi: 10.1073/pnas.0409072102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0409072102</ArticleId><ArticleId IdType="pmc">PMC544620</ArticleId><ArticleId IdType="pubmed">15657137</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96(5):1024&#x2013;1032.e3. doi: 10.1016/j.neuron.2017.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.11.013</ArticleId><ArticleId IdType="pmc">PMC5948105</ArticleId><ArticleId IdType="pubmed">29216449</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 1999;96(26):15233&#x2013;15238. doi: 10.1073/pnas.96.26.15233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.26.15233</ArticleId><ArticleId IdType="pmc">PMC24803</ArticleId><ArticleId IdType="pubmed">10611368</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer&#x2019;s disease model. Ann Neurol. 2000;47(6):739&#x2013;747. doi: 10.1002/1531-8249(200006)47:6&lt;739::AID-ANA6&gt;3.0.CO;2-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(200006)47:6&lt;739::AID-ANA6&gt;3.0.CO;2-8</ArticleId><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of &#x3b2;-amyloidosis. Neuron. 2017;96(5):1013&#x2013;1023.e4. doi: 10.1016/j.neuron.2017.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.11.014</ArticleId><ArticleId IdType="pmc">PMC5728673</ArticleId><ArticleId IdType="pubmed">29216448</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-&#x3b2; amyloidosis. J Neurosci. 2011;31(49):18007&#x2013;18012. doi: 10.1523/JNEUROSCI.3773-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3773-11.2011</ArticleId><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="pubmed">22159114</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y. Reducing human apolipoprotein E levels attenuates age-dependent A&#x3b2; accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci. 2012;32(14):4803&#x2013;4811. doi: 10.1523/JNEUROSCI.0033-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0033-12.2012</ArticleId><ArticleId IdType="pmc">PMC3433173</ArticleId><ArticleId IdType="pubmed">22492035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadowski MJ, et al. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2006;103(49):18787&#x2013;18792. doi: 10.1073/pnas.0604011103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0604011103</ArticleId><ArticleId IdType="pmc">PMC1654132</ArticleId><ArticleId IdType="pubmed">17116874</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer&#x2019;s diseases. Neurobiol Dis. 2014;72 Pt A:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253862</ArticleId><ArticleId IdType="pubmed">25173806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118(2):671&#x2013;682. doi: 10.1172/JCI33622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI33622</ArticleId><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004;279(39):40987&#x2013;40993. doi: 10.1074/jbc.M407963200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407963200</ArticleId><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, et al. The LXR agonist TO901317 selectively lowers hippocampal A&#x3b2;42 and improves memory in the Tg2576 mouse model of Alzheimer&#x2019;s disease. Mol Cell Neurosci. 2007;34(4):621&#x2013;628. doi: 10.1016/j.mcn.2007.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2007.01.011</ArticleId><ArticleId IdType="pubmed">17336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, et al. Deletion of Abca1 increases A&#x3b2; deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280(52):43236&#x2013;43242. doi: 10.1074/jbc.M508780200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508780200</ArticleId><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mace BE, Maeda N, Schmechel DE. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience. 2004;124(4):725&#x2013;733. doi: 10.1016/j.neuroscience.2003.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2003.10.011</ArticleId><ArticleId IdType="pubmed">15026113</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, et al. Effects of CD2-associated protein deficiency on amyloid-&#x3b2; in neuroblastoma cells and in an APP transgenic mouse model. Mol Neurodegener. 2015;10:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4374406</ArticleId><ArticleId IdType="pubmed">25887956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Hyman BT. Alzheimer&#x2019;s disease: what multiphoton microscopy teaches us. Neuroscientist. 2002;8(5):386&#x2013;390. doi: 10.1177/107385802236963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/107385802236963</ArticleId><ArticleId IdType="pubmed">12374422</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29626112</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>May</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>Amyloid blood biomarker detects Alzheimer's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e8763</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201708763</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid-&#x3b2; (A&#x3b2;) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross-sectional BioFINDER cohort. In a further population-based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis in baseline samples with a positive likelihood ratio of 7.9; that is, those who were diagnosed with AD over the years were 7.9 times more likely to test positive. This assay may open avenues for blood screening of early AD stages as a funnel for further more invasive and expensive tests.</AbstractText><CopyrightInformation>&#xa9; 2018 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nabers</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biophysics, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perna</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biophysics, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mons</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schartner</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biophysics, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;ldenhaupt</LastName><ForeName>J&#xf6;rn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biophysics, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saum</LastName><ForeName>Kai-Uwe</ForeName><Initials>KU</Initials><AffiliationInfo><Affiliation>Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holleczek</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Saarland Cancer Registry, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychotherapy and Psychosomatics, University of Halle, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerwert</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8759-5964</Identifier><AffiliationInfo><Affiliation>Department of Biophysics, Ruhr-University Bochum, Bochum, Germany gerwert@bph.rub.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Hermann</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Aging Research (NAR), University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ESTHER</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease diagnosis</Keyword><Keyword MajorTopicYN="N">BioFINDER</Keyword><Keyword MajorTopicYN="N">amyloid&#x2010;&#x3b2; in blood plasma</Keyword><Keyword MajorTopicYN="N">immuno&#x2010;infrared&#x2010;sensor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29626112</ArticleId><ArticleId IdType="pmc">PMC5938617</ArticleId><ArticleId IdType="doi">10.15252/emmm.201708763</ArticleId><ArticleId IdType="pii">emmm.201708763</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM et&#xa0;al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795&#x2013;804</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at national institute on aging Alzheimer disease centers, 2005&#x2013;2010. J Neuropathol Exp Neurol 71: 266&#x2013;273</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368: 387&#x2013;403</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131&#x2013;144</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Mattsson N, Sch&#xf6;ll M, Hansson O, Zetterberg H (2015) Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 36: 297&#x2013;309</Citation><ArticleIdList><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallucci V, D'Amelio M, Cecconi F (2012) A&#x3b2; toxicity in Alzheimer's disease. Mol Neurobiol 45: 366&#x2013;378</Citation><ArticleIdList><ArticleId IdType="pubmed">22415442</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R et&#xa0;al (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG&#x2010;2 criteria. Lancet Neurol 13: 614&#x2013;629</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiandaca MS, Mapstone ME, Cheema AK, Federoff HJ (2014) The critical need for defining preclinical biomarkers in Alzheimer's disease. Alzheimers Dement 10: S196&#x2013;S212</Citation><ArticleIdList><ArticleId IdType="pubmed">24924671</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiandaca MS, Zhong X, Cheema AK, Orquiza MH, Chidambaram S, Tan MT, Gresenz CR, FitzGerald KT, Nalls MA, Singleton AB et&#xa0;al (2015) Plasma 24&#x2010;metabolite panel predicts preclinical transition to clinical stages of Alzheimer's disease. Front Neurol 6: 237</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4642213</ArticleId><ArticleId IdType="pubmed">26617567</ArticleId></ArticleIdList></Reference><Reference><Citation>Garczarek F, Gerwert K (2006) Functional waters in intraprotein proton transfer monitored by FTIR difference spectroscopy. Nature 439: 109&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">16280982</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, L&#xf6;nneborg A, Wyss&#x2010;Coray T, Soares H et&#xa0;al (2014) The future of blood&#x2010;based biomarkers for Alzheimer's disease. Alzheimers Dement 10: 115&#x2013;131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4128378</ArticleId><ArticleId IdType="pubmed">23850333</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong G&#x2010;S, Heun R, Jessen F, Popp J, Hentschel F, Kelemen P, Schulz A, Maier W, K&#xf6;lsch H (2009) Gene variations in GSTM3 are a risk factor for Alzheimer's disease. Neurobiol Aging 30: 691&#x2013;696</Citation><ArticleIdList><ArticleId IdType="pubmed">17904251</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Mielke MM, Vemuri P, Roberts RO, Machulda MM et&#xa0;al (2016) Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population&#x2010;based, longitudinal cohort study. Lancet Neurol 15: 56&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4784263</ArticleId><ArticleId IdType="pubmed">26597325</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeschke R, Guyatt GH, Sackett DL (1994) Users&#x2019; guides to the medical literature. JAMA 271: 703&#x2013;707</Citation><ArticleIdList><ArticleId IdType="pubmed">8309035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ, Amyloid Biomarker Study Group , Aalten P, Aarsland D et&#xa0;al (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta&#x2010;analysis. JAMA 313: 1924&#x2013;1938</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC (2013) Self&#x2010;propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501: 45&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundqvist R, Lilja J, Thomas BA, Lotjonen J, Villemagne VL, Rowe CC, Thurfjell L (2013) Implementation and validation of an adaptive template registration method for 18F&#x2010;Flutemetamol imaging data. J Nucl Med 54: 1472&#x2013;1478</Citation><ArticleIdList><ArticleId IdType="pubmed">23740104</ArticleId></ArticleIdList></Reference><Reference><Citation>Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM et&#xa0;al (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20: 415&#x2013;418</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360460</ArticleId><ArticleId IdType="pubmed">24608097</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinelli JE, Cecato JF, Bartholomeu D, Montiel JM (2014) Comparison of the diagnostic accuracy of neuropsychological tests in differentiating Alzheimer's disease from mild cognitive impairment: can the montreal cognitive assessment be better than the Cambridge cognitive examination. Dement Geriatr Cogn Dis Extra 4: 113&#x2013;121</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067730</ArticleId><ArticleId IdType="pubmed">24987399</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R et&#xa0;al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 7: 263&#x2013;269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabers A, Ollesch J, Schartner J, K&#xf6;tting C, Genius J, Hafermann H, Klafki H, Gerwert K, Wiltfang J (2016a) Amyloid&#x2010;&#x3b2;&#x2010;secondary structure distribution in cerebrospinal fluid and blood measured by an immuno&#x2010;infrared&#x2010;sensor: a biomarker candidate for Alzheimer's disease. Anal Chem 88: 2755&#x2013;2762</Citation><ArticleIdList><ArticleId IdType="pubmed">26828829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabers A, Ollesch J, Schartner J, K&#xf6;tting C, Genius J, Hau&#xdf;mann U, Klafki H, Wiltfang J, Gerwert K (2016b) An infrared sensor analysing label&#x2010;free the secondary structure of the Abeta peptide in presence of complex fluids. J Biophotonics 9: 224&#x2013;234</Citation><ArticleIdList><ArticleId IdType="pubmed">25808829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor&#xe9; V, Fowler C, Li Q&#x2010;X, Martins R, Rowe C et&#xa0;al (2018) High performance plasma amyloid&#x2010;&#x3b2; biomarkers for Alzheimer's disease. Nature 554: 249&#x2013;254</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, Posner H, Hall J, Johnson L et&#xa0;al (2017) Blood&#x2010;based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's Dement 13: 45&#x2013;58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218961</ArticleId><ArticleId IdType="pubmed">27870940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC et&#xa0;al (2017) Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's Dement 13: 841&#x2013;849</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, H&#xe4;gerstr&#xf6;m D, Wollmer P, Minthon L et&#xa0;al (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;&#x2010;Amyloid 42. JAMA Neurol 71: 1282</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R et&#xa0;al (2013) Predicting Alzheimer disease with &#x3b2;&#x2010;amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 74: 905&#x2013;913</Citation><ArticleIdList><ArticleId IdType="pubmed">24448836</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarroukh R, Cerf E, Derclaye S, Dufrene YF, Goormaghtigh E, Ruysschaert J, Raussens V (2011) Transformation of amyloid &#x3b2;(1&#x2010;40) oligomers into fibrils is characterized by a major change in secondary structure. Cell Mol Life Sci 68: 1429&#x2013;1438</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11114854</ArticleId><ArticleId IdType="pubmed">20853129</ArticleId></ArticleIdList></Reference><Reference><Citation>Saum K&#x2010;U, Dieffenbach AK, Jansen EHJM, Sch&#xf6;ttker B, Holleczek B, Hauer K, Brenner H (2015) Association between oxidative stress and frailty in an elderly german population: results from the ESTHER Cohort Study. Gerontology 61: 407&#x2013;415</Citation><ArticleIdList><ArticleId IdType="pubmed">25924722</ArticleId></ArticleIdList></Reference><Reference><Citation>Schartner J, G&#xfc;ldenhaupt J, Mei B, R&#xf6;gner M, Muhler M, Gerwert K, K&#xf6;tting C (2013) Universal method for protein immobilization on chemically functionalized germanium investigated by ATR&#x2010;FTIR difference spectroscopy. J Am Chem Soc 135: 4079&#x2013;4087</Citation><ArticleIdList><ArticleId IdType="pubmed">23414555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussi&#xe8;re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y et&#xa0;al (2016) The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer's disease. Nature 537: 50&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ et&#xa0;al (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 7: 280&#x2013;292</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacholder S, Silverman DT, McLaughlin JK, Mandel JS (1992) Selection of controls in case&#x2010;control studies. III. Design options. Am J Epidemiol 135: 1042&#x2013;1050</Citation><ArticleIdList><ArticleId IdType="pubmed">1595690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17: 5&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, Arrighi HM (2012) Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta&#x2010;analysis. Neuroepidemiology 38: 1&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pubmed">22179327</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Rieves D, Ganley C (2012) Brain amyloid imaging&#x2013;FDA approval of florbetapir F18 injection. N Engl J Med 367: 885&#x2013;887</Citation><ArticleIdList><ArticleId IdType="pubmed">22931256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao LN, Long H, Mu Y, Chew LY (2012) The toxicity of amyloid &#x3b2; oligomers. Int J Mol Sci 13: 7303&#x2013;7327</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3397527</ArticleId><ArticleId IdType="pubmed">22837695</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Lejnine S, Spond J, Zhang C, Ramaraj TC, Holder DJ, Dai H, Weiner R, Laterza OF (2015) A candidate plasma protein classifier to identify Alzheimer's disease. J Alzheimers Dis 43: 549&#x2013;563</Citation><ArticleIdList><ArticleId IdType="pubmed">25114072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29628304</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-0024</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Molecular therapy : the journal of the American Society of Gene Therapy</Title><ISOAbbreviation>Mol Ther</ISOAbbreviation></Journal><ArticleTitle>Targeting Amyloid-&#x3b2; Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-&#x3b2; Production.</ArticleTitle><Pagination><StartPage>1539</StartPage><EndPage>1551</EndPage><MedlinePgn>1539-1551</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ymthe.2018.02.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1525-0016(18)30105-9</ELocationID><Abstract><AbstractText>Alterations in amyloid beta precursor protein (APP) have been implicated in cognitive decline in Alzheimer's disease (AD),&#xa0;which is accelerated in Down syndrome/Trisomy 21 (DS/TS21), likely due to the extra copy of the APP gene, located on chromosome 21. Proteolytic cleavage of APP generates amyloid-&#x3b2; (A&#x3b2;) peptide, the primary component of senile plaques associated with AD. Reducing A&#x3b2; production is predicted to lower plaque burden and mitigate AD symptoms. Here, we designed a splice-switching antisense oligonucleotide (SSO) that causes skipping of the APP exon that encodes proteolytic cleavage sites required for A&#x3b2; peptide production. The SSO induced exon skipping in Down syndrome cell lines, resulting in a reduction of A&#x3b2;. Treatment of mice with the SSO resulted in widespread distribution in the brain accompanied by APP exon skipping and a reduction of A&#x3b2;. Overall, we show that an alternatively spliced isoform of APP encodes a cleavage-incompetent protein that does not produce A&#x3b2; peptide and that promoting the production of this isoform with an SSO can reduce A&#x3b2; in&#xa0;vivo. These findings demonstrate the utility of using SSOs to induce a spliced isoform of APP to reduce A&#x3b2; as a potential approach for treating AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Anatomy, Center for Genetic Diseases, Chicago Medical School and School of Graduate and Postdoctoral Studies, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinrich</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Anatomy, Center for Genetic Diseases, Chicago Medical School and School of Graduate and Postdoctoral Studies, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roman</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, DePaul University, Chicago, IL 60614, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norrbom</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marr</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norstrom</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, DePaul University, Chicago, IL 60614, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hastings</LastName><ForeName>Michelle L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Anatomy, Center for Genetic Diseases, Chicago Medical School and School of Graduate and Postdoctoral Studies, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA. Electronic address: michelle.hastings@rosalindfranklin.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD010662</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther</MedlineTA><NlmUniqueID>100890581</NlmUniqueID><ISSNLinking>1525-0016</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Down syndrome</Keyword><Keyword MajorTopicYN="N">amyloid beta</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">antisense oligonucleotides</Keyword><Keyword MajorTopicYN="N">splicing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29628304</ArticleId><ArticleId IdType="pmc">PMC5986716</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2018.02.029</ArticleId><ArticleId IdType="pii">S1525-0016(18)30105-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheltens P., Blennow K., Breteler M.M., de Strooper B., Frisoni G.B., Salloway S., Van der Flier W.M. Alzheimer&#x2019;s disease. Lancet. 2016;388:505&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63&#x2013;75.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association 2016 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2016;12:459&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Tcw J., Goate A.M. Genetics of &#x3b2;-amyloid precursor protein in Alzheimer&#x2019;s disease. Cold Spring Harb. Perspect. Med. 2017;7:a024539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5453386</ArticleId><ArticleId IdType="pubmed">28003277</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I., Karran E., De Strooper B. The toxic A&#x3b2; oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat. Neurosci. 2012;15:349&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J., Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 2016;8:595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., Cruchaga C., Goate A.M. Alzheimer&#x2019;s disease genetics: from the bench to the clinic. Neuron. 2014;83:11&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120741</ArticleId><ArticleId IdType="pubmed">24991952</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller U.C., Deller T., Korte M. Not just amyloid: physiological functions of the amyloid precursor protein family. Nat. Rev. Neurosci. 2017;18:281&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">28360418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawkins E., Small D.H. Insights into the physiological function of the &#x3b2;-amyloid precursor protein: beyond Alzheimer&#x2019;s disease. J.&#xa0;Neurochem. 2014;129:756&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4314671</ArticleId><ArticleId IdType="pubmed">24517464</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Koo E.H. Biology and pathophysiology of the amyloid precursor protein. Mol. Neurodegener. 2011;6:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098799</ArticleId><ArticleId IdType="pubmed">21527012</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyrks T., Weidemann A., Multhaup G., Salbaum J.M., Lemaire H.G., Kang J., M&#xfc;ller-Hill B., Masters C.L., Beyreuther K. Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer&#x2019;s disease. EMBO J. 1988;7:949&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC454420</ArticleId><ArticleId IdType="pubmed">2900137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., M&#xfc;ller-Hill B. The precursor of Alzheimer&#x2019;s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco W., Bupp K., Magendantz M., Gusella J.F., Tanzi R.E., Solomon F. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor. Proc. Natl. Acad. Sci. USA. 1992;89:10758&#x2013;10762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50421</ArticleId><ArticleId IdType="pubmed">1279693</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco W., Gurubhagavatula S., Paradis M.D., Romano D.M., Sisodia S.S., Hyman B.T., Neve R.L., Tanzi R.E. Isolation and characterization of APLP2 encoding a homologue of the Alzheimer&#x2019;s associated amyloid beta protein precursor. Nat. Genet. 1993;5:95&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">8220435</ArticleId></ArticleIdList></Reference><Reference><Citation>Norstrom E. Metabolic processing of the amyloid precursor protein&#x2014;new pieces of the Alzheimer&#x2019;s puzzle. Discov. Med. 2017;23:269&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">28595039</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew R.J., Kellett K.A., Thinakaran G., Hooper N.M. A Greek tragedy: the growing complexity of Alzheimer amyloid precursor protein proteolysis. J.&#xa0;Biol. Chem. 2016;291:19235&#x2013;19244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016663</ArticleId><ArticleId IdType="pubmed">27474742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia S.S., Koo E.H., Beyreuther K., Unterbeck A., Price D.L. Evidence that beta-amyloid protein in Alzheimer&#x2019;s disease is not derived by normal processing. Science. 1990;248:492&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">1691865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G., Koo E.H. Amyloid precursor protein trafficking, processing, and function. J.&#xa0;Biol. Chem. 2008;283:29615&#x2013;29619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Iwatsubo T., Wolfe M.S. Presenilins and &#x3b3;-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a006304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253024</ArticleId><ArticleId IdType="pubmed">22315713</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M., Nagashima Y., Sano Y., Ishihara S., Morishima-Kawashima M., Funamoto S., Ihara Y. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J.&#xa0;Neurosci. 2009;29:13042&#x2013;13052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L., Bammens L., Benilova I., Vandersteen A., Benurwar M., Borgers M., Lismont S., Zhou L., Van Cleynenbreugel S., Esselmann H. The mechanism of &#x3b3;-secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Kuhn P.H., Haass C., Kennedy M.E., Rajendran L., Wong P.C., Lichtenthaler S.F. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J.&#xa0;Neurochem. 2014;130:4&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086641</ArticleId><ArticleId IdType="pubmed">24646365</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Lessons from a failed &#x3b3;-secretase Alzheimer trial. Cell. 2014;159:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">25417150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanoisel&#xe9;e H.M., Nicolas G., Wallon D., Rovelet-Lecrux A., Lacour M., Rousseau S., Richard A.C., Pasquier F., Rollin-Sillaire A., Martinaud O., Collaborators of the CNR-MAJ project APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med. 2017;14:e1002270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5370101</ArticleId><ArticleId IdType="pubmed">28350801</ArticleId></ArticleIdList></Reference><Reference><Citation>Marr R.A., Hafez D.M. Amyloid-beta and Alzheimer&#x2019;s disease: the role of neprilysin-2 in amyloid-beta clearance. Front. Aging Neurosci. 2014;6:187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4131500</ArticleId><ArticleId IdType="pubmed">25165447</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., Goate A.M. Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry. 2015;77:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Atwal J.K., Steinberg S., Snaedal J., Jonsson P.V., Bjornsson S., Stefansson H., Sulem P., Gudbjartsson D., Maloney J. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonarakis S.E. Down syndrome and the complexity of genome dosage imbalance. Nat. Rev. Genet. 2017;18:147&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">28029161</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro P., Zaman S., Holland A. Alzheimer&#x2019;s disease in people with Down&#x2019;s syndrome: the prospects for and the challenges of developing preventative treatments. J.&#xa0;Neurol. 2017;264:804&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374178</ArticleId><ArticleId IdType="pubmed">27778163</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson V.E., Stewart W., Smith D.H. Traumatic brain injury and amyloid-&#x3b2; pathology: a link to Alzheimer&#x2019;s disease? Nat. Rev. Neurosci. 2010;11:361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979339</ArticleId><ArticleId IdType="pubmed">20216546</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird S.M., Sohrabi H.R., Sutton T.A., Weinborn M., Rainey-Smith S.R., Brown B., Patterson L., Taddei K., Gupta V., Carruthers M. Cerebral amyloid-&#x3b2; accumulation and deposition following traumatic brain injury&#x2014;a narrative review and meta-analysis of animal studies. Neurosci. Biobehav. Rev. 2016;64:215&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">26899257</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiteri C., Mostafavi S., Honey C.J., De Jager P.L., Bennett D.A. Genetic variants in Alzheimer disease&#x2014;molecular and brain network approaches. Nat. Rev. Neurol. 2016;12:413&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5017598</ArticleId><ArticleId IdType="pubmed">27282653</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes D.E., Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet Neurol. 2011;10:819&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Havens M.A., Duelli D.M., Hastings M.L. Targeting RNA splicing for disease therapy. Wiley Interdiscip. Rev. RNA. 2013;4:247&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631270</ArticleId><ArticleId IdType="pubmed">23512601</ArticleId></ArticleIdList></Reference><Reference><Citation>Havens M.A., Hastings M.L. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016;44:6549&#x2013;6563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001604</ArticleId><ArticleId IdType="pubmed">27288447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.F., Baker B.F., Pham N., Swayze E., Geary R.S. Pharmacology of antisense drugs. Annu. Rev. Pharmacol. Toxicol. 2017;57:81&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">27732800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigo F., Chun S.J., Norris D.A., Hung G., Lee S., Matson J., Fey R.A., Gaus H., Hua Y., Grundy J.S. Pharmacology of a central nervous system delivered 2&#x2032;-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J.&#xa0;Pharmacol. Exp. Ther. 2014;350:46&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4056267</ArticleId><ArticleId IdType="pubmed">24784568</ArticleId></ArticleIdList></Reference><Reference><Citation>McClorey G., Wood M.J. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr. Opin. Pharmacol. 2015;24:52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">26277332</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan L., Dreyfuss G. Splicing-correcting therapy for SMA. Cell. 2017;170:5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28666123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y., Sahashi K., Rigo F., Hung G., Horev G., Bennett C.F., Krainer A.R. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 2011;478:123&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191865</ArticleId><ArticleId IdType="pubmed">21979052</ArticleId></ArticleIdList></Reference><Reference><Citation>Glascock J., Lenz M., Hobby K., Jarecki J. Cure SMA and our patient community celebrate the first approved drug for SMA. Gene Ther. 2017;24:498&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">28504658</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohn T.T., Ivins K.J., Bahr B.A., Cotman C.W., Cribbs D.H. A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis. J.&#xa0;Neurochem. 2000;74:2331&#x2013;2342.</Citation><ArticleIdList><ArticleId IdType="pubmed">10820193</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel K.S., Meckler X., Chen Y., Nguyen P.D., Seidah N.G., Vassar R., Wong P.C., Fukata M., Kounnas M.Z., Thinakaran G. Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. J.&#xa0;Biol. Chem. 2009;284:3793&#x2013;3803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635050</ArticleId><ArticleId IdType="pubmed">19074428</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiki Y., Hubbard A.L., Fowler S., Lazarow P.B. Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. J.&#xa0;Cell Biol. 1982;93:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112113</ArticleId><ArticleId IdType="pubmed">7068762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrich A.J., Jodelka F.M., Chang J.L., Brutman D., Bruno A.M., Briggs C.A., James B.D., Stutzmann G.E., Bennett D.A., Miller S.A. Therapeutic correction of ApoER2 splicing in Alzheimer&#x2019;s disease mice using antisense oligonucleotides. EMBO Mol. Med. 2016;8:328&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818756</ArticleId><ArticleId IdType="pubmed">26902204</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Miller T.M., Yamanaka K., Monia B.P., Condon T.P., Hung G., Lobsiger C.S., Ward C.M., McAlonis-Downes M., Wei H. Antisense oligonucleotide therapy for neurodegenerative disease. J.&#xa0;Clin. Invest. 2006;116:2290&#x2013;2296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D., Privitera L., Fa&#x2019; M., Staniszewski A., Hashimoto G., Aziz F., Sakurai M., Ribe E.M., Troy C.M., Mercken M. Endogenous amyloid-&#x3b2; is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 2011;69:819&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4071456</ArticleId><ArticleId IdType="pubmed">21472769</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller B.C., Eckman E.A., Sambamurti K., Dobbs N., Chow K.M., Eckman C.B., Hersh L.B., Thiele D.L. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in&#xa0;vivo. Proc. Natl. Acad. Sci. USA. 2003;100:6221&#x2013;6226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC156353</ArticleId><ArticleId IdType="pubmed">12732730</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334:1081&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">22116877</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauwenberghe C., Van Broeckhoven C., Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet. Med. 2016;18:421&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857183</ArticleId><ArticleId IdType="pubmed">26312828</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164:603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M., Theuns J., Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 2012;33:1340&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin M.C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., Goate A., Rossor M., Roques P., Hardy J. Early-onset Alzheimer&#x2019;s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991;353:844&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">1944558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerri&#xe8;re A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K., Brouwers N., Gijselinck I., Theuns J., Goossens D., Wauters J., Del-Favero J., Cruts M., van Duijn C.M., Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer&#x2019;s dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977&#x2013;2983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Doran E., Keator D., Head E., Phelan M.J., Kim R., Totoiu M., Barrio J.R., Small G.W., Potkin S.G., Lott I.T. Down syndrome, partial trisomy 21, and absence of Alzheimer&#x2019;s disease: the role of APP. J.&#xa0;Alzheimers Dis. 2017;56:459&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662115</ArticleId><ArticleId IdType="pubmed">27983553</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasher V.P., Farrer M.J., Kessling A.M., Fisher E.M., West R.J., Barber P.C., Butler A.C. Molecular mapping of Alzheimer-type dementia in Down&#x2019;s syndrome. Ann. Neurol. 1998;43:380&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506555</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta S.A., Tajiri N., Sanberg P.R., Kaneko Y., Borlongan C.V. Increased amyloid precursor protein and Tau expression manifests as key secondary cell death in chronic traumatic brain injury. J.&#xa0;Cell. Physiol. 2017;232:665&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5484295</ArticleId><ArticleId IdType="pubmed">27699791</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D., Watanabe H., Wu B., Lee S.H., Li Y., Tsvetkov E., Bolshakov V.Y., Shen J., Kelleher R.J., 3rd Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer&#x2019;s disease. Neuron. 2015;85:967&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358812</ArticleId><ArticleId IdType="pubmed">25741723</ArticleId></ArticleIdList></Reference><Reference><Citation>Veugelen S., Saito T., Saido T.C., Ch&#xe1;vez-Guti&#xe9;rrez L., De Strooper B. Familial Alzheimer&#x2019;s disease mutations in presenilin generate amyloidogenic A&#x3b2; peptide seeds. Neuron. 2016;90:410&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">27100199</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaruga M., Veugelen S., Benurwar M., Lismont S., Sepulveda-Falla D., Lleo A., Ryan N.S., Lashley T., Fox N.C., Murayama S. Qualitative changes in human &#x3b3;-secretase underlie familial Alzheimer&#x2019;s disease. J.&#xa0;Exp. Med. 2015;212:2003&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4647268</ArticleId><ArticleId IdType="pubmed">26481686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V.B., Farr S.A., Flood J.F., Kamlesh V., Franko M., Banks W.A., Morley J.E. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides. 2000;21:1769&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">11150636</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan N.B., Siegel G.J. Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576. Neuroscience. 2007;146:143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955231</ArticleId><ArticleId IdType="pubmed">17303345</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarthy M., Chen S., Dodd P.R., Veedu R.N. Nucleic acid-based theranostics for tackling Alzheimer&#x2019;s disease. Theranostics. 2017;7:3933&#x2013;3947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5667416</ArticleId><ArticleId IdType="pubmed">29109789</ArticleId></ArticleIdList></Reference><Reference><Citation>Khvorova A., Watts J.K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 2017;35:238&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5517098</ArticleId><ArticleId IdType="pubmed">28244990</ArticleId></ArticleIdList></Reference><Reference><Citation>Deyts C., Thinakaran G., Parent A.T. APP receptor? To be or not to be. Trends Pharmacol. Sci. 2016;37:390&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846520</ArticleId><ArticleId IdType="pubmed">26837733</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl R., Schilling S., Soba P., Rupp C., Hartmann T., Wagner K., Merdes G., Eggert S., Kins S. Shedding of APP limits its synaptogenic activity and cell adhesion properties. Front. Cell. Neurosci. 2014;8:410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253958</ArticleId><ArticleId IdType="pubmed">25520622</ArticleId></ArticleIdList></Reference><Reference><Citation>Mockett B.G., Richter M., Abraham W.C., M&#xfc;ller U.C. Therapeutic potential of secreted amyloid precursor protein APPs&#x3b1;. Front. Mol. Neurosci. 2017;10:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293819</ArticleId><ArticleId IdType="pubmed">28223920</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J., Chiao P., Bussi&#xe8;re T., Weinreb P.H., Williams L., Maier M., Dunstan R., Salloway S., Chen T., Ling Y. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature. 2016;537:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y., Vickers T.A., Baker B.F., Bennett C.F., Krainer A.R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 2007;5:e73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820610</ArticleId><ArticleId IdType="pubmed">17355180</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker B.F., Lot S.S., Condon T.P., Cheng-Flournoy S., Lesnik E.A., Sasmor H.M., Bennett C.F. 2&#x2032;-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J.&#xa0;Biol. Chem. 1997;272:11994&#x2013;12000.</Citation><ArticleIdList><ArticleId IdType="pubmed">9115264</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer O., Marr R.A., Rockenstein E., Crews L., Coufal N.G., Gage F.H., Verma I.M., Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 2005;8:1343&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentz J.J., Jodelka F.M., Hinrich A.J., McCaffrey K.E., Farris H.E., Spalitta M.J., Bazan N.G., Duelli D.M., Rigo F., Hastings M.L. Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness. Nat. Med. 2013;19:345&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657744</ArticleId><ArticleId IdType="pubmed">23380860</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(&#x2212;Delta Delta C(T)) method. Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafez D.M., Huang J.Y., Richardson J.C., Masliah E., Peterson D.A., Marr R.A. F-spondin gene transfer improves memory performance and reduces amyloid-&#x3b2; levels in mice. Neuroscience. 2012;223:465&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3471376</ArticleId><ArticleId IdType="pubmed">22863679</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29632371</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector.</ArticleTitle><Pagination><StartPage>647</StartPage><EndPage>657</EndPage><MedlinePgn>647-657</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-018-0004-z</ELocationID><Abstract><AbstractText>Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems. Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-&#x3b2; (A&#x3b2;) peptides, and that they displayed GABAergic neuron degeneration. ApoE4 increased A&#x3b2; production in human, but not in mouse, neurons. Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4. Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4. Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chengzhong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najm</LastName><ForeName>Ramsey</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental and Stem Cell Biology Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Dah-Eun</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balestra</LastName><ForeName>Maureen E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Seo Yeon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Zachary A</ForeName><Initials>ZA</Initials><Identifier Source="ORCID">0000-0002-5991-3053</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malloy</LastName><ForeName>Mary J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yadong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental and Stem Cell Biology Program, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG048291</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048030</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI027763</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056305</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059330" MajorTopicYN="N">GABAergic Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29632371</ArticleId><ArticleId IdType="mid">NIHMS938026</ArticleId><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0004-z</ArticleId><ArticleId IdType="pii">10.1038/s41591-018-0004-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Schneider LS, Koo EH. Anti-A&#x3b2; therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 2011;69:203&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058906</ArticleId><ArticleId IdType="pubmed">21262461</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. J. Am. Med. Assoc. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry. 2011;16:903&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y. A&#x3b2;-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med. 2010;16:287&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">20537952</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Huang Y. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron. 2012;76:871&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4891195</ArticleId><ArticleId IdType="pubmed">23217737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron. 2010;66:631&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956420</ArticleId><ArticleId IdType="pubmed">20547123</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahata N, et al. Anti-A&#x3b2; drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS ONE. 2011;6:e25788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3184175</ArticleId><ArticleId IdType="pubmed">21984949</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T, et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 2011;20:4530&#x2013;4539.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900357</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012;2:789&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532907</ArticleId><ArticleId IdType="pubmed">23063362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T, et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular A&#x3b2; and differential drug responsiveness. Cell Stem Cell. 2013;12:487&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">23434393</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, et al. Effect of potent &#x3b3;-secretase modulator in human neurons derived from multiple presenillin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol. 2014 doi: 10.1001/jamaneurol.2014.2482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2482</ArticleId><ArticleId IdType="pmc">PMC4374637</ArticleId><ArticleId IdType="pubmed">25285942</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecht WJ, et al. Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 2004;24:2527&#x2013;2534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729489</ArticleId><ArticleId IdType="pubmed">15014128</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris FM, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer&#x2019;s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. USA. 2003;100:10966&#x2013;10971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196910</ArticleId><ArticleId IdType="pubmed">12939405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E, Mandelkow EM. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci. 2007;27:2896&#x2013;2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff G, et al. The presenilin-1 &#x394;E9 mutation results in reduced &#x3b3;-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. Cell Rep. 2013;5:974&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867011</ArticleId><ArticleId IdType="pubmed">24239350</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, et al. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci. Transl. Med. 2011;3:89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995;14:879&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">7718249</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA. 2011;108:5819&#x2013;5824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham M, et al. hPSC-derived maturing GABAergic interneurons ameliorate seizures and abnormal behavior in epileptic mice. Cell Stem Cell. 2014;15:559&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270101</ArticleId><ArticleId IdType="pubmed">25517465</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholas CR, et al. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell. 2013;12:573&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699205</ArticleId><ArticleId IdType="pubmed">23642366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn S, Kim TG, Kim KS, Chung S. Differentiation of human pluripotent stem cells into Medial Ganglionic Eminence vs. Caudal Ganglionic Eminence cells. Methods. 2016;101:103&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786472</ArticleId><ArticleId IdType="pubmed">26364591</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong H, et al. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Reports. 2013;1:226&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849235</ArticleId><ArticleId IdType="pubmed">24319659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak AC, et al. Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014;71:1228&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4714860</ArticleId><ArticleId IdType="pubmed">25111166</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, et al. Profile and regulation of apolipoprotein E (apoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the apoE locus. J. Neurosci. 2006;26:4985&#x2013;4994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, et al. Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS. J. Neurosci. 2008;28:1452&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671590</ArticleId><ArticleId IdType="pubmed">18256266</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P-T, et al. Specific regional transcription of apolipoprotein E in human brain neurons. Am. J. Pathol. 1999;154:601&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850012</ArticleId><ArticleId IdType="pubmed">10027417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener. 2013;8:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640999</ArticleId><ArticleId IdType="pubmed">23601557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 2006;103:5644&#x2013;5651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HK, et al. Small-molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J. Biol. Chem. 2012;287:5253&#x2013;5266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285306</ArticleId><ArticleId IdType="pubmed">22158868</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodbeck J, et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J. Biol. Chem. 2011;286:17217&#x2013;17226. J. Biol. Chem. 286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3089564</ArticleId><ArticleId IdType="pubmed">21454574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Huang Y. Small-molecule structure correctors target abnormal protein structure and function: Structure corrector rescue of apolipoprotein E4-associated neuropathology. J. Med. Chem. 2012;55:8997&#x2013;9008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4904786</ArticleId><ArticleId IdType="pubmed">23013167</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y. Reducing human apolipoprotein E levels attenuates age-dependent A&#x3b2; accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 2012;32:4803&#x2013;4811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433173</ArticleId><ArticleId IdType="pubmed">22492035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, et al. Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of &#x3b2;-amyloidosis. Neuron. 2017;96:1013&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728673</ArticleId><ArticleId IdType="pubmed">29216448</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, et al. ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron. 2017;96:1024&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948105</ArticleId><ArticleId IdType="pubmed">29216449</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YA, Zhou B, Wernig M, S&#xfc;dhof TC. ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and A&#x3b2; Secretion. Cell. 2017;168:427&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, et al. Self-Assembly of HEK Cell-Secreted ApoE Particles Resemble ApoE-Enrichment of Lipoproteins as a Ligand for the LDL Receptor-Related Protein. Biochemistry. 2006;45:381&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564845</ArticleId><ArticleId IdType="pubmed">16401069</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Zwilling Y, et al. Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci. 2010;30:13707&#x2013;13717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988475</ArticleId><ArticleId IdType="pubmed">20943911</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung L, et al. Apolipoprotein E4 causes age- and sex-dependent impairments of hilar GABAergic interneurons and learning and memory deficits in mice. PLoS ONE. 2012;7:e53569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534053</ArticleId><ArticleId IdType="pubmed">23300939</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, et al. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell. 2009;5:634&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992822</ArticleId><ArticleId IdType="pubmed">19951691</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong LM, et al. Inhibitory interneuron progenitor transplantation restores normal learning and memory in apoE4 knock-in mice without or with A&#x3b2; accumulation. J Neurosci. 2014;34:9506&#x2013;9515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4099537</ArticleId><ArticleId IdType="pubmed">25031394</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuriel T, et al. Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer's disease-like pathology. Nat Commun. 2017;8:1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684208</ArticleId><ArticleId IdType="pubmed">29133888</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoferle J, et al. Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice. J Neurosci. 2014;34:14069&#x2013;14078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198545</ArticleId><ArticleId IdType="pubmed">25319703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie AK, et al. Apolipoprotein E4 causes age-dependent disruption of slow gamma oscillations during hippocampal sharp-wave ripples. Neuron. 2016;90:740&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5097044</ArticleId><ArticleId IdType="pubmed">27161522</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat. Protoc. 2007;2:3081&#x2013;3089.</Citation><ArticleIdList><ArticleId IdType="pubmed">18079707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers SM, et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibiton of SMAD signaling. Nat. Biotechnol. 2009;27:275&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756723</ArticleId><ArticleId IdType="pubmed">19252484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu BY, Zhang SC. Differentiation of spinal motor neurons from pluripotent human stem cells. Nat. Protoc. 2009;4:1295&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789120</ArticleId><ArticleId IdType="pubmed">19696748</ArticleId></ArticleIdList></Reference><Reference><Citation>Krencik R, Weick JP, Liu Y, Zhang ZJ, Zhang SC. Specification of transplantable astroglial subtypes from human pluripotent stem cells. Nat Biotechnol. 2011;29:528&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111840</ArticleId><ArticleId IdType="pubmed">21602806</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29632177</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>115</Volume><Issue>17</Issue><PubDate><Year>2018</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;-Amyloid accumulation in the human brain after one night of sleep deprivation.</ArticleTitle><Pagination><StartPage>4483</StartPage><EndPage>4488</EndPage><MedlinePgn>4483-4488</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1721694115</ELocationID><Abstract><AbstractText>The effects of acute sleep deprivation on &#x3b2;-amyloid (A&#x3b2;) clearance in the human brain have not been documented. Here we used PET and <sup>18</sup>F-florbetaben to measure brain A&#x3b2; burden (ABB) in 20 healthy controls tested after a night of rested sleep (baseline) and after a night of sleep deprivation. We show that one night of sleep deprivation, relative to baseline, resulted in a significant increase in A&#x3b2; burden in the right hippocampus and thalamus. These increases were associated with mood worsening following sleep deprivation, but were not related to the genetic risk (APOE genotype) for Alzheimer's disease. Additionally, baseline ABB in a range of subcortical regions and the precuneus was inversely associated with reported night sleep hours. APOE genotyping was also linked to subcortical ABB, suggesting that different Alzheimer's disease risk factors might independently affect ABB in nearby brain regions. In summary, our findings show adverse effects of one-night sleep deprivation on brain ABB and expand on prior findings of higher A&#x3b2; accumulation with chronic less sleep.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 the Author(s). Published by PNAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shokri-Kojori</LastName><ForeName>Ehsan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6846-3173</Identifier><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892; ehsan.shokrikojori@nih.gov gene-jack.wang@nih.gov nvolkow@nida.nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gene-Jack</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892; ehsan.shokrikojori@nih.gov gene-jack.wang@nih.gov nvolkow@nida.nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiers</LastName><ForeName>Corinde E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demiral</LastName><ForeName>Sukru B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sung Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindgren</LastName><ForeName>Elsa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zehra</LastName><ForeName>Amna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Gregg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manza</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Tansha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Piramal Pharma Inc., Boston, MA 02108.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomasi</LastName><ForeName>Dardo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benveniste</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Yale School of Medicine, New Haven, CT 06510.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volkow</LastName><ForeName>Nora D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892; ehsan.shokrikojori@nih.gov gene-jack.wang@nih.gov nvolkow@nida.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS100366</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">beta amyloid</Keyword><Keyword MajorTopicYN="N">glymphatic system</Keyword><Keyword MajorTopicYN="N">hippocampus</Keyword><Keyword MajorTopicYN="N">sleep</Keyword></KeywordList><CoiStatement>Conflict of interest statement: S.D.S. was an employee of Piramal Pharma Inc., which partly supported the radiotracer for this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29632177</ArticleId><ArticleId IdType="pmc">PMC5924922</ArticleId><ArticleId IdType="doi">10.1073/pnas.1721694115</ArticleId><ArticleId IdType="pii">1721694115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nedergaard M. Neuroscience. Garbage truck of the brain. Science. 2013;340:1529&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749839</ArticleId><ArticleId IdType="pubmed">23812703</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre H, Kostrikov S, Mehta RI, Nedergaard M. Perivascular spaces, glymphatic dysfunction, and small vessel disease. Clin Sci (Lond) 2017;131:2257&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567781</ArticleId><ArticleId IdType="pubmed">28798076</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342:373&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J-E, et al. Amyloid-&#x3b2; dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabuchi M, et al. Sleep interacts with a&#x3b2; to modulate intrinsic neuronal excitability. Curr Biol. 2015;25:702&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366315</ArticleId><ArticleId IdType="pubmed">25754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, et al. Self-reported sleep and &#x3b2;-amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013;70:1537&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918480</ArticleId><ArticleId IdType="pubmed">24145859</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BM, et al. AIBL Research Group The relationship between sleep quality and brain amyloid burden. Sleep (Basel) 2016;39:1063&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835305</ArticleId><ArticleId IdType="pubmed">27091528</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher KE, et al. Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging. 2015;36:2568&#x2013;2576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4523445</ArticleId><ArticleId IdType="pubmed">26059712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y-ES, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70:587&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y-ES, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology&#x2014;A bidirectional relationship. Nat Rev Neurol. 2014;10:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979317</ArticleId><ArticleId IdType="pubmed">24366271</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid &#x3b2;-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. Is amyloid-&#x3b2; harmful to the brain? Insights from human imaging studies. Brain. 2016;139:23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4990654</ArticleId><ArticleId IdType="pubmed">26614753</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Gottesman RF. Sleep disturbance: An emerging opportunity for Alzheimer&#x2019;s disease prevention? Int Psychogeriatr. 2017;29:529&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5493989</ArticleId><ArticleId IdType="pubmed">27938445</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. The effect of body posture on brain glymphatic transport. J Neurosci. 2015;35:11034&#x2013;11044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4524974</ArticleId><ArticleId IdType="pubmed">26245965</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci Transl Med. 2012;4:147ra111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooms S, et al. Effect of 1 night of total sleep deprivation on cerebrospinal fluid &#x3b2;-amyloid 42 in healthy middle-aged men: A randomized clinical trial. JAMA Neurol. 2014;71:971&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">24887018</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543097</ArticleId><ArticleId IdType="pubmed">23002015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu XL, et al. Blood-derived amyloid-&#x3b2; protein induces Alzheimer&#x2019;s disease pathologies. Mol Psychiatry. October 31, 2017 doi: 10.1038/mp.2017.204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.204</ArticleId><ArticleId IdType="pubmed">29086767</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2007;4:191&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, et al. Sleep deprivation induced plasma amyloid-&#x3b2; transport disturbance in healthy young adults. J Alzheimers Dis. 2017;57:899&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">28304302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, et al. Effect of sleep on overnight CSF amyloid-&#x3b2; kinetics. Ann Neurol. December 8, 2017 doi: 10.1002/ana.25117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25117</ArticleId><ArticleId IdType="pmc">PMC5876097</ArticleId><ArticleId IdType="pubmed">29220873</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, et al. Imaging of amyloid &#x3b2; in Alzheimer&#x2019;s disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol. 2008;7:129&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191617</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodero-Tavoletti MT, et al. In vitro characterization of [18F]-florbetaben, an A&#x3b2; imaging radiotracer. Nucl Med Biol. 2012;39:1042&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">22503458</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">21764791</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3:13&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339690</ArticleId><ArticleId IdType="pubmed">25741488</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni R, Gillberg P-G, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer&#x2019;s disease brain tissue. Brain. 2013;136:2217&#x2013;2227.</Citation><ArticleIdList><ArticleId IdType="pubmed">23757761</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamin G, Teplow DB. Pittsburgh compound-B (PiB) binds amyloid &#x3b2;-protein protofibrils. J Neurochem. 2017;140:210&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5225051</ArticleId><ArticleId IdType="pubmed">27943341</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative MRI of hippocampal volume loss in early Alzheimer&#x2019;s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132:1067&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santi S, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001;22:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: A novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer&#x2019;s disease? Trends Neurosci. 2016;39:552&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4967375</ArticleId><ArticleId IdType="pubmed">27325209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YS, et al. Slow wave sleep disruption increases cerebrospinal fluid amyloid-&#x3b2; levels. Brain. 2017;140:2104&#x2013;2111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790144</ArticleId><ArticleId IdType="pubmed">28899014</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A &#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Aron L, Yankner BA. Neurodegenerative disorders: Neural synchronization in Alzheimer&#x2019;s disease. Nature. 2016;540:207&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">27929001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, et al. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng O, et al. Short-term sleep deprivation stimulates hippocampal neurogenesis in rats following global cerebral ischemia/reperfusion. PLoS One. 2015;10:e0125877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4454510</ArticleId><ArticleId IdType="pubmed">26039740</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes C, et al. Detrimental role of prolonged sleep deprivation on adult neurogenesis. Front Cell Neurosci. 2015;9:140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396387</ArticleId><ArticleId IdType="pubmed">25926773</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, et al. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci Transl Med. 2011;3:89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2010;133:3336&#x2013;3348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol. 2010;68:319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Rapid appearance and local toxicity of amyloid-&#x3b2; plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Schain A, Grutzendler J. Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci Rep. 2011;1:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216507</ArticleId><ArticleId IdType="pubmed">22355538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman SM, Herdener N, Frankola KA, Mughal MR, Mattson MP. Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical A&#x3b2; and pTau in a mouse model of Alzheimer&#x2019;s disease. Brain Res. 2013;1529:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779872</ArticleId><ArticleId IdType="pubmed">23856323</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao HY, et al. Chronic sleep restriction induces cognitive deficits and cortical beta-amyloid deposition in mice via BACE1-antisense activation. CNS Neurosci Ther. 2017;23:233&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492718</ArticleId><ArticleId IdType="pubmed">28145081</ArticleId></ArticleIdList></Reference><Reference><Citation>Camus V, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39:621&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315642</ArticleId><ArticleId IdType="pubmed">22252372</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85:296&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350773</ArticleId><ArticleId IdType="pubmed">25611508</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z, Hussain MD, Yan L-J. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer&#x2019;s disease. Int J Neurosci. 2014;124:307&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">23930978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu B, et al. Sleep disturbance induces neuroinflammation and impairment of learning and memory. Neurobiol Dis. 2012;48:348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3461115</ArticleId><ArticleId IdType="pubmed">22776332</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehlin D, et al. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer&#x2019;s disease. Nat Commun. 2016;7:10759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762893</ArticleId><ArticleId IdType="pubmed">26892305</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JC, et al. Frontal lobe metabolic decreases with sleep deprivation not totally reversed by recovery sleep. Neuropsychopharmacology. 2006;31:2783&#x2013;2792.</Citation><ArticleIdList><ArticleId IdType="pubmed">16880772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma N, Dinges DF, Basner M, Rao H. How acute total sleep loss affects the attending brain: A meta-analysis of neuroimaging studies. Sleep (Basel) 2015;38:233&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4288604</ArticleId><ArticleId IdType="pubmed">25409102</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullich S, et al. Validation of non-invasive tracer kinetic analysis of 18F-florbetaben PET using a dual time-window acquisition protocol. J Nucl Med. 2017:jnumed.117.200964.</Citation><ArticleIdList><ArticleId IdType="pubmed">29175981</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology. 2010;35:192&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055427</ArticleId><ArticleId IdType="pubmed">19693001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller AD, Meerlo P, McGinty D, Mistlberger RE. Sleep and adult neurogenesis: Implications for cognition and mood. In: Meerlo P, Benca RM, Abel T, editors. Sleep, Neuronal Plasticity and Brain Function. Springer; Heidelberg, Germany: 2013. pp. 151&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">24218292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dissel S, et al. Enhanced sleep reverses memory deficits and underlying pathology in Drosophila models of Alzheimer&#x2019;s disease. Neurobiol Sleep Circadian Rhythms. 2017;2:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662006</ArticleId><ArticleId IdType="pubmed">29094110</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser MF, et al. WU-Minn HCP Consortium The minimal preprocessing pipelines for the Human Connectome Project. Neuroimage. 2013;80:105&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720813</ArticleId><ArticleId IdType="pubmed">23668970</ArticleId></ArticleIdList></Reference><Reference><Citation>Catafau AM, et al. Cerebellar amyloid-&#x3b2; plaques: How frequent are they, and do they influence 18F-florbetaben SUV ratios? J Nucl Med. 2016;57:1740&#x2013;1745.</Citation><ArticleIdList><ArticleId IdType="pubmed">27363836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullich S, et al. Optimal reference region to measure longitudinal amyloid-beta change with 18F-florbetaben PET. J Nucl Med. 2017:jnumed.116.187351.</Citation><ArticleIdList><ArticleId IdType="pubmed">28183994</ArticleId></ArticleIdList></Reference><Reference><Citation>Heurling K, Buckley C, Van Laere K, Vandenberghe R, Lubberink M. Parametric imaging and quantitative analysis of the PET amyloid ligand [(18)F]flutemetamol. Neuroimage. 2015;121:184&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">26209803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Prins ND, van Berckel BN. Amyloid imaging in clinical trials. Alzheimers Res Ther. 2013;5:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978734</ArticleId><ArticleId IdType="pubmed">23953396</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">9417971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345505</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">2748771</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe YM, et al. Sleep quality in young and middle age-period is associated with cerebral amyloid burden in cognitively normal elderly people. Alzheimers Dement. 2016;12(Suppl):P171&#x2013;P172.</Citation></Reference><Reference><Citation>Westwood AJ, et al. Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia. Neurology. 2017;88:1172&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373785</ArticleId><ArticleId IdType="pubmed">28228567</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106&#x2013;118, and erratum (2013), 10.1038/nmeurol.2013.32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Correlations between apolipoprotein E &#x3b5;4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA. 2005;102:8299&#x2013;8302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149416</ArticleId><ArticleId IdType="pubmed">15932949</ArticleId></ArticleIdList></Reference><Reference><Citation>Corneveaux JJ, et al. Association of CR1, CLU and PICALM with Alzheimer&#x2019;s disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet. 2010;19:3295&#x2013;3301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908469</ArticleId><ArticleId IdType="pubmed">20534741</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, et al. Analysis of fMRI time-series revisited. Neuroimage. 1995;2:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343589</ArticleId></ArticleIdList></Reference><Reference><Citation>Poline J-B, Worsley KJ, Evans AC, Friston KJ. Combining spatial extent and peak intensity to test for activations in functional imaging. Neuroimage. 1997;5:83&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29625071</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Apr</Month><Day>05</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>Human Hippocampal Neurogenesis Persists throughout Aging.</ArticleTitle><Pagination><StartPage>589</StartPage><EndPage>599.e5</EndPage><MedlinePgn>589-599.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2018.03.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(18)30121-8</ELocationID><Abstract><AbstractText>Adult hippocampal neurogenesis declines in aging rodents and primates. Aging humans are thought to exhibit waning neurogenesis and exercise-induced angiogenesis, with a resulting volumetric decrease in the neurogenic hippocampal dentate gyrus (DG) region, although concurrent changes in these parameters are not well studied. Here we assessed whole autopsy hippocampi from healthy human individuals ranging from 14 to 79 years of age. We found similar numbers of intermediate neural progenitors and thousands of immature neurons in the DG, comparable numbers of glia and mature granule neurons, and equivalent DG volume across ages. Nevertheless, older individuals have less angiogenesis and neuroplasticity and a smaller quiescent progenitor pool in anterior-mid DG, with no changes in posterior DG. Thus, healthy older subjects without cognitive impairment, neuropsychiatric disease, or treatment display preserved neurogenesis. It is possible that ongoing hippocampal neurogenesis sustains human-specific cognitive function throughout life and that declines may be linked to compromised cognitive-emotional resilience.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boldrini</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, NY 10032, USA; Division of Molecular Imaging and Neuropathology, NYS Psychiatric Institute, New York, NY 10032, USA. Electronic address: mb928@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulmore</LastName><ForeName>Camille A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Division of Molecular Imaging and Neuropathology, NYS Psychiatric Institute, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartt</LastName><ForeName>Alexandria N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Division of Molecular Imaging and Neuropathology, NYS Psychiatric Institute, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simeon</LastName><ForeName>Laika R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Division of Molecular Imaging and Neuropathology, NYS Psychiatric Institute, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlova</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Integrative Neuroscience, NYS Psychiatric Institute, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poposka</LastName><ForeName>Verica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Forensic Medicine, Ss. Cyril &amp; Methodius University, Skopje 1000, Republic of Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosoklija</LastName><ForeName>Gorazd B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, NY 10032, USA; Division of Molecular Imaging and Neuropathology, NYS Psychiatric Institute, New York, NY 10032, USA; Macedonian Academy of Sciences &amp; Arts, 2, Ss. Cyril &amp; Methodius University, Skopje 1000, Republic of Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stankov</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Forensic Medicine, Ss. Cyril &amp; Methodius University, Skopje 1000, Republic of Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arango</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, NY 10032, USA; Division of Molecular Imaging and Neuropathology, NYS Psychiatric Institute, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dwork</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; Division of Molecular Imaging and Neuropathology, NYS Psychiatric Institute, New York, NY 10032, USA; Macedonian Academy of Sciences &amp; Arts, 2, Ss. Cyril &amp; Methodius University, Skopje 1000, Republic of Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hen</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, NY 10032, USA; Department of Neuroscience, Columbia University, New York, NY 10032, USA; Department of Pharmacology, Columbia University, New York, NY 10032, USA; Division of Integrative Neuroscience, NYS Psychiatric Institute, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>J John</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, NY 10032, USA; Division of Molecular Imaging and Neuropathology, NYS Psychiatric Institute, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH083862</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH098786</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH064168</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 MH086466</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH094888</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS090415</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH090964</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH040210</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Trends Mol Med. 2018 Jun;24(6):521-522. doi: 10.1016/j.molmed.2018.04.002.</RefSource><PMID Version="1">29699864</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2018 Dec 6;23(6):780-781. doi: 10.1016/j.stem.2018.11.006.</RefSource><PMID Version="1">30526879</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2018 Dec 6;23(6):782-783. doi: 10.1016/j.stem.2018.10.025.</RefSource><PMID Version="1">30526880</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="Y">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ki-67</Keyword><Keyword MajorTopicYN="N">NeuN</Keyword><Keyword MajorTopicYN="N">PSA-NCAM</Keyword><Keyword MajorTopicYN="N">Sox2</Keyword><Keyword MajorTopicYN="N">dentate gyrus</Keyword><Keyword MajorTopicYN="N">doublecortin</Keyword><Keyword MajorTopicYN="N">granule cells</Keyword><Keyword MajorTopicYN="N">nestin</Keyword><Keyword MajorTopicYN="N">neural progenitor</Keyword><Keyword MajorTopicYN="N">volume</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29625071</ArticleId><ArticleId IdType="mid">NIHMS954375</ArticleId><ArticleId IdType="pmc">PMC5957089</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2018.03.015</ArticleId><ArticleId IdType="pii">S1934-5909(18)30121-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aimone JB, Deng W, Gage FH. Resolving new memories: a critical look at the dentate gyrus, adult neurogenesis, and pattern separation. Neuron. 2011;70:589&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240575</ArticleId><ArticleId IdType="pubmed">21609818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Abdallah NM, Slomianka L, Lipp HP. Reversible effect of X-irradiation on proliferation, neurogenesis, and cell death in the dentate gyrus of adult mice. Hippocampus. 2007;17:1230&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">17764075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann O, Liebl J, Bernard S, Alkass K, Yeung MS, Steier P, Kutschera W, Johnson L, Land&#xe9;n M, Druid H, et al. The age of olfactory bulb neurons in humans. Neuron. 2012;74:634&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">22632721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann O, Spalding KL, Fris&#xe9;n J. Adult Neurogenesis in Humans. Cold Spring Harb. Perspect. Biol. 2015;7:a018994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4484963</ArticleId><ArticleId IdType="pubmed">26134318</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, John Mann J, Arango V. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology. 2009;34:2376&#x2013;2389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743790</ArticleId><ArticleId IdType="pubmed">19606083</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Hen R, Underwood MD, Rosoklija GB, Dwork AJ, Mann JJ, Arango V. Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biol. Psychiatry. 2012;72:562&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3438317</ArticleId><ArticleId IdType="pubmed">22652019</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Santiago AN, Hen R, Dwork AJ, Rosoklija GB, Tamir H, Arango V, John Mann J. Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. Neuropsychopharmacology. 2013;38:1068&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629406</ArticleId><ArticleId IdType="pubmed">23303074</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Butt TH, Santiago AN, Tamir H, Dwork AJ, Rosoklija GB, Arango V, Hen R, Mann JJ. Benzodiazepines and the potential trophic effect of antidepressants on dentate gyrus cells in mood disorders. Int. J. Neuropsychopharmacol. 2014;17:1923&#x2013;1933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4374628</ArticleId><ArticleId IdType="pubmed">24969726</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaguidi MA, Wheeler MA, Shapiro JS, Stadel RP, Sun GJ, Ming GL, Song H. In vivo clonal analysis reveals self-renewing and multipotent adult neural stem cell characteristics. Cell. 2011;145:1142&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124562</ArticleId><ArticleId IdType="pubmed">21664664</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, Hoffmann T, Meyer A, Durieux S, Koel-Simmelink MA, Orth M, Scheltens P, Lues I, Teunissen CE. Glutaminyl cyclase activity correlates with levels of Ab peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer&#x2019;s disease patients. Alzheimers Res. Ther. 2017;9:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5461753</ArticleId><ArticleId IdType="pubmed">28587659</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amour KA, Gage FH. Genetic and functional differences between multipotent neural and pluripotent embryonic stem cells. Proc. Natl. Acad. Sci. USA. 2003;100(Suppl 1):11866&#x2013;11872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC304100</ArticleId><ArticleId IdType="pubmed">12923297</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty AM, Bender AR, Raz N, Ofen N. Age differences in hippocampal subfield volumes from childhood to late adulthood. Hippocampus. 2016;26:220&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718822</ArticleId><ArticleId IdType="pubmed">26286891</ArticleId></ArticleIdList></Reference><Reference><Citation>Dranovsky A, Picchini AM, Moadel T, Sisti AC, Yamada A, Kimura S, Leonardo ED, Hen R. Experience dictates stem cell fate in the adult hippocampus. Neuron. 2011;70:908&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124009</ArticleId><ArticleId IdType="pubmed">21658584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekstrand J, Hellsten J, Tingstr&#xf6;m A. Environmental enrichment, exercise and corticosterone affect endothelial cell proliferation in adult rat hippocampus and prefrontal cortex. Neurosci. Lett. 2008;442:203&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">18625288</ArticleId></ArticleIdList></Reference><Reference><Citation>Encinas JM, Michurina TV, Peunova N, Park JH, Tordo J, Peterson DA, Fishell G, Koulakov A, Enikolopov G. Division-coupled astrocytic differentiation and age-related depletion of neural stem cells in the adult hippocampus. Cell Stem Cell. 2011;8:566&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286186</ArticleId><ArticleId IdType="pubmed">21549330</ArticleId></ArticleIdList></Reference><Reference><Citation>Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 1976;33:766&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">938196</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM, et al. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci. USA. 2011;108:3017&#x2013;3022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041121</ArticleId><ArticleId IdType="pubmed">21282661</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, Perfilieva E, Bj&#xf6;rk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH. Neurogenesis in the adult human hippocampus. Nat. Med. 1998;4:1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Reeves AJ, Fallah M, Tanapat P, Gross CG, Fuchs E. Hippocampal neurogenesis in adult Old World primates. Proc. Natl. Acad. Sci. USA. 1999;96:5263&#x2013;5267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21852</ArticleId><ArticleId IdType="pubmed">10220454</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding AJ, Halliday GM, Kril JJ. Variation in hippocampal neuron number with age and brain volume. Cereb. Cortex. 1998;8:710&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">9863698</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison PJ, Heath PR, Eastwood SL, Burnet PWJ, McDonald B, Pearson RCA. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci. Lett. 1995;200:151&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">9064599</ArticleId></ArticleIdList></Reference><Reference><Citation>Head D, Snyder AZ, Girton LE, Morris JC, Buckner RL. Frontal-hippocampal double dissociation between normal aging and Alzheimer&#x2019;s disease. Cereb. Cortex. 2005;15:732&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">15371293</ArticleId></ArticleIdList></Reference><Reference><Citation>Heine VM, Zareno J, Maslam S, Jo&#xeb;ls M, Lucassen PJ. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur. J. Neurosci. 2005;21:1304&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15813940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho NF, Hooker JM, Sahay A, Holt DJ, Roffman JL. In vivo imaging of adult human hippocampal neurogenesis: progress, pitfalls and promise. Mol. Psychiatry. 2013;18:404&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711219</ArticleId><ArticleId IdType="pubmed">23439487</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Increased hippocampal neurogenesis in Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 2004;101:343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314187</ArticleId><ArticleId IdType="pubmed">14660786</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, Chen JW, Lee RT, Wagers AJ, Rubin LL. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344:630&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123747</ArticleId><ArticleId IdType="pubmed">24797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly TM, Mann JJ. Validity of DSM-III-R diagnosis by psychological autopsy: a comparison with clinician ante-mortem diagnosis. Acta Psychiatr. Scand. 1996;94:337&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">9124080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. Early determination and long-term persistence of adult-generated new neurons in the hippocampus of mice. Development. 2003;130:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">12466205</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoth R, Singec I, Ditter M, Pantazis G, Capetian P, Meyer RP, Horvat V, Volk B, Kempermann G. Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years. PLoS ONE. 2010;5:e8809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813284</ArticleId><ArticleId IdType="pubmed">20126454</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler SJ, Williams NI, Stanton GB, Cameron JL, Greenough WT. Maturation time of new granule cells in the dentate gyrus of adult macaque monkeys exceeds six months. Proc. Natl. Acad. Sci. USA. 2011;108:10326&#x2013;10331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121825</ArticleId><ArticleId IdType="pubmed">21646517</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornack DR, Rakic P. Continuation of neurogenesis in the hippocampus of the adult macaque monkey. Proc. Natl. Acad. Sci. USA. 1999;96:5768&#x2013;5773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21935</ArticleId><ArticleId IdType="pubmed">10318959</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuner B, Kozorovitskiy Y, Gross CG, Gould E. Diminished adult neurogenesis in the marmoset brain precedes old age. Proc. Natl. Acad. Sci. USA. 2007;104:17169&#x2013;17173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040400</ArticleId><ArticleId IdType="pubmed">17940008</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis DA. The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology. 2002;26:143&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790510</ArticleId></ArticleIdList></Reference><Reference><Citation>Louissaint A, Jr, Rao S, Leventhal C, Goldman SA. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron. 2002;34:945&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086642</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, D&#xfc;zel S, Goerke M, Becke A, Sobieray U, Neumann K, L&#xf6;vden M, Lindenberger U, B&#xe4;ckman L, Braun-Dullaeus R, et al. Vascular hippocampal plasticity after aerobic exercise in older adults. Mol. Psychiatry. 2015;20:585&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311366</ArticleId></ArticleIdList></Reference><Reference><Citation>Malykhin NV, Bouchard TP, Camicioli R, Coupland NJ. Aging hippocampus and amygdala. Neuroreport. 2008;19:543&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">18388735</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganas LN, Zhang X, Li Y, Hazel RD, Smith SD, Wagshul ME, Henn F, Benveniste H, Djuric PM, Enikolopov G, Maletic-Savatic M. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. Science. 2007;318:980&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039561</ArticleId><ArticleId IdType="pubmed">17991865</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurya SK, Mishra R. Pax6 interacts with Iba1 and shows age-associated alterations in brain of aging mice. J. Chem. Neuroanat. 2017;82:60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">28476689</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann. N Y Acad. Sci. 2001;933:265&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">12000027</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokr&#xfd; J, Ehrmann J, Karbanov&#xe1; J, C&#xed;zkov&#xe1; D, Soukup T, Such&#xe1;nek J, Filip S, Kol&#xe1;r Z. Expression of intermediate filament nestin in blood vessels of neural and non-neural tissues. Acta Med. (Hradec Kralove) 2008;51:173&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">19271685</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton PR, Long JM, Lei DL, Howard V, Jucker M, Calhoun ME, Ingram DK. Age and gender effects on microglia and astrocyte numbers in brains of mice. Brain Res. 2002;956:30&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">12426043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngwenya LB, Heyworth NC, Shwe Y, Moore TL, Rosene DL. Age-related changes in dentate gyrus cell numbers, neurogenesis, and associations with cognitive impairments in the rhesus monkey. Front. Syst. Neurosci. 2015;9:102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4500920</ArticleId><ArticleId IdType="pubmed">26236203</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xed;Dh&#xfa;ill CM, Fox GB, Pittock SJ, O&#x2019;Connell AW, Murphy KJ, Regan CM. Polysialylated neural cell adhesion molecule expression in the dentate gyrus of the human hippocampal formation from infancy to old age. J. Neurosci. Res. 1999;55:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9890438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira AC, Huddleston DE, Brickman AM, Sosunov AA, Hen R, McKhann GM, Sloan R, Gage FH, Brown TR, Small SA. An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc. Natl. Acad. Sci. USA. 2007;104:5638&#x2013;5643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838482</ArticleId><ArticleId IdType="pubmed">17374720</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter LS, Chui HC, Saperia D, Athanikar J. Microangiopathy and the colocalization of heparan sulfate proteoglycan with amyloid in senile plaques of Alzheimer&#x2019;s disease. Brain Res. 1990;508:13&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">2140065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramm P, Couillard-Despres S, Pl&#xf6;tz S, Rivera FJ, Krampert M, Lehner B, Kremer W, Bogdahn U, Kalbitzer HR, Aigner L. A nuclear magnetic resonance biomarker for neural progenitor cells: is it all neurogenesis? Stem Cells. 2009;27:420&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">18988707</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards BA, Frankland PW. The Persistence and Transience of Memory. Neuron. 2017;94:1071&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">28641107</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A, Pickar D, Linnoila M, Doran AR, Paul SM. Cerebrospinal fluid monoamine and monoamine metabolite levels and the dexamethasone suppression test in depression. Relationship to life events. Arch. Gen. Psychiatry. 1986;43:356&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">2420302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahay A, Scobie KN, Hill AS, O&#x2019;Carroll CM, Kheirbek MA, Burghardt NS, Fenton AA, Dranovsky A, Hen R. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature. 2011;472:466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084370</ArticleId><ArticleId IdType="pubmed">21460835</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi F, Kovacs K, Cusimano MD, Horvath E, Bell CD, Rotondo F, Scheithauer BW. Immunohistochemical expression of nestin in adenohypophysial vessels during development of pituitary infarction. J. Neurosurg. 2008;108:118&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">18173320</ArticleId></ArticleIdList></Reference><Reference><Citation>Saravia F, Beauquis J, Pietranera L, De Nicola AF. Neuroprotective effects of estradiol in hippocampal neurons and glia of middle age mice. Psychoneuroendocrinology. 2007;32:480&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">17459595</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloesser RJ, Lehmann M, Martinowich K, Manji HK, Herkenham M. Environmental enrichment requires adult neurogenesis to facilitate the recovery from psychosocial stress. Mol. Psychiatry. 2010;15:1152&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990187</ArticleId><ArticleId IdType="pubmed">20308988</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 2000;182:311&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">10653597</ArticleId></ArticleIdList></Reference><Reference><Citation>Simi&#x107; G, Kostovi&#x107; I, Winblad B, Bogdanovi&#x107; N. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer&#x2019;s disease. J. Comp. Neurol. 1997;379:482&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">9067838</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J, Christian KM, Ming GL, Song H. Modification of hippocampal circuitry by adult neurogenesis. Dev. Neurobiol. 2012;72:1032&#x2013;1043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710549</ArticleId><ArticleId IdType="pubmed">22354697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrells SF, Paredes MF, Cebrian-Silla A, Sandoval K, Qi D, Kelley KW, James D, Mayer S, Chang J, Auguste KI, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature. 2018;555:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6179355</ArticleId><ArticleId IdType="pubmed">29513649</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Bostr&#xf6;m E, Westerlund I, Vial C, Buchholz BA, et al. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013;153:1219&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394608</ArticleId><ArticleId IdType="pubmed">23746839</ArticleId></ArticleIdList></Reference><Reference><Citation>Thored P, Wood J, Arvidsson A, Cammenga J, Kokaia Z, Lindvall O. Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke. 2007;38:3032&#x2013;3039.</Citation><ArticleIdList><ArticleId IdType="pubmed">17901386</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Census Bureau. The Nation&#x2019;s Older Population Is Still Growing, Census Bureau Reports. Release Number: CB17-100. 2017  https://www.census.gov/newsroom/press-releases/2017/cb17-100.html.</Citation></Reference><Reference><Citation>Vagnucci AH, Jr, Li WW. Alzheimer&#x2019;s disease and angiogenesis. Lancet. 2003;361:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598159</ArticleId></ArticleIdList></Reference><Reference><Citation>Varbanov H, Dityatev A. Regulation of extrasynaptic signaling by polysialylated NCAM: Impact for synaptic plasticity and cognitive functions. Mol. Cell. Neurosci. 2017;81:12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">27865768</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner-Schmidt JL, Duman RS. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc. Natl. Acad. Sci. USA. 2007;104:4647&#x2013;4652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838655</ArticleId><ArticleId IdType="pubmed">17360578</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ. New stereological methods for counting neurons. Neurobiol. Aging. 1993;14:275&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">8367009</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Gundersen HJ. Unbiased stereological estimation of the number of neurons in the human hippocampus. J. Comp. Neurol. 1990;296:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">2358525</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer&#x2019;s disease. Lancet. 1994;344:769&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MV, Hen R. Functional dissociation of adult-born neurons along the dorsoventral axis of the dentate gyrus. Hippocampus. 2014;24:751&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222246</ArticleId><ArticleId IdType="pubmed">24550158</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Goh A, Chen SH, Qiu A. Evolution of hippocampal shapes across the human lifespan. Hum. Brain Mapp. 2013;34:3075&#x2013;3085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870440</ArticleId><ArticleId IdType="pubmed">22815197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu DX, Di Giorgio FP, Yao J, Marchetto MC, Brennand K, Wright R, Mei A, McHenry L, Lisuk D, Grasmick JM, et al. Modeling hippocampal neurogenesis using human pluripotent stem cells. Stem Cell Reports. 2014;2:295&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964286</ArticleId><ArticleId IdType="pubmed">24672753</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29513649</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>555</Volume><Issue>7696</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults.</ArticleTitle><Pagination><StartPage>377</StartPage><EndPage>381</EndPage><MedlinePgn>377-381</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature25975</ELocationID><Abstract><AbstractText>New neurons continue to be generated in the subgranular zone of the dentate gyrus of the adult mammalian hippocampus. This process has been linked to learning and memory, stress and exercise, and is thought to be altered in neurological disease. In humans, some studies have suggested that hundreds of new neurons are added to the adult dentate gyrus every day, whereas other studies find many fewer putative new neurons. Despite these discrepancies, it is generally believed that the adult human hippocampus continues to generate new neurons. Here we show that a defined population of progenitor cells does not coalesce in the subgranular zone during human fetal or postnatal development. We also find that the number of proliferating progenitors and young neurons in the dentate gyrus declines sharply during the first year of life and only a few isolated young neurons are observed by 7 and 13 years of age. In adult patients with epilepsy and healthy adults (18-77 years; n&#x2009;=&#x2009;17 post-mortem samples from controls; n&#x2009;=&#x2009;12 surgical resection samples from patients with epilepsy), young neurons were not detected in the dentate gyrus. In the monkey (Macaca mulatta) hippocampus, proliferation of neurons in the subgranular zone was found in early postnatal life, but this diminished during juvenile development as neurogenesis decreased. We conclude that recruitment of young neurons to the primate hippocampus decreases rapidly during the first years of life, and that neurogenesis in the dentate gyrus does not continue, or is extremely rare, in adult humans. The early decline in hippocampal neurogenesis raises questions about how the function of the dentate gyrus differs between humans and other species in which adult hippocampal neurogenesis is preserved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sorrells</LastName><ForeName>Shawn F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Mercedes F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cebrian-Silla</LastName><ForeName>Arantxa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratorio de Neurobiolog&#xed;a Comparada, Instituto Cavanilles, Universidad de Valencia, CIBERNED, Valencia, 46980, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandoval</LastName><ForeName>Kadellyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Dashi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Medical Neurobiology and Institutes of Brain Science, Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Kevin W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>David Geffen School of Medicine, Department of Neurosurgery, Intellectual Development and Disabilities Research Center, University of California Los Angeles, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auguste</LastName><ForeName>Kurtis I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Edward F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Antonio J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Unidad de Cirug&#xed;a de la Epilepsia, Hospital Universitario La Fe, Valencia 46026, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kriegstein</LastName><ForeName>Arnold R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathern</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oldham</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Verdugo</LastName><ForeName>Jose Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Laboratorio de Neurobiolog&#xed;a Comparada, Instituto Cavanilles, Universidad de Valencia, CIBERNED, Valencia, 46980, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhengang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Medical Neurobiology and Institutes of Brain Science, Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez-Buylla</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 MH108898</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007618</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH113896</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS091537</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS083823</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 MH103003</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS083823</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS083513</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS028478</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2018 Mar 15;555(7696):315-316. doi: 10.1038/d41586-018-02629-3.</RefSource><PMID Version="1">29542697</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2018 May;19(5):252-253. doi: 10.1038/nrn.2018.34.</RefSource><PMID Version="1">29618803</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Mol Med. 2018 Jun;24(6):521-522. doi: 10.1016/j.molmed.2018.04.002.</RefSource><PMID Version="1">29699864</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurosurgery. 2018 Sep 1;83(3):E133-E137. doi: 10.1093/neuros/nyy252.</RefSource><PMID Version="1">29873751</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Epilepsy Curr. 2018 Sep-Oct;18(5):329-331. doi: 10.5698/1535-7597.18.5.329.</RefSource><PMID Version="1">30464737</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mol Psychiatry. 2020 Oct;25(10):2207-2209. doi: 10.1038/s41380-018-0337-5.</RefSource><PMID Version="1">30617274</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2019 Mar;567(7749):433. doi: 10.1038/d41586-019-00891-7.</RefSource><PMID Version="1">30911155</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>ACS Chem Neurosci. 2019 May 15;10(5):2091-2093. doi: 10.1021/acschemneuro.9b00196.</RefSource><PMID Version="1">31007011</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuroscientist. 2019 Aug;25(4):285. doi: 10.1177/1073858419859505.</RefSource><PMID Version="1">31514645</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047109" MajorTopicYN="N">Fetal Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="Y">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing financial interests.</b> The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29513649</ArticleId><ArticleId IdType="mid">NIHMS940823</ArticleId><ArticleId IdType="pmc">PMC6179355</ArticleId><ArticleId IdType="doi">10.1038/nature25975</ArticleId><ArticleId IdType="pii">nature25975</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altman J, Das GD. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol. 1965;124:319&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">5861717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornack DR, Rakic P. Continuation of neurogenesis in the hippocampus of the adult macaque monkey. Proc Natl Acad Sci U S A. 1999;96:5768&#x2013;5773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21935</ArticleId><ArticleId IdType="pubmed">10318959</ArticleId></ArticleIdList></Reference><Reference><Citation>Seri B, Garc&#xed;a-Verdugo JM, McEwen BS, Alvarez-Buylla A. Astrocytes give rise to new neurons in the adult mammalian hippocampus. J Neurosci. 2001;21:7153&#x2013;7160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762987</ArticleId><ArticleId IdType="pubmed">11549726</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, et al. Functional neurogenesis in the adult hippocampus. Nature. 2002;415:1030&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Patzke N, et al. In contrast to many other mammals, cetaceans have relatively small hippocampi that appear to lack adult neurogenesis. Brain Struct Funct. 2015;220:361&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8734557</ArticleId><ArticleId IdType="pubmed">24178679</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. Nature. 1997;386:493&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087407</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci. 1999;2:266&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195220</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugert S, et al. Quiescent and active hippocampal neural stem cells with distinct morphologies respond selectively to physiological and pathological stimuli and aging. Cell Stem Cell. 2010;6:445&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">20452319</ArticleId></ArticleIdList></Reference><Reference><Citation>Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003;28:1562&#x2013;1571.</Citation><ArticleIdList><ArticleId IdType="pubmed">12838272</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill AS, Sahay A, Hen R. Increasing Adult Hippocampal Neurogenesis is Sufficient to Reduce Anxiety and Depression-Like Behaviors. Neuropsychopharmacology. 2015;40:2368&#x2013;2378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4538351</ArticleId><ArticleId IdType="pubmed">25833129</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, et al. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013;153:1219&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394608</ArticleId><ArticleId IdType="pubmed">23746839</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis CV, Suh LS, Rodriguez ML, Kril JJ, Sutherland GT. Human adult neurogenesis across the ages: An immunohistochemical study. Neuropathol Appl Neurobiol. 2016;42:621&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5125837</ArticleId><ArticleId IdType="pubmed">27424496</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoth R, et al. Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years. PLoS One. 2010;5:e8809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813284</ArticleId><ArticleId IdType="pubmed">20126454</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, et al. Developmental profile of neurogenesis in prenatal human hippocampus: an immunohistochemical study. Int J Dev Neurosci. 2014;38:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24999120</ArticleId></ArticleIdList></Reference><Reference><Citation>Venere M, et al. Sox1 marks an activated neural stem/progenitor cell in the hippocampus. Development. 2012;139:3938&#x2013;3949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472585</ArticleId><ArticleId IdType="pubmed">22992951</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh H, et al. In vivo fate analysis reveals the multipotent and self-renewal capacities of Sox2+ neural stem cells in the adult hippocampus. Cell Stem Cell. 2007;1:515&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2185820</ArticleId><ArticleId IdType="pubmed">18371391</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner B, et al. Type-2 cells as link between glial and neuronal lineage in adult hippocampal neurogenesis. Glia. 2006;54:805&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">16958090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanai N, et al. Corridors of migrating neurons in the human brain and their decline during infancy. Nature. 2011;478:382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197903</ArticleId><ArticleId IdType="pubmed">21964341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, et al. Identification and characterization of neuroblasts in the subventricular zone and rostral migratory stream of the adult human brain. Cell Res. 2011;21:1534&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365638</ArticleId><ArticleId IdType="pubmed">21577236</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, et al. Hippocampal neurogenesis in adult Old World primates. Proc Natl Acad Sci U S A. 1999;96:5263&#x2013;5267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21852</ArticleId><ArticleId IdType="pubmed">10220454</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornack DR, Rakic P. The generation, migration, and differentiation of olfactory neurons in the adult primate brain. Proc Natl Acad Sci U S A. 2001;98:4752&#x2013;4757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31906</ArticleId><ArticleId IdType="pubmed">11296302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama T, Osumi N, Katsuyama Y. The germinal matrices in the developing dentate gyrus are composed of neuronal progenitors at distinct differentiation stages. Dev Dyn. 2013;242:1442&#x2013;1453.</Citation><ArticleIdList><ArticleId IdType="pubmed">24038449</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman J, Bayer SA. Mosaic organization of the hippocampal neuroepithelium and the multiple germinal sources of dentate granule cells. J Comp Neurol. 1990;301:325&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">2262594</ArticleId></ArticleIdList></Reference><Reference><Citation>Komitova M, Eriksson PS. Sox-2 is expressed by neural progenitors and astroglia in the adult rat brain. Neurosci Lett. 2004;369:24&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">15380301</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Breunig JJ, Arellano JI, Macklis JD, Rakic P. Everything that glitters isn&#x2019;t gold: a critical review of postnatal neural precursor analyses. Cell Stem Cell. 2007;1:612&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">18371403</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E. How widespread is adult neurogenesis in mammals. Nat Rev Neurosci. 2007;8:481&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">17514200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews KJ, et al. Evidence for reduced neurogenesis in the aging human hippocampus despite stable stem cell markers. Aging Cell. 2017 doi: 10.1111/acel.12641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12641</ArticleId><ArticleId IdType="pmc">PMC5595679</ArticleId><ArticleId IdType="pubmed">28766905</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahrner A, et al. Granule cell dispersion is not accompanied by enhanced neurogenesis in temporal lobe epilepsy patients. Exp Neurol. 2007;203:320&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">17049346</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckenhoff MF, Rakic P. Nature and fate of proliferative cells in the hippocampal dentate gyrus during the life span of the rhesus monkey. J Neurosci. 1988;8:2729&#x2013;2747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569394</ArticleId><ArticleId IdType="pubmed">3411351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathern GW, et al. Seizures Decrease Postnatal Neurogenesis and Granule Cell Development in the Human Fascia tDentata. Epilepsia. 2002;43:68&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">12121298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken TE, et al. A comprehensive transcriptional map of primate brain development. Nature. 2016;535:367&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325728</ArticleId><ArticleId IdType="pubmed">27409810</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HJ, et al. Spatio-temporal transcriptome of the human brain. Nature. 2011;478:483&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566780</ArticleId><ArticleId IdType="pubmed">22031440</ArticleId></ArticleIdList></Reference><Reference><Citation>Workman AD, Charvet CJ, Clancy B, Darlington RB, Finlay BL. Modeling transformations of neurodevelopmental sequences across mammalian species. J Neurosci. 2013;33:7368&#x2013;7383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928428</ArticleId><ArticleId IdType="pubmed">23616543</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29653606</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>535</StartPage><EndPage>562</EndPage><MedlinePgn>535-562</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2018.02.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(18)30072-4</ELocationID><Abstract><AbstractText>In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines. This unifying update is labeled a "research framework" because its intended use is for observational and interventional research, not routine clinical care. In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in&#xa0;vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct. The research framework focuses on the diagnosis of AD with biomarkers in living persons. Biomarkers are grouped into those of &#x3b2; amyloid deposition, pathologic tau, and neurodegeneration [AT(N)]. This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures. The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available. We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures. However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six-stage numeric scheme. It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms. We appreciate the concern that this biomarker-based research framework has the potential to be misused. Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice. Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers. There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document). Thus, biomarker-based research should not be considered a template for all research into age-related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study. Importantly, this framework should be examined in diverse populations. Although it is possible that &#x3b2;-amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia. We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia. This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address: jack.clifford@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Medical &amp; Scientific Relations, Alzheimer's Association, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>Billy</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Office of Drug Evaluation, FDA, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haeberlein</LastName><ForeName>Samantha Budd</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Public Health and Neuroscience, University of California Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Prothena Biosciences, Inc., San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation and Hospital Clinic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Standford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phelps</LastName><ForeName>Creighton</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Formerly at National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rankin</LastName><ForeName>Katherine P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Molecular Imaging, Austin Health, University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, VU University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siemers</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Formerly at Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Heather M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Medical &amp; Scientific Relations, Alzheimer's Association, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Contributors</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Alzheimers Dement. 2018 Apr;14(4):576-578. doi: 10.1016/j.jalz.2018.03.004.</RefSource><PMID Version="1">29653608</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054561" MajorTopicYN="N">National Institute on Aging (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease diagnosis</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease imaging</Keyword><Keyword MajorTopicYN="N">Amyloid PET</Keyword><Keyword MajorTopicYN="N">Biomarkers Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">CSF biomarkers Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Preclinical Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Tau PET</Keyword></KeywordList><CoiStatement>The authors&#x2019; conflict of interest statements can be viewed online at https://doi.org/10.1016/j.jalz.2018.02.018.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Elliott</LastName><ForeName>Cerise</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Laurie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverberg</LastName><ForeName>Nina</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29653606</ArticleId><ArticleId IdType="mid">NIHMS960157</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pii">S1552-5260(18)30072-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging and the Alzheimer&#x2019;s Assocation Workgroup. Alzheimers Dement. 2011;7:263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging and Alzheimer&#x2019;s Association Workgroup. Alzheimers Dement. 2011;7:270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Assocation workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carillo M, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:257&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096735</ArticleId><ArticleId IdType="pubmed">21514247</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74:807&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis of age-related cognitive decline. Neurology. 2010;75:1070&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942064</ArticleId><ArticleId IdType="pubmed">20844243</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ, Morris JC, et al. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology. 2014;83:434&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132573</ArticleId><ArticleId IdType="pubmed">24951474</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TL, Blazey T, Jack CR, Jr, Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2013;110:E4502&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 2015;72:316&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6 226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer&#x2019;s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417794</ArticleId><ArticleId IdType="pubmed">27012484</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131:1630&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of Florbetapir-PET for Imaging B-Amyloid Pathology. JAMA. 2011;305:275&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer&#x2019;s disease spectrum. Brain. 2015;138:1370&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407190</ArticleId><ArticleId IdType="pubmed">25805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer&#x2019;s disease: Specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement. 2015;11:975&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">26141264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic M, Abrahamson E, Kofler J, Paljug W, Debnath ML, Price J, et al.   Neuropathology and biochemical correlations of [F-18]AV-1451 and [C-11]PiB PET imaging in a subject with Alzheimer&#x2019;s disease. In: Johnson KA, Jagust WE, Klunk WE, Mathis CA, editors. 11th Human Amyloid Imaging. Miami, Florida: 2017. p. 157. Available at:  www.worldeventsforum.com/hai.</Citation></Reference><Reference><Citation>Seo SW, Ayakta N, Grinberg LT, Villeneuve S, Lehmann M, Reed B, et al. Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. Neuroimage Clin. 2017;13:130&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5144753</ArticleId><ArticleId IdType="pubmed">27981028</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer&#x2019;s disease. Trends Pharmacol Sci. 2015;36:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">25496902</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2014;41:816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">24514874</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-Tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimer&#x2019;s disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J Neurosci. 2013;33:5553&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3687777</ArticleId><ArticleId IdType="pubmed">23536070</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, Weigand SD, Vemuri R, Lowe VJ, et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol. 2013;73:472&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660408</ArticleId><ArticleId IdType="pubmed">23424032</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12:957&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, Blankenstein MA, et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. 2013;81:1409&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">24049134</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology. 2015;84:508&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336071</ArticleId><ArticleId IdType="pubmed">25568301</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC, Bourgeat P, Dore V, Savage G, Brown B, Laws S, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer&#x2019;s disease pathophysiology (SNAP) or Alzheimer&#x2019;s disease pathology: a longitudinal study. Lancet Neurol. 2016;15:1044&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27450471</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging. 2016;44:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4913039</ArticleId><ArticleId IdType="pubmed">27318129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, Amariglio R, et al. Heterogeneity in suspected non-Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol. 2016;73:1185&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5266522</ArticleId><ArticleId IdType="pubmed">27548655</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer&#x2019;s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik PJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804562</ArticleId><ArticleId IdType="pubmed">23686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN, et al. Suspected non-AD pathology in mild cognitive impairment. Neurobiol Aging. 2015;36:3152&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641774</ArticleId><ArticleId IdType="pubmed">26422359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, et al. Longitudinal beta-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-alzheimer disease pathophysiology. JAMA Neurol. 2016;73:1192&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237381</ArticleId><ArticleId IdType="pubmed">27548756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013;70:1512&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962545</ArticleId><ArticleId IdType="pubmed">24166579</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun. 2014;2:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008258</ArticleId><ArticleId IdType="pubmed">24602322</ArticleId></ArticleIdList></Reference><Reference><Citation>Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013;80:1048&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">23390179</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W, et al. Prevalence and prognosis of Alzheimer&#x2019;s disease at the mild cognitive impairment stage. Brain. 2015;138:1327&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013930</ArticleId><ArticleId IdType="pubmed">25693589</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene JA. The abnormal and the pathological: Cholesterol, statins, and the threshold of disease. In: Tone A, Siegel Watkins E, editors. Medicating Modern America: Prescription Drugs in History. New York: University Press; 2007. pp. 193&#x2013;228.</Citation></Reference><Reference><Citation>Karlawish J. Desktop medicine. JAMA. 2010;304:2061&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">21063017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3 111 cm 33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="pubmed">22133718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol. 2013;9:54&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643203</ArticleId><ArticleId IdType="pubmed">23183885</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, et al. Alzheimer&#x2019;s disease is not &#x201c;brain aging&#x201d;: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121:571&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179861</ArticleId><ArticleId IdType="pubmed">21516511</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, Blacker D, Gomez-Isla T, Betensky RA, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol. 2014;75:597&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016558</ArticleId><ArticleId IdType="pubmed">24585367</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Leurgans S, Aggarwal NT, Shah RC, Arvanitakis Z, James BD, et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85:528&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4540250</ArticleId><ArticleId IdType="pubmed">26180136</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370:322&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370:311&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5240413</ArticleId><ArticleId IdType="pubmed">28093088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9:414&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164552</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer&#x2019;s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800236</ArticleId><ArticleId IdType="pubmed">23375563</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Kennedy KM, Devous MD, Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78:387&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280058</ArticleId><ArticleId IdType="pubmed">22302550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64:388&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648510</ArticleId><ArticleId IdType="pubmed">18991338</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer&#x2019;s disease: a new lexicon. Lancet Neurol. 2010;9:1118&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid pet positivity in dementia syndromes: A meta-analysis. JAMA. 2015;313:1939&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer&#x2019;s disease. Neurobiol Aging. 1991;12:295&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BE, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Jacqmin-Gadda H, Le Goff M, Thomas RG, Raman R, Gamst AC, et al. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. 2014;10:S400&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169767</ArticleId><ArticleId IdType="pubmed">24656849</ArticleId></ArticleIdList></Reference><Reference><Citation>van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, et al. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013;9:481&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23232269</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer&#x2019;s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer&#x2019;s disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">22628162</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer&#x2019;s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129:3035&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, et al. Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease. Sci Transl Med. 2016;8 338ra66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Schultz AP, Marshall GA, Boot B, Gomez-Isla T, Dumurgier J, et al. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology. 2016;87:920&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035159</ArticleId><ArticleId IdType="pubmed">27473132</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Seab JP, Jagust WJ, Wong ST, Roos MS, Reed BR, Budinger TF. Quantitative NMR measurements of hippocampal atrophy in Alzheimer&#x2019;s disease. Magn Reson Med. 1988;8:200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3210957</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Cram WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer&#x2019;s disease with voxel-compression mapping of serial magnetic resonance images. Lancet. 2001;358:201&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476837</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer&#x2019;s disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Besson FL, La Joie R, Doeuvre L, Gaubert M, Mezenge F, Egret S, et al. Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer&#x2019;s disease. J Neurosci. 2015;35:10402&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605120</ArticleId><ArticleId IdType="pubmed">26203136</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer&#x2019;s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, Weigand SD, Vemuri R, Lowe VJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-amyloidosis. JAMA Neurol. 2013;70:1030&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884555</ArticleId><ArticleId IdType="pubmed">23797806</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuro-pathol. 2013;126:365&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23900711</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, et al. Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol. 2013;74:905&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">24448836</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2013;40:104&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510420</ArticleId><ArticleId IdType="pubmed">22961445</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15:169&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584433</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 2007;78:461&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117838</ArticleId><ArticleId IdType="pubmed">17098843</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA. 2017;317:2305&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73:85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710552</ArticleId><ArticleId IdType="pubmed">26595683</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KV, Rentz DM, Mormino EC, Schultz AP, Amariglio RE, Quiroz Y, et al. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017;88:1431&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5386436</ArticleId><ArticleId IdType="pubmed">28283594</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabrier MA, Blurton-Jones M, Agazaryan AA, Nerhus JL, Martinez-Coria H, Laferla FM. Soluble abeta promotes wild-type tau pathology in vivo. J Neurosci. 2012;32:17345&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586232</ArticleId><ArticleId IdType="pubmed">23197725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, Snowdon DA, Markesbery WR. The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord. 2009;23:152&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752689</ArticleId><ArticleId IdType="pubmed">19484916</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, et al. A data-driven model of biomarker changes in sporadic Alzheimer&#x2019;s disease. Brain. 2014;137:2564&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132648</ArticleId><ArticleId IdType="pubmed">25012224</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, Jasielec MS, Weng H, Fagan AM, Benzinger TL, Head D, et al. Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology. 2016;86:1499&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836885</ArticleId><ArticleId IdType="pubmed">27009258</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Horng A, Fero A, Jagust WJ. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology. 2016;86:1377&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4831042</ArticleId><ArticleId IdType="pubmed">26968515</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69:98&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22213792</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measure and magnetic resonance imaging atophy both predict time-to-progression from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2010;133:3336&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer&#x2019;s disease. Alzheimers Dement. 2017;13:205&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Cohen A, Bi W, Weissfeld L, Aizenstein H, McDade E, et al. Alzheimer&#x2019;s Association International Conference 2012. Vancouver, British Columbia, Canada: Alzheimer&#x2019;s Associaton; 2012. Why we need two cutoffs for amyloid-imaging: Early versus Alzheimer&#x2019;s-like amyloid-positivity; pp. P453&#x2013;4.</Citation></Reference><Reference><Citation>Denoix P. Enquete permanente dans les centres anticancereux. Bull Inst Natl Hyg. 1946;1:12&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20986738</ArticleId></ArticleIdList></Reference><Reference><Citation>Brierly JD, Gospodarowicz MK, Wittekind C. 2017 Chichester. 8. West Sussex, UK: Wiley-Blackwell; 2017. TNM Classification of Malignant Tumours, 8th Edition.</Citation></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer&#x2019;s disease. Lancet Neurol. 2003;2:605&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139:2249&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958902</ArticleId><ArticleId IdType="pubmed">27286736</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol. 2013;74:826&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Minthon L, Blennow K, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85:1240&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4607601</ArticleId><ArticleId IdType="pubmed">26354982</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos P, Kriett L, Haller B, Klupp E, Gray K, Grimmer T, et al. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer&#x2019;s disease. Alzheimers Dement. 2014;10:684&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24857233</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer&#x2019;s disease. Brain. 2015;138:772&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339769</ArticleId><ArticleId IdType="pubmed">25541191</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain. 2016;139:1226&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, et al. Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Ann Neurol. 2016;80:379&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016232</ArticleId><ArticleId IdType="pubmed">27398953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Scholl M, Strandberg O, Smith R, Palmqvist S, Insel PS, et al. 18F&#x2013;AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer&#x2019;s disease. EMBO Mol Med. 2017;9:1212&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>Makaretz SJ, Quimby M, Collins J, Makris N, McGinnis S, Schultz A, et al. Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2017 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964045</ArticleId><ArticleId IdType="pubmed">28986472</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4906968</ArticleId><ArticleId IdType="pubmed">27296779</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea NV, Anton-Fernandez A, et al. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol. 2017;81:117&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5319193</ArticleId><ArticleId IdType="pubmed">27997036</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, Siao Tick Chong M, Anton-Fernandez A, Verwer EE, Saez-Calveras N, Meltzer AC, et al. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. Acta Neuropathol. 2017;134:619&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5772971</ArticleId><ArticleId IdType="pubmed">28612291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80:247&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Shultz A, Betensky RA, Becker JA, Sepulcre J, Rentz DM, et al. Tau positron emission tomographic imaging in aging and early Alzheimer&#x2019;s disease. Ann Neurol. 2016;79:110&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl M, Lockhart SN, Schonhaut DR, O&#x2019;Neil JP, Janabi M, Ossenkoppele R, et al. PET Imaging of tau deposition in the aging human brain. Neuron. 2016;89:971&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe V, Wiste HJ, Pandey M, Senjem M, Boeve B, Josephs KA, et al. Tau-PET imaging with AV-1451 in Alzheimer&#x2019;s disease. In: Johnson KA, Jagust W, Klunk W, Mathis C, editors. Human Amyloid Imaging. Miami Beach, FL: World Events Forum, Inc; 2016. p. 114.</Citation></Reference><Reference><Citation>Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand 18F&#x2013;AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Lee SH, Lee JH, Choi Y-C, Ryu YH, et al. Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer&#x2019;s disease. Neurobiol Aging. 2017;53:103&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">28254589</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips JS, Das SR, McMillan CT, Irwin DJ, Roll EE, Da Re F, et al. Tau PET imaging predicts cognition in atypical variants of Alzheimer&#x2019;s disease. Human Brain Mapping. 2018;39:691&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5764792</ArticleId><ArticleId IdType="pubmed">29105977</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl M, Ossenkoppele R, Strandberg O, Palmqvist S, Jogi J, Ohlsson T, et al. Distinct 18F&#x2013;AV-1451 tau PET retention patterns in early- and late-onset Alzheimer&#x2019;s disease. Brain. 2017;140:2286&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">29050382</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrallah IM, Chen YJ, Hsieh MK, Philips JS, Ternes K, Stockbower G, et al. 18F&#x2013;Flortaucipir PET-MRI correlations in non-amnestic and amnestic variants of Alzheimer Disease. J Nucl Med. 2018;59:299&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348438</ArticleId><ArticleId IdType="pubmed">28747523</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, et al. Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 2017;74:427&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470368</ArticleId><ArticleId IdType="pubmed">28241163</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks SM, Lockhart SN, Baker SL, Jagust WJ. Tau and beta-amyloid are associated with medial temporal lobe structure, function, and memory encoding in normal aging. J Neurosci. 2017;37:3192&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373113</ArticleId><ArticleId IdType="pubmed">28213439</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD, Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">27230925</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">14706948</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26:231&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">8748926</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006;67:1600&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101890</ArticleId></ArticleIdList></Reference><Reference><Citation>Skillback T, Rosen C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol. 2014;71:476&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">24566866</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Otto M, Teipel SJ, Zinkowski R, Blennow K, DeBernardis J, et al. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging. 2006;27:10&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298235</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, et al. Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50&#x2013;95 years: a cross-sectional study. Lancet Neurol. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516534</ArticleId><ArticleId IdType="pubmed">28456479</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer&#x2019;s disease. Neuroscience. 2000;95:721&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10670438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L, et al. Correlates of hippocampal neuron number in Alzheimer&#x2019;s disease and ischemic vascular dementia. Ann Neurol. 2005;57:896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851673</ArticleId><ArticleId IdType="pubmed">15929035</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkhof F, Polvikoski TM, van Straaten EC, Kalaria RN, Sulkava R, Aronen HJ, et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology. 2007;69:1521&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923614</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology. 2012;79:1809&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475623</ArticleId><ArticleId IdType="pubmed">23019259</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80:1784&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mezenge F, et al. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer&#x2019;s disease. Brain. 2016;139:2528&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6276935</ArticleId><ArticleId IdType="pubmed">27357349</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BR, Lind M, Wagen A, Rembach A, Frugier TJ, Li OX, et al. Biochemically-defined pools of A&#x3b2;-amyloid in Alzheimer&#x2019;s disease: correlation with A&#x3b2;-PET imaging and a first approximation of accumulation rates of A&#x3b2;. Brain. 2017;140:1486&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28383676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72:599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490232</ArticleId><ArticleId IdType="pubmed">23109154</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62:406&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17879383</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5091047</ArticleId><ArticleId IdType="pubmed">27694152</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, An Y, Nails M, Sojkova J, Swaminathan S, Zhou Y, et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry. 2013;73:422&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535537</ArticleId><ArticleId IdType="pubmed">23022416</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer&#x2019;s disease. Biol Psychiatry. 2010;68:903&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011944</ArticleId><ArticleId IdType="pubmed">21035623</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Parbo P, Ismail R, Hansen KV, Amidi A, Marup FH, Gottrup H, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer&#x2019;s disease. Brain. 2017;140:2002&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">28575151</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo G, Veronese M, Tonietto M, Bodini B, Stankoff B, Wimberley C, et al. Generalization of endothelial modelling of TSPO PET imaging: considerations on tracer affinities. J Cereb Blood Flow Metab. 2017 271678X17742004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6501510</ArticleId><ArticleId IdType="pubmed">29135382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan-Jones WR, Surendranathan A, Passamonti L, Vazquez Rodriguez P, Arnold R, Mak E, et al. Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open. 2017;7:e013187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5223666</ArticleId><ArticleId IdType="pubmed">28064175</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer&#x2019;s disease. Brain Res. 2010;1362:13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20875798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694558</ArticleId><ArticleId IdType="pubmed">26366630</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Skillback T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73:60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624219</ArticleId><ArticleId IdType="pubmed">26524180</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, O&#x2019;Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SM, Katsins A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 1231-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">19759102</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, et al. Early and late change on the preclinical Alzheimer&#x2019;s cognitive composite in clinically normal older individuals with elevated amyloid-beta. Alzheimers Dement. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573651</ArticleId><ArticleId IdType="pubmed">28253478</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Penman AD, Catellier DJ, Coker LH, Shibata DK, Sharrett AR, et al. Vascular risk factors and longitudinal changes on brain MRI: the ARIC study. Neurology. 2011;76:1879&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115812</ArticleId><ArticleId IdType="pubmed">21543737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Klunk WE, Mathis C, Coleman RL, Price J, Becker JT, et al. Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology. 2014;83:1804&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240431</ArticleId><ArticleId IdType="pubmed">25305156</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders : DSM-5. 5. Washington, D.C.: 2013.</Citation></Reference><Reference><Citation>Reed BR, Mungas D, Farias ST, Harvey D, Beckett L, Widaman K, et al. Measuring cognitive reserve based on the decomposition of episodic memory variance. Brain. 2010;133:2196&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139935</ArticleId><ArticleId IdType="pubmed">20591858</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67:353&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074985</ArticleId><ArticleId IdType="pubmed">20373347</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Roberts RO, Lowe VJ, et al. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol. 2012;72:730&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539211</ArticleId><ArticleId IdType="pubmed">23280791</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Santa Cruz K, Hemmy LS, Woltjer R, Leverenz JB, Montine KS, et al. Ecology of the aging human brain. Arch Neurol. 2011;68:1049&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218566</ArticleId><ArticleId IdType="pubmed">21825242</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn B. Services USDoHaH, Administration FaD, (CDER) CfDEaR, (CBER) CfBEaR. Silver Spring, MD: Office of the Federal Register, National Archives and Records Administration; 2018. Early Alzheimer&#x2019;s Disease: Developing Drugs for Treatment; Draft Guidance for Industry; pp. 7060&#x2013;1.</Citation></Reference><Reference><Citation>Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7114305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684483</ArticleId><ArticleId IdType="pubmed">26096665</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer CE, Qian W, Schweizer TA, Ismail Z, Smith EE, Millikin CR, et al. Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer&#x2019;s disease. Alzheimers Dement. 2017;3:385&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651446</ArticleId><ArticleId IdType="pubmed">29067344</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease. Neuroimage. 2017;157:448&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Southekal S, Devous MD, Sr, Kennedy I, Navitsky M, Lu M, Joshi AD, et al. Flortaucipir F 18 Quantitation using a Parametric Estimate of Reference Signal Intensity (PERSI) J Nucl Med. 2017 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">29191858</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB. What is normal in normal aging? Effects of aging, amyloid and Alzheimer&#x2019;s disease on the cerebral cortex and the hippocampus. Prog Neurobiol. 2014;117:20&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4343307</ArticleId><ArticleId IdType="pubmed">24548606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron. 2013;77:219&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558930</ArticleId><ArticleId IdType="pubmed">23352159</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhovd KB, Krogsrud SK, Amlien IK, Bartsch H, Bjornerud A, Due-Tonnessen P, et al. Neurodevelopmental origins of lifespan changes in brain and cognition. Proc Natl Acad Sci USA. 2016;113:9357&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995982</ArticleId><ArticleId IdType="pubmed">27432992</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138:2020&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, Benzinger T, Devous M, Jagust W, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dementia. 2015;11:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Jack CR, Jr, Bocchetta M, Bauer C, Frederiksen KS, Liu Y, et al. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement. 2015;11:111&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4422168</ArticleId><ArticleId IdType="pubmed">25267715</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer&#x2019;s disease: an update from the Alzheimer&#x2019;s Association Global Biomarkers Consortium. Alzheimers Dement. 2013;9:137&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23274154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, et al. CSF Abeta1-42-an excellent but complicated Alzheimer&#x2019;s biomarker - a route to standardisation. Clin Chim Acta. 2017;467:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27216941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59:1152&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230690</ArticleId><ArticleId IdType="pubmed">21884802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature. 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Dage JL, Wennberg AM, Airey DC, Hagen CE, Knopman DS, Machulda MM, et al. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement. 2016;12:1226&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5148697</ArticleId><ArticleId IdType="pubmed">27436677</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18:691&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853869</ArticleId><ArticleId IdType="pubmed">19749406</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz WD, Keene CD, Hawes SE, Hubbard RA, Longstreth WT, Jr, Woltjer RL, et al. Alzheimer&#x2019;s disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging. 2017;53:83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385292</ArticleId><ArticleId IdType="pubmed">28236716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ighodaro ET, Nelson PT, Kukull WA, Schmitt FA, Abner EL, Caban-Holt A, et al. Challenges and Considerations Related to Studying Dementia in Blacks/African Americans. J Alzheimers Dis. 2017;60:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889715</ArticleId><ArticleId IdType="pubmed">28731440</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles &#x201c;do count&#x201d; when staging disease severity. J Neuropathol Exp Neurol. 2007;66:1136&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034246</ArticleId><ArticleId IdType="pubmed">18090922</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O&#x2019;Brien RJ. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol. 2008;64:168&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694129</ArticleId><ArticleId IdType="pubmed">18496870</ArticleId></ArticleIdList></Reference><Reference><Citation>Au R, Seshadri S, Knox K, Beiser A, Himali JJ, Cabral HJ, et al. The Framingham Brain Donation Program: neuropathology along the cognitive continuum. Curr Alzheimer Res. 2012;9:673&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622706</ArticleId><ArticleId IdType="pubmed">22471865</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50&#x2013;89 years: a cross-sectional study. Lancet Neurol. 2014;13:997&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324499</ArticleId><ArticleId IdType="pubmed">25201514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One. 2009;4:e4144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2607544</ArticleId><ArticleId IdType="pubmed">19127292</ArticleId></ArticleIdList></Reference><Reference><Citation>Abner EL, Nelson PT, Kryscio RJ, Schmitt FA, Fardo DW, Woltjer RL, et al. Diabetes is associated with cerebrovascular but not Alzheimer&#x2019;s disease neuropathology. Alzheimers Dement. 2016;12:882&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958598</ArticleId><ArticleId IdType="pubmed">26812281</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet. 2014;10:el004606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, et al. Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability. In Vivo. Neuron. 2016;92:796&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392364</ArticleId><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li AM, et al. Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies. Neuron. 2014;82:1271&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s Disease. Neuron. 2013;80:1347&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Latorre E, Birar VC, Sheerin AN, Jeynes JCC, Hooper A, Dawe HR, et al. Small molecule modulation of splicing factor expression is associated with rescue from cellular senescence. BMC Cell Biol. 2017;18:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645932</ArticleId><ArticleId IdType="pubmed">29041897</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Knopman DS, Lesnick TG, Przybelski SA, Mielke MM, Graff-Radford J, et al. Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals. JAMA Neural. 2017;74:718&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5649401</ArticleId><ArticleId IdType="pubmed">28418521</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neural. 2015;78:439&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, Knopman DS, Gunter JL, Graff-Radford J, Vemuri P, Boeve BF, et al. Cascading network failure across the Alzheimer&#x2019;s disease spectrum. Brain. 2016;139:547&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4805086</ArticleId><ArticleId IdType="pubmed">26586695</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer&#x2019;s disease in the United States. Alzheimers Dement. 2018;14:121&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803316</ArticleId><ArticleId IdType="pubmed">29233480</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasson U, Blennow K, Zetterberg H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement. 2016;3:98&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941042</ArticleId><ArticleId IdType="pubmed">27453931</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24222016</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29653873</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2215-0374</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>May</Month></PubDate></JournalIssue><Title>The lancet. Psychiatry</Title><ISOAbbreviation>Lancet Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Long-term risk of dementia among people with traumatic brain injury in Denmark: a population-based observational cohort study.</ArticleTitle><Pagination><StartPage>424</StartPage><EndPage>431</EndPage><MedlinePgn>424-431</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2215-0366(18)30065-8</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2215-0366(18)30065-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Traumatic brain injury (TBI) has been associated with increased risk of dementia; however, large-scale studies with long follow-up have been scarce. We investigated the association between TBI, including severity and number of TBIs, and the subsequent long-term risk of dementia.</AbstractText><AbstractText Label="METHODS">We did a nationwide population-based observational cohort study in Denmark using information on citizens from national registries. We used the Danish Civil Registration System to establish a population-based cohort consisting of all people born in Denmark who were living in the country on Jan 1, 1995, and who were at least 50 years old at some point during follow-up (between 1999 and 2013). We obtained information on TBIs from the Danish National Patient Register (NPR), and obtained information on dementia by combining data recorded in the NPR, the Danish Psychiatric Central Register, and the Danish National Prescription Registry (DNPR). The long-term risk of dementia after TBI was established using survival analysis. We used three prespecified models for each of the three analyses: different time periods since the TBI, multiple TBIs, and sex. The first model adjusted for sociodemographic factors, the second model added medical and neurological comorbidities, and the third added psychiatric comorbidities.</AbstractText><AbstractText Label="FINDINGS">We used data from a cohort of 2&#x2008;794&#x2008;852 people for a total of 27&#x2008;632&#x2008;020 person-years (mean 9&#xb7;89 years per patient) at risk of dementia. 132&#x2008;093 individuals (4&#xb7;7%) had at least one TBI during 1977-2013, and 126&#x2008;734 (4&#xb7;5%) had incident dementia during 1999-2013. The fully adjusted risk of all-cause dementia in people with a history of TBI was higher (hazard ratio [HR] 1&#xb7;24, 95% CI 1&#xb7;21-1&#xb7;27) than in those without a history of TBI, as was the specific risk of Alzheimer's disease (1&#xb7;16, 1&#xb7;12-1&#xb7;22). The risk of dementia was highest in the first 6 months after TBI (HR 4&#xb7;06, 3&#xb7;79-4&#xb7;34) and also increased with increasing number of events (1&#xb7;22, 1&#xb7;19-1&#xb7;25 with one TBI to 2&#xb7;83, 2&#xb7;14-3&#xb7;75 with five or more TBIs). Furthermore, TBI was associated with a higher risk of dementia (1&#xb7;29, 1&#xb7;26-1&#xb7;33) in people with TBI than in individuals with a non-TBI fracture not involving the skull or spine. The younger a person was when sustaining a TBI, the higher the HRs for dementia when stratified by time since TBI.</AbstractText><AbstractText Label="INTERPRETATION">TBI was associated with an increased risk of dementia both compared with people without a history of TBI and with people with non-TBI trauma. Greater efforts to prevent TBI and identify strategies to ameliorate the risk and impact of subsequent dementia are needed.</AbstractText><AbstractText Label="FUNDING">Lundbeck Foundation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fann</LastName><ForeName>Jesse R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA. Electronic address: fann@uw.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribe</LastName><ForeName>Anette Riisgaard</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>The Research Unit for General Practice and Section for General Medical Practice, Department of Public Health, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Henrik Schou</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>The Research Unit for General Practice and Section for General Medical Practice, Department of Public Health, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenger-Gr&#xf8;n</LastName><ForeName>Morten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Research Unit for General Practice and Section for General Medical Practice, Department of Public Health, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benros</LastName><ForeName>Michael Eriksen</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vestergaard</LastName><ForeName>Mogens</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Research Unit for General Practice and Section for General Medical Practice, Department of Public Health, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Psychiatry</MedlineTA><NlmUniqueID>101638123</NlmUniqueID><ISSNLinking>2215-0366</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Psychiatry. 2018 May;5(5):383-384. doi: 10.1016/S2215-0366(18)30136-6.</RefSource><PMID Version="1">29653874</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Psychiatry. 2018 Oct;5(10):782. doi: 10.1016/S2215-0366(18)30183-4.</RefSource><PMID Version="1">30274670</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Psychiatry. 2018 Oct;5(10):782-783. doi: 10.1016/S2215-0366(18)30187-1.</RefSource><PMID Version="1">30274671</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="N">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="Y">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29653873</ArticleId><ArticleId IdType="doi">10.1016/S2215-0366(18)30065-8</ArticleId><ArticleId IdType="pii">S2215-0366(18)30065-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29687257</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>136</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Diffusible, highly bioactive oligomers represent a critical minority of soluble A&#x3b2; in Alzheimer's disease brain.</ArticleTitle><Pagination><StartPage>19</StartPage><EndPage>40</EndPage><MedlinePgn>19-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-018-1846-7</ELocationID><Abstract><AbstractText>Significant data suggest that soluble A&#x3b2; oligomers play an important role in Alzheimer's disease (AD), but there is great confusion over what exactly constitutes an A&#x3b2; oligomer and which oligomers are toxic. Most studies have utilized synthetic A&#x3b2; peptides, but the relevance of these test tube experiments to the conditions that prevail in AD is uncertain. A few groups have studied A&#x3b2; extracted from human brain, but they employed vigorous tissue homogenization which is likely to release insoluble A&#x3b2; that was sequestered in plaques during life. Several studies have found such extracts to possess disease-relevant activity and considerable efforts are being made to purify and better understand the forms of A&#x3b2; therein. Here, we compared the abundance of A&#x3b2; in AD extracts prepared by traditional homogenization versus using a far gentler extraction, and assessed their bioactivity via real-time imaging of iPSC-derived human neurons plus the sensitive functional assay of long-term potentiation. Surprisingly, the amount of A&#x3b2; retrieved by gentle extraction constituted only a small portion of that released by traditional homogenization, but this readily diffusible fraction retained all of the A&#x3b2;-dependent neurotoxic activity. Thus, the bulk of A&#x3b2; extractable from AD brain was innocuous, and only the small portion that was aqueously diffusible caused toxicity. This unexpected finding predicts that generic anti-oligomer therapies, including A&#x3b2; antibodies now in trials, may be bound up by the large pool of inactive oligomers, whereas agents that specifically target the small pool of diffusible, bioactive A&#x3b2; would be more useful. Furthermore, our results indicate that efforts to purify and target toxic A&#x3b2; must employ assays of disease-relevant activity. The approaches described here should enable these efforts, and may assist the study of other disease-associated aggregation-prone proteins.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-0718-6261</Identifier><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zemin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Tiernan T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8784-8105</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Massachusetts General Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA. dwalsh3@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046275</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG046275</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039904" MajorTopicYN="N">Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyloid &#x3b2;-protein</Keyword><Keyword MajorTopicYN="N">Automated live-cell imaging</Keyword><Keyword MajorTopicYN="N">Long-term potentiation</Keyword><Keyword MajorTopicYN="N">Neuritic dystrophy</Keyword><Keyword MajorTopicYN="N">Soluble aggregates</Keyword><Keyword MajorTopicYN="N">iPSC-derived human neurons</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29687257</ArticleId><ArticleId IdType="mid">NIHMS1042122</ArticleId><ArticleId IdType="pmc">PMC6647843</ArticleId><ArticleId IdType="doi">10.1007/s00401-018-1846-7</ArticleId><ArticleId IdType="pii">10.1007/s00401-018-1846-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ (2011) Alzheimer&#x2019;s disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci 31: 7259&#x2013;7263</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622598</ArticleId><ArticleId IdType="pubmed">21593310</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat Neurosci 15: 349&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Borlikova GG, Trejo M, Mably AJ, Mc Donald JM, Sala Frigerio C, Regan CM, Murphy KJ, Masliah E, Walsh DM (2013) Alzheimer brain-derived amyloid beta-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging 34: 1315&#x2013;1327</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570694</ArticleId><ArticleId IdType="pubmed">23182244</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Jiang H, Wildburger N, Esparza TJ (2017) Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer&#x2019;s disease. Alzheimers Res Ther 9: 62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5561579</ArticleId><ArticleId IdType="pubmed">28818091</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL (2008) Alzheimer&#x2019;s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 29: 1334&#x2013;1347</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, Ihara Y (1999) Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol 154: 271&#x2013;279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853431</ArticleId><ArticleId IdType="pubmed">9916941</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Wildburger NC, Jiang H, Gangolli M, Cairns NJ, Bateman RJ, Brody DL (2016) Soluble Amyloid-beta Aggregates from Human Alzheimer&#x2019;s Disease Brains. Sci Rep 6: 38187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5137165</ArticleId><ArticleId IdType="pubmed">27917876</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL (2013) Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73: 104&#x2013;119</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563737</ArticleId><ArticleId IdType="pubmed">23225543</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J (2011) Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun 2: 336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156817</ArticleId><ArticleId IdType="pubmed">21654636</ArticleId></ArticleIdList></Reference><Reference><Citation>Funato H, Enya M, Yoshimura M, Morishima-Kawashima M, Ihara Y (1999) Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am J Pathol 155: 23&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866667</ArticleId><ArticleId IdType="pubmed">10393832</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283: 29639&#x2013;29643</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573087</ArticleId><ArticleId IdType="pubmed">18723507</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE (2014) Open questions for Alzheimer&#x2019;s disease immunotherapy. Alzheimers Res Ther 6: 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4056616</ArticleId><ArticleId IdType="pubmed">24393284</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Schneider LS, Koo EH (2011) Anti-abeta therapeutics in Alzheimer&#x2019;s disease: the need for a paradigm shift. Neuron 69: 203&#x2013;213</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058906</ArticleId><ArticleId IdType="pubmed">21262461</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, ADNI (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain 133: 3336&#x2013;3348</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, Muhs A, Lashuel HA (2011) Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem 286: 8585&#x2013;8596</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048741</ArticleId><ArticleId IdType="pubmed">21156804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, O&#x2019;Nuallain B, Hong W, Boyd JD, Lagomarsino VN, O&#x2019;Malley TT, Liu W, Vanderburg CR, Frosch MP, Young-Pearse TL, Selkoe DJ, Walsh DM (2018) A new paradigm to assess the therapeutic potential of anti-A&#x3b2; antibodies for Alzheimer&#x2019;s disease. Submitted</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6041266</ArticleId><ArticleId IdType="pubmed">29992960</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108: 5819&#x2013;5824</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L (1997) Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 94: 1550&#x2013;1555</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones KR, Reichardt LF (1990) Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc Natl Acad Sci U S A 87: 8060&#x2013;8064</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54892</ArticleId><ArticleId IdType="pubmed">2236018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM (2012) Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J Exp Med 209: 2149&#x2013;2156</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501350</ArticleId><ArticleId IdType="pubmed">23129750</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Cullen WK, Hu NW, Rowan MJ (2012) Alzheimer&#x2019;s disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain 5: 25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3502131</ArticleId><ArticleId IdType="pubmed">22805374</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11: 556&#x2013;561</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271: 4077&#x2013;4081</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, Moller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P (2014) Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer&#x2019;s disease. Alzheimers Res Ther 6: 16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054967</ArticleId><ArticleId IdType="pubmed">25031633</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Glabe CG, Kayed R (2011) Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem 286: 22122&#x2013;22130</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121356</ArticleId><ArticleId IdType="pubmed">21507938</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, Ashe KH (2015) Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration. Cell Rep 11: 1760&#x2013;1771</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494129</ArticleId><ArticleId IdType="pubmed">26051935</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer&#x2019;s disease. Am J Pathol 155: 853&#x2013;862</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mably AJ, Liu W, Mc Donald JM, Dodart JC, Bard F, Lemere CA, O&#x2019;Nuallain B, Walsh DM (2015) Anti-Abeta antibodies incapable of reducing cerebral Abeta oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol Dis 82: 372&#x2013;384</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641028</ArticleId><ArticleId IdType="pubmed">26215784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, O&#x2019;Malley TT, Liu W, Mably AJ, Brinkmalm G, Portelius E, Wittbold WM 3rd, Frosch MP, Walsh DM (2015) The aqueous phase of Alzheimer&#x2019;s disease brain contains assemblies built from approximately 4 and approximately 7 kDa Abeta species. Alzheimers Dement 11: 1286&#x2013;1305</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4592782</ArticleId><ArticleId IdType="pubmed">25846299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133: 1328&#x2013;1341</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859152</ArticleId><ArticleId IdType="pubmed">20403962</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D, Walsh DM (2012) The levels of water-soluble and triton-soluble Abeta are increased in Alzheimer&#x2019;s disease brain. Brain Res 1450: 138&#x2013;147</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319647</ArticleId><ArticleId IdType="pubmed">22440675</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4&#x2013;10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8: 1263&#x2013;1269</Citation><ArticleIdList><ArticleId IdType="pubmed">12379850</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer&#x2019;s disease. Ann Neurol 46: 860&#x2013;866</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S, Noda M, Fukunari A, Muramatsu S, Itokazu Y, Sato K, Takahashi H, Teplow DB, Nabeshima Y, Kakita A, Imahori K, Hoshi M (2009) Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem 284: 32895&#x2013;32905</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781705</ArticleId><ArticleId IdType="pubmed">19759000</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG (1989) The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Natl Acad Sci U S A 86: 6338&#x2013;6342</Citation><ArticleIdList><ArticleId IdType="pmc">PMC297834</ArticleId><ArticleId IdType="pubmed">2503832</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ (1995) Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270: 9564&#x2013;9570</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR (1996) Morphology and toxicity of Abeta-(1&#x2013;42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer&#x2019;s disease. J Biol Chem 271: 20631&#x2013;20635</Citation><ArticleIdList><ArticleId IdType="pubmed">8702810</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C, Fadeeva JV, Minogue AM, Citron M, Van Leuven F, Staufenbiel M, Paganetti P, Selkoe DJ, Walsh DM (2010) beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. FEBS J 277: 1503&#x2013;1518</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847843</ArticleId><ArticleId IdType="pubmed">20163459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE (2012) Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS One 7: e32014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280222</ArticleId><ArticleId IdType="pubmed">22355408</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Molecular Medicine 8: 595&#x2013;608</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. (1992) Isolation and quantification of soluble Alzheimer&#x2019;s beta-peptide from biological fluids. Nature 359: 325&#x2013;327</Citation><ArticleIdList><ArticleId IdType="pubmed">1406936</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med 14: 837&#x2013;842</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Walsh DM (2009) Alzheimer&#x2019;s disease: synaptic dysfunction and Abeta. Mol Neurodegener 4: 48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788538</ArticleId><ArticleId IdType="pubmed">19930651</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM (2011) Isolation of low-n amyloid beta-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol 670: 33&#x2013;44</Citation><ArticleIdList><ArticleId IdType="pubmed">20967581</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson J, Bladon CM, Yates CM, Harmar AJ (1988) An antiserum to the C-terminus of the Alzheimer amyloid precursor recognizes a soluble 70 kDa protein. FEBS Lett 237: 196&#x2013;198</Citation><ArticleIdList><ArticleId IdType="pubmed">2971568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui L, Wang Y, Ju LH, Chen M (2012) Epigenetic regulation of reelin and brain-derived neurotrophic factor genes in long-term potentiation in rat medial prefrontal cortex. Neurobiol Learn Mem 97: 425&#x2013;440</Citation><ArticleIdList><ArticleId IdType="pubmed">22469747</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczepankiewicz O, Linse B, Meisl G, Thulin E, Frohm B, Sala Frigerio C, Colvin MT, Jacavone AC, Griffin RG, Knowles T, Walsh DM, Linse S (2015) N-Terminal Extensions Retard Abeta42 Fibril Formation but Allow Cross-Seeding and Coaggregation with Abeta42. J Am Chem Soc 137: 14673&#x2013;14685</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412961</ArticleId><ArticleId IdType="pubmed">26535489</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM (2012) Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15: 1227&#x2013;1235</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431439</ArticleId><ArticleId IdType="pubmed">22820466</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhaya AR, Lungrin I, Yamaguchi H, Fandrich M, Thal DR (2012) High-molecular weight Abeta oligomers and protofibrils are the predominant Abeta species in the native soluble protein fraction of the AD brain. J Cell Mol Med 16: 287&#x2013;295</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823292</ArticleId><ArticleId IdType="pubmed">21418518</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola KL, Klein WL (2015) Amyloid beta oligomers in Alzheimer&#x2019;s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol 129: 183&#x2013;206</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390393</ArticleId><ArticleId IdType="pubmed">25604547</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer&#x2019;s disease. Neuron 44: 181&#x2013;193</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Teplow DB (2012) Alzheimer&#x2019;s disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 107: 101&#x2013;124</Citation><ArticleIdList><ArticleId IdType="pubmed">22482449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dickson DW, Trojanowski JQ, Lee VM (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer&#x2019;s disease from normal and pathologic aging. Exp Neurol 158: 328&#x2013;337</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Jackson RJ, Hong W, Taylor WM, Corbett GT, Moreno A, Liu W, Li S, Frosch MP, Slutsky I, Young-Pearse TL, Spires-Jones TL, Walsh DM (2017) Human Brain-Derived Abeta Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. J Neurosci 37: 11947&#x2013;11966</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719975</ArticleId><ArticleId IdType="pubmed">29101243</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson D, Castano E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly ES Jr., Esh C, Luehrs DC, Stine WB, Rowse LM, Emmerling MR, Roher AE (2005) Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer&#x2019;s disease. Neurol Res 27: 869&#x2013;881</Citation><ArticleIdList><ArticleId IdType="pubmed">16354549</ArticleId></ArticleIdList></Reference><Reference><Citation>Welzel AT, Maggio JE, Shankar GM, Walker DE, Ostaszewski BL, Li S, Klyubin I, Rowan MJ, Seubert P, Walsh DM, Selkoe DJ (2014) Secreted amyloid beta-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry 53: 3908&#x2013;3921</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4070750</ArticleId><ArticleId IdType="pubmed">24840308</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, Hornburg D, Evans LD, Moore S, Daria A, Hampel H, Muller V, Giudici C, Nuscher B, Wenninger-Weinzierl A, Kremmer E, Heneka MT, Thal DR, Giedraitis V, Lannfelt L, Muller U, Livesey FJ, Meissner F, Herms J, Konnerth A, Marie H, Haass C (2015) eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 526: 443&#x2013;447</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570618</ArticleId><ArticleId IdType="pubmed">26322584</ArticleId></ArticleIdList></Reference><Reference><Citation>Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, Rydel RE (2005) Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci 25: 1071&#x2013;1080</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725948</ArticleId><ArticleId IdType="pubmed">15689542</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Li S, Xu H, Walsh DM, Selkoe DJ (2017) Large Soluble Oligomers of Amyloid beta-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. J Neurosci 37: 152&#x2013;163</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5214627</ArticleId><ArticleId IdType="pubmed">28053038</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, O&#x2019;Malley TT, Kanmert D, Jerecic J, Zieske LR, Zetterberg H, Hyman BT, Walsh DM, Selkoe DJ (2015) A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res Ther 7: 14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369838</ArticleId><ArticleId IdType="pubmed">25802556</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, Lu T (2009) Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem 284: 4755&#x2013;4759</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643502</ArticleId><ArticleId IdType="pubmed">18957434</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng H, Guo M, Martins-Taylor K, Wang X, Zhang Z, Park JW, Zhan S, Kronenberg MS, Lichtler A, Liu HX, Chen FP, Yue L, Li XJ, Xu RH (2010) Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. PLoS One 5: e11853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912324</ArticleId><ArticleId IdType="pubmed">20686615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, Xu W, Yang N, Danko T, Chen L, Wernig M, Sudhof TC (2013) Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78: 785&#x2013;798</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29686045</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>19</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Subthreshold Amyloid Predicts Tau Deposition in Aging.</ArticleTitle><Pagination><StartPage>4482</StartPage><EndPage>4489</EndPage><MedlinePgn>4482-4489</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0485-18.2018</ELocationID><Abstract><AbstractText>Current approaches to the early detection of Alzheimer's disease (AD) rely upon classifying individuals as "positive" or "negative" for biomarkers related to the core pathology of &#x3b2;-amyloid (A&#x3b2;). However, the accumulation of A&#x3b2; begins slowly, years before biomarkers become abnormal. We used longitudinal [<sup>11</sup>C] Pittsburgh Compound B PET scanning and neuropsychological assessment to investigate the earliest changes in AD pathology and how it affects memory in cognitively normal older humans (<i>N</i> = 71; mean age 75 years; 35% male). We used [<sup>18</sup>F] AV-1451 PET scanning at the end of the observation period to measure subsequent tau deposition in a subset of our sample (<i>N</i> = 37). We found evidence for an inverted-U relationship between baseline A&#x3b2; levels and A&#x3b2; slope in asymptomatic older adults, suggesting a slowing of A&#x3b2; accumulation even in cognitively normal adults. In participants who were nominally amyloid negative, both the rate of amyloid accumulation and the baseline levels of A&#x3b2; predicted early tau deposition in cortical Braak regions associated with AD. Amyloid measures were only sensitive to memory decline as baseline levels of A&#x3b2; increased, suggesting that pathological accumulation occurs before impacting memory. These findings support the necessity of early intervention with amyloid-lowering therapies even in those who are amyloid negative.<b>SIGNIFICANCE STATEMENT</b> The progressive nature of Alzheimer's disease (AD) necessitates the earliest possible detection of pathological or cognitive change if disease progression is to be slowed. We examined cognitively normal older adults in whom AD pathology is starting to develop, with the goal of early detection of AD pathology or cognitive changes. We found amyloid measures to be sensitive early on in predicting subsequent early tau deposition. Further, it appears that rates of amyloid accumulation already begin to slow in preclinical AD, suggesting that it is a relatively late stage of AD progression. Thus, it is crucial to examine older adults early, before amyloid levels have saturated, to intervene to slow disease progression.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 the authors 0270-6474/18/384482-08$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leal</LastName><ForeName>Stephanie L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-8082-8291</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, California 94720, stephanieleal@berkeley.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lockhart</LastName><ForeName>Samuel N</ForeName><Initials>SN</Initials><Identifier Source="ORCID">0000-0002-0893-5420</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, California 94720.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maass</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, California 94720.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Magdeburg, Germany 39120, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Rachel K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, California 94720.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-4458-113X</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, California 94720.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California 94720.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 AG054116</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurosci. 2018 Oct 24;38(43):9123-9125. doi: 10.1523/JNEUROSCI.1592-18.2018.</RefSource><PMID Version="1">30355622</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Neurosci. 2018 Oct 24;38(43):9126-9128. doi: 10.1523/JNEUROSCI.1813-18.2018.</RefSource><PMID Version="1">30355623</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">preclinical</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>11</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29686045</ArticleId><ArticleId IdType="pmc">PMC5943976</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0485-18.2018</ArticleId><ArticleId IdType="pii">JNEUROSCI.0485-18.2018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baker SL, Lockhart SN, Price JC, He M, Huesman RH, Schonhaut D, Faria J, Rabinovici G, Jagust WJ (2017) Reference tissue-based kinetic evaluation of 18F-AV-1451 in aging and dementia. J Nucl Med 58:332&#x2013;338. 10.2967/jnumed.116.175273</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.116.175273</ArticleId><ArticleId IdType="pmc">PMC5288744</ArticleId><ArticleId IdType="pubmed">27587706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's Disease. N Engl J Med 367:795&#x2013;804. 10.1056/NEJMoa1202753</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom GS. (2014) Amyloid-&#x3b2; and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505&#x2013;508. 10.1001/jamaneurol.2013.5847</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.5847</ArticleId><ArticleId IdType="pubmed">24493463</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351&#x2013;357. 10.1016/S0197-4580(97)00056-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(97)00056-0</ArticleId><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Csel&#xe9;nyi Z, Farde L (2015) Quantification of Blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio. J Cereb Blood Flow Metab 35:1485&#x2013;1493. 10.1038/jcbfm.2015.66</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2015.66</ArticleId><ArticleId IdType="pmc">PMC4640337</ArticleId><ArticleId IdType="pubmed">25873425</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31:968&#x2013;980. 10.1016/j.neuroimage.2006.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.021</ArticleId><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS (2017) Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 317:2305&#x2013;2316. 10.1001/jama.2017.6669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.6669</ArticleId><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DA. (2014) The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement 10:372&#x2013;380. 10.1016/j.jalz.2013.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.11.003</ArticleId><ArticleId IdType="pubmed">24589433</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013a) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207&#x2013;216. 10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, Pankratz VS, Senjem ML, Gunter JL, Mielke MM, Lowe VJ, Boeve BF, Petersen RC (2013b) Brain &#x3b2;-amyloid load approaches a plateau. Neurology 80:890&#x2013;896. 10.1212/WNL.0b013e3182840bbe</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182840bbe</ArticleId><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11:1&#x2013;15.e4. 10.1016/j.jalz.2014.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.07.003</ArticleId><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal SL, Landau SM, Bell RK, Jagust WJ (2017) Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline. Elife 6:e22978. 10.7554/eLife.22978</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.22978</ArticleId><ArticleId IdType="pmc">PMC5325620</ArticleId><ArticleId IdType="pubmed">28177283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF, Josephs KA, Fang P, Pandey MK, Murray ME, Kantarci K, Jones DT, Vemuri P, Graff-Radford J, Schwarz CG, Machulda MM, Mielke MM, Roberts RO, Knopman DS, Petersen RC, et al. (2018) Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain 141:271&#x2013;287. 10.1093/brain/awx320</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx320</ArticleId><ArticleId IdType="pmc">PMC5837250</ArticleId><ArticleId IdType="pubmed">29228201</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust WJ (2017) Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage 157:448&#x2013;463. 10.1016/j.neuroimage.2017.05.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.05.058</ArticleId><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks SM, Lockhart SN, Baker SL, Jagust WJ (2017) Tau and &#x3b2;-amyloid are associated with medial temporal lobe structure, function and memory encoding in normal aging. J Neurosci 37:3192&#x2013;3201. 10.1523/JNEUROSCI.3769-16.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3769-16.2017</ArticleId><ArticleId IdType="pmc">PMC5373113</ArticleId><ArticleId IdType="pubmed">28213439</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479&#x2013;486. 10.1212/WNL.41.4.479</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.41.4.479</ArticleId><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ (2009) Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132:1310&#x2013;1323. 10.1093/brain/awn320</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn320</ArticleId><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Brandel MG, Madison CM, Marks S, Baker SL, Jagust WJ (2012) A&#x3b2; Deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb Cortex 22:1813&#x2013;1823. 10.1093/cercor/bhr255</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhr255</ArticleId><ArticleId IdType="pmc">PMC3388896</ArticleId><ArticleId IdType="pubmed">21945849</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. (2012) Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov 11:657&#x2013;660. 10.1038/nrd3842</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3842</ArticleId><ArticleId IdType="pubmed">22935790</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 139:1551&#x2013;1567. 10.1093/brain/aww027</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww027</ArticleId><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, Beaudry T, Kang MS, Soucy JP, Labbe A, Gauthier S, Rosa-Neto P (2017) Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimers Dement 13:644&#x2013;653. 10.1016/j.jalz.2016.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.11.005</ArticleId><ArticleId IdType="pubmed">28024995</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; alzheimer's disease. Ann Neurol 45:358&#x2013;368. 10.1002/1531-8249(199903)45:3&lt;358::AID-ANA12&gt;3.0.CO;2-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199903)45:3&lt;358::AID-ANA12&gt;3.0.CO;2-X</ArticleId><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC (1998) Correction for partial volume effects in PET: principle and validation. J Nucl Med 39:904&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ (2016) PET imaging of tau deposition in the aging human brain. Neuron 89:971&#x2013;982. 10.1016/j.neuron.2016.01.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Shcherbinin S, Schwarz AJ, Joshi A, Navitsky M, Flitter M, Shankle WR, Devous MD Sr, Mintun MA (2016) Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med 57:1535&#x2013;1542. 10.2967/jnumed.115.170027</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.170027</ArticleId><ArticleId IdType="pubmed">27151986</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, et al. (2011a) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:280&#x2013;292. 10.1016/j.jalz.2011.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR Jr, Aisen PS (2011b) Testing the right target and right drug at the right stage. Sci Transl Med 3:111cm33. 10.1126/scitranslmed.3002609</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002609</ArticleId><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="pubmed">22133718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P (2014) The A4 study: stopping AD before symptoms begin? Sci Transl Med 6:228fs13. 10.1126/scitranslmed.3007941</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007941</ArticleId><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59:733&#x2013;748. 10.1093/jnen/59.8.733</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/59.8.733</ArticleId><ArticleId IdType="pubmed">10952063</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791&#x2013;1800. 10.1212/WNL.58.12.1791</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.12.1791</ArticleId><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Landau S, Aisen PS, Petersen RC, Mintun M, Jagust W, Weiner MW (2017) Association between tau deposition and antecedent amyloid-&#x3b2; accumulation rates in normal and early symptomatic individuals. Brain 140:1499&#x2013;1512. 10.1093/brain/awx046</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx046</ArticleId><ArticleId IdType="pubmed">28334939</ArticleId></ArticleIdList></Reference><Reference><Citation>van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, Scheltens P, Lammertsma AA, Boellaard R (2013) Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med 54:1570&#x2013;1576. 10.2967/jnumed.112.113654</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.112.113654</ArticleId><ArticleId IdType="pubmed">23940304</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, Ch&#xe9;telat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL (2012) Regional dynamics of amyloid-&#x3b2; deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 135:2126&#x2013;2139. 10.1093/brain/aws125</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws125</ArticleId><ArticleId IdType="pubmed">22628162</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL (2013) Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12:357&#x2013;367. 10.1016/S1474-4422(13)70044-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70044-9</ArticleId><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, et al. (2015) Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 138:2020&#x2013;2033. 10.1093/brain/awv112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv112</ArticleId><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM (2013) Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 12:957&#x2013;965. 10.1016/S1474-4422(13)70194-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70194-7</ArticleId><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh KA, Butters N, Hughes JP, Mohs RC, Heyman A (1992) Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 49:448&#x2013;452. 10.1001/archneur.1992.00530290030008</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1992.00530290030008</ArticleId><ArticleId IdType="pubmed">1580805</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooten D, Guehl NJ, Verwer EE, Shoup TM, Yokell DL, Zubcevik N, Vasdev N, Zafonte RD, Johnson KA, Fakhri G El, Normandin MD (2017) Pharmacokinetic evaluation of the tau PET radiotracer [18F]T807 ([18F]AV-1451) in human subjects. J Nucl Med 58:484&#x2013;491. 10.2967/jnumed.115.170910</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.170910</ArticleId><ArticleId IdType="pmc">PMC5334185</ArticleId><ArticleId IdType="pubmed">27660144</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29777097</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>GWAS on family history of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>99</StartPage><MedlinePgn>99</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">99</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-018-0150-6</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a public health priority for the 21st century. Risk reduction currently revolves around lifestyle changes with much research trying to elucidate the biological underpinnings. We show that self-report of parental history of Alzheimer's dementia for case ascertainment in a genome-wide association study of 314,278 participants from UK Biobank (27,696 maternal cases, 14,338 paternal cases) is a valid proxy for an AD genetic study. After meta-analysing with published consortium data (n&#x2009;=&#x2009;74,046 with 25,580 cases across the discovery and replication analyses), three new AD-associated loci (P&#x2009;&lt;&#x2009;5&#x2009;&#xd7;&#x2009;10<sup>-8</sup>) are identified. These contain genes relevant for AD and neurodegeneration: ADAM10, BCKDK/KAT8 and ACE. Novel gene-based loci include drug targets such as VKORC1 (warfarin dose). We report evidence that the association of SNPs in the TOMM40 gene with AD is potentially mediated by both gene expression and DNA methylation in the prefrontal cortex. However, it is likely that multiple variants are affecting the trait and gene methylation/expression. Our discovered loci may help to elucidate the biological mechanisms underlying AD and, as they contain genes that are drug targets for other diseases and disorders, warrant further exploration for potential precision medicine applications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marioni</LastName><ForeName>Riccardo E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK. riccardo.marioni@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK. riccardo.marioni@ed.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McRae</LastName><ForeName>Allan F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0001-5286-5485</Identifier><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagenaars</LastName><ForeName>Saskia P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>W David</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Gail</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Centre for Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH8 9YL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gale</LastName><ForeName>Catharine R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starr</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Departments of Neuroscience, Neurology and Genetics and Genomic Sciences, Ronald M. Loeb Center for Alzheimer's disease, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porteous</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0003-1249-6106</Identifier><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2001-2474</Identifier><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queensland Brain Institute, University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deary</LastName><ForeName>Ian J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wray</LastName><ForeName>Naomi R</ForeName><Initials>NR</Initials><Identifier Source="ORCID">0000-0001-7421-3357</Identifier><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queensland Brain Institute, University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visscher</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-2143-8760</Identifier><AffiliationInfo><Affiliation>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queensland Brain Institute, University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K026992/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U147585827</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054014</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UU_12011/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U147585819</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A620_1014</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L015382/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG049508</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UU_12011/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400491</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U147585824</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Transl Psychiatry. 2019 Jun 6;9(1):161. doi: 10.1038/s41398-019-0498-2.</RefSource><PMID Version="1">31171767</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008487" MajorTopicYN="N">Medical History Taking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29777097</ArticleId><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="doi">10.1038/s41398-018-0150-6</ArticleId><ArticleId IdType="pii">10.1038/s41398-018-0150-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222. doi: 10.1016/j.cell.2012.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.040</ArticleId><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet. Med. 2016;18:421&#x2013;430. doi: 10.1038/gim.2015.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.117</ArticleId><ArticleId IdType="pmc">PMC4857183</ArticleId><ArticleId IdType="pubmed">26312828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 2013;45:1452&#x2013;1458. doi: 10.1038/ng.2802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbett RA, Russ TC, Deary IJ, Starr JM. Dementia ascertainment using existing data in UK longitudinal and cohort studies: a systematic review of methodology. BMC Psychiatry. 2017;17:239. doi: 10.1186/s12888-017-1401-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-017-1401-4</ArticleId><ArticleId IdType="pmc">PMC5496178</ArticleId><ArticleId IdType="pubmed">28673273</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, Erlich Y, Pickrell JK. Case-control association mapping by proxy using family history of 363 disease. Nat. Genet. 2017;49:325&#x2013;331. doi: 10.1038/ng.3766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3766</ArticleId><ArticleId IdType="pubmed">28092683</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft, C. et al. Genome-wide genetic data on ~500,000 UK Biobank participants. (2017) Preprint at https://www.biorxiv.org/content/early/2017/07/20/166298.</Citation></Reference><Reference><Citation>Wain LV, et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. Lancet Respir. Med. 2015;3:769&#x2013;781. doi: 10.1016/S2213-2600(15)00283-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(15)00283-0</ArticleId><ArticleId IdType="pmc">PMC4593935</ArticleId><ArticleId IdType="pubmed">26423011</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, et al. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 2010;42:565&#x2013;569. doi: 10.1038/ng.608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.608</ArticleId><ArticleId IdType="pmc">PMC3232052</ArticleId><ArticleId IdType="pubmed">20562875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd-Jones LR, Robinson MR, Yang J, Visscher PM. Transformation of summary statistics from linear mixed model association on all-or-none traits to odds ratio. Genetics. 2018;208:1397&#x2013;1408. doi: 10.1534/genetics.117.300360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.117.300360</ArticleId><ArticleId IdType="pmc">PMC5887138</ArticleId><ArticleId IdType="pubmed">29429966</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;2191. doi: 10.1093/bioinformatics/btq340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq340</ArticleId><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B, et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet. 2015;47:1236&#x2013;1241. doi: 10.1038/ng.3406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3406</ArticleId><ArticleId IdType="pmc">PMC4797329</ArticleId><ArticleId IdType="pubmed">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan BK, et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 2015;47:291&#x2013;295. doi: 10.1038/ng.3211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3211</ArticleId><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Taskesen E, Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat. Commun. 2017;8:1826. doi: 10.1038/s41467-017-01261-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01261-5</ArticleId><ArticleId IdType="pmc">PMC5705698</ArticleId><ArticleId IdType="pubmed">29184056</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 2015;11:e1004219. doi: 10.1371/journal.pcbi.1004219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1004219</ArticleId><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium et al. A map of human genome variation from population-scale sequencing. Nature467, 1061&#x2013;1073 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042601</ArticleId><ArticleId IdType="pubmed">20981092</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet. 2016;48:481&#x2013;487. doi: 10.1038/ng.3538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3538</ArticleId><ArticleId IdType="pubmed">27019110</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe AE, et al. Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex. Nat. Neurosci. 2016;19:40&#x2013;47. doi: 10.1038/nn.4181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4181</ArticleId><ArticleId IdType="pmc">PMC4783176</ArticleId><ArticleId IdType="pubmed">26619358</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31:3555&#x2013;3557. doi: 10.1093/bioinformatics/btv402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv402</ArticleId><ArticleId IdType="pmc">PMC4626747</ArticleId><ArticleId IdType="pubmed">26139635</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiela MJ, Chanock SJ. LDassoc: an online tool for interactively exploring genome-wide association study results and prioritizing variants for functional investigation. Bioinformatics. 2017;34:887&#x2013;889. doi: 10.1093/bioinformatics/btx561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx561</ArticleId><ArticleId IdType="pmc">PMC6030966</ArticleId><ArticleId IdType="pubmed">28968746</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr JM, Whalley LJ. ACE Inhibitors: Central Actions. New York: Raven Press; 1994.</Citation></Reference><Reference><Citation>Elkins JS, Douglas VC, Johnston SC. Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology. 2004;62:363&#x2013;368. doi: 10.1212/01.WNL.0000106823.72493.FF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000106823.72493.FF</ArticleId><ArticleId IdType="pubmed">14872014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann DJ, et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer&#x2019;s disease. Am. J. Epidemiol. 2005;162:305&#x2013;317. doi: 10.1093/aje/kwi202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwi202</ArticleId><ArticleId IdType="pubmed">16033878</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, et al. ACE gene is associated with Alzheimer&#x2019;s disease and atrophy of hippocampus and amygdala. Neurobiol. Aging. 2005;26:1153&#x2013;1159. doi: 10.1016/j.neurobiolaging.2004.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.09.011</ArticleId><ArticleId IdType="pubmed">15917098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochemsen HM, et al. The association of angiotensin-converting enzyme with biomarkers for Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 2014;6:27. doi: 10.1186/alzrt257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt257</ArticleId><ArticleId IdType="pmc">PMC4075229</ArticleId><ArticleId IdType="pubmed">24987467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JSK, et al. Genome-wide association study of CSF levels of 59 alzheimer&#x2019;s disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet. 2014;10:e1004758. doi: 10.1371/journal.pgen.1004758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004758</ArticleId><ArticleId IdType="pmc">PMC4207667</ArticleId><ArticleId IdType="pubmed">25340798</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh J, et al. ADAM10 missense mutations potentiate &#x3b2;-amyloid accumulation by impairing prodomain chaperone function. Neuron. 2013;80:385&#x2013;401. doi: 10.1016/j.neuron.2013.08.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.08.035</ArticleId><ArticleId IdType="pmc">PMC4105199</ArticleId><ArticleId IdType="pubmed">24055016</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X-Z, Sun S, Tan C-C, Yu J-T, Tan L. The role of ADAM10 in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2017;58:303&#x2013;322. doi: 10.3233/JAD-170061.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170061</ArticleId><ArticleId IdType="pubmed">28409746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M, et al. Potential late-onset Alzheimer&#x2019;s disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum. Mol. Genet. 2009;18:3987&#x2013;3996. doi: 10.1093/hmg/ddp323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp323</ArticleId><ArticleId IdType="pmc">PMC2748890</ArticleId><ArticleId IdType="pubmed">19608551</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi F, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433. doi: 10.1371/journal.pgen.1000433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000433</ArticleId><ArticleId IdType="pmc">PMC2652833</ArticleId><ArticleId IdType="pubmed">19300499</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadelius M, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharm. J. 2005;5:262&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol. Psychiatry. 2016;21:108. doi: 10.1038/mp.2015.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.23</ArticleId><ArticleId IdType="pmc">PMC4573764</ArticleId><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>International Genomics of Alzheimer&#x2019;s Disease Consortium (IGAP). Convergent genetic and expression data implicate immunity in Alzheimer&#x2019;s disease. Alzheimers Dement.11, 658&#x2013;671 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672734</ArticleId><ArticleId IdType="pubmed">25533204</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun. 2018;9:224. doi: 10.1038/s41467-017-02317-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02317-2</ArticleId><ArticleId IdType="pmc">PMC5768719</ArticleId><ArticleId IdType="pubmed">29335400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, et al. Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J. Neurol. Neurosurg. Psychiatry. 2017;88:152&#x2013;164. doi: 10.1136/jnnp-2016-314411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314411</ArticleId><ArticleId IdType="pmc">PMC5237405</ArticleId><ArticleId IdType="pubmed">27899424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikram MA, et al. Genetics of vascular dementia&#x2014;review from the ICVD working group. BMC Med. 2017;15:48. doi: 10.1186/s12916-017-0813-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-017-0813-9</ArticleId><ArticleId IdType="pmc">PMC5338082</ArticleId><ArticleId IdType="pubmed">28260527</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29695589</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>21</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>22</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.</ArticleTitle><Pagination><StartPage>e1889</StartPage><EndPage>e1897</EndPage><MedlinePgn>e1889-e1897</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000005550</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS">In this phase 2 trial, 431 patients with mild to moderate AD 50 to 80 years of age were randomized 2:1 (crenezumab:placebo). Patients received low-dose subcutaneous crenezumab 300 mg or placebo every 2 weeks (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks. Primary outcome measures were change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) and Clinical Dementia Rating-Sum of Boxes scores from baseline to week 73.</AbstractText><AbstractText Label="RESULTS">The primary and secondary endpoints were not met. In an exploratory post hoc analysis, a reduction in decline on the ADAS-Cog12 was observed in the high-dose group. Separation from the placebo group on the ADAS-Cog12 was greatest in the milder subsets of AD patients and reached statistical significance in the group with Mini-Mental State Examination scores of 22 to 26. In both groups, there was a significant increase in CSF &#x3b2;-amyloid<sub>1-42</sub> levels that correlated with crenezumab CSF levels. The overall rate of adverse events was balanced between groups. One case of amyloid-related imaging abnormalities indicative of vasogenic edema or effusions was reported.</AbstractText><AbstractText Label="CONCLUSIONS">Although prespecified criteria for testing treatment effects were not met, these data suggest a potential treatment effect in patients with mild AD treated with high-dose crenezumab. Together with the safety profile for crenezumab, these data support the exploration of crenezumab treatment at even higher doses in patients with early AD.</AbstractText><AbstractText Label="CLINICALTRIALSGOV IDENTIFIER">NCT 01343966.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class II evidence that, for people with AD, crenezumab does not significantly improve cognition or function at 18 months. The study is rated Class II because &lt;80% of enrolled patients completed the study.</AbstractText><CopyrightInformation>&#xa9; 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany. cumminj@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brody</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friesenhahn</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabe</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunstein</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quartino</LastName><ForeName>Angelica</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honigberg</LastName><ForeName>Lee A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Reina N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortensen</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>O8AS5277H0</RegistryNumber><NameOfSubstance UI="C573372">crenezumab</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29695589</ArticleId><ArticleId IdType="pmc">PMC5962917</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000005550</ArticleId><ArticleId IdType="pii">WNL.0000000000005550</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer's Association Report. Alzheimer's disease facts and figures. Alzheimers Dement 2017;13:325&#x2013;373.</Citation></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic A&#x3b2; oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012;15:349.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZX, Tan L, Liu J, Yu JT. The essential role of soluble A&#x3b2; oligomers in Alzheimer's disease. Mol Neurobiol 2016;53:1905.</Citation><ArticleIdList><ArticleId IdType="pubmed">25833098</ArticleId></ArticleIdList></Reference><Reference><Citation>Adolfsson O, Pihlgren M, Toni N, et al. . An effector-reduced anti-&#x3b2;-amyloid (A&#x3b2;) antibody with unique binding properties promotes neuroprotection and glial engulfment of A&#x3b2;. J Neurosci 2012;32:9677&#x2013;9689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622286</ArticleId><ArticleId IdType="pubmed">22787053</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, et al. . Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015;14:388&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing B, Bachstetter AD, Van Eldik LJ. Microglial p38alpha MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFalpha. Mol Neurodegener 2011;6:84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292986</ArticleId><ArticleId IdType="pubmed">22185458</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller JP, Stavenhagen JB, Teeling JL. New roles for Fc receptors in neurodegeneration: the impact on Immunotherapy for Alzheimer's disease. Front Neurosci 2014;8:235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139653</ArticleId><ArticleId IdType="pubmed">25191216</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, et al. . Two Phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasser R, Ostrowitzki S, Scheltens P, et al. . Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: results from SCarlet RoAD: a global, multicenter trial. Alzheimers Dement 2015;11:P331&#x2013;P332.</Citation></Reference><Reference><Citation>Wilcock DM, Alamed J, Gottschall PE, et al. . Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006;26:5340&#x2013;5346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675288</ArticleId><ArticleId IdType="pubmed">16707786</ArticleId></ArticleIdList></Reference><Reference><Citation>Ultsch M, Li B, Maurer T, et al. . Structure of crenezumab complex with A&#x3b2; shows loss of &#x3b2;-hairpin. Sci Rep 2016;6:39374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5171940</ArticleId><ArticleId IdType="pubmed">27996029</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh RL, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 1986;5:165&#x2013;173.</Citation></Reference><Reference><Citation>O'Bryant SE, Waring SC, Cullum CM, et al. . Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's Research Consortium study. Arch Neurol 2008;65:1091&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409562</ArticleId><ArticleId IdType="pubmed">18695059</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type, 4: evaluation of intervention. Ann Neurol 1992;31:242&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">1637132</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Raman R, Emond J, et al. . Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:122&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526369</ArticleId><ArticleId IdType="pubmed">20921876</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. . Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S13&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. . An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T, Zetterberg H, Teunissen CE, et al. . Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement 2016;12:517&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">26555316</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimers Dement 2015;11:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">24613705</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Farlow M, Aisen PS. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med 2014;370:1460.</Citation><ArticleIdList><ArticleId IdType="pubmed">24716687</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussiere T, et al. . The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer's disease. Nature 2016;537:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Williams L, Miao X, O'Gorman J. Randomized, double-blind, phase 1b study of BIIB037, an anti-amyloid beta monocloncal antibody, in patients with prodromal or mild Alzheimer's disease. Neurodegener Dis 2015;15(suppl 1):311.</Citation></Reference><Reference><Citation>Lasser R, Ostrowitzki S, Scheltens P, et al. . Efficacy and safety of gantenerumab from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD. JPAD 2015;2:275.</Citation></Reference><Reference><Citation>Chong CP, Street PR. Pneumonia in the elderly: a review of the epidemiology, pathogenesis, microbiology, and clinical features. South Med J 2008;101:1141&#x2013;1145; quiz 1132, 1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">19088525</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29719179</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>378</Volume><Issue>18</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>03</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1691</StartPage><EndPage>1703</EndPage><MedlinePgn>1691-1703</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1706441</ELocationID><Abstract><AbstractText Label="BACKGROUND">Alzheimer's disease is characterized by the deposition of amyloid-beta (A&#x3b2;) plaques in the brain. A&#x3b2; is produced from the sequential cleavage of amyloid precursor protein by &#x3b2;-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) followed by &#x3b3;-secretase. Verubecestat is an oral BACE-1 inhibitor that reduces the A&#x3b2; level in the cerebrospinal fluid of patients with Alzheimer's disease.</AbstractText><AbstractText Label="METHODS">We conducted a randomized, double-blind, placebo-controlled, 78-week trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had a clinical diagnosis of mild-to-moderate Alzheimer's disease. The coprimary outcomes were the change from baseline to week 78 in the score on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog; scores range from 0 to 70, with higher scores indicating worse dementia) and in the score on the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL; scores range from 0 to 78, with lower scores indicating worse function).</AbstractText><AbstractText Label="RESULTS">A total of 1958 patients underwent randomization; 653 were randomly assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 652 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 653 to receive matching placebo. The trial was terminated early for futility 50 months after onset, which was within 5 months before its scheduled completion, and after enrollment of the planned 1958 patients was complete. The estimated mean change from baseline to week 78 in the ADAS-cog score was 7.9 in the 12-mg group, 8.0 in the 40-mg group, and 7.7 in the placebo group (P=0.63 for the comparison between the 12-mg group and the placebo group and P=0.46 for the comparison between the 40-mg group and the placebo group). The estimated mean change from baseline to week 78 in the ADCS-ADL score was -8.4 in the 12-mg group, -8.2 in the 40-mg group, and -8.9 in the placebo group (P=0.49 for the comparison between the 12-mg group and the placebo group and P=0.32 for the comparison between the 40-mg group and the placebo group). Adverse events, including rash, falls and injuries, sleep disturbance, suicidal ideation, weight loss, and hair-color change, were more common in the verubecestat groups than in the placebo group.</AbstractText><AbstractText Label="CONCLUSIONS">Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events. (Funded by Merck; ClinicalTrials.gov number, NCT01739348 .).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Egan</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kost</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sur</LastName><ForeName>Cyrille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukai</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Tiffini</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furtek</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahoney</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harper Mozley</LastName><ForeName>Lyn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michelson</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From Merck Research Laboratories, Merck, Kenilworth, NJ (M.F.E., J.K., C.S., Y. Mukai, T.V., C.F., E.M., L.H.M., Y. Mo, D.M.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); and Leuven Institute of Neuroscience and Disease, Alzheimer Research Center, and the Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, and Neurology, University Hospitals - both in Leuven, Belgium (R.V.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01739348</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM109025</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003499">Cyclic S-Oxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013829">Thiadiazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>J1I0P6WT7T</RegistryNumber><NameOfSubstance UI="C000613570">verubecestat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Z Gerontol Geriatr. 2018 Jul;51(5):597-599. doi: 10.1007/s00391-018-1416-6.</RefSource><PMID Version="1">29948153</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol. 2018 Sep;265(9):2162-2163. doi: 10.1007/s00415-018-9018-1.</RefSource><PMID Version="1">30132064</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003499" MajorTopicYN="N">Cyclic S-Oxides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013829" MajorTopicYN="N">Thiadiazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29719179</ArticleId><ArticleId IdType="mid">NIHMS1046479</ArticleId><ArticleId IdType="pmc">PMC6776074</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1706441</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL Alzheimer&#x2019;s disease. Nat Rev Dis Primers 2015;1:15056.</Citation><ArticleIdList><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med 2016;8:595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Vassar R. Targeting the &#x3b2; secretase BACE1 for Alzheimer&#x2019;s disease therapy. Lancet Neurol 2014;13:319&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086426</ArticleId><ArticleId IdType="pubmed">24556009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature 2016;537:50&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med 2014;370:322&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med 2014;370:311&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer&#x2019;s disease. N Engl J Med 2013;369:341&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">23883379</ArticleId></ArticleIdList></Reference><Reference><Citation>Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the &#x3b3;-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012;69:1430&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22892585</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, et al. Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott JD, Li SW, Brunskill AP, et al. Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-a &#x3b2;-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer&#x2019;s disease. J Med Chem 2016;59:10435&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">27933948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy ME, Stamford AW, Chen X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS &#x3b2;-amyloid in animal models and in Alzheimer&#x2019;s disease patients. Sci Transl Med 2016;8:363ra150.</Citation><ArticleIdList><ArticleId IdType="pubmed">27807285</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 1984; 34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnostic and statistical manual of mental disorders, 4th ed., text revision: DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry 1984;141:1356&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:Suppl 2:S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44: 2308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Fero A, Baker SL, et al. Measurement of longitudinal &#x3b2;-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 2015;56:567&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5313473</ArticleId><ArticleId IdType="pubmed">25745095</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo Y, Stromswold J, Wilson K, et al. A multinational study distinguishing Alzheimer&#x2019;s and healthy patients using cerebrospinal fluid tau/A&#x3b2;42 cutoff with conordance to amyloid positron emission tomography imaging. Alzheimers Dement (Amst) 2017;6:201&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5357677</ArticleId><ArticleId IdType="pubmed">28349119</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Sano M. Current Alzheimer&#x2019;s disease clinical trials: methods and placebo outcomes. Alzheimers Dement 2009;5:388&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321732</ArticleId><ArticleId IdType="pubmed">19751918</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer&#x2019;s disease patients. Alzheimers Dement 2016;12: 110&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26238576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ba M, Kong M, Li X, Ng KP, Rosa-Neto P, Gauthier S. Is ApoE s 4 a good biomarker for amyloid pathology in late onset Alzheimer&#x2019;s disease? Transl Neuro-degener 2016;5:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112745</ArticleId><ArticleId IdType="pubmed">27891223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, et al. Effects of A&#x3b2; immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak G, Fox N, Clegg S, et al. Changes in brain volume with bapineuzumab in mild to moderate Alzheimer&#x2019;s disease. J Alzheimers Dis 2016;49:1123&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">26639957</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer&#x2019;s disease: implications for prevention trials. Neuron 2014;84:608&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285623</ArticleId><ArticleId IdType="pubmed">25442939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29728653</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Mapping interactions with the chaperone network reveals factors that protect against tau aggregation.</ArticleTitle><Pagination><StartPage>384</StartPage><EndPage>393</EndPage><MedlinePgn>384-393</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41594-018-0057-1</ELocationID><Abstract><AbstractText>A network of molecular chaperones is known to bind proteins ('clients') and balance their folding, function and turnover. However, it is often unclear which chaperones are critical for selective recognition of individual clients. It is also not clear why these key chaperones might fail in protein-aggregation diseases. Here, we utilized human microtubule-associated protein tau (MAPT or tau) as a model client to survey interactions between ~30 purified chaperones and ~20 disease-associated tau variants (~600 combinations). From this large-scale analysis, we identified human DnaJA2 as an unexpected, but potent, inhibitor of tau aggregation. DnaJA2 levels were correlated with tau pathology in human brains, supporting the idea that it is an important regulator of tau homeostasis. Of note, we found that some disease-associated tau variants were relatively immune to interactions with chaperones, suggesting a model in which avoiding physical recognition by chaperone networks may contribute to disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Sue-Ann</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-4593-3368</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Condello</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freilich</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillies</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arhar</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oroz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2687-3013</Identifier><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE), G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadavath</LastName><ForeName>Harindranath</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE), G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-7068-7299</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assimon</LastName><ForeName>Victoria A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Jennifer N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunyak</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jungsoon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Francis T F</ForeName><Initials>FTF</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>llawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zweckstetter</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2536-6581</Identifier><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE), G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max-Planck-Institut f&#xfc;r Biophysikalische Chemie, Goettingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center G&#xf6;ttingen, University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickey</LastName><ForeName>Chad A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-3834-3159</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gestwicki</LastName><ForeName>Jason E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-6125-3154</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, CA, USA. jason.gestwicki@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, CA, USA. jason.gestwicki@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS059690</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM145304</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM064337</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM104980</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM111084</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494645">DNAJA2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050956">HSP40 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050956" MajorTopicYN="N">HSP40 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29728653</ArticleId><ArticleId IdType="mid">NIHMS951441</ArticleId><ArticleId IdType="pmc">PMC5942583</ArticleId><ArticleId IdType="doi">10.1038/s41594-018-0057-1</ArticleId><ArticleId IdType="pii">10.1038/s41594-018-0057-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem. 2013;82:323&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">23746257</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehme M, et al. A Chaperome Subnetwork Safeguards Proteostasis in Aging and Neurodegenerative Disease. Cell Rep. 2014;9:1135&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255334</ArticleId><ArticleId IdType="pubmed">25437566</ArticleId></ArticleIdList></Reference><Reference><Citation>Taipale M, et al. A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways. Cell. 2014;158:434&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104544</ArticleId><ArticleId IdType="pubmed">25036637</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodina A, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016;538:397&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5283383</ArticleId><ArticleId IdType="pubmed">27706135</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu TW, et al. Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases. Cell. 2008;134:769&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650088</ArticleId><ArticleId IdType="pubmed">18775310</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto RI. The heat shock response: Systems biology of proteotoxic stress in aging and disease. Cold Spring Harb Symp Quant Biol. 2011;76:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22371371</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther DM, et al. Widespread Proteome Remodeling and Aggregation in Aging C. elegans. Cell. 2015;161:919&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643853</ArticleId><ArticleId IdType="pubmed">25957690</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4:49&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12511861</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu AL, Murphy CT, Kenyon C. Regulation of Aging and Age-Related Disease by DAF-16 and Heat-Shock Factor. Science. 2003;300:1142&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">12750521</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313:1604&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902091</ArticleId></ArticleIdList></Reference><Reference><Citation>Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci. 2000;97:1589&#x2013;1594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26479</ArticleId><ArticleId IdType="pubmed">10677504</ArticleId></ArticleIdList></Reference><Reference><Citation>Abisambra JF, et al. Phosphorylation Dynamics Regulate Hsp27-Mediated Rescue of Neuronal Plasticity Deficits in Tau Transgenic Mice. 2010;30:15374&#x2013;15382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073547</ArticleId><ArticleId IdType="pubmed">21084594</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK, et al. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci. 2009;29:12079&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775811</ArticleId><ArticleId IdType="pubmed">19793966</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar V, Kuiper EFE, Pandey A, Braakman I, Kampinga HH. Versatile members of the DNAJ family show Hsp70 dependent anti-aggregation activity on RING1 mutant parkin C289G. Sci Rep. 2016;6:34830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5054386</ArticleId><ArticleId IdType="pubmed">27713507</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Young ZT, Mok SA, Gestwicki JE. Therapeutic Strategies for Restoring Tau Homeostasis. Cold Spring Harb Perspect Med. 2017 doi: 10.1101/cshperspect.a024612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024612</ArticleId><ArticleId IdType="pmc">PMC5540800</ArticleId><ArticleId IdType="pubmed">28159830</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AD, et al. Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol. 2012;7:1677&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3477299</ArticleId><ArticleId IdType="pubmed">22769591</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardana CG, et al. The human tau interactome: binding to the ribonucleoproteome, and impaired binding of the P301L mutant to chaperones and the proteasome. Mol Cell Proteomics. 2015;14:3000&#x2013;3014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4638042</ArticleId><ArticleId IdType="pubmed">26269332</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK, et al. The Hsp90 Cochaperone, FKBP51, Increases Tau Stability and Polymerizes Microtubules. 2010;30:591&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830818</ArticleId><ArticleId IdType="pubmed">20071522</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss K, Combs B, Patterson KR, Binder LI, Gamblin TC. Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry. 2012;51:888&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278803</ArticleId><ArticleId IdType="pubmed">22236337</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem. 2001;276:48165&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 2000;97:5129&#x2013;5134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee VMY. Characterization of two VQIXXK motifs for tau fibrillization in vitro. Biochemistry. 2006;45:15692&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">17176091</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18:421&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857183</ArticleId><ArticleId IdType="pubmed">26312828</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara H, Inaguma Y, Goto S, Inagaki T, Kato K. &#x3b1;B crystallin and HSP28 are enhanced in the cerebral cortex of patients with Alzheimer&#x2019;s disease. J Neurol Sci. 1993;119:203&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">8277336</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, et al. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. 2008;118:1877&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323189</ArticleId><ArticleId IdType="pubmed">18431510</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugata H, et al. A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles. Neurosci Lett. 2009;459:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen J, et al. Decreased expression of the mitochondrial matrix proteases Lon and ClpP in cells from a patient with hereditary spastic paraplegia (SPG13) Neuroscience. 2008;153:474&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">18378094</ArticleId></ArticleIdList></Reference><Reference><Citation>Howarth JL, Glover CPJ, Uney JB. HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease. J Neurochem. 2009;108:945&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779461</ArticleId><ArticleId IdType="pubmed">19183265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, et al. Heat shock protein (Hsp) 70 is an activator of the Hsp104 motor. Proc Natl Acad Sci. 2013;110:8513&#x2013;8518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3666692</ArticleId><ArticleId IdType="pubmed">23650362</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan S, et al. Genetic selection designed to stabilize proteins uncovers a chaperone called Spy. Nat Struct Mol Biol. 2011;18:262&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079333</ArticleId><ArticleId IdType="pubmed">21317898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennon CW, et al. Folding Optimization in Vivo Uncovers New Chaperones. J Mol Biol. 2015;427:2983&#x2013;2994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4569523</ArticleId><ArticleId IdType="pubmed">26003922</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerbury JJ, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007;21:2312&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412999</ArticleId></ArticleIdList></Reference><Reference><Citation>Arimon M, Grimminger V, Sanz F, Lashuel HA. Hsp104 Targets Multiple Intermediates on the Amyloid Pathway and Suppresses the Seeding Capacity of A?? Fibrils and Protofibrils. J Mol Biol. 2008;384:1157&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">18851977</ArticleId></ArticleIdList></Reference><Reference><Citation>Glover JR, Lindquist S. Hsp104, Hsp70, and Hsp40: A novel chaperone system that rescues previously aggregated proteins. Cell. 1998;94:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674429</ArticleId></ArticleIdList></Reference><Reference><Citation>Niblock M, Gallo J. Tau alternative splicing in familial and sporadic tauopathies. Biochem Soc Trans. 2012;40:677&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">22817715</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK, et al. Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J. 2013;27:1450&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606536</ArticleId><ArticleId IdType="pubmed">23271055</ArticleId></ArticleIdList></Reference><Reference><Citation>Young ZT, et al. Stabilizing the Hsp70-Tau Complex Promotes Turnover in Models of Tauopathy. Cell Chem Biol. 2016;23:992&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4992411</ArticleId><ArticleId IdType="pubmed">27499529</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P, Knowles TPJ, Linse S. On the lag phase in amyloid fibril formation. Phys Chem Chem Phys. 2015;17:7606&#x2013;7618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498454</ArticleId><ArticleId IdType="pubmed">25719972</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P, Knowles TPJ, Linse S. On the lag phase in amyloid fibril formation. Phys Chem Chem Phys. 2015;17:7606&#x2013;7618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498454</ArticleId><ArticleId IdType="pubmed">25719972</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P, et al. Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat Commun. 2016;7:10948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820785</ArticleId><ArticleId IdType="pubmed">27009901</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, et al. Human Hsp70 Disaggregase Reverses Parkinson&#x2019;s-Linked &#x3b1;-Synuclein Amyloid Fibrils. Mol Cell. 2015;59:781&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5072489</ArticleId><ArticleId IdType="pubmed">26300264</ArticleId></ArticleIdList></Reference><Reference><Citation>Verba KA, et al. Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase. Science. 2016;352:1542&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373496</ArticleId><ArticleId IdType="pubmed">27339980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschke E, Goswami D, Southworth D, Griffin PR, Agard DA. Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles. Cell. 2014;157:1685&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087167</ArticleId><ArticleId IdType="pubmed">24949977</ArticleId></ArticleIdList></Reference><Reference><Citation>Karag&#xf6;z GE, et al. Hsp90-Tau Complex Reveals Molecular Basis for Specificity in Chaperone Action. Cell. 2014;156:963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263503</ArticleId><ArticleId IdType="pubmed">24581495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G, Basha E, Wysocki VH, Vierling E. Insights into small heat shock protein and substrate structure during chaperone action derived from hydrogen/deuterium exchange and mass spectrometry. J Biol Chem. 2008;283:26634&#x2013;26642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546550</ArticleId><ArticleId IdType="pubmed">18621732</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: Sites, regulation, and molecular mechanism of neurofibrillary degeneration. Adv Alzheimer&#x2019;s Dis. 2012;3:123&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">22710920</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K, et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer&#x2019;s disease. Cell. 2012;149:232&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601591</ArticleId><ArticleId IdType="pubmed">22464332</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs B, Hamel C, Kanaan NM. Pathological conformations involving the amino terminus of tau occur early in Alzheimer&#x2019;s disease and are differentially detected by monoclonal antibodies. Neurobiol Dis. 2016;94:18&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4983528</ArticleId><ArticleId IdType="pubmed">27260838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012;287:19440&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Cell biology. A Unifying Role for Prions in Neurodegenerative Diseases. Science. 2012;336:1511&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942086</ArticleId><ArticleId IdType="pubmed">22723400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H, Holmes BB, Sanders DW, Bieschke J, Diamond MI. Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular. 2015;290:14893&#x2013;14903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463437</ArticleId><ArticleId IdType="pubmed">25887395</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Article Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies. Neuron. 2014;82:1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontaine SN, et al. Isoform Selective Genetic Inhibition of Constitutive Cytosolic Hsp70 Activity Promotes Client Tau Degradation Using an Altered Co-chaperone Complement. J Biol Chem. 2015;290:13115&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505567</ArticleId><ArticleId IdType="pubmed">25864199</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci. 2006;26:6985&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673930</ArticleId><ArticleId IdType="pubmed">16807328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendreau KL, Hall GF. Tangles, Toxicity, and Tau Secretion in AD - New Approaches to a Vexing Problem. Front Neurol. 2013;4:160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3801151</ArticleId><ArticleId IdType="pubmed">24151487</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, et al. Propagation of tau pathology in Alzheimer&#x2019;s disease: Identification of novel therapeutic targets. Alzheimer&#x2019;s Res Ther. 2013;5:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978816</ArticleId><ArticleId IdType="pubmed">24152385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikura T, Ito N. Peptidyl-prolyl isomerase activity of FK506 binding protein 12 prevents tau peptide from aggregating. Protein Eng Des Sel. 2013;26:539&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">23832849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B, et al. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol. 2015;41:24&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329416</ArticleId><ArticleId IdType="pubmed">25556536</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004;114:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CL, et al. Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation. Biochemistry. 2011;50:10876&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237831</ArticleId><ArticleId IdType="pubmed">22085312</ArticleId></ArticleIdList></Reference><Reference><Citation>Winsor CP. The Gompertz Curve as a Growth Curve. Proc Natl Acad Sci. 1932;18:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1076153</ArticleId><ArticleId IdType="pubmed">16577417</ArticleId></ArticleIdList></Reference><Reference><Citation>R-Core-Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2013.</Citation></Reference><Reference><Citation>Coppola G, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer&#x2019;s diseases. Hum Mol Genet. 2012;21:3500&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack J, Schneider A, Mandelkow EM, Hyman B. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 2002;103:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015;21:1154&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598295</ArticleId><ArticleId IdType="pubmed">26390242</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011;2:252&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="pubmed">21427723</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsetti V, et al. Identification of a caspase-derived N-terminal tau fragment in cellular and animal Alzheimer&#x2019;s disease models. Mol Cell Neurosci. 2008;38:381&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18511295</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Biernat J, Mandelkow E. Purification of Recombinant Tau Protein and Preparation of Alzheimer-Paired Helical Filaments In Vitro. Methods Mol Biol. 2005;299:35&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980594</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukrasch MD, et al. Sites of tau important for aggregation populate {beta}-structure and bind to microtubules and polyanions. J Biol Chem. 2005;280:24978&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">15855160</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AD, Bernard SM, Skiniotis G, Gestwicki JE. Visualization and functional analysis of the oligomeric states of Escherichia coli heat shock protein 70 (Hsp70/DnaK) Cell Stress Chaperones. 2012;17:313&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312962</ArticleId><ArticleId IdType="pubmed">22076723</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, et al. Chemical screens against a reconstituted multiprotein complex: Myricetin blocks DnaJ regulation of DnaK through an allosteric mechanism. Chem Biol. 2011;18:210&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057461</ArticleId><ArticleId IdType="pubmed">21338918</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, Gestwicki JE. Binding of human nucleotide exchange factors to heat shock protein 70 (Hsp70) generates functionally distinct complexes in vitro. J Biol Chem. 2014;289:1402&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3894324</ArticleId><ArticleId IdType="pubmed">24318877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, et al. BAG3 Is a Modular, Scaffolding Protein that physically Links Heat Shock Protein 70 (Hsp70) to the Small Heat Shock Proteins. J Mol Biol. 2017;429:128&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5186407</ArticleId><ArticleId IdType="pubmed">27884606</ArticleId></ArticleIdList></Reference><Reference><Citation>Makley LN, et al. Pharmacological chaperone for &#x3b1;-crystallin partially restores transparency in cataract models. Science. 2015;350:674&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725592</ArticleId><ArticleId IdType="pubmed">26542570</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunyak BM, Nakamura RL, Frankel AD, Gestwicki JE. Selective Targeting of Cells via Bispecific Molecules That Exploit Coexpression of Two Intracellular Proteins. ACS Chem Biol. 2015;10:2441&#x2013;2447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4714926</ArticleId><ArticleId IdType="pubmed">26322864</ArticleId></ArticleIdList></Reference><Reference><Citation>Assimon VA, Southworth DR, Gestwicki JE. Specific Binding of Tetratricopeptide Repeat Proteins to Heat Shock Protein 70 (Hsp70) and Heat Shock Protein 90 (Hsp90) Is Regulated by Affinity and Phosphorylation. Biochemistry. 2015;54:7120&#x2013;7131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4714923</ArticleId><ArticleId IdType="pubmed">26565746</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson MR, Easterbrook-Smith SB. Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgG. Biochim Biophys Acta (BBA)/Protein Struct Mol. 1992;1159:319&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">1390937</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima Y, et al. Heme-dependent activation of neuronal nitric oxide synthase by cytosol is due to an hsp70-dependent, thioredoxin-mediated thiol - Disulfide interchange in the heme/substrate binding cleft. Biochemistry. 2011;50:7146&#x2013;7156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156863</ArticleId><ArticleId IdType="pubmed">21755988</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29728565</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>A self-destructive nanosweeper that captures and clears amyloid &#x3b2;-peptides.</ArticleTitle><Pagination><StartPage>1802</StartPage><MedlinePgn>1802</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1802</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-018-04255-z</ELocationID><Abstract><AbstractText>Cerebral amyloid &#x3b2;-peptide (A&#x3b2;) accumulation resulting from an imbalance between A&#x3b2; production and clearance is one of the most important causes in the formation of Alzheimer's disease (AD). In order to preserve the maintenance of A&#x3b2; homeostasis and have a notable AD therapy, achieving a method to clear up A&#x3b2; plaques becomes an emerging task. Herein, we describe a self-destructive nanosweeper based on multifunctional peptide-polymers that is capable of capturing and clearing A&#x3b2; for the effective treatment of AD. The nanosweeper recognize and bind A&#x3b2; via co-assembly through hydrogen bonding interactions. The A&#x3b2;-loaded nanosweeper enters cells and upregulates autophagy thus promoting the degradation of A&#x3b2;. As a result, the nanosweeper decreases the cytotoxicity of A&#x3b2; and rescues memory deficits of AD transgenic mice. We believe that this resourceful and synergistic approach has valuable potential as an AD treatment strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Northeast Normal University, 130024, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yao-Xin</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou, 510006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Pei-Pei</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Guo-Bin</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Zeng-Ying</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bing-Nan</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Northeast Normal University, 130024, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Northeast Normal University, 130024, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing-Ping</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Northeast Normal University, 130024, Changchun, China. zhangjp162@nenu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China. wanglei@nanoctr.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), 100190, Beijing, China. wanghao@nanoctr.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, 100049, Beijing, China. wanghao@nanoctr.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071186">Beclin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>3WJQ0SDW1A</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>9012-76-4</RegistryNumber><NameOfSubstance UI="D048271">Chitosan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071186" MajorTopicYN="N">Beclin-1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048271" MajorTopicYN="N">Chitosan</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29728565</ArticleId><ArticleId IdType="pmc">PMC5935695</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-04255-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-018-04255-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer&#x2019;s disease. Nature. 2004;430:631&#x2013;639. doi: 10.1038/nature02621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02621</ArticleId><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh SE, et al. The adaptive immune system restrains Alzheimer&#x2019;s disease pathogenesis by modulating microglial function. Proc. Natl Acad. Sci. USA. 2016;113:1316&#x2013;1325. doi: 10.1073/pnas.1525466113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1525466113</ArticleId><ArticleId IdType="pmc">PMC4780638</ArticleId><ArticleId IdType="pubmed">26884167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindo SS, et al. Small molecule modulators of copper-induced A&#x3b2; aggregation. J. Am. Chem. Soc. 2009;131:16663&#x2013;16665. doi: 10.1021/ja907045h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja907045h</ArticleId><ArticleId IdType="pmc">PMC3417132</ArticleId><ArticleId IdType="pubmed">19877631</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli A, et al. A small molecule targeting the multifactorial nature of Alzheimer&#x2019;s disease. Angew. Chem. Int. Ed. 2007;46:3689&#x2013;3692. doi: 10.1002/anie.200700256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.200700256</ArticleId><ArticleId IdType="pubmed">17397121</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W, De Strooper B. Alzheimer&#x2019;s disease neurons fail the acid test. Cell. 2010;141:1112&#x2013;1114. doi: 10.1016/j.cell.2010.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.009</ArticleId><ArticleId IdType="pubmed">20602994</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, et al. Maintenance of amyloid beta peptide homeostasis by artificial chaperones based on mixed-shell polymeric micelles. Angew. Chem. Int. Ed. 2014;53:8985&#x2013;8990. doi: 10.1002/anie.201400735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201400735</ArticleId><ArticleId IdType="pubmed">24985739</ArticleId></ArticleIdList></Reference><Reference><Citation>Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer&#x2019;s disease. Nature. 2016;539:187&#x2013;196. doi: 10.1038/nature20412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20412</ArticleId><ArticleId IdType="pubmed">27830780</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng J, Li M, Ren J, Wang E, Qu X. Polyoxometalates as inhibitors of the aggregation of amyloid beta peptides associated with Alzheimer&#x2019;s disease. Angew. Chem. Int. Ed. 2011;50:4184&#x2013;4188. doi: 10.1002/anie.201007067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201007067</ArticleId><ArticleId IdType="pubmed">21433228</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002;8:1263&#x2013;1269. doi: 10.1038/nm790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm790</ArticleId><ArticleId IdType="pubmed">12379850</ArticleId></ArticleIdList></Reference><Reference><Citation>Yovel Y, Franz MO, Stilz P, Schnitzler HU. Plant classification from bat-like echolocation signals. PLoS Comput. Biol. 2008;4:e1000032. doi: 10.1371/journal.pcbi.1000032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1000032</ArticleId><ArticleId IdType="pmc">PMC2267002</ArticleId><ArticleId IdType="pubmed">18369425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature. 2006;443:774&#x2013;779. doi: 10.1038/nature05290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05290</ArticleId><ArticleId IdType="pubmed">17051203</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Mihara H. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation. Acc. Chem. Res. 2008;41:1309&#x2013;1318. doi: 10.1021/ar8000475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ar8000475</ArticleId><ArticleId IdType="pubmed">18937396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrnhoefer DE, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 2008;15:558&#x2013;566. doi: 10.1038/nsmb.1437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.1437</ArticleId><ArticleId IdType="pubmed">18511942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisilevsky R, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer&#x2019;s disease. Nat. Med. 1995;1:143&#x2013;148. doi: 10.1038/nm0295-143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0295-143</ArticleId><ArticleId IdType="pubmed">7585011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, et al. Nanotheranostics: Congo Red/Rutin-MNPs with enhanced magnetic resonance imaging and H2O2-responsive therapy of Alzheimer&#x2019;s disease in APPswe/PS1dE9 transgenic mice. Adv. Mater. 2015;27:5499&#x2013;5505. doi: 10.1002/adma.201502227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201502227</ArticleId><ArticleId IdType="pubmed">26270904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Traceable nanoparticle delivery of small interfering RNA and retinoic acid with temporally release ability to control neural stem cell differentiation for Alzheimer&#x2019;s disease therapy. Adv. Mater. 2016;28:6345&#x2013;6352. doi: 10.1002/adma.201600554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201600554</ArticleId><ArticleId IdType="pubmed">27168033</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo SI, et al. Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: functional similarities with proteins. Angew. Chem. Int. Ed. 2011;50:5110&#x2013;5115. doi: 10.1002/anie.201007824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201007824</ArticleId><ArticleId IdType="pmc">PMC3516928</ArticleId><ArticleId IdType="pubmed">21495130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles LA, Crespi GAN, Doughty L, Parker MW. Bapineuzumab captures the N-terminus of the Alzheimer&#x2019;s disease amyloid-beta peptide in a helical conformation. Sci. Rep. 2013;3:1302&#x2013;1302. doi: 10.1038/srep01302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep01302</ArticleId><ArticleId IdType="pmc">PMC3575012</ArticleId><ArticleId IdType="pubmed">23416764</ArticleId></ArticleIdList></Reference><Reference><Citation>Mccartney, M. Margaret McCartney: The &#x201c;breakthrough&#x201d; drug that&#x2019;s not been shown to help in Alzheimer&#x2019;s disease. BMJ351,&#xa0;h4064 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26208710</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N. Engl. J. Med. 2014;370:322&#x2013;333. doi: 10.1056/NEJMoa1304839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings, J. L., Morstorf, T. &amp; Zhong, K. Alzheimer&#x2019;s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6,&#xa0;37 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell. Sci. 2007;120:4081&#x2013;4091. doi: 10.1242/jcs.019265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.019265</ArticleId><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z, et al. Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer&#x2019;s disease? J. Neurosci. Res. 2012;90:1105&#x2013;1118. doi: 10.1002/jnr.23011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23011</ArticleId><ArticleId IdType="pubmed">22344941</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. The role of autophagy in neurodegenerative disease. Nat. Med. 2013;19:983&#x2013;997. doi: 10.1038/nm.3232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3232</ArticleId><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S. Role of autophagy in neurodegenerative diseases. Curr. Sci. 2011;101:514&#x2013;519.</Citation></Reference><Reference><Citation>Qiao ZY, et al. A general strategy for facile synthesis and in situ screening of self-assembled polymer-peptide nanomaterials. Adv. Mater. 2016;28:1859&#x2013;1867. doi: 10.1002/adma.201504564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201504564</ArticleId><ArticleId IdType="pubmed">26698326</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, et al. &#x3b2;-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer&#x2019;s therapy. Nat. Med. 1998;4:822&#x2013;826. doi: 10.1038/nm0798-822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0798-822</ArticleId><ArticleId IdType="pubmed">9662374</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallitto MM, Ghanta J, Heinzelman P, Kiessling LL, Murphy RM. Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry. 1999;38:3570&#x2013;3578. doi: 10.1021/bi982119e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi982119e</ArticleId><ArticleId IdType="pubmed">10090743</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji-Kawata S, et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature. 2013;494:201&#x2013;206. doi: 10.1038/nature11866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11866</ArticleId><ArticleId IdType="pmc">PMC3788641</ArticleId><ArticleId IdType="pubmed">23364696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Self-assembled autophagy-inducing polymeric nanoparticles for breast cancer interference in-vivo. Adv. Mater. 2015;27:2627&#x2013;2634. doi: 10.1002/adma.201405926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201405926</ArticleId><ArticleId IdType="pubmed">25786652</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie H, et al. Inhibition of beta-amyloid peptide self-assembly and cytotoxicity by poly(LVFF-co-beta-amino ester) J. Pept. Sci. 2015;21:608&#x2013;614. doi: 10.1002/psc.2784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psc.2784</ArticleId><ArticleId IdType="pubmed">25931322</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao N, et al. Transition-metal-substituted polyoxometalate derivatives as functional anti-amyloid agents for Alzheimer&#x2019;s disease. Nat. Commun. 2014;5:3422.</Citation><ArticleIdList><ArticleId IdType="pubmed">24595206</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445&#x2013;544. doi: 10.4161/auto.19496.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.19496</ArticleId><ArticleId IdType="pmc">PMC3404883</ArticleId><ArticleId IdType="pubmed">22966490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccarato, F., Cavallini, L. &amp; Alexandre, A. The pH-s ensitive dye acridine orange as a tool to monitor exocytosis/endocytosis in synaptosomes. J. Neurochem.72, 625&#x2013;633 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9930734</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YX, et al. An in situ intracellular self-assembly strategy for quantitatively and temporally monitoring autophagy. ACS Nano. 2017;11:1826&#x2013;1839. doi: 10.1021/acsnano.6b07843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.6b07843</ArticleId><ArticleId IdType="pubmed">28112893</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun LQ, et al. Neuronic autophagy contributes to p-connexin 43 degradation in hippocampal astrocytes following traumatic brain injury in rats. Mol. Med. Rep. 2015;11:4419&#x2013;4423. doi: 10.3892/mmr.2015.3264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2015.3264</ArticleId><ArticleId IdType="pubmed">25626126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz R, Perezvillegas EM, Bachiller S, Rosa JL, Armengol JA. HERC 1 ubiquitin ligase mutation affects neocortical, CA3 hippocampal and spinal cord projection neurons: an ultrastructural study. Front. Neuroanat. 2016;10:42. doi: 10.3389/fnana.2016.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2016.00042</ArticleId><ArticleId IdType="pmc">PMC4834294</ArticleId><ArticleId IdType="pubmed">27147983</ArticleId></ArticleIdList></Reference><Reference><Citation>Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat. Rev. Mol. Cell. Biol. 2007;8:622&#x2013;632. doi: 10.1038/nrm2217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2217</ArticleId><ArticleId IdType="pubmed">17637737</ArticleId></ArticleIdList></Reference><Reference><Citation>Doze P, Van Waarde A, Elsinga PH, Hendrikse NH, Vaalburg W. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse. 2000;36:66&#x2013;74. doi: 10.1002/(SICI)1098-2396(200004)36:1&lt;66::AID-SYN7&gt;3.0.CO;2-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-2396(200004)36:1&lt;66::AID-SYN7&gt;3.0.CO;2-J</ArticleId><ArticleId IdType="pubmed">10700027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrikse NH, et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmac. 1998;124:1413&#x2013;1418. doi: 10.1038/sj.bjp.0701979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0701979</ArticleId><ArticleId IdType="pmc">PMC1565536</ArticleId><ArticleId IdType="pubmed">9723952</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Q, et al. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer&#x2019;s disease by accelerating the clearance of amyloid-beta. ACS Nano. 2014;8:2345&#x2013;2359. doi: 10.1021/nn4058215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn4058215</ArticleId><ArticleId IdType="pubmed">24527692</ArticleId></ArticleIdList></Reference><Reference><Citation>JohnsonWood K, et al. Amyloid precursor protein processing and A beta(42) deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl Acad. Sci. USA. 1997;94:1550&#x2013;1555. doi: 10.1073/pnas.94.4.1550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.4.1550</ArticleId><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun YL, et al. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J. Neurosci. 1998;18:3261&#x2013;3272. doi: 10.1523/JNEUROSCI.18-09-03261.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-09-03261.1998</ArticleId><ArticleId IdType="pmc">PMC6792658</ArticleId><ArticleId IdType="pubmed">9547235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29801024</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.</ArticleTitle><Pagination><StartPage>989</StartPage><EndPage>998</EndPage><MedlinePgn>989-998</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.0821</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The strongest genetic risk factor for Alzheimer disease (AD), the apolipoprotein E (APOE) gene, has a stronger association among women compared with men. Yet limited work has evaluated the association between APOE alleles and markers of AD neuropathology in a sex-specific manner.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate sex differences in the association between APOE and markers of AD neuropathology measured in cerebrospinal fluid (CSF) during life or in brain tissue at autopsy.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This multicohort study selected data from 10 longitudinal cohort studies of normal aging and AD. Cohorts had variable recruitment criteria and follow-up intervals and included population-based and clinic-based samples. Inclusion in our analysis required APOE genotype data and either CSF data available for analysis. Analyses began on November 6, 2017, and were completed on December 20, 2017.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Biomarker analyses included levels of &#x3b2;-amyloid 42, total tau, and phosphorylated tau measured in CSF. Autopsy analyses included Consortium to Establish a Registry for Alzheimer's Disease staging for neuritic plaques and Braak staging for neurofibrillary tangles.</AbstractText><AbstractText Label="RESULTS">Of the 1798 patients in the CSF biomarker cohort, 862 were women, 226 had AD, 1690 were white, and the mean (SD) age was 70 [9] years. Of the 5109 patients in the autopsy cohort, 2813 were women, 4953 were white, and the mean (SD) age was 84 (9) years. After correcting for multiple comparisons using the Bonferroni procedure, we observed a statistically significant interaction between APOE-&#x3b5;4 and sex on CSF total tau (&#x3b2;&#x2009;=&#x2009;0.41; 95% CI, 0.27-0.55; P&#x2009;&lt;&#x2009;.001) and phosphorylated tau (&#x3b2;&#x2009;=&#x2009;0.24; 95% CI, 0.09-0.38; P&#x2009;=&#x2009;.001), whereby APOE showed a stronger association among women compared with men. Post hoc analyses suggested this sex difference was present in amyloid-positive individuals (&#x3b2;&#x2009;=&#x2009;0.41; 95% CI, 0.20-0.62; P&#x2009;&lt;&#x2009;.001) but not among amyloid-negative individuals (&#x3b2;&#x2009;=&#x2009;0.06; 95% CI, -0.18 to 0.31; P&#x2009;=&#x2009;.62). We did not observe sex differences in the association between APOE and &#x3b2;-amyloid 42, neuritic plaque burden, or neurofibrillary tangle burden.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">We provide robust evidence of a stronger association between APOE-&#x3b5;4 and CSF tau levels among women compared with men across multiple independent data sets. Interestingly, APOE-&#x3b5;4 is not differentially associated with autopsy measures of neurofibrillary tangles. Together, the sex difference in the association between APOE and CSF measures of tau and the lack of a sex difference in the association with neurofibrillary tangles at autopsy suggest that APOE may modulate risk for neurodegeneration in a sex-specific manner, particularly in the presence of amyloidosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hohman</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumitrescu</LastName><ForeName>Logan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thambisetty</LastName><ForeName>Madhav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Clinical and Translational Neuroscience, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>John T MacDonald Foundation Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hussman Institute for Human Genomics, University of Miami School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunkle</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hussman Institute for Human Genomics, University of Miami School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gifford</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>William S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Shubhabrata</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Unit of Clinical and Translational Neuroscience, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, the Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jefferson</LastName><ForeName>Angela L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Genetics Consortium and the Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059869</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL111516</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037639</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AG041906</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG033655</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056534</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>U24 AG041689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019085</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG045966</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD023680</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049164</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG046373</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HD043483</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100980</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034962</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG006375</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Larson reports royalties from UpToDate. Dr Schneider reports personal fees from Avid Radiopharmaceuticals and Navidea Biopharmaceuticals outside the submitted work. Dr Zetterberg has served at advisory boards of Eli Lilly, Roche Diagnostics, and Pharmasum Therapeutics and is one of the founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures&#x2013;based platform company at the University of Gothenburg. Dr Blennow has served at advisory boards of Alzheon, Eli Lilly, IBL International, Fujirebio, Merck, and Roche Diagnostics and is one of the founders of Brain Biomarker Solutions in Gothenburg AB.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29801024</ArticleId><ArticleId IdType="mid">NIHMS972166</ArticleId><ArticleId IdType="pmc">PMC6142927</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.0821</ArticleId><ArticleId IdType="pii">2679880</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921-923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridge PG, Hoyt KB, Boehme K, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) . Assessment of the genetic variance of late-onset Alzheimer&#x2019;s disease. Neurobiol Aging. 2016;41:200.e13-200.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4948179</ArticleId><ArticleId IdType="pubmed">27036079</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA. 1997;278(16):1349-1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu SC, Pa J, Kukull W, et al. . Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017;74(10):1178-1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Apolipoprotein E, not fibrillar &#x3b2;-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci. 2012;32(50):18227-18233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3537830</ArticleId><ArticleId IdType="pubmed">23238736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, van der Flier WM, Zwan MD, et al. . Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology. 2013;80(4):359-365.</Citation><ArticleIdList><ArticleId IdType="pubmed">23255822</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, DeStefano AL, Sachdev PS, et al. . APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. Neurology. 2013;81(3):292-300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770168</ArticleId><ArticleId IdType="pubmed">23858411</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider AL, Zhou Y, et al. . The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE. Neurology. 2016;87(5):473-480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. . Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523-527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA. Association of APOE with tau-tangle pathology with and without &#x3b2;-amyloid. Neurobiol Aging. 2016;37:19-25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4716785</ArticleId><ArticleId IdType="pubmed">26481403</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Garai K, et al. . ApoE influences amyloid-&#x3b2; (A&#x3b2;) clearance despite minimal apoE/A&#x3b2; association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110(19):E1807-E1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651443</ArticleId><ArticleId IdType="pubmed">23620513</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Seeley WW, Zhou J, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Gender modulates the APOE &#x3b5;4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci. 2012;32(24):8254-8262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394933</ArticleId><ArticleId IdType="pubmed">22699906</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age, sex, and APOE &#x3b5;4 effects on memory, brain structure, and &#x3b2;-amyloid across the adult life span. JAMA Neurol. 2015;72(5):511-519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428984</ArticleId><ArticleId IdType="pubmed">25775353</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age-specific and sex-specific prevalence of cerebral &#x3b2;-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16(6):435-444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516534</ArticleId><ArticleId IdType="pubmed">28456479</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Shofer JB, Petrie EC, et al. . Cerebrospinal fluid biomarkers for Alzheimer&#x2019;s and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults. Alzheimers Res Ther. 2017;9(1):48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496132</ArticleId><ArticleId IdType="pubmed">28673336</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci. 2004;1019(1):24-28.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246987</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Zetterberg H, van Harten AC, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Alzheimer&#x2019;s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain. 2015;138(pt 9):2701-2715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643624</ArticleId><ArticleId IdType="pubmed">26220940</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD; Alzheimer&#x2019;s Disease Neuroimaging Initiative Investigators . Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563-573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampedro F, Vilaplana E, de Leon MJ, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget. 2015;6(29):26663-26674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694943</ArticleId><ArticleId IdType="pubmed">26397226</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson AL, Gifford KA, Acosta LMY, et al. . The Vanderbilt Memory &amp; Aging Project: study design and baseline cohort overview. J Alzheimers Dis. 2016;52(2):539-559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4866875</ArticleId><ArticleId IdType="pubmed">26967211</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Koscik RL, Jonaitis EM, et al. . The Wisconsin Registry for Alzheimer&#x2019;s Prevention: a review of findings and current directions. Alzheimers Dement (Amst). 2017;10:130-142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5755749</ArticleId><ArticleId IdType="pubmed">29322089</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Soldan A, Gottesman R, et al. . Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. Curr Alzheimer Res. 2014;11(8):773-784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4163954</ArticleId><ArticleId IdType="pubmed">25212916</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) . Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet. 2014;10(9):e1004606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res. 2012;9(6):628-645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646-663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Higdon R, Bowen JD, et al. . Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59(11):1737-1746.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433261</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):436-441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193-1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghekar A, Li S, Lu Y, et al. ; BIOCARD Research Team . CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology. 2013;81(20):1753-1758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821715</ArticleId><ArticleId IdType="pubmed">24132375</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendlin BB, Carlsson CM, Johnson SC, et al. . CSF T-Tau/A&#x3b2;42 predicts white matter microstructure in healthy adults at risk for Alzheimer&#x2019;s disease. PLoS One. 2012;7(6):e37720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3368882</ArticleId><ArticleId IdType="pubmed">22701578</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. . The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479-486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Gouras GK, Greenfield JP, et al. . Estrogen reduces neuronal generation of Alzheimer &#x3b2;-amyloid peptides. Nat Med. 1998;4(4):447-451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Green PS, Gridley KE, Simpkins JW. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett. 1996;218(3):165-168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8945754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Yao J, Mao Z, Chen S, Wang Y, Brinton RD. 17&#x3b2;-Estradiol regulates insulin-degrading enzyme expression via an ER&#x3b2;/PI3-K pathway in hippocampus: relevance to Alzheimer&#x2019;s prevention. Neurobiol Aging. 2011;32(11):1949-1963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889185</ArticleId><ArticleId IdType="pubmed">20053478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozovsky I, Hoving S, Anderson CP, O&#x2019;Callaghan J, Finch CE. Equine estrogens induce apolipoprotein E and glial fibrillary acidic protein in mixed glial cultures. Neurosci Lett. 2002;323(3):191-194.</Citation><ArticleIdList><ArticleId IdType="pubmed">11959417</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-de-la-Rosa M, Silva I, Nilsen J, et al. . Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2005;1052(1):210-224.</Citation><ArticleIdList><ArticleId IdType="pubmed">16024764</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Zhang F, Jiang S, et al. . Estrogen receptor-&#x3b1; is localized to neurofibrillary tangles in Alzheimer&#x2019;s disease. Sci Rep. 2016;6:20352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738266</ArticleId><ArticleId IdType="pubmed">26837465</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava RA, Srivastava N, Averna M, et al. . Estrogen up-regulates apolipoprotein E (ApoE) gene expression by increasing ApoE mRNA in the translating pool via the estrogen receptor alpha-mediated pathway. J Biol Chem. 1997;272(52):33360-33366.</Citation><ArticleIdList><ArticleId IdType="pubmed">9407129</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Broestl L, Worden K. Sex and gonadal hormones in mouse models of Alzheimer&#x2019;s disease: what is relevant to the human condition? Biol Sex Differ. 2012;3(1):24-24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3524653</ArticleId><ArticleId IdType="pubmed">23126652</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer&#x2019;s disease. Lancet Neurol. 2003;2(10):605-613.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference><Reference><Citation>Koran MEI, Wagener M, Hohman TJ; Alzheimer&#x2019;s Neuroimaging Initiative . Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav. 2017;11(1):205-213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972701</ArticleId><ArticleId IdType="pubmed">26843008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher A, Grundman M, Jack CR Jr, et al. ; Alzheimer&#x2019;s Disease Cooperative Study . Sex, apolipoprotein E &#x3b5; 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005;62(6):953-957.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956166</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy [published correction appears in Nat Rev Neurol. 2013. doi: 10.1038/nmeurol.2013.32]. Nat Rev Neurol. 2013;9(2):106-118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghebremedhin E, Schultz C, Thal DR, et al. . Gender and age modify the association between APOE and AD-related neuropathology. Neurology. 2001;56(12):1696-1701.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425936</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xea;ne G, Beiser A, Au R, et al. . Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement. 2015;11(3):310-320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4092061</ArticleId><ArticleId IdType="pubmed">24418058</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciottolo M, Christensen A, Moser A, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer&#x2019;s disease of humans and mice. Neurobiol Aging. 2016;37:47-57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687024</ArticleId><ArticleId IdType="pubmed">26686669</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29768203</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Unconventional Secretion Mediates the Trans-cellular Spreading of Tau.</ArticleTitle><Pagination><StartPage>2039</StartPage><EndPage>2055</EndPage><MedlinePgn>2039-2055</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2018.04.056</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(18)30615-6</ELocationID><Abstract><AbstractText>The progressive deposition of misfolded hyperphosphorylated tau is a pathological hallmark of tauopathies, including Alzheimer's disease. However, the underlying molecular mechanisms governing the intercellular spreading of tau species remain elusive. Here, we show that full-length soluble tau is unconventionally secreted by direct translocation across the plasma membrane. Increased secretion is favored by tau hyperphosphorylation, which provokes microtubule detachment and increases the availability of free protein inside cells. Using a series of binding assays, we show that free tau interacts with components enriched at the inner leaflet of the plasma membrane, finally leading to its translocation across the plasma membrane mediated by sulfated proteoglycans. We provide further evidence that secreted soluble tau species spread trans-cellularly and are sufficient for the induction of intracellular tau aggregation in adjacent cells. Our study demonstrates the mechanistic details of tau secretion and provides insights into the initiation and progression of tau pathology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katsinelos</LastName><ForeName>Taxiarchis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Schaller Research Group at the University of Heidelberg and the DKFZ, Proteostasis in Neurodegenerative Disease (B180), INF 581, 69120 Heidelberg, Germany; Heidelberg University Biochemistry Center (BZH), INF 328, 69120 Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, INF 234, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeitler</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Heidelberg University Biochemistry Center (BZH), INF 328, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Heidelberg University Biochemistry Center (BZH), INF 328, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karakatsani</LastName><ForeName>Andromachi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Heidelberg University Biochemistry Center (BZH), INF 328, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Hans-Michael</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Heidelberg University Biochemistry Center (BZH), INF 328, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nachman</LastName><ForeName>Eliana</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Schaller Research Group at the University of Heidelberg and the DKFZ, Proteostasis in Neurodegenerative Disease (B180), INF 581, 69120 Heidelberg, Germany; German Cancer Research Center (DKFZ), DKFZ-ZMBH Alliance, Center for Molecular Biology of Heidelberg University (ZMBH), INF 282, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steringer</LastName><ForeName>Julia P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Heidelberg University Biochemistry Center (BZH), INF 328, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz de Almodovar</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Heidelberg University Biochemistry Center (BZH), INF 328, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nickel</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Heidelberg University Biochemistry Center (BZH), INF 328, 69120 Heidelberg, Germany. Electronic address: walter.nickel@bzh.uni-heidelberg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahn</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Schaller Research Group at the University of Heidelberg and the DKFZ, Proteostasis in Neurodegenerative Disease (B180), INF 581, 69120 Heidelberg, Germany. Electronic address: thomas.r.jahn@abbvie.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011509">Proteoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Trends Mol Med. 2018 Jul;24(7):595-597. doi: 10.1016/j.molmed.2018.05.006.</RefSource><PMID Version="1">29807705</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011509" MajorTopicYN="N">Proteoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">hyperphosphorylation</Keyword><Keyword MajorTopicYN="N">tau aggregation</Keyword><Keyword MajorTopicYN="N">tau protein</Keyword><Keyword MajorTopicYN="N">trans-cellular spreading</Keyword><Keyword MajorTopicYN="N">unconventional secretion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29768203</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.04.056</ArticleId><ArticleId IdType="pii">S2211-1247(18)30615-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29799981</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging.</ArticleTitle><Pagination><StartPage>999</StartPage><EndPage>1007</EndPage><MedlinePgn>999-1007</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.0975</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Amyloid-&#x3b2; (A&#x3b2;), tau, and cerebral small vessel disease (CSVD), which occasionally coexist, are the most common causes of cognitive impairments in older people. However, whether tau is observed in patients with subcortical vascular cognitive impairment (SVCI), as well as its associations with A&#x3b2; and CSVD, are not yet established. More importantly, the role of tau underlying cognitive impairments in SVCI is unknown.</AbstractText><AbstractText Label="OBJECTIVE">To investigate the extent and the role of tau in patients with SVCI using 18F-AV1451, which is a new ligand to detect neurofibrillary tangles in vivo.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study recruited 64 patients with SVCI from June 2015 to December 2016 at Samsung Medical Center, Seoul, Korea. The patients had significant ischemia on brain magnetic resonance imaging, defined as periventricular white matter hyperintensity at least 10 mm and deep white matter hyperintensity at least 25 mm. We excluded 3 patients with SVCI owing to segmentation error during AV1451 positron emission tomography analysis.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">We calculated CSVD scores based on the volumes of white matter hyperintensities, numbers of lacunes, and microbleeds using magnetic resonance imaging data. The presence of A&#x3b2; was assessed using fluorine 18-labeled (18F) florbetaben positron emission tomography. Tau was measured using 18F-AV1451 positron emission tomography. We determined the spreading order of tau by sorting the regional frequencies of cortical involvement. We evaluated the complex associations between A&#x3b2;, CSVD, AV1451 uptake, and cognition in patients with SVCI.</AbstractText><AbstractText Label="RESULTS">Of the 61 patients with SVCI, 44 (72.1%) were women and the mean (SD) age was 78.7 (6.3) years. Patients with SVCI, especially patients with A&#x3b2;-negative SVCI, showed higher AV1451 uptake in the inferior temporal areas compared with normal control individuals. In patients with SVCI, A&#x3b2; positivity and CSVD score were each independently associated with increased AV1451 uptake in the medial temporal and inferior temporal regions, respectively. Involvement frequency of AV1451 uptake in the fusiform gyrus, inferior temporal, and precuneus regions were higher than that in the parahippocampal region. In patients with SVCI, higher AV1451 uptake in the inferior temporal and medial temporal regions correlated with worse language and general cognitive function. In patients with SVCI, A&#x3b2; positivity and CSVD score each correlated with worse general cognitive function, which was completely mediated by AV1451 uptake in the entorhinal cortex and inferior temporal gyrus, respectively.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Our findings suggest that in SVCI, both A&#x3b2; and CSVD were independently associated with increased tau accumulation. Furthermore, tau burden played a pivotal role because it was the final common pathway for the cognitive impairment in patients with SVCI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hee Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Samsung Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seongbeom</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Samsung Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Young Kyoung</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Samsung Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>San Lee</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyung Hee University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Hyemin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Samsung Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeshin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Samsung Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kangwon National University College of Medicine, Chuncheon-si, Gangwon-do, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ko Woon</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Samsung Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Chonbuk National University Medical School and Hospital, Jeonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Young Hoon</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jae Yong</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of RI-Convergence Research, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Seung Hwan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Departments of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Center for Imaging of Neurodegenerative Diseases, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Center for Neuroscience, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyoo</LastName><ForeName>Chul Hyoung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Duk L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Samsung Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Sang Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Samsung Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Imaging of Neurodegenerative Diseases, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Design and Evaluation, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2019 Jan 1;76(1):117. doi: 10.1001/jamaneurol.2018.3887.</RefSource><PMID Version="1">30535226</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2019 Jan 1;76(1):116-117. doi: 10.1001/jamaneurol.2018.3884.</RefSource><PMID Version="1">30535279</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059345" MajorTopicYN="N">Cerebral Small Vessel Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29799981</ArticleId><ArticleId IdType="pmc">PMC6142932</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.0975</ArticleId><ArticleId IdType="pii">2680671</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kalaria RN, Erkinjuntti T. Small vessel disease and subcortical vascular dementia. J Clin Neurol. 2006;2(1):1-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854938</ArticleId><ArticleId IdType="pubmed">20396480</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Kim SH, Kim GH, et al. . Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology. 2011;77(1):18-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">21593437</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, Arteaga J, Chen G, et al. . [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer&#x2019;s disease. Alzheimers Dement. 2013;9(6):666-676.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247-258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Vanmechelen E, et al. . Cerebrospinal fluid markers for Alzheimer&#x2019;s disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2000;2(3-4):199-206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214084</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu L, Ng G, Tan EK, Liao P, Kandiah N, Zeng L. Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer&#x2019;s disease mice. Sci Rep. 2016;6:23964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4822118</ArticleId><ArticleId IdType="pubmed">27050297</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Yang JJ, Kwon H, et al. . Relative impact of amyloid-&#x3b2;, lacunes, and downstream imaging markers on cognitive trajectories. Brain. 2016;139(pt 9):2516-2527.</Citation><ArticleIdList><ArticleId IdType="pubmed">27329772</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Reed BR, Wirth M, et al. . Cortical thickness mediates the effect of &#x3b2;-amyloid on episodic memory. Neurology. 2014;82(9):761-767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945649</ArticleId><ArticleId IdType="pubmed">24489134</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Reed BR, Madison CM, et al. . Vascular risk and A&#x3b2; interact to reduce cortical thickness in AD vulnerable brain regions. Neurology. 2014;83(1):40-47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114172</ArticleId><ArticleId IdType="pubmed">24907234</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y, Na DL. Seoul Neuropsychological Screening Battery (SNSB). Incheon, South Korea: Human Brain Research &amp; Consulting; 2003.</Citation></Reference><Reference><Citation>Ahn HJ, Chin J, Park A, et al. . Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci. 2010;25(7):1071-1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890886</ArticleId><ArticleId IdType="pubmed">20592901</ArticleId></ArticleIdList></Reference><Reference><Citation>Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology. 2014;83(14):1228-1234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4180484</ArticleId><ArticleId IdType="pubmed">25165388</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardlaw JM, Smith EE, Biessels GJ, et al. ; Standards for Reporting Vascular Changes on Neuroimaging (STRIVE v1) . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714437</ArticleId><ArticleId IdType="pubmed">23867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthel H, Gertz HJ, Dresel S, et al. ; Florbetaben Study Group . Cerebral amyloid-&#x3b2; PET with florbetaben (18F) in patients with Alzheimer&#x2019;s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424-435.</Citation><ArticleIdList><ArticleId IdType="pubmed">21481640</ArticleId></ArticleIdList></Reference><Reference><Citation>Polvikoski TM, van Straaten EC, Barkhof F, et al. . Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology. 2010;75(23):2071-2078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995533</ArticleId><ArticleId IdType="pubmed">21048201</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer&#x2019;s disease: findings from neuropathological and neuroimaging studies. J Alzheimers Dis. 2014;42(suppl 4):S421-S429.</Citation><ArticleIdList><ArticleId IdType="pubmed">25227313</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri MM, Joachim C, Sloan C, et al. . Cerebral subcortical small vessel disease in subjects with pathologically confirmed Alzheimer disease: a clinicopathologic study in the Oxford Project to Investigate Memory and Ageing (OPTIMA). Alzheimer Dis Assoc Disord. 2014;28(1):30-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">23842286</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Wang H, Chen LN, et al. . Remarkable impairment of Wnt/&#x3b2;-catenin signaling in the brains of the mice infected with scrapie agents. J Neurochem. 2015;136(4):731-740.</Citation><ArticleIdList><ArticleId IdType="pubmed">26526056</ArticleId></ArticleIdList></Reference><Reference><Citation>Song B, Ao Q, Wang Z, et al. . Phosphorylation of tau protein over time in rats subjected to transient brain ischemia. Neural Regen Res. 2013;8(34):3173-3182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146185</ArticleId><ArticleId IdType="pubmed">25206638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartz AM, Bauer B, Soldner EL, et al. . Amyloid-&#x3b2; contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke. 2012;43(2):514-523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761312</ArticleId><ArticleId IdType="pubmed">22116809</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Benzinger TL, Su Y, et al. . Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between &#x3b2;-amyloid and tauopathy. JAMA Neurol. 2016;73(9):1070-1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237382</ArticleId><ArticleId IdType="pubmed">27454922</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Landau S, Aisen PS, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association between tau deposition and antecedent amyloid-&#x3b2; accumulation rates in normal and early symptomatic individuals. Brain. 2017;140(5):1499-1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28334939</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Locascio JJ, Makaretz SJ, et al. . Tau positron emission tomographic imaging in the lewy body diseases. JAMA Neurol. 2016;73(11):1334-1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5287290</ArticleId><ArticleId IdType="pubmed">27654968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Lowe VJ, Boeve BF, et al. . AV-1451 tau and &#x3b2;-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol. 2017;81(1):58-67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299616</ArticleId><ArticleId IdType="pubmed">27863444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29799986</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Interactive Associations of Vascular Risk and &#x3b2;-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.</ArticleTitle><Pagination><StartPage>1124</StartPage><EndPage>1131</EndPage><MedlinePgn>1124-1131</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.1123</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Identifying asymptomatic individuals at high risk of impending cognitive decline because of Alzheimer disease is crucial for successful prevention of dementia. Vascular risk and &#x3b2;-amyloid (A&#x3b2;) pathology commonly co-occur in older adults and are significant causes of cognitive impairment.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether vascular risk and A&#x3b2; burden act additively or synergistically to promote cognitive decline in clinically normal older adults; and, secondarily, to evaluate the unique influence of vascular risk on prospective cognitive decline beyond that of commonly used imaging biomarkers, including A&#x3b2; burden, hippocampal volume, fludeoxyglucose F18-labeled (FDG) positron emission tomography (PET), and white matter hyperintensities, a marker of cerebrovascular disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this longitudinal observational study, we examined clinically normal older adults from the Harvard Aging Brain Study. Participants were required to have baseline imaging data (FDG-PET, A&#x3b2;-PET, and magnetic resonance imaging), baseline medical data to quantify vascular risk, and at least 1 follow-up neuropsychological visit. Data collection began in 2010 and is ongoing. Data analysis was performed on data collected between 2010 and 2017.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Vascular risk was quantified using the Framingham Heart Study general cardiovascular disease (FHS-CVD) risk score. We measured A&#x3b2; burden with Pittsburgh Compound-B PET. Cognition was measured annually with the Preclinical Alzheimer Cognitive Composite. Models were corrected for baseline age, sex, years of education, and apolipoprotein E &#x3b5;4 status.</AbstractText><AbstractText Label="RESULTS">Of the 223 participants, 130 (58.3%) were women. The mean (SD) age was 73.7 (6.0) years, and the mean (SD) follow-up time was 3.7 (1.2) years. Faster cognitive decline was associated with both a higher FHS-CVD risk score (&#x3b2;&#x2009;=&#x2009;-0.064; 95% CI, -0.094 to -0.033; P&#x2009;&lt;&#x2009;.001) and higher A&#x3b2; burden (&#x3b2;&#x2009;=&#x2009;-0.058; 95% CI, -0.079 to -0.037; P&#x2009;&lt;&#x2009;.001). The interaction of the FHS-CVD risk score and A&#x3b2; burden with time was significant (&#x3b2;&#x2009;=&#x2009;-0.040, 95% CI, -0.062 to -0.018; P&#x2009;&lt;&#x2009;.001), suggesting a synergistic effect. The FHS-CVD risk score remained robustly associated with prospective cognitive decline (&#x3b2;&#x2009;=&#x2009;-0.055; 95% CI, -0.086 to -0.024; P&#x2009;&lt;&#x2009;.001), even after adjustment for A&#x3b2; burden, hippocampal volume, FDG-PET uptake, and white matter hyperintensities.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, vascular risk was associated with prospective cognitive decline in clinically normal older adults, both alone and synergistically with A&#x3b2; burden. Vascular risk may complement imaging biomarkers in assessing risk of prospective cognitive decline in preclinical Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rabin</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viswanathan</LastName><ForeName>Anand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilpatrick</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Rachel F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hyun-Sik</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Properzi</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Vaishnavi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirn</LastName><ForeName>Dylan R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papp</LastName><ForeName>Kathryn V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG053509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026484</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG049087</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023401</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015896</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023043</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR021110</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG053422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG028726</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG040197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Schultz reports receiving fees as a consultant for Janssen Pharmaceuticals and Biogen. Dr Papp reports receiving fees as a consultant for Biogen. Dr Marshall reports receiving research salary support from Eisai Inc and Eli Lilly and Company. Dr Rentz reports having served as a consultant for Eli Lilly, Biogen Idec, and Lundbeck Pharmaceuticals and serving as a member of the Scientific Advisory Board for Neurotrack. Dr Johnson reports receiving fees as a consultant for Bayer, GE Healthcare, Janssen Alzheimer&#x2019;s Immunotherapy, Siemens Medical Solutions, Genzyme, Novartis, Biogen, Roche, ISIS Pharma, AZTherapy, GEHC, Lundberg, and Abbvie; acting as a site coinvestigator for Lilly/Avid, Pfizer, Janssen Immunotherapy, and Navidea; and speaking at symposia sponsored by Janssen Alzheimer&#x2019;s Immunotherapy and Pfizer. Dr Sperling reports having served as a paid consultant for Abbvie, Biogen, Bracket, Genentech, Lundbeck, Roche, and Sanofi; serving as a coinvestigator for Avid, Eli Lilly, and Janssen Alzheimer Immunotherapy clinical trials; speaking at symposia sponsored by Eli Lilly, Biogen, and Janssen; and receiving research support from Janssen Pharmaceuticals and Eli Lilly and Co. All activities were outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29799986</ArticleId><ArticleId IdType="pmc">PMC6143121</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.1123</ArticleId><ArticleId IdType="pii">2680896</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280-292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Hampel H, Feldman HH, et al. ; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer&#x2019;s Association on &#x201c;the Preclinical State of AD&#x201d;; July 23, 2015; Washington DC, USA . Preclinical Alzheimer&#x2019;s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292-323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417794</ArticleId><ArticleId IdType="pubmed">27012484</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study . Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. . Synergistic effect of &#x3b2;-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71(11):1379-1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC, Bourgeat P, Dor&#xe9; V, et al. ; AIBL Research Group . Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer&#x2019;s disease pathophysiology (SNAP) or Alzheimer&#x2019;s disease pathology: a longitudinal study. Lancet Neurol. 2016;15(10):1044-1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">27450471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. . Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45(3):358-368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid-&#x3b2;&#x2013;associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012;69(6):709-713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423526</ArticleId><ArticleId IdType="pubmed">22529247</ArticleId></ArticleIdList></Reference><Reference><Citation>Selby JV, Peng T, Karter AJ, et al. . High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care. 2004;10(2, pt 2):163-170.</Citation><ArticleIdList><ArticleId IdType="pubmed">15005509</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Elias PK, Sullivan LM, Wolf PA, D&#x2019;Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord. 2003;27(2):260-268.</Citation><ArticleIdList><ArticleId IdType="pubmed">12587008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaffashian S, Dugravot A, Nabi H, et al. . Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. Eur Heart J. 2011;32(18):2326-2332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3172575</ArticleId><ArticleId IdType="pubmed">21606085</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet Neurol. 2011;10(9):819-828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Albert MS, Alonso A, et al. . Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74(10):1246-1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710244</ArticleId><ArticleId IdType="pubmed">28783817</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Reitz C, Honig LS, Tang M-X, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65(4):545-551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1619350</ArticleId><ArticleId IdType="pubmed">16116114</ArticleId></ArticleIdList></Reference><Reference><Citation>Satizabal CL, Beiser AS, Chouraki V, Ch&#xea;ne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523-532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4943081</ArticleId><ArticleId IdType="pubmed">26863354</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813-817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer&#x2019;s disease. Lancet. 1999;354(9182):919-920.</Citation><ArticleIdList><ArticleId IdType="pubmed">10489957</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekry D, Duyckaerts C, Moulias R, et al. . Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol. 2002;103(5):481-487.</Citation><ArticleIdList><ArticleId IdType="pubmed">11935264</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62(7):1148-1155.</Citation><ArticleIdList><ArticleId IdType="pubmed">15079015</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. Subcortical infarcts, Alzheimer&#x2019;s disease pathology, and memory function in older persons. Ann Neurol. 2007;62(1):59-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">17503514</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. . Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain. 2015;138(pt 3):761-771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339775</ArticleId><ArticleId IdType="pubmed">25595145</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchant NL, Reed BR, DeCarli CS, et al. . Cerebrovascular disease, &#x3b2;-amyloid, and cognition in aging. Neurobiol Aging. 2012;33(5):1006.e25-1006.e36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3274647</ArticleId><ArticleId IdType="pubmed">22048124</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchant NL, Reed BR, Sanossian N, et al. . The aging brain and cognition: contribution of vascular injury and a&#x3b2; to mild cognitive dysfunction. JAMA Neurol. 2013;70(4):488-495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771392</ArticleId><ArticleId IdType="pubmed">23400560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Yang JJ, Kwon H, et al. . Relative impact of amyloid-&#x3b2;, lacunes, and downstream imaging markers on cognitive trajectories. Brain. 2016;139(pt 9):2516-2527.</Citation><ArticleIdList><ArticleId IdType="pubmed">27329772</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Seo SW, Kim C, et al. . Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol Aging. 2014;35(1):254-260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849054</ArticleId><ArticleId IdType="pubmed">23932881</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol. 2012;11(3):272-282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359329</ArticleId><ArticleId IdType="pubmed">22341035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardlaw JM, Smith EE, Biessels GJ, et al. ; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1) . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714437</ArticleId><ArticleId IdType="pubmed">23867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheri S, Gasparovic C, Huisa BN, et al. . Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke. 2011;42(8):2158-2163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3584170</ArticleId><ArticleId IdType="pubmed">21719768</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder HM, Corriveau RA, Craft S, et al. . Vascular contributions to cognitive impairment and dementia including Alzheimer&#x2019;s disease. Alzheimers Dement. 2015;11(6):710-717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731036</ArticleId><ArticleId IdType="pubmed">25510382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB, Scuteri A, Black SE, et al. ; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia . Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672-2713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, et al. . Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17(1):37-49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale-Revised. San Antonio, TX: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>D&#x2019;Agostino RB Sr, Vasan RS, Pencina MJ, et al. . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753.</Citation><ArticleIdList><ArticleId IdType="pubmed">18212285</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufouil C, Beiser A, McLure LA, et al. . Revised Framingham stroke risk profile to reflect temporal trends. Circulation. 2017;135(12):1145-1159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504355</ArticleId><ArticleId IdType="pubmed">28159800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, Perea RD, Buckley RF, et al. . Global white matter diffusion characteristics predict longitudinal cognitive change independently of amyloid status in clinically normal older adults [published online February 7, 2018]. Cereb Cortex. doi:10.1093/cercor/bhy031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhy031</ArticleId><ArticleId IdType="pmc">PMC6499008</ArticleId><ArticleId IdType="pubmed">29425267</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207-1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. . Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341-355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M, Rosano C, Butters M, et al. . A fully automated method for quantifying and localizing white matter hyperintensities on MR images. Psychiatry Res. 2006;148(2-3):133-142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761950</ArticleId><ArticleId IdType="pubmed">17097277</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KRA, Shire EH, Sperling RA, Johnson KA, Buckner RL. Failure to modulate attentional control in advanced aging linked to white matter pathology. Cereb Cortex. 2012;22(5):1038-1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328340</ArticleId><ArticleId IdType="pubmed">21765181</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakana S, Jiang H, Nagae-Poetscher LM, van Zijl PC, Mori S. Fiber tract-based atlas of human white matter anatomy. Radiology. 2004;230(1):77-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645885</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. ; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Alzheimer&#x2019;s Disease Cooperative Study . The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Papp KV, Rentz DM, et al. . Early and late change on the preclinical Alzheimer&#x2019;s cognitive composite in clinically normal older individuals with elevated amyloid &#x3b2;. Alzheimers Dement. 2017;13(9):1004-1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573651</ArticleId><ArticleId IdType="pubmed">28253478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WAIS-R Manual: Wechsler Adult Intelligence Scale&#x2014;Revised. New York, NY: The Psychological Corporation; 1981.</Citation></Reference><Reference><Citation>Grober E, Lipton RB, Hall C, Crystal H. Memory impairment on free and cued selective reminding predicts dementia. Neurology. 2000;54(4):827-832.</Citation><ArticleIdList><ArticleId IdType="pubmed">10690971</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Brisson D, Marchant NL, Gaudet D. The potential applications of Apolipoprotein E in personalized medicine. Front Aging Neurosci. 2014;6:154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4085650</ArticleId><ArticleId IdType="pubmed">25071563</ArticleId></ArticleIdList></Reference><Reference><Citation>Honjo K, Black SE, Verhoeff NPLG. Alzheimer&#x2019;s disease, cerebrovascular disease, and the &#x3b2;-amyloid cascade. Can J Neurol Sci. 2012;39(6):712-728.</Citation><ArticleIdList><ArticleId IdType="pubmed">23227576</ArticleId></ArticleIdList></Reference><Reference><Citation>Roseborough A, Ramirez J, Black SE, Edwards JD. Associations between amyloid &#x3b2; and white matter hyperintensities: A systematic review. Alzheimers Dement. 2017;13(10):1154-1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">28322203</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Iadecola C. Impaired A&#x3b2; clearance: a potential link between atherosclerosis and Alzheimer&#x2019;s disease. Front Aging Neurosci. 2015;7:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468824</ArticleId><ArticleId IdType="pubmed">26136682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. . Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443-1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="pubmed">28399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Faust M, Auer F, et al. . White matter hyperintensities predict amyloid increase in Alzheimer&#x2019;s disease. Neurobiol Aging. 2012;33(12):2766-2773.</Citation><ArticleIdList><ArticleId IdType="pubmed">22410648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, Goos JDC, Teunissen CE, et al. . Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol. 2014;71(7):855-862.</Citation><ArticleIdList><ArticleId IdType="pubmed">24818585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29769247</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>361</Volume><PubDate><Year>2018</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial.</ArticleTitle><Pagination><StartPage>k1675</StartPage><MedlinePgn>k1675</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">k1675</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.k1675</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To estimate the effect of a moderate to high intensity aerobic and strength exercise training programme on cognitive impairment and other outcomes in people with mild to moderate dementia.</AbstractText><AbstractText Label="DESIGN">Multicentre, pragmatic, investigator masked, randomised controlled trial.</AbstractText><AbstractText Label="SETTING">National Health Service primary care, community and memory services, dementia research registers, and voluntary sector providers in 15 English regions.</AbstractText><AbstractText Label="PARTICIPANTS">494 people with dementia: 329 were assigned to an aerobic and strength exercise programme and 165 were assigned to usual care. Random allocation was 2:1 in favour of the exercise arm.</AbstractText><AbstractText Label="INTERVENTIONS">Usual care plus four months of supervised exercise and support for ongoing physical activity, or usual care only. Interventions were delivered in community gym facilities and NHS premises.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was score on the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) at 12 months. Secondary outcomes included activities of daily living, neuropsychiatric symptoms, health related quality of life, and carer quality of life and burden. Physical fitness (including the six minute walk test) was measured in the exercise arm during the intervention.</AbstractText><AbstractText Label="RESULTS">The average age of participants was 77 (SD 7.9) years and 301/494 (61%) were men. By 12 months the mean ADAS-cog score had increased to 25.2 (SD 12.3) in the exercise arm and 23.8 (SD 10.4) in the usual care arm (adjusted between group difference -1.4, 95% confidence interval -2.6 to -0.2, P=0.03). This indicates greater cognitive impairment in the exercise group, although the average difference is small and clinical relevance uncertain. No differences were found in secondary outcomes or preplanned subgroup analyses by dementia type (Alzheimer's disease or other), severity of cognitive impairment, sex, and mobility. Compliance with exercise was good. Over 65% of participants (214/329) attended more than three quarters of scheduled sessions. Six minute walking distance improved over six weeks (mean change 18.1 m, 95% confidence interval 11.6 m to 24.6 m).</AbstractText><AbstractText Label="CONCLUSION">A moderate to high intensity aerobic and strength exercise training programme does not slow cognitive impairment in people with mild to moderate dementia. The exercise training programme improved physical fitness, but there were no noticeable improvements in other clinical outcomes.</AbstractText><AbstractText Label="TRIAL REGISTRATION">Current Controlled Trials ISRCTN10416500.</AbstractText><CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Centre for Rehabilitation Research and Centre for Statistics in Medicine, Nuffield Department of Orthopaedics Rheumatology &amp; Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK sarah.lamb@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheehan</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Coventry and Warwickshire Partnership Trust, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atherton</LastName><ForeName>Nicky</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Coventry and Warwickshire Partnership Trust, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Vivien</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mistry</LastName><ForeName>Dipesh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dosanjh</LastName><ForeName>Sukhdeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slowther</LastName><ForeName>Anne Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Division of Health Sciences, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Iftekhar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrou</LastName><ForeName>Stavros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lall</LastName><ForeName>Ranjit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DAPA Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN10416500.</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>09/80/04</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0501681</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0700452</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2018 Sep 18;169(6):JC34. doi: 10.7326/ACPJC-2018-169-6-034.</RefSource><PMID Version="1">30242407</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005081" MajorTopicYN="N">Exercise Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010809" MajorTopicYN="N">Physical Fitness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055070" MajorTopicYN="N">Resistance Training</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work, other than funding arrangements for the trial described in body of the text; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29769247</ArticleId><ArticleId IdType="pmc">PMC5953238</ArticleId><ArticleId IdType="doi">10.1136/bmj.k1675</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince MJ. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. Alzheimers Disease International. ADI, 2015.</Citation></Reference><Reference><Citation>Gallaway PJ, Miyake H, Buchowski MS, et al. Physical Activity: A Viable Way to Reduce the Risks of Mild Cognitive Impairment, Alzheimer&#x2019;s Disease, and Vascular Dementia in Older Adults. Brain Sci 2017;7:22. 10.3390/brainsci7020022&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci7020022</ArticleId><ArticleId IdType="pmc">PMC5332965</ArticleId><ArticleId IdType="pubmed">28230730</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KM, Girens RE, Larson SK, et al. A spectrum of exercise training reduces soluble A&#x3b2; in a dose-dependent manner in a mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis 2016;85:218-24. 10.1016/j.nbd.2015.11.004&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.11.004</ArticleId><ArticleId IdType="pubmed">26563933</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev 2015;(4):CD006489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426996</ArticleId><ArticleId IdType="pubmed">25874613</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot C, Hooghiemstra AM, Raijmakers PG, et al. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev 2016;25:13-23. 10.1016/j.arr.2015.11.005&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2015.11.005</ArticleId><ArticleId IdType="pubmed">26607411</ArticleId></ArticleIdList></Reference><Reference><Citation>Atherton N, Bridle C, Brown D, et al. Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trial. Trials 2016;17:165. 10.1186/s13063-016-1288-2&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-016-1288-2</ArticleId><ArticleId IdType="pmc">PMC4807539</ArticleId><ArticleId IdType="pubmed">27015659</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association Diagnostic and statistical manual of mental disorders (DSM-5&#xae;). American Psychiatric Publishing, 2013.</Citation></Reference><Reference><Citation>Vertesi A, Lever JA, Molloy DW, et al. Standardized Mini-Mental State Examination. Use and interpretation. Can Fam Physician 2001;47:2018-23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2018449</ArticleId><ArticleId IdType="pubmed">11723596</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D, Spanjers K, Atherton N, et al. Development of an exercise intervention to improve cognition in people with mild to moderate dementia: Dementia And Physical Activity (DAPA) Trial, registration ISRCTN32612072. Physiotherapy 2015;101:126-34. 10.1016/j.physio.2015.01.002&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physio.2015.01.002</ArticleId><ArticleId IdType="pubmed">25724322</ArticleId></ArticleIdList></Reference><Reference><Citation>Luxton N, Alison JA, Wu J, Mackey MG. Relationship between field walking tests and incremental cycle ergometry in COPD. Respirology 2008;13:856-62. 10.1111/j.1440-1843.2008.01355.x&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1843.2008.01355.x</ArticleId><ArticleId IdType="pubmed">18811884</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#x2019;s disease. NICE technology appraisal guidance 2011;217.</Citation></Reference><Reference><Citation>World Health Organization The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines Version 5. World Health Organization, 2010.</Citation></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer&#x2019;s Disease Assessment Scale that broaden its scope. The Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S13-21. 10.1097/00002093-199700112-00003&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199700112-00003</ArticleId><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996;25:113-20. 10.1093/ageing/25.2.113&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/25.2.113</ArticleId><ArticleId IdType="pubmed">8670538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14. 10.1212/WNL.44.12.2308&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.12.2308</ArticleId><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol Group EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208. 10.1016/0168-8510(90)90421-9&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-8510(90)90421-9</ArticleId><ArticleId IdType="pubmed">10109801</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer&#x2019;s disease: patient and caregiver reports. J Ment Health Aging 1999;5:21-32.</Citation></Reference><Reference><Citation>Beecham JK, Knapp M. Costing psychiatric interventions http://www.dirum org/instruments/details/44: DIRUM; 1992. Accessed 26 June 2015.</Citation></Reference><Reference><Citation>Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980;20:649-55. 10.1093/geront/20.6.649&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geront/20.6.649</ArticleId><ArticleId IdType="pubmed">7203086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer&#x2019;s disease: systematic review of randomised clinical trials. BMJ 2005;331:321-7. 10.1136/bmj.331.7512.321&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.331.7512.321</ArticleId><ArticleId IdType="pmc">PMC1183129</ArticleId><ArticleId IdType="pubmed">16081444</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001;5:1-56. 10.3310/hta5330&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/hta5330</ArticleId><ArticleId IdType="pubmed">11701102</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G, Maracy M, Dowrick C, et al. ODIN group Estimating psychological treatment effects from a randomised controlled trial with both non-compliance and loss to follow-up. Br J Psychiatry 2003;183:323-31. 10.1192/bjp.183.4.323&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.183.4.323</ArticleId><ArticleId IdType="pubmed">14519610</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma N, Beretvas SN, Pascual B, Masdeu JC, Markey MK, Alzheimer&#x2019;s Disease Neuroimaging Initiative New scoring methodology improves the sensitivity of the Alzheimer&#x2019;s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. Alzheimers Res Ther 2015;7:64. 10.1186/s13195-015-0151-0&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0151-0</ArticleId><ArticleId IdType="pmc">PMC4642693</ArticleId><ArticleId IdType="pubmed">26560146</ArticleId></ArticleIdList></Reference><Reference><Citation>Little RJA, Rubin DB. Statistical Analysis with Missing Data. John Wiley &amp; Sons, Inc, 1986.</Citation></Reference><Reference><Citation>Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract 2017;23:377-81. 10.1111/jep.12629&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jep.12629</ArticleId><ArticleId IdType="pubmed">27592691</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster L, Groskreutz D, Grinbergs-Saull A, et al. Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. PLoS One 2017;12:e0179521. 10.1371/journal.pone.0179521&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0179521</ArticleId><ArticleId IdType="pmc">PMC5491018</ArticleId><ArticleId IdType="pubmed">28662127</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitk&#xe4;l&#xe4; KH, P&#xf6;ysti MM, Laakkonen ML, et al. Effects of the Finnish Alzheimer disease exercise trial (FINALEX): a randomized controlled trial. JAMA Intern Med 2013;173:894-901. 10.1001/jamainternmed.2013.359&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.359</ArticleId><ArticleId IdType="pubmed">23589097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bean JF, Herman S, Kiely DK, et al. Increased Velocity Exercise Specific to Task (InVEST) training: a pilot study exploring effects on leg power, balance, and mobility in community-dwelling older women. J Am Geriatr Soc 2004;52:799-804. 10.1111/j.1532-5415.2004.52222.x&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2004.52222.x</ArticleId><ArticleId IdType="pubmed">15086665</ArticleId></ArticleIdList></Reference><Reference><Citation>Toots A, Littbrand H, Lindel&#xf6;f N, et al. Effects of a High-Intensity Functional Exercise Program on Dependence in Activities of Daily Living and Balance in Older Adults with Dementia. J Am Geriatr Soc 2016;64:55-64. 10.1111/jgs.13880&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.13880</ArticleId><ArticleId IdType="pmc">PMC4722852</ArticleId><ArticleId IdType="pubmed">26782852</ArticleId></ArticleIdList></Reference><Reference><Citation>Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer&#x2019;s disease. Mt Sinai J Med 2010;77:69-81. 10.1002/msj.20159&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/msj.20159</ArticleId><ArticleId IdType="pmc">PMC2925685</ArticleId><ArticleId IdType="pubmed">20101721</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudo M, Komiyama T, Aoyagi R, Nagamatsu T, Higaki Y, Ando S. Executive function after exhaustive exercise. Eur J Appl Physiol 2017;117:2029-38. 10.1007/s00421-017-3692-z&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00421-017-3692-z</ArticleId><ArticleId IdType="pubmed">28780602</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipryan L, Tschakert G, Hofmann P. Acute and Post-Exercise Physiological Responses to High-Intensity Interval Training in Endurance and Sprint Athletes. J Sports Sci Med 2017;16:219-29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5465984</ArticleId><ArticleId IdType="pubmed">28630575</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela M, Brayne C, Sachdev P, Wilcock G, Matthews F, Medical Research Council Cognitive Function and Ageing Study Cognitive lifestyle and long-term risk of dementia and survival after diagnosis in a multicenter population-based cohort. Am J Epidemiol 2011;173:1004-12. 10.1093/aje/kwq476&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq476</ArticleId><ArticleId IdType="pubmed">21378129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29802388</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>811</StartPage><EndPage>819</EndPage><MedlinePgn>811-819</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-018-0154-9</ELocationID><Abstract><AbstractText>There is a need for new therapeutic targets with which to prevent Alzheimer's disease (AD), a major contributor to aging-related cognitive decline. Here we report the construction and validation of a molecular network of the aging human frontal cortex. Using RNA sequence data from 478 individuals, we first build a molecular network using modules of coexpressed genes and then relate these modules to AD and its neuropathologic and cognitive endophenotypes. We confirm these associations in two independent AD datasets. We also illustrate the use of the network in prioritizing amyloid- and cognition-associated genes for in vitro validation in human neurons and astrocytes. These analyses based on unique cohorts enable us to resolve the role of distinct cortical modules that have a direct effect on the accumulation of AD pathology from those that have a direct effect on cognitive decline, exemplifying a network approach to complex diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mostafavi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Statistics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Canadian Institute for Advanced Research, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaiteri</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasaki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jishu</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3679-6579</Identifier><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taga</LastName><ForeName>Mariko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials><Identifier Source="ORCID">0000-0002-6382-9428</Identifier><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patrick</LastName><ForeName>Ellis</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komashko</LastName><ForeName>Vitalina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCabe</LastName><ForeName>Cristin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradshaw</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Root</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regev</LastName><ForeName>Aviv</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young-Pearse</LastName><ForeName>Tracy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA. david_a_bennett@rush.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="Y">Metabolic Networks and Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Financial Interest Statement. There are no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29802388</ArticleId><ArticleId IdType="mid">NIHMS962042</ArticleId><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0154-9</ArticleId><ArticleId IdType="pii">10.1038/s41593-018-0154-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hebert LE, Weuve J, Scherr PA &amp; Evans DA Alzheimer disease in the United States (2010&#x2013;2050) estimated using the 2010 census. Neurology 80, 1778&#x2013;1783, doi:10.1212/WNL.0b013e31828726f5 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828726f5</ArticleId><ArticleId IdType="pmc">PMC3719424</ArticleId><ArticleId IdType="pubmed">23390181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Morstorf T &amp; Zhong K Alzheimer&#x2019;s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6, 37, doi:10.1186/alzrt269 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt269</ArticleId><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE &amp; Bennett DA The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of neurology 66, 200&#x2013;208 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nature genetics 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiteri C, Mostafavi S, Honey CJ, De Jager PL &amp; Bennett DA Genetic variants in Alzheimer disease - molecular and brain network approaches. Nat Rev Neurol 12, 413&#x2013;427, doi:10.1038/nrneurol.2016.84 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.84</ArticleId><ArticleId IdType="pmc">PMC5017598</ArticleId><ArticleId IdType="pubmed">27282653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra K, Carvunis AR, Ramesh SK &amp; Ideker T Integrative approaches for finding modular structure in biological networks. Nat Rev Genet 14, 719&#x2013;732, doi:10.1038/nrg3552 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3552</ArticleId><ArticleId IdType="pmc">PMC3940161</ArticleId><ArticleId IdType="pubmed">24045689</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN, Gandal MJ &amp; Geschwind DH Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat Rev Genet 16, 441&#x2013;458, doi:10.1038/nrg3934 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3934</ArticleId><ArticleId IdType="pmc">PMC4699316</ArticleId><ArticleId IdType="pubmed">26149713</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson M et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med 6, 82, doi:10.1186/s13073-014-0082-6 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-014-0082-6</ArticleId><ArticleId IdType="pmc">PMC4254417</ArticleId><ArticleId IdType="pubmed">25473422</ArticleId></ArticleIdList></Reference><Reference><Citation>Geschwind DH &amp; Konopka G Neuroscience in the era of functional genomics and systems biology. Nature 461, 908&#x2013;915, doi:10.1038/nature08537 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08537</ArticleId><ArticleId IdType="pmc">PMC3645852</ArticleId><ArticleId IdType="pubmed">19829370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiteri C, Ding Y, French B, Tseng GC &amp; Sibille E Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders. Genes Brain Behav 13, 13&#x2013;24, doi:10.1111/gbb.12106 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gbb.12106</ArticleId><ArticleId IdType="pmc">PMC3896950</ArticleId><ArticleId IdType="pubmed">24320616</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B &amp; Horvath S A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 4, Article17, doi:10.2202/1544-6115.1128 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.2202/1544-6115.1128</ArticleId><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720, doi:10.1016/j.cell.2013.03.030 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.03.030</ArticleId><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Woltjer RL, Goodenbour JM, Horvath S &amp; Geschwind DH Genes and pathways underlying regional and cell type changes in Alzheimer&#x2019;s disease. Genome Med 5, 48 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706780</ArticleId><ArticleId IdType="pubmed">23705665</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA et al. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Annals of neurology 74, 478&#x2013;489 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845973</ArticleId><ArticleId IdType="pubmed">23798485</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR et al. Age-specific population frequencies of cerebral &#x3b2;-amyloidosis and neurodegeneration among people with normal cognitive function aged 50&#x2013;89 years: a cross-sectional study. The Lancet Neurology 13, 997&#x2013;1005 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324499</ArticleId><ArticleId IdType="pubmed">25201514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z &amp; Wilson RS Overview and findings from the religious orders study. Curr Alzheimer Res 9, 628&#x2013;645 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res 9, 646&#x2013;663 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS et al. Conscientiousness, dementia related pathology, and trajectories of cognitive aging. Psychology and aging 30, 74 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4361241</ArticleId><ArticleId IdType="pubmed">25664558</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA et al. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol 74, 478&#x2013;489, doi:10.1002/ana.23964 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23964</ArticleId><ArticleId IdType="pmc">PMC3845973</ArticleId><ArticleId IdType="pubmed">23798485</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD &amp; Tibshirani R Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America 100, 9440&#x2013;9445, doi:10.1073/pnas.1530509100 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1530509100</ArticleId><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiteri C et al. Identifying robust communities and multi-community nodes by combining top-down and bottom-up approaches to clustering. Sci Rep 5, 16361, doi:10.1038/srep16361 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep16361</ArticleId><ArticleId IdType="pmc">PMC4637843</ArticleId><ArticleId IdType="pubmed">26549511</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P &amp; Horvath S WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics 9, 1 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Luo R, Oldham MC &amp; Horvath S Is my network module preserved and reproducible? PLoS Comput Biol 7, e1001057, doi:10.1371/journal.pcbi.1001057 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1001057</ArticleId><ArticleId IdType="pmc">PMC3024255</ArticleId><ArticleId IdType="pubmed">21283776</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan C &amp; Boyd DD Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. Molecular and cellular biology 26, 6357&#x2013;6371 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592829</ArticleId><ArticleId IdType="pubmed">16914722</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarin M et al. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell reports 10, 633&#x2013;644 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25620700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancarci BO et al. Cross-Laboratory Analysis of Brain Cell Type Transcriptomes with Applications to Interpretation of Bulk Tissue Data. eNeuro 4, doi:10.1523/ENEURO.0212-17.2017 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0212-17.2017</ArticleId><ArticleId IdType="pmc">PMC5707795</ArticleId><ArticleId IdType="pubmed">29204516</ArticleId></ArticleIdList></Reference><Reference><Citation>Koller D &amp; Friedman N Probabilistic graphical models: principles and techniques. (MIT press, 2009).</Citation></Reference><Reference><Citation>Raber J, Huang Y &amp; Ashford JW ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiology of aging 25, 641&#x2013;650 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15172743</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Boyle PA, Leurgans S, Schneider JA &amp; Bennett DA Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiology of aging 35, 819&#x2013;826 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3882071</ArticleId><ArticleId IdType="pubmed">24199961</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet 10, e1004606 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel JM et al. Relation of genomic variants for Alzheimer disease dementia to common neuropathologies. Neurology, 10.1212/WNL. 0000000000002909 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970661</ArticleId><ArticleId IdType="pubmed">27371493</ArticleId></ArticleIdList></Reference><Reference><Citation>Battle A et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res 24, 14&#x2013;24, doi:10.1101/gr.155192.113 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.155192.113</ArticleId><ArticleId IdType="pmc">PMC3875855</ArticleId><ArticleId IdType="pubmed">24092820</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PH, O&#x2019;Dushlaine C, Thomas B &amp; Purcell SM INRICH: interval-based enrichment analysis for genome-wide association studies. Bioinformatics 28, 1797&#x2013;1799 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381960</ArticleId><ArticleId IdType="pubmed">22513993</ArticleId></ArticleIdList></Reference><Reference><Citation>Chibnik LB et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Annals of neurology 69, 560&#x2013;569 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066288</ArticleId><ArticleId IdType="pubmed">21391232</ArticleId></ArticleIdList></Reference><Reference><Citation>Per&#xe4;l&#xe4; N, Sariola H &amp; Immonen T More than nervous: the emerging roles of plexins. Differentiation 83, 77&#x2013;91 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22099179</ArticleId></ArticleIdList></Reference><Reference><Citation>Suwa A, Kurama T &amp; Shimokawa T SHIP2 and its involvement in various diseases. Expert opinion on therapeutic targets 14, 727&#x2013;737 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20536411</ArticleId></ArticleIdList></Reference><Reference><Citation>Soeda Y et al. The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain. Molecular Endocrinology 24, 1965&#x2013;1977 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5417391</ArticleId><ArticleId IdType="pubmed">20829391</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K et al. Brain insulin resistance demonstrated in Alzheimer&#x2019;s disease is closely associated with elevated IRS-1 pS and cognitive deficits. Alzheimer&#x2019;s &amp; Dementia 7, S683 (2011).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29861287</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types.</ArticleTitle><Pagination><StartPage>1141</StartPage><EndPage>1154.e7</EndPage><MedlinePgn>1141-1154.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2018.05.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(18)30380-5</ELocationID><Abstract><AbstractText>The apolipoprotein E4 (APOE4) variant is the single greatest genetic risk factor for sporadic Alzheimer's disease (sAD). However, the cell-type-specific functions of APOE4 in relation to AD pathology remain understudied. Here, we utilize CRISPR/Cas9 and induced pluripotent stem cells (iPSCs) to examine APOE4 effects on human brain cell types. Transcriptional profiling identified hundreds of differentially expressed genes in each cell type, with the most affected involving synaptic function (neurons), lipid metabolism (astrocytes), and immune response (microglia-like cells). APOE4 neurons exhibited increased synapse number and elevated A&#x3b2;<sub>42</sub> secretion relative to isogenic APOE3 cells while APOE4 astrocytes displayed impaired A&#x3b2; uptake and cholesterol accumulation. Notably, APOE4 microglia-like cells exhibited altered morphologies, which correlated with reduced A&#x3b2; phagocytosis. Consistently, converting APOE4 to APOE3 in brain cell types from sAD iPSCs was sufficient to attenuate multiple AD-related pathologies. Our study establishes a reference for human cell-type-specific changes associated with the APOE4 variant. VIDEO ABSTRACT.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yuan-Ta</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jinsoo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Heather M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Hsin-Lan</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penney</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cam</LastName><ForeName>Hugh P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gjoneska</LastName><ForeName>Elizabeta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raja</LastName><ForeName>Waseem K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Jemmie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rueda</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kritskiy</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdurrob</LastName><ForeName>Fatema</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Zhuyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milo</LastName><ForeName>Blerta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chung Jong</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Harvard University, John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmsaouri</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Dilip</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Tak</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: lhtsai@mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH113279</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 AG036106</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048056</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2018 Aug;14(8):450-451. doi: 10.1038/s41582-018-0034-7.</RefSource><PMID Version="1">29915370</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2018 Aug;19(8):442-443. doi: 10.1038/s41583-018-0032-1.</RefSource><PMID Version="1">29934560</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2018 Jun 27;98(6):1294. doi: 10.1016/j.neuron.2018.06.011.</RefSource><PMID Version="1">29953873</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009940" MajorTopicYN="N">Organoids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">A&#x3b2; uptake</Keyword><Keyword MajorTopicYN="N">CRISPR/Cas9</Keyword><Keyword MajorTopicYN="N">cerebral organoids</Keyword><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">early endosomes</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">immune response</Keyword></KeywordList><CoiStatement><b>Declaration of interests</b>. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29861287</ArticleId><ArticleId IdType="mid">NIHMS971235</ArticleId><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.05.008</ArticleId><ArticleId IdType="pii">S0896-6273(18)30380-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association. Alzheimer&#x2019;s disease facts and Figures. Alzheimer&#x2019;s &amp; Dementia. 2016;12(4)  http://www.alz.org.</Citation><ArticleIdList><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez XA, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M, Linares C, Granizo E, Garcia-Fantini M, Marey J, et al. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. Int J Neuropsychopharmacol 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4926802</ArticleId><ArticleId IdType="pubmed">27207906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Busskamp V, Lewis NE, Guye P, Ng AHM, Shipman SL, Byrne SM, Sanjana NE, Murn J, Li Y, Li S, et al. Rapid neurogenesis through transcriptional activation in human stem cells. Mol Syst Biol. 2014;10:760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299601</ArticleId><ArticleId IdType="pubmed">25403753</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcoen D, Elias L, Yu X. What does it take to produce a breakthrough drug? Nat Rev Drug Discov. 2015;14:161&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">25722234</ArticleId></ArticleIdList></Reference><Reference><Citation>Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer&#x2019;s disease. Nature. 2016;539:187&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830780</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Jiang P, Xue H, Peterson SE, Tran HT, McCann AE, Parast MM, Li S, Pleasure DE, Laurent LC, et al. Role of astroglia in Down&#x2019;s syndrome revealed by patient-derived human-induced pluripotent stem cells. Nat Commun. 2014;5:4430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109022</ArticleId><ArticleId IdType="pubmed">25034944</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009;37:W305&#x2013;W311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703978</ArticleId><ArticleId IdType="pubmed">19465376</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G. Mechanisms of disease: new therapeutic strategies for Alzheimer&#x2019;s disease--targeting APP processing in lipid rafts. Nat Clin Pract Neurol. 2007;3:374&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880530</ArticleId><ArticleId IdType="pubmed">17611486</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe EP, Tuzer F, Gregory BD, Donahue G, Gosai SJ, Cohen J, Leung YY, Yetkin E, Nativio R, Wang LS, et al. Changes in the Transcriptome of Human Astrocytes Accompanying Oxidative Stress-Induced Senescence. Front Aging Neurosci. 2016;8:208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5005348</ArticleId><ArticleId IdType="pubmed">27630559</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U, Scott DA, Ganguly A, Koo EH, Tang Y, Roy S. Activity-Induced Convergence of APP and BACE-1 in Acidic Microdomains via an Endocytosis-Dependent Pathway. Neuron. 2013;79:447&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3741682</ArticleId><ArticleId IdType="pubmed">23931995</ArticleId></ArticleIdList></Reference><Reference><Citation>de Strooper B, Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164:603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, Goate AM. Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, Shankar GM, Costantino IM, Carroll MC, Mayadas TN, et al. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar A&#x3b2; by microglia. Glia. 2012;60:993&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325361</ArticleId><ArticleId IdType="pubmed">22438044</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16413480</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;ritz C, Mauch DH, N&#xe4;gler K, Pfrieger FW. Role of glia-derived cholesterol in synaptogenesis: new revelations in the synapseglia affair. J Physiol Paris. 2002;96:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">12445904</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, Jaeger BN, O&#x2019;Connor C, Fitzpatrick C, Pasillas MP. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356:6344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, &#xd6;hrfelt A, Blennow K, Hardy J, Schott J, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer&#x2019;s disease. Mol Neurodegener. 2016;11:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer&#x2019;s disease. J Clin Invest. 1999;103:R15&#x2013;R21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408154</ArticleId><ArticleId IdType="pubmed">10079115</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YWA, Zhou B, Wernig M, S&#xfc;dhof TC. ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and A&#x3b2; Secretion. Cell. 2017b;168:427&#x2013;441. e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016;540:230&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656389</ArticleId><ArticleId IdType="pubmed">27929004</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 2017;169:1276&#x2013;1290. e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15195085</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828108</ArticleId><ArticleId IdType="pubmed">20080505</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, et al. Anti-ApoE antibody given after plaque onset decreases A&#x3b2; accumulation and improves brain function in a mouse model of A&#x3b2; amyloidosis. J Neurosci. 2014a;34:7281&#x2013;7292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028501</ArticleId><ArticleId IdType="pubmed">24849360</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014b;30:923&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YH, Jiao SS, Wang YR, Bu XL, Yao XQ, Xiang Y, Wang QH, Wang L, Deng J, Li J, et al. Associations Between ApoE&#x3b5;4 Carrier Status and Serum BDNF Levels--New Insights into the Molecular Mechanism of ApoE&#x3b5;4 Actions in Alzheimer&#x2019;s Disease. Mol Neurobiol. 2015;51:1271&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pubmed">24986007</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquer C, Laine J, Dauphinot L, Hanbouch L, Lemercier-Neuillet C, Pierrot N, Bossers K, Le M, Corlier F, Benstaali C, et al. Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer&#x2019;s disease early phenotypes. Mol Neurodegener. 2014;9:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4280040</ArticleId><ArticleId IdType="pubmed">25524049</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Tsuda M, Yoshinaga R, Tozaki-Saitoh H, Ozato K, Tamura T, Inoue K. IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Cell Rep. 2012;1:334&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158926</ArticleId><ArticleId IdType="pubmed">22832225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, De Jager PL, Ransohoff RM, Regev A, Tsai LH. Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 2017;21:366&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauch DH, N&#xe4;gler K, Schumacher S, G&#xf6;ritz C, M&#xfc;ller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701931</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research. 2010;20:1297&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooijaart SP, Berb&#xe9;e JFP, van Heemst D, Havekes LM, de Craen AJM, Slagboom PE, Rensen PCN, Westendorp RGJ. ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med. 2006;3:e176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1457005</ArticleId><ArticleId IdType="pubmed">16671834</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J, Li Y, Yuan B, Mitalipova M, Omer A, Corcoran S, Bakiasi G, Tsai LH, Aubourg P, Ransohoff RM, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med. 2016;22:1358&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Venkatasubramanian M, Chaudhri VK, Aronow BJ, Salomonis N, Singh H, Grimes HL. Single-cell analysis of mixed-lineage states leading to a binary cell fate choice. Nature. 2016;537:698&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5161694</ArticleId><ArticleId IdType="pubmed">27580035</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, Olsen KM, Gregg A, Noggle S, Tessier-Lavigne M. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature. 2016;533:125&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">27120160</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrato G, Nguyen T, Macosko EZ, Sherwood JL, Min Yang S, Berger DR, Maria N, Scholvin J, Goldman M, Kinney JP, et al. Cell diversity and network dynamics in photosensitive human brain organoids. Nature. 2017;545:48&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5659341</ArticleId><ArticleId IdType="pubmed">28445462</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja WK, Mungenast AE, Lin YT, Ko T, Abdurrob F, Seo J, Tsai LH. Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer&#x2019;s Disease Phenotypes. PLoS One. 2016;11:e0161969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5021368</ArticleId><ArticleId IdType="pubmed">27622770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281&#x2013;2308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JT, Thorvaldsd&#xf3;ttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346182</ArticleId><ArticleId IdType="pubmed">21221095</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell. 2014;158:15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">24995975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarius H, Heneka MT. Microglia in Alzheimer&#x2019;s disease. J Clin Invest. 2017;127:3240&#x2013;3249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669553</ArticleId><ArticleId IdType="pubmed">28862638</ArticleId></ArticleIdList></Reference><Reference><Citation>Seipel K, O&#x2019;Brien SP, Iannotti E, Medley QG, Streuli M. Tara, a novel F-actin binding protein, associates with the Trio guanine nucleotide exchange factor and regulates actin cytoskeletal organization. J Cell Sci. 2001;114:389&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148140</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics. 2012;28:1353&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348564</ArticleId><ArticleId IdType="pubmed">22492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahin H, Walsh T, Sobe T, Abu Sa&#x2019;ed J, Abu Rayan A, Lynch ED, Lee MK, Avraham KB, King MC, Kanaan M. Mutations in a novel isoform of TRIOBP that encodes a filamentous-actin binding protein are responsible for DFNB28 recessive nonsyndromic hearing loss. Am J Hum Genet. 2006;78:144&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1380212</ArticleId><ArticleId IdType="pubmed">16385458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, Bowman AB, Aschner M. Role of astrocytes in brain function and disease. Toxicol Pathol. 2011;39:115&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6218934</ArticleId><ArticleId IdType="pubmed">21075920</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USa. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USa. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Theendakara V, Peters-Libeu CA, Spilman P, Poksay KS, Bredesen DE, Rao RV. Direct Transcriptional Effects of Apolipoprotein E. J Neurosci. 2016;36:685&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719010</ArticleId><ArticleId IdType="pubmed">26791201</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh WH, Gleeson PA. Dysregulation of intracellular trafficking and endosomal sorting in Alzheimer&#x2019;s disease: controversies and unanswered questions. Biochem J. 2016;473:1977&#x2013;1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">27407168</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334321</ArticleId><ArticleId IdType="pubmed">22383036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Holtzman DM. TREM2 Function in Alzheimer&#x2019;s Disease and Neurodegeneration. ACS Chem Neurosci. 2016;7:420&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">26854967</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME, Yoon SY, Yuan H, Li G, Miller ZA, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small molecule structure corrector. Nat Med. 2018 doi: 10.1038/s41591-018-0004-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0004-z</ArticleId><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="pubmed">29632371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med. 2003;9:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612547</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006;26:4985&#x2013;4994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Fang Y, Lian Y, Chen Y, Wu T, Zheng Y, Zong H, Sun L, Zhang R, Wang Z, et al. Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer&#x2019;s disease induced by a&#x3b2;1-42. PLoS One. 2015;10:e0122415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388634</ArticleId><ArticleId IdType="pubmed">25849905</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, et al. Model-based analysis of ChiP-Seq (MACS) Genome Biol. 2008;9:R137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592715</ArticleId><ArticleId IdType="pubmed">18798982</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MSB, Li G, et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron. 2016;89:37&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Davis MD, Martens YA, Shinohara M, Graff-Radford NR, Younkin SG, Wszolek ZK, Kanekiyo T, Bu G. APOE &#x3b5;4/&#x3b5;4 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum Mol Genet. 2017;26:2690&#x2013;2700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886091</ArticleId><ArticleId IdType="pubmed">28444230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30009200</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-9503</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>832</StartPage><EndPage>842</EndPage><MedlinePgn>832-842</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.582</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The genetic bases of Alzheimer's disease remain uncertain. An international effort to fully articulate genetic risks and protective factors is underway with the hope of identifying potential therapeutic targets and preventive strategies. The goal here was to identify and characterize the frequency and impact of rare and ultra-rare variants in Alzheimer's disease, using whole-exome sequencing in 20,197 individuals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a gene-based collapsing analysis of loss-of-function ultra-rare variants in a case-control study design with data from the Washington Heights-Inwood Columbia Aging Project, the Alzheimer's Disease Sequencing Project and unrelated individuals from the Institute of Genomic Medicine at Columbia University.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 19 cases carrying extremely rare <i>SORL1</i> loss-of-function variants among a collection of 6,965 cases and a single loss-of-function variant among 13,252 controls (<i>P</i> = 2.17 &#xd7; 10<sup>-8</sup>; OR: 36.2 [95% CI: 5.8-1493.0]). Age-at-onset was 7 years earlier for patients with <i>SORL1</i> qualifying variant compared with noncarriers. No other gene attained a study-wide level of statistical significance, but multiple top-ranked genes, including <i>GRID2IP</i>,<i>WDR76</i> and <i>GRN,</i> were among candidates for follow-up studies.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">This study implicates ultra-rare, loss-of-function variants in <i>SORL1</i> as a significant genetic risk factor for Alzheimer's disease and provides a comprehensive dataset comparing the burden of rare variation in nearly all human genes in Alzheimer's disease cases and controls. This is the first investigation to establish a genome-wide statistically significant association between multiple extremely rare loss-of-function variants in <i>SORL1</i> and Alzheimer's disease in a large whole-exome study of unrelated cases and controls.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raghavan</LastName><ForeName>Neha S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brickman</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manly</LastName><ForeName>Jennifer J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schupf</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Department of Epidemiology Mailman School of Public Health College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lantigua</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolock</LastName><ForeName>Charles J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Institute of Genomic Medicine Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamalakaran</LastName><ForeName>Sitharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Genomic Medicine Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrovski</LastName><ForeName>Slave</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Genomic Medicine Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AstraZeneca Centre for Genomics Research Precision Medicine and Genomics IMED Biotech Unit AstraZeneca Cambridge CB2 0AA United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosto</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Neurology College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Genomic Medicine Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Department of Epidemiology Mailman School of Public Health College of Physicians and Surgeons Columbia University The New York Presbyterian Hospital New York New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Sequencing Project</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 AG052427</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100011I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL105756</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG003079</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023629</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085081</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100012C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 HL102419</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100009I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085080</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG003067</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100010C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100008C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL080295</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH098126</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100008I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100005G</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085082</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL130114</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100007C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268200800007C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085086</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085083</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100011C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG051876</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS078059</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG047133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG003273</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD048805</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG007672</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS053998</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100006C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG041689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HD080642</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201200036C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH097971</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC055222</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100005I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS077303</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049508</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085079</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052410</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 TR001875</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100009C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100005C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100007I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049506</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000040</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Ann Clin Transl Neurol. 2019 Feb 25;6(2):416. doi: 10.1002/acn3.742.</RefSource><PMID Version="1">30847376</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30009200</ArticleId><ArticleId IdType="pmc">PMC6043775</ArticleId><ArticleId IdType="doi">10.1002/acn3.582</ArticleId><ArticleId IdType="pii">ACN3582</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Consortium UK, Walter K, Min JL, et al. The UK10K project identifies rare variants in health and disease. Nature 2015;526:82&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4773891</ArticleId><ArticleId IdType="pubmed">26367797</ArticleId></ArticleIdList></Reference><Reference><Citation>Keinan A, Clark AG. Recent explosive human population growth has resulted in an excess of rare genetic variants. Science 2012;336:740&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586590</ArticleId><ArticleId IdType="pubmed">22582263</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Gail MH, Weinberg CR, et al. Distribution of allele frequencies and effect sizes and their interrelationships for common genetic susceptibility variants. Proc Natl Acad Sci USA 2011;108:18026&#x2013;18031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207674</ArticleId><ArticleId IdType="pubmed">22003128</ArticleId></ArticleIdList></Reference><Reference><Citation>Auer PL, Lettre G. Rare variant association studies: considerations, challenges and opportunities. Genome Med 2015;7:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4337325</ArticleId><ArticleId IdType="pubmed">25709717</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015;347:1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kc Epi. Epilepsy Phenome/Genome P. Ultra&#x2010;rare genetic variation in common epilepsies: a case&#x2010;control sequencing study. Lancet Neurol 2017;16:135&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">28102150</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Bis JC, Martin ER, et al. The Alzheimer's Disease Sequencing Project: study design and sample selection. Neurol Genet 2017;3:e194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5646177</ArticleId><ArticleId IdType="pubmed">29184913</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS&#x2010;ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Segal J, Stewart WF, et al. A validation study of the Dementia Questionnaire. Arch Neurol 1994;51:901&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080390</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt JS. M.; Folstein, M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol. Behav Neurol 1988;1:111&#x2013;117.</Citation></Reference><Reference><Citation>Farrell CM, O'Leary NA, Harte RA, et al. Current status and new features of the Consensus Coding Sequence database. Nucleic Acids Res 2014;42:D865&#x2013;D872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965069</ArticleId><ArticleId IdType="pubmed">24217909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein&#x2010;coding genetic variation in 60,706 humans. Nature 2016;536:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim&#x2010;Verbaas CA, Harold D, et al. Meta&#x2010;analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta&#x2010;analysis of genomewide association scans. Bioinformatics 2010;26:2190&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell KL, Hyman BT, Growdon JH, Hedley&#x2010;Whyte ET. Application of the National Institute on Aging (NIA)&#x2010;Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1999;58():1147&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pubmed">10560657</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007;114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Hannequin D, Coutant S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early&#x2010;onset Alzheimer disease. Mol Psychiatr 2012;17:875&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">22472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G, Charbonnier C, Wallon D, et al. SORL1 rare variants: a major risk factor for familial early&#x2010;onset Alzheimer's disease. Mol Psychiatry 2016;21:831&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">26303663</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen J, van den Bossche T, van der Zee J, et al. A comprehensive study of the genetic impact of rare variants in SORL1 in European early&#x2010;onset Alzheimer's disease. Acta Neuropathol 2016;132:213&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947104</ArticleId><ArticleId IdType="pubmed">27026413</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuccaro ML, Carney RM, Zhang Y, et al. SORL1 mutations in early&#x2010; and late&#x2010;onset Alzheimer disease. Neurol Genet 2016;2:e116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5082932</ArticleId><ArticleId IdType="pubmed">27822510</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H, van der Lee SJ, Hulsman M, et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. Eur J Hum Genet 2017;25:973&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567154</ArticleId><ArticleId IdType="pubmed">28537274</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin&#x2010;related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C, Charbonnier C, Grenier&#x2010;Boley B, et al. Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol Aging 2017;59:e1&#x2013;e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28789839</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, Zhang Y, Lee JH, et al. Coding mutations in SORL1 and Alzheimer disease. Ann Neurol 2015;77:215&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367199</ArticleId><ArticleId IdType="pubmed">25382023</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoda T, Mochizuki C, Yamashita T, et al. Binding of glutamate receptor delta2 to its scaffold protein, Delphilin, is regulated by PKA. Biochem Biophys Res Commun 2006;350:748&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">17027646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late&#x2010;onset Alzheimer's disease families. PLoS ONE 2012;7:e31039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Kahn A, Cheng R, et al. Disease&#x2010;related mutations among Caribbean Hispanics with familial dementia. Mol Genet Genomic Med 2014;2:430&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4190878</ArticleId><ArticleId IdType="pubmed">25333068</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, McKay A, Singh PP, et al. Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci 2017;18:325&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6040832</ArticleId><ArticleId IdType="pubmed">28435163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley BJ, Haidar W, Boeve BF, et al. Alzheimer disease&#x2010;like phenotype associated with the c.154delA mutation in progranulin. Arch Neurol 2010;67:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902004</ArticleId><ArticleId IdType="pubmed">20142525</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, Lehmann M, Yokoyama JS, et al. Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol 2013;70:774&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3743672</ArticleId><ArticleId IdType="pubmed">23609919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Schupf N, et al. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community&#x2010;based cohort. Arch Neurol 2007;64:501&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639214</ArticleId><ArticleId IdType="pubmed">17420311</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29874583</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Excess Synaptojanin 1 Contributes to Place Cell Dysfunction and Memory Deficits in the Aging Hippocampus in Three Types of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>2967</StartPage><EndPage>2975</EndPage><MedlinePgn>2967-2975</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2018.05.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(18)30744-7</ELocationID><Abstract><AbstractText>The phosphoinositide phosphatase synaptojanin 1 (SYNJ1) is a key regulator of synaptic function. We first tested whether SYNJ1 contributes to phenotypic variations in familial Alzheimer's disease (FAD) and show that SYNJ1 polymorphisms are associated with age of onset in both early- and late-onset human FAD cohorts. We then interrogated whether SYNJ1 levels could directly affect memory. We show that increased SYNJ1 levels in autopsy brains from adults with Down syndrome (DS/AD) are inversely correlated with synaptophysin levels, a direct readout of synaptic integrity. We further report age-dependent cognitive decline in a mouse model overexpressing murine Synj1 to the levels observed in human sporadic AD, triggered through hippocampal hyperexcitability and defects in the spatial reproducibility of place fields. Taken together, our findings suggest that SYNJ1 contributes to memory deficits in the aging hippocampus in all forms of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Andre M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; ICVS/3B's, PT Government Associate Laboratory, 4806-909 Braga/Guimar&#xe3;es, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; G. H. Sergievsky Center, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahmani</LastName><ForeName>Eden</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Micevska</LastName><ForeName>Elizabeta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontaine</LastName><ForeName>Gaelle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, UPMC Univ Paris 06, Inserm U1127, CNRS UMR7225, ICM, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potier</LastName><ForeName>Marie-Claude</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, UPMC Univ Paris 06, Inserm U1127, CNRS UMR7225, ICM, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536-0230, USA; Department of Pharmacology &amp; Nutritional Sciences, University of Kentucky, Lexington, KY 40506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Frederick A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536-0230, USA; Department of Neurology, University of Kentucky, Lexington, KY 40506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lott</LastName><ForeName>Ira T</ForeName><Initials>IT</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Kentucky, Lexington, KY 40506, USA; Department of Pediatrics and Neurology, School of Medicine, University of California, Irvine (UCI), Orange, CA 92668, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Vel&#xe1;zquez</LastName><ForeName>Ivonne Z</ForeName><Initials>IZ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Puerto Rico School of Medicine, San Juan, PR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonarakis</LastName><ForeName>Stylianos E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School and University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; G. H. Sergievsky Center, Columbia University Medical Center, New York, NY 10032, USA; Departments of Epidemiology and Neurology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussaini</LastName><ForeName>S Abid</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marquer</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA. Electronic address: cm3244@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG050425</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD064993</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG051876</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG051412</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD065160</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.-</RegistryNumber><NameOfSubstance UI="C097702">synaptojanin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.2</RegistryNumber><NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071037" MajorTopicYN="N">Place Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long-term memory</Keyword><Keyword MajorTopicYN="N">SYNJ1</Keyword><Keyword MajorTopicYN="N">hyperexcitability</Keyword><Keyword MajorTopicYN="N">in&#xa0;vivo electrophysiology</Keyword><Keyword MajorTopicYN="N">neurodegenerative disorders</Keyword><Keyword MajorTopicYN="N">single nucleotide polymorphisms</Keyword><Keyword MajorTopicYN="N">synaptic dysfunction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29874583</ArticleId><ArticleId IdType="mid">NIHMS976402</ArticleId><ArticleId IdType="pmc">PMC6040810</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.05.011</ArticleId><ArticleId IdType="pii">S2211-1247(18)30744-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alharby E, Albalawi AM, Nasir A, Alhijji SA, Mahmood A, Ramzan K, Abdusamad F, Aljohani A, Abdelsalam O, Eldardear A, et al. (2017). A homozygous potentially pathogenic variant in the PAXBP1 gene in a large family with global developmental delay and myopathic hypotonia. Clin. Genet 92, 579&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">28542722</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonarakis SE (2017). Down syndrome and the complexity of genome dosage imbalance. Nat. Rev. Genet 18, 147&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">28029161</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai Y, Ijuin T, Takenawa T, Becker LE, and Takashima S (2002). Excessive expression of synaptojanin in brains with Down syndrome. Brain Dev 24, 67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">11891094</ArticleId></ArticleIdList></Reference><Reference><Citation>Athan ES, Williamson J, Ciappa A, Santana V, Romas SN, Lee JH, Rondon H, Lantigua RA, Medrano M, Torres M, et al. (2001). A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA 286, 2257&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">11710891</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin-Tse C, Halbritter J, Zariwala MA, Gilberti RM, Gee HY, Hellman N, Pathak N, Liu Y, Panizzi JR, Patel-King RS, et al. (2013). Zebrafish ciliopathy screen plus human mutational analysis identifies C21orf59 and CCDC65 defects as causing primary ciliary dyskinesia. Am. J. Hum. Genet 93, 672&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791264</ArticleId><ArticleId IdType="pubmed">24094744</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman DE, Dall&#x2019;Armi C, Voronov SV, McIntire LBJ, Zhang H, Moore AZ, Staniszewski A, Arancio O, Kim TW, and Di Paolo G (2008). Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. Nat. Neurosci 11, 547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2532986</ArticleId><ArticleId IdType="pubmed">18391946</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao M, Wu Y, Ashrafi G, McCartney AJ, Wheeler H, Bushong EA, Boassa D, Ellisman MH, Ryan TA, and De Camilli P (2017). Parkinson Sac domain mutation in synaptojanin 1 impairs clathrin uncoating at synapses and triggers dystrophic changes in dopaminergic axons. Neuron 93, 882&#x2013;896.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340420</ArticleId><ArticleId IdType="pubmed">28231468</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, and Nixon RA (2000). Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol 157, 277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Petanceska S, Peterhoff CM, Terio NB, Epstein CJ, Villar A, Carlson EJ, Staufenbiel M, and Nixon RA (2003). App gene dosage modulates endosomal abnormalities of Alzheimer&#x2019;s disease in a segmental trisomy 16 mouse model of down syndrome. J. Neurosci 23, 6788&#x2013;6792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740714</ArticleId><ArticleId IdType="pubmed">12890772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Meigs JB, and Dupuis J (2013). Sequence kernel association test for quantitative traits in family samples. Genet. Epidemiol 37, 196&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3642218</ArticleId><ArticleId IdType="pubmed">23280576</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Wang C, Conomos MP, Stilp AM, Li Z, Sofer T, Szpiro AA, Chen W, Brehm JM, Celed&#xf3;n JC, et al. (2016). Control for population structure and relatedness for binary traits in genetic association studies via logistic mixed models. Am. J. Hum. Genet 98, 653&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4833218</ArticleId><ArticleId IdType="pubmed">27018471</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CYK, Thompson EA, and Wijsman EM (2013). GIGI: an approach to effective imputation of dense genotypes on large pedigrees. Am. J. Hum. Genet 92, 504&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617386</ArticleId><ArticleId IdType="pubmed">23561844</ArticleId></ArticleIdList></Reference><Reference><Citation>Corlier F, Rivals I, Lagarde J, Hamelin L, Corne H, Dauphinot L, Ando K, Cossec JC, Fontaine G, Doroth&#xe9;e G, et al.; Clinical ImaBio3 Team (2015). Modifications of the endosomal compartment in peripheral blood mononuclear cells and fibroblasts from Alzheimer&#x2019;s disease patients. Transl. Psychiatry 5, e595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5068716</ArticleId><ArticleId IdType="pubmed">26151923</ArticleId></ArticleIdList></Reference><Reference><Citation>Cossec JC, Lavaur J, Berman DE, Rivals I, Hoischen A, Stora S, Ripoll C, Mircher C, Grattau Y, Olivomarin JC, et al. (2012). Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Hum. Mol. Genet 21, 3156&#x2013;3172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384382</ArticleId><ArticleId IdType="pubmed">22511594</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremona O, Di Paolo G, Wenk MR, L&#xfc;thi A., Kim WT, Takei K, Daniell L, Nemoto Y, Shears SB, Flavell RA, et al. (1999). Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell 99, 179&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10535736</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremona O, Nimmakayalu M, Haffner C, Bray-Ward P, Ward DC, and De Camilli P (2000). Assignment of SYNJ1 to human chromosome 21q22.2 and Synj12 to the murine homologous region on chromosome 16C3-4 by in situ hybridization. Cytogenet. Cell Genet 88, 89&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">10773674</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaneau O, Zagury JF, and Marchini J (2013). Improved whole-chromosome phasing for disease and population genetic studies. Nat. Methods 10, 5&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23269371</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paolo G, Moskowitz HS, Gipson K, Wenk MR, Voronov S, Obayashi M, Flavell R, Fitzsimonds RM, Ryan TA, and De Camilli P (2004). Impaired PtdIns(4,5)P2 synthesis in nerve terminals produces defects in synaptic vesicle trafficking. Nature 431, 415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">15386003</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao Y, Guo X, Li Y, Sun K, Lu L, Jiang L, Fu X, Zhu H, Sun H, Wang H, and Wu Z (2012). Pax3/7BP is a Pax7- and Pax3-binding protein that regulates the proliferation of muscle precursor cells by an epigenetic mechanism. Cell Stem Cell 11, 231&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">22862948</ArticleId></ArticleIdList></Reference><Reference><Citation>Downes EC, Robson J, Grailly E, Abdel-All Z, Xuereb J, Brayne C, Holland A, Honer WG, and Mukaetova-Ladinska EB (2008). Loss of synaptophysin and synaptosomal-associated protein 25-kDa (SNAP-25) in elderly Down syndrome individuals. Neuropathol. Appl. Neurobiol 34, 12&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18005332</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong LW, and De Camilli P (2008). Regulation of postsynaptic AMPA responses by synaptojanin 1. Proc. Natl. Acad. Sci. U S A 105, 17561&#x2013;17566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2579885</ArticleId><ArticleId IdType="pubmed">18987319</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyant-Mar&#xe9;chal L, Rovelet-Lecrux A, Goumidi L, Cousin E, Hannequin D, Raux G, Penet C, Ricard S, Mac&#xe9; S, Amouyel P, et al. (2007). Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology 68, 684&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325276</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie BN, Donnelly P, and Marchini J (2009). A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 5, e1000529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689936</ArticleId><ArticleId IdType="pubmed">19543373</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B, Fuchsberger C, Stephens M, Marchini J, and Abecasis GR (2012). Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet 44, 955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696580</ArticleId><ArticleId IdType="pubmed">22820512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussaini SA, Kempadoo KA, Thuault SJ, Siegelbaum SA, and Kandel ER (2011). Increased size and stability of CA1 and CA3 place fields in HCN1 knockout mice. Neuron 72, 643&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435580</ArticleId><ArticleId IdType="pubmed">22099465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe KM, Grimes DT, Schottenfeld-Roames J, Werner ME, Ku TSJ, Kim SK, Pelliccia JL, Morante NFC, Mitchell BJ, and Burdine RD (2016). c21orf59/kurly Controls Both Cilia Motility and Polarization. Cell Rep 14, 1841&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4775428</ArticleId><ArticleId IdType="pubmed">26904945</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, and Nixon RA (2010). Alzheimer&#x2019;s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. U S A 107, 1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WT, Chang S, Daniell L, Cremona O, Di Paolo G, and De Camilli P (2002). Delayed reentry of recycling vesicles into the fusion-competent synaptic vesicle pool in synaptojanin 1 knockout mice. Proc. Natl. Acad. Sci. U S A 99, 17143&#x2013;17148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139283</ArticleId><ArticleId IdType="pubmed">12481038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirola L, Behari M, Shishir C, and Thelma BK (2016). Identification of a novel homozygous mutation Arg459Pro in SYNJ1 gene of an Indian family with autosomal recessive juvenile Parkinsonism. Parkinsonism Relat. Disord 31, 124&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">27496670</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs CE, Karkheiran S, Powell JC, Cao M, Makarov V, Darvish H, Di Paolo G, Walker RH, Shahidi GA, Buxbaum JD, et al. (2013). The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum. Mutat 34, 1200&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790461</ArticleId><ArticleId IdType="pubmed">23804563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al.; European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology (2013). Metaanalysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet 45, 1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Landman N, Jeong SY, Shin SY, Voronov SV, Serban G, Kang MS, Park MK, Di Paolo G, Chung S, and Kim TW (2006). Presenilin mutations linked to familial Alzheimer&#x2019;s disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc. Natl. Acad. Sci. U S A 103, 19524&#x2013;19529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748258</ArticleId><ArticleId IdType="pubmed">17158800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Barral S, Reitz C, Medrano M, Lantigua R, Jim&#xe9;nez-Velazquez IZ, Rogaeva E, St George-Hyslop PH, and Mayeux R (2011). Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch. Neurol 68, 320&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268783</ArticleId><ArticleId IdType="pubmed">21059989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Vardarajan B, Lantigua R, Reyes-Dumeyer D, Ortmann W, Graham RR, Bhangale T, Behrens TW, Medrano M, et al. (2015). Genetic modifiers of age at onset in carriers of the G206A mutation in PSEN1 with familial Alzheimer disease among Caribbean Hispanics. JAMA Neurol 72, 1043&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010776</ArticleId><ArticleId IdType="pubmed">26214276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv H, Jia L, and Jia J (2008). Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer&#x2019;s disease. Neurobiol. Aging 29, 194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">17112637</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani M, Lee SY, Lucast L, Cremona O, Di Paolo G, De Camilli P, and Ryan TA (2007). The dual phosphatase activity of synaptojanin1 is required for both efficient synaptic vesicle endocytosis and reavailability at nerve terminals. Neuron 56, 1004&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653591</ArticleId><ArticleId IdType="pubmed">18093523</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin SB, Dowling ALS, Lianekhammy J, Lott IT, Doran E, Murphy MP, Beckett TL, Schmitt FA, and Head E (2014). Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer&#x2019;s disease. J. Alzheimers Dis 42, 767&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4392817</ArticleId><ArticleId IdType="pubmed">24927707</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Terry RD, DeTeresa RM, and Hansen LA (1989). Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett 103, 234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">2505201</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Terry RD, Alford M, DeTeresa R, and Hansen LA (1991). Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer&#x2019;s disease. Am. J. Pathol 138, 235&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886043</ArticleId><ArticleId IdType="pubmed">1899001</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntire LB, Berman DE, Myaeng J, Staniszewski A, Arancio O, Di Paolo G, and Kim TW (2012). Reduction of synaptojanin 1 ameliorates synaptic and behavioral impairments in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci 32, 15271&#x2013;15276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711720</ArticleId><ArticleId IdType="pubmed">23115165</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, and Stadlan EM (1984). Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 34, 939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson PS, Garcia EP, Slepnev VI, David C, Zhang X, Grabs D, Sossin WS, Bauerfeind R, Nemoto Y, and De Camilli P (1996). A presynaptic inositol-5-phosphatase. Nature 379, 353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">8552192</ArticleId></ArticleIdList></Reference><Reference><Citation>Olgiati S, De Rosa A, Quadri M, Criscuolo C, Breedveld GJ, Picillo M, Pappat&#xe0; S, Quarantelli M, Barone P, De Michele G, and Bonifati V (2014). PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family. Neurogenetics 15, 183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">24816432</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, Wu B, Xu F, Erro R, Amboni M, et al.; International Parkinsonism Genetics Network (2013). Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum. Mutat 34, 1208&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">23804577</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, and LaFerla FM (2010). Alzheimer&#x2019;s disease. N. Engl. J. Med 362, 329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W Jr., Kaye J, and Manczak M (2005). Differential loss of synaptic proteins in Alzheimer&#x2019;s disease: implications for synaptic dysfunction. J. Alzheimers Dis 7, 103&#x2013;117, discussion 173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851848</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Brayne C, and Mayeux R (2011). Epidemiology of Alzheimer disease. Nat. Rev. Neurol 7, 137&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339565</ArticleId><ArticleId IdType="pubmed">21304480</ArticleId></ArticleIdList></Reference><Reference><Citation>Romas SN, Santana V, Williamson J, Ciappa A, Lee JH, Rondon HZ, Estevez P, Lantigua R, Medrano M, Torres M, et al. (2002). Familial Alzheimer disease among Caribbean Hispanics: a reexamination of its association with APOE. Arch. Neurol 59, 87&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790235</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoub TR, deToledo-Morrell L, Stebbins GT, Leurgans S, Bennett DA, and Shah RC (2006). Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U S A 103, 10041&#x2013;10045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479867</ArticleId><ArticleId IdType="pubmed">16785436</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, and Roses AD (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U S A 90, 1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, and Katzman R (1991). Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol 30, 572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosto G, Fu H, Vardarajan BN, Lee JH, Cheng R, Reyes-Dumeyer D, Lantigua R, Medrano M, Jimenez-Velazquez IZ, Elkind MSV, et al. (2015). F-box/LRR-repeat protein 7 is genetically associated with Alzheimer&#x2019;s disease. Ann. Clin. Transl. Neurol 2, 810&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4554442</ArticleId><ArticleId IdType="pubmed">26339675</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhauwaert R, Kuenen S, Masius R, Bademosi A, Manetsberger J, Schoovaerts N, Bounti L, Gontcharenko S, Swerts J, Vilain S, et al. (2017). The SAC1 domain in synaptojanin is required for autophagosome maturation at presynaptic terminals. EMBO J 36, 1392&#x2013;1411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5430236</ArticleId><ArticleId IdType="pubmed">28331029</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstreken P, Koh TW, Schulze KL, Zhai RG, Hiesinger PR, Zhou Y, Mehta SQ, Cao Y, Roos J, and Bellen HJ (2003). Synaptojanin is recruited by endophilin to promote synaptic vesicle uncoating. Neuron 40, 733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622578</ArticleId></ArticleIdList></Reference><Reference><Citation>Voronov SV, Frere SG, Giovedi S, Pollina EA, Borel C, Zhang H, Schmidt C, Akeson EC, Wenk MR, Cimasoni L, et al. (2008). Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down&#x2019;s syndrome. Proc. Natl. Acad. Sci. U S A 105, 9415&#x2013;9420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2453748</ArticleId><ArticleId IdType="pubmed">18591654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL, Fisher EM, and Strydom A (2015). A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat. Rev. Neurosci 16, 564&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4678594</ArticleId><ArticleId IdType="pubmed">26243569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Marchani EE, Cheung CYK, Steinbart EJ, Schellenberg GD, Bird TD, and Wijsman EM (2013). Genome scan in familial late-onset Alzheimer&#x2019;s disease: a locus on chromosome 6 contributes to age-at-onset. Am. J. Med. Genet. B. Neuropsychiatr. Genet 162B, 201&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654841</ArticleId><ArticleId IdType="pubmed">23355194</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Zhong M, Zhao J, Rhee H, Caesar I, Knight EM, Volpicelli-Daley L, Bustos V, Netzer W, Liu L, et al. (2013). Reduction of synaptojanin 1 accelerates A&#x1d66; clearance and attenuates cognitive deterioration in an Alzheimer mouse model. J. Biol. Chem 288, 32050&#x2013;32063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814799</ArticleId><ArticleId IdType="pubmed">24052255</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Zhong M, Elder GA, Sano M, Holtzman DM, Gandy S, Cardozo C, Haroutunian V, Robakis NK, and Cai D (2015). Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer&#x2019;s disease pathogenesis. Proc. Natl. Acad. Sci. U S A 112, 11965&#x2013;11970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586834</ArticleId><ArticleId IdType="pubmed">26372964</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29874575</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Tau Activates Transposable Elements in Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>2874</StartPage><EndPage>2880</EndPage><MedlinePgn>2874-2880</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2018.05.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(18)30722-8</ELocationID><Abstract><AbstractText>Aging and neurodegenerative disease are characterized by genomic instability in neurons, including aberrant activation and mobilization of transposable elements (TEs). Integrating studies of human postmortem brain tissue and Drosophila melanogaster models, we investigate TE activation in association with Tau pathology in Alzheimer's disease (AD). Leveraging RNA sequencing from 636 human brains, we discover differential expression for several retrotransposons in association with neurofibrillary tangle burden and highlight evidence for global TE transcriptional activation among the long interspersed nuclear element 1 and endogenous retrovirus clades. In addition, we detect Tau-associated, active chromatin signatures at multiple HERV-Fc1 genomic loci. To determine whether Tau is sufficient to induce&#xa0;TE activation, we profile retrotransposons in Drosophila expressing human wild-type or mutant Tau throughout the brain. We discover heterogeneous response profiles, including both age- and genotype-dependent activation of TE expression by&#xa0;Tau. Our results implicate TE activation and associated genomic instability in Tau-mediated AD mechanisms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Caiwei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA; Jan and Dan Duncan Neurologic Research Institute, Texas Children's Hospital, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hyun-Hwan</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurologic Research Institute, Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Yi-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurologic Research Institute, Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA; Cell Circuits Program, Broad Institute, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA; Cell Circuits Program, Broad Institute, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhandong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurologic Research Institute, Texas Children's Hospital, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA; Jan and Dan Duncan Neurologic Research Institute, Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: joshua.shulman@bcm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG057339</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM120033</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050631</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053960</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR029965</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004251">DNA Transposable Elements</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004251" MajorTopicYN="N">DNA Transposable Elements</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alu</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">ERV</Keyword><Keyword MajorTopicYN="N">LINE1</Keyword><Keyword MajorTopicYN="N">MAPT</Keyword><Keyword MajorTopicYN="N">RNA sequencing</Keyword><Keyword MajorTopicYN="N">chromatin</Keyword><Keyword MajorTopicYN="N">genomic instability</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">retrotransposon</Keyword></KeywordList><CoiStatement>DECLARATION OF INTERESTS. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29874575</ArticleId><ArticleId IdType="mid">NIHMS1506631</ArticleId><ArticleId IdType="pmc">PMC6181645</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.05.004</ArticleId><ArticleId IdType="pii">S2211-1247(18)30722-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adamec E, Vonsattel JP, and Nixon RA (1999). DNA strand breaks in Alzheimer&#x2019;s disease. Brain Res. 849, 67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">10592288</ArticleId></ArticleIdList></Reference><Reference><Citation>Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, Wallace JL, Deacon RM, Warren K, and Power C (2004). Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat. Neurosci 7, 1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">15452578</ArticleId></ArticleIdList></Reference><Reference><Citation>Baillie JK, Barnett MW, Upton KR, Gerhardt DJ, Richmond TA, De Sapio F, Brennan PM, Rizzu P, Smith S, Fell M, et al. (2011). Somatic retrotransposition alters the genetic landscape of the human brain. Nature 479, 534&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224101</ArticleId><ArticleId IdType="pubmed">22037309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao W, Kojima KK, and Kohany O (2015). Repbase Update, a database of repetitive elements in eukaryotic genomes. Mob. DNA 6, 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4455052</ArticleId><ArticleId IdType="pubmed">26045719</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;nit L, Calteau A, and Heidmann T (2003). Characterization of the low-copy HERV-Fc family: evidence for recent integrations in primates of elements with coding envelope genes. Virology 312, 159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890629</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV, and Kazazian HH Jr. (2003). Hot L1s account for the bulk of retrotrans-position in the human population. Proc. Natl. Acad. Sci. USA 100, 5280&#x2013;5285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC154336</ArticleId><ArticleId IdType="pubmed">12682288</ArticleId></ArticleIdList></Reference><Reference><Citation>Coufal NG, Garcia-Perez JL, Peng GE, Yeo GW, Mu Y, Lovci MT, Morell M, O&#x2019;Shea KS, Moran JV, and Gage FH (2009). L1 retrotransposition in human neural progenitor cells. Nature 460, 1127&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909034</ArticleId><ArticleId IdType="pubmed">19657334</ArticleId></ArticleIdList></Reference><Reference><Citation>Coufal NG, Garcia-Perez JL, Peng GE, Marchetto MCN, Muotri AR, Mu Y, Carson CT, Macia A, Moran JV, and Gage FH (2011). Ataxia telangiectasia mutated (ATM) modulates long interspersed element-1 (L1) retro-transposition in human neural stem cells. Proc. Natl. Acad. Sci. USA 108, 20382&#x2013;20387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3251057</ArticleId><ArticleId IdType="pubmed">22159035</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, Eaton ML, Keenan BT, Ernst J, McCabe C, et al. (2014). Alzheimer&#x2019;s disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat. Neurosci 17, 1156&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4292795</ArticleId><ArticleId IdType="pubmed">25129075</ArticleId></ArticleIdList></Reference><Reference><Citation>Deininger P (2011). Alu elements: know the SINEs. Genome Biol. 12, 236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334610</ArticleId><ArticleId IdType="pubmed">22204421</ArticleId></ArticleIdList></Reference><Reference><Citation>Douville R, Liu J, Rothstein J, and Nath A (2011). Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann. Neurol 69, 141&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3052883</ArticleId><ArticleId IdType="pubmed">21280084</ArticleId></ArticleIdList></Reference><Reference><Citation>Evrony GD, Cai X, Lee E, Hills LB, Elhosary PC, Lehmann HS, Parker JJ, Atabay KD, Gilmore EC, Poduri A, et al. (2012). Single-neuron sequencing analysis of L1 retrotransposition and somatic mutation in the human brain. Cell 151, 483&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567441</ArticleId><ArticleId IdType="pubmed">23101622</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Hemberg M, Lewis J, and Feany MB (2014). Tau promotes neurodegeneration through global chromatin relaxation. Nat. Neurosci 17, 357&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012297</ArticleId><ArticleId IdType="pubmed">24464041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai LH, and Kellis M (2015). Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature 518, 365&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Heppner FL, Ransohoff RM, and Becher B (2015). Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci 16, 358&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991443</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubley R, Finn RD, Clements J, Eddy SR, Jones TA, Bao W, Smit AFA, and Wheeler TJ (2016). The Dfam database of repetitive DNA families. Nucleic Acids Res. 44 (D1), D81&#x2013;D89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702899</ArticleId><ArticleId IdType="pubmed">26612867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong HH, Yalamanchili HK, Guo C, Shulman JM, and Liu Z (2018). An ultra-fast and scalable quantification pipeline for transposable elements from next generation sequencing data. Pac. Symp. Biocomput 23, 168&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">29218879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi A, DeCarli C, and Schneider JA (2017). Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 134, 171&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663642</ArticleId><ArticleId IdType="pubmed">28488154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassiotis G, and Stoye JP (2016). Immune responses to endogenous retro-elements: taking the bad with the good. Nat. Rev. Immunol 16, 207&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">27026073</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V, Merlo P, DuBoff B, Fulga TA, Sharp KA, Campbell SD, G&#xf6;tz J, and Feany MB (2012). A neuroprotective role for the DNA damage checkpoint in tauopathy. Aging Cell 11, 360&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">22181010</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein H-U, McCabe C, Gjoneska E, Sullivan SE, Kaskow BJ, Tang A, Smith RV, Xu J, Pfenning AR, Bernstein BE, et al. (2018). Epigenome-wide study uncovers tau pathology-driven changes of chromatin organization in the aging human brain. bioRxiv. 10.1101/273789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/273789</ArticleId><ArticleId IdType="pmc">PMC6516529</ArticleId><ArticleId IdType="pubmed">30559478</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug L, Chatterjee N, Borges-Monroy R, Hearn S, Liao WW, Morrill K, Prazak L, Rozhkov N, Theodorou D, Hammell M, and Dubnau J (2017). Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. PLoS Genet. 13, e1006635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5354250</ArticleId><ArticleId IdType="pubmed">28301478</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin HL, and Moran JV (2011). Dynamic interactions between transposable elements and their hosts. Nat. Rev. Genet 12, 615&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192332</ArticleId><ArticleId IdType="pubmed">21850042</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Jin Y, Prazak L, Hammell M, and Dubnau J (2012). Transposable elements in TDP-43-mediated neurodegenerative disorders. PLoS ONE 7, e44099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3434193</ArticleId><ArticleId IdType="pubmed">22957047</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Prazak L, Chatterjee N, Gr&#xfc;ninger S, Krug L, Theodorou D, and Dubnau J (2013). Activation of transposable elements during aging and neuronal decline in Drosophila. Nat. Neurosci 16, 529&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821974</ArticleId><ArticleId IdType="pubmed">23563579</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee MH, Henderson L, Tyagi R, Bachani M, Steiner J, Campanac E, Hoffman DA, von Geldern G, Johnson K, et al. (2015). Human endogenous retrovirus-K contributes to motor neuron disease. Sci. Transl. Med 7, 307ra153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Madabhushi R, Pan L, and Tsai LH (2014). DNA damage and its links to neurodegeneration. Neuron 83, 266&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564444</ArticleId><ArticleId IdType="pubmed">25033177</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlor RL, Parkhurst SM, and Corces VG (1986). The Drosophila melanogaster gypsy transposable element encodes putative gene products homologous to retroviral proteins. Mol. Cell. Biol 6, 1129&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC367623</ArticleId><ArticleId IdType="pubmed">3023871</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell PH, Burhans WC, and Curcio MJ (2011). Retrotransposition is associated with genome instability during chronological aging. Proc. Natl. Acad. Sci. USA 108, 20376&#x2013;20381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3251071</ArticleId><ArticleId IdType="pubmed">22021441</ArticleId></ArticleIdList></Reference><Reference><Citation>Morandi E, Tanasescu R, Tarlinton RE, Constantinescu CS, Zhang W, Tench C, and Gran B (2017). The association between human endogenous retroviruses and multiple sclerosis: a systematic review and meta-analysis. PLoS ONE 12, e0172415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5313176</ArticleId><ArticleId IdType="pubmed">28207850</ArticleId></ArticleIdList></Reference><Reference><Citation>Muotri AR, Chu VT, Marchetto MCN, Deng W, Moran JV, and Gage FH (2005). Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. Nature 435, 903&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">15959507</ArticleId></ArticleIdList></Reference><Reference><Citation>Muotri AR, Marchetto MCN, Coufal NG, Oefner R, Yeo G, Nakashima K, and Gage FH (2010). L1 retrotransposition in neurons is modulated by MeCP2. Nature 468, 443&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059197</ArticleId><ArticleId IdType="pubmed">21085180</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrat PN, DasGupta S, Wang J, Theurkauf W, Weng Z, Rosbash M, and Waddell S (2013). Transposition-driven genomic heterogeneity in the Drosophila brain. Science 340, 91&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887341</ArticleId><ArticleId IdType="pubmed">23559253</ArticleId></ArticleIdList></Reference><Reference><Citation>Protasova MS, Gusev FE, Grigorenko AP, Kuznetsova IL, Rogaev EI, and Andreeva TV (2017). Quantitative analysis of L1-retrotransposons in Alzheimer&#x2019;s disease and aging. Biochemistry (Mosc.) 82, 962&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">28941465</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Gonzales PK, Cook CN, Gendron TF, Daughrity LM, Song Y, Ebbert MTW, van Blitterswijk M, Zhang YJ, Jansen-West K, et al. (2017). Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients. Hum. Mol. Genet 26, 3421&#x2013;3431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886204</ArticleId><ArticleId IdType="pubmed">28637276</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, and LaFerla FM (2010). Alzheimer&#x2019;s disease. N. Engl. J. Med 362, 329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldi TK, Ash PE, Wilson G, Gonzales P, Garrido-Lecca A, Roberts CM, Dostal V, Gendron TF, Stein LD, Blumenthal T, et al. (2014). TDP-1, the Caenorhabditis elegans ortholog of TDP-43, limits the accumulation of double-stranded RNA. EMBO J. 33, 2947&#x2013;2966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282642</ArticleId><ArticleId IdType="pubmed">25391662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H, Qurashi A, Poidevin M, Nelson DL, Li H, and Jin P (2012). Retrotransposon activation contributes to fragile X premutation rCGG-mediated neurodegeneration. Hum. Mol. Genet 21, 57&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235010</ArticleId><ArticleId IdType="pubmed">21940752</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WG, Kaneko H, Fowler BJ, Bogdanovich S, et al. (2012). DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflamma-some and MyD88. Cell 149, 847&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351582</ArticleId><ArticleId IdType="pubmed">22541070</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton KR, Gerhardt DJ, Jesuadian JS, Richardson SR, S&#xe1;nchez-Luque FJ, Bodea GO, Ewing AD, Salvador-Palomeque C, van der Knaap MS, Brennan PM, et al. (2015). Ubiquitous L1 mosaicism in hippocampal neurons. Cell 161, 228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4398972</ArticleId><ArticleId IdType="pubmed">25860606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, and Feany MB (2001). Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JG, Jones BC, Jiang N, Chang C, Hosier S, Wickremesinghe P, Garcia M, Hartnett DA, Burhenn L, Neretti N, and Helfand SL (2016). Chromatin-modifying genetic interventions suppress age-associated transposable element activation and extend life span in Drosophila. Proc. Natl. Acad. Sci. USA 113, 11277&#x2013;11282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056045</ArticleId><ArticleId IdType="pubmed">27621458</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29889941</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1070</EndPage><MedlinePgn>1062-1070</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.1346</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Previous studies have evaluated the diagnostic effect of amyloid positron emission tomography (PET) in selected research cohorts. However, these research populations do not reflect daily practice, thus hampering clinical implementation of amyloid imaging.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the association of amyloid PET with changes in diagnosis, diagnostic confidence, treatment, and patients' experiences in an unselected memory clinic cohort.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Amyloid PET using fluoride-18 florbetaben was offered to 866 patients who visited the tertiary memory clinic at the VU University Medical Center between January 2015 and December 2016 as part of their routine diagnostic dementia workup. Of these patients, 476 (55%) were included, 32 (4%) were excluded, and 358 (41%) did not participate. To enrich this sample, 31 patients with mild cognitive impairment from the University Medical Center Utrecht memory clinic were included. For each patient, neurologists determined a preamyloid and postamyloid PET diagnosis that existed of both a clinical syndrome (dementia, mild cognitive impairment, or subjective cognitive decline) and a suspected etiology (Alzheimer disease [AD] or non-AD), with a confidence level ranging from 0% to 100%. In addition, the neurologist determined patient treatment in terms of ancillary investigations, medication, and care. Each patient received a clinical follow-up 1 year after being scanned.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Primary outcome measures were post-PET changes in diagnosis, diagnostic confidence, and patient treatment.</AbstractText><AbstractText Label="RESULTS">Of the 507 patients (mean [SD] age, 65 (8) years; 201 women [39%]; mean [SD] Mini-Mental State Examination score, 25 [4]), 164 (32%) had AD dementia, 70 (14%) non-AD dementia, 114 (23%) mild cognitive impairment, and 159 (31%) subjective cognitive decline. Amyloid PET results were positive for 242 patients (48%). The suspected etiology changed for 125 patients (25%) after undergoing amyloid PET, more often due to a negative (82 of 265 [31%]) than a positive (43 of 242 [18%]) PET result (P&#x2009;&lt;&#x2009;.01). Post-PET changes in suspected etiology occurred more frequently in patients older (&gt;65 years) than younger (&lt;65 years) than the typical age at onset of 65 years (74 of 257 [29%] vs 51 of 250 [20%]; P&#x2009;&lt;&#x2009;.05). Mean diagnostic confidence (SD) increased from 80 (13) to 89 (13%) (P&#x2009;&lt;&#x2009;.001). In 123 patients (24%), there was a change in patient treatment post-PET, mostly related to additional investigations and therapy.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This prospective diagnostic study provides a bridge between validating amyloid PET in a research setting and implementing this diagnostic tool in daily clinical practice. Both amyloid-positive and amyloid-negative results had substantial associations with changes in diagnosis and treatment, both in patients with and without dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Wilde</LastName><ForeName>Arno</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Biostatistics, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelkmans</LastName><ForeName>Wiesje</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouwman</LastName><ForeName>Femke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verwer</LastName><ForeName>Jurre</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groot</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiology &amp; Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Buchem</LastName><ForeName>Marieke M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwan</LastName><ForeName>Marissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology &amp; Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaqub</LastName><ForeName>Maqsood</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology &amp; Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunneman</LastName><ForeName>Marleen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam Neuroscience, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smets</LastName><ForeName>Ellen M A</ForeName><Initials>EMA</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam Neuroscience, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Radiology &amp; Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institutes of Neurology and Healthcare Engineering, University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lammertsma</LastName><ForeName>Adriaan A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Radiology &amp; Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Piramal Imaging GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Lier</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>BV Cyclotron, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biessels</LastName><ForeName>Geert Jan</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Berckel</LastName><ForeName>Bart N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology &amp; Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>TLA7312TOI</RegistryNumber><NameOfSubstance UI="C527756">4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2018 Sep 1;75(9):1045-1046. doi: 10.1001/jamaneurol.2018.1010.</RefSource><PMID Version="1">29889928</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="Y">Clinical Decision-Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013267" MajorTopicYN="N">Stilbenes</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Lammertsma is currently the principal investigator of a study sponsored by Avid. Research programs of Dr van der Flier have been funded by ZonMW, the Netherlands Organization of Scientific Research, Seventh European Framework Programme, Alzheimer Nederland, Cardiovascular Onderzoek Nederland, Stichting Dioraphte, Gieskes-Strijbis fonds, Boehringer Ingelheim, Piramal Imaging, Roche BV, Janssen Stellar, and Combinostics. All funding is paid to her institution. Dr Barkhof is a consultant for Biogen-Idec, Janssen Alzheimer Immunotherapy, Bayer-Schering, Merck-Serono, Roche, Novartis, Genzume, and Sanofi-Aventis; has received sponsoring from European Commission&#x2013;Horizon 2020, National Institute for Health Research&#x2013;University College London Hospitals Biomedical Research Centre, Scottish Multiple Sclerosis Register, TEVA, Novartis, and Toshiba; is supported by the University College London Hospitals NHS Foundation Trust Biomedical Research Center; and serves on the editorial boards of <i>Radiology</i>, <i>Brain</i>, <i>Neuroradiology</i>, <i>Multiple Sclerosis Journal</i>, and <i>Neurology</i>. Dr Stephens is a full-time employee of Piramal Imaging GmbH and owns stock. Dr van Lier is a full-time employee of BV Cyclotron VU. Dr Scheltens has acquired grant support (for the institution) from GE Healthcare, Danone Research, Piramal, and Merck. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Lilly, GE Healthcare, Novartis, Sanofi, Nutricia, Probiodrug, Biogen, Roche, Avraham, and EIP Pharma. No other disclosures are reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29889941</ArticleId><ArticleId IdType="pmc">PMC6143118</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.1346</ArticleId><ArticleId IdType="pii">2683867</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. . Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Blennow K, Breteler MMB, et al. . Alzheimer&#x2019;s disease. Lancet. 2016;388(10043):505-517.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, et al. ; AV-45-A16 Study Group . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3b2; plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669-678.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Beach TG, Zanette M, et al. . [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer&#x2019;s disease: specific detection of advanced phases of amyloid-&#x3b2; pathology. Alzheimers Dement. 2015;11(8):975-985.</Citation><ArticleIdList><ArticleId IdType="pubmed">26141264</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabri O, Sabbagh MN, Seibyl J, et al. ; Florbetaben Phase 3 Study Group . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer&#x2019;s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964-974.</Citation><ArticleIdList><ArticleId IdType="pubmed">25824567</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo JM, Waddell B, Khan Z, Pal S. A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer&#x2019;s disease. Alzheimers Dement (Amst). 2015;1(1):5-13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876886</ArticleId><ArticleId IdType="pubmed">27239488</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Minoshima S, Bohnen NI, et al. ; Alzheimer&#x2019;s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce . Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer&#x2019;s Association. Alzheimers Dement. 2013;9(1):e-1-e-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733252</ArticleId><ArticleId IdType="pubmed">23360977</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58(11):1711-1717.</Citation><ArticleIdList><ArticleId IdType="pubmed">28818990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiotis K, Saint-Aubert L, Boccardi M, et al. ; Geneva Task Force for the Roadmap of Alzheimer&#x2019;s Biomarkers . Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer&#x2019;s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214-227.</Citation><ArticleIdList><ArticleId IdType="pubmed">28317650</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wilde A, van Maurik IS, Kunneman M, et al. . Alzheimer&#x2019;s biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimers Dement (Amst). 2017;6:143-151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5318541</ArticleId><ArticleId IdType="pubmed">28239639</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, Ramakers IH, Biessels GJ, et al. . The Dutch Parelsnoer Institute&#x2014;neurodegenerative diseases; methods, design and baseline results. BMC Neurol. 2014;14(1):254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301568</ArticleId><ArticleId IdType="pubmed">25551191</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Flier WM, Pijnenburg YAL, Prins N, et al. . Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41(1):313-327.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614907</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Agid Y, Calne D, et al. . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710059</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54(suppl 5):S15-S19.</Citation><ArticleIdList><ArticleId IdType="pubmed">12833363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n GC, Tatemichi TK, Erkinjuntti T, et al. . Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250-260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, et al. . Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546-1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. ; Consortium on DLB . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1983.</Citation></Reference><Reference><Citation>Mishel MH. The measurement of uncertainty in illness. Nurs Res. 1981;30(5):258-263.</Citation><ArticleIdList><ArticleId IdType="pubmed">6912987</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhage F. Intelligentie en Leeftijd: Onderzoek Bij Nederlanders Van Twaalf Tot Zevenenzeventig Jaar [Intelligence and Age: Study with Dutch People Aged 12 to 77]. Assen, Netherlands: van Gorcum; 1964.</Citation></Reference><Reference><Citation>Frisoni GB, Boccardi M, Barkhof F, et al. . Strategic roadmap for an early diagnosis of Alzheimer&#x2019;s disease based on biomarkers. Lancet Neurol. 2017;16(8):661-676.</Citation><ArticleIdList><ArticleId IdType="pubmed">28721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidman DA, Zamrini E, Sabbagh MN, et al. . Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia. Neurocase. 2017;23(1):41-51.</Citation><ArticleIdList><ArticleId IdType="pubmed">28376695</ArticleId></ArticleIdList></Reference><Reference><Citation>Degerman Gunnarsson M, Lindau M, Santillo AF, et al. . Re-evaluation of clinical dementia diagnoses with Pittsburgh compound B positron emission tomography. Dement Geriatr Cogn Dis Extra. 2013;3(1):472-481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3919484</ArticleId><ArticleId IdType="pubmed">24516415</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederiksen KS, Hasselbalch SG, Hejl AM, Law I, H&#xf8;jgaard L, Waldemar G. Added diagnostic value of (11)C-PiB-PET in memory clinic patients with uncertain diagnosis. Dement Geriatr Cogn Dis Extra. 2012;2(1):610-621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551383</ArticleId><ArticleId IdType="pubmed">23341826</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;necker S, Prix C, Raiser T, et al. . [Amyloid positron-emission-tomography with [18&#x2009;F]-florbetaben in the diagnostic workup of dementia patients]. Nervenarzt. 2017;88(2):156-161.</Citation><ArticleIdList><ArticleId IdType="pubmed">27913818</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensa&#xef;dane MR, Beauregard J-M, Poulin S, et al. . Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers. J Alzheimers Dis. 2016;52(4):1251-1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">27104896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccaldi M, Jonveaux T, Verger A, et al. . Impact of florbetaben PET imaging on diagnosis and management of patients with suspected Alzheimer&#x2019;s disease eligible for CSF analysis in France. J Nucl Med. 2017;58(suppl 1):561-561.</Citation></Reference><Reference><Citation>Khan SR, Patel NH, Wallitt KL, et al. . First experience of 100 clinical F-18 florbetapir (Amyvid) PET/CT scans in the investigation of cognitive impairment: imaging characteristics, inter-observer agreement, confidence of read and clinical outcomes. Eur J Nucl Med Mol Imaging. 2016;43:S624-S624.</Citation></Reference><Reference><Citation>Zwan MD, Bouwman FH, Konijnenberg E, et al. . Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9(1):2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5240413</ArticleId><ArticleId IdType="pubmed">28093088</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea YF, Ha J, Lee SC, Chu LW. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer&#x2019;s disease and other dementias in a regional memory clinic in Hong Kong. Hong Kong Med J. 2016;22(4):327-333.</Citation><ArticleIdList><ArticleId IdType="pubmed">27313272</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Juan P, Ghosh PM, Hagen J, et al. . Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014;82(3):230-238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3902757</ArticleId><ArticleId IdType="pubmed">24353340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Prins ND, Pijnenburg YAL, et al. . Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9(4):414-421.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsis EM, Bender HA, Kostakoglu L, et al. . A consecutive case series experience with [18&#x2009;F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener. 2014;9(1):10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913628</ArticleId><ArticleId IdType="pubmed">24484858</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundman M, Johnson KA, Lu M, et al. ; 18F-AV-45-A17 Study Group . Effect of amyloid imaging on the diagnosis and management of patients with cognitive decline: impact of appropriate use criteria. Dement Geriatr Cogn Disord. 2016;41(1-2):80-92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625826</ArticleId><ArticleId IdType="pubmed">26745445</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccardi M, Altomare D, Ferrari C, et al. ; Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Working Group . Assessment of the incremental diagnostic value of florbetapir f 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET With [18F]-florbetapir (INDIA-FBP) study. JAMA Neurol. 2016;73(12):1417-1424.</Citation><ArticleIdList><ArticleId IdType="pubmed">27802513</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Haider JM, Goukasian N, et al. . Critical review of the appropriate use criteria for amyloid imaging: effect on diagnosis and patient care. Alzheimers Dement (Amst). 2016;5:15-22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5198877</ArticleId><ArticleId IdType="pubmed">28054024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Siderowf A, Dubois B, et al. . Effectiveness of florbetapir PET imaging in changing patient management. Dement Geriatr Cogn Disord. 2017;44(3-4):129-143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806476</ArticleId><ArticleId IdType="pubmed">28787712</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PSJ, Paterson RW, Dickson J, et al. . Diagnosing dementia in the clinical setting: can amyloid pet provide additional value over cerebrospinal fluid? J Alzheimers Dis. 2016;54(4):1297-1302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181662</ArticleId><ArticleId IdType="pubmed">27567830</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Johnson DK, Liebmann EP, Bothwell RJ, Morris JK, Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017;13(9):1024-1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582024</ArticleId><ArticleId IdType="pubmed">28263740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, La Joie R, Villain N, et al. . Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer&#x2019;s disease. Neuroimage Clin. 2013;2:356-365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777672</ArticleId><ArticleId IdType="pubmed">24179789</ArticleId></ArticleIdList></Reference><Reference><Citation>Grill JD, Johnson DK, Burns JM. Should we disclose amyloid imaging results to cognitively normal individuals? Neurodegener Dis Manag. 2013;3(1):43-51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184474</ArticleId><ArticleId IdType="pubmed">25285157</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JS, Dunn LB, Rabinovici GD. Amyloid imaging, risk disclosure and Alzheimer&#x2019;s disease: ethical and practical issues. Neurodegener Dis Manag. 2013;3(3):219-229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498486</ArticleId><ArticleId IdType="pubmed">26167204</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte MM, Foster NL, Fleisher AS, et al. . Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations. Alzheimers Dement (Amst). 2015;1(3):358-367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878065</ArticleId><ArticleId IdType="pubmed">27239516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Maruff P, Getter C, Snyder PJ. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. Alzheimers Dement. 2016;12(4):454-458.</Citation><ArticleIdList><ArticleId IdType="pubmed">26750717</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. . Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>van Harten AC, Visser PJ, Pijnenburg YAL, et al. . Cerebrospinal fluid A&#x3b2;42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013;9(5):481-487.</Citation><ArticleIdList><ArticleId IdType="pubmed">23232269</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305-2316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingler JH, Klunk WE. Disclosure of amyloid imaging results to research participants: has the time come? Alzheimers Dement. 2013;9(6):741-744.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758392</ArticleId><ArticleId IdType="pubmed">23415310</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29901708</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1522-9645</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>33</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>European heart journal</Title><ISOAbbreviation>Eur Heart J</ISOAbbreviation></Journal><ArticleTitle>Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension.</ArticleTitle><Pagination><StartPage>3119</StartPage><EndPage>3125</EndPage><MedlinePgn>3119-3125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/eurheartj/ehy288</ELocationID><Abstract><AbstractText Label="AIMS">To examine associations of diastolic and systolic blood pressure (SBP) at age 50, 60, and 70&#x2009;years with incidence of dementia, and whether cardiovascular disease (CVD) over the follow-up mediates this association.</AbstractText><AbstractText Label="METHODS AND RESULTS">Systolic and diastolic blood pressure were measured on 8639 persons (32.5% women) from the Whitehall II cohort study in 1985, 1991, 1997, and 2003. Incidence of dementia (n dementia/n total&#x2009;=&#x2009;385/8639) was ascertained from electronic health records followed-up until 2017. Cubic splines using continuous blood pressure measures suggested SBP &#x2265;130&#x2009;mmHg at age 50 but not at age 60 or 70 was associated with increased risk of dementia, confirmed in Cox regression analyses adjusted for sociodemographic factors, health behaviours, and time varying chronic conditions [hazard ratio (HR) 1.38; 95% confidence interval (95% CI) 1.11, 1.70]. Diastolic blood pressure was not associated with dementia. Participants with longer exposure to hypertension (SBP&#x2009;&#x2265;&#x2009;130&#x2009;mmHg) between mean ages of 45 and 61&#x2009;years had an increased risk of dementia compared to those with no or low exposure to hypertension (HR 1.29, 95% CI 1.00, 1.66). In multi-state models, SBP &#x2265;&#x2009;130&#x2009;mmHg at 50&#x2009;years of age was associated with greater risk of dementia in those free of CVD over the follow-up (HR 1.47, 95% CI 1.15, 1.87).</AbstractText><AbstractText Label="CONCLUSION">Systolic blood pressure &#x2265;130&#x2009;mmHg at age 50, below the conventional &#x2265;140&#x2009;mmHg threshold used to define hypertension, is associated with increased risk of dementia; in these persons this excess risk is independent of CVD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abell</LastName><ForeName>Jessica G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>INSERM, U1018, Centre for Research in Epidemiology and Population Health, Universit&#xe9; Paris-Saclay, H&#xf4;pital Paul Brousse, B&#xe2;t 15/16, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivim&#xe4;ki</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dugravot</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM, U1018, Centre for Research in Epidemiology and Population Health, Universit&#xe9; Paris-Saclay, H&#xf4;pital Paul Brousse, B&#xe2;t 15/16, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabak</LastName><ForeName>Adam G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>INSERM, U1018, Centre for Research in Epidemiology and Population Health, Universit&#xe9; Paris-Saclay, H&#xf4;pital Paul Brousse, B&#xe2;t 15/16, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, 1st Department of Medicine, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fayosse</LastName><ForeName>Aurore</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM, U1018, Centre for Research in Epidemiology and Population Health, Universit&#xe9; Paris-Saclay, H&#xf4;pital Paul Brousse, B&#xe2;t 15/16, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shipley</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabia</LastName><ForeName>S&#xe9;verine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>INSERM, U1018, Centre for Research in Epidemiology and Population Health, Universit&#xe9; Paris-Saclay, H&#xf4;pital Paul Brousse, B&#xe2;t 15/16, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh-Manoux</LastName><ForeName>Archana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM, U1018, Centre for Research in Epidemiology and Population Health, Universit&#xe9; Paris-Saclay, H&#xf4;pital Paul Brousse, B&#xe2;t 15/16, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034454</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RG/16/11/32334</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG056477</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RG/13/2/30098</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024227/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K013351/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG013196</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J</MedlineTA><NlmUniqueID>8006263</NlmUniqueID><ISSNLinking>0195-668X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Heart J. 2018 Sep 1;39(33):3126-3127. doi: 10.1093/eurheartj/ehy409.</RefSource><PMID Version="1">30052872</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015438" MajorTopicYN="N">Health Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013599" MajorTopicYN="N">Systole</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29901708</ArticleId><ArticleId IdType="pmc">PMC6122131</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehy288</ArticleId><ArticleId IdType="pii">5032485</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C, Invest H.. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008;7:683&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18614402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J, Grp PC.. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742805</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio C, Laurent S, Debette S.. Is hypertension associated with an accelerated aging of the brain? Hypertension 2014;63:894&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">24566080</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Rhew IC, Shofer JB, Kukull WA, Breitner JCS, Peskind E, Bowen JD, McCormick W, Teri L, Crane PK, Larson EB.. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J Am Geriatr Soc 2007;55:1161&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17661953</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu CX, Winblad B, Fratiglioni L.. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033691</ArticleId></ArticleIdList></Reference><Reference><Citation>Duron E, Hanon O.. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis 2008;101:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">18477946</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ.. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794848</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Kasagi F, Sasaki H, Masunari N, Mimori Y, Suzuki G.. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc 2003;51:410&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12588587</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K.. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668425</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jonsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H.. Defeating Alzheimer&#x2019;s disease and other dementias: a priority for European science and society. Lancet Neurol 2016;15:455&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">26987701</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Wolf PA, D&#x2019;Agostino RB, Cobb J, White LR.. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993;138:353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">8213741</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ.. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia aging study. JAMA 1995;274:1846&#x2013;1851.</Citation><ArticleIdList><ArticleId IdType="pubmed">7500533</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Xue Q-L, Masaki K, Petrovitch H, Ross GW, White LR, Launer LJ.. Change in blood pressure and incident dementia a 32-year prospective study. Hypertension 2009;54:233&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136040</ArticleId><ArticleId IdType="pubmed">19564551</ArticleId></ArticleIdList></Reference><Reference><Citation>ESH/ESC Task Force for the Management of Arterial Hypertension. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159&#x2013;2219.</Citation><ArticleIdList><ArticleId IdType="pubmed">23771844</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB.. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014;16:14&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8031779</ArticleId><ArticleId IdType="pubmed">24341872</ArticleId></ArticleIdList></Reference><Reference><Citation>Chobanian AV. Hypertension in 2017-what is the right target? JAMA 2017;317:579&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">28135357</ArticleId></ArticleIdList></Reference><Reference><Citation>Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF.. Prodromal Alzheimer&#x2019;s disease: successive emergence of the clinical symptoms. Ann Neurol 2008;64:492&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">19067364</ArticleId></ArticleIdList></Reference><Reference><Citation>Weuve J, Tchetgen Tchetgen EJ, Glymour MM, Beck TL, Aggarwal NT, Wilson RS, Evans DA, Mendes de Leon CF.. Accounting for bias due to selective attrition: the example of smoking and cognitive decline. Epidemiology 2012;23:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237815</ArticleId><ArticleId IdType="pubmed">21989136</ArticleId></ArticleIdList></Reference><Reference><Citation>19.Harrell FE., Jr.Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.</Citation></Reference><Reference><Citation>Orsini N, Greenland S.. A procedure to tabulate and plot results after flexible modeling of a quantitative covariate. Stata J 2011;11:1&#x2013;29.</Citation></Reference><Reference><Citation>Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A.. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">8609748</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu CX, von Strauss E, Fastbom J, Winblad B, Fratiglioni L.. Low blood pressure and risk of dementia in the Kungsholmen project. A 6-year follow-up study. Arch Neurol 2003;60:223&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580707</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C, Gill C, Huppert FA, Barkley C, Gehlhaar E, Girling DM, O&#x2019;Connor DW, Paykel ES.. Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 1998;9:175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">9622006</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyas SL, Manfreda J, Strain LA, Montgomery PR.. Risk factors for Alzheimer&#x2019;s disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol 2001;30:590&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">11416089</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R.. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002;58:1175&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971083</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuller LH, Lopez OL, Newman A, Beauchamp NJ, Burke G, Dulberg C, Fitzpatrick A, Fried L, Haan MN.. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology 2003;22:13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566949</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein AR, Wu Y, Mortimer JA, Schellenberg GD, McCormick WC, Bowen JD, McCurry S, Larson EB.. Developmental and vascular risk factors for Alzheimer&#x2019;s disease. Neurobiol Aging 2005;26:325&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639310</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, Sigurdsson S, Kjartansson O, Aspelund T, Lopez OL, Jonnson PV, Harris TB, van Buchem M, Gudnason V, Launer LJ;. Age, Gene/Environment Susceptibility-Reykjavik Study Investigators. Joint effect of mid- and late-life blood pressure on the brain: the AGES-Reykjavik study. Neurology 2014;82:2187&#x2013;2195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113458</ArticleId><ArticleId IdType="pubmed">24898928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes TM, Sink KM.. Hypertension and its role in cognitive function: current evidence and challenges for the future. Am J Hypertens 2016;29:149&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4989128</ArticleId><ArticleId IdType="pubmed">26563965</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Petersen RC, Rocca WA, Larson EB, Ganguli M.. Passive case-finding for Alzheimer&#x2019;s disease and dementia in two U.S. communities. Alzheimers Dement 2011;7:53&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137259</ArticleId><ArticleId IdType="pubmed">21255743</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29937276</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus.</ArticleTitle><Pagination><StartPage>64</StartPage><EndPage>82.e7</EndPage><MedlinePgn>64-82.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2018.05.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(18)30421-5</ELocationID><Abstract><AbstractText>Investigators have long suspected that pathogenic microbes might contribute to the onset and progression of Alzheimer's disease (AD) although definitive evidence has not been presented. Whether such findings represent a causal contribution, or reflect opportunistic passengers of neurodegeneration, is also difficult to resolve. We constructed multiscale networks of the late-onset AD-associated virome, integrating genomic, transcriptomic, proteomic, and histopathological data across four brain regions from human post-mortem tissue. We observed increased human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7) from subjects with AD compared with controls. These results were replicated in two additional, independent and geographically dispersed cohorts. We observed regulatory relationships linking viral abundance and modulators of APP metabolism, including induction of APBB2, APPBP2, BIN1, BACE1, CLU, PICALM, and PSEN1 by HHV-6A. This study elucidates networks linking molecular, clinical, and neuropathological features with viral activity and is consistent with viral activity constituting a general feature of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Readhead</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departments of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Icahn Institute of Genomic Sciences and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; ASU-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ 85287-5001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haure-Mirande</LastName><ForeName>Jean-Vianney</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funk</LastName><ForeName>Cory C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, 98109-5263, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, 98109-5263, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, 98109-5263, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; James J. Peters VA Medical Center, 130 West Kingsbridge Road, New York, NY 10468, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>James J. Peters VA Medical Center, 130 West Kingsbridge Road, New York, NY 10468, USA; Department of Psychiatry, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Winnie S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix, AZ 85014, USA; Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckmann</LastName><ForeName>Noam D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Departments of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Icahn Institute of Genomic Sciences and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Nathan D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, 98109-5263, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix, AZ 85014, USA; Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA; Department of Psychiatry, University of Arizona, Phoenix, AZ 85721, USA; Banner Alzheimer's Institute, Phoenix, AZ 85006, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadt</LastName><ForeName>Eric E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Departments of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Icahn Institute of Genomic Sciences and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Sema4, Stamford, CT 06902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehrlich</LastName><ForeName>Michelle E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Departments of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Icahn Institute of Genomic Sciences and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Neurology, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandy</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; James J. Peters VA Medical Center, 130 West Kingsbridge Road, New York, NY 10468, USA; Department of Psychiatry, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Center for NFL Neurological Care, Department of Neurology, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudley</LastName><ForeName>Joel T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Departments of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Icahn Institute of Genomic Sciences and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; ASU-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ 85287-5001, USA. Electronic address: joel.dudley@mssm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG058469</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 EB020406</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG058469</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 AG049649</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C466684">APBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101410">BIN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C532623">Mirn155 microRNA, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034041">Monomeric Clathrin Assembly Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439003">PICALM protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Trends Neurosci. 2018 Sep;41(9):570-573. doi: 10.1016/j.tins.2018.07.001.</RefSource><PMID Version="1">30033181</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Front Mol Neurosci. 2018 Sep 20;11:340. doi: 10.3389/fnmol.2018.00340.</RefSource><PMID Version="1">30294260</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2019 Dec 18;104(6):1034-1035. doi: 10.1016/j.neuron.2019.11.009.</RefSource><PMID Version="1">31855626</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2019 Dec 18;104(6):1036-1037. doi: 10.1016/j.neuron.2019.11.008.</RefSource><PMID Version="1">31855627</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Bioinform Comput Biol. 2020 Feb;18(1):2050012. doi: 10.1142/S0219720020500122.</RefSource><PMID Version="1">32336252</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018792" MajorTopicYN="N">Encephalitis, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015654" MajorTopicYN="Y">Herpesvirus 6, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016199" MajorTopicYN="Y">Herpesvirus 7, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064307" MajorTopicYN="N">Microbiota</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034041" MajorTopicYN="N">Monomeric Clathrin Assembly Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019349" MajorTopicYN="N">Roseolovirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">HHV-6A</Keyword><Keyword MajorTopicYN="N">HHV-6B</Keyword><Keyword MajorTopicYN="N">HHV-7</Keyword><Keyword MajorTopicYN="N">Roseolovirus</Keyword><Keyword MajorTopicYN="N">human herpesvirus</Keyword><Keyword MajorTopicYN="N">integrative genomics</Keyword><Keyword MajorTopicYN="N">multiscale networks</Keyword><Keyword MajorTopicYN="N">network biology</Keyword><Keyword MajorTopicYN="N">systems biology</Keyword></KeywordList><CoiStatement>Declarations of Interests. The authors declare that they have no competing financial interests in relation to the work described.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29937276</ArticleId><ArticleId IdType="mid">NIHMS975797</ArticleId><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.05.023</ArticleId><ArticleId IdType="pii">S0896-6273(18)30421-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agostini S,et al. (2016). Lack of evidence for a role of HHV-6 in the pathogenesis of Alzheimer&#x2019;s disease. J Alzheimers Dis, 49, 229&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">26444787</ArticleId></ArticleIdList></Reference><Reference><Citation>Albright AV,et al. (1998). The effect of human herpesvirus-6 (HHV-6) on cultured human neural cells: oligodendrocytes and microglia. J Neurovirol, 4, 486&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9839646</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M,et al. (2016). Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci Data, 3, 160089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Altschul SF,et al. (1990). Basic local alignment search tool. J Mol Biol, 215, 403&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">2231712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ament S,et al. (2017). TReNA: Fit transcriptional regulatory networks using gene expression, priors, machine learning. R package version 0.99.10 ed.</Citation></Reference><Reference><Citation>Aran D,et al. (2017). xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol, 18, 220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688663</ArticleId><ArticleId IdType="pubmed">29141660</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbuckle JH,et al. (2010). The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proc Natl Acad Sci U S A, 107, 5563&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851814</ArticleId><ArticleId IdType="pubmed">20212114</ArticleId></ArticleIdList></Reference><Reference><Citation>Artusi S,et al. (2016). Visualization of DNA G-quadruplexes in herpes simplex virus 1-infected cells. Nucleic Acids Res, 44, 10343&#x2013;10353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5137459</ArticleId><ArticleId IdType="pubmed">27794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudoin JD,et al. (2013). Exploring mRNA 3&#x2019;-UTR G-quadruplexes: evidence of roles in both alternative polyadenylation and mRNA shortening. Nucleic Acids Res, 41, 5898&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675481</ArticleId><ArticleId IdType="pubmed">23609544</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y,et al. (1995). Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological, 57, 289&#x2013;300.</Citation></Reference><Reference><Citation>Bennett DA,et al. (2012a). Overview and findings from the religious orders study. Curr Alzheimer Res, 9, 628&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA,et al. (2012b). Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res, 9, 646&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier A,et al. (2013). Transcriptional profiling reveals molecular signatures associated with HIV permissiveness in Th1Th17 cells and identifies peroxisome proliferator-activated receptor gamma as an intrinsic negative regulator of viral replication. Retrovirology, 10, 160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898812</ArticleId><ArticleId IdType="pubmed">24359430</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle AP,et al. (2008). F-Seq: a feature density estimator for high-throughput sequence tags. Bioinformatics, 24, 2537&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732284</ArticleId><ArticleId IdType="pubmed">18784119</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H,et al. (2006). Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol, 112, 389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Brister JR,et al. (2015). NCBI viral genomes resource. Nucleic Acids Res, 43, D571&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383986</ArticleId><ArticleId IdType="pubmed">25428358</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A,et al. (2017). Necroptosis activation in Alzheimer&#x2019;s disease. Nat Neurosci, 20, 1236&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pubmed">28758999</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone I,et al. (2014). Herpes virus in Alzheimer&#x2019;s disease: relation to progression of the disease. Neurobiol Aging, 35, 122&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23916950</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartharius K,et al. (2005). MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics, 21, 2933&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">15860560</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli E,et al. (2017). HHV-6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis. Virol J, 14, 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5234148</ArticleId><ArticleId IdType="pubmed">28081700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cen S,et al. (2001). Incorporation of lysyl-tRNA synthetase into human immunodeficiency virus type 1. J Virol, 75, 5043&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114908</ArticleId><ArticleId IdType="pubmed">11333884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LK,et al. (2005). Activation of Sp1-mediated transcription by Rta of Epstein-Barr virus via an interaction with MCAF1. Nucleic Acids Res, 33, 6528&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1298921</ArticleId><ArticleId IdType="pubmed">16314315</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EY,et al. (2012). Expression2Kinases: mRNA profiling linked to multiple upstream regulatory layers. Bioinformatics, 28, 105&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244772</ArticleId><ArticleId IdType="pubmed">22080467</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z,et al. (2008). Genetic association of neurotrophic tyrosine kinase receptor type 2 (NTRK2) With Alzheimer&#x2019;s disease. Am J Med Genet B Neuropsychiatr Genet, 147, 363&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17918233</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohain A,et al. (2016). Exploring the Reproducibility of Probabilistic Causal Molecular Network Models. Pac Symp Biocomput, 22, 120&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5161348</ArticleId><ArticleId IdType="pubmed">27896968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J,et al. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol, 26, 1367&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmanis S,et al. (2015). A survey of human brain transcriptome diversity at the single cell level. Proc Natl Acad Sci U S A, 112, 7285&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466750</ArticleId><ArticleId IdType="pubmed">26060301</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW,et al. (1992). Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging, 13, 179&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">1311804</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A,et al. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 29, 15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA,et al. (2017). A&#x3b2; protects against herpesviridae infections in brain.</Citation></Reference><Reference><Citation>Epel ES,et al. (2016). Meditation and vacation effects have an impact on disease-associated molecular phenotypes. Transl Psychiatry, 6, e880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5022094</ArticleId><ArticleId IdType="pubmed">27576169</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzen O,et al. (2016). Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science, 353, 827&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5534139</ArticleId><ArticleId IdType="pubmed">27540175</ArticleId></ArticleIdList></Reference><Reference><Citation>Garant JM,et al. (2015). G4RNA: an RNA G-quadruplex database. Database (Oxford), 2015, bav059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5630937</ArticleId><ArticleId IdType="pubmed">26200754</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto G,et al. (2008). Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res, 36, 6608&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582607</ArticleId><ArticleId IdType="pubmed">18940871</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomes Project, C.,et al. (2015). A global reference for human genetic variation. Nature, 526, 68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T,et al. (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci, 16, 4491&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottwein E,et al. (2007). A viral microRNA functions as an orthologue of cellular miR-155. Nature, 450, 10969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614920</ArticleId><ArticleId IdType="pubmed">18075594</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady SL,et al. (2012). Herpes simplex virus 1 infection activates poly(ADP-ribose) polymerase and triggers the degradation of poly(ADP-ribose) glycohydrolase. J Virol, 86, 8259&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421676</ArticleId><ArticleId IdType="pubmed">22623791</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusmao EG,et al. (2016). Analysis of computational footprinting methods for DNase sequencing experiments. Nat Methods, 13, 303&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26901649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha HC,et al. (2001). Poly(ADP-ribose) polymerase-1 is required for efficient HIV-1 integration. Proc Natl Acad Sci U S A, 98, 3364&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30659</ArticleId><ArticleId IdType="pubmed">11248084</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V,et al. (1998). Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol, 55, 1185&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740112</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrich D,et al. (1989). Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat. J Virol, 63, 2585&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250732</ArticleId><ArticleId IdType="pubmed">2657100</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauw JJ,et al. (1994). Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology, 44, 2015&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969952</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B,et al. (2011). Genotype imputation with thousands of genomes. G3 (Bethesda), 1, 457&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276165</ArticleId><ArticleId IdType="pubmed">22384356</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie BN,et al. (2009). A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet, 5, e1000529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689936</ArticleId><ArticleId IdType="pubmed">19543373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu SD,et al. (2011). miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res, 39, D163&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013699</ArticleId><ArticleId IdType="pubmed">21071411</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y,et al. (2004). Elevation of the level and activity of acid ceramidase in Alzheimer&#x2019;s disease brain. Eur J Neurosci, 20, 3489&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15610181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT,et al. (1984). Alzheimer&#x2019;s disease: cell-specific pathology isolates the hippocampal formation. Science, 225, 1168&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF (2014). Herpes simplex virus type 1 and Alzheimer&#x2019;s disease: increasing evidence for a major role of the virus. Front Aging Neurosci, 6, 202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4128394</ArticleId><ArticleId IdType="pubmed">25157230</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF,et al. (2016). Microbes and Alzheimer&#x2019;s Disease. J Alzheimers Dis, 51, 979&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457904</ArticleId><ArticleId IdType="pubmed">26967229</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL,et al. (2004). Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet, 13, 15970.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaddurah-Daouk R,et al. (2011). Metabolomic changes in autopsy-confirmed Alzheimer&#x2019;s disease. Alzheimers Dement, 7, 309&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061205</ArticleId><ArticleId IdType="pubmed">21075060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaddurah-Daouk R,et al. (2013). Alterations in metabolic pathways and networks in Alzheimer&#x2019;s disease. Transl Psychiatry, 3, e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3641405</ArticleId><ArticleId IdType="pubmed">23571809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersey PJ,et al. (2016). Ensembl Genomes 2016: more genomes, more complexity. Nucleic Acids Res, 44, D574&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702859</ArticleId><ArticleId IdType="pubmed">26578574</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S,et al. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity, 47, 566&#x2013;581 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar DK,et al. (2016). Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer&#x2019;s disease. Sci Transl Med, 8, 340ra72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachmann A,et al. (2017). Massive Mining of Publicly Available RNA-seq Data from Human and Mouse. bioRxiv.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893633</ArticleId><ArticleId IdType="pubmed">29636450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachmann A,et al. (2010). ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics, 26, 2438&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944209</ArticleId><ArticleId IdType="pubmed">20709693</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC,et al. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet, 45, 1452&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander ES,et al. (2001). Initial sequencing and analysis of the human genome. Nature, 409, 860&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237011</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B,et al. (2012). Fast gapped-read alignment with Bowtie 2. Nat Methods, 9, 357&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Law CW,et al. (2014). voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol, 15, R29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053721</ArticleId><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S,et al. (2012). Optimal tests for rare variant effects in sequencing association studies. Biostatistics, 13, 762&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3440237</ArticleId><ArticleId IdType="pubmed">22699862</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H,et al. (2009a). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics, 25, 1754&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H,et al. (2009b). The Sequence Alignment/Map format and SAMtools. Bioinformatics, 25, 2078&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS,et al. (2008). Altered neuronal gene expression in brain regions differentially affected by Alzheimer&#x2019;s disease: a reference data set. Physiol Genomics, 33, 240&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826117</ArticleId><ArticleId IdType="pubmed">18270320</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS,et al. (2010). Neuronal gene expression in non-demented individuals with intermediate Alzheimer&#x2019;s Disease neuropathology. Neurobiol Aging, 31, 549&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844804</ArticleId><ArticleId IdType="pubmed">18572275</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS,et al. (2007). Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics, 28, 311&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2259385</ArticleId><ArticleId IdType="pubmed">17077275</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y,et al. (2013). The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res, 41, e108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664803</ArticleId><ArticleId IdType="pubmed">23558742</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y,et al. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 30, 923&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WR,et al. (2002). Herpesviruses in brain and Alzheimer&#x2019;s disease. J Pathol, 197, 395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">12115887</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HP,et al. (2010a). Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer&#x2019;s disease. J Clin Lab Anal, 24, 182&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647671</ArticleId><ArticleId IdType="pubmed">20486200</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ,et al. (2010b). A versatile gene-based test for genome-wide association studies. Am J Hum Genet, 87, 139&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896770</ArticleId><ArticleId IdType="pubmed">20598278</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H,et al. (2015a). Reactivated herpes simplex infection increases the risk of Alzheimer&#x2019;s disease. Alzheimers Dement, 11, 593&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25043910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H,et al. (2015b). Herpes simplex infection and the risk of Alzheimer&#x2019;s disease: A nested case-control study. Alzheimers Dement, 11, 587&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">25304990</ArticleId></ArticleIdList></Reference><Reference><Citation>Madeira C,et al. (2015). d-serine levels in Alzheimer&#x2019;s disease: implications for novel biomarker development. Transl Psychiatry, 5, e561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4471283</ArticleId><ArticleId IdType="pubmed">25942042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak J,et al. (1997). Primer tRNAs for reverse transcription. J Virol, 71, 8087&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192263</ArticleId><ArticleId IdType="pubmed">9343157</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcais G,et al. (2011). A fast, lock-free approach for efficient parallel counting of occurrences of k-mers. Bioinformatics, 27, 764&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051319</ArticleId><ArticleId IdType="pubmed">21217122</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastroeni D,et al. (2018). Laser-captured microglia in the Alzheimer&#x2019;s and Parkinson&#x2019;s brain reveal unique regional expression profiles and suggest a potential role for hepatitis B in the Alzheimer&#x2019;s brain. Neurobiol Aging, 63, 12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6686891</ArticleId><ArticleId IdType="pubmed">29207277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiussi S,et al. (2007). Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression. Infect Agent Cancer, 2, 18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170434</ArticleId><ArticleId IdType="pubmed">17931416</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton PJ,et al. (1980). Herpes-simplex viral genome and senile and presenile dementias of Alzheimer and Pick. Lancet, 1, 1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">6103379</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA,et al. (2011). Strategies for aggregating gene expression data: the collapseRows R function. BMC Bioinformatics, 12, 322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166942</ArticleId><ArticleId IdType="pubmed">21816037</ArticleId></ArticleIdList></Reference><Reference><Citation>Millstein J,et al. (2009). Disentangling molecular relationships with a causal inference test. BMC Genet, 10, 23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224661</ArticleId><ArticleId IdType="pubmed">19473544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS,et al. (1991). The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology, 41, 479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A,et al. (2015). VEGAS2: Software for More Flexible Gene-Based Testing. Twin Res Hum Genet, 18, 86&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">25518859</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori Y,et al. (1998). Analysis of human herpesvirus 6 U3 gene, which is a positional homolog of human cytomegalovirus UL 24 gene. Virology, 249, 129&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740784</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43, 2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Murat P,et al. (2014). G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation. Nat Chem Biol, 10, 358&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188979</ArticleId><ArticleId IdType="pubmed">24633353</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy JV,et al. (1976). Encephalopathy following measles infection in children with chronic illness. J Pediatr, 88, 937&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">1271191</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM,et al. (2015). Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 12, 453&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739640</ArticleId><ArticleId IdType="pubmed">25822800</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida K,et al. (1999). Aminoacylation of tRNAs encoded by Chlorella virus CVK2. Virology, 263, 220&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10544096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA,et al. (2005). Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol, 64, 113&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Nousiainen L,et al. (2013). Human kinome analysis reveals novel kinases contributing to virus infection and retinoic-acid inducible gene I-induced type I and type III IFN gene expression. Innate Immun, 19, 51630.</Citation><ArticleIdList><ArticleId IdType="pubmed">23405030</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard HB (2017). Targeting Fyn Kinase in Alzheimer&#x2019;s Disease. Biol Psychiatry.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5729051</ArticleId><ArticleId IdType="pubmed">28709498</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulou C,et al. (2015). Nucleotide Pool Depletion Induces G-Quadruplex-Dependent Perturbation of Gene Expression. Cell Rep, 13, 2491&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4695339</ArticleId><ArticleId IdType="pubmed">26686635</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl J (2009). Causality, Cambridge university press.</Citation></Reference><Reference><Citation>Pearl JR,et al. (2017). Genome-scale transcriptional regulatory network models of psychiatric and neurodegenerative disorders. bioRxiv.</Citation><ArticleIdList><ArticleId IdType="pubmed">30772379</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper J,et al. (2013). Wellington: a novel method for the accurate identification of digital genomic footprints from DNase-seq data. Nucleic Acids Res, 41, e201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834841</ArticleId><ArticleId IdType="pubmed">24071585</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusty BK,et al. (2016). Possible Chromosomal and Germline Integration of Human Herpesvirus 7 (HHV-7). J Gen Virol.</Citation><ArticleIdList><ArticleId IdType="pubmed">28284243</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusty BK,et al. (2013). Reactivation of chromosomally integrated human herpesvirus-6 by telomeric circle formation. PLoS Genet, 9, e1004033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868596</ArticleId><ArticleId IdType="pubmed">24367281</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampelli S,et al. (2016). ViromeScan: a new tool for metagenomic viral community profiling. BMC Genomics, 17, 165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774116</ArticleId><ArticleId IdType="pubmed">26932765</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B,et al. (2016). Molecular systems evaluation of oligomerogenic APP(E693Q) and fibrillogenic APP(KM670/671NL)/PSEN1(Deltaexon9) mouse models identifies shared features with human Alzheimer&#x2019;s brain molecular pathology. Mol Psychiatry, 21, 1099&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4862938</ArticleId><ArticleId IdType="pubmed">26552589</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes D,et al. (2015). G-quadruplexes and their regulatory roles in biology. Nucleic Acids Res, 43, 8627&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605312</ArticleId><ArticleId IdType="pubmed">26350216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME,et al. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 43, e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD,et al. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26, 139&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Rode AB,et al. (2016). tRNA Shifts the G-quadruplex-Hairpin Conformational Equilibrium in RNA towards the Hairpin Conformer. Angew Chem Int Ed Engl, 55, 14315&#x2013;14319.</Citation><ArticleIdList><ArticleId IdType="pubmed">27511794</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotmistrovsky K,et al. (2011). BMTagger: Best Match Tagger for removing human reads from metagenomics datasets.</Citation></Reference><Reference><Citation>Rouillard AD,et al. (2016). The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database (Oxford), 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930834</ArticleId><ArticleId IdType="pubmed">27374120</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang Y,et al. (2014). Probing the interaction between U24 and the SH3 domain of Fyn tyrosine kinase. Biochemistry, 53, 6092&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25225878</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz M,et al. (2004). Thrombin induces Sp1-mediated antiviral effects in cytomegalovirus-infected human retinal pigment epithelial cells. Med Microbiol Immunol, 193, 195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">13680213</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabalin AA (2012). Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics, 28, 1353&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348564</ArticleId><ArticleId IdType="pubmed">22492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Shugar D (1999). Viral and host-cell protein kinases: enticing antiviral targets and relevance of nucleoside, and viral thymidine, kinases. Pharmacol Ther, 82, 315&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10454209</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigur&#xf0;sson B (1954). Rida, a chronic encephalitis of sheep: with general remarks on infections which develop slowly and some of their special characteristics.</Citation></Reference><Reference><Citation>Sjogren T,et al. (1952). Morbus Alzheimer and morbus Pick; a genetic, clinical and patho-anatomical study. Acta Psychiatr Neurol Scand Suppl, 82, 1&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">13171126</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth GK (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 3, Article3.</Citation><ArticleIdList><ArticleId IdType="pubmed">16646809</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J,et al. (2015). miR-155 is involved in Alzheimer&#x2019;s disease by regulating T lymphocyte function. Front Aging Neurosci, 7, 61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4415416</ArticleId><ArticleId IdType="pubmed">25983691</ArticleId></ArticleIdList></Reference><Reference><Citation>Soscia SJ,et al. (2010). The Alzheimer&#x2019;s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One, 5, e9505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831066</ArticleId><ArticleId IdType="pubmed">20209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA,et al. (2011). Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement, 7, 280&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH,et al. (1994). Immunohistochemical evidence for apoptosis in Alzheimer&#x2019;s disease. Neuroreport, 5, 2529&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">7696596</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A,et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 102, 15545&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson CM,et al. (2010). SRp40 and SRp55 promote the translation of unspliced human immunodeficiency virus type 1 RNA. J Virol, 84, 6748&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903291</ArticleId><ArticleId IdType="pubmed">20427542</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka-Taya K,et al. (2004). Human herpesvirus 6 (HHV-6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV-6 DNA. J Med Virol, 73, 465&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">15170644</ArticleId></ArticleIdList></Reference><Reference><Citation>Thai TH,et al. (2007). Regulation of the germinal center response by microRNA-155. Science, 316, 604&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463289</ArticleId></ArticleIdList></Reference><Reference><Citation>Toribara NW,et al. (1993). Human gastric mucin. Identification of a unique species by expression cloning. J Biol Chem, 268, 5879&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680650</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton JW,et al. (2014). Staying alive: cell death in antiviral immunity. Mol Cell, 54, 273&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010939</ArticleId><ArticleId IdType="pubmed">24766891</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Auwera GA,et al. (2013). From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics, 43, 11 10 1&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243306</ArticleId><ArticleId IdType="pubmed">25431634</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R,et al. (1999). A stop-codon mutation in the BRI gene associated with familial British dementia. Nature, 399, 776&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R,et al. (2000). A decamer duplication in the 3&#x2019; region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci U S A, 97, 4920&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18333</ArticleId><ArticleId IdType="pubmed">10781099</ArticleId></ArticleIdList></Reference><Reference><Citation>Westman G,et al. (2017). Decreased HHV-6 IgG in Alzheimer&#x2019;s Disease. Frontiers in Neurology, 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316842</ArticleId><ArticleId IdType="pubmed">28265256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J,et al. (2012). Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer&#x2019;s disease. Neuroscience, 210, 363&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426239</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodbury ME,et al. (2015). miR-155 Is Essential for Inflammation-Induced Hippocampal Neurogenic Dysfunction. J Neurosci, 35, 9764&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4571507</ArticleId><ArticleId IdType="pubmed">26134658</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B,et al. (2016). Sequence Kernel Association Test of Multiple Continuous Phenotypes. Genet Epidemiol, 40, 91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724299</ArticleId><ArticleId IdType="pubmed">26782911</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo S,et al. (2015). Integrative analysis of DNA methylation and gene expression data identifies EPAS1 as a key regulator of COPD. PLoS Genet, 11, e1004898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287352</ArticleId><ArticleId IdType="pubmed">25569234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaharia M,et al. (2011). Faster and more accurate sequence alignment with SNAP. arXiv preprint arXiv:1111.5572.</Citation></Reference><Reference><Citation>Zhang B,et al. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell, 153, 707&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y,et al. (2001). Productive infection of primary macrophages with human herpesvirus 7. J Virol, 75, 10511&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114628</ArticleId><ArticleId IdType="pubmed">11581422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y,et al. (2009). A functional MicroRNA-155 ortholog encoded by the oncogenic Marek&#x2019;s disease virus. J Virol, 83, 489&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2612317</ArticleId><ArticleId IdType="pubmed">18945769</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30456353</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2575-1077</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Life science alliance</Title><ISOAbbreviation>Life Sci Alliance</ISOAbbreviation></Journal><ArticleTitle>Neuronal A&#x3b2;42 is enriched in small vesicles at the presynaptic side of synapses.</ArticleTitle><Pagination><StartPage>e201800028</StartPage><MedlinePgn>e201800028</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e201800028</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.26508/lsa.201800028</ELocationID><Abstract><AbstractText>The amyloid &#x3b2;-peptide (A&#x3b2;) is a physiological ubiquitously expressed peptide suggested to be involved in synaptic function, long-term potentiation, and memory function. The 42 amino acid-long variant (A&#x3b2;42) forms neurotoxic oligomers and amyloid plaques and plays a key role in the loss of synapses and other pathogenic events of Alzheimer disease. Still, the exact localization of A&#x3b2;42 in neurons and at synapses has not been reported. Here, we used super-resolution microscopy and show that A&#x3b2;42 was present in small vesicles in presynaptic compartments, but not in postsynaptic compartments, in the neurites of hippocampal neurons. Some of these vesicles appeared to lack synaptophysin, indicating that they differ from the synaptic vesicles responsible for neurotransmitter release. The A&#x3b2;42-containing vesicles existed in presynapses connected to stubby spines and mushroom spines, and were also present in immature presynapses. These vesicles were scarce in other parts of the neurites, where A&#x3b2;42 was instead present in large, around 200-600 nm, vesicular structures. Three-dimensional super-resolution microscopy confirmed that A&#x3b2;42 was present in the presynapse and absent in the postsynapse.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4432-3955</Identifier><AffiliationInfo><Affiliation>Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jans</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Applied Physics, Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tjernberg</LastName><ForeName>Lars O</ForeName><Initials>LO</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schedin-Weiss</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2143-7052</Identifier><AffiliationInfo><Affiliation>Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Life Sci Alliance</MedlineTA><NlmUniqueID>101728869</NlmUniqueID><ISSNLinking>2575-1077</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30456353</ArticleId><ArticleId IdType="pmc">PMC6238618</ArticleId><ArticleId IdType="doi">10.26508/lsa.201800028</ArticleId><ArticleId IdType="pii">LSA-2018-00028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raskin J, Cummings J, Hardy J, Schuh K, Dean RA (2015) Neurobiology of Alzheimer's disease: Integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res 12: 712&#x2013;712. 10.2174/1567205012666150701103107</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205012666150701103107</ArticleId><ArticleId IdType="pmc">PMC5384474</ArticleId><ArticleId IdType="pubmed">26412218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Holtzman DM (2013) Biomarker modeling of Alzheimer's disease. Neuron 80: 1347&#x2013;1358. 10.1016/j.neuron.2013.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.003</ArticleId><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101&#x2013;112. 10.1038/nrm2101</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2101</ArticleId><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox KC, Lacor PN, Pitt J, Klein WL (2011) Abeta oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol 31: 939&#x2013;948. 10.1007/s10571-011-9691-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-011-9691-4</ArticleId><ArticleId IdType="pmc">PMC3146579</ArticleId><ArticleId IdType="pubmed">21538118</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Karran E (2016) The cellular phase of Alzheimer's disease. Cell 164: 603&#x2013;615. 10.1016/j.cell.2015.12.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.056</ArticleId><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Bogdanovic N, Nakagawa H, Volkmann I, Aoki M, Winblad B, Sakai J, Tjernberg LO (2012) Analysis of microdissected neurons by 18O mass spectrometry reveals altered protein expression in Alzheimer's disease. J Cell Mol Med 16: 1686&#x2013;1700. 10.1111/j.1582-4934.2011.01441.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2011.01441.x</ArticleId><ArticleId IdType="pmc">PMC3822682</ArticleId><ArticleId IdType="pubmed">21883897</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161: 1869&#x2013;1879. 10.1016/s0002-9440(10)64463-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)64463-x</ArticleId><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson P, Loganathan K, Sekiguchi M, Matsuba Y, Hui K, Tsubuki S, Tanaka M, Iwata N, Saito T, Saido TC (2013) A&#x3b2; secretion and plaque formation depend on autophagy. Cell Rep 5: 61&#x2013;69. 10.1016/j.celrep.2013.08.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.08.042</ArticleId><ArticleId IdType="pubmed">24095740</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Hyman BT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82: 756&#x2013;771. 10.1016/j.neuron.2014.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.05.004</ArticleId><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Fluhrer R, Haass C (2008) Intramembrane proteolysis by gamma-secretase. J Biol Chem 283: 29627&#x2013;29631. 10.1074/jbc.r800010200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.r800010200</ArticleId><ArticleId IdType="pmc">PMC2662049</ArticleId><ArticleId IdType="pubmed">18650432</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Lammich S, Haass C (2009) Function, regulation and therapeutic properties of beta-secretase (BACE1). Semin Cell Dev Biol 20: 175&#x2013;182. 10.1016/j.semcdb.2009.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2009.01.003</ArticleId><ArticleId IdType="pubmed">19429494</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan A, Hartley DM, Lashuel HA (2010) Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research. Nat Protoc 5: 1186&#x2013;1209. 10.1038/nprot.2010.72</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2010.72</ArticleId><ArticleId IdType="pubmed">20539293</ArticleId></ArticleIdList></Reference><Reference><Citation>Welander H, Franberg J, Graff C, Sundstrom E, Winblad B, Tjernberg LO (2009) Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110: 697&#x2013;706. 10.1111/j.1471-4159.2009.06170.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06170.x</ArticleId><ArticleId IdType="pubmed">19457079</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS (2001) Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APPAbeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. Nature 414: 643&#x2013;648. 10.1038/414643a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/414643a</ArticleId><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL (1990) Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA 87: 1561&#x2013;1565. 10.1073/pnas.87.4.1561</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.4.1561</ArticleId><ArticleId IdType="pmc">PMC53515</ArticleId><ArticleId IdType="pubmed">1689489</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E (2010) Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol 119: 523&#x2013;541. 10.1007/s00401-010-0679-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0679-9</ArticleId><ArticleId IdType="pmc">PMC3183823</ArticleId><ArticleId IdType="pubmed">20354705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren JL, Ahmed S, Schedin-Weiss S, Gouras GK, Winblad B, Tjernberg LO, Frykman S (2015) ADAM10 and BACE1 are localized to synaptic vesicles. J Neurochem 135: 606&#x2013;615. 10.1111/jnc.13287</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13287</ArticleId><ArticleId IdType="pubmed">26296617</ArticleId></ArticleIdList></Reference><Reference><Citation>Schedin-Weiss S, Caesar I, Winblad B, Blom H, Tjernberg LO (2016) Super-resolution microscopy reveals gamma-secretase at both sides of the neuronal synapse. Acta Neuropathol Commun 4: 29 10.1186/s40478-016-0296-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0296-5</ArticleId><ArticleId IdType="pmc">PMC4818506</ArticleId><ArticleId IdType="pubmed">27036709</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren JL, Ahmed S, Winblad B, Gouras GK, Tjernberg LO, Frykman S (2014) Activity-independent release of the amyloid beta-peptide from rat brain nerve terminals. Neurosci Lett 566: 125&#x2013;130. 10.1016/j.neulet.2014.02.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.02.050</ArticleId><ArticleId IdType="pubmed">24602978</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Volkmann I, Tjernberg LO, Winblad B, Bogdanovic N (2008) Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain. Neuroreport 19: 1085&#x2013;1089. 10.1097/wnr.0b013e328302c858</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wnr.0b013e328302c858</ArticleId><ArticleId IdType="pubmed">18596605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Bogdanovic N, Volkmann I, Aoki M, Winblad B, Tjernberg LO (2010) Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Abeta42 and Alzheimer's disease neuropathology. Acta Neuropathol 119: 543&#x2013;554. 10.1007/s00401-010-0661-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0661-6</ArticleId><ArticleId IdType="pubmed">20198479</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA (2003) Synaptic pathology in Alzheimer's disease: A review of ultrastructural studies. Neurobiol Aging 24: 1029&#x2013;1046. 10.1016/j.neurobiolaging.2003.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2003.08.002</ArticleId><ArticleId IdType="pubmed">14643375</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 24: 1023&#x2013;1027. 10.1016/j.neurobiolaging.2003.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2003.09.001</ArticleId><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani A, Huang B, Bergan J, Dulac C, Zhuang X (2010) Superresolution imaging of chemical synapses in the brain. Neuron 68: 843&#x2013;856. 10.1016/j.neuron.2010.11.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.021</ArticleId><ArticleId IdType="pmc">PMC3057101</ArticleId><ArticleId IdType="pubmed">21144999</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571&#x2013;1577. 10.1001/jama.283.12.1571</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.12.1571</ArticleId><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Philipson O, Lord A, Lalowski M, Soliymani R, Baumann M, Thyberg J, Bogdanovic N, Olofsson T, Tjernberg LO, Ingelsson M, et al. (2012) The arctic amyloid-beta precursor protein (AbetaPP) mutation results in distinct plaques and accumulation of N- and C-truncated Abeta. Neurobiol Aging 33: 1010.e1&#x2013;1010.e13. 10.1016/j.neurobiolaging.2011.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.022</ArticleId><ArticleId IdType="pubmed">22118948</ArticleId></ArticleIdList></Reference><Reference><Citation>Schedin-Weiss S, Inoue M, Hromadkova L, Teranishi Y, Yamamoto NG, Wiehager B, Bogdanovic N, Winblad B, Sandebring-Matton A, Frykman S, et al. (2017) Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with gamma-secretase and regulates neuronal amyloid beta-peptide levels. Alzheimers Res Ther 9: 57 10.1186/s13195-017-0279-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0279-1</ArticleId><ArticleId IdType="pmc">PMC5540560</ArticleId><ArticleId IdType="pubmed">28764767</ArticleId></ArticleIdList></Reference><Reference><Citation>Imig C, Min SW, Krinner S, Arancillo M, Rosenmund C, Sudhof TC, Rhee J, Brose N, Cooper BH (2014) The morphological and molecular nature of synaptic vesicle priming at presynaptic active zones. Neuron 84: 416&#x2013;431. 10.1016/j.neuron.2014.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.10.009</ArticleId><ArticleId IdType="pubmed">25374362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, et al. (2005) Macroautophagy: A novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 171: 87&#x2013;98. 10.1083/jcb.200505082</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200505082</ArticleId><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahl SJ, Hell SW, Jakobs S (2017) Fluorescence nanoscopy in cell biology. Nat Rev Mol Cell Biol 18: 685&#x2013;701. 10.1038/nrm.2017.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.71</ArticleId><ArticleId IdType="pubmed">28875992</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust MJ, Bates M, Zhuang X (2006) Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). Nat Methods 3: 793&#x2013;795. 10.1038/nmeth929</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth929</ArticleId><ArticleId IdType="pmc">PMC2700296</ArticleId><ArticleId IdType="pubmed">16896339</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilemann M, van de Linde S, Schuttpelz M, Kasper R, Seefeldt B, Mukherjee A, Tinnefeld P, Sauer M (2008) Subdiffraction-resolution fluorescence imaging with conventional fluorescent probes. Angewandte Chemie 47: 6172&#x2013;6176. 10.1002/anie.200802376</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.200802376</ArticleId><ArticleId IdType="pubmed">18646237</ArticleId></ArticleIdList></Reference><Reference><Citation>Folling J, Bossi M, Bock H, Medda R, Wurm CA, Hein B, Jakobs S, Eggeling C, Hell SW (2008) Fluorescence nanoscopy by ground-state depletion and single-molecule return. Nat Methods 5: 943&#x2013;945. 10.1038/nmeth.1257</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1257</ArticleId><ArticleId IdType="pubmed">18794861</ArticleId></ArticleIdList></Reference><Reference><Citation>Fath T, Ke YD, Gunning P, Gotz J, Ittner LM (2009) Primary support cultures of hippocampal and substantia nigra neurons. Nat Protoc 4: 78&#x2013;85. 10.1038/nprot.2008.199</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.199</ArticleId><ArticleId IdType="pubmed">19131959</ArticleId></ArticleIdList></Reference><Reference><Citation>Schedin-Weiss S, Inoue M, Teranishi Y, Yamamoto NG, Karlstrom H, Winblad B, Tjernberg LO (2013) Visualizing active enzyme complexes using a photoreactive inhibitor for proximity ligation: Application on gamma-secretase. PLoS One 8: e63962 10.1371/journal.pone.0063962</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0063962</ArticleId><ArticleId IdType="pmc">PMC3663845</ArticleId><ArticleId IdType="pubmed">23717518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey GT, Vaughan JC, Chen KH, Bates M, Zhuang X (2011) Evaluation of fluorophores for optimal performance in localization-based super-resolution imaging. Nat Methods 8: 1027&#x2013;1036. 10.1038/nmeth.1768</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1768</ArticleId><ArticleId IdType="pmc">PMC3272503</ArticleId><ArticleId IdType="pubmed">22056676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga M, Imamoto N, Sakata-Sogawa K (2008) Highly inclined thin illumination enables clear single-molecule imaging in cells. Nat Methods 5: 159&#x2013;161. 10.1038/nmeth1171</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth1171</ArticleId><ArticleId IdType="pubmed">18176568</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernhem K, Brismar H (2018) SMLocalizer, a GPU accelerated ImageJ plugin for single molecule localization microscopy. Bioinformatics 34: 137&#x2013;138. 10.1093/bioinformatics/btx553</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx553</ArticleId><ArticleId IdType="pmc">PMC5870682</ArticleId><ArticleId IdType="pubmed">28968783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30001512</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's Disease-Associated &#x3b2;-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection.</ArticleTitle><Pagination><StartPage>56</StartPage><EndPage>63.e3</EndPage><MedlinePgn>56-63.e3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2018.06.030</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(18)30526-9</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; peptide (A&#x3b2;) fibrilization and deposition as &#x3b2;-amyloid are hallmarks of Alzheimer's disease (AD) pathology. We recently reported A&#x3b2; is an innate immune protein that protects against fungal and bacterial infections. Fibrilization pathways mediate A&#x3b2; antimicrobial activities. Thus, infection can seed and dramatically accelerate &#x3b2;-amyloid deposition. Here, we show A&#x3b2; oligomers bind herpesvirus surface glycoproteins, accelerating &#x3b2;-amyloid deposition and leading to protective viral entrapment activity in 5XFAD mouse and 3D human neural cell culture infection models against neurotropic herpes simplex virus 1 (HSV1) and human herpesvirus 6A and B. Herpesviridae are linked to AD, but it has been unclear how viruses may induce &#x3b2;-amyloidosis in brain. These data support the notion that A&#x3b2; might play a protective role in CNS innate immunity, and suggest an AD etiological mechanism in which herpesviridae infection may directly promote A&#x3b2;&#xa0;amyloidosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eimer</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129, USA; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vijaya Kumar</LastName><ForeName>Deepak Kumar</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129, USA; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navalpur Shanmugam</LastName><ForeName>Nanda Kumar</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129, USA; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Alex S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129, USA; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Teryn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129, USA; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Washicosky</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129, USA; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gy&#xf6;rgy</LastName><ForeName>Bence</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breakefield</LastName><ForeName>Xandra O</ForeName><Initials>XO</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129, USA; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. Electronic address: tanzi@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moir</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129, USA; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. Electronic address: moir@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI081990</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Trends Neurosci. 2018 Sep;41(9):570-573. doi: 10.1016/j.tins.2018.07.001.</RefSource><PMID Version="1">30033181</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2018 Dec 19;100(6):1527-1532. doi: 10.1016/j.neuron.2018.11.043.</RefSource><PMID Version="1">30571943</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020803" MajorTopicYN="N">Encephalitis, Herpes Simplex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018792" MajorTopicYN="N">Encephalitis, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006564" MajorTopicYN="Y">Herpesviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018259" MajorTopicYN="N">Herpesvirus 1, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015654" MajorTopicYN="N">Herpesvirus 6, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019349" MajorTopicYN="N">Roseolovirus Infections</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyloid-&#x3b2;</Keyword><Keyword MajorTopicYN="N">antimicrobial peptide</Keyword><Keyword MajorTopicYN="N">herpes simplex virus 1</Keyword><Keyword MajorTopicYN="N">herpesviridae</Keyword><Keyword MajorTopicYN="N">herpesvirus glycoprotein</Keyword><Keyword MajorTopicYN="N">human herpesvirus 6</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">oligomers</Keyword><Keyword MajorTopicYN="N">&#x3b2;-amyloid peptide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30001512</ArticleId><ArticleId IdType="mid">NIHMS982565</ArticleId><ArticleId IdType="pmc">PMC6075814</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.06.030</ArticleId><ArticleId IdType="pii">S0896-6273(18)30526-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alonso R, Pisa D, Marina AI, Morato E, Rabano A, and Carrasco L (2014). Fungal infection in patients with Alzheimer&#x2019;s disease. J Alzheimers Dis 41, 301&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614898</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki-Sasaki K, Ando Y, Nakamura M, Kitagawa K, Ikemizu S, Kawaji T, Yamashita T, Ueda M, Hirano K, Yamada M, et al. (2005). Lactoferrin Glu561Asp facilitates secondary amyloidosis in the cornea. Br J Ophthalmol 89, 684&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1772658</ArticleId><ArticleId IdType="pubmed">15923502</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnusch CJ, Branderhorst H, de Kruijff B, Liskamp RMJ, Breukink E, and Pieters RJ (2007). Enhanced membrane pore formation by multimeric/oligomeric antimicrobial peptides. Biochemistry 46, 13437&#x2013;13442.</Citation><ArticleIdList><ArticleId IdType="pubmed">17944489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, Frost EH, and Fulop T Jr. (2015). &#x3b2;-Amyloid peptides display protective activity against the human Alzheimer&#x2019;s disease-associated herpes simplex virus-1. Biogerontology 16, 85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">25376108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgade K, Le Page A, Bocti C, Witkowski JM, Dupuis G, Frost EH, and Fulop T (2016). Protective Effect of Amyloid-&#x3b2; Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model. J Alzheimers Dis 50, 1227&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">26836158</ArticleId></ArticleIdList></Reference><Reference><Citation>Campadelli-Fiume G, Mirandola P, and Menotti L (1999). Human herpesvirus 6: An emerging pathogen. Emerg Infect Dis 5, 353&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2640789</ArticleId><ArticleId IdType="pubmed">10341172</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter CJ (2008). Interactions between the products of the Herpes simplex genome and Alzheimer&#x2019;s disease susceptibility genes: relevance to pathological-signalling cascades. Neurochem Int 52, 920&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164103</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo GM, Cummings JA, Yang W, Judge ME, Sheardown MJ, Rimvall K, Hansen JB, and Snow AD (1998). Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan&#x2019;s enhancement of islet amyloid polypeptide (amylin) fibril formation. DiA&#x3b2;etes 47, 612&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">9568695</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D&#x2019;Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, et al. (2014). A three-dimensional human neural cell culture model of Alzheimer&#x2019;s disease. Nature 515, 274&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H, Pazgier M, Jung G, Nuccio S-P, Castillo PA, de Jong MF, Winter MG, Winter SE, Wehkamp J, Shen B, et al. (2012). Human &#x3b1;-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science 337, 477&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4332406</ArticleId><ArticleId IdType="pubmed">22722251</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciornei CD, Tapper H, Bjartell A, Sternby NH, and Bodelsson M (2006). Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovas Disord 6, 49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764755</ArticleId><ArticleId IdType="pubmed">17181861</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer MH (1907). The Physiology of Glycosuria. Cal State J Med 5, 229&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1652174</ArticleId><ArticleId IdType="pubmed">18734160</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, and Tanzi RE (2013). Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid &#x3b2;. Neuron 78, 631&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn S, Br&#xfc;ning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik CU, Bulic B, and Weggen S (2011). Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer&#x2019;s disease attenuate the response of cultured cells to &#x3b3;-secretase modulators regardless of their potency and structure. J Neurochem 116, 385&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">21091478</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris SA, and Harris EA (2015). Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer&#x2019;s Disease. J Alzheimers Dis 48, 319&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923765</ArticleId><ArticleId IdType="pubmed">26401998</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, Lehrer RI, and Herold BC (2006). Human alpha- and &#x3b2;-defensins block multiple steps in herpes simplex virus infection. J Immunol 177, 8658&#x2013;8666.</Citation><ArticleIdList><ArticleId IdType="pubmed">17142766</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock DT, and Latz E (2015). Innate immunity in Alzheimer&#x2019;s disease. Nat Immunol 16, 229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">25689443</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill JA, and Venna N (2014). Human herpesvirus 6 and the nervous system. Handb Clin Neurol 123, 327&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">25015494</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ, Chertov O, and Lubkowski J (2000). The structure of human &#x3b2;-defensin-2 shows evidence of higher order oligomerization. J Biol Chem 275, 32911&#x2013;32918.</Citation><ArticleIdList><ArticleId IdType="pubmed">10906336</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF (2014). Herpes simplex virus type 1 and Alzheimer&#x2019;s disease: increasing evidence for a major role of the virus. Front Aging Neurosci 6, 202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4128394</ArticleId><ArticleId IdType="pubmed">25157230</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter C, Clerici M, Cosby SL, et al. (2016). Microbes and Alzheimer&#x2019;s Disease. J Alzheimers Dis 51, 979&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457904</ArticleId><ArticleId IdType="pubmed">26967229</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, and Jamieson GA (1997). Herpes simplex virus type 1 in brain and risk of Alzheimer&#x2019;s disease. Lancet 349, 241&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">9014911</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamieson GA, Maitland NJ, Wilcock GK, Craske J, and Itzhaki RF (1991). Latent herpes simplex virus type 1 in normal and Alzheimer&#x2019;s disease brains. J Med Virol 33, 224&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">1649907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kee KH, Lee MJ, Shen SS, Suh JH, Lee O-J, Cho HY, Ayala AG, and Ro JY (2008). Amyloidosis of seminal vesicles and ejaculatory ducts: a histologic analysis of 21 cases among 447 prostatectomy specimens. Ann Diagn Pathol 12, 235&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">18620988</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, Lefkowitz A, McColl G, Goldstein LE, Tanzi RE, and Moir RD (2016). Amyloid-&#x3b2; peptide protects against microbial infection in mouse and worm models of Alzheimer&#x2019;s disease. Sci Transl Med 8, 340ra372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis PA, Piper S, Baker M, Onstead L, Murphy MP, Hardy J, Wang R, McGowan E, and Golde TE (2001). Expression of BRI-amyloid &#x3b2; peptide fusion proteins: a novel method for specific high-level expression of amyloid &#x3b2; peptides. Biochim Biophys Acta 1537, 58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476963</ArticleId></ArticleIdList></Reference><Reference><Citation>Linke RP, Joswig R, Murphy CL, Wang S, Zhou H, Gross U, Rocken C, Westermark P, Weiss DT, and Solomon A (2005). Senile seminal vesicle amyloid is derived from semenogelin I. J Lab Clin Med 145, 187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15962837</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna S, Cameron DJ, and Ethell DW (2013). Amyloid-&#x3b2; and APP deficiencies cause severe cerebrovascular defects: important work for an old villain. PLoS ONE 8, e75052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3764155</ArticleId><ArticleId IdType="pubmed">24040383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lusso P (1996). Human herpesvirus 6 (HHV-6). Antiviral Res 31, 1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">8793005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawanda F, and Wallace R (2013). Can Infections Cause Alzheimer&#x2019;s Disease? Epidemiol Rev.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707877</ArticleId><ArticleId IdType="pubmed">23349428</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeoch DJ, and Gatherer D (2005). Integrating reptilian herpesviruses into the family herpesviridae. J Virol 79, 725&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC538573</ArticleId><ArticleId IdType="pubmed">15613300</ArticleId></ArticleIdList></Reference><Reference><Citation>Millucci L, Paccagnini E, Ghezzi L, Bernardini G, Braconi D, Laschi M, Consumi M, Spreafico A, Tanganelli P, Lupetti P, et al. (2011). Different factors affecting human ANP amyloid aggregation and their implications in congestive heart failure. PLoS ONE 6, e21870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144199</ArticleId><ArticleId IdType="pubmed">21814559</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. (2006). Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice. J Neurosci 26, 10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, and Shai Y (1999). Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J 341 ( Pt 3), 501&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220385</ArticleId><ArticleId IdType="pubmed">10417311</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachon-Ibanez ME, Smani Y, Pachon J, and Sanchez-Cespedes J (2017). Perspectives for clinical use of engineered human host defense antimicrobial peptides. FEMS Microbiol Rev 41, 323&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435762</ArticleId><ArticleId IdType="pubmed">28521337</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe1;lffy R, Gardl&#xed;k R, Behuliak M, Kadasi L, Turna J, and Celec P (2009). On the physiology and pathophysiology of antimicrobial peptides. Mol Med 15, 51&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2583110</ArticleId><ArticleId IdType="pubmed">19015736</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, and Petersen W (2002). Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. J Pathol 198, 369&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12375270</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira HA, Kumar P, and Grammas P (1996). Expression of CAP37, a novel inflammatory mediator, in Alzheimer&#x2019;s disease. Neurobiol Aging 17, 753&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892348</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, et al. (2013). Dissecting phenotypic traits linked to human resilience to Alzheimer&#x2019;s pathology. Brain 136, 2510&#x2013;2526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722351</ArticleId><ArticleId IdType="pubmed">23824488</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisa D, Alonso R, Rabano A, Rodal I, and Carrasco L (2015). Different Brain Regions are Infected with Fungi in Alzheimer&#x2019;s Disease. Sci Rep 5, 15015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4606562</ArticleId><ArticleId IdType="pubmed">26468932</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B, Haure-Mirande J-V, Funk CC, Richards MA, Shannon P, Haroutunian V, Sano M, Liang WS, Beckmann ND, Price ND, et al. (2018). Multiscale analysis of independent Alzheimer&#x2019;s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron 99, this issue, 64&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinholz M, Ruzicka T, and Schauber J (2012). Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol 24, 126&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346901</ArticleId><ArticleId IdType="pubmed">22577261</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpa M, Grillo A, Scarpa M, Brun P, Castoro C, Pozza A, Cavallo D, Faggian D, Ruffolo C, D&#x2019;Inc&#xe0; R, et al. (2012). Innate immune environment in ileal pouch mucosa: &#x3b1;5 defensin up-regulation as predictor of chronic/relapsing pouchitis. J Gastrointest Surg 16, 188&#x2013;201- discussion 201&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">21983950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sood R, Domanov Y, Pieti&#xe4;inen M, Kontinen VP, and Kinnunen PKJ (2008). Binding of LL-37 to model biomembranes: insight into target vs host cell recognition. Biochim Biophys Acta 1778, 983&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">18166145</ArticleId></ArticleIdList></Reference><Reference><Citation>Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, and Moir RD (2010). The Alzheimer&#x2019;s disease-associated amyloid &#x3b2;-protein is an antimicrobial peptide. PLoS ONE 5, e9505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831066</ArticleId><ArticleId IdType="pubmed">20209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrent M, Pulido D, Nogu&#xe9;s M.V.r., and Boix E (2012). Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation. PLoS Pathog 8, e1003005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486885</ArticleId><ArticleId IdType="pubmed">23133388</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai P-W, Yang C-Y, Chang H-T, and Lan C-Y (2011a). Characterizing the role of cell-wall &#x3b2;&#x2212;1,3-exoglucanase Xog1p in Candida albicans adhesion by the human antimicrobial peptide LL-37. PLoS ONE 6, e21394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119699</ArticleId><ArticleId IdType="pubmed">21713010</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai P-W, Yang C-Y, Chang H-T, and Lan C-Y (2011b). Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS ONE 6, e17755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056723</ArticleId><ArticleId IdType="pubmed">21448240</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeng NS, Chung CH, Lin FH, Chiang CP, Yeh CB, Huang SY, Lu RB, Chang HA, Kao YC, Yeh HW, et al. (2018). Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan. Neurotherapeutics.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935641</ArticleId><ArticleId IdType="pubmed">29488144</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, Wesseling P, van den Heuvel LPWJ, de Waal RMW, and Verbeek MM (2003). Heparan sulphate proteoglycans in Alzheimer&#x2019;s disease and amyloid-related disorders. Lancet Neurol 2, 482&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12878436</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Li Y, Wang X, Chen W, Sun H, and Wang J (2014). Lipopolysaccharide induces amyloid formation of antimicrobial peptide HAL-2. Biochim Biophys Acta.</Citation><ArticleIdList><ArticleId IdType="pubmed">25109934</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson DJ, Lander AD, and Selkoe DJ (1997). Heparin-binding properties of the amyloidogenic peptides A&#x3b2; and amylin. Dependence on aggregation state and inhibition by Congo red. J Biol Chem 272, 31617&#x2013;31624.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395501</ArticleId></ArticleIdList></Reference><Reference><Citation>White MR, Kandel R, Tripathi S, Condon D, Qi L, Taubenberger J, and Hartshorn KL (2014). Alzheimer&#x2019;s associated &#x3b2;-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS ONE 9, e101364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4079246</ArticleId><ArticleId IdType="pubmed">24988208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak MA, Itzhaki RF, Shipley SJ, and Dobson CB (2007). Herpes simplex virus infection causes cellular &#x3b2;-amyloid accumulation and secretase upregulation. Neurosci Lett 429, 95&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">17980964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak MA, Mee AP, and Itzhaki RF (2009). Herpes simplex virus type 1 DNA is located within Alzheimer&#x2019;s disease amyloid plaques. J Pathol 217, 131&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">18973185</ArticleId></ArticleIdList></Reference><Reference><Citation>Xhindoli D, Pacor S, Guida F, Antcheva N, and Tossi A (2014). Native oligomerization determines the mode of action and biological activities of human cathelicidin LL-37. Biochem J 457, 263&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117320</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi Y, Nagase T, Tomita T, Nakamura K, Fukuhara S, Amano T, Yamamoto H, Ide Y, Suzuki M, Teramoto S, et al. (2007). &#x3b2;-defensin overexpression induces progressive muscle degeneration in mice. Am J Physiol, Cell Physiol 292, C2141&#x2013;2149.</Citation><ArticleIdList><ArticleId IdType="pubmed">17215327</ArticleId></ArticleIdList></Reference><Reference><Citation>Yount NY, Bayer AS, Xiong YQ, and Yeaman MR (2006). Advances in antimicrobial peptide immunobiology. Biopolymers 84, 435&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">16736494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Lee W-H, Shen J-H, Li H, and Zhang Y (2008). Identification of novel semenogelin I-derived antimicrobial peptide from liquefied human seminal plasma. Peptides 29, 505&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">18314226</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29950669</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>941</StartPage><EndPage>951</EndPage><MedlinePgn>941-951</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-018-0175-4</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by beta-amyloid accumulation, phosphorylated tau formation, hyperactivation of glial cells, and neuronal loss. The mechanisms of AD pathogenesis, however, remain poorly understood, partially due to the lack of relevant models that can comprehensively recapitulate multistage intercellular interactions in human AD brains. Here we present a new three-dimensional (3D) human AD triculture model using neurons, astrocytes, and microglia in a 3D microfluidic platform. Our model provided key representative AD features: beta-amyloid aggregation, phosphorylated tau accumulation, and neuroinflammatory activity. In particular, the model mirrored microglial recruitment, neurotoxic activities such as axonal cleavage, and NO release damaging AD neurons and astrocytes. Our model will serve to facilitate the development of more precise human brain models for basic mechanistic studies in neural-glial interactions and drug discovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Mechanical Engineering and Engineering Science, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Science, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Nanoscale Science Program, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetzel</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Mechanical Engineering and Engineering Science, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Science, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Nanoscale Science Program, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marriott</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Science, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dr&#xe9;au</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Science, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Avanzo</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Doo Yeon</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-6969-0340</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-7032-1454</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hansang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1829-2462</Identifier><AffiliationInfo><Affiliation>Department of Mechanical Engineering and Engineering Science, University of North Carolina at Charlotte, Charlotte, NC, USA. h.cho@uncc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Science, University of North Carolina at Charlotte, Charlotte, NC, USA. h.cho@uncc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA. h.cho@uncc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Nanoscale Science Program, University of North Carolina at Charlotte, Charlotte, NC, USA. h.cho@uncc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG014713</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2018 Jul;21(7):899-900. doi: 10.1038/s41593-018-0177-2.</RefSource><PMID Version="1">29950667</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Financial Interests Statement. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29950669</ArticleId><ArticleId IdType="mid">NIHMS970886</ArticleId><ArticleId IdType="pmc">PMC6800152</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0175-4</ArticleId><ArticleId IdType="pii">10.1038/s41593-018-0175-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>2016 Alzheimer&#x2019;s disease facts and figures. Alzheimer&#x2019;s &amp; Dementia 12, 459&#x2013;509 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE &amp; Bertram L Twenty Years of the Alzheimer&#x2019;s Disease Amyloid Hypothesis: A Genetic Perspective. Cell 120, 545&#x2013;555 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E &amp; De Strooper B The amyloid cascade hypothesis: are we poised for success or failure? Journal of Neurochemistry 139, 237&#x2013;252 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27255958</ArticleId></ArticleIdList></Reference><Reference><Citation>A Armstrong R A critical analysis of the &#x2018;amyloid cascade hypothesis&#x2019;. Folia Neuropathologica 3, 211&#x2013;225 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25310732</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquet D et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533, 125&#x2013;129 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27120160</ArticleId></ArticleIdList></Reference><Reference><Citation>Tubsuwan A et al. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer&#x2019;s disease patient carrying a L150P mutation in PSEN-1. Stem Cell Research 16, 110&#x2013;112 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27345792</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S et al. APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons. Cell Reports 11, 689&#x2013;696 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431668</ArticleId><ArticleId IdType="pubmed">25921538</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore CR et al. The familial Alzheimer&#x2019;s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Human Molecular Genetics 23, 3523&#x2013;3536 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049307</ArticleId><ArticleId IdType="pubmed">24524897</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproul AA et al. Characterization and Molecular Profiling of PSEN1 Familial Alzheimer&#x2019;s Disease iPSC-Derived Neural Progenitors. PLOS ONE 9, e84547 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885572</ArticleId><ArticleId IdType="pubmed">24416243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T et al. Modeling Alzheimer&#x2019;s Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular A&#x3b2; and Differential Drug Responsiveness. Cell Stem Cell 12, 487&#x2013;496 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23434393</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T et al. Establishment of Induced Pluripotent Stem Cells from Centenarians for Neurodegenerative Disease Research. PLOS ONE 7, e41572 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405135</ArticleId><ArticleId IdType="pubmed">22848530</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch P et al. Presenilin-1 L166P Mutant Human Pluripotent Stem Cell&#x2013;Derived Neurons Exhibit Partial Loss of &#x3b3;-Secretase Activity in Endogenous Amyloid-&#x3b2; Generation. The American Journal of Pathology 180, 2404&#x2013;2416 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22510327</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. A human stem cell model of early Alzheimer&#x2019;s disease pathology in Down syndrome. Science Translational Medicine 4, 124ra29&#x2013;124ra29 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129935</ArticleId><ArticleId IdType="pubmed">22344463</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA et al. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature 482, 216&#x2013;220 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH et al. A three-dimensional human neural cell culture model of Alzheimer&#x2019;s disease. Nature 515, 274&#x2013;278 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YH et al. A 3D human neural cell culture system for modeling Alzheimer&#x2019;s disease. Nat Protoc 10, 985&#x2013;1006 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4499058</ArticleId><ArticleId IdType="pubmed">26068894</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Avanzo C et al. Alzheimer&#x2019;s in 3D culture: Challenges and perspectives. Bioessays 37, 1139&#x2013;1148 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4674791</ArticleId><ArticleId IdType="pubmed">26252541</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Kim YH, Quinti L, Tanzi RE &amp; Kim DY 3D culture models of Alzheimer&#x2019;s disease: a road map to a &#x201c;cure-in-a-dish&#x201d;. Mol Neurodegener 11, 75 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5148918</ArticleId><ArticleId IdType="pubmed">27938410</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674&#x2013;678 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A et al. Alzheimer&#x2019;s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron 78, 631&#x2013;643 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O et al. Identification of a unique TGF-&#x3b2;&#x2013;dependent molecular and functional signature in microglia. Nature Neuroscience 17, 131&#x2013;143 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Crehan H, Hardy J &amp; Pocock J Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis 54, 139&#x2013;149 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23454195</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R et al. TREM2Variants in Alzheimer&#x2019;s Disease. New England Journal of Medicine 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Li Y, Cyras C, Sanan DA &amp; Cordell B Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle. Journal of Biological Chemistry 275, 31770&#x2013;31777 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10918055</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z-N et al. Layered hydrogels accelerate iPSC-derived neuronal maturation and reveal migration defects caused by MeCP2 dysfunction. Proceedings of the National Academy of Sciences 113, 3185&#x2013;3190 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812712</ArticleId><ArticleId IdType="pubmed">26944080</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S et al. Three-dimensional extracellular matrix-mediated neural stem cell differentiation in a microfluidic device. Lab Chip 12, 2305&#x2013;2308 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22622966</ArticleId></ArticleIdList></Reference><Reference><Citation>Tischbirek C, Birkner A, Jia H, Sakmann B &amp; Konnerth A Deep two-photon brain imaging with a red-shifted fluorometric Ca2+ indicator. Proc Natl Acad Sci USA 112, 11377&#x2013;11382 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568712</ArticleId><ArticleId IdType="pubmed">26305966</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury El JB et al. CD36 Mediates the Innate Host Response to &#x3b2;-Amyloid. The Journal of Experimental Medicine 197, 1657&#x2013;1666 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193948</ArticleId><ArticleId IdType="pubmed">12796468</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury El J et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nature Medicine 13, 432&#x2013;438 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion JP Neurofibrillary Tangles and Alzheimer&#x2019;s Disease. European Neurology 40, 130&#x2013;140 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9748670</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S-Q et al. Deficiency of macrophage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer&#x2019;s disease. J Neuroinflammation 12, 177 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574615</ArticleId><ArticleId IdType="pubmed">26382037</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE et al. Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-&#x3b2; pathology. Brain 139, 1265&#x2013;1281 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Papageorgiou IE et al. TLR4-activated microglia require IFN-&#x3b3; to induce severe neuronal dysfunction and death in situ. Proceedings of the National Academy of Sciences 113, 212&#x2013;217 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711883</ArticleId><ArticleId IdType="pubmed">26699475</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne TC et al. IFN-&#x3b3; Production by amyloid &#x3b2;-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer&#x2019;s disease. J. Immunol 190, 2241&#x2013;2251 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23365075</ArticleId></ArticleIdList></Reference><Reference><Citation>Garwood CJ, Pooler AM, Atherton J, Hanger DP &amp; Noble W Astrocytes are important mediators of A&#x3b2;-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death &amp; Disease 2, e167&#x2013;e167 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168992</ArticleId><ArticleId IdType="pubmed">21633390</ArticleId></ArticleIdList></Reference><Reference><Citation>White JA, Manelli AM, Holmberg KH, Van Eldik LJ &amp; LaDu MJ Differential effects of oligomeric and fibrillar amyloid-&#x3b2;1&#x2013;42 on astrocyte-mediated inflammation. Neurobiol Dis 18, 459&#x2013;465 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15755672</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao BG &amp; Link H IFN-gamma production of adult rat astrocytes triggered by TNF-alpha. Neuroreport 9, 1487&#x2013;1490 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9631453</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashioka S, Klegeris A, Schwab C, Yu S &amp; McGeer PL Differential expression of interferon-&#x3b3; receptor on human glial cells in vivo and in vitro. Journal of Neuroimmunology 225, 91&#x2013;99 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20554027</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H et al. Microfluidic Chemotaxis Platform for Differentiating the Roles of Soluble and Bound Amyloid-&#x3b2; on Microglial Accumulation. Scientific Reports 3, 169 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3650586</ArticleId><ArticleId IdType="pubmed">23665843</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits HA et al. Amyloid-&#x3b2;-induced chemokine production in primary human macrophages and astrocytes. Journal of Neuroimmunology 127, 160&#x2013;168 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12044988</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer&#x2019;s disease pathology. Nature Communications 6, 7967 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557123</ArticleId><ArticleId IdType="pubmed">26284939</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes SE et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nature Neuroscience 9, 1512&#x2013;1519 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17115040</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou Y et al. Microglial migration mediated by ATP-induced ATP release from lysosomes. Cell Research 22, 1022&#x2013;1033 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367529</ArticleId><ArticleId IdType="pubmed">22231629</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez de Lara MJ &amp; Pintor J Presence and release of ATP from the retina in an Alzheimer&#x2019;s disease model. J. Alzheimers Dis. 43, 177&#x2013;181 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25061048</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson JU et al. Suppression of Inflammation with Conditional Deletion of the Prostaglandin E2 EP2 Receptor in Macrophages and Brain Microglia. J Neurosci 33, 16016&#x2013;16032 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787507</ArticleId><ArticleId IdType="pubmed">24089506</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29963623</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>The neuronal S100B protein is a calcium-tuned suppressor of amyloid-&#x3b2; aggregation.</ArticleTitle><Pagination><StartPage>eaaq1702</StartPage><MedlinePgn>eaaq1702</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eaaq1702</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.aaq1702</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) aggregation and neuroinflammation are consistent features in Alzheimer's disease (AD) and strong candidates for the initiation of neurodegeneration. S100B is one of the most abundant proinflammatory proteins that is chronically up-regulated in AD and is found associated with senile plaques. This recognized biomarker for brain distress may, thus, play roles in amyloid aggregation which remain to be determined. We report a novel role for the neuronal S100B protein as suppressor of A&#x3b2;42 aggregation and toxicity. We determined the structural details of the interaction between monomeric A&#x3b2;42 and S100B, which is favored by calcium binding to S100B, possibly involving conformational switching of disordered A&#x3b2;42 into an &#x3b1;-helical conformer, which locks aggregation. From nuclear magnetic resonance experiments, we show that this dynamic interaction occurs at a promiscuous peptide-binding region within the interfacial cleft of the S100B homodimer. This physical interaction is coupled to a functional role in the inhibition of A&#x3b2;42 aggregation and toxicity and is tuned by calcium binding to S100B. S100B delays the onset of A&#x3b2;42 aggregation by interacting with A&#x3b2;42 monomers inhibiting primary nucleation, and the calcium-bound state substantially affects secondary nucleation by inhibiting fibril surface-catalyzed reactions through S100B binding to growing A&#x3b2;42 oligomers and fibrils. S100B protects cells from A&#x3b2;42-mediated toxicity, rescuing cell viability and decreasing apoptosis induced by A&#x3b2;42 in cell cultures. Together, our findings suggest that molecular targeting of S100B could be translated into development of novel approaches to ameliorate AD neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crist&#xf3;v&#xe3;o</LastName><ForeName>Joana S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-3833-0016</Identifier><AffiliationInfo><Affiliation>Biosystems and Integrative Sciences Institute, Faculdade de Ci&#xea;ncias, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Qu&#xed;mica e Bioqu&#xed;mica, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Vanessa K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Center for Integrated Protein Science Munich, Department of Chemistry, Technische Universit&#xe4;t M&#xfc;nchen, Lichtenbergstrasse 4, 85748 Garching, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz Zentrum M&#xfc;nchen, Deutsches Forschungszentrum f&#xfc;r Gesundheit und Umwelt, Ingolst&#xe4;dter Landstrasse 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardoso</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investiga&#xe7;&#xe3;o e Inova&#xe7;&#xe3;o em Sa&#xfa;de, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leal</LastName><ForeName>S&#xf3;nia S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0001-8445-0065</Identifier><AffiliationInfo><Affiliation>Biosystems and Integrative Sciences Institute, Faculdade de Ci&#xea;ncias, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Qu&#xed;mica e Bioqu&#xed;mica, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biosystems and Integrative Sciences Institute, Faculdade de Ci&#xea;ncias, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Qu&#xed;mica e Bioqu&#xed;mica, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botelho</LastName><ForeName>Hugo M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0002-4208-1086</Identifier><AffiliationInfo><Affiliation>Biosystems and Integrative Sciences Institute, Faculdade de Ci&#xea;ncias, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;bl</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Integrated Protein Science Munich, Department of Chemistry, Technische Universit&#xe4;t M&#xfc;nchen, Lichtenbergstrasse 4, 85748 Garching, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz Zentrum M&#xfc;nchen, Deutsches Forschungszentrum f&#xfc;r Gesundheit und Umwelt, Ingolst&#xe4;dter Landstrasse 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5985-863X</Identifier><AffiliationInfo><Affiliation>Biosystems and Integrative Sciences Institute, Faculdade de Ci&#xea;ncias, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Qu&#xed;mica e Bioqu&#xed;mica, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kierdorf</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alemi</LastName><ForeName>Mobina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investiga&#xe7;&#xe3;o e Inova&#xe7;&#xe3;o em Sa&#xfa;de, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madl</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9725-5231</Identifier><AffiliationInfo><Affiliation>Center for Integrated Protein Science Munich, Department of Chemistry, Technische Universit&#xe4;t M&#xfc;nchen, Lichtenbergstrasse 4, 85748 Garching, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz Zentrum M&#xfc;nchen, Deutsches Forschungszentrum f&#xfc;r Gesundheit und Umwelt, Ingolst&#xe4;dter Landstrasse 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fritz</LastName><ForeName>G&#xfc;nter</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4571-8812</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reif</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7368-7198</Identifier><AffiliationInfo><Affiliation>Center for Integrated Protein Science Munich, Department of Chemistry, Technische Universit&#xe4;t M&#xfc;nchen, Lichtenbergstrasse 4, 85748 Garching, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz Zentrum M&#xfc;nchen, Deutsches Forschungszentrum f&#xfc;r Gesundheit und Umwelt, Ingolst&#xe4;dter Landstrasse 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Cl&#xe1;udio M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0003-4662-6933</Identifier><AffiliationInfo><Affiliation>Biosystems and Integrative Sciences Institute, Faculdade de Ci&#xea;ncias, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Qu&#xed;mica e Bioqu&#xed;mica, Universidade de Lisboa, 1749-016 Lisboa, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P 28854</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>W 1226</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064568">S100 Calcium Binding Protein beta Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579160">S100B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054730" MajorTopicYN="N">Protein Interaction Domains and Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064568" MajorTopicYN="N">S100 Calcium Binding Protein beta Subunit</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>6</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29963623</ArticleId><ArticleId IdType="pmc">PMC6025902</ArticleId><ArticleId IdType="doi">10.1126/sciadv.aaq1702</ArticleId><ArticleId IdType="pii">aaq1702</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masters C. L., Bateman R., Blennow K., Rowe C. C., Sperling R. A., Cummings J. L., Alzheimer&#x2019;s disease. Nat. Rev. Dis. Primers 1, 15056 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S., Gondo T., Hoshii Y., Takahashi M., Yamada M., Ishihara T., Confocal observation of senile plaques in Alzheimer&#x2019;s disease: Senile plaque morphology and relationship between senile plaques and astrocytes. Pathol. Int. 48, 332&#x2013;340 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9704339</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Zhao R., Gao K., Wei Z., Yin M. Y., Lau L. T., Chui D., Yu A. C., Astrocytes: Implications for neuroinflammatory pathogenesis of Alzheimer&#x2019;s disease. Curr. Alzheimer Res. 8, 67&#x2013;80 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21143158</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshak D. R., Pesce S. A., Stanley L. C., Griffin W. S., Increased S100 beta neurotrophic activity in Alzheimer&#x2019;s disease temporal lobe. Neurobiol. Aging 13, 1&#x2013;7 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1371849</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng J. G., Mrak R. E., Griffin W. S., S100&#x3b2; protein expression in Alzheimer disease: Potential role in the pathogenesis of neuritic plaques. J. Neurosci. Res. 39, 398&#x2013;404 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7884819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak R. E., Griffinbc W. S., The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer&#x2019;s disease. Neurobiol. Aging 22, 915&#x2013;922 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11754999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorci G., Bianchi R., Riuzzi F., Tubaro C., Arcuri C., Giambanco I., Donato R., S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond. Cardiovasc. Psychiatry Neurol. 2010, 656481 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933911</ArticleId><ArticleId IdType="pubmed">20827421</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorp T., Diez J., Heizmann C. W., Fritz G., The crystal structures of human S100B in the zinc- and calcium-loaded state at three pH values reveal zinc ligand swapping. Biochim. Biophys. Acta 1813, 1083&#x2013;1091 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20950652</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho S. B., Botelho H. M., Leal S. S., Cardoso I., Fritz G., Gomes C. M., Intrinsically disordered and aggregation prone regions underlie &#x3b2;-aggregation in S100 proteins. PLOS ONE 8, e76629 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3788126</ArticleId><ArticleId IdType="pubmed">24098542</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz G., Botelho H. M., Morozova-Roche L. A., Gomes C. M., Natural and amyloid self-assembly of S100 proteins: Structural basis of functional diversity. FEBS J. 277, 4578&#x2013;4590 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20977662</ArticleId></ArticleIdList></Reference><Reference><Citation>Botelho H. M., Fritz G., Gomes C. M., Analysis of S100 oligomers and amyloids. Methods Mol. Biol. 849, 373&#x2013;386 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22528103</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothermundt M., Peters M., Prehn J. H., Arolt V., S100B in brain damage and neurodegeneration. Microsc. Res. Tech. 60, 614&#x2013;632 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12645009</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#xf1;a L. A., Brecher C. W., Marshak D. R., &#x3b2;-Amyloid regulates gene expression of glial trophic substance S100&#x3b2; in C6 glioma and primary astrocyte cultures. Brain Res. Mol. Brain Res. 34, 118&#x2013;126 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8750867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng J. G., Mrak R. E., Bales K. R., Cordell B., Paul S. M., Jones R. A., Woodward S., Zhou X. Q., McGinness J. M., Griffin W. S. T., Overexpression of the neuritotrophic cytokine S100&#x3b2; precedes the appearance of neuritic &#x3b2;-amyloid plaques in APPV717F mice. J. Neurochem. 74, 295&#x2013;301 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903403</ArticleId><ArticleId IdType="pubmed">10617132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori T., Koyama N., Arendash G. W., Horikoshi-Sakuraba Y., Tan J., Town T., Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer&#x2019;s disease. Glia 58, 300&#x2013;314 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795105</ArticleId><ArticleId IdType="pubmed">19705461</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft J. M., Watterson D. M., Marks A., Van Eldik L. J., Enhanced susceptibility of S-100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human &#x3b2;-amyloid. Glia 51, 209&#x2013;216 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15810011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori T., Town T., Tan J., Yada N., Horikoshi Y., Yamamoto J., Shimoda T., Kamanaka Y., Tateishi N., Asano T., Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J. Pharmacol. Exp. Ther. 318, 571&#x2013;578 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16709678</ArticleId></ArticleIdList></Reference><Reference><Citation>Roltsch E., Holcomb L., Young K. A., Marks A., Zimmer D. B., PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition in response to S100B ablation. J. Neuroinflammation 7, 78 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996465</ArticleId><ArticleId IdType="pubmed">21080947</ArticleId></ArticleIdList></Reference><Reference><Citation>Businaro R., Leone S., Fabrizi C., Sorci G., Donato R., Lauro G. M., Fumagalli L., S100B protects LAN-5 neuroblastoma cells against A&#x3b2; amyloid-induced neurotoxicity via RAGE engagement at low doses but increases A&#x3b2; amyloid neurotoxicity at high doses. J. Neurosci. Res. 83, 897&#x2013;906 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16477616</ArticleId></ArticleIdList></Reference><Reference><Citation>Santamaria-Kisiel L., Rintala-Dempsey A. C., Shaw G. S., Calcium-dependent and -independent interactions of the S100 protein family. Biochem J. 396, 201&#x2013;214 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1462724</ArticleId><ArticleId IdType="pubmed">16683912</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen J. L., Indurthi V. S. K., Neau D. B., Vetter S. W., Colbert C. L., Structural insights into the binding of the human receptor for advanced glycation end products (RAGE) by S100B, as revealed by an S100B-RAGE-derived peptide complex. Acta Crystallogr. D Biol. Crystallogr. 71, 1176&#x2013;1183 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427201</ArticleId><ArticleId IdType="pubmed">25945582</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder P. T., Lin J., Bair C. L., Charpentier T. H., Yang D., Liriano M., Varney K. M., Lee A., Oppenheim A. B., Adhya S., Carrier F., Weber D. J., Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. Biochim. Biophys. Acta 1763, 1284&#x2013;1297 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17010455</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustandi R. R., Baldisseri D. M., Weber D. J., Structure of the negative regulatory domain of p53 bound to S100B(beta beta). Nat. Struct. Biol. 7, 570&#x2013;574 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10876243</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpell L. C., Alzheimer&#x2019;s amyloid fibrils: Structure and assembly. Biochim. Biophys. Acta 1502, 16&#x2013;30 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10899428</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvet J., Danielsson J., Damberg P., Oleszczuk M., Gr&#xe4;slund A., Positioning of the Alzheimer A&#x3b2;(1&#x2013;40) peptide in SDS micelles using NMR and paramagnetic probes. J. Biomol. NMR 39, 63&#x2013;72 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17657567</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;bl C., Madl T., Simon B., Sattler M., NMR approaches for structural analysis of multidomain proteins and complexes in solution. Prog. Nucl. Magn. Reson. Spectrosc. 80, 26&#x2013;63 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24924266</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A. A., Chou R.-H., Li H., Yang L.-W., Yu C., Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling. Biochim. Biophys. Acta 1834, 2606&#x2013;2619 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24063890</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S. I. A., Linse S., Luheshi L. M., Hellstrand E., White D. A., Rajah L., Otzen D. E., Vendruscolo M., Dobson C. M., Knowles T. P. J., Proliferation of amyloid-&#x3b2;42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. U.S.A. 110, 9758&#x2013;9763 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683769</ArticleId><ArticleId IdType="pubmed">23703910</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G., Kirkegaard J. B., Arosio P., Michaels T. C. T., Vendruscolo M., Dobson C. M., Linse S., Knowles T. P. J., Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat. Protoc. 11, 252&#x2013;272 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26741409</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P., Vendruscolo M., Dobson C. M., Knowles T. P., Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol. Sci. 35, 127&#x2013;135 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24560688</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S. I. A., Arosio P., Presto J., Kurudenkandy F. R., Biverst&#xe5;l H., Dolfe L., Dunning C., Yang X., Frohm B., Vendruscolo M., Johansson J., Dobson C. M., Fisahn A., Knowles T. P. J., Linse S., A molecular chaperone breaks the catalytic cycle that generates toxic A&#x3b2; oligomers. Nat. Struct. Mol. Biol. 22, 207&#x2013;213 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4595974</ArticleId><ArticleId IdType="pubmed">25686087</ArticleId></ArticleIdList></Reference><Reference><Citation>S. B. Carvalho, I. Cardoso, H. M. Botelho, K. Yanamandra, G. Fritz, C. M. Gomes, L. A. Morozova-Roche, Structural heterogeneity and bioimaging of S100 amyloid assemblies, in Bionanoimaging: Protein Misfolding and Aggregation, V. Uversky, Y. Lyubchenko, Eds. (Elsevier, 2013), vol. 18, pp. 197&#x2013;212.</Citation></Reference><Reference><Citation>Arosio P., Michaels T. C. T., Linse S., M&#xe5;nsson C., Emanuelsson C., Presto J., Johansson J., Vendruscolo M., Dobson C. M., Knowles T. P. J., Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 7, 10948 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820785</ArticleId><ArticleId IdType="pubmed">27009901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Abelein A., Nilsson H. E., Leppert A., Andrade-Talavera Y., Tambaro S., Hemmingsson L., Roshan F., Landreh M., Biverst&#xe5;l H., Koeck P. J. B., Presto J., Hebert H., Fisahn A., Johansson J., Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state. Nat. Commun. 8, 2081 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5727130</ArticleId><ArticleId IdType="pubmed">29234026</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal S. S., Botelho H. M., Gomes C. M., Metal ions as modulators of protein conformation and misfolding in neurodegeneration. Coord. Chem. Rev. 256, 2253&#x2013;2270 (2012).</Citation></Reference><Reference><Citation>Cristovao J. S., Santos R., Gomes C. M., Metals and neuronal metal binding proteins implicated in Alzheimer&#x2019;s disease. Oxid. Med. Cell. Longevity 2016, 9812178 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4736980</ArticleId><ArticleId IdType="pubmed">26881049</ArticleId></ArticleIdList></Reference><Reference><Citation>Donato R., S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33, 637&#x2013;668 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11390274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer D. B., Wright Sadosky P., Weber D. J., Molecular mechanisms of S100-target protein interactions. Microsc. Res. Tech. 60, 552&#x2013;559 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12645003</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C., Casta&#xf1;o E. M., Frangione B., Inestrosa N. C., The &#x3b1;-helical to &#x3b2;-strand transition in the amino-terminal fragment of the amyloid &#x3b2;-peptide modulates amyloid formation. J. Biol. Chem. 270, 3063&#x2013;3067 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7852387</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., Thulin E., Minogue A. M., Gustavsson N., Pang E., Teplow D. B., Linse S., A facile method for expression and purification of the Alzheimer&#x2019;s disease-associated amyloid beta-peptide. FEBS J. 276, 1266&#x2013;1281 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702495</ArticleId><ArticleId IdType="pubmed">19175671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29992960</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>An in vitro paradigm to assess potential anti-A&#x3b2; antibodies for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>2676</StartPage><MedlinePgn>2676</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2676</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-018-05068-w</ELocationID><Abstract><AbstractText>Although the amyloid &#x3b2;-protein (A&#x3b2;) is believed to play an initiating role in Alzheimer's disease (AD), the molecular characteristics of the key pathogenic A&#x3b2; forms are not well understood. As a result, it has proved difficult to identify optimal agents that target disease-relevant forms of A&#x3b2;. Here, we combined the use of A&#x3b2;-rich aqueous extracts of brain samples from AD patients as a source of human A&#x3b2; and live-cell imaging of iPSC-derived human neurons to develop a bioassay capable of quantifying the relative protective effects of multiple anti-A&#x3b2; antibodies. We report the characterization of 1C22, an aggregate-preferring murine anti-A&#x3b2; antibody, which better protects against forms of A&#x3b2; oligomers that are toxic to neurites than do the murine precursors of the clinical immunotherapeutics, bapineuzumab and solanezumab. These results suggest further examination of 1C22 is warranted, and that this bioassay maybe useful as a primary screen to identify yet more potent anti-A&#x3b2; therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Ming</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5550-7533</Identifier><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Nuallain</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagomarsino</LastName><ForeName>Valentina N</ForeName><Initials>VN</Initials><Identifier Source="ORCID">0000-0003-3195-1899</Identifier><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Tiernan T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderburg</LastName><ForeName>Charles R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Massachusetts General Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Massachusetts General Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young-Pearse</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. dselkoe@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. dwalsh3@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046275</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>5D6PWO0333</RegistryNumber><NameOfSubstance UI="C550616">solanezumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>NC11WKO35D</RegistryNumber><NameOfSubstance UI="C545458">bapineuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29992960</ArticleId><ArticleId IdType="pmc">PMC6041266</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-05068-w</ArticleId><ArticleId IdType="pii">10.1038/s41467-018-05068-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu J, Yang B, Ke J, Li W, Suen WC. Antibody-based drugs and approaches against amyloid-beta species for Alzheimer&#x2019;s disease immunotherapy. Drugs Aging. 2016;33:685&#x2013;697. doi: 10.1007/s40266-016-0406-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40266-016-0406-x</ArticleId><ArticleId IdType="pubmed">27699633</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE. Open questions for Alzheimer&#x2019;s disease immunotherapy. Alzheimer&#x2019;s Res. Ther. 2014;6:3. doi: 10.1186/alzrt233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt233</ArticleId><ArticleId IdType="pmc">PMC4056616</ArticleId><ArticleId IdType="pubmed">24393284</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck CH. Anti-amyloid-beta monoclonal antibodies for Alzheimer&#x2019;s disease: pitfalls and promise. Biol. Psychiatry. 2017;83:311&#x2013;319. doi: 10.1016/j.biopsych.2017.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.08.010</ArticleId><ArticleId IdType="pmc">PMC5767539</ArticleId><ArticleId IdType="pubmed">28967385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohyama K, Matsumoto Y. Alzheimer&#x2019;s disease and immunotherapy: what is wrong with clinical trials? Immunotargets Ther. 2015;4:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918245</ArticleId><ArticleId IdType="pubmed">27471709</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 2016;8:595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Teplow DB. Alzheimer&#x2019;s disease and the amyloid beta-protein. Progress. Mol. Biol. Transl. Sci. 2012;107:101&#x2013;124. doi: 10.1016/B978-0-12-385883-2.00012-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-385883-2.00012-6</ArticleId><ArticleId IdType="pubmed">22482449</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, et al. High tissue content of soluble A&#x3b2; 1-40 is linked to cerebral amyloid angiopathy. Am. J. Pathol. 1994;145:452&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887395</ArticleId><ArticleId IdType="pubmed">8053502</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabaton M, et al. Soluble amyloid b protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem. Biophys. Res. Commun. 1994;200:1598&#x2013;1603. doi: 10.1006/bbrc.1994.1634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1994.1634</ArticleId><ArticleId IdType="pubmed">8185615</ArticleId></ArticleIdList></Reference><Reference><Citation>Teller JK, et al. Presence of soluble amyloid &#x3b2;-peptide precedes amyloid plaque formation in Down&#x2019;s syndrome. Nat. Med. 1996;2:93&#x2013;95. doi: 10.1038/nm0196-93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0196-93</ArticleId><ArticleId IdType="pubmed">8564851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, et al. Water-soluble Ab (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 1996;271:4077&#x2013;4081. doi: 10.1074/jbc.271.8.4077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.8.4077</ArticleId><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Maarouf CL, et al. Alzheimer&#x2019;s disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS ONE. 2011;6:e27291. doi: 10.1371/journal.pone.0027291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027291</ArticleId><ArticleId IdType="pmc">PMC3210154</ArticleId><ArticleId IdType="pubmed">22087282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Glabe CG, Kayed R. Amyloid-&#x3b2; annular protofibrils evade fibrillar fate in Alzheimer disease brain. J. Biol. Chem. 2011;266:22122&#x2013;22130. doi: 10.1074/jbc.M111.236257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.236257</ArticleId><ArticleId IdType="pmc">PMC3121356</ArticleId><ArticleId IdType="pubmed">21507938</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhaya AR, Lungrin I, Yamaguchi H, Fandrich M, Tal DR. High-molecular weight A&#x3b2; oligomers and protofibrils are the predominant A&#x3b2; species in the native soluble protein fraction of the AD brain. J. Cell. Mol. Med. 2011;20:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823292</ArticleId><ArticleId IdType="pubmed">21418518</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehlin D, et al. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS ONE. 2012;7:e32014. doi: 10.1371/journal.pone.0032014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032014</ArticleId><ArticleId IdType="pmc">PMC3280222</ArticleId><ArticleId IdType="pubmed">22355408</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore BD, et al. Overlapping profiles of Abeta peptides in the Alzheimer&#x2019;s disease and pathological aging brains. Alzheimers Res. Ther. 2012;4:18. doi: 10.1186/alzrt121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt121</ArticleId><ArticleId IdType="pmc">PMC3506932</ArticleId><ArticleId IdType="pubmed">22621179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J. Neurosci. 2012;32:15181&#x2013;15192. doi: 10.1523/JNEUROSCI.1542-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1542-12.2012</ArticleId><ArticleId IdType="pmc">PMC3493562</ArticleId><ArticleId IdType="pubmed">23100439</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch. Neurol. 2009;66:190&#x2013;199. doi: 10.1001/archneurol.2008.565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.565</ArticleId><ArticleId IdType="pmc">PMC3618974</ArticleId><ArticleId IdType="pubmed">19204155</ArticleId></ArticleIdList></Reference><Reference><Citation>van Helmond Z, Heesom K, Love S. Characterisation of two antibodies to oligomeric Ab and their use in ELISAs on human brain tissue homogenates. J. Neurosci. Methods. 2009;176:206&#x2013;212. doi: 10.1016/j.jneumeth.2008.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2008.09.002</ArticleId><ArticleId IdType="pubmed">18824027</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 2012;73:104&#x2013;119. doi: 10.1002/ana.23748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23748</ArticleId><ArticleId IdType="pmc">PMC3563737</ArticleId><ArticleId IdType="pubmed">23225543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. CRISPR/Cas9 mediated genome editing of Helicoverpa armigera with mutations of an ABC transporter gene HaABCA2 confers resistance to Bacillus thuringiensis Cry2A toxins. Insect Biochem. Mol. Biol. 2017;87:147&#x2013;153. doi: 10.1016/j.ibmb.2017.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ibmb.2017.07.002</ArticleId><ArticleId IdType="pubmed">28705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, et al. The aqueous phase of Alzheimer&#x2019;s disease brain contains assemblies built from approximately 4 and approximately 7&#x2009;kDa Abeta species. Alzheimer&#x2019;s Dement. 2015;11:1286&#x2013;1305. doi: 10.1016/j.jalz.2015.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.01.005</ArticleId><ArticleId IdType="pmc">PMC4592782</ArticleId><ArticleId IdType="pubmed">25846299</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, et al. Alzheimer&#x2019;s disease type neuronal tau phyerphosphorylation induced by Ab oligomers. Neurobiol. Aging. 2008;29:1334&#x2013;1347. doi: 10.1016/j.neurobiolaging.2007.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.029</ArticleId><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry AE, et al. Alzheimer&#x2019;s disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J. Neurosci. 2011;31:7259&#x2013;7263. doi: 10.1523/JNEUROSCI.6500-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6500-10.2011</ArticleId><ArticleId IdType="pmc">PMC6622598</ArticleId><ArticleId IdType="pubmed">21593310</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir D, et al. Interaction between prion protein and toxic amyloid &#x3b2; assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2011;2:1341&#x2013;1351. doi: 10.1038/ncomms1341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1341</ArticleId><ArticleId IdType="pmc">PMC3156817</ArticleId><ArticleId IdType="pubmed">21654636</ArticleId></ArticleIdList></Reference><Reference><Citation>Adolfsson O, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J. Neurosci. 2012;32:9677&#x2013;9689. doi: 10.1523/JNEUROSCI.4742-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4742-11.2012</ArticleId><ArticleId IdType="pmc">PMC6622286</ArticleId><ArticleId IdType="pubmed">22787053</ArticleId></ArticleIdList></Reference><Reference><Citation>Borlikova GG, et al. Alzheimer brain-derived Abeta impairs synaptic remodeling and memory consolidation. Neurobiol. Aging. 2012;34:1315&#x2013;1327. doi: 10.1016/j.neurobiolaging.2012.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.10.028</ArticleId><ArticleId IdType="pmc">PMC3570694</ArticleId><ArticleId IdType="pubmed">23182244</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, et al. Human brain-derived Abeta oligomers bind to synapses and disrupt synaptic activity in a manner that requires APP. J. Neurosci. 2017;37:11947&#x2013;11966. doi: 10.1523/JNEUROSCI.2009-17.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2009-17.2017</ArticleId><ArticleId IdType="pmc">PMC5719975</ArticleId><ArticleId IdType="pubmed">29101243</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F, et al. Soluble Abeta seeds are potent inducers of cerebral beta-amyloid deposition. J. Neurosci. 2011;31:14488&#x2013;14495. doi: 10.1523/JNEUROSCI.3088-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3088-11.2011</ArticleId><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohr J, et al. Purified and synthetic Alzheimer&#x2019;s amyloid beta (Abeta) prions. Proc. Natl Acad. Sci. USA. 2012;109:11025&#x2013;11030. doi: 10.1073/pnas.1206555109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206555109</ArticleId><ArticleId IdType="pmc">PMC3390876</ArticleId><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta dimers isolated directly from Alzheimer&#x2019;s disease brains impair synaptic plasticity and memory. Nat. Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi A, et al. Isolation and characterisation of patient-derived, toxic, high mass amyloid beta-protein assembly from Alzheimer&#x2019;s Disease brains. J. Biol. Chem. 2009;284:32895&#x2013;32905. doi: 10.1074/jbc.M109.000208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.000208</ArticleId><ArticleId IdType="pmc">PMC2781705</ArticleId><ArticleId IdType="pubmed">19759000</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex induce tau hyperphospohrylation and neuritic degeneration. Proc. Natl Acad. Sci. USA. 2011;108:5819&#x2013;5824. doi: 10.1073/pnas.1017033108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017033108</ArticleId><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Li S, Xu H, Walsh DM, Selkoe DJ. Large soluble oligomers of amyloid beta-protein from alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J. Neurosci. 2017;37:152&#x2013;163. doi: 10.1523/JNEUROSCI.1698-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1698-16.2016</ArticleId><ArticleId IdType="pmc">PMC5214627</ArticleId><ArticleId IdType="pubmed">28053038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, W. et al. Diffusible forms of A&#x3b2; derived from Alzheimer disease brain disrupt synaptic plasticity. Acta Neuropathologica.&#xa0;136: 19-41&#xa0;(2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647843</ArticleId><ArticleId IdType="pubmed">29687257</ArticleId></ArticleIdList></Reference><Reference><Citation>https://clinicaltrials.gov (2018).</Citation></Reference><Reference><Citation>Bohrmann B, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimer&#x2019;s Dis. 2012;28:49&#x2013;69. doi: 10.3233/JAD-2011-110977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110977</ArticleId><ArticleId IdType="pubmed">21955818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer&#x2019;s disease. Nature. 2016;537:50&#x2013;56. doi: 10.1038/nature19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradier L, Cohen C, Blanchard V, Debeir T, Alam J. SAR228810: an antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA) Alzheimer&#x2019;s Dement. 2013;9:808&#x2013;809. doi: 10.1016/j.jalz.2013.05.1678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.05.1678</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, et al. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils&#x2013;a new target for immunotherapy with BAN2401 in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res. Ther. 2014;6:16. doi: 10.1186/alzrt246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt246</ArticleId><ArticleId IdType="pmc">PMC4054967</ArticleId><ArticleId IdType="pubmed">25031633</ArticleId></ArticleIdList></Reference><Reference><Citation>Englund H, et al. Sensitive ELISA detection of amyloid-&#x3b2; protofibrils in biological samples. J. Neurochem. 2007;103:334&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">17623042</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer&#x2019;s disease. Neuron. 2003;38:547&#x2013;554. doi: 10.1016/S0896-6273(03)00294-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00294-0</ArticleId><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA, et al. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer&#x2019;s disease. Peptides. 2002;23:2223&#x2013;2226. doi: 10.1016/S0196-9781(02)00261-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0196-9781(02)00261-9</ArticleId><ArticleId IdType="pubmed">12535702</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, et al. Bapineuzumab for mild to moderate Alzheimer&#x2019;s disease in two global, randomized, phase 3 trials. Alzheimer&#x2019;s Res. Ther. 2016;8:18. doi: 10.1186/s13195-016-0189-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0189-7</ArticleId><ArticleId IdType="pmc">PMC4866415</ArticleId><ArticleId IdType="pubmed">27176461</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 2012;69:198&#x2013;207. doi: 10.1001/archneurol.2011.1538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.1538</ArticleId><ArticleId IdType="pubmed">21987394</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker S, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J. Alzheimers Dis. 2015;43:575&#x2013;588. doi: 10.3233/JAD-140741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140741</ArticleId><ArticleId IdType="pubmed">25096615</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. The A4 study: stopping AD before symptoms begin? Sci. Transl. Med. 2014;6:228fs213. doi: 10.1126/scitranslmed.3007941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007941</ArticleId><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. The DIAN-TU next generation Alzheimer&#x2019;s prevention trial: adaptive design and disease progression model. Alzheimer&#x2019;s Dement. 2017;13:8&#x2013;19. doi: 10.1016/j.jalz.2016.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.005</ArticleId><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Delnomdedieu M, et al. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res. Ther. 2016;8:12. doi: 10.1186/s13195-016-0177-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0177-y</ArticleId><ArticleId IdType="pmc">PMC4772335</ArticleId><ArticleId IdType="pubmed">26925577</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, et al. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J. Neurosci. 2010;30:14411&#x2013;14419. doi: 10.1523/JNEUROSCI.3537-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3537-10.2010</ArticleId><ArticleId IdType="pmc">PMC2987723</ArticleId><ArticleId IdType="pubmed">20980598</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Malley TT, et al. Abeta dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. Biochem. J. 2014;461:413&#x2013;426. doi: 10.1042/BJ20140219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20140219</ArticleId><ArticleId IdType="pubmed">24785004</ArticleId></ArticleIdList></Reference><Reference><Citation>Linse S. Monomer-dependent secondary nucleation in amyloid formation. Biophys. Rev. 2017;9:329&#x2013;338. doi: 10.1007/s12551-017-0289-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12551-017-0289-z</ArticleId><ArticleId IdType="pmc">PMC5578932</ArticleId><ArticleId IdType="pubmed">28812278</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadzhieva M, et al. Impact of antigen density on the binding mechanism of IgG antibodies. Sci. Rep. 2017;7:3767. doi: 10.1038/s41598-017-03942-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-03942-z</ArticleId><ArticleId IdType="pmc">PMC5476644</ArticleId><ArticleId IdType="pubmed">28630473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YS, Carp RI, Callahan SM, Wisniewski HM. Adrenal involvement in scrapie-induced obesity. Proc. Soc. Exp. Biol. Med. 1988;189:21&#x2013;27. doi: 10.3181/00379727-189-42774.</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-189-42774</ArticleId><ArticleId IdType="pubmed">3141932</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles RB, et al. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 1999;96:5274&#x2013;5279. doi: 10.1073/pnas.96.9.5274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.9.5274</ArticleId><ArticleId IdType="pmc">PMC21854</ArticleId><ArticleId IdType="pubmed">10220456</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, et al. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J. Neuropathol. Exp. Neurol. 2013;72:1182&#x2013;1192. doi: 10.1097/NEN.0000000000000016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0000000000000016</ArticleId><ArticleId IdType="pmc">PMC3962953</ArticleId><ArticleId IdType="pubmed">24226270</ArticleId></ArticleIdList></Reference><Reference><Citation>Espuny-Camacho I, et al. Hallmarks of Alzheimer&#x2019;s disease in stem-cell-derived human neurons transplanted into mouse brain. Neuron. 2017;93:1066&#x2013;1081 e1068. doi: 10.1016/j.neuron.2017.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.001</ArticleId><ArticleId IdType="pubmed">28238547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785&#x2013;798. doi: 10.1016/j.neuron.2013.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.05.029</ArticleId><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves JP, Lo CY, Klinman DM, Epstein SL. Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates. Hybridoma. 1995;14:235&#x2013;242. doi: 10.1089/hyb.1995.14.235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hyb.1995.14.235</ArticleId><ArticleId IdType="pubmed">7590785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A, et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer&#x2019;s disease. Neurobiol. Dis. 2009;36:425&#x2013;434. doi: 10.1016/j.nbd.2009.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.08.007</ArticleId><ArticleId IdType="pubmed">19703562</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A, et al. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer&#x2019;s disease transgenic mice. FEBS J. 2009;276:995&#x2013;1006. doi: 10.1111/j.1742-4658.2008.06836.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2008.06836.x</ArticleId><ArticleId IdType="pmc">PMC2752010</ArticleId><ArticleId IdType="pubmed">19215301</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177. doi: 10.1038/22124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/22124</ArticleId><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer&#x2019;s disease model. Nat. Neurosci. 2002;5:452&#x2013;457. doi: 10.1038/nn842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn842</ArticleId><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Born HA, et al. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer&#x2019;s disease. J. Neurosci. 2014;34:3826&#x2013;3840. doi: 10.1523/JNEUROSCI.5171-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5171-13.2014</ArticleId><ArticleId IdType="pmc">PMC3951689</ArticleId><ArticleId IdType="pubmed">24623762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, et al. Normal cognition in transgenic BRI2-Abeta mice. Mol. Neurodegener. 2013;8:15. doi: 10.1186/1750-1326-8-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-15</ArticleId><ArticleId IdType="pmc">PMC3658944</ArticleId><ArticleId IdType="pubmed">23663320</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer&#x2019;s Association Research Roundtable Workgroup. Alzheimer&#x2019;s Dement. 2011;7:367&#x2013;385. doi: 10.1016/j.jalz.2011.05.2351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.05.2351</ArticleId><ArticleId IdType="pmc">PMC3693547</ArticleId><ArticleId IdType="pubmed">21784348</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer&#x2019;s disease conundrum? Trends Neurosci. 2001;24:219&#x2013;224. doi: 10.1016/S0166-2236(00)01749-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(00)01749-5</ArticleId><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer&#x2019;s disease. Neuron. 2004;44:181&#x2013;193. doi: 10.1016/j.neuron.2004.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.09.010</ArticleId><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat. Neurosci. 2012;15:349&#x2013;357. doi: 10.1038/nn.3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3028</ArticleId><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K, et al. Specific uptake of an amyloid-beta protofibril-binding antibody-tracer in AbetaPP transgenic mouse brain. J. Alzheimers Dis. 2013;37:29&#x2013;40. doi: 10.3233/JAD-130029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130029</ArticleId><ArticleId IdType="pubmed">23780660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mably AJ, et al. Anti-Abeta antibodies incapable of reducing cerebral Abeta oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol. Dis. 2015;82:372&#x2013;384. doi: 10.1016/j.nbd.2015.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.07.008</ArticleId><ArticleId IdType="pmc">PMC4641028</ArticleId><ArticleId IdType="pubmed">26215784</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D, Walsh DM. The levels of water-soluble and triton-soluble Abeta are increased in Alzheimer&#x2019;s disease brain. Brain Res. 2012;1450:138&#x2013;147. doi: 10.1016/j.brainres.2012.02.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.02.041</ArticleId><ArticleId IdType="pmc">PMC3319647</ArticleId><ArticleId IdType="pubmed">22440675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30679421</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Neuropathological correlates and genetic architecture of microglial activation in elderly human brain.</ArticleTitle><Pagination><StartPage>409</StartPage><MedlinePgn>409</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">409</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-018-08279-3</ELocationID><Abstract><AbstractText>Microglia, the resident immune cells of the brain, have important roles in brain health. However, little is known about the regulation and consequences of microglial activation in the aging human brain. Here we report that the proportion of morphologically activated microglia (PAM) in postmortem cortical tissue is strongly associated with &#x3b2;-amyloid, tau-related neuropathology, and the rate of cognitive decline. Effect sizes for PAM measures are substantial, comparable to that of APOE &#x3b5;4, the strongest genetic risk factor for Alzheimer's disease, and mediation models support an upstream role for microglial activation in Alzheimer's disease via accumulation of tau. Further, we identify a common variant (rs2997325) influencing PAM that also affects in vivo microglial activation measured by [<sup>11</sup>C]-PBR28 PET in an independent cohort. Thus, our analyses begin to uncover pathways regulating resident neuroinflammation and identify overlaps of PAM's genetic architecture with those of Alzheimer's disease and several other traits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Felsky</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Population and Medical Genetics, Broad Institute of MIT and Harvard, 320 Charles Street, Cambridge, MA, 02141, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roostaei</LastName><ForeName>Tina</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7699-9007</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer's Disease Center, Center for Neuroimaging, Department of Radiology and Imaging Sciences, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, 355 West 16th Street, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risacher</LastName><ForeName>Shannon L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer's Disease Center, Center for Neuroimaging, Department of Radiology and Imaging Sciences, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, 355 West 16th Street, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradshaw</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petyuk</LastName><ForeName>Vlad</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-4076-151X</Identifier><AffiliationInfo><Affiliation>Pacific Northwest National Laboratory, Richland, WA, 99354, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL, 60612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL, 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1376-8532</Identifier><AffiliationInfo><Affiliation>Indiana Alzheimer's Disease Center, Center for Neuroimaging, Department of Radiology and Imaging Sciences, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, 355 West 16th Street, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL, 60612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL, 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Population and Medical Genetics, Broad Institute of MIT and Harvard, 320 Charles Street, Cambridge, MA, 02141, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 LM011384</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG054936</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01LM012535</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG15819</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03AG054936</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS084965</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG30146</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG046152</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012535</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS084965</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG048015</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069338" MajorTopicYN="Y">Neuropathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30679421</ArticleId><ArticleId IdType="pmc">PMC6345810</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-08279-3</ArticleId><ArticleId IdType="pii">10.1038/s41467-018-08279-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e17. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizee MR, et al. Isolation of primary microglia from the human post-mortem brain: effects of ante- and post-mortem variables. Acta Neuropathol. Commun. 2017;5:16. doi: 10.1186/s40478-017-0418-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0418-8</ArticleId><ArticleId IdType="pmc">PMC5316206</ArticleId><ArticleId IdType="pubmed">28212663</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Nicola D, Boche D. Post-mortem analysis of neuroinflammatory changes in human Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 2015;7:42. doi: 10.1186/s13195-015-0126-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0126-1</ArticleId><ArticleId IdType="pmc">PMC4405851</ArticleId><ArticleId IdType="pubmed">25904988</ArticleId></ArticleIdList></Reference><Reference><Citation>Taipa R, et al. Inflammatory pathology markers (activated microglia and reactive astrocytes) in early and late onset Alzheimer disease: a post-mortem study. Neuropathol. Appl. Neurobiol. 2017;44:298&#x2013;313. doi: 10.1111/nan.12445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12445</ArticleId><ArticleId IdType="pubmed">29044639</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopperton KE, Mohammad D, Tr&#xe9;panier MO, Giuliano V, Bazinet RP. Markers of microglia in post-mortem brain samples from patients with Alzheimer&#x2019;s disease: a systematic review. Mol. Psychiatry. 2018;23:177&#x2013;198. doi: 10.1038/mp.2017.246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.246</ArticleId><ArticleId IdType="pmc">PMC5794890</ArticleId><ArticleId IdType="pubmed">29230021</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies DS, Ma J, Jegathees T, Goldsbury C. Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer&#x2019;s disease. Brain Pathol. Zur. Switz. 2017;27:795&#x2013;808. doi: 10.1111/bpa.12456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12456</ArticleId><ArticleId IdType="pmc">PMC8029278</ArticleId><ArticleId IdType="pubmed">27862631</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, G&#xf3;mez-Isla T, Growdon JH, Frosch MP, Hyman BT. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am. J. Pathol. 2013;182:2332&#x2013;2344. doi: 10.1016/j.ajpath.2013.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2013.02.031</ArticleId><ArticleId IdType="pmc">PMC3668030</ArticleId><ArticleId IdType="pubmed">23602650</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Nicola D, Fransen NL, Suzzi S, Perry VH. Regulation of microglial proliferation during chronic neurodegeneration. J. Neurosci. 2013;33:2481&#x2013;2493. doi: 10.1523/JNEUROSCI.4440-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4440-12.2013</ArticleId><ArticleId IdType="pmc">PMC6619184</ArticleId><ArticleId IdType="pubmed">23392676</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197&#x2013;2204. doi: 10.1212/01.wnl.0000271090.28148.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000271090.28148.24</ArticleId><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85:528&#x2013;534. doi: 10.1212/WNL.0000000000001834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001834</ArticleId><ArticleId IdType="pmc">PMC4540250</ArticleId><ArticleId IdType="pubmed">26180136</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer&#x2019;s disease. Am. J. Pathol. 2011;179:1373&#x2013;1384. doi: 10.1016/j.ajpath.2011.05.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.05.047</ArticleId><ArticleId IdType="pmc">PMC3157187</ArticleId><ArticleId IdType="pubmed">21777559</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium, et al. Genetic effects on gene expression across human tissues. Nature. 2017;550:204&#x2013;213. doi: 10.1038/nature24277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24277</ArticleId><ArticleId IdType="pmc">PMC5776756</ArticleId><ArticleId IdType="pubmed">29022597</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333:1456&#x2013;1458. doi: 10.1126/science.1202529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1202529</ArticleId><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Notter T, Meyer U. Microglia and schizophrenia: where next? Mol. Psychiatry. 2017;22:788&#x2013;789. doi: 10.1038/mp.2017.67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.67</ArticleId><ArticleId IdType="pubmed">28348384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan KJ, et al. A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants. Sci. Transl. Med. 2017;9:eaai7635. doi: 10.1126/scitranslmed.aai7635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7635</ArticleId><ArticleId IdType="pmc">PMC5945290</ArticleId><ArticleId IdType="pubmed">29263232</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, et al. A transcriptomic atlas of aged human microglia. Nat. Commun. 2018;9:539. doi: 10.1038/s41467-018-02926-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-02926-5</ArticleId><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick, E. et al. A cortical immune network map identifies a subset of human microglia involved in Tau pathology. Preprint at https://www.biorxiv.org/content/early/2017/12/14/234351 (2018)</Citation></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91:328&#x2013;340. doi: 10.1016/j.neuron.2016.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.06.015</ArticleId><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2013;581.e9. doi: 10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifaz L, et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8&#x2009;+&#x2009;T cell tolerance. J. Exp. Med. 2002;196:1627&#x2013;1638. doi: 10.1084/jem.20021598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021598</ArticleId><ArticleId IdType="pmc">PMC2196060</ArticleId><ArticleId IdType="pubmed">12486105</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukaya T, et al. Conditional ablation of CD205&#x2009;+&#x2009;conventional dendritic cells impacts the regulation of T-cell immunity and homeostasis in vivo. Proc. Natl Acad. Sci. USA. 2012;109:11288&#x2013;11293. doi: 10.1073/pnas.1202208109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1202208109</ArticleId><ArticleId IdType="pmc">PMC3396526</ArticleId><ArticleId IdType="pubmed">22736794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl WC, et al. Stroke incidentally identified using improved positron emission tomography for microglial activation. Arch. Neurol. 2009;66:1288&#x2013;1289. doi: 10.1001/archneurol.2009.208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.208</ArticleId><ArticleId IdType="pmc">PMC2762117</ArticleId><ArticleId IdType="pubmed">19822787</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson JE, et al. Microglial activation in white matter lesions and nonlesional white matter of ageing brains. Neuropathol. Appl. Neurobiol. 2007;33:670&#x2013;683. doi: 10.1111/j.1365-2990.2007.00890.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2007.00890.x</ArticleId><ArticleId IdType="pubmed">17990995</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuitemaker A, et al. Microglial activation in healthy aging. Neurobiol. Aging. 2012;33:1067&#x2013;1072. doi: 10.1016/j.neurobiolaging.2010.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.09.016</ArticleId><ArticleId IdType="pubmed">21051106</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah, M. et al. A single cell-based atlas of human microglial states reveals associations with neurological disorders and histopathological features of the aging brain. Preprint at https://www.biorxiv.org/content/early/2018/06/11/343780 (2018)</Citation></Reference><Reference><Citation>Bisht K, et al. Dark microglia: a new phenotype predominantly associated with pathological states. Glia. 2016;64:826&#x2013;839. doi: 10.1002/glia.22966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22966</ArticleId><ArticleId IdType="pmc">PMC4949554</ArticleId><ArticleId IdType="pubmed">26847266</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat. Neurosci. 2017;20:1162&#x2013;1171. doi: 10.1038/nn.4597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4597</ArticleId><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr. Alzheimer Res. 2012;9:628&#x2013;645. doi: 10.2174/156720512801322573.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322573</ArticleId><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Overview and findings from the rush Memory and Aging Project. Curr. Alzheimer Res. 2012;9:646&#x2013;663. doi: 10.2174/156720512801322663.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322663</ArticleId><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jager PLD, et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci. Data. 2018;5:180142. doi: 10.1038/sdata.2018.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.142</ArticleId><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoder KK, et al. Influence of TSPO genotype on 11C-PBR28 standardized uptake values. J. Nucl. Med. 2013;54:1320&#x2013;1322. doi: 10.2967/jnumed.112.118885.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.112.118885</ArticleId><ArticleId IdType="pmc">PMC3740346</ArticleId><ArticleId IdType="pubmed">23785173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B, et al. An xQTL map integrates the genetic architecture of the human brain&#x2019;s transcriptome and epigenome. Nat. Neurosci. 2017;20:1418. doi: 10.1038/nn.4632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4632</ArticleId><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiteri C, et al. Identifying robust communities and multi-community nodes by combining top-down and bottom-up approaches to clustering. Sci. Rep. 2015;5:16361. doi: 10.1038/srep16361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep16361</ArticleId><ArticleId IdType="pmc">PMC4637843</ArticleId><ArticleId IdType="pubmed">26549511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat. Neurosci. 2018;21:811&#x2013;819. doi: 10.1038/s41593-018-0154-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0154-9</ArticleId><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Petyuk VA, Qian WJ, Smith RD, Smith DJ. Mapping protein abundance patterns in the brain using voxelation combined with liquid chromatography and mass spectrometry. Methods San Diego Calif. 2010;50:77. doi: 10.1016/j.ymeth.2009.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2009.07.009</ArticleId><ArticleId IdType="pmc">PMC2818068</ArticleId><ArticleId IdType="pubmed">19654045</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreev VP, et al. Label-free quantitative LC&#x2013;MS proteomics of Alzheimer&#x2019;s disease and normally aged human brains. J. Proteome Res. 2012;11:3053&#x2013;3067. doi: 10.1021/pr3001546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr3001546</ArticleId><ArticleId IdType="pmc">PMC3445701</ArticleId><ArticleId IdType="pubmed">22559202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann. Neurol. 2012;72:599&#x2013;609. doi: 10.1002/ana.23654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23654</ArticleId><ArticleId IdType="pmc">PMC3490232</ArticleId><ArticleId IdType="pubmed">23109154</ArticleId></ArticleIdList></Reference><Reference><Citation>R. Core Team. R: A Language and Environment for Statistical Computing. (R Foundation For Statistical Computing, Vienna, Austria, 2014).</Citation></Reference><Reference><Citation>Efron B, Tibshirani R. Improvements on cross-validation: the .632&#x2009;+&#x2009;Bootstrap method. J. Am. Stat. Assoc. 1997;92:548&#x2013;560.</Citation></Reference><Reference><Citation>Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007;81:559&#x2013;575. doi: 10.1086/519795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519795</ArticleId><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 2006;38:904&#x2013;909. doi: 10.1038/ng1847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1847</ArticleId><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Taskesen E, Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat. Commun. 2017;8:1826. doi: 10.1038/s41467-017-01261-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01261-5</ArticleId><ArticleId IdType="pmc">PMC5705698</ArticleId><ArticleId IdType="pubmed">29184056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 2014;46:310&#x2013;315. doi: 10.1038/ng.2892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2892</ArticleId><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle AP, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790&#x2013;1797. doi: 10.1101/gr.137323.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.137323.112</ArticleId><ArticleId IdType="pmc">PMC3431494</ArticleId><ArticleId IdType="pubmed">22955989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901&#x2013;D906. doi: 10.1093/nar/gkm958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkm958</ArticleId><ArticleId IdType="pmc">PMC2238889</ArticleId><ArticleId IdType="pubmed">18048412</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe4;gi R, et al. SCOPA and META-SCOPA: software for the analysis and aggregation of genome-wide association studies of multiple correlated phenotypes. BMC Bioinforma. 2017;18:25. doi: 10.1186/s12859-016-1437-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-016-1437-3</ArticleId><ArticleId IdType="pmc">PMC5225593</ArticleId><ArticleId IdType="pubmed">28077070</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, T. Efficient calculation for multi-SNP genetic risk scores. Presented at the American Society of Human Genetics Annual Meeting (2012). https://cran.r-project.org/web/packages/gtx/vignettes/ashg2012.pdf</Citation></Reference><Reference><Citation>Euesden J, Lewis CM, O&#x2019;Reilly PF. PRSice: Polygenic Risk Score software. Bioinformatics. 2015;31:1466&#x2013;1468. doi: 10.1093/bioinformatics/btu848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu848</ArticleId><ArticleId IdType="pmc">PMC4410663</ArticleId><ArticleId IdType="pubmed">25550326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30014145</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.</ArticleTitle><Pagination><StartPage>1215</StartPage><EndPage>1224</EndPage><MedlinePgn>1215-1224</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.1836</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Synaptic loss is well established as the major structural correlate of cognitive impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could accelerate the development of disease-modifying treatments for AD. Synaptic vesicle glycoprotein 2A is an essential vesicle membrane protein expressed in virtually all synapses and could serve as a suitable target for synaptic density.</AbstractText><AbstractText Label="OBJECTIVE">To compare hippocampal synaptic vesicle glycoprotein 2A (SV2A) binding in participants with AD and cognitively normal participants using positron emission tomographic (PET) imaging.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study recruited 10 participants with AD and 11 participants who were cognitively normal between November 2015 and June 2017. We hypothesized a reduction in hippocampal SV2A binding in AD, based on the early degeneration of entorhinal cortical cell projections to the hippocampus (via the perforant path) and hippocampal SV2A reductions that had been observed in postmortem studies. Participants underwent high-resolution PET scanning with ((R)-1-((3-(11C-methyl-11C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one), a compound more commonly known as 11C-UCB-J, for SV2A. They also underwent high-resolution PET scanning with carbon 11-labeled Pittsburgh Compound B (11C-PiB) for &#x3b2;-amyloid, magnetic resonance imaging, and cognitive and neurologic evaluation.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Outcomes were 11C-UCB-J-specific binding (binding potential [BPND]) via PET imaging in brain regions of interest in participants with AD and participants who were cognitively normal.</AbstractText><AbstractText Label="RESULTS">Ten participants with AD (5 male and 5 female; mean [SD] age, 72.7 [6.3] years; 10 [100%] &#x3b2;-amyloid positive) were compared with 11 participants who were cognitively normal (5 male and 6 female; mean [SD] age, 72.9 [8.7] years; 11 [100%] &#x3b2;-amyloid negative). Participants with AD spanned the disease stages from amnestic mild cognitive impairment (n&#x2009;=&#x2009;5) to mild dementia (n&#x2009;=&#x2009;5). Participants with AD had significant reduction in hippocampal SV2A specific binding (41%) compared with cognitively normal participants, as assessed by 11C-UCB-J-PET BPND (cognitively normal participants: mean [SD] BPND, 1.47 [0.37]; participants with AD: 0.87 [0.50]; P&#x2009;=&#x2009;.005). These reductions remained significant after correction for atrophy (ie, partial volume correction; participants who were cognitively normal: mean [SD], 2.71 [0.46]; participants with AD: 2.15 [0.55]; P&#x2009;=&#x2009;.02). Hippocampal SV2A-specific binding BPND was correlated with a composite episodic memory score in the overall sample (R&#x2009;=&#x2009;0.56; P&#x2009;=&#x2009;.01).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">To our knowledge, this is the first study to investigate synaptic density in vivo in AD using 11C-UCB-J-PET imaging. This approach may provide a direct measure of synaptic density, and it therefore holds promise as an in vivo biomarker for AD and as an outcome measure for trials of disease-modifying therapies, particularly those targeted at the preservation and restoration of synapses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ming-Kai</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecca</LastName><ForeName>Adam P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naganawa</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finnema</LastName><ForeName>Sjoerd J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toyonaga</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shu-Fei</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najafzadeh</LastName><ForeName>Soheila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ropchan</LastName><ForeName>Jim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yihuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Julia W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalak</LastName><ForeName>Hannah R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nabulsi</LastName><ForeName>Nabeel B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnsten</LastName><ForeName>Amy F T</ForeName><Initials>AFT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yiyun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG057794</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG052560</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000618323">1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011760">Pyrrolidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>148845-93-6</RegistryNumber><NameOfSubstance UI="C076414">SV2A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2018 Oct 1;75(10):1181-1183. doi: 10.1001/jamaneurol.2018.1643.</RefSource><PMID Version="1">30014142</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="Y">Amnesia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="Y">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="Y">Pyridines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011760" MajorTopicYN="Y">Pyrrolidinones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="Y">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict</b><b> of Interest Disclosures:</b> Dr Chen reports research support from the Dana Foundation and research support from Eli Lilly and clinical trials from Merck, outside the submitted work. Dr Huang reports research grants from the UCB and Eli Lilly outside the submitted work. Drs Huang and Carson have a patent for a newer version of the tracer pending. Dr Carson reports grants from National Institutes of Health for the conduct of the study. Dr Carson also reports having received grants from AstraZeneca, Astellas, Eli Lilly, Pfizer, Taisho, and UCB, outside the submitted work. Dr van Dyck reports consulting fees from Kyowa Kirin, Roche, Merck, Eli Lilly, and Janssen and grants for clinical trials from Biogen, Novartis, Eli Lilly, Merck, Eisai, Janssen, Roche, Genentech, Toyama, and TauRx, outside the submitted work. No other disclosures are reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30014145</ArticleId><ArticleId IdType="pmc">PMC6233853</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.1836</ArticleId><ArticleId IdType="pii">2687472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association 2017 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2017;13(4):325-373. doi:10.1016/j.jalz.2017.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Albert MS, Knopman DS, et al. . Introduction to the recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):257-262. doi:10.1016/j.jalz.2011.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.004</ArticleId><ArticleId IdType="pmc">PMC3096735</ArticleId><ArticleId IdType="pubmed">21514247</ArticleId></ArticleIdList></Reference><Reference><Citation>Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer&#x2019;s disease and Lewy body disease. Biochem Pharmacol. 2014;88(4):508-516. doi:10.1016/j.bcp.2014.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2014.01.015</ArticleId><ArticleId IdType="pmc">PMC3973539</ArticleId><ArticleId IdType="pubmed">24462903</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Neltner JH, Nelson PT. Is synaptic loss a unique hallmark of Alzheimer&#x2019;s disease? Biochem Pharmacol. 2014;88(4):517-528. doi:10.1016/j.bcp.2013.12.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2013.12.028</ArticleId><ArticleId IdType="pmc">PMC4230706</ArticleId><ArticleId IdType="pubmed">24412275</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298(5594):789-791. doi:10.1126/science.1074069</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1074069</ArticleId><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, et al. . Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572-580. doi:10.1002/ana.410300410</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410300410</ArticleId><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457-464. doi:10.1002/ana.410270502</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410270502</ArticleId><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham E, Crews L, Ubhi K, et al. . Progressive accumulation of amyloid-beta oligomers in Alzheimer&#x2019;s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J. 2010;277(14):3051-3067. doi:10.1111/j.1742-4658.2010.07719.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2010.07719.x</ArticleId><ArticleId IdType="pmc">PMC2933033</ArticleId><ArticleId IdType="pubmed">20573181</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68(18):1501-1508. doi:10.1212/01.wnl.0000260698.46517.8f</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000260698.46517.8f</ArticleId><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol Aging. 2006;27(10):1372-1384. doi:10.1016/j.neurobiolaging.2005.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.09.012</ArticleId><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Scheff MA, Mufson EJ. Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer&#x2019;s disease. J Alzheimers Dis. 2011;24(3):547-557. doi:10.3233/JAD-2011-101782</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101782</ArticleId><ArticleId IdType="pmc">PMC3098316</ArticleId><ArticleId IdType="pubmed">21297265</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Ansari MA, et al. . Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2015;43(3):1073-1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313125</ArticleId><ArticleId IdType="pubmed">25147118</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer&#x2019;s disease. Neurosci Lett. 1994;174(1):67-72. doi:10.1016/0304-3940(94)90121-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(94)90121-X</ArticleId><ArticleId IdType="pubmed">7970158</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207-1218. doi:10.1016/j.neurobiolaging.2009.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.07.002</ArticleId><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiers CE, Shokri-Kojori E, Wong CT, et al. . Cannabis abusers show hypofrontality and blunted brain responses to a stimulant challenge in females but not in males. Neuropsychopharmacology. 2016;41(10):2596-2605. doi:10.1038/npp.2016.67</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2016.67</ArticleId><ArticleId IdType="pmc">PMC4987858</ArticleId><ArticleId IdType="pubmed">27156854</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi K, Onishi A, Fujiwara Y, Ishiwata K, Ishii K. Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucose levels in cognitively normal volunteers. J Nucl Med. 2015;56(2):229-233. doi:10.2967/jnumed.114.150045</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.114.150045</ArticleId><ArticleId IdType="pubmed">25572094</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns CM, Chen K, Kaszniak AW, et al. . Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology. 2013;80(17):1557-1564. doi:10.1212/WNL.0b013e31828f17de</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828f17de</ArticleId><ArticleId IdType="pmc">PMC3662330</ArticleId><ArticleId IdType="pubmed">23535495</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Drzezga A, Bartenstein P, M&#xf6;ller HJ, Schwaiger M, Hampel H. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer&#x2019;s disease: a double-blind cross-over trial. Psychopharmacology (Berl). 2006;187(1):86-94. doi:10.1007/s00213-006-0408-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-006-0408-1</ArticleId><ArticleId IdType="pubmed">16767418</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994;14(9):5223-5235. doi:10.1523/JNEUROSCI.14-09-05223.1994</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.14-09-05223.1994</ArticleId><ArticleId IdType="pmc">PMC6577109</ArticleId><ArticleId IdType="pubmed">8083732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajjalieh SM, Peterson K, Linial M, Scheller RH. Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci U S A. 1993;90(6):2150-2154. doi:10.1073/pnas.90.6.2150</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.6.2150</ArticleId><ArticleId IdType="pmc">PMC46043</ArticleId><ArticleId IdType="pubmed">7681585</ArticleId></ArticleIdList></Reference><Reference><Citation>Janz R, S&#xfc;dhof TC. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience. 1999;94(4):1279-1290. doi:10.1016/S0306-4522(99)00370-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(99)00370-X</ArticleId><ArticleId IdType="pubmed">10625067</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabulsi NB, Mercier J, Holden D, et al. . Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. J Nucl Med. 2016;57(5):777-784. doi:10.2967/jnumed.115.168179</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.168179</ArticleId><ArticleId IdType="pubmed">26848175</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnema SJ, Nabulsi NB, Eid T, et al. . Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8(348):348ra96. doi:10.1126/scitranslmed.aaf6667</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6667</ArticleId><ArticleId IdType="pubmed">27440727</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnema SJ, Nabulsi NB, Mercier J, et al. . Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans [published online January 1, 2017]. J Cereb Blood Flow Metab. doi:10.1177/0271678X17724947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X17724947</ArticleId><ArticleId IdType="pmc">PMC6259313</ArticleId><ArticleId IdType="pubmed">28792356</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci. 1996;16(14):4491-4500. doi:10.1523/JNEUROSCI.16-14-04491.1996</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.16-14-04491.1996</ArticleId><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960-969. doi:10.1097/NEN.0b013e318232a379</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Molina-Porcel L, Corrada MM, et al. . Perforant path synaptic loss correlates with cognitive impairment and Alzheimer&#x2019;s disease in the oldest-old. Brain. 2014;137(pt 9):2578-2587. doi:10.1093/brain/awu190</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu190</ArticleId><ArticleId IdType="pmc">PMC4132652</ArticleId><ArticleId IdType="pubmed">25012223</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Weigand SD, et al. . An operational approach to National Institute on Aging-Alzheimer&#x2019;s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71(6):765-775. doi:10.1002/ana.22628</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22628</ArticleId><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. . Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825. doi:10.1073/pnas.0900345106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900345106</ArticleId><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22(12):1440-1452. doi:10.1097/01.WCB.0000033967.83623.34</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.WCB.0000033967.83623.34</ArticleId><ArticleId IdType="pubmed">12468889</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecca AP, Barcelos NM, Wang S, et al. . Cortical &#x3b2;-amyloid burden, gray matter, and memory in adults at varying APOE &#x3b5;4 risk for Alzheimer&#x2019;s disease. Neurobiol Aging. 2018;61:207-214. doi:10.1016/j.neurobiolaging.2017.09.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.09.027</ArticleId><ArticleId IdType="pmc">PMC5722236</ArticleId><ArticleId IdType="pubmed">29111487</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Head D, Parker J, et al. . A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23(2):724-738. doi:10.1016/j.neuroimage.2004.06.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2004.06.018</ArticleId><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B. FreeSurfer. Neuroimage. 2012;62(2):774-781. doi:10.1016/j.neuroimage.2012.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.01.021</ArticleId><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Roberts KN, Ikonomovic MD, Mufson EJ. Synapse stability in the precuneus early in the progression of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013;35(3):599-609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000262</ArticleId><ArticleId IdType="pubmed">23478309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuljis RO. Lesions in the pulvinar in patients with Alzheimer&#x2019;s disease. J Neuropathol Exp Neurol. 1994;53(2):202-211. doi:10.1097/00005072-199403000-00012</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199403000-00012</ArticleId><ArticleId IdType="pubmed">8120542</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer PT, Hellwig S, Amtage F, et al. . Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52(3):393-400. doi:10.2967/jnumed.110.083683</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.110.083683</ArticleId><ArticleId IdType="pubmed">21321269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A, Almkvist O, Forsberg A, et al. . Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer&#x2019;s disease. Neurobiol Aging. 2012;33(1):198.e1-198.e14. doi:10.1016/j.neurobiolaging.2010.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.06.015</ArticleId><ArticleId IdType="pubmed">20688420</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Vieitez E, Carter SF, Chiotis K, et al. . Comparison of early-phase 11c-deuterium-l-deprenyl and 11c-pittsburgh compound b pet for assessing brain perfusion in Alzheimer disease. J Nucl Med. 2016;57(7):1071-1077. doi:10.2967/jnumed.115.168732</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.168732</ArticleId><ArticleId IdType="pubmed">26912447</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow AD, Nochlin D, Sekiguichi R, Carlson SS. Identification in immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer&#x2019;s disease. Exp Neurol. 1996;138(2):305-317. doi:10.1006/exnr.1996.0069</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1996.0069</ArticleId><ArticleId IdType="pubmed">8620929</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30038280</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies.</ArticleTitle><Pagination><StartPage>1038</StartPage><EndPage>1048</EndPage><MedlinePgn>1038-1048</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-018-0194-1</ELocationID><Abstract><AbstractText>Transposable elements, known colloquially as 'jumping genes', constitute approximately 45% of the human genome. Cells utilize epigenetic defenses to limit transposable element jumping, including formation of silencing heterochromatin and generation of piwi-interacting RNAs (piRNAs), small RNAs that facilitate clearance of transposable element transcripts. Here we utilize Drosophila melanogaster and postmortem human brain samples to identify transposable element dysregulation as a key mediator of neuronal death in tauopathies, a group of neurodegenerative disorders that are pathologically characterized by deposits of tau protein in the brain. Mechanistically, we find that heterochromatin decondensation and reduction of piwi and piRNAs drive transposable element dysregulation in tauopathy. We further report a significant increase in transcripts of the endogenous retrovirus class of transposable elements in human Alzheimer's disease and progressive supranuclear palsy, suggesting that transposable element dysregulation is conserved in human tauopathy. Taken together, our data identify heterochromatin decondensation, piwi and piRNA depletion and consequent transposable element dysregulation as a pharmacologically targetable, mechanistic driver of neurodegeneration in tauopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Wenyan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nutrition and Food Security, School of Public Health, Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samimi</LastName><ForeName>Hanie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Texas State University, San Marcos, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamez</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6026-1876</Identifier><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zare</LastName><ForeName>Habil</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5902-6238</Identifier><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Bess</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1212-8138</Identifier><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA. bfrost@uthscsa.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, Texas, USA. bfrost@uthscsa.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, San Antonio, Texas, USA. bfrost@uthscsa.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057896</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS088429</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004251">DNA Transposable Elements</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2018 Oct;14(10):569. doi: 10.1038/s41582-018-0056-1.</RefSource><PMID Version="1">30093688</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D031204" MajorTopicYN="N">Caloric Restriction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004251" MajorTopicYN="N">DNA Transposable Elements</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020271" MajorTopicYN="N">Heredodegenerative Disorders, Nervous System</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Financial Interests Statement.</b> The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30038280</ArticleId><ArticleId IdType="mid">NIHMS976583</ArticleId><ArticleId IdType="pmc">PMC6095477</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0194-1</ArticleId><ArticleId IdType="pii">10.1038/s41593-018-0194-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chuong EB, Elde NC &amp; Feschotte C Regulatory activities of transposable elements: from conflicts to benefits. Nature reviews. Genetics 18, 71&#x2013;86, doi:10.1038/nrg.2016.139 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg.2016.139</ArticleId><ArticleId IdType="pmc">PMC5498291</ArticleId><ArticleId IdType="pubmed">27867194</ArticleId></ArticleIdList></Reference><Reference><Citation>Slotkin RK &amp; Martienssen R Transposable elements and the epigenetic regulation of the genome. Nature reviews. Genetics 8, 272&#x2013;285, doi:10.1038/nrg2072 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2072</ArticleId><ArticleId IdType="pubmed">17363976</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennecke J et al. Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila. Cell 128, 1089&#x2013;1103, doi:10.1016/j.cell.2007.01.043 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.01.043</ArticleId><ArticleId IdType="pubmed">17346786</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W et al. Activation of transposable elements during aging and neuronal decline in Drosophila. Nature neuroscience 16, 529&#x2013;531, doi:10.1038/nn.3368 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3368</ArticleId><ArticleId IdType="pmc">PMC3821974</ArticleId><ArticleId IdType="pubmed">23563579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JG et al. Chromatin-modifying genetic interventions suppress age-associated transposable element activation and extend life span in Drosophila. Proceedings of the National Academy of Sciences of the United States of America 113, 11277&#x2013;11282, doi:10.1073/pnas.1604621113 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1604621113</ArticleId><ArticleId IdType="pmc">PMC5056045</ArticleId><ArticleId IdType="pubmed">27621458</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns KH Transposable elements in cancer. Nature reviews. Cancer 17, 415&#x2013;424, doi:10.1038/nrc.2017.35 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2017.35</ArticleId><ArticleId IdType="pubmed">28642606</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Jin Y, Prazak L, Hammell M &amp; Dubnau J Transposable elements in TDP-43-mediated neurodegenerative disorders. PloS one 7, e44099, doi:10.1371/journal.pone.0044099 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044099</ArticleId><ArticleId IdType="pmc">PMC3434193</ArticleId><ArticleId IdType="pubmed">22957047</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W et al. Human endogenous retrovirus-K contributes to motor neuron disease. Science translational medicine 7, 307ra153, doi:10.1126/scitranslmed.aac8201 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac8201</ArticleId><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug L et al. Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. PLoS genetics 13, doi:10.1371/journal.pgen.1006635 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006635</ArticleId><ArticleId IdType="pmc">PMC5354250</ArticleId><ArticleId IdType="pubmed">28301478</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Hemberg M, Lewis J &amp; Feany MB Tau promotes neurodegeneration through global chromatin relaxation. Nature neuroscience 17, 357&#x2013;366, doi:10.1038/nn.3639 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3639</ArticleId><ArticleId IdType="pmc">PMC4012297</ArticleId><ArticleId IdType="pubmed">24464041</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711&#x2013;714, doi:10.1126/science.1062382 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1062382</ArticleId><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M et al. Association of missense and 5&#x2019;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702&#x2013;705, doi:10.1038/31508 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL &amp; Feany MB Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Molecular biology of the cell 18, 5060&#x2013;5068, doi:10.1091/mbc.E07-04-0327 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E07-04-0327</ArticleId><ArticleId IdType="pmc">PMC2096612</ArticleId><ArticleId IdType="pubmed">17928404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias-Santagata D, Fulga TA, Duttaroy A &amp; Feany MB Oxidative stress mediates tau-induced neurodegeneration in Drosophila. The Journal of clinical investigation 117, 236&#x2013;245, doi:10.1172/JCI28769 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI28769</ArticleId><ArticleId IdType="pmc">PMC1697799</ArticleId><ArticleId IdType="pubmed">17173140</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V et al. A neuroprotective role for the DNA damage checkpoint in tauopathy. Aging cell 11, 360&#x2013;362, doi:10.1111/j.1474-9726.2011.00778.x (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2011.00778.x</ArticleId><ArticleId IdType="pubmed">22181010</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Bardai FH &amp; Feany MB Lamin Dysfunction Mediates Neurodegeneration in Tauopathies. Current biology : CB 26, 129&#x2013;136, doi:10.1016/j.cub.2015.11.039 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2015.11.039</ArticleId><ArticleId IdType="pmc">PMC4713335</ArticleId><ArticleId IdType="pubmed">26725200</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlo P et al. p53 prevents neurodegeneration by regulating synaptic genes. Proceedings of the National Academy of Sciences of the United States of America 111, 18055&#x2013;18060, doi:10.1073/pnas.1419083111 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1419083111</ArticleId><ArticleId IdType="pmc">PMC4273405</ArticleId><ArticleId IdType="pubmed">25453105</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V et al. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Current biology : CB 16, 230&#x2013;241, doi:10.1016/j.cub.2005.12.042 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2005.12.042</ArticleId><ArticleId IdType="pubmed">16461276</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiss GK et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nature biotechnology 26, 317&#x2013;325, doi:10.1038/nbt1385 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1385</ArticleId><ArticleId IdType="pubmed">18278033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardai FH et al. A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations In Vivo. The Journal of neuroscience : the official journal of the Society for Neuroscience 38, 108&#x2013;119, doi:10.1523/jneurosci.1550-17.2017 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.1550-17.2017</ArticleId><ArticleId IdType="pmc">PMC5761430</ArticleId><ArticleId IdType="pubmed">29138281</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly MT, Faulkner GJ, Dubnau J, Ponomarev I &amp; Gage FH The role of transposable elements in health and diseases of the central nervous system. The Journal of neuroscience : the official journal of the Society for Neuroscience 33, 17577&#x2013;17586, doi:10.1523/jneurosci.3369-13.2013 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.3369-13.2013</ArticleId><ArticleId IdType="pmc">PMC3818539</ArticleId><ArticleId IdType="pubmed">24198348</ArticleId></ArticleIdList></Reference><Reference><Citation>Muotri AR et al. Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. Nature 435, 903&#x2013;910, doi:10.1038/nature03663 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03663</ArticleId><ArticleId IdType="pubmed">15959507</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelisson A et al. About the origin of retroviruses and the co-evolution of the gypsy retrovirus with the Drosophila flamenco host gene. Genetica 100, 29&#x2013;37 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9440256</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevel-Ninio M, Pelisson A, Kinder J, Campos AR &amp; Bucheton A The flamenco locus controls the gypsy and ZAM retroviruses and is required for Drosophila oogenesis. Genetics 175, 1615&#x2013;1624, doi:10.1534/genetics.106.068106 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.106.068106</ArticleId><ArticleId IdType="pmc">PMC1855114</ArticleId><ArticleId IdType="pubmed">17277359</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Gotz J &amp; Feany MB Connecting the dots between tau dysfunction and neurodegeneration. Trends in cell biology 25, 46&#x2013;53, doi:10.1016/j.tcb.2014.07.005 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2014.07.005</ArticleId><ArticleId IdType="pmc">PMC4275400</ArticleId><ArticleId IdType="pubmed">25172552</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarot E, Payen-Groschene G, Bucheton A &amp; Pelisson A Evidence for a piwi-dependent RNA silencing of the gypsy endogenous retrovirus by the Drosophila melanogaster flamenco gene. Genetics 166, 1313&#x2013;1321 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1470774</ArticleId><ArticleId IdType="pubmed">15082550</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy J, Sarkar A, Parida S, Ghosh Z &amp; Mallick B Small RNA sequencing revealed dysregulated piRNAs in Alzheimer&#x2019;s disease and their probable role in pathogenesis. Molecular BioSystems 13, 565&#x2013;576, doi:10.1039/C6MB00699J (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C6MB00699J</ArticleId><ArticleId IdType="pubmed">28127595</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu W et al. Transcriptome-wide piRNA profiling in human brains of Alzheimer&#x2019;s disease. Neurobiology of aging 57, 170&#x2013;177, doi:10.1016/j.neurobiolaging.2017.05.020 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.020</ArticleId><ArticleId IdType="pmc">PMC5542056</ArticleId><ArticleId IdType="pubmed">28654860</ArticleId></ArticleIdList></Reference><Reference><Citation>Siomi MC, Sato K, Pezic D &amp; Aravin AA PIWI-interacting small RNAs: the vanguard of genome defence. Nature reviews. Molecular cell biology 12, 246&#x2013;258, doi:10.1038/nrm3089 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3089</ArticleId><ArticleId IdType="pubmed">21427766</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghildiyal M et al. Endogenous siRNAs derived from transposons and mRNAs in Drosophila somatic cells. Science 320, 1077&#x2013;1081, doi:10.1126/science.1157396 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1157396</ArticleId><ArticleId IdType="pmc">PMC2953241</ArticleId><ArticleId IdType="pubmed">18403677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EJ et al. Identification of piRNAs in the central nervous system. RNA (New York, N.Y.) 17, 1090&#x2013;1099, doi:10.1261/rna.2565011 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.2565011</ArticleId><ArticleId IdType="pmc">PMC3096041</ArticleId><ArticleId IdType="pubmed">21515829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamparini AL et al. Vreteno, a gonad-specific protein, is essential for germline development and primary piRNA biogenesis in Drosophila. Development (Cambridge, England) 138, 4039&#x2013;4050, doi:10.1242/dev.069187 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.069187</ArticleId><ArticleId IdType="pmc">PMC3160098</ArticleId><ArticleId IdType="pubmed">21831924</ArticleId></ArticleIdList></Reference><Reference><Citation>Eissenberg JC, Morris GD, Reuter G &amp; Hartnett T The heterochromatin-associated protein HP-1 is an essential protein in Drosophila with dosage-dependent effects on position-effect variegation. Genetics 131, 345&#x2013;352 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1205009</ArticleId><ArticleId IdType="pubmed">1644277</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter G, Dorn R, Wustmann G, Friede B &amp; Rauh G Third chromosome suppressor of position-effect variegation loci in Drosophila melanogaster. Molecular and General Genetics 202, 481&#x2013;487 (1986).</Citation></Reference><Reference><Citation>Fedoroff NV Presidential address. Transposable elements, epigenetics, and genome evolution. Science 338, 758&#x2013;767 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23145453</ArticleId></ArticleIdList></Reference><Reference><Citation>Longo VD et al. Interventions to Slow Aging in Humans: Are We Ready? Aging cell 14, 497&#x2013;510, doi:10.1111/acel.12338 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12338</ArticleId><ArticleId IdType="pmc">PMC4531065</ArticleId><ArticleId IdType="pubmed">25902704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultana T, Zamborlini A, Cristofari G &amp; Lesage P Integration site selection by retroviruses and transposable elements in eukaryotes. Nature reviews. Genetics 18, 292&#x2013;308, doi:10.1038/nrg.2017.7 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg.2017.7</ArticleId><ArticleId IdType="pubmed">28286338</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates JA et al. (&#x2212;)-2&#x2019;-deoxy-3&#x2019;-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrobial agents and chemotherapy 36, 733&#x2013;739 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189378</ArticleId><ArticleId IdType="pubmed">1380229</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PR, Tirian L, Vunjak M &amp; Brennecke J A heterochromatin-dependent transcription machinery drives piRNA expression. Nature 549, 54&#x2013;59, doi:10.1038/nature23482 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23482</ArticleId><ArticleId IdType="pmc">PMC5590728</ArticleId><ArticleId IdType="pubmed">28847004</ArticleId></ArticleIdList></Reference><Reference><Citation>Brower-Toland B et al. Drosophila PIWI associates with chromatin and interacts directly with HP1a. Genes &amp; development 21, 2300&#x2013;2311, doi:10.1101/gad.1564307 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1564307</ArticleId><ArticleId IdType="pmc">PMC1973144</ArticleId><ArticleId IdType="pubmed">17875665</ArticleId></ArticleIdList></Reference><Reference><Citation>Klattenhoff C et al. The Drosophila HP1 homologue Rhino is required for transposon silencing and piRNA production by dual strand clusters. Cell 138, 1137&#x2013;1149, doi:10.1016/j.cell.2009.07.014 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.07.014</ArticleId><ArticleId IdType="pmc">PMC2770713</ArticleId><ArticleId IdType="pubmed">19732946</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Cao M et al. Human endogenous retroviruses and cancer. Cancer Biology &amp; Medicine 13, 483&#x2013;488, doi:10.20892/j.issn.2095-3941.2016.0080 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.20892/j.issn.2095-3941.2016.0080</ArticleId><ArticleId IdType="pmc">PMC5250606</ArticleId><ArticleId IdType="pubmed">28154780</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi R, Li W, Parades D, Bianchet MA &amp; Nath A Inhibition of human endogenous retrovirus-K by antiretroviral drugs. Retrovirology 14, doi:10.1186/s12977-017-0347-4 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12977-017-0347-4</ArticleId><ArticleId IdType="pmc">PMC5361811</ArticleId><ArticleId IdType="pubmed">28330477</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuong EB, Elde NC &amp; Feschotte C Regulatory evolution of innate immunity through co-option of endogenous retroviruses. Science 351, 1083&#x2013;1087, doi:10.1126/science.aad5497 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad5497</ArticleId><ArticleId IdType="pmc">PMC4887275</ArticleId><ArticleId IdType="pubmed">26941318</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock DT &amp; Latz E Innate immunity in Alzheimer&#x2019;s disease. Nature immunology 16, 229&#x2013;236, doi:10.1038/ni.3102 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3102</ArticleId><ArticleId IdType="pubmed">25689443</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>METHODS-ONLY REFERENCES</Title><Reference><Citation>Fischer JA, Giniger E, Maniatis T &amp; Ptashne M GAL4 activates transcription in Drosophila. Nature 332, 853&#x2013;856, doi:10.1038/332853a0 (1988).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/332853a0</ArticleId><ArticleId IdType="pubmed">3128741</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietzl G et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448, 151&#x2013;156, doi:10.1038/nature05954 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05954</ArticleId><ArticleId IdType="pubmed">17625558</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickersheim ML &amp; Blumenstiel JP Terminator oligo blocking efficiently eliminates rRNA from Drosophila small RNA sequencing libraries. BioTechniques 55, 269&#x2013;272, doi:10.2144/000114102 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.2144/000114102</ArticleId><ArticleId IdType="pmc">PMC4077022</ArticleId><ArticleId IdType="pubmed">24215643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopylova E, Noe L &amp; Touzet H SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics (Oxford, England) 28, 3211&#x2013;3217, doi:10.1093/bioinformatics/bts611 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts611</ArticleId><ArticleId IdType="pubmed">23071270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger AM, Lohse M &amp; Usadel B Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (Oxford, England) 30, 2114&#x2013;2120, doi:10.1093/bioinformatics/btu170 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu170</ArticleId><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Gramates LS et al. FlyBase at 25: looking to the future. Nucleic acids research 45, D663&#x2013;D671, doi:10.1093/nar/gkw1016 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw1016</ArticleId><ArticleId IdType="pmc">PMC5210523</ArticleId><ArticleId IdType="pubmed">27799470</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Duggal G, Love MI, Irizarry RA &amp; Kingsford C
Salmon provides fast and bias-aware quantification of transcript expression. Nature methods
14, 417, doi:10.1038/nmeth.419710.1038/nmeth.4197https://www.nature.com/articles/nmeth.4197#supplementary-informationhttps://www.nature.com/articles/nmeth.4197#supplementary-information (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4197</ArticleId><ArticleId IdType="pmc">PMC5600148</ArticleId><ArticleId IdType="pubmed">28263959</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W &amp; Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology 15, 550, doi:10.1186/s13059-014-0550-8 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinsella RJ et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database : the journal of biological databases and curation 2011, bar030, doi:10.1093/database/bar030 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/database/bar030</ArticleId><ArticleId IdType="pmc">PMC3170168</ArticleId><ArticleId IdType="pubmed">21785142</ArticleId></ArticleIdList></Reference><Reference><Citation>Foroushani A et al. Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications. BMC medical genomics 10, 16, doi:10.1186/s12920-017-0253-6 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-017-0253-6</ArticleId><ArticleId IdType="pmc">PMC5353782</ArticleId><ArticleId IdType="pubmed">28298217</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R: A language and environment for statistical computing. (2010).</Citation></Reference><Reference><Citation>Wagner GP, Kin K &amp; Lynch VJ Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory in Biosciences 131, 281&#x2013;285, doi:10.1007/s12064-012-0162-3 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12064-012-0162-3</ArticleId><ArticleId IdType="pubmed">22872506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sai Lakshmi S &amp; Agrawal S piRNABank: a web resource on classified and clustered Piwi-interacting RNAs. Nucleic acids research 36, D173&#x2013;177, doi:10.1093/nar/gkm696 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkm696</ArticleId><ArticleId IdType="pmc">PMC2238943</ArticleId><ArticleId IdType="pubmed">17881367</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M et al. Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Scientific data 3, 160089, doi:10.1038/sdata.2016.89 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.89</ArticleId><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodes RJ &amp; Buckholtz N Accelerating Medicines Partnership: Alzheimer&#x2019;s Disease (AMP-AD) Knowledge Portal Aids Alzheimer&#x2019;s Drug Discovery through Open Data Sharing. Expert opinion on therapeutic targets 20, 389&#x2013;391, doi:10.1517/14728222.2016.1135132 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.2016.1135132</ArticleId><ArticleId IdType="pubmed">26853544</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. American journal of human genetics 81, 559&#x2013;575, doi:10.1086/519795 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519795</ArticleId><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL et al. Principal components analysis corrects for stratification in genome-wide association studies. Nature genetics 38, 904&#x2013;909, doi:10.1038/ng1847 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1847</ArticleId><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder A et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC molecular biology 7, 3, doi:10.1186/1471-2199-7-3 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2199-7-3</ArticleId><ArticleId IdType="pmc">PMC1413964</ArticleId><ArticleId IdType="pubmed">16448564</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao W, Kojima KK &amp; Kohany O Repbase Update, a database of repetitive elements in eukaryotic genomes. Mobile DNA 6, 11, doi:10.1186/s13100-015-0041-9 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13100-015-0041-9</ArticleId><ArticleId IdType="pmc">PMC4455052</ArticleId><ArticleId IdType="pubmed">26045719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H ggplot2: Elegant Graphics for Data Analysis. (Springer International Publishing, 2016).</Citation></Reference><Reference><Citation>Wald A Tests of Statistical Hypotheses Concerning Several Parameters When the Number of Observations is Large. Transactions of the American Mathematical Society 54, 426&#x2013;482, doi:10.2307/1990256 (1943).</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/1990256</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30037778</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>1050</StartPage><EndPage>1060</EndPage><MedlinePgn>1050-1060</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2018.05.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(18)30333-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Depression and cognitive impairment are often comorbid in older adults, but optimal treatment strategies remain unclear. In a two-site study, the efficacy and safety of add-on donepezil versus placebo were compared in depressed patients with cognitive impairment receiving stable antidepressant treatment.</AbstractText><AbstractText Label="METHODS">A randomized, double-blind, placebo-controlled trial was conducted in older adults with depression and cognitive impairment (https://clinicaltrials.gov/ct2/show/NCT01658228; NCT01658228). Patients received open-label antidepressant treatment for 16 weeks, initially with citalopram and then with venlafaxine, if needed, followed by random assignment to add-on donepezil 5-10&#x2009;mg daily or placebo for another 62 weeks. Outcome measures were neuropsychological test performance (Alzheimer's Disease Assessment Scale-Cognitive subscale [ADAS-Cog] and Selective Reminding Test [SRT] total immediate recall) and instrumental activities of daily living (Functional Activities Questionnaire).</AbstractText><AbstractText Label="RESULTS">Of 81 patients who signed informed consent, 79 patients completed the baseline evaluation. Open antidepressant treatment was associated with improvement in depression in 63.93% responders by week 16. In the randomized trial, there were no treatment group differences between donepezil and placebo on dementia conversion rates, ADAS-Cog, SRT total immediate recall, or FAQ. Neither baseline cognitive impairment severity nor apolipoprotein E e4 genotype influenced donepezil efficacy. Donepezil was associated with more adverse effects than placebo.</AbstractText><AbstractText Label="CONCLUSION">The results do not support adjunctive off-label cholinesterase inhibitor treatment in patients with depression and cognitive impairment. The findings highlight the need to prioritize discovery of novel treatments for this highly prevalent population with comorbid illnesses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>Davangere P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY; Department of Psychiatry, Columbia University Medical Center, New York, NY. Electronic address: dpd3@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelton</LastName><ForeName>Gregory H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY; Department of Psychiatry, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Antonio</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY; Department of Psychiatry, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciarleglio</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY; Department of Psychiatry, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scodes</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY; Department of Psychiatry, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY; Department of Psychiatry, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunsford</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beyer</LastName><ForeName>John L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Radiology, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sneed</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY; Department of Psychiatry, Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciovacco</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>Pudugramam Murali</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01658228</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG040093</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041795</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">antidepressants</Keyword><Keyword MajorTopicYN="N">cholinesterase inhibitor</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">depression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30037778</ArticleId><ArticleId IdType="mid">NIHMS1013581</ArticleId><ArticleId IdType="pmc">PMC6396676</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2018.05.008</ArticleId><ArticleId IdType="pii">S1064-7481(18)30333-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hanninen T, Hallikainen M, Koivisto K, et al.: A follow-up study of age-associated memory impairment: neuropsychological predictors of dementia. J Am Geriatr Soc 1995; 43:1007&#x2013;1015</Citation><ArticleIdList><ArticleId IdType="pubmed">7657916</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonker C, Geerlings MI, Schmand B: Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 2000; 15:983&#x2013;991</Citation><ArticleIdList><ArticleId IdType="pubmed">11113976</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazer D, Hughes DC, George LK: The epidemiology of depression in an elderly community population. Gerontologist 1987; 27:281&#x2013;287</Citation><ArticleIdList><ArticleId IdType="pubmed">3609795</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt DB, Zembar MJ, Niederehe G: Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychol Bull 1995; 117:285&#x2013;305</Citation><ArticleIdList><ArticleId IdType="pubmed">7724692</ArticleId></ArticleIdList></Reference><Reference><Citation>Arve S, Tilvis RS, Lehtonen A, et al.: Coexistence of lowered mood and cognitive impairment of elderly people in five birth cohorts. Aging (Milano) 1999; 11:90&#x2013;95</Citation><ArticleIdList><ArticleId IdType="pubmed">10386168</ArticleId></ArticleIdList></Reference><Reference><Citation>Charney DS,Reynolds CF III,Lewis L,et al.:Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry 2003; 60:664&#x2013;672</Citation><ArticleIdList><ArticleId IdType="pubmed">12860770</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS: Depression in the elderly. Lancet 2005;365:1961&#x2013;1970</Citation><ArticleIdList><ArticleId IdType="pubmed">15936426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Mendes de Leon CF, et al.: Depressive symptoms, cognitive decline,and risk of AD in older persons. Neurology 2002; 59:364&#x2013;370</Citation><ArticleIdList><ArticleId IdType="pubmed">12177369</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F, Frisardi V, Capurso C, et al.: Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psychiatry 2010; 18:98&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pubmed">20104067</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Sano M, Tang MX, et al.: Depressed mood and the incidence of Alzheimer&#x2019;s disease in the elderly living in the community. Arch Gen Psychiatry 1996; 53:175&#x2013;182</Citation><ArticleIdList><ArticleId IdType="pubmed">8629893</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourao RJ, Mansur G, Malloy-Diniz LF, et al.: Depressive symptoms increase the risk of progression to dementia in subjects with mild cognitive impairment: systematic review and meta-analysis. Int J Geriatr Psychiatry 2016; 31:905&#x2013;911</Citation><ArticleIdList><ArticleId IdType="pubmed">26680599</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning KJ, Alexopoulos GS, Banerjee S, et al.: Executive functioning complaints and escitalopram treatment response in late-life depression. Am J Geriatr Psychiatry 2015; 23:440&#x2013;445</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4043930</ArticleId><ArticleId IdType="pubmed">24388222</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183&#x2013;194</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Ferris S, Kluger A, et al.: Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63:651&#x2013;657</Citation><ArticleIdList><ArticleId IdType="pubmed">15326237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu PH, Edland SD, Teng E, et al.: Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 2009; 72:2115&#x2013;2121</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2697965</ArticleId><ArticleId IdType="pubmed">19528519</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CF III, Butters MA, Lopez O, et al.: Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 2011; 68:51&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3076045</ArticleId><ArticleId IdType="pubmed">21199965</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Pelton GH, Marston K, et al.: Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 2003; 18:123&#x2013;130</Citation><ArticleIdList><ArticleId IdType="pubmed">12571820</ArticleId></ArticleIdList></Reference><Reference><Citation>Nebes RD, Pollock BG, Houck PR, et al.: Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res 2003; 37:99&#x2013;108</Citation><ArticleIdList><ArticleId IdType="pubmed">12842163</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelton GH, Harper OL, Tabert MH, et al.: Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int J Geriatr Psychiatry 2008; 23:670&#x2013;676</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3104294</ArticleId><ArticleId IdType="pubmed">18088076</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelton GH, Andrews H, Roose SP, et al.: Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design. Contemp Clin Trials 2014; 37:200&#x2013;208</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3981878</ArticleId><ArticleId IdType="pubmed">24315979</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Y, Li L, Zhou TY, et al.: Alzheimer&#x2019;s disease progression model based on integrated biomarkers and clinical measures. Acta Pharmacol Sin 2014; 35:1111&#x2013;1120</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155529</ArticleId><ArticleId IdType="pubmed">25088003</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Lee S, Manly J, et al.: Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology 2015; 84:182&#x2013;189</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336090</ArticleId><ArticleId IdType="pubmed">25471394</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Christianson TJ, Kremers WK, et al.: Association between olfactory dysfunction and amnestic mild cognitive impairment and Alzheimer disease dementia. JAMA Neurol 2016; 73:93&#x2013;101</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710557</ArticleId><ArticleId IdType="pubmed">26569387</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelton GH, Soleimani L, Roose SP, et al.: Olfactory deficits predict cognitive improvement on donepezil in patients with depression and cognitive impairment: a randomized controlled pilot study. Alzheimer Dis Assoc Disord 2016; 30:67&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4764438</ArticleId><ArticleId IdType="pubmed">26398910</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Lentz C, Chunga RE, et al.: Change in odor identification impairment is associated with improvement with cholinesterease inhibitor treatment in mild cognitive impairment. J Alzheimers Dis 2017; 60:1525&#x2013;1531</Citation><ArticleIdList><ArticleId IdType="pubmed">29081417</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan KR, Charles HC, Doraiswamy PM, et al.: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer&#x2019;s disease. Am J Psychiatry 2003; 160:2003&#x2013;2011</Citation><ArticleIdList><ArticleId IdType="pubmed">14594748</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Pradhaban G, Liu X, et al.: Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007; 68:828&#x2013;836</Citation><ArticleIdList><ArticleId IdType="pubmed">17353470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung JK, Plitman E, Nakajima S, et al.: Lifetime history of depression predicts increased amyloid-beta accumulation in patients with mild cognitive impairment. J Alzheimers Dis 2015; 45:907&#x2013;919</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8928889</ArticleId><ArticleId IdType="pubmed">25633681</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Meyers BS, Young RC, et al.: Clinically defined vascular depression. Am J Psychiatry 1997; 154:562&#x2013;565</Citation><ArticleIdList><ArticleId IdType="pubmed">9090349</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffens DC, Otey E, Alexopoulos GS, et al.: Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry 2006; 63:130&#x2013;138</Citation><ArticleIdList><ArticleId IdType="pubmed">16461855</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al.: The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association work-groups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement 2011; 7:270&#x2013;279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MD, Paradis CF, Houck PR, et al.: Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41:237&#x2013;248</Citation><ArticleIdList><ArticleId IdType="pubmed">1594710</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH Jr, et al.: Measurement of functional activities in older adults in the community. J Gerontol 1982; 37:323&#x2013;329</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazekas F, Chawluk JB, Alavi A, et al.: MR signal abnormalities at 1.5 T in Alzheimer&#x2019;s dementia and normal aging. AJR Am J Roentgenol 1987; 149:351&#x2013;356</Citation><ArticleIdList><ArticleId IdType="pubmed">3496763</ArticleId></ArticleIdList></Reference><Reference><Citation>Rorden C, Brett M: Stereotaxic display of brain lesions. Behav Neurol 2000; 12:191&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pubmed">11568431</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimontel MA, Reinlieb ME, Johnert LC, et al.: The external validity of MRI-defined vascular depression. Int J Geriatr Psychiatry 2013; 28:1189&#x2013;1196</Citation><ArticleIdList><ArticleId IdType="pubmed">23447432</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Disabato BM, Hranilovich J, et al.: Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry 2012; 169:1185&#x2013;1193</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752387</ArticleId><ArticleId IdType="pubmed">23534057</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzheimer PE III, Meeks TW, Kelley ME, et al.: A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry 2008; 23:625&#x2013;631</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407281</ArticleId><ArticleId IdType="pubmed">18058832</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan KR, Taylor WD, McQuoid DR, et al.: Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry 2004; 55:390&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pubmed">14960292</ArticleId></ArticleIdList></Reference><Reference><Citation>Malouf R, Birks J: Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004; (1):CD004395</Citation><ArticleIdList><ArticleId IdType="pubmed">14974068</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30046111</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>560</Volume><Issue>7717</Issue><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>191</EndPage><MedlinePgn>185-191</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-018-0368-8</ELocationID><Abstract><AbstractText>Ageing is a major risk factor for many neurological pathologies, but its mechanisms remain unclear. Unlike other tissues, the parenchyma of the central nervous system (CNS) lacks lymphatic vasculature and waste products are removed partly through a paravascular route. (Re)discovery and characterization of meningeal lymphatic vessels has prompted an assessment of their role in waste clearance from the CNS. Here we show that meningeal lymphatic vessels drain macromolecules from the CNS (cerebrospinal and interstitial fluids) into the cervical lymph nodes in mice. Impairment of meningeal lymphatic function slows paravascular influx of macromolecules into the brain and efflux of macromolecules from the interstitial fluid, and induces cognitive impairment in mice. Treatment of aged mice with vascular endothelial growth factor C enhances meningeal lymphatic drainage of macromolecules from the cerebrospinal fluid, improving brain perfusion and learning and memory performance. Disruption of meningeal lymphatic vessels in transgenic mouse models of Alzheimer's disease promotes amyloid-&#x3b2; deposition in the meninges, which resembles human meningeal pathology, and aggravates parenchymal amyloid-&#x3b2; accumulation. Meningeal lymphatic dysfunction may be an aggravating factor in Alzheimer's disease pathology and in age-associated cognitive decline. Thus, augmentation of meningeal lymphatic function might be a promising therapeutic target for preventing or delaying age-associated neurological diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Da Mesquita</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA. sd8tf@virginia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA. sd8tf@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louveau</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaccari</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Virginia Image and Video Analysis Laboratory, Department of Electrical and Computer Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smirnov</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornelison</LastName><ForeName>R Chase</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kingsmore</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contarino</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mathematics, University of Trento, Povo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onengut-Gumuscu</LastName><ForeName>Suna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farber</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raper</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Virginia Health System, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viar</LastName><ForeName>Kenneth E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Romie D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabhi</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Stephen S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munson</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering and Mechanics, College of Engineering, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>M Beatriz</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overall</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acton</LastName><ForeName>Scott T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Virginia Image and Video Analysis Laboratory, Department of Electrical and Computer Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA. kipnis@virginia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA. kipnis@virginia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 CA222563</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057496</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2018 Aug;560(7717):172-174. doi: 10.1038/d41586-018-05763-0.</RefSource><PMID Version="1">30076374</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2018 Dec;564(7734):E7. doi: 10.1038/s41586-018-0689-7.</RefSource><PMID Version="1">30397347</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2018 Dec;24(12):1781. doi: 10.1038/s41591-018-0281-6.</RefSource><PMID Version="1">30523314</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Transl Med. 2019 Mar;7(Suppl 1):S2. doi: 10.21037/atm.2019.01.06.</RefSource><PMID Version="1">31032283</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008578" MajorTopicYN="N">Meninges</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010477" MajorTopicYN="N">Perfusion</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>: Jonathan Kipnis is an Advisor to PureTech Health/Ariya</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30046111</ArticleId><ArticleId IdType="mid">NIHMS975829</ArticleId><ArticleId IdType="pmc">PMC6085146</ArticleId><ArticleId IdType="doi">10.1038/s41586-018-0368-8</ArticleId><ArticleId IdType="pii">10.1038/s41586-018-0368-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hasek M, Chutna J, Sladecek M, Lodin Z. Immunological tolerance and tumor allografts in the brain. Nature. 1977;268:68&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">887149</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, Harris TH, Kipnis J. Revisiting the Mechanisms of CNS Immune Privilege. Trends Immunol. 2015;36:569&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593064</ArticleId><ArticleId IdType="pubmed">26431936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis J. Multifaceted interactions between adaptive immunity and the central nervous system. Science. 2016;353:766&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5590839</ArticleId><ArticleId IdType="pubmed">27540163</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund A, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015;212:991&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493418</ArticleId><ArticleId IdType="pubmed">26077718</ArticleId></ArticleIdList></Reference><Reference><Citation>Absinta M, et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. Elife. 2017;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626482</ArticleId><ArticleId IdType="pubmed">28971799</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, et al. Central role for PICALM in amyloid-beta blood-brain barrier transcytosis and clearance. Nat Neurosci. 2015;18:978&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482781</ArticleId><ArticleId IdType="pubmed">26005850</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer&#x2019;s disease. J Neurosci. 2011;31:11159&#x2013;11171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 2017;169:1276&#x2013;1290. e1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4:147ra111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress BT, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014;76:845&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245362</ArticleId><ArticleId IdType="pubmed">25204284</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng W, et al. Suppression of glymphatic fluid transport in a mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis. 2016;93:215&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980916</ArticleId><ArticleId IdType="pubmed">27234656</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer&#x2019;s disease in the United States. Alzheimers Dement. 2018;14:121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803316</ArticleId><ArticleId IdType="pubmed">29233480</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2018;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880171</ArticleId><ArticleId IdType="pubmed">28716886</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim CL, Duffy LK, Morris JH, Selkoe DJ. Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer&#x2019;s disease and normal aging. Brain Res. 1988;474:100&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">3214703</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, et al. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Abeta accumulation and memory deficits. Mol Neurodegener. 2015;10:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631089</ArticleId><ArticleId IdType="pubmed">26526066</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier S, Ferland G, Tuchweber B. Lymphatic absorption of retinol in young, mature, and old rats: influence of dietary restriction. FASEB J. 1996;10:1085&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">8801171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hos D, Bachmann B, Bock F, Onderka J, Cursiefen C. Age-related changes in murine limbal lymphatic vessels and corneal lymphangiogenesis. Exp Eye Res. 2008;87:427&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">18755186</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai T, Bridenbaugh EA, Gashev AA. Aging-associated alterations in contractility of rat mesenteric lymphatic vessels. Microcirculation. 2011;18:463&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3148320</ArticleId><ArticleId IdType="pubmed">21466607</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammela T, et al. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med. 2011;3:69ra11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21307301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilarski WW, et al. Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis. Angiogenesis. 2014;17:347&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978193</ArticleId><ArticleId IdType="pubmed">23892627</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobedo N, et al. Restoration of lymphatic function rescues obesity in Prox1-haploinsufficient mice. JCI Insight. 2016;1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786184</ArticleId><ArticleId IdType="pubmed">26973883</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringstad G, Vatnehol SAS, Eide PK. Glymphatic MRI in idiopathic normal pressure hydrocephalus. Brain. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841149</ArticleId><ArticleId IdType="pubmed">28969373</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeppenfeld DM, et al. Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. JAMA Neurol. 2017;74:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">27893874</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudy JW, Huff NC, Matus-Amat P. Understanding contextual fear conditioning: insights from a two-process model. Neurosci Biobehav Rev. 2004;28:675&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">15555677</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen SF, et al. Oxytocin enhances hippocampal spike transmission by modulating fast-spiking interneurons. Nature. 2013;500:458&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5283693</ArticleId><ArticleId IdType="pubmed">23913275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, et al. Hypothalamic programming of systemic ageing involving IKK-beta, NF-kappaB and GnRH. Nature. 2013;497:211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756938</ArticleId><ArticleId IdType="pubmed">23636330</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebl J, et al. Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2. Nat Commun. 2015;6:7274.</Citation><ArticleIdList><ArticleId IdType="pubmed">26027726</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeltsch M, et al. CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation. Circulation. 2014;129:1962&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">24552833</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JW, et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell. 2006;17:576&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356570</ArticleId><ArticleId IdType="pubmed">16291864</ArticleId></ArticleIdList></Reference><Reference><Citation>Saaristo A, et al. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med. 2002;196:719&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2194057</ArticleId><ArticleId IdType="pubmed">12235206</ArticleId></ArticleIdList></Reference><Reference><Citation>Karkkainen MJ, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A. 2001;98:12677&#x2013;12682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60113</ArticleId><ArticleId IdType="pubmed">11592985</ArticleId></ArticleIdList></Reference><Reference><Citation>Joukov V, et al. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem. 1998;273:6599&#x2013;6602.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506953</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, et al. Vascular endothelial growth factor receptor 3 controls neural stem cell activation in mice and humans. Cell Rep. 2015;10:1158&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4685253</ArticleId><ArticleId IdType="pubmed">25704818</ArticleId></ArticleIdList></Reference><Reference><Citation>Meshi D, et al. Hippocampal neurogenesis is not required for behavioral effects of environmental enrichment. Nat Neurosci. 2006;9:729&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">16648847</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer&#x2019;s disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci. 2010;30:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064502</ArticleId><ArticleId IdType="pubmed">20053918</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2013;4:2932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945879</ArticleId><ArticleId IdType="pubmed">24336108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, et al. Addendum: The antibody aducanumab reduces Abeta plaques in Alzheimer&#x2019;s disease. Nature. 2017;546:564.</Citation><ArticleIdList><ArticleId IdType="pubmed">28640269</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard BC, et al. Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer&#x2019;s Disease. J Alzheimers Dis. 2015;45:1223&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">25697701</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey NL, et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet. 2005;37:1072&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">16170315</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinder LM, Vincent AM, Hayes JM, McLean LL, Feldman EL. Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy. Exp Neurol. 2013;239:102&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534788</ArticleId><ArticleId IdType="pubmed">23059459</ArticleId></ArticleIdList></Reference><Reference><Citation>Caicco MJ, et al. A hydrogel composite system for sustained epi-cortical delivery of Cyclosporin A to the brain for treatment of stroke. J Control Release. 2013;166:197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">23306024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning B, et al. Ultrasound-aided Multi-parametric Photoacoustic Microscopy of the Mouse Brain. Sci Rep. 2015;5:18775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4685318</ArticleId><ArticleId IdType="pubmed">26688368</ArticleId></ArticleIdList></Reference><Reference><Citation>Derecki NC, et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature. 2012;484:105&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321067</ArticleId><ArticleId IdType="pubmed">22425995</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, et al. Impaired spatial memory in mice lacking CD3zeta is associated with altered NMDA and AMPA receptors signaling independent of T-cell deficiency. J Neurosci. 2013;33:18672&#x2013;18685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618807</ArticleId><ArticleId IdType="pubmed">24259588</ArticleId></ArticleIdList></Reference><Reference><Citation>Derecki NC, et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med. 2010;207:1067&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867291</ArticleId><ArticleId IdType="pubmed">20439540</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C. Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn Mem. 2004;11:337&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419737</ArticleId><ArticleId IdType="pubmed">15169864</ArticleId></ArticleIdList></Reference><Reference><Citation>Garthe A, Kempermann G. An old test for new neurons: refining the Morris water maze to study the functional relevance of adult hippocampal neurogenesis. Front Neurosci. 2013;7:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3642504</ArticleId><ArticleId IdType="pubmed">23653589</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010</Citation></Reference><Reference><Citation>Harrow J, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22:1760&#x2013;1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431492</ArticleId><ArticleId IdType="pubmed">22955987</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600148</ArticleId><ArticleId IdType="pubmed">28263959</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 2015;4:1521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712774</ArticleId><ArticleId IdType="pubmed">26925227</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3:1724&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994707</ArticleId><ArticleId IdType="pubmed">17907809</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28:882&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307112</ArticleId><ArticleId IdType="pubmed">22257669</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolde R. Pheatmap: pretty heatmaps. R package version. 2012;61</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30046032</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound.</ArticleTitle><Pagination><StartPage>2336</StartPage><MedlinePgn>2336</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2336</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-018-04529-6</ELocationID><Abstract><AbstractText>Magnetic resonance-guided focused ultrasound in combination with intravenously injected microbubbles has been shown to transiently open the blood-brain barrier, and reduce beta-amyloid and tau pathology in animal models of Alzheimer's disease. Here, we used focused ultrasound to open the blood-brain barrier in five patients with early to moderate Alzheimer's disease in a phase I safety trial. In all patients, the blood-brain barrier within the target volume was safely, reversibly, and repeatedly opened. Opening the blood-brain barrier did not result in serious clinical or radiographic adverse events, as well as no clinically significant worsening on cognitive scores at three months compared to baseline. Beta-amyloid levels were measured before treatment using [<sup>18</sup>F]-florbetaben PET to confirm amyloid deposition at the target site. Exploratory analysis suggested no group-wise changes in amyloid post-sonication. The results of this safety and feasibility study support the continued investigation of focused ultrasound as a potential novel treatment and delivery strategy for patients with Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipsman</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada. nir.lipsman@sunnybrook.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada. nir.lipsman@sunnybrook.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, M4N 3M5, Canada. nir.lipsman@sunnybrook.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bethune</LastName><ForeName>Allison J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuexi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyn</LastName><ForeName>Chinthaka</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aubert</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, M5S 3H7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutet</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Gwenn S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences and Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, 21218, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hynynen</LastName><ForeName>Kullervo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biophysics, University of Toronto, Toronto, M5S 3H7, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, M5S 3H7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EB003268</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>TLA7312TOI</RegistryNumber><NameOfSubstance UI="C527756">4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="Y">Blood-Brain Barrier</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045423" MajorTopicYN="N">Microbubbles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013267" MajorTopicYN="N">Stilbenes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="Y">Ultrasonography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>N.L. (chair), K.H., and S.E.B. have received an honorarium for serving on an expert steering committee on focused ultrasound in AD. K.H. is an inventor on intellectual property owned by Brigham and Women&#x2019;s hospital in Boston and Sunnybrook Research Institute in Toronto related to intracranial focused ultrasound technology. Y.M., A.J.B., Y.H., B.L., M.M., N.H., C.H., I.A., A.B., and G.S.S. declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30046032</ArticleId><ArticleId IdType="pmc">PMC6060168</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-04529-6</ArticleId><ArticleId IdType="pii">10.1038/s41467-018-04529-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Karran E, De Strooper B. The amyloid cascade hypothesis: are we poised for success or failure? J. Neurochem. 2016;139(Suppl. 2):237&#x2013;252. doi: 10.1111/jnc.13632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13632</ArticleId><ArticleId IdType="pubmed">27255958</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x2019;s disease. N. Engl. J. Med. 2014;370:311&#x2013;321. doi: 10.1056/NEJMoa1312889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1312889</ArticleId><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N. Engl. J. Med. 2014;370:322&#x2013;333. doi: 10.1056/NEJMoa1304839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, et al. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature. 2016;537:50&#x2013;56. doi: 10.1038/nature19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin. Drug Deliv. 2016;13:963&#x2013;975. doi: 10.1517/17425247.2016.1171315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2016.1171315</ArticleId><ArticleId IdType="pubmed">27020469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003;9:589&#x2013;595. doi: 10.1038/nm850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm850</ArticleId><ArticleId IdType="pubmed">12669033</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin D, Forsayeth J, Bankiewicz KS. Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J. Neurosci. Methods. 2010;187:46&#x2013;51. doi: 10.1016/j.jneumeth.2009.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2009.12.008</ArticleId><ArticleId IdType="pmc">PMC2865230</ArticleId><ArticleId IdType="pubmed">20026357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendricks BK, Cohen-Gadol AA, Miller JC. Novel delivery methods bypassing the blood-brain and blood-tumor barriers. Neurosurg. Focus. 2015;38:E10. doi: 10.3171/2015.1.FOCUS14767.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2015.1.FOCUS14767</ArticleId><ArticleId IdType="pubmed">25727219</ArticleId></ArticleIdList></Reference><Reference><Citation>Boado RJ, Zhou QH, Lu JZ, Hui EKW, Pardridge WM. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol. Pharm. 2010;7:237&#x2013;244. doi: 10.1021/mp900235k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/mp900235k</ArticleId><ArticleId IdType="pmc">PMC2858389</ArticleId><ArticleId IdType="pubmed">19921848</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatore MF, et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp. Neurol. 2006;202:497&#x2013;505. doi: 10.1016/j.expneurol.2006.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2006.07.015</ArticleId><ArticleId IdType="pubmed">16962582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima-Hosoyama S, et al. A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys. PLoS ONE. 2012;7:e39036. doi: 10.1371/journal.pone.0039036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039036</ArticleId><ArticleId IdType="pmc">PMC3380056</ArticleId><ArticleId IdType="pubmed">22745701</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynynen K, Jolesz FA. Demonstration of potential noninvasive ultrasound brain therapy through an intact skull. Ultrasound Med. Biol. 1998;24:275&#x2013;283. doi: 10.1016/S0301-5629(97)00269-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0301-5629(97)00269-X</ArticleId><ArticleId IdType="pubmed">9550186</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias WJ, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 2016;375:730&#x2013;739. doi: 10.1056/NEJMoa1600159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1600159</ArticleId><ArticleId IdType="pubmed">27557301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar, V. K. et al. Cost-effectiveness of focused ultrasound, radiosurgery, and DBS for essential tremor. Mov. Disord.32, 1165&#x2013;1173 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28370272</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano A, et al. MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes. Neurology. 2017;89:771&#x2013;775. doi: 10.1212/WNL.0000000000004268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004268</ArticleId><ArticleId IdType="pubmed">28747452</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung HH, et al. Bilateral thermal capsulotomy with MR-guided focused ultrasound for patients with treatment-refractory obsessive-compulsive disorder: a proof-of-concept study. Mol. Psychiatry. 2015;20:1205&#x2013;1211. doi: 10.1038/mp.2014.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2014.154</ArticleId><ArticleId IdType="pubmed">25421403</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001;220:640&#x2013;646. doi: 10.1148/radiol.2202001804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2202001804</ArticleId><ArticleId IdType="pubmed">11526261</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisbet RM, et al. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain. 2017;140:1220&#x2013;1230. doi: 10.1093/brain/awx052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx052</ArticleId><ArticleId IdType="pmc">PMC5405237</ArticleId><ArticleId IdType="pubmed">28379300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o JF, et al. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer&#x2019;s disease. PLoS ONE. 2010;5:e10549. doi: 10.1371/journal.pone.0010549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010549</ArticleId><ArticleId IdType="pmc">PMC2868024</ArticleId><ArticleId IdType="pubmed">20485502</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond SB, et al. Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer&#x2019;s disease mouse models. PLoS ONE. 2008;3:e2175. doi: 10.1371/journal.pone.0002175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002175</ArticleId><ArticleId IdType="pmc">PMC2364662</ArticleId><ArticleId IdType="pubmed">18478109</ArticleId></ArticleIdList></Reference><Reference><Citation>Aryal M, Vykhodtseva N, Zhang YZ, McDannold N. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. J. Control. Release. 2015;204:60&#x2013;69. doi: 10.1016/j.jconrel.2015.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.02.033</ArticleId><ArticleId IdType="pmc">PMC4385501</ArticleId><ArticleId IdType="pubmed">25724272</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz RJ, et al. Focused ultrasound delivery of Raman nanoparticles across the blood-brain barrier: potential for targeting experimental brain tumors. Nanomedicine. 2014;10:1075&#x2013;1087. doi: 10.1016/j.nano.2013.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2013.12.006</ArticleId><ArticleId IdType="pmc">PMC4074278</ArticleId><ArticleId IdType="pubmed">24374363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc. Natl Acad. Sci. USA. 2006;103:11719&#x2013;11723. doi: 10.1073/pnas.0604318103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0604318103</ArticleId><ArticleId IdType="pmc">PMC1544236</ArticleId><ArticleId IdType="pubmed">16868082</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;venot E, et al. Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound. Hum. Gene Ther. 2012;23:1144&#x2013;1155. doi: 10.1089/hum.2012.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2012.013</ArticleId><ArticleId IdType="pmc">PMC3498907</ArticleId><ArticleId IdType="pubmed">22838844</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess A, et al. Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier. PLoS ONE. 2011;6:e27877. doi: 10.1371/journal.pone.0027877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027877</ArticleId><ArticleId IdType="pmc">PMC3218061</ArticleId><ArticleId IdType="pubmed">22114718</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o JF, et al. Amyloid-&#x3b2; plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp. Neurol. 2013;248:16&#x2013;29. doi: 10.1016/j.expneurol.2013.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.05.008</ArticleId><ArticleId IdType="pmc">PMC4000699</ArticleId><ArticleId IdType="pubmed">23707300</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinenga G, G&#xf6;tz J. Scanning ultrasound removes amyloid-&#x3b2; and restores memory in an Alzheimer&#x2019;s disease mouse model. Sci. Transl. Med. 2015;7:278ra33. doi: 10.1126/scitranslmed.aaa2512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa2512</ArticleId><ArticleId IdType="pubmed">25761889</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess A, et al. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. Radiology. 2014;273:736&#x2013;745. doi: 10.1148/radiol.14140245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.14140245</ArticleId><ArticleId IdType="pmc">PMC4314115</ArticleId><ArticleId IdType="pubmed">25222068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullich S, et al. Optimal reference region to measure longitudinal amyloid-&#x3b2; change with (18)F-Florbetaben PET. J. Nucl. Med. 2017;58:1300&#x2013;1306. doi: 10.2967/jnumed.116.187351.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.116.187351</ArticleId><ArticleId IdType="pubmed">28183994</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor CW, Hynynen K. Patterns of thermal deposition in the skull during transcranial focused ultrasound surgery. IEEE Trans. Biomed. Eng. 2004;51:1693&#x2013;1706. doi: 10.1109/TBME.2004.831516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TBME.2004.831516</ArticleId><ArticleId IdType="pubmed">15490817</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpentier A, et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci. Transl. Med. 2016;8:343re2. doi: 10.1126/scitranslmed.aaf6086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6086</ArticleId><ArticleId IdType="pubmed">27306666</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85:296. doi: 10.1016/j.neuron.2014.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.032</ArticleId><ArticleId IdType="pmc">PMC4350773</ArticleId><ArticleId IdType="pubmed">25611508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N, et al. Lack of widespread BBB disruption in Alzheimer&#x2019;s disease models: focus on therapeutic antibodies. Neuron. 2015;88:289&#x2013;297. doi: 10.1016/j.neuron.2015.09.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.09.036</ArticleId><ArticleId IdType="pubmed">26494278</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci. Transl. Med. 2012;4:147ra111. doi: 10.1126/scitranslmed.3003748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003748</ArticleId><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;269. doi: 10.1016/j.jalz.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Alkins R, Schwartz ML, Hynynen K. Opening the blood-brain barrier with MR imaging-guided focused ultrasound: preclinical testing on a trans-human skull porcine model. Radiology. 2017;282:123&#x2013;130. doi: 10.1148/radiol.2016152154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2016152154</ArticleId><ArticleId IdType="pmc">PMC5179309</ArticleId><ArticleId IdType="pubmed">27420647</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly MA, Hynynen K. Blood-brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology. 2012;263:96&#x2013;106. doi: 10.1148/radiol.11111417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.11111417</ArticleId><ArticleId IdType="pmc">PMC3309801</ArticleId><ArticleId IdType="pubmed">22332065</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldjian JA, Whitlow CT, Alzheimer&#x2019;s Disease Neuroimaging Initiative. Whither the hippocampus? FDG-PET hippocampal hypometabolism in Alzheimer disease revisited. AJNR Am. J. Neuroradiol. 2012;33:1975&#x2013;1982. doi: 10.3174/ajnr.A3113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A3113</ArticleId><ArticleId IdType="pmc">PMC7964612</ArticleId><ArticleId IdType="pubmed">22700745</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30082275</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>215</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau.</ArticleTitle><Pagination><StartPage>2235</StartPage><EndPage>2245</EndPage><MedlinePgn>2235-2245</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20180653</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is an age-associated neurodegenerative disease characterized by amyloidosis, tauopathy, and activation of microglia, the brain resident innate immune cells. We show that a RiboTag translational profiling approach can bypass biases due to cellular enrichment/cell sorting. Using this approach in models of amyloidosis, tauopathy, and aging, we revealed a common set of alterations and identified a central APOE-driven network that converged on CCL3 and CCL4 across all conditions. Notably, aged females demonstrated a significant exacerbation of many of these shared transcripts in this APOE network, revealing a potential mechanism for increased AD susceptibility in females. This study has broad implications for microglial transcriptomic approaches and provides new insights into microglial pathways associated with different pathological aspects of aging and AD.</AbstractText><CopyrightInformation>&#xa9; 2018 Kang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Silvia S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0003-2766-3632</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL kang.silvia@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebbert</LastName><ForeName>Mark T W</ForeName><Initials>MTW</Initials><Identifier Source="ORCID">0000-0001-9158-4440</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Kelsey E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuewei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sens</LastName><ForeName>Jonathon P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocher</LastName><ForeName>Jeanne-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-3390-2994</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL fryer.john@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG047327</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 MH103632</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG049992</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG057997</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS094137</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100693</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496534">Ccl3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496535">Ccl4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054405">Chemokine CCL3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054407">Chemokine CCL4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054405" MajorTopicYN="N">Chemokine CCL3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054407" MajorTopicYN="N">Chemokine CCL4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30082275</ArticleId><ArticleId IdType="pmc">PMC6122978</ArticleId><ArticleId IdType="doi">10.1084/jem.20180653</ArticleId><ArticleId IdType="pii">jem.20180653</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Austermann J., Friesenhagen J., Fassl S.K., Petersen B., Ortkras T., Burgmann J., Barczyk-Kahlert K., Faist E., Zedler S., Pirr S., et al. . 2014. Alarmins MRP8 and MRP14 induce stress tolerance in phagocytes under sterile inflammatory conditions. Cell Reports. 9:2112&#x2013;2123. 10.1016/j.celrep.2014.11.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.11.020</ArticleId><ArticleId IdType="pubmed">25497086</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik S.H., Cha M.-Y., Hyun Y.-M., Cho H., Hamza B., Kim D.K., Han S.-H., Choi H., Kim K.H., Moon M., et al. . 2014. Migration of neutrophils targeting amyloid plaques in Alzheimer&#x2019;s disease mouse model. Neurobiol. Aging. 35:1286&#x2013;1292. 10.1016/j.neurobiolaging.2014.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.01.003</ArticleId><ArticleId IdType="pmc">PMC4248665</ArticleId><ArticleId IdType="pubmed">24485508</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C., Kang S.S., Carlomagno Y., Lin W.L., Yue M., Kurti A., Shinohara M., Jansen-West K., Perkerson E., Castanedes-Casey M., et al. . 2015. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. Hum. Mol. Genet. 24:6198&#x2013;6212. 10.1093/hmg/ddv336</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv336</ArticleId><ArticleId IdType="pmc">PMC4599677</ArticleId><ArticleId IdType="pubmed">26276810</ArticleId></ArticleIdList></Reference><Reference><Citation>Corneveaux J.J., Myers A.J., Allen A.N., Pruzin J.J., Ramirez M., Engel A., Nalls M.A., Chen K., Lee W., Chewning K., et al. . 2010. Association of CR1, CLU and PICALM with Alzheimer&#x2019;s disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum. Mol. Genet. 19:3295&#x2013;3301. 10.1093/hmg/ddq221</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq221</ArticleId><ArticleId IdType="pmc">PMC2908469</ArticleId><ArticleId IdType="pubmed">20534741</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D., Grutzendler J., Yang G., Kim J.V., Zuo Y., Jung S., Littman D.R., Dustin M.L., and Gan W.-B.. 2005. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8:752&#x2013;758. 10.1038/nn1472</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1472</ArticleId><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle J.P., Dougherty J.D., Heiman M., Schmidt E.F., Stevens T.R., Ma G., Bupp S., Shrestha P., Shah R.D., Doughty M.L., et al. . 2008. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell. 135:749&#x2013;762. 10.1016/j.cell.2008.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.10.029</ArticleId><ArticleId IdType="pmc">PMC2763427</ArticleId><ArticleId IdType="pubmed">19013282</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou A.G., and Goate A.M.. 2017. Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12:43 10.1186/s13024-017-0184-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0184-x</ArticleId><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson M.A., and Banks W.A.. 2011. Cytokine and chemokine responses in serum and brain after single and repeated injections of lipopolysaccharide: multiplex quantification with path analysis. Brain Behav. Immun. 25:1637&#x2013;1648. 10.1016/j.bbi.2011.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2011.06.006</ArticleId><ArticleId IdType="pmc">PMC3389494</ArticleId><ArticleId IdType="pubmed">21704698</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S.K., Younkin S., et al. Alzheimer Genetic Analysis Group . 2013. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:117&#x2013;127. 10.1056/NEJMoa1211851</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>He H., Geng T., Chen P., Wang M., Hu J., Kang L., Song W., and Tang H.. 2016. NK cells promote neutrophil recruitment in the brain during sepsis-induced neuroinflammation. Sci. Rep. 6:27711 10.1038/srep27711</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep27711</ArticleId><ArticleId IdType="pmc">PMC4897692</ArticleId><ArticleId IdType="pubmed">27270556</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S.E., Kingery N.D., Ohsumi T.K., Borowsky M.L., Wang L.C., Means T.K., and El Khoury J.. 2013. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 16:1896&#x2013;1905. 10.1038/nn.3554</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3554</ArticleId><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D.M., Morris J.C., and Goate A.M.. 2011. Alzheimer&#x2019;s disease: the challenge of the second century. Sci. Transl. Med. 3:77sr1 10.1126/scitranslmed.3002369</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002369</ArticleId><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwashyna T.J., Ely E.W., Smith D.M., and Langa K.M.. 2010. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 304:1787&#x2013;1794. 10.1001/jama.2010.1553</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.1553</ArticleId><ArticleId IdType="pmc">PMC3345288</ArticleId><ArticleId IdType="pubmed">20978258</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S.S., Ren Y., Liu C.-C., Kurti A., Baker K.E., Bu G., Asmann Y., and Fryer J.D.. 2018. Lipocalin-2 protects the brain during inflammatory conditions. Mol. Psychiatry. 23:344&#x2013;350. 10.1038/mp.2016.243</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2016.243</ArticleId><ArticleId IdType="pmc">PMC5503822</ArticleId><ArticleId IdType="pubmed">28070126</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B., et al. . 2017. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 169:1276&#x2013;1290.e17. 10.1016/j.cell.2017.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Koellhoffer E.C., McCullough L.D., and Ritzel R.M.. 2017. Old Maids: Aging and Its Impact on Microglia Function. Int. J. Mol. Sci. 18:769 10.3390/ijms18040769</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18040769</ArticleId><ArticleId IdType="pmc">PMC5412353</ArticleId><ArticleId IdType="pubmed">28379162</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G., Halle A., Matyash V., Rinnenthal J.L., Eom G.D., Bernhardt U., Miller K.R., Prokop S., Kettenmann H., and Heppner F.L.. 2013. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 8:e60921 10.1371/journal.pone.0060921</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060921</ArticleId><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-C., Liu C.-C., Kanekiyo T., Xu H., and Bu G.. 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9:106&#x2013;118. 10.1038/nrneurol.2012.263</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.263</ArticleId><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangold C.A., Wronowski B., Du M., Masser D.R., Hadad N., Bixler G.V., Brucklacher R.M., Ford M.M., Sonntag W.E., and Freeman W.M.. 2017. Sexually divergent induction of microglial-associated neuroinflammation with hippocampal aging. J. Neuroinflammation. 14:141 10.1186/s12974-017-0920-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0920-8</ArticleId><ArticleId IdType="pmc">PMC5521082</ArticleId><ArticleId IdType="pubmed">28732515</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak D., Roth T.L., and McGavern D.B.. 2014. Microglia development and function. Annu. Rev. Immunol. 32:367&#x2013;402. 10.1146/annurev-immunol-032713-120240</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032713-120240</ArticleId><ArticleId IdType="pmc">PMC5001846</ArticleId><ArticleId IdType="pubmed">24471431</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A., Kirchhoff F., and Helmchen F.. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 308:1314&#x2013;1318. 10.1126/science.1110647</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1110647</ArticleId><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D., Mazzitelli S., Ito Y., DeWitt J.P., Mifflin L., Zou C., Das S., Adiconis X., Chen H., Zhu H., et al. . 2017. RIPK1 mediates a disease-associated microglial response in Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 114:E8788&#x2013;E8797. 10.1073/pnas.1714175114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1714175114</ArticleId><ArticleId IdType="pmc">PMC5642727</ArticleId><ArticleId IdType="pubmed">28904096</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst C.N., Yang G., Ninan I., Savas J.N., Yates J.R. III, Lafaille J.J., Hempstead B.L., Littman D.R., and Gan W.-B.. 2013. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 155:1596&#x2013;1609. 10.1016/j.cell.2013.11.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.11.030</ArticleId><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedel B.C., Thompson P.M., and Brinton R.D.. 2016. Age, APOE and sex: Triad of risk of Alzheimer&#x2019;s disease. J. Steroid Biochem. Mol. Biol. 160:134&#x2013;147. 10.1016/j.jsbmb.2016.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2016.03.012</ArticleId><ArticleId IdType="pmc">PMC4905558</ArticleId><ArticleId IdType="pubmed">26969397</ArticleId></ArticleIdList></Reference><Reference><Citation>Saijo K., and Glass C.K.. 2011. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 11:775&#x2013;787. 10.1038/nri3086</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3086</ArticleId><ArticleId IdType="pubmed">22025055</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter M.W., and Stevens B.. 2017. Microglia emerge as central players in brain disease. Nat. Med. 23:1018&#x2013;1027. 10.1038/nm.4397</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4397</ArticleId><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz E., Yang L., Su T., Morris D.R., McKnight G.S., and Amieux P.S.. 2009. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc. Natl. Acad. Sci. USA. 106:13939&#x2013;13944. 10.1073/pnas.0907143106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0907143106</ArticleId><ArticleId IdType="pmc">PMC2728999</ArticleId><ArticleId IdType="pubmed">19666516</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Yamada K., Liddelow S.A., Smith S.T., Zhao L., Luo W., Tsai R.M., Spina S., Grinberg L.T., Rojas J.C., et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative . 2017. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 549:523&#x2013;527. 10.1038/nature24016</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J.D., Ulland T.K., Mahan T.E., Nystr&#xf6;m S., Nilsson K.P., Song W.M., Zhou Y., Reinartz M., Choi S., Jiang H., et al. . 2018. ApoE facilitates the microglial response to amyloid plaque pathology. J. Exp. Med. 215:1047&#x2013;1058. 10.1084/jem.20171265</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171265</ArticleId><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Brink S.C., Sage F., V&#xe9;rtesy &#xc1;., Spanjaard B., Peterson-Maduro J., Baron C.S., Robin C., and van Oudenaarden A.. 2017. Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations. Nat. Methods. 14:935&#x2013;936. 10.1038/nmeth.4437</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4437</ArticleId><ArticleId IdType="pubmed">28960196</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., van Zoelen M.A.D., Nacken W., Foell D., van der Poll T., Sorg C., and Roth J.. 2007. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13:1042&#x2013;1049. 10.1038/nm1638</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1638</ArticleId><ArticleId IdType="pubmed">17767165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenaro E., Pietronigro E., Della Bianca V., Piacentino G., Marongiu L., Budui S., Turano E., Rossi B., Angiari S., Dusi S., et al. . 2015. Neutrophils promote Alzheimer&#x2019;s disease-like pathology and cognitive decline via LFA-1 integrin. Nat. Med. 21:880&#x2013;886. 10.1038/nm.3913</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3913</ArticleId><ArticleId IdType="pubmed">26214837</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30108311</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation.</ArticleTitle><Pagination><StartPage>1859</StartPage><EndPage>1875</EndPage><MedlinePgn>1859-1875</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-018-0112-7</ELocationID><Abstract><AbstractText>The Alzheimer's Disease Sequencing Project (ADSP) undertook whole exome sequencing in 5,740 late-onset Alzheimer disease (AD) cases and 5,096 cognitively normal controls primarily of European ancestry (EA), among whom 218 cases and 177 controls were Caribbean Hispanic (CH). An age-, sex- and APOE based risk score and family history were used to select cases most likely to harbor novel AD risk variants and controls least likely to develop AD by age 85 years. We tested ~1.5 million single nucleotide variants (SNVs) and 50,000 insertion-deletion polymorphisms (indels) for association to AD, using multiple models considering individual variants as well as gene-based tests aggregating rare, predicted functional, and loss of function variants. Sixteen single variants and 19 genes that met criteria for significant or suggestive associations after multiple-testing correction were evaluated for replication in four independent samples; three with whole exome sequencing (2,778 cases, 7,262 controls) and one with genome-wide genotyping imputed to the Haplotype Reference Consortium panel (9,343 cases, 11,527 controls). The top findings in the discovery sample were also followed-up in the ADSP whole-genome sequenced family-based dataset (197 members of 42 EA families and 501 members of 157 CH families). We identified novel and predicted functional genetic variants in genes previously associated with AD. We also detected associations in three novel genes: IGHG3 (p&#x2009;=&#x2009;9.8&#x2009;&#xd7;&#x2009;10<sup>-7</sup>), an immunoglobulin gene whose antibodies interact with &#x3b2;-amyloid, a long non-coding RNA AC099552.4 (p&#x2009;=&#x2009;1.2&#x2009;&#xd7;&#x2009;10<sup>-7</sup>), and a zinc-finger protein ZNF655 (gene-based p&#x2009;=&#x2009;5.0&#x2009;&#xd7;&#x2009;10<sup>-6</sup>). The latter two suggest an important role for transcriptional regulation in AD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Medicine (General Internal Medicine), University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jian</LastName><ForeName>Xueqiu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kunkle</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Yuning</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7358-7055</Identifier><AffiliationInfo><Affiliation>Departments of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton-Nelson</LastName><ForeName>Kara L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>William S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Case Western Reserve University, Cleveland Heights, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salerno</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Human Genome Sequencing Center and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lancour</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7266-1022</Identifier><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yiyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0001-6702-8268</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience and Ronald M Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcora</LastName><ForeName>Edoardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Ronald M Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Najaf</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9088-234X</Identifier><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Below</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Genetics and CNR-MAJ, Normandie Universit&#xe9;, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Centre Hospitalier du Rouvray, Sotteville-l&#xe8;s-, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charbonnier</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genetics and CNR-MAJ, Normandie Universit&#xe9;, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jaeyoon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6431-9454</Identifier><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Medicine (General Internal Medicine), University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cupples</LastName><ForeName>L Adrienne</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Departments of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team VINTAGE, UMR 1219, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debette</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team VINTAGE, UMR 1219, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Institute for Neurodegenerative Diseases, Bordeaux University Hospital, Memory Clinic, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleuze</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut Fran&#xe7;ois Jacob, Direction de le Recherche Fondamentale, CEA, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulton</LastName><ForeName>Lucinda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>McDonnell Genome Institute, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Stacey B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genin</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Inserm UMR-1078, CHRU Brest, Universit&#xe9; Brest, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Human Genome Sequencing Center and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience and Ronald M Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenier-Boley</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Namrata</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Case Western Reserve University, Cleveland Heights, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havulinna</LastName><ForeName>Aki S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helisalmi</LastName><ForeName>Seppo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine - Neurology and Department of Neurology, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howrigan</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics and Genetic Analysis Platform, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric &amp; Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0372-8585</Identifier><AffiliationInfo><Affiliation>Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaprio</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3716-2455</Identifier><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konrad</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzma</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lander</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lathrop</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McGill University and G&#xe9;nome Qu&#xe9;bec Innovation Centre, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehtim&#xe4;ki</LastName><ForeName>Terho</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Honghuang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3043-3942</Identifier><AffiliationInfo><Affiliation>Department of Medicine (Computational Biomedicine), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattila</LastName><ForeName>Kari</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muzny</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Human Genome Sequencing Center and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasser</LastName><ForeName>Waleed</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Human Genome Sequencing Center and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neale</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-1513-6077</Identifier><AffiliationInfo><Affiliation>Program in Medical and Population Genetics and Genetic Analysis Platform, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric &amp; Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolas</LastName><ForeName>Ga&#xeb;l</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9391-7800</Identifier><AffiliationInfo><Affiliation>Department of Genetics and CNR-MAJ, Normandie Universit&#xe9;, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Devanshi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perola</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Tartu, Estonian Genome Center, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Psaty</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Medicine (General Internal Medicine), University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Services, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quenez</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Genetics and CNR-MAJ, Normandie Universit&#xe9;, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajabli</LastName><ForeName>Farid</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redon</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Inserm, CNRS, Univ. Nantes, CHU Nantes, l'institut du thorax, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remes</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine - Neurology and Department of Neurology, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Clinical Neuroscience, Neurology, University of Oulu and Medical Research Center, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salomaa</LastName><ForeName>Veikko</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarnowski</LastName><ForeName>Chloe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Clinical Division of Neurogeriatrics, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Reinhold</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Clinical Division of Neurogeriatrics, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine - Neurology and Department of Neurology, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thornton</LastName><ForeName>Timothy A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosto</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzourio</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team VINTAGE, UMR 1219, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-1606-8643</Identifier><AffiliationInfo><Affiliation>Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valladares</LastName><ForeName>Otto</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Weixin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijsman</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine (Medical Genetics), University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Richard K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>McDonnell Genome Institute, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witten</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worley</LastName><ForeName>Kim C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Human Genome Sequencing Center and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Departments of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Sequencing Project</CollectiveName></Author><Author ValidYN="Y"><LastName>Bellenguez</LastName><ForeName>Celine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1240-7874</Identifier><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-0829-7817</Identifier><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurki</LastName><ForeName>Mitja I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics and Genetic Analysis Platform, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric &amp; Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palotie</LastName><ForeName>Aarno</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics and Genetic Analysis Platform, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric &amp; Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0949-8752</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric &amp; Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boerwinkle</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Human Genome Sequencing Center and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-9268-810X</Identifier><AffiliationInfo><Affiliation>Departments of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Destefano</LastName><ForeName>Anita L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Departments of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Jos&#xe9;e</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-9621-2942</Identifier><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fornage</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Departments of Biostatistics, Boston University School of Public Health, Boston, MA, USA. farrer@bu.Edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA. farrer@bu.Edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology, Boston University School of Medicine, Boston, MA, USA. farrer@bu.Edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. farrer@bu.Edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Boston University School of Medicine, Boston, MA, USA. farrer@bu.Edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL105756</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058635</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023629</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085081</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100012C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 HL102419</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100009I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085080</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058654</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AG052427</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG003067</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100010C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG054936</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100008C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL080295</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100008I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100005G</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085082</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG067501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL130114</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100007C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268200800007C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG066107</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085086</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085083</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I 904</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>HHSN268201100011I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100011C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096902</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG047133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG003273</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049607</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018522</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100006C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG041689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201200036C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100005I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC055222</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058589</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049508</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085079</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052410</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096814</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033040</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048927</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG003079</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100009C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL070825</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012535</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100005C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100007I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049506</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051741">Kruppel-Like Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496408">ZNF655 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Mol Psychiatry. 2020 Aug;25(8):1901-1903. doi: 10.1038/s41380-019-0529-7.</RefSource><PMID Version="1">31636380</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051741" MajorTopicYN="N">Kruppel-Like Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073359" MajorTopicYN="Y">Exome Sequencing</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Celine Bellenguez received personal fees from Genoscrenn unrelated to current study. HS reports grants from Austrian Science Fond (FWF) and &#xd6;sterreichische Nationalbank Anniversary Fund during the conduct of the study. AMG received grants from NIA, Genentech, Pfizer, and Astra Zeneca as well as personal fees from Finnegan HC, Cognition Therapeutics, Dickstein Shapiro, Genentech, and Amgen, all unrelated to the current study. In addition, AMG has a patent (US20070258898) issued, and a patent with royalties paid by Taconic. J-FD received grants and personal fees from IPSEN and Novartis, and personal fees from Newron. MAP-V received personal fees from Athena Neurosciences unrelated to current study. The other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30108311</ArticleId><ArticleId IdType="mid">NIHMS1000844</ArticleId><ArticleId IdType="pmc">PMC6375806</ArticleId><ArticleId IdType="doi">10.1038/s41380-018-0112-7</ArticleId><ArticleId IdType="pii">10.1038/s41380-018-0112-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Escott-Price V, Bellenguez C, Wang LS, Choi SH, Harold D, Jones L, et al. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. PLoS One. 2014;9:e94661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055488</ArticleId><ArticleId IdType="pubmed">24922517</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain. 2015;138:3673&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006219</ArticleId><ArticleId IdType="pubmed">26490334</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45:1452&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz A, Heilmann S, Becker T, Hernandez I, Wagner H, Thelen M, et al. Follow-up of loci from the International Genomics of Alzheimer's Disease Project identifies TRIP4 as a novel susceptibility gene. Transl Psychiatry. 2014;4:e358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944635</ArticleId><ArticleId IdType="pubmed">24495969</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, Ghani M, Kahn A, Sheikh S, Sato C, Barral S, et al. Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci. Ann Neurol. 2015;78:487&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546546</ArticleId><ArticleId IdType="pubmed">26101835</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, Zhang Y, Lee JH, Cheng R, Bohm C, Ghani M, et al. Coding mutations in SORL1 and Alzheimer disease. Ann Neurol. 2015;77:215&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367199</ArticleId><ArticleId IdType="pubmed">25382023</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S, Stefansson H, Jonsson T, Johannsdottir H, Ingason A, Helgason H, et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nat Genet. 2015;47:445&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue MW, Schu M, Vardarajan BN, Farrell J, Bennett DA, Buxbaum JD, et al. Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. Alzheimers Dement. 2014;10:609&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253055</ArticleId><ArticleId IdType="pubmed">25172201</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Asai H, Zeldich E, Drapeau E, Chen C, Chung J, et al. PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation. Ann Neurol. 2014;76:379&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830273</ArticleId><ArticleId IdType="pubmed">25043464</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel-Smith MK, Hunkapiller J, Bhangale TR, Srinivasan K, Maloney JA, Atwal JK, et al. A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nat Med. 2014;20:1452&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301587</ArticleId><ArticleId IdType="pubmed">25419706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet. 2008;40:695&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527050</ArticleId><ArticleId IdType="pubmed">18509313</ArticleId></ArticleIdList></Reference><Reference><Citation>Schork NJ, Murray SS, Frazer KA, Topol EJ. Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev. 2009;19:212&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914559</ArticleId><ArticleId IdType="pubmed">19481926</ArticleId></ArticleIdList></Reference><Reference><Citation>Surakka I, Horikoshi M, Magi R, Sarin AP, Mahajan A, Lagou V, et al. The impact of low-frequency and rare variants on lipid levels. Nat Genet. 2015;47:589&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4757735</ArticleId><ArticleId IdType="pubmed">25961943</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet. 2001;69:124&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1226027</ArticleId><ArticleId IdType="pubmed">11404818</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet. 2014;59:5&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">24196381</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;48:1279&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388176</ArticleId><ArticleId IdType="pubmed">27548312</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Bis JC, Martin ER, Choi S-H, DeStefano A, van Duijn C, et al. The Alzheimer&#x2019;s Disease Sequencing Project: study design and sample selection. Neurol Genet. 2017;3:e194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5646177</ArticleId><ArticleId IdType="pubmed">29184913</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med. 1993;117:132&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8427562</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley T, Brody J, Dupuis J, Cupples A Meta-analysis of a rare-variant association test: University of Auckland; 2012. http://stattech.wordpress.fos.auckland.ac.nz/files/2012/11/skat-meta-paper.pdf. Technical report.</Citation></Reference><Reference><Citation>Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet. 2012;91:224&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415556</ArticleId><ArticleId IdType="pubmed">22863193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C, Charbonnier C, Grenier-Boley B, Quenez O, Le Guennec K, Nicolas G, et al. Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol Aging. 2017;59:220 e221&#x2013;220 e229.</Citation><ArticleIdList><ArticleId IdType="pubmed">28789839</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh PR, Danecek P, Palamara PF, Fuchsberger C, A Reshef Y, K Finucane H, et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat Genet. 2016;48:1443&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5096458</ArticleId><ArticleId IdType="pubmed">27694958</ArticleId></ArticleIdList></Reference><Reference><Citation>Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38:209&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415888</ArticleId></ArticleIdList></Reference><Reference><Citation>Blue EE, Bis JC, Dorschner MO, Tsuang D, Barral SM, Beecham G, et al. Genetic variation in genes underlying diverse dementias may explain a small proportion of cases in the Alzheimer&#x2019;s Disease Sequencing Project. Dement Ger Cog Disorders. 2018;45:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5971141</ArticleId><ArticleId IdType="pubmed">29486463</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Vardarajan BN, Blue E, Barral S, Haines JL, Bush WS, et al. Whole-genome sequencing in familial late-onset Alzheimer's disease identifies variation in AD candidate genes. Alzheimer Dement. 2017;13:P571&#x2013;P572.</Citation></Reference><Reference><Citation>Yan Q, Tiwari HK, Yi N, Gao G, Zhang K, Lin WY, et al. A sequence kernel association test for dichotomous traits in family samples under a generalized linear mixed model. Hum Hered. 2015;79:60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825859</ArticleId><ArticleId IdType="pubmed">25791389</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, Erlich Y, Pickrell JK. Case-control association mapping by proxy using family history of disease. Nat Genet. 2017;49:325&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28092683</ArticleId></ArticleIdList></Reference><Reference><Citation>Neph S, Kuehn MS, Reynolds AP, Haugen E, Thurman RE, Johnson AK, et al. BEDOPS: high-performance genomic feature operations. Bioinformatics. 2012;28:1919&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389768</ArticleId><ArticleId IdType="pubmed">22576172</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832824</ArticleId><ArticleId IdType="pubmed">20110278</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22:1760&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431492</ArticleId><ArticleId IdType="pubmed">22955987</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, De Roeck A, Van den Bossche T, Van Cauwenberghe C, Bettens K, Vermeulen S, et al. Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. Lancet Neurol. 2015;14:814&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">26141617</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue MW, Schu M, Vardarajan BN, Farrell J, Lunetta KL, Jun G, et al. A search for genetic risk variants for age-related macular degeneration in Alzheimer disease genes and pathways. Neurobiol Aging. 2014;35:1510.e7&#x2013;e1510.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961547</ArticleId><ArticleId IdType="pubmed">24439028</ArticleId></ArticleIdList></Reference><Reference><Citation>Saftig P, Hartmann D, Lullmann-Rauch R, Wolff J, Evers M, Koster A, et al. Mice deficient in lysosomal acid phosphatase develop lysosomal storage in the kidney and central nervous system. J Biol Chem. 1997;272:18628&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">9228031</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannan AU, Roussa E, Kraus C, Rickmann M, Maenner J, Nayernia K, et al. Mutation in the gene encoding lysosomal acid phosphatase (Acp2) causes cerebellum and skin malformation in mouse. Neurogenetics. 2004;5:229&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">15503243</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlard M, Romero-Portillo F, Germani A, Depaux A, Regnier-Ricard F, Gisselbrecht S, et al. Characterization of VIK-1: a new Vav-interacting Kruppel-like protein. Oncogene. 2005;24:28&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">15558030</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and diseases. Physiol Rev. 2010;90:1337&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975554</ArticleId><ArticleId IdType="pubmed">20959618</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodrich JA, Kugel JF. Non-coding-RNA regulators of RNA polymerase II transcription. Nature Rev Molec Cell Biol. 2006;7:612&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16723972</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler AA, Webb WM, Lubin FD. Regulatory RNAs and control of epigenetic mechanisms: expectations for cognition and cognitive dysfunction. Epigenomics. 2016;8:135&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5514977</ArticleId><ArticleId IdType="pubmed">26366811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciarlo E, Massone S, Penna I, Nizzari M, Gigoni A, Dieci G, et al. An intronic ncRNA-dependent regulation of SORL1 expression affecting A&#x3b2; formation is upregulated in post-mortem Alzheimer's disease brain samples. Dis Model Mech. 2013;6:424&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597024</ArticleId><ArticleId IdType="pubmed">22996644</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DY, Moon J, Lee ST, Jung KH, Park DK, Yoo JS, et al. Distinct expression of long non-coding RNAs in an Alzheimer's disease model. J Alzheimers Dis. 2015;45:837&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">25624420</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B, Acero L, Williams AD, Koeppen HP, Weber A, Schwarz HP, et al. Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry. 2008;47:12254&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18956886</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey JP. Immunoglobulin GM genes as functional risk and protective factors for the development of Alzheimer's disease. J Alzheimers Dis. 2009;17:753&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19542624</ArticleId></ArticleIdList></Reference><Reference><Citation>Adekar SP, Klyubin I, Macy S, Rowan MJ, Solomon A, Dessain SK, et al. Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains. J Biol Chem. 2010;285:1066&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801233</ArticleId><ArticleId IdType="pubmed">19889627</ArticleId></ArticleIdList></Reference><Reference><Citation>He WB, Banerjee S, Meng LL, Du J, Gong F, Huang H, et al. Whole-exome sequencing identifies a homozygous donor splice-site mutation in STAG3 that causes primary ovarian insufficiency. Clin Genet 2018;93-340&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">28393351</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrichs P, Schlotterer A, Sticht C, Kolibabka M, Wohlfart P, Dietrich A, et al. Hyperglycaemic memory affects the neurovascular unit of the retina in a diabetic mouse model. Diabetologia. 2017;60:1354&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28321468</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittaluga A, Feligioni M, Longordo F, Luccini E, Raiteri M. Trafficking of presynaptic AMPA receptors mediating neurotransmitter release: neuronal selectivity and relationships with sensitivity to cyclothiazide. Neuropharmacology. 2006;50:286&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242162</ArticleId></ArticleIdList></Reference><Reference><Citation>Pountney DL, Raftery MJ, Chegini F, Blumbergs PC, Gai WP. NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture. Acta Neuropathol. 2008;116:603&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">18836734</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Castillo N, Cormand B, Roncero C, Sanchez-Mora C, Grau-Lopez L, Gonzalvo B, et al. Candidate pathway association study in cocaine dependence: the control of neurotransmitter release. World J Biol Psychiatry. 2012;13:126&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">21426264</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai C, Sugai T, Iritani S, Niizato K, Nakamura R, Makifuchi T, et al. A quantitative study on the expression of synapsin II and N-ethylmaleimide-sensitive fusion protein in schizophrenic patients. Neurosci Lett. 2001;305:185&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403936</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Cheng R, Rogaeva E, Lee JH, Tokuhiro S, Zou F, et al. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol. 2011;68:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086666</ArticleId><ArticleId IdType="pubmed">21220680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Andersen OM. Sorting receptor SORLA-a trafficking path to avoid Alzheimer disease. J Cell Sci. 2013;126:2751&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23813966</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavioli EC, de Medeiros IU, Monteiro MC, Calo G, Romao PR. Nociceptin/orphanin FQ-NOP receptor system in inflammatory and immune-mediated diseases. Vitam Horm. 2015;97:241&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25677775</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Mouttalib O. Nociceptin/orphanin-FQ modulation of learning and memory. Vitam Horm. 2015;97:323&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">25677778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto R, Noguchi H, Hori H, Nakabayashi T, Suzuki T, Iwata N, et al. A genetic variation in the dysbindin gene (DTNBP1) is associated with memory performance in healthy controls. World J Biol Psychiatry. 2010;11:431&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19353385</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto R, Noguchi H, Hori H, Ohi K, Yasuda Y, Takeda M, et al. Association between the dysbindin gene (DTNBP1) and cognitive functions in Japanese subjects. Psychiatry Clin Neurosci. 2009;63:550&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19496996</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmi H, Idoyaga J, Suda K, Suda N, Kennedy K, Noda M, et al. A new triggering receptor expressed on myeloid cells (Trem) family member, Trem-like 4, binds to dead cells and is a DNAX activation protein 12-linked marker for subsets of mouse macrophages and dendritic cells. J Immunol. 2009;182:1278&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843158</ArticleId><ArticleId IdType="pubmed">19155473</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentrup T, Fluhrer R, Schroder B. Latest emerging functions of SPP/SPPL intramembrane proteases. Eur J Cell Biol. 2017;96:372&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">28366434</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkerk AJ, Schot R, Dumee B, Schellekens K, Swagemakers S, Bertoli-Avella AM, et al. Mutation in the AP4M1 gene provides a model for neuroaxonal injury in cerebral palsy. Am J Hum Genet. 2009;85:40&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706965</ArticleId><ArticleId IdType="pubmed">19559397</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh WH, Tan JZ, Zulkefli KL, Houghton FJ, Gleeson PA. Amyloid precursor protein traffics from the Golgi directly to early endosomes in an Arl5b- and AP4-dependent pathway. Traffic. 2017;18:159&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">28000370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30126037</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-9726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Aging cell</Title><ISOAbbreviation>Aging Cell</ISOAbbreviation></Journal><ArticleTitle>Tau protein aggregation is associated with cellular senescence in the brain.</ArticleTitle><Pagination><StartPage>e12840</StartPage><MedlinePgn>e12840</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e12840</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/acel.12840</ELocationID><Abstract><AbstractText>Tau protein accumulation is the most common pathology among degenerative brain diseases, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), traumatic brain injury (TBI), and over twenty others. Tau-containing neurofibrillary tangle (NFT) accumulation is the closest correlate with cognitive decline and cell loss (Arriagada, Growdon, Hedley-Whyte, &amp; Hyman, ), yet mechanisms mediating tau toxicity are poorly understood. NFT formation does not induce apoptosis (de Calignon, Spires-Jones, Pitstick, Carlson, &amp; Hyman, 2009), which suggests that secondary mechanisms are driving toxicity. Transcriptomic analyses of NFT-containing neurons microdissected from postmortem AD brain revealed an expression profile consistent with cellular senescence. This complex stress response induces aberrant cell cycle activity, adaptations to maintain survival, cellular remodeling, and metabolic dysfunction. Using four AD transgenic mouse models, we found that NFTs, but not A&#x3b2; plaques, display a senescence-like phenotype. Cdkn2a transcript level, a hallmark measure of senescence, directly correlated with brain atrophy and NFT burden in mice. This relationship extended to postmortem brain tissue from humans with PSP to indicate a phenomenon common to tau toxicity. Tau transgenic mice with late-stage pathology were treated with senolytics to remove senescent cells. Despite the advanced age and disease progression, MRI brain imaging and histopathological analyses indicated a reduction in total NFT density, neuron loss, and ventricular enlargement. Collectively, these findings indicate a strong association between the presence of NFTs and cellular senescence in the brain, which contributes to neurodegeneration. Given the prevalence of tau protein deposition among neurodegenerative diseases, these findings have broad implications for understanding, and potentially treating, dozens of brain diseases.</AbstractText><CopyrightInformation>&#xa9; 2018 The Authors. Aging Cell published by the Anatomical Society and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Musi</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>San Antonio Geriatric Research, Education and Clinical Center, South Texas Veterans Health Care System, San Antonio, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valentine</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sickora</LastName><ForeName>Kathryn R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baeuerle</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Cody S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Research Imaging Institute, University of Texas Health Science Center San Antonio, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orr</LastName><ForeName>Miranda E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-0418-2724</Identifier><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>San Antonio Geriatric Research, Education and Clinical Center, South Texas Veterans Health Care System, San Antonio, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, San Antonio, Texas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AG021890</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM113896</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK089229</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-DK089229</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK080157</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG044271</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-DK80157</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>IK2 BX003804</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aging Cell</MedlineTA><NlmUniqueID>101130839</NlmUniqueID><ISSNLinking>1474-9718</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000614131">CDKN2A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C417743">Cdkn2a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9IKM0I5T1E</RegistryNumber><NameOfSubstance UI="D011794">Quercetin</NameOfSubstance></Chemical><Chemical><RegistryNumber>RBZ1571X5H</RegistryNumber><NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016922" MajorTopicYN="Y">Cellular Senescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019941" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011794" MajorTopicYN="N">Quercetin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">cellular senescence</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">senolytic</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30126037</ArticleId><ArticleId IdType="pmc">PMC6260915</ArticleId><ArticleId IdType="doi">10.1111/acel.12840</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arendt, T. (2012). Cell cycle activation and aneuploid neurons in Alzheimer's disease. Molecular Neurobiology, 46(1), 125&#x2013;135. 10.1007/s12035-012-8262-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8262-0</ArticleId><ArticleId IdType="pubmed">22528601</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt, T. , Rodel, L. , Gartner, U. , &amp; Holzer, M. (1996). Expression of the cyclin&#x2010;dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport, 7(18), 3047&#x2013;3049.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116237</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada, P. V. , Growdon, J. H. , Hedley&#x2010;Whyte, E. T. , &amp; Hyman, B. T. (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology, 42(3 Pt 1), 631&#x2013;639. 10.1212/WNL.42.3.631</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.3.631</ArticleId><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker, D. J. , Wijshake, T. , Tchkonia, T. , LeBrasseur, N. K. , Childs, B. G. , van de Sluis, B. , &#x2026; van Deursen, J. M. (2011). Clearance of p16Ink4a&#x2010;positive senescent cells delays ageing&#x2010;associated disorders. Nature, 479(7372), 232&#x2013;236. 10.1038/nature10600</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10600</ArticleId><ArticleId IdType="pmc">PMC3468323</ArticleId><ArticleId IdType="pubmed">22048312</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett, T. , Wilhite, S. E. , Ledoux, P. , Evangelista, C. , Kim, I. F. , Tomashevsky, M. , &#x2026; Soboleva, A. (2013). NCBI GEO: Archive for functional genomics data sets&#x2013;update. Nucleic Acids Researchearch, 41(D1), D991&#x2013;D995. 10.1093/nar/gks1193</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, R. E. , Robbins, A. B. , Hu, M. , Cao, X. , Betensky, R. A. , Clark, T. , &#x2026; Hyman, B. T. (2018). Tau induces blood vessel abnormalities and angiogenesis&#x2010;related gene expression in P301L transgenic mice and human Alzheimer's disease. Proceedings of the National Academy of Sciences USA, 115(6), E1289&#x2013;E1298. 10.1073/pnas.1710329115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710329115</ArticleId><ArticleId IdType="pmc">PMC5819390</ArticleId><ArticleId IdType="pubmed">29358399</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero, B. , Wang, Y. , Diaz, A. , Tasset, I. , Juste, Y. R. , Stiller, B. , &#x2026; Cuervo, A. M. (2018). Interplay of pathogenic forms of human tau with different autophagic pathways. Aging Cell, 17(1), 10.1111/acel.12692</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12692</ArticleId><ArticleId IdType="pmc">PMC5770880</ArticleId><ArticleId IdType="pubmed">29024336</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs, B. G. , Baker, D. J. , Wijshake, T. , Conover, C. A. , Campisi, J. , &amp; van Deursen, J. M. (2016). Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science, 354(6311), 472&#x2013;477. 10.1126/science.aaf6659</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6659</ArticleId><ArticleId IdType="pmc">PMC5112585</ArticleId><ArticleId IdType="pubmed">27789842</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppe, J. P. , Patil, C. K. , Rodier, F. , Krtolica, A. , Beausejour, C. M. , Parrinello, S. , &#x2026; Campisi, J. (2010). A human&#x2010;like senescence&#x2010;associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One, 5(2), e9188 10.1371/journal.pone.0009188</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009188</ArticleId><ArticleId IdType="pmc">PMC2820538</ArticleId><ArticleId IdType="pubmed">20169192</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia&#x2010;Melo, C. , Marques, F. D. , Anderson, R. , Hewitt, G. , Hewitt, R. , Cole, J. , &#x2026; Passos, J. F. (2016). Mitochondria are required for pro&#x2010;ageing features of the senescent phenotype. EMBO Journal, 35(7), 724&#x2013;742. 10.15252/embj.201592862</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201592862</ArticleId><ArticleId IdType="pmc">PMC4818766</ArticleId><ArticleId IdType="pubmed">26848154</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon, A. , Spires&#x2010;Jones, T. L. , Pitstick, R. , Carlson, G. A. , &amp; Hyman, B. T. (2009). Tangle&#x2010;bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. Journal of Neuropathology and Experimental Neurology, 68(7), 757&#x2013;761. 10.1097/NEN.0b013e3181a9fc66</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181a9fc66</ArticleId><ArticleId IdType="pmc">PMC2756569</ArticleId><ArticleId IdType="pubmed">19535996</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimri, G. P. , Lee, X. , Basile, G. , Acosta, M. , Scott, G. , Roskelley, C. , et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proceedings of the National Academy of Sciences USA, 92(20), 9363&#x2013;9367. 10.1073/pnas.92.20.9363</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.20.9363</ArticleId><ArticleId IdType="pmc">PMC40985</ArticleId><ArticleId IdType="pubmed">7568133</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunckley, T. , Beach, T. G. , Ramsey, K. E. , Grover, A. , Mastroeni, D. , Walker, D. G. , &#x2026; Stephan, D. A. (2006). Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiology of Aging, 27(10), 1359&#x2013;1371. 10.1016/j.neurobiolaging.2005.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.08.013</ArticleId><ArticleId IdType="pmc">PMC2259291</ArticleId><ArticleId IdType="pubmed">16242812</ArticleId></ArticleIdList></Reference><Reference><Citation>Flament, S. , Delacourte, A. , Verny, M. , Hauw, J. J. , &amp; Javoy&#x2010;Agid, F. (1991). Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathologica, 81(6), 591&#x2013;596. 10.1007/BF00296367</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00296367</ArticleId><ArticleId IdType="pubmed">1831952</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost, B. , Bardai, F. H. , &amp; Feany, M. B. (2016). Lamin dysfunction mediates neurodegeneration in Tauopathies. Current Biology, 26(1), 129&#x2013;136. 10.1016/j.cub.2015.11.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2015.11.039</ArticleId><ArticleId IdType="pmc">PMC4713335</ArticleId><ArticleId IdType="pubmed">26725200</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbig, U. , Ferreira, M. , Condel, L. , Carey, D. , &amp; Sedivy, J. M. (2006). Cellular senescence in aging primates. Science, 311(5765), 1257 10.1126/science.1122446</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1122446</ArticleId><ArticleId IdType="pubmed">16456035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover, B. R. , Reed, M. N. , Su, J. , Penrod, R. D. , Kotilinek, L. A. , Grant, M. K. , &#x2026; Liao, D. (2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron, 68(6), 1067&#x2013;1081. 10.1016/j.neuron.2010.11.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.030</ArticleId><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutter, E. , Renner, K. , Pfister, G. , Stockl, P. , Jansen&#x2010;Durr, P. , &amp; Gnaiger, E. (2004). Senescence&#x2010;associated changes in respiration and oxidative phosphorylation in primary human fibroblasts. Biochemical Journal, 380(Pt 3), 919&#x2013;928. 10.1042/BJ20040095</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20040095</ArticleId><ArticleId IdType="pmc">PMC1224220</ArticleId><ArticleId IdType="pubmed">15018610</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurk, D. , Wang, C. , Miwa, S. , Maddick, M. , Korolchuk, V. , Tsolou, A. , &#x2026; von Zglinicki, T. (2012). Postmitotic neurons develop a p21&#x2010;dependent senescence&#x2010;like phenotype driven by a DNA damage response. Aging Cell, 11(6), 996&#x2013;1004. 10.1111/j.1474-9726.2012.00870.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2012.00870.x</ArticleId><ArticleId IdType="pmc">PMC3533793</ArticleId><ArticleId IdType="pubmed">22882466</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkland, J. L. , Tchkonia, T. , Zhu, Y. , Niedernhofer, L. J. , &amp; Robbins, P. D. (2017). The clinical potential of senolytic drugs. Journal of the American Geriatrics Society, 65(10), 2297&#x2013;2301. 10.1111/jgs.14969</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14969</ArticleId><ArticleId IdType="pmc">PMC5641223</ArticleId><ArticleId IdType="pubmed">28869295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer, A. , Green, J. , Pollard, J. Jr , &amp; Tugendreich, S. (2014). Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics, 30(4), 523&#x2013;530. 10.1093/bioinformatics/btt703</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt703</ArticleId><ArticleId IdType="pmc">PMC3928520</ArticleId><ArticleId IdType="pubmed">24336805</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent, C. , Buee, L. , &amp; Blum, D. (2018). Tau and neuroinflammation: What impact for Alzheimer's disease and Tauopathies? Biomed J, 41(1), 21&#x2013;33. 10.1016/j.bj.2018.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2018.01.003</ArticleId><ArticleId IdType="pmc">PMC6138617</ArticleId><ArticleId IdType="pubmed">29673549</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, R. , &amp; Shen, Y. (2013). An old method facing a new challenge: Re&#x2010;visiting housekeeping proteins as internal reference control for neuroscience research. Life Sciences, 92(13), 747&#x2013;751. 10.1016/j.lfs.2013.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2013.02.014</ArticleId><ArticleId IdType="pmc">PMC3614345</ArticleId><ArticleId IdType="pubmed">23454168</ArticleId></ArticleIdList></Reference><Reference><Citation>Makrecka&#x2010;Kuka, M. , Krumschnabel, G. , &amp; Gnaiger, E. (2015). High&#x2010;resolution respirometry for simultaneous measurement of oxygen and hydrogen peroxide fluxes in permeabilized cells, tissue homogenate and isolated mitochondria. Biomolecules, 5(3), 1319&#x2013;1338. 10.3390/biom5031319</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom5031319</ArticleId><ArticleId IdType="pmc">PMC4598754</ArticleId><ArticleId IdType="pubmed">26131977</ArticleId></ArticleIdList></Reference><Reference><Citation>Moritz, C. P. (2017). Tubulin or not tubulin: Heading toward total protein staining as loading control in Western Blots. Proteomics, 17(20), 1600189&#x2013;1600200. 10.1002/pmic.201600189</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201600189</ArticleId><ArticleId IdType="pubmed">28941183</ArticleId></ArticleIdList></Reference><Reference><Citation>Morsch, R. , Simon, W. , &amp; Coleman, P. D. (1999). Neurons may live for decades with neurofibrillary tangles. Journal of Neuropathology and Experimental Neurology, 58(2), 188&#x2013;197. 10.1097/00005072-199902000-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199902000-00008</ArticleId><ArticleId IdType="pubmed">10029101</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir, E. R. , Shen, Q. , &amp; Duong, T. Q. (2008). Cerebral blood flow MRI in mice using the cardiac&#x2010;spin&#x2010;labeling technique. Magnetic Resonance in Medicine, 60(3), 744&#x2013;748. 10.1002/mrm.21721</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.21721</ArticleId><ArticleId IdType="pmc">PMC2581653</ArticleId><ArticleId IdType="pubmed">18727091</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilson, A. N. , English, K. C. , Gerson, J. E. , Barton Whittle, T. , Nicolas Crain, C. , Xue, J. , &#x2026; Kayed, R. (2017). Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases. Journal of Alzheimer's Disease, 55(3), 1083&#x2013;1099. 10.3233/JAD-160912</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160912</ArticleId><ArticleId IdType="pmc">PMC5147514</ArticleId><ArticleId IdType="pubmed">27716675</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo, S. , Caccamo, A. , Shepherd, J. D. , Murphy, M. P. , Golde, T. E. , Kayed, R. , &#x2026; LaFerla, F. M. (2003). Triple&#x2010;transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron, 39(3), 409&#x2013;421. 10.1016/S0896-6273(03)00434-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogrodnik, M. , Miwa, S. , Tchkonia, T. , Tiniakos, D. , Wilson, C. L. , Lahat, A. , &#x2026; Jurk, D. (2017). Cellular senescence drives age&#x2010;dependent hepatic steatosis. Nature Communications, 8, 15691 10.1038/ncomms15691</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15691</ArticleId><ArticleId IdType="pmc">PMC5474745</ArticleId><ArticleId IdType="pubmed">28608850</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr, M. E. , Garbarino, V. R. , Salinas, A. , &amp; Buffenstein, R. (2015). Sustained high levels of neuroprotective, high molecular weight, phosphorylated tau in the longest&#x2010;lived rodent. Neurobiology of Aging, 36(3), 1496&#x2013;1504. 10.1016/j.neurobiolaging.2014.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.12.004</ArticleId><ArticleId IdType="pmc">PMC4869521</ArticleId><ArticleId IdType="pubmed">25576082</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr, M. E. , Pitstick, R. , Canine, B. , Ashe, K. H. , &amp; Carlson, G. A. (2012). Genotype&#x2010;specific differences between mouse CNS stem cell lines expressing frontotemporal dementia mutant or wild type human tau. PLoS One, 7(6), e39328 10.1371/journal.pone.0039328</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039328</ArticleId><ArticleId IdType="pmc">PMC3377636</ArticleId><ArticleId IdType="pubmed">22723997</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr, M. E. , Salinas, A. , Buffenstein, R. , &amp; Oddo, S. (2014). Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. Neurobiology of Aging, 35(6), 1233&#x2013;1242. 10.1016/j.neurobiolaging.2013.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.12.006</ArticleId><ArticleId IdType="pmc">PMC3973159</ArticleId><ArticleId IdType="pubmed">24411482</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr, M. E. , Sullivan, A. C. , &amp; Frost, B. (2017). A brief overview of tauopathy: Causes, consequences, and therapeutic strategies. Trends in Pharmacological Sciences, 38(7), 637&#x2013;648. 10.1016/j.tips.2017.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2017.03.011</ArticleId><ArticleId IdType="pmc">PMC5476494</ArticleId><ArticleId IdType="pubmed">28455089</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, K. H. , Hallows, J. L. , Chakrabarty, P. , Davies, P. , &amp; Vincent, I. (2007). Conditional neuronal simian virus 40 T antigen expression induces Alzheimer&#x2010;like tau and amyloid pathology in mice. Journal of Neuroscience, 27(11), 2969&#x2013;2978. 10.1523/JNEUROSCI.0186-07.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0186-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672567</ArticleId><ArticleId IdType="pubmed">17360920</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesta, D. , Hoppel, F. , Macek, C. , Messner, H. , Faulhaber, M. , Kobel, C. , &#x2026; Gnaiger, E. (2011). Similar qualitative and quantitative changes of mitochondrial respiration following strength and endurance training in normoxia and hypoxia in sedentary humans. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 301(4), R1078&#x2013;R1087. 10.1152/ajpregu.00285.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00285.2011</ArticleId><ArticleId IdType="pubmed">21775647</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins, N. D. , &amp; Scheltens, P. (2015). White matter hyperintensities, cognitive impairment and dementia: An update. Nature Reviews. Neurology, 11(3), 157&#x2013;165. 10.1038/nrneurol.2015.10</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.10</ArticleId><ArticleId IdType="pubmed">25686760</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodier, F. , Coppe, J. P. , Patil, C. K. , Hoeijmakers, W. A. , Munoz, D. P. , Raza, S. R. , &#x2026; Campisi, J. (2009). Persistent DNA damage signalling triggers senescence&#x2010;associated inflammatory cytokine secretion. Nature Cell Biology, 11(8), 973&#x2013;979. 10.1038/ncb1909</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1909</ArticleId><ArticleId IdType="pmc">PMC2743561</ArticleId><ArticleId IdType="pubmed">19597488</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen, A. , &amp; Kaarniranta, K. (2011). Control of p53 and NF&#x2010;kappaB signaling by WIP1 and MIF: Role in cellular senescence and organismal aging. Cellular Signalling, 23(5), 747&#x2013;752. 10.1016/j.cellsig.2010.10.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2010.10.012</ArticleId><ArticleId IdType="pubmed">20940041</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz, K. , Lewis, J. , Spires, T. , Paulson, J. , Kotilinek, L. , Ingelsson, M. , &#x2026; Ashe, K. H. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science, 309(5733), 476&#x2013;481. 10.1126/science.1113694</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1113694</ArticleId><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedelnikova, O. A. , Horikawa, I. , Zimonjic, D. B. , Popescu, N. C. , Bonner, W. M. , &amp; Barrett, J. C. (2004). Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double&#x2010;strand breaks. Nature Cell Biology, 6(2), 168&#x2013;170. 10.1038/ncb1095</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1095</ArticleId><ArticleId IdType="pubmed">14755273</ArticleId></ArticleIdList></Reference><Reference><Citation>Severino, J. , Allen, R. G. , Balin, S. , Balin, A. , &amp; Cristofalo, V. J. (2000). Is beta&#x2010;galactosidase staining a marker of senescence in vitro and in vivo? Experimental Cell Research, 257(1), 162&#x2013;171. 10.1006/excr.2000.4875</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/excr.2000.4875</ArticleId><ArticleId IdType="pubmed">10854064</ArticleId></ArticleIdList></Reference><Reference><Citation>Seward, M. E. , Swanson, E. , Norambuena, A. , Reimann, A. , Cochran, J. N. , Li, R. , &#x2026; Bloom, G. S. (2013). Amyloid&#x2010;beta signals through tau to drive ectopic neuronal cell cycle re&#x2010;entry in Alzheimer's disease. Journal of Cell Science, 126(Pt 5), 1278&#x2013;1286. 10.1242/jcs.1125880</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.1125880</ArticleId><ArticleId IdType="pmc">PMC3635465</ArticleId><ArticleId IdType="pubmed">23345405</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen, Q. , Huang, S. , &amp; Duong, T. Q. (2015). Ultra&#x2010;high spatial resolution basal and evoked cerebral blood flow MRI of the rat brain. Brain Research, 1599, 126&#x2013;136. 10.1016/j.brainres.2014.12.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.12.049</ArticleId><ArticleId IdType="pmc">PMC4366194</ArticleId><ArticleId IdType="pubmed">25557404</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert, L. C. , Quinn, J. F. , Moore, M. M. , Corbridge, E. , Ball, M. J. , Murdoch, G. , &#x2026; Kaye, J. A. (2003). Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology, 61(4), 487&#x2013;492. 10.1212/01.WNL.0000079053.77227.14</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000079053.77227.14</ArticleId><ArticleId IdType="pubmed">12939422</ArticleId></ArticleIdList></Reference><Reference><Citation>Strupp, J. P. (1996). Stimulate: A GUI based fMRI analysis software package. Neuroimage, 3(3), S607.</Citation></Reference><Reference><Citation>Wang, L. , Li, C. , Sun, Q. , Xia, D. , &amp; Kao, C. Y. (2009). Active contours driven by local and global intensity fitting energy with application to brain MR image segmentation. Computerized Medical Imaging and Graphics, 33(7), 520&#x2013;531. 10.1016/j.compmedimag.2009.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compmedimag.2009.04.010</ArticleId><ArticleId IdType="pubmed">19482457</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. , Martinez&#x2010;Vicente, M. , Kruger, U. , Kaushik, S. , Wong, E. , Mandelkow, E. M. , &#x2026; Mandelkow, E. (2009). Tau fragmentation, aggregation and clearance: The dual role of lysosomal processing. Human Molecular Genetics, 18(21), 4153&#x2013;4170. 10.1093/hmg/ddp367</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp367</ArticleId><ArticleId IdType="pmc">PMC2758146</ArticleId><ArticleId IdType="pubmed">19654187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann, S. , Maury, E. A. , Kirk, M. J. , Saqran, L. , Roe, A. , DeVos, S. L. , &#x2026; Hyman, B. T. (2015). Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO Journal, 34(24), 3028&#x2013;3041. 10.15252/embj.201592748</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201592748</ArticleId><ArticleId IdType="pmc">PMC4687785</ArticleId><ArticleId IdType="pubmed">26538322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells, J. A. , O'Callaghan, J. M. , Holmes, H. E. , Powell, N. M. , Johnson, R. A. , Siow, B. , &#x2026; Lythgoe, M. F. (2015). In vivo imaging of tau pathology using multi&#x2010;parametric quantitative MRI. Neuroimage, 111, 369&#x2013;378. 10.1016/j.neuroimage.2015.02.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2015.02.023</ArticleId><ArticleId IdType="pmc">PMC4626540</ArticleId><ArticleId IdType="pubmed">25700953</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, Y. , Tchkonia, T. , Pirtskhalava, T. , Gower, A. C. , Ding, H. , Giorgadze, N. , &#x2026; Kirkland, J. L. (2015). The Achilles' heel of senescent cells: From transcriptome to senolytic drugs. Aging Cell, 14(4), 644&#x2013;658. 10.1111/acel.12344</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12344</ArticleId><ArticleId IdType="pmc">PMC4531078</ArticleId><ArticleId IdType="pubmed">25754370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30134156</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Living Neurons with Tau Filaments Aberrantly Expose Phosphatidylserine and Are Phagocytosed by Microglia.</ArticleTitle><Pagination><StartPage>1939</StartPage><EndPage>1948.e4</EndPage><MedlinePgn>1939-1948.e4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2018.07.072</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(18)31190-2</ELocationID><Abstract><AbstractText>Tau protein forms insoluble filamentous inclusions that are closely associated with nerve cell death in many neurodegenerative diseases. How neurons die in these tauopathies is unclear. We report that living neurons with tau inclusions from P301S-tau mice expose abnormally high amounts of phosphatidylserine because of the production of reactive oxygen species (ROS). Consequently, co-cultured phagocytes (BV2 cells or primary microglia) identify and phagocytose the living neurons, thereby engulfing insoluble tau inclusions. To facilitate engulfment, neurons induce contacting microglia to secrete the opsonin milk-fat-globule EGF-factor-8 (MFGE8) and nitric oxide (NO), whereas neurons with tau inclusions are rescued when MFGE8 or NO production is prevented. MFGE8 expression is elevated in transgenic P301S-tau mouse brains with tau inclusions and in tau inclusion-rich brain regions of several human tauopathies, indicating shared mechanisms of disease. Preventing phagocytosis of living neurons will preserve them for treatments that inhibit tau aggregation and toxicity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brelstaff</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tolkovsky</LastName><ForeName>Aviva M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge, CB2 0AH, UK. Electronic address: amt1004@cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spillantini</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge, CB2 0AH, UK. Electronic address: mgs11@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NC/L000741/1</GrantID><Acronym>NC3RS_</Acronym><Agency>National Centre for the Replacement, Refinement and Reduction of Animals in Research</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010718">Phosphatidylserines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010718" MajorTopicYN="N">Phosphatidylserines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MFGE8</Keyword><Keyword MajorTopicYN="N">cell death</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">nitric oxide</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword><Keyword MajorTopicYN="N">phosphatidylserine</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">tauopathies</Keyword></KeywordList><CoiStatement>DECLARATION OF INTERESTS. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30134156</ArticleId><ArticleId IdType="mid">NIHMS1505383</ArticleId><ArticleId IdType="pmc">PMC6161320</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.07.072</ArticleId><ArticleId IdType="pii">S2211-1247(18)31190-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Barres BA, and Bennett ML (2013). Microglia: scapegoat, saboteur, or something else? Science 330, 156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431634</ArticleId><ArticleId IdType="pubmed">23307732</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, et al. (2002). Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano K, Miwa M, Miwa K, Hanayama R, Nagase H, Nagata S, and Tanaka M (2004). Masking of phosphatidylserine inhibits apoptotic cell engulf- ment and induces autoantibody production in mice. J. Exp. Med. 200, 459&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211927</ArticleId><ArticleId IdType="pubmed">15302904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, and Spill- antini MG (2004). Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol. 165,&gt;1643&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618683</ArticleId><ArticleId IdType="pubmed">15509534</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A, Bugiani O, Ghetti B, and Spillantini MG (2011). Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener. Dis. 8,&gt; 221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3214942</ArticleId><ArticleId IdType="pubmed">21212632</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche D, Perry VH, and Nicoll JA (2013). Review: activation patterns of microglia and their identification in the human brain. Neuropathol. Appl. Neuro- biol. 39,&gt; 3&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">23252647</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddaert J, Kinugawa K, Lambert JC, Boukhtouche F, Zoll J, Merval R, Blanc-Brude O, Mann D, Berr C, Vilar J, et al. (2007). Evidence of a role for lactadherin in Alzheimer&#x2019;s disease. Am. J. Pathol. 170,&gt; 921&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864868</ArticleId><ArticleId IdType="pubmed">17322377</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#xf3;s M, Llorens-Martin M, Jurado-Arjona J, Hern&#xe1;ndez F, R&#xe1;bano A, and Avila J (2016). Direct evidence of internalization of tau by microglia in vitro and in vivo. J. Alzheimers Dis. 50, 77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">26638867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#xf3;s M, Perea JR, and Avila J (2017). Alzheimer&#x2019;s disease as an inflammatory disease. Biomol. Concepts 8, 37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">28231054</ArticleId></ArticleIdList></Reference><Reference><Citation>Brelstaff J, Ossola B, Neher JJ, Klingstedt T, Nilsson KP, Goedert M, Spillantini MG, and Tolkovsky AM (2015a). The fluorescent pentameric oli- gothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. Front. Neurosci. 9, 184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4448042</ArticleId><ArticleId IdType="pubmed">26074756</ArticleId></ArticleIdList></Reference><Reference><Citation>Brelstaff J, Spillantini MG, and Tolkovsky AM (2015b). pFTAA: a high affinity oligothiophene probe that detects filamentous tau in vivo and in cultured neurons. Neural Regen. Res. 10, 1746&#x2013;1747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4705778</ArticleId><ArticleId IdType="pubmed">26807101</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GC, and Neher JJ (2014). Microglial phagocytosis of live neurons. Nat. Rev. Neurosci. 15, 209&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">24646669</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GC, Vilalta A, and Fricker M (2015). Phagoptosis&#x2014;cell death by phagocytosis-plays central roles in physiology, host defense and pathology. Curr. Mol. Med. 15, 842&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">26511705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugiani O, Murrell JR, Giaccone G, Hasegawa M, Ghigo G, Tabaton M, Morbin M, Primavera A, Carella F, Solaro C, et al. (1999). Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J. Neuropathol. Exp. Neurol. 58, 667&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">10374757</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, and Karran E (2016). The cellular phase of Alzheimer&#x2019;s disease. Cell 164, 603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, Hitomi J, Germscheid M, Ch&#x2019;en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, et al. (2008). Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4,313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434866</ArticleId><ArticleId IdType="pubmed">18408713</ArticleId></ArticleIdList></Reference><Reference><Citation>Delobel P, Lavenir I, Fraser G, Ingram E, Holzer M, Ghetti B, Spillantini MG, Crowther RA, and Goedert M (2008). Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am. J. Pathol. 172, 123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2189621</ArticleId><ArticleId IdType="pubmed">18079436</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, and Stam FC (1982). Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 57, 239&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">6812382</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, and Nagata S (2002). Identification of afactorthat linksapoptotic cellsto phagocytes. Nature 417, 182&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">12000961</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornik TC, Vilalta A, and Brown GC (2016). Activated microglia cause reversible apoptosis of pheochromocytoma cells, inducing their cell death by phagocytosis. J. Cell Sci. 129,&gt; 65&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4732292</ArticleId><ArticleId IdType="pubmed">26567213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, et al. (1998). Association of missenseand 50-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Jebelli J, Piers T, and Pocock J (2015). Selective depletion of microglia from cerebellar granule cell cultures using L-leucine methyl ester. J. Vis. Exp. (101), e52983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545156</ArticleId><ArticleId IdType="pubmed">26275019</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen HL, and Horvitz HR (2016). Both the apoptotic suicide pathway and phagocytosis are required for a programmed cell death in Caenorhabditis elegans. BMC Biol. 14, 39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867531</ArticleId><ArticleId IdType="pubmed">27185172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki H, Murayama S, Tomonaga M, Izumiyama N, and Shimada H (1987). Neurofibrillary tangles in human upper cervical ganglia. Morphological study with immunohistochemistry and electron microscopy. Acta Neuropa- thol. 75, 156&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">3434223</ArticleId></ArticleIdList></Reference><Reference><Citation>Krahling S, Callahan MK, Williamson P, and Schlegel RA (1999). Exposure of phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes by macrophages. Cell Death Differ. 6, 183&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">10200565</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranich J, Krautler NJ, Falsig J, Ballmer B, Li S, Hutter G, Schwarz P, Moos R, Julius C, Miele G, and Aguzzi A (2010). Engulfment of cerebral apoptotic bodies controls the course of prion disease in a mouse strain- dependent manner. J. Exp. Med. 207, 2271&#x2013;2281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947076</ArticleId><ArticleId IdType="pubmed">20837697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagos-Cabr&#xe9; R, Alvarez A, Kong M, Burgos-Bravo F, C&#xe1;rdenas A, Rojas-Mancilla E, P&#xe9;rez-Nu&#xf1;ez R, Herrera-Molina R, Rojas F, Schneider P, et al. (2017). &#x3b1;v&#x3b2;3 Integrin regulates astrocyte reactivity. J. Neuroinflammation 14, 194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5622429</ArticleId><ArticleId IdType="pubmed">28962574</ArticleId></ArticleIdList></Reference><Reference><Citation>Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, Lamb BT, and Bhaskar K (2015). Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain 138, 1738&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542622</ArticleId><ArticleId IdType="pubmed">25833819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellone M, Kestoras D, Andrews MR, Dassie E, Crowther RA, Stokin GB, Tinsley J, Horne G, Goedert M, Tolkovsky AM, and Spillantini MG (2013). Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies. J. Neurosci. 33, 18175&#x2013;18189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3828468</ArticleId><ArticleId IdType="pubmed">24227726</ArticleId></ArticleIdList></Reference><Reference><Citation>Merino MM, Rhiner C, Lopez-Gay JM, Buechel D, Hauert B, and Moreno E (2015). Elimination of unfit cells maintains tissue health and prolongs lifespan. Cell 160, 461&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313366</ArticleId><ArticleId IdType="pubmed">25601460</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Murrell JR, Gearing M, Spillantini MG, Goedert M, Crowther RA, Levey AI, Jones R, Green J, Shoffner JM, et al. (1999). Tau pathology in a family with dementia and a P301L mutation in tau. J. Neuropathol. Exp. Neurol. 58, 335&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218629</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata S, Suzuki J, Segawa K, and Fujii T (2016). Exposure of phospha tidylserine on the cell surface. Cell Death Differ. 23, 952&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987739</ArticleId><ArticleId IdType="pubmed">26891692</ArticleId></ArticleIdList></Reference><Reference><Citation>Neher JJ, Neniskyte U, Zhao JW, Bal-Price A, Tolkovsky AM, and Brown GC (2011). Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J. Immunol. 186,&gt; 4973&#x2013;4983.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402900</ArticleId></ArticleIdList></Reference><Reference><Citation>Neher JJ, Emmrich JV, Fricker M, Mander PK, Thery C, and Brown GC (2013). Phagocytosis executes delayed neuronal death after focal brain ischemia. Proc. Natl. Acad. Sci. USA 110,&gt; E4098&#x2013;E4107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3808587</ArticleId><ArticleId IdType="pubmed">24101459</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura M, Namba Y, Ikeda K, Akiguchi I, and Oda M (1993). Neurofibrillary tangles in the neurons of spinal dorsal root ganglia of patients with progressive supranuclear palsy. Acta Neuropathol. 85, 453&#x2013;457</Citation><ArticleIdList><ArticleId IdType="pubmed">8388145</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, G&#xf6;tz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T, Lee VM, Trojanowski JQ, et al. (2000). Axonopathy and amyotrophy in micetransgenicfor human four-repeat tau protein. Acta Neuro- pathol. 99, 469&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805089</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothlin CV, Carrera-Silva EA, Bosurgi L, and Ghosh S (2015). TAM receptor signaling in immune homeostasis. Annu. Rev. Immunol. 33, 355&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491918</ArticleId><ArticleId IdType="pubmed">25594431</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, and Stevens B (2017). Microglia emerge as central players in brain disease. Nat. Med. 23, 1018&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar A, Sengupta D, Mandal S, Sen G, DuttaChowdhury K, and Chandra Sadhukhan G (2015).Treatment with garlic restores membrane thiol content and ameliorates lead induced earlydeath oferythrocytes in mice. Environ. Toxicol. 30, 396&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">23997012</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada M, Suzumura A, Yamamoto H, and Marunouchi T (1990). Activation and proliferation of the isolated microglia by colony stimulating factor-1 and possible involvement of protein kinase C. Brain Res. 509, 119&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">2306629</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber R, Ousingsawat J, Wanitchakool P, Sirianant L, Benedetto R, Reiss K, and Kunzelmann K (2018). Regulation of TMEM16A/ANO1 and TMEM16F/ANO6 ion currents and phospholipid scrambling by Ca2+ and plasma membrane lipid. J. Physiol. 596, 217&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5767690</ArticleId><ArticleId IdType="pubmed">29134661</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestre JS, Thery C, Hamard G, Boddaert J, Aguilar B, Delcayre A, Houbron C, Tamarat R, Blanc-Brude O, Heeneman S, et al. (2005). Lac- tadherin promotes VEGF-dependent neovascularization. Nat. Med. 11, 499&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834428</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhrao SK, Neal JW, Gasque P, Morgan BP, and Newman GR (1996). Roleofcomplementinthe aetiologyofPick&#x2019;sdisease? J. Neuropathol. Exp. Neurol. 55, 578&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">8627348</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, and Green KN (2017). Inflammation in Alzheimer&#x2019;s disease: Lessons learned from microglia-depletion models. Brain Behav. Immun. 61, 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218993</ArticleId><ArticleId IdType="pubmed">27395435</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, and Goedert M (2013). Tau pathology and neurodegeneration. Lancet Neurol. 12, 609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, and Ghetti B (1997). Familial multiplesystem tauopathywith preseniledementia: a disease with abundant neuronal and glial tau filaments. Proc. Natl. Acad. Sci. USA 94,&gt; 4113&#x2013;4118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20577</ArticleId><ArticleId IdType="pubmed">9108114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S, Schubert D, and Maher P (2001). Oxytosis: a novel form of programmed cell death. Curr. Top. Med. Chem. 1, 497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">11895126</ArticleId></ArticleIdList></Reference><Reference><Citation>Trouplin V, Boucherit N, Gorvel L, Conti F, Mottola G, and Ghigo E (2013). Bone marrow-derived macrophage production. J. Vis. Exp. (81), e50966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991821</ArticleId><ArticleId IdType="pubmed">24300014</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyurin VA, Balasubramanian K, Winnica D, Tyurina YY, Vikulina AS, He RR, Kapralov AA, Macphee CH, and Kagan VE (2014). Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic &#x2018;eat-me&#x2019; signals: cleavage and inhibition of phagocytosis by Lp-PLA2. Cell Death Differ. 21, 825&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978307</ArticleId><ArticleId IdType="pubmed">24464221</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang WS, and Stockwell BR (2016). Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26, 165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4764384</ArticleId><ArticleId IdType="pubmed">26653790</ArticleId></ArticleIdList></Reference><Reference><Citation>Zargarian S, Shlomovitz I, Erlich Z, Hourizadeh A, Ofir-Birin Y, Croker BA, Regev-Rudzki N, Edry-Botzer L, and Gerlic M (2017). Phosphatidyl- serine externalization, &#x2018;&#x2018;necroptotic bodies&#x2019;&#x2019; release, and phagocytosis during necroptosis. PLoS Biol. 15,&gt; e2002711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501695</ArticleId><ArticleId IdType="pubmed">28650960</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30125269</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1696</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature biotechnology</Title><ISOAbbreviation>Nat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells.</ArticleTitle><Pagination><StartPage>865</StartPage><EndPage>874</EndPage><MedlinePgn>865-874</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nbt.4226</ELocationID><Abstract><AbstractText>The neurovascular unit (NVU) regulates metabolic homeostasis as well as drug pharmacokinetics and pharmacodynamics in the central nervous system. Metabolic fluxes and conversions over the NVU rely on interactions between brain microvascular endothelium, perivascular pericytes, astrocytes and neurons, making it difficult to identify the contributions of each cell type. Here we model the human NVU using microfluidic organ chips, allowing analysis of the roles of individual cell types in NVU functions. Three coupled chips model influx across the blood-brain barrier (BBB), the brain parenchymal compartment and efflux across the BBB. We used this linked system to mimic the effect of intravascular administration of the psychoactive drug methamphetamine and to identify previously unknown metabolic coupling between the BBB and neurons. Thus, the NVU system offers an in vitro approach for probing transport, efficacy, mechanism of action and toxicity of neuroactive drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maoz</LastName><ForeName>Ben M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Disease Biophysics Group, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Faculty of Engineering, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herland</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Micro and Nanosystems, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swedish Medical Nanoscience Center, Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>FitzGerald</LastName><ForeName>Edward A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-0603-1241</Identifier><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grevesse</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Disease Biophysics Group, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidoudez</LastName><ForeName>Charles</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0953-7800</Identifier><AffiliationInfo><Affiliation>Small Molecule Mass Spectrometry Facility, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacheco</LastName><ForeName>Alan R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Bioinformatics and Biological Design Center, Boston University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheehy</LastName><ForeName>Sean P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Disease Biophysics Group, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Tae-Eun</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dauth</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Biophysics Group, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mannix</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vascular Biology Program and Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budnik</LastName><ForeName>Nikita</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Biophysics Group, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shores</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Disease Biophysics Group, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Disease Biophysics Group, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nawroth</LastName><ForeName>Janna C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Disease Biophysics Group, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segr&#xe8;</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4859-1914</Identifier><AffiliationInfo><Affiliation>Graduate Program in Bioinformatics and Biological Design Center, Boston University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Department of Biomedical Engineering, Department of Physics, Boston University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budnik</LastName><ForeName>Bogdan</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-3622-2003</Identifier><AffiliationInfo><Affiliation>Mass Spectrometry and Proteomics Resource Laboratory, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingber</LastName><ForeName>Donald E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vascular Biology Program and Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Kevin Kit</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Disease Biophysics Group, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS072030</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Biotechnol</MedlineTA><NlmUniqueID>9604648</NlmUniqueID><ISSNLinking>1087-0156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>44RAL3456C</RegistryNumber><NameOfSubstance UI="D008694">Methamphetamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056656" MajorTopicYN="Y">Lab-On-A-Chip Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008694" MajorTopicYN="N">Methamphetamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30125269</ArticleId><ArticleId IdType="mid">NIHMS1769272</ArticleId><ArticleId IdType="pmc">PMC9254231</ArticleId><ArticleId IdType="doi">10.1038/nbt.4226</ArticleId><ArticleId IdType="pii">nbt.4226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banks WA From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat. Rev. Drug Discov. 15, 275&#x2013;292 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26794270</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh Y &amp; Suzuki N Control of brain capillary blood flow. J. Cereb. Blood Flow Metab. 32, 1167&#x2013;1176 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390803</ArticleId><ArticleId IdType="pubmed">22293984</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ &amp; Allaman I A cellular perspective on brain energy metabolism and functional imaging. Neuron 86, 883&#x2013;901 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25996133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecrux C &amp; Hamel E The neurovascular unit in brain function and disease. Acta Physiol. (Oxf.) 203, 47&#x2013;59 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21272266</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilopoulou CG, Margarity M &amp; Klapa MI Metabolomic analysis in brain research: opportunities and challenges. Front. Physiol. 7, 183 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878281</ArticleId><ArticleId IdType="pubmed">27252656</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren MS et al. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol. Res. 59, 404&#x2013;413 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19429473</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik P &amp; Cucullo L In vitro blood-brain barrier models: current and perspective technologies. J. Pharm. Sci. 101, 1337&#x2013;1354 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288147</ArticleId><ArticleId IdType="pubmed">22213383</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth R &amp; Kim H Characterization of a microfluidic in vitro model of the blood-brain barrier (&#xb5;BBB). Lab Chip 12, 1784&#x2013;1792 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22422217</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhakarpandian B et al. SyM-BBB: a microfluidic blood brain barrier model. Lab Chip 13, 1093&#x2013;1101 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613157</ArticleId><ArticleId IdType="pubmed">23344641</ArticleId></ArticleIdList></Reference><Reference><Citation>Griep LM et al. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed. Microdevices 15, 145&#x2013;150 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22955726</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JA et al. Recreating blood-brain barrier physiology and structure on chip: A novel neurovascular microfluidic bioreactor. Biomicrofluidics 9, 054124 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627929</ArticleId><ArticleId IdType="pubmed">26576206</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JA et al. Metabolic consequences of inflammatory disruption of the blood-brain barrier in an organ-on-chip model of the human neurovascular unit. J. Neuroinflammation 13, 306 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5153753</ArticleId><ArticleId IdType="pubmed">27955696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballabh P, Braun A &amp; Nedergaard M The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1&#x2013;13 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15207256</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA et al. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer&#x2019;s disease. Peptides 23, 2223&#x2013;2226 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12535702</ArticleId></ArticleIdList></Reference><Reference><Citation>Easton AS &amp; Fraser PA Variable restriction of albumin diffusion across inflamed cerebral microvessels of the anaesthetized rat. J. Physiol. (Lond.) 475, 147&#x2013;157 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160362</ArticleId><ArticleId IdType="pubmed">8189387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Nelson AR, Betsholtz C &amp; Zlokovic BV Establishment and dysfunction of the blood-brain barrier. Cell 163, 1064&#x2013;1078 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655822</ArticleId><ArticleId IdType="pubmed">26590417</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacques PF et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 7&#x2013;9 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8616944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridley AJ Rho GTPases and cell migration. J. Cell Sci. 114, 2713&#x2013;2722 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11683406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneh-Barkay D &amp; Wiley CA Brain extracellular matrix in neurodegeneration. Brain Pathol. 19, 573&#x2013;585 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742568</ArticleId><ArticleId IdType="pubmed">18662234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL et al. Genomic analysis of reactive astrogliosis. J. Neurosci. 32, 6391&#x2013;6410 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D, Laux T, Xu L, Schneider C &amp; Caroni P Shared and unique roles of CAP23 and GAP43 in actin regulation, neurite outgrowth, and anatomical plasticity. J. Cell Biol. 149, 1443&#x2013;1454 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175140</ArticleId><ArticleId IdType="pubmed">10871284</ArticleId></ArticleIdList></Reference><Reference><Citation>Northrop NA &amp; Yamamoto BK Methamphetamine effects on blood-brain barrier structure and function. Front. Neurosci. 9, 69 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4349189</ArticleId><ArticleId IdType="pubmed">25788874</ArticleId></ArticleIdList></Reference><Reference><Citation>Turowski P &amp; Kenny BA The blood-brain barrier and methamphetamine: open sesame? Front. Neurosci. 9, 156 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419855</ArticleId><ArticleId IdType="pubmed">25999807</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Banerjee A, Banks WA &amp; Ercal N N-acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells. Brain Res. 1275, 87&#x2013;95 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702674</ArticleId><ArticleId IdType="pubmed">19374890</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto Y et al. The pharmacokinetic properties of methamphetamine in rats with previous repeated exposure to methamphetamine: the differences between LongEvans and Wistar rats. Exp. Anim. 56, 119&#x2013;129 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17460357</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankel PS, Alburges ME, Bush L, Hanson GR &amp; Kish SJ Brain levels of neuropeptides in human chronic methamphetamine users. Neuropharmacology 53, 447&#x2013;454 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2526021</ArticleId><ArticleId IdType="pubmed">17688891</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;langer M, Allaman I &amp; Magistretti PJ Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 14, 724&#x2013;738 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22152301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS et al. The human cerebrospinal fluid metabolome. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871, 164&#x2013;173 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18502700</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger C et al. The mouse brain metabolome: region-specific signatures and response to excitotoxic neuronal injury. Am. J. Pathol. 185, 1699&#x2013;1712 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25934215</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman SM et al. Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse. Mol. Psychiatry 13, 897&#x2013;908 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786221</ArticleId><ArticleId IdType="pubmed">17938635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng T et al. The metabolic impact of methamphetamine on the systemic metabolism of rats and potential markers of methamphetamine abuse. Mol. Biosyst. 10, 1968&#x2013;1977 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24825823</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Pehar M, Cassina P, Beckman JS &amp; Barbeito L Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTRdependent motor neuron apoptosis. J. Neurochem. 97, 687&#x2013;696 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16524372</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanelli SA, Solenski NJ, Rosenthal RE &amp; Fiskum G Mechanisms of ischemic neuroprotection by acetyl-l-carnitine. Ann. NY Acad. Sci. 1053, 153&#x2013;161 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4454400</ArticleId><ArticleId IdType="pubmed">16179519</ArticleId></ArticleIdList></Reference><Reference><Citation>Verleysdonk S, Martin H, Willker W, Leibfritz D &amp; Hamprecht B Rapid uptake and degradation of glycine by astroglial cells in culture: synthesis and release of serine and lactate. Glia 27, 239&#x2013;248 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10457370</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredholm BB, Chen JF, Cunha RA, Svenningsson P &amp; Vaugeois JM Adenosine and brain function. Int. Rev. Neurobiol. 63, 191&#x2013;270 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15797469</ArticleId></ArticleIdList></Reference><Reference><Citation>Schousboe A &amp; Sonnewald U The Glutamate/GABA-Glutamine Cycle (Springer, 2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27885624</ArticleId></ArticleIdList></Reference><Reference><Citation>Culic O, Gruwel ML &amp; Schrader J Energy turnover of vascular endothelial cells. Am. J. Physiol. 273, C205&#x2013;C213 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9252458</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner DA &amp; Adamson DC Neuronal-astrocyte metabolic interactions: understanding the transition into abnormal astrocytoma metabolism. J. Neuropathol. Exp. Neurol. 70, 167&#x2013;176 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045672</ArticleId><ArticleId IdType="pubmed">21293295</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xf6;er S &amp; Brookes N Transfer of glutamine between astrocytes and neurons. J. Neurochem. 77, 705&#x2013;719 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11331400</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Haynes TE, Li H &amp; Meininger CJ Glutamine metabolism in endothelial cells: ornithine synthesis from glutamine via pyrroline-5-carboxylate synthase. Comp. Biochem. Physiol. A Mol. Integr. Physiol 126, 115&#x2013;123 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10908859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia SN &amp; Ingber DE Microfluidic organs-on-chips. Nat. Biotechnol. 32, 760&#x2013;772 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25093883</ArticleId></ArticleIdList></Reference><Reference><Citation>Prantil-Baun R et al. Physiologically based pharmacokinetic and pharmacodynamic analysis enabled by microfluidically linked organs-on-chips. Annu. Rev. Pharmacol. Toxicol. 58, 37&#x2013;64 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29309256</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida Y et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117, 333&#x2013;345 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21291474</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz MJ et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391&#x2013;399 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243026</ArticleId><ArticleId IdType="pubmed">22996553</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik N et al. Comparison of the gene expression profiles of human fetal cortical astrocytes with pluripotent stem cell derived neural stem cells identifies human astrocyte markers and signaling pathways and transcription factors active in human astrocytes. PLoS One 9, e96139 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029581</ArticleId><ArticleId IdType="pubmed">24848099</ArticleId></ArticleIdList></Reference><Reference><Citation>Urich E, Lazic SE, Molnos J, Wells I &amp; Freskg&#xe5;rd PO Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One 7, e38149 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364980</ArticleId><ArticleId IdType="pubmed">22675443</ArticleId></ArticleIdList></Reference><Reference><Citation>Procaccini C et al. Role of metabolism in neurodegenerative disorders. Metabolism 65, 1376&#x2013;1390 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27506744</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims NR &amp; Muyderman H Mitochondria, oxidative metabolism and cell death in stroke. Biochim. Biophys. Acta 1802, 80&#x2013;91 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19751827</ArticleId></ArticleIdList></Reference><Reference><Citation>Giza CC &amp; Hovda DA The neurometabolic cascade of concussion. J. Athl. Train. 36, 228&#x2013;235 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155411</ArticleId><ArticleId IdType="pubmed">12937489</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S et al. Predicting network activity from high throughput metabolomics. PLOS Comput. Biol. 9, e1003123 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701697</ArticleId><ArticleId IdType="pubmed">23861661</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S et al. Constructing a fish metabolic network model. Genome Biol. 11, R115 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156954</ArticleId><ArticleId IdType="pubmed">21114829</ArticleId></ArticleIdList></Reference><Reference><Citation>The M, MacCoss MJ, Noble WS &amp; K&#xe4;ll L Fast and accurate protein false discovery rates on large-scale proteomics data sets with percolator 3.0. J. Am. Soc. Mass Spectrom. 27, 1719&#x2013;1727 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5059416</ArticleId><ArticleId IdType="pubmed">27572102</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichler GS, Huang S &amp; Ingber DE Gene Expression Dynamics Inspector (GEDI): for integrative analysis of expression profiles. Bioinformatics 19, 2321&#x2013;2322 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14630665</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebermeister W et al. Visual account of protein investment in cellular functions. Proc. Natl. Acad. Sci. USA 111, 8488&#x2013;8493 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060655</ArticleId><ArticleId IdType="pubmed">24889604</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M &amp; Goto S KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27&#x2013;30 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447&#x2013;D452 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383874</ArticleId><ArticleId IdType="pubmed">25352553</ArticleId></ArticleIdList></Reference><Reference><Citation>Orth JD, Thiele I &amp; Palsson BO What is flux balance analysis? Nat. Biotechnol. 28, 245&#x2013;248 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108565</ArticleId><ArticleId IdType="pubmed">20212490</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma A &amp; Palsson BO Metabolic capabilities of Escherichia coli: I. synthesis of biosynthetic precursors and cofactors. J. Theor. Biol. 165, 477&#x2013;502 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">21322280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis NE et al. Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat. Biotechnol. 28, 1279&#x2013;1285 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140076</ArticleId><ArticleId IdType="pubmed">21102456</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte NC et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl. Acad. Sci. USA 104, 1777&#x2013;1782 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794290</ArticleId><ArticleId IdType="pubmed">17267599</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellenberger J et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. Nat. Protoc. 6, 1290&#x2013;1307 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319681</ArticleId><ArticleId IdType="pubmed">21886097</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves PM &amp; Rebec GV Introduction to Biological Psychology (W.C. Brown, 1988). doi:10.1038/nbt.4226</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4226</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30150661</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration.</ArticleTitle><Pagination><StartPage>1209</StartPage><EndPage>1217</EndPage><MedlinePgn>1209-1217</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-018-0213-2</ELocationID><Abstract><AbstractText>Innate immune cells recruited to inflammatory sites have short life spans and originate from the marrow, which is distributed throughout the long and flat bones. While bone marrow production and release of leukocyte increases after stroke, it is currently unknown whether its activity rises homogeneously throughout the entire hematopoietic system. To address this question, we employed spectrally resolved in vivo cell labeling in the murine skull and tibia. We show that in murine models of stroke and aseptic meningitis, skull bone marrow-derived neutrophils are more likely to migrate to the adjacent brain tissue than cells that reside in the tibia. Confocal microscopy of the skull-dura interface revealed myeloid cell migration through microscopic vascular channels crossing the inner skull cortex. These observations point to a direct local interaction between the brain and the skull bone marrow through the meninges.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herisson</LastName><ForeName>Fanny</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frodermann</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5566-6692</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Courties</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohde</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandoorne</LastName><ForeName>Katrien</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojtkiewicz</LastName><ForeName>Gregory R</ForeName><Initials>GR</Initials><Identifier Source="ORCID">0000-0002-3148-8411</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masson</LastName><ForeName>Gustavo Santos</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinegoni</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jiwon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University College of Medicine, Goyang, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong-Eog</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University College of Medicine, Goyang, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissleder</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swirski</LastName><ForeName>Filip K</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moskowitz</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Stroke and Neurovascular Regulation Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahrendorf</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4021-1887</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology, Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. mnahrendorf@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. mnahrendorf@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL128264</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS084863</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL131495</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 HL139598</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR066261</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Trends Neurosci. 2018 Dec;41(12):877-879. doi: 10.1016/j.tins.2018.09.011.</RefSource><PMID Version="1">30327142</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008582" MajorTopicYN="N">Meningitis, Aseptic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012886" MajorTopicYN="N">Skull</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013977" MajorTopicYN="N">Tibia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing financial interests. The authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30150661</ArticleId><ArticleId IdType="mid">NIHMS1500752</ArticleId><ArticleId IdType="pmc">PMC6148759</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0213-2</ArticleId><ArticleId IdType="pii">10.1038/s41593-018-0213-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swirski FK &amp; Nahrendorf M Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339, 161&#x2013;166 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891792</ArticleId><ArticleId IdType="pubmed">23307733</ArticleId></ArticleIdList></Reference><Reference><Citation>Jickling GC et al. Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J Cereb Blood Flow Metab 35, 888&#x2013;901 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4640255</ArticleId><ArticleId IdType="pubmed">25806703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel H &amp; Iadecola C Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol 69, 576&#x2013;581 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586409</ArticleId><ArticleId IdType="pubmed">22782509</ArticleId></ArticleIdList></Reference><Reference><Citation>Offner H et al. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab 26, 654&#x2013;665 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16121126</ArticleId></ArticleIdList></Reference><Reference><Citation>Courties G, Moskowitz MA &amp; Nahrendorf M The innate immune system after ischemic injury: lessons to be learned from the heart and brain. JAMA Neurol 71, 233&#x2013;236 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946050</ArticleId><ArticleId IdType="pubmed">24296962</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelderblom M, Sobey CG, Kleinschnitz C &amp; Magnus T Danger signals in stroke. Ageing Res Rev 24, 77&#x2013;82 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26210897</ArticleId></ArticleIdList></Reference><Reference><Citation>Courties G et al. Ischemic stroke activates hematopoietic bone marrow stem cells. Circ Res 116, 407&#x2013;417 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312511</ArticleId><ArticleId IdType="pubmed">25362208</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison SJ &amp; Scadden DT The bone marrow niche for haematopoietic stem cells. Nature 505, 327&#x2013;334 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514480</ArticleId><ArticleId IdType="pubmed">24429631</ArticleId></ArticleIdList></Reference><Reference><Citation>Itkin T et al. Distinct bone marrow blood vessels differentially regulate haematopoiesis. Nature 532, 323&#x2013;328 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450701</ArticleId><ArticleId IdType="pubmed">27074509</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamache DA, Povlishock JT &amp; Ellis EF Carrageenan-induced brain inflammation. Characterization of the model. J Neurosurg 65, 679&#x2013;685 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3772456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda Y, Kondo M &amp; Kelsoe G Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med 201, 1771&#x2013;1780 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1952536</ArticleId><ArticleId IdType="pubmed">15939792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill WD et al. SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol 63, 84&#x2013;96 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14748564</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidt T et al. Chronic variable stress activates hematopoietic stem cells. Nat Med 20, 754&#x2013;758 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087061</ArticleId><ArticleId IdType="pubmed">24952646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenker W &amp; Kubik S Brain cooling in humans--anatomical considerations. Anat Embryol (Berl) 193, 1&#x2013;13 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8838492</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeeb N, Mortazavi MM, Tubbs RS &amp; Cohen-Gadol AA The cranial dura mater: a review of its history, embryology, and anatomy. Childs Nerv Syst 28, 827&#x2013;837 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22526439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershkovitz I et al. The elusive diploic veins: anthropological and anatomical perspective. Am J Phys Anthropol 108, 345&#x2013;358 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10096685</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel de Lazaro G, de la Cuetara JM, Pisova H, Lorenzo C &amp; Bruner E Diploic vessels and computed tomography: Segmentation and comparison in modern humans and fossil hominids. Am J Phys Anthropol 159, 313&#x2013;324 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26498859</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchinetti CF et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365, 2188&#x2013;2197 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282172</ArticleId><ArticleId IdType="pubmed">22150037</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaud JP, Bellavance MA, Prefontaine P &amp; Rivest S Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. Cell Rep 5, 646&#x2013;653 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24210819</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokop S et al. Impact of peripheral myeloid cells on amyloid-beta pathology in Alzheimer&#x2019;s disease-like mice. J Exp Med 212, 1811&#x2013;1818 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612091</ArticleId><ArticleId IdType="pubmed">26458768</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenaro E et al. Neutrophils promote Alzheimer&#x2019;s disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med 21, 880&#x2013;886 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26214837</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L et al. Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer Abeta Peptides. Circ Res 121, 258&#x2013;269 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522360</ArticleId><ArticleId IdType="pubmed">28515043</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G, Park L, Anrather J &amp; Iadecola C Brain perivascular macrophages: characterization and functional roles in health and disease. J Mol Med (Berl) 95, 1143&#x2013;1152 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5812456</ArticleId><ArticleId IdType="pubmed">28782084</ArticleId></ArticleIdList></Reference><Reference><Citation>Abtin A et al. Perivascular macrophages mediate neutrophil recruitment during bacterial skin infection. Nat Immunol 15, 45&#x2013;53 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4097073</ArticleId><ArticleId IdType="pubmed">24270515</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-de-Puig I et al. Neutrophil recruitment to the brain in mouse and human ischemic stroke. Acta Neuropathol 129, 239&#x2013;257 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25548073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartholomaus I et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462, 94&#x2013;98 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19829296</ArticleId></ArticleIdList></Reference><Reference><Citation>Coles JA, Myburgh E, Brewer JM &amp; McMenamin PG Where are we? The anatomy of the murine cortical meninges revisited for intravital imaging, immunology, and clearance of waste from the brain. Prog Neurobiol 156, 107&#x2013;148 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28552391</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337&#x2013;341 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund A et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212, 991&#x2013;999 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493418</ArticleId><ArticleId IdType="pubmed">26077718</ArticleId></ArticleIdList></Reference><Reference><Citation>McKittrick CM, Lawrence CE &amp; Carswell HV Mast cells promote blood brain barrier breakdown and neutrophil infiltration in a mouse model of focal cerebral ischemia. J Cereb Blood Flow Metab 35, 638&#x2013;647 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4420882</ArticleId><ArticleId IdType="pubmed">25564235</ArticleId></ArticleIdList></Reference><Reference><Citation>Arac A et al. Evidence that meningeal mast cells can worsen stroke pathology in mice. Am J Pathol 184, 2493&#x2013;2504 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188278</ArticleId><ArticleId IdType="pubmed">25134760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellner J &amp; Leib SL In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation. Neurobiol Dis 21, 647&#x2013;656 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16257222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger P et al. Neutrophils: Between host defence, immune modulation, and tissue injury. PLoS Pathog 11, e1004651 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357453</ArticleId><ArticleId IdType="pubmed">25764063</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Leak RK, Keep RF &amp; Chen J Translational Stroke Research on Blood-Brain Barrier Damage: Challenges, Perspectives, and Goals. Transl Stroke Res 7, 89&#x2013;92 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808584</ArticleId><ArticleId IdType="pubmed">26757714</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan TM &amp; Folch A Biomolecular gradients in cell culture systems. Lab Chip 8, 34&#x2013;57 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3848882</ArticleId><ArticleId IdType="pubmed">18094760</ArticleId></ArticleIdList></Reference><Reference><Citation>Lelios I &amp; Greter M Isolation of leukocytes from mouse central nervous system. Methods Mol Biol 1193, 15&#x2013;19 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25150992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY et al. Direct Imaging of Cerebral Thromboemboli Using Computed Tomography and Fibrin-targeted Gold Nanoparticles. Theranostics 5, 1098&#x2013;1114 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4508499</ArticleId><ArticleId IdType="pubmed">26199648</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30158706</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>561</Volume><Issue>7721</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structures of filaments from Pick's disease reveal a novel tau protein fold.</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>140</EndPage><MedlinePgn>137-140</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-018-0454-y</ELocationID><Abstract><AbstractText>The ordered assembly of tau protein into abnormal filamentous inclusions underlies many human neurodegenerative diseases<sup>1</sup>. Tau assemblies seem to spread through specific neural networks in each disease<sup>2</sup>, with short filaments having the greatest seeding activity<sup>3</sup>. The abundance of tau inclusions strongly correlates with disease symptoms<sup>4</sup>. Six tau isoforms are expressed in the normal adult human brain-three isoforms with four microtubule-binding repeats each (4R tau) and three isoforms that lack the second repeat (3R tau)<sup>1</sup>. In various diseases, tau filaments can be composed of either 3R or 4R tau, or of both. Tau filaments have distinct cellular and neuroanatomical distributions<sup>5</sup>, with morphological and biochemical differences suggesting that they may be able to adopt disease-specific molecular conformations<sup>6,7</sup>. Such conformers may give rise to different neuropathological phenotypes<sup>8,9</sup>, reminiscent of prion strains<sup>10</sup>. However, the underlying structures are not known. Using electron cryo-microscopy, we recently reported the structures of tau filaments from patients with Alzheimer's disease, which contain both 3R and 4R tau<sup>11</sup>. Here we determine the structures of tau filaments from patients with Pick's disease, a neurodegenerative disorder characterized by frontotemporal dementia. The filaments consist of residues Lys254-Phe378 of 3R tau, which are folded differently from the tau filaments in Alzheimer's disease, establishing the existence of conformers of assembled tau. The observed tau fold in the filaments of patients with Pick's disease explains the selective incorporation of 3R tau in Pick bodies, and the differences in phosphorylation relative to the tau filaments of Alzheimer's disease. Our findings show how tau can adopt distinct folds in the human brain in different diseases, an essential step for understanding the formation and propagation of molecular conformers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murshudov</LastName><ForeName>Garib</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garringer</LastName><ForeName>Holly J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowther</LastName><ForeName>R Anthony</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. scheres@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. mg@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105192716</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A025_1012</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2018 Nov;14(11):633. doi: 10.1038/s41582-018-0076-x.</RefSource><PMID Version="1">30232384</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="N">Pick Disease of the Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Author Information. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30158706</ArticleId><ArticleId IdType="mid">NIHMS1500333</ArticleId><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="doi">10.1038/s41586-018-0454-y</ArticleId><ArticleId IdType="pii">10.1038/s41586-018-0454-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Eisenberg DS &amp; Crowther RA Propagation of tau aggregates and neurodegeneration. Annu. Rev. Neurosci 40, 189&#x2013;210 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Del Tredici K Potential pathways of abnormal tau and alpha-synuclein dissemination in sporadic Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Cold Spring Harb. Perspect. Biol 8, a023630 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088528</ArticleId><ArticleId IdType="pubmed">27580631</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson SJ et al. Short fibrils constitute the major species of seed-competent tau in the brains of mice transgenic for human P301S tau. J. Neurosci 36, 762&#x2013;772 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719013</ArticleId><ArticleId IdType="pubmed">26791207</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock GK &amp; Esiri MM Plaques, tangles and dementia. A quantitative study. J. Neurol. Sci 56, 343&#x2013;356 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7175555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B et al. Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol. Appl. Neurobiol 41, 24&#x2013;46 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329416</ArticleId><ArticleId IdType="pubmed">25556536</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA &amp; Goedert M Abnormal tau-containing filaments in neurodegenerative diseases. J. Struct. Biol 130, 271&#x2013;279 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10940231</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 131, 267&#x2013;280 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl Acad. Sci. U S A 110, 9535&#x2013;9540 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan S et al. Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J. Neurosci 37, 11406&#x2013;11423 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5700423</ArticleId><ArticleId IdType="pubmed">29054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J Mammalian prions and their wider relevance in neurodegenerative diseases. Nature 539, 217&#x2013;226 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27830781</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasool CG &amp; Selkoe DJ Sharing of specific antigens by degenerating neurons in Pick&#x2019;s disease and Alzheimer&#x2019;s disease. N. Engl. J. Med 312, 700&#x2013;705 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">2579334</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock NJ, Mirra SS, Binder LI, Hansen LA &amp; Wood JG Filamentous aggregates in Pick&#x2019;s disease, progressive supranuclear palsy, and Alzheimer&#x2019;s disease share antigenic determinants with microtubule-associated protein, tau. Lancet 328, 1211 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">2430155</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, Tolnay M, Langui D, Goedert M &amp; Spillantini MG Pick&#x2019;s disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta. Neuropathol 92, 588&#x2013;596 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8960316</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A et al. Specific pathological tau protein variants characterize Pick&#x2019;s disease. J. Neuropathol. Exp. Neurol 55, 159&#x2013;168 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8786374</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, Sergeant N, Wattez A, Gauvreau D &amp; Robitaille Y Vulnerable neuronal subsets in Alzheimer&#x2019;s and Pick&#x2019;s disease are distinguished by their tau isoform distribution and phosphorylation. Ann. Neurol 43, 193&#x2013;204 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9485060</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz DG, Morris HR &amp; Rossor M Pick&#x2019;s Disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders (eds Dickson DW &amp; Weller RO) pp. 156&#x2013;164 (Wiley-Blackwell, 2011).</Citation></Reference><Reference><Citation>Wischik CM et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc. Natl Acad. Sci. U S A 85, 4884&#x2013;4888 (1988).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280541</ArticleId><ArticleId IdType="pubmed">2455299</ArticleId></ArticleIdList></Reference><Reference><Citation>Rewcastle NB &amp; Ball MJ Electron microscopic structure of the &#x201c;inclusion bodies&#x201d; in Pick&#x2019;s disease. Neurology 18, 1205&#x2013;1213 (1968).</Citation><ArticleIdList><ArticleId IdType="pubmed">4178657</ArticleId></ArticleIdList></Reference><Reference><Citation>Schochet SS, Lampert PW &amp; Lindenberg R Fine structure of the Pick and Hirano bodies in a case of Pick&#x2019;s disease. Acta Neuropathol. 11, 330&#x2013;337 (1968).</Citation><ArticleIdList><ArticleId IdType="pubmed">4179487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Coblentz JM &amp; Terry RD Pick&#x2019;s disease. A clinical and ultrastructural study. Arch. Neurol 26, 97&#x2013;108 (1972).</Citation><ArticleIdList><ArticleId IdType="pubmed">4332733</ArticleId></ArticleIdList></Reference><Reference><Citation>He S &amp; Scheres SHW Helical reconstruction in RELION. J. Struct. Biol 198, 163&#x2013;176 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc. Natl Acad. Sci. U S A 88, 2288&#x2013;2292 (1991).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG &amp; Davies P Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res 48, 128&#x2013;132 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL et al. Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J. Exp. Med 213, 2635&#x2013;2654 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW et al. Early frontotemporal dementia targets neurons unique to apes and humans. Ann. Neurol 60, 660&#x2013;667 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17187353</ArticleId></ArticleIdList></Reference><Reference><Citation>Miki Y et al. An autopsy case of incipient Pick&#x2019;s disease: immunohistochemical profile of early-stage Pick body formation. Neuropathology 34, 386&#x2013;391 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24444359</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Potier MC, Ulrich J &amp; Crowther RA Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. Embo J. 8, 393&#x2013;399 (1989).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC400819</ArticleId><ArticleId IdType="pubmed">2498079</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D &amp; Crowther RA Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron 3, 519&#x2013;526 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasmer C et al. Amyloid fibrils of the HET-s(218&#x2013;289) prion form a beta solenoid with a triangular hydrophobic core. Science 319, 1523&#x2013;1526 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18339938</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Yamaguchi Y, Mishra SK, Higuchi M &amp; Sahara N Tau Filaments and the Development of Positron Emission Tomography Tracers. Front. Neurol 9, 70 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818396</ArticleId><ArticleId IdType="pubmed">29497399</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ &amp; Crowther RA Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8, 159&#x2013;168 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J. Biol. Chem 290, 1049&#x2013;1065 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain 131, 72&#x2013;89 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow JL et al. Whole-exome sequencing in familial Parkinson disease. JAMA Neurol. 73, 68&#x2013;75 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4946647</ArticleId><ArticleId IdType="pubmed">26595808</ArticleId></ArticleIdList></Reference><Reference><Citation>Saijo E et al. Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid. Acta Neuropathol. 133, 751&#x2013;765 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28293793</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331&#x2013;332 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K Gctf: Real-time CTF determination and correction. J. Struct. Biol 193, 1&#x2013;12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol 180, 519&#x2013;530 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Leiro R &amp; Scheres SH Unravelling biological macromolecules with cryo-electron microscopy. Nature 537, 339&#x2013;346 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074357</ArticleId><ArticleId IdType="pubmed">27629640</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24&#x2013;35 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG &amp; Cowtan K Features and development of Coot. Acta Crystallogr. D 66, 486&#x2013;501 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213&#x2013;221 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA &amp; Dodson EJ Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240&#x2013;255 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12&#x2013;21 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J. Biol. Chem 270, 18917&#x2013;18922 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7642549</ArticleId></ArticleIdList></Reference><Reference><Citation>Litersky JM et al. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem. J 316 ( Pt 2), 655&#x2013;660 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1217397</ArticleId><ArticleId IdType="pubmed">8687413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30352114</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6173</ISSN><JournalIssue CitedMedium="Internet"><Volume>136</Volume><Issue>11</Issue><PubDate><Year>2018</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA ophthalmology</Title><ISOAbbreviation>JAMA Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings.</ArticleTitle><Pagination><StartPage>1242</StartPage><EndPage>1248</EndPage><MedlinePgn>1242-1248</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaophthalmol.2018.3556</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Biomarker testing for asymptomatic, preclinical Alzheimer disease (AD) is invasive and expensive. Optical coherence tomographic angiography (OCTA) is a noninvasive technique that allows analysis of retinal and microvascular anatomy, which is altered in early-stage AD.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether OCTA can detect early retinal alterations in cognitively normal study participants with preclinical AD diagnosed by criterion standard biomarker testing.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This case-control study included 32 participants recruited from the Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri. Results of extensive neuropsychometric testing determined that all participants were cognitively normal. Participants underwent positron emission tomography and/or cerebral spinal fluid testing to determine biomarker status. Individuals with prior ophthalmic disease, media opacity, diabetes, or uncontrolled hypertension were excluded. Data were collected from July 1, 2016, through September 30, 2017, and analyzed from July 30, 2016, through December 31, 2017.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Automated measurements of retinal nerve fiber layer thickness, ganglion cell layer thickness, inner and outer foveal thickness, vascular density, macular volume, and foveal avascular zone were collected using an OCTA system from both eyes of all participants. Separate model III analyses of covariance were used to analyze individual data outcome.</AbstractText><AbstractText Label="RESULTS">Fifty-eight eyes from 30 participants (53% female; mean [SD] age, 74.5 [5.6] years; age range, 62-92 years) were included in the analysis. One participant was African American and 29 were white. Fourteen participants had biomarkers positive for AD and thus a diagnosis of preclinical AD (mean [SD] age, 73.5 [4.7] years); 16 without biomarkers served as a control group (mean [SD] age, 75.4 [6.6] years). The foveal avascular zone was increased in the biomarker-positive group compared with controls (mean [SD], 0.364 [0.095] vs 0.275 [0.060] mm2; P&#x2009;=&#x2009;.002). Mean (SD) inner foveal thickness was decreased in the biomarker-positive group (66.0 [9.9] vs 75.4 [10.6] &#x3bc;m; P&#x2009;=&#x2009;.03).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study suggests that cognitively healthy individuals with preclinical AD have retinal microvascular abnormalities in addition to architectural alterations and that these changes occur at earlier stages of AD than has previously been demonstrated. Longitudinal studies in larger cohorts are needed to determine whether this finding has value in identifying preclinical AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Bryhim</LastName><ForeName>Bliss Elizabeth</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Vision Science, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apte</LastName><ForeName>Rajendra S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Vision Science, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Developmental Biology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Blue Sky Neurology, Denver, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coble</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Stavern</LastName><ForeName>Gregory P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Vision Science, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Ophthalmol</MedlineTA><NlmUniqueID>101589539</NlmUniqueID><ISSNLinking>2168-6165</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Ophthalmol. 2018 Nov 1;136(11):1249-1250. doi: 10.1001/jamaophthalmol.2018.3569.</RefSource><PMID Version="1">30352117</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012164" MajorTopicYN="N">Retinal Diseases</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30352114</ArticleId><ArticleId IdType="pmc">PMC6248182</ArticleId><ArticleId IdType="doi">10.1001/jamaophthalmol.2018.3556</ArticleId><ArticleId IdType="pii">2697402</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association 2016 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2016;12(4):459-509. doi:10.1016/j.jalz.2016.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.001</ArticleId><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer&#x2019;s disease. Lancet. 2011;377(9770):1019-1031. doi:10.1016/S0140-6736(10)61349-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61349-9</ArticleId><ArticleId IdType="pubmed">21371747</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640-651. doi:10.1016/j.bcp.2013.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2013.12.024</ArticleId><ArticleId IdType="pmc">PMC3992261</ArticleId><ArticleId IdType="pubmed">24398425</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. doi:10.1002/ana.20009</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20009</ArticleId><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Frosch MP, Freeman SH, et al. . Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64(3):431-434. doi:10.1001/archneur.64.3.431</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.3.431</ArticleId><ArticleId IdType="pubmed">17353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Rosenberg PB, Zhou Y, et al. . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913-920. doi:10.2967/jnumed.109.069088</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.109.069088</ArticleId><ArticleId IdType="pmc">PMC3101877</ArticleId><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Sperling RA, Gidicsin CM, et al. ; AV45-A11 study group . Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer&#x2019;s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5)(suppl):S72-S83. doi:10.1016/j.jalz.2012.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.10.007</ArticleId><ArticleId IdType="pmc">PMC3800236</ArticleId><ArticleId IdType="pubmed">23375563</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. ; AV45-A07 Study Group . Use of florbetapir-PET for imaging beta-amyloid pathology [published correction appears in JAMA. 2011;305(11):1096]. JAMA. 2011;305(3):275-283. doi:10.1001/jama.2010.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.2008</ArticleId><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144. doi:10.1038/nrneurol.2010.4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.4</ArticleId><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Blennow K, Breteler MMB, et al. . Alzheimer&#x2019;s disease. Lancet. 2016;388(10043):505-517. doi:10.1016/S0140-6736(15)01124-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)01124-1</ArticleId><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2016;43(2):374-385. doi:10.1007/s00259-015-3228-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-015-3228-x</ArticleId><ArticleId IdType="pmc">PMC4700091</ArticleId><ArticleId IdType="pubmed">26613792</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer&#x2019;s disease. Alzheimers Dement. 2015;11(1):58-69. doi:10.1016/j.jalz.2014.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.02.004</ArticleId><ArticleId IdType="pmc">PMC4386839</ArticleId><ArticleId IdType="pubmed">24795085</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. . Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80(19):1784-1791. doi:10.1212/WNL.0b013e3182918ca6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182918ca6</ArticleId><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer&#x2019;s disease: a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015;82:593-606. doi:10.1016/j.nbd.2015.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.08.014</ArticleId><ArticleId IdType="pubmed">26311408</ArticleId></ArticleIdList></Reference><Reference><Citation>Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer&#x2019;s disease. Invest Ophthalmol Vis Sci. 2007;48(5):2285-2289. doi:10.1167/iovs.06-1029</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.06-1029</ArticleId><ArticleId IdType="pubmed">17460292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CY-L, Ong YT, Ikram MK, et al. . Microvascular network alterations in the retina of patients with Alzheimer&#x2019;s disease. Alzheimers Dement. 2014;10(2):135-142. doi:10.1016/j.jalz.2013.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.06.009</ArticleId><ArticleId IdType="pubmed">24439169</ArticleId></ArticleIdList></Reference><Reference><Citation>Golzan SM, Goozee K, Georgevsky D, et al. . Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2017;9(1):13. doi:10.1186/s13195-017-0239-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0239-9</ArticleId><ArticleId IdType="pmc">PMC5335799</ArticleId><ArticleId IdType="pubmed">28253913</ArticleId></ArticleIdList></Reference><Reference><Citation>Feke GT, Hyman BT, Stern RA, Pasquale LR. Retinal blood flow in mild cognitive impairment and Alzheimer&#x2019;s disease. Alzheimers Dement (Amst). 2015;1(2):144-151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876882</ArticleId><ArticleId IdType="pubmed">27239502</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Wei Y, Shi Y, et al. . Altered macular microvasculature in mild cognitive impairment and Alzheimer disease [published online October 16, 2017]. J Neuroophthalmol. doi:10.1097/WNO.0000000000000580</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNO.0000000000000580</ArticleId><ArticleId IdType="pmc">PMC5902666</ArticleId><ArticleId IdType="pubmed">29040211</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo-Rodriguez I, Smailagic N, Roqu&#xe9; I Figuls M, et al. . Mini-Mental State Examination (MMSE) for the detection of Alzheimer&#x2019;s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;(3):CD010783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464748</ArticleId><ArticleId IdType="pubmed">25740785</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xe4;ih&#xe4; I, Isoaho R, Ojanlatva A, Viramo P, Sulkava R, Kivel&#xe4; SL. Poor performance in the Mini-Mental State Examination due to causes other than dementia. Scand J Prim Health Care. 2001;19(1):34-38. doi:10.1080/028134301300034620</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/028134301300034620</ArticleId><ArticleId IdType="pubmed">11303545</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Bressler SB, Edwards AR, Andreoli CM, et al. ; for the Diabetic Retinopathy Clinical Research Network/Writing Committee . Reproducibility of Optovue RTVue optical coherence tomography retinal thickness measurements and conversion to equivalent Zeiss Stratus metrics in diabetic macular edema. Transl Vis Sci Technol. 2015;4(1):5. doi:10.1167/tvst.4.1.5</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.4.1.5</ArticleId><ArticleId IdType="pmc">PMC4306266</ArticleId><ArticleId IdType="pubmed">25635237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer&#x2019;s disease. N Engl J Med. 1986;315(8):485-487. doi:10.1056/NEJM198608213150804</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198608213150804</ArticleId><ArticleId IdType="pubmed">3736630</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal pathology in Alzheimer&#x2019;s disease, I: ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging. 1996;17(3):377-384. doi:10.1016/0197-4580(96)00010-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00010-3</ArticleId><ArticleId IdType="pubmed">8725899</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH. Retinal pathology in Alzheimer&#x2019;s disease, II: regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996;17(3):385-395. doi:10.1016/0197-4580(96)00009-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00009-7</ArticleId><ArticleId IdType="pubmed">8725900</ArticleId></ArticleIdList></Reference><Reference><Citation>Park KW, Yoon HJ, Kang D-Y, Kim BC, Kim S, Kim JW. Regional cerebral blood flow differences in patients with mild cognitive impairment between those who did and did not develop Alzheimer&#x2019;s disease. Psychiatry Res. 2012;203(2-3):201-206. doi:10.1016/j.pscychresns.2011.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2011.12.007</ArticleId><ArticleId IdType="pubmed">22980226</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Testa C, Geroldi C, et al. . Cerebral perfusion correlates of conversion to Alzheimer&#x2019;s disease in amnestic mild cognitive impairment. J Neurol. 2007;254(12):1698-1707. doi:10.1007/s00415-007-0631-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-007-0631-7</ArticleId><ArticleId IdType="pubmed">17990057</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobili F, Frisoni GB, Portet F, et al. . Brain SPECT in subtypes of mild cognitive impairment: findings from the DESCRIPA multicenter study. J Neurol. 2008;255(9):1344-1353. doi:10.1007/s00415-008-0897-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-008-0897-4</ArticleId><ArticleId IdType="pubmed">18958573</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Pax AB. Increased collagen content of cerebral microvessels in Alzheimer&#x2019;s disease. Brain Res. 1995;705(1-2):349-352. doi:10.1016/0006-8993(95)01250-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(95)01250-8</ArticleId><ArticleId IdType="pubmed">8821769</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jong GI, De Vos RA, Steur EN, Luiten PG. Cerebrovascular hypoperfusion: a risk factor for Alzheimer&#x2019;s disease? animal model and postmortem human studies. Ann N Y Acad Sci. 1997;826:56-74. doi:10.1111/j.1749-6632.1997.tb48461.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1997.tb48461.x</ArticleId><ArticleId IdType="pubmed">9329681</ArticleId></ArticleIdList></Reference><Reference><Citation>Christov A, Ottman J, Hamdheydari L, Grammas P. Structural changes in Alzheimer&#x2019;s disease brain microvessels. Curr Alzheimer Res. 2008;5(4):392-395. doi:10.2174/156720508785132334</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720508785132334</ArticleId><ArticleId IdType="pubmed">18690836</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas E, De Jong GI, de Vos RA, Jansen Steur EN, Luiten PG. Pathological features of cerebral cortical capillaries are doubled in Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease. Acta Neuropathol. 2000;100(4):395-402. doi:10.1007/s004010000195</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010000195</ArticleId><ArticleId IdType="pubmed">10985698</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat. 2005;206(4):319-348. doi:10.1111/j.1469-7580.2005.00395.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7580.2005.00395.x</ArticleId><ArticleId IdType="pmc">PMC1571489</ArticleId><ArticleId IdType="pubmed">15817102</ArticleId></ArticleIdList></Reference><Reference><Citation>Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. . Identification of amyloid plaques in retinas from Alzheimer&#x2019;s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011;54S1:S204-S217. doi:10.1016/j.neuroimage.2010.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.06.020</ArticleId><ArticleId IdType="pmc">PMC2991559</ArticleId><ArticleId IdType="pubmed">20550967</ArticleId></ArticleIdList></Reference><Reference><Citation>Koronyo Y, Biggs D, Barron E, et al. . Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer&#x2019;s disease. JCI Insight. 2017;2(16):93621. doi:10.1172/jci.insight.93621</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.93621</ArticleId><ArticleId IdType="pmc">PMC5621887</ArticleId><ArticleId IdType="pubmed">28814675</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai Y, Lu B, Ljubimov AV, et al. . Ocular changes in TgF344-AD rat model of Alzheimer&#x2019;s disease. Invest Ophthalmol Vis Sci. 2014;55(1):523-534. doi:10.1167/iovs.13-12888</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.13-12888</ArticleId><ArticleId IdType="pmc">PMC3907137</ArticleId><ArticleId IdType="pubmed">24398104</ArticleId></ArticleIdList></Reference><Reference><Citation>La Morgia C, Ross-Cisneros FN, Koronyo Y, et al. . Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79(1):90-109. doi:10.1002/ana.24548</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24548</ArticleId><ArticleId IdType="pmc">PMC4737313</ArticleId><ArticleId IdType="pubmed">26505992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho C-Y, Troncoso JC, Knox D, Stark W, Eberhart CG. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer&#x2019;s and Parkinson&#x2019;s disease patients. Brain Pathol. 2014;24(1):25-32. doi:10.1111/bpa.12070</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12070</ArticleId><ArticleId IdType="pmc">PMC3976129</ArticleId><ArticleId IdType="pubmed">23714377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;n C, Hoffmann NA, Ochs SM, et al. . Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One. 2012;7(12):e53547. doi:10.1371/journal.pone.0053547</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0053547</ArticleId><ArticleId IdType="pmc">PMC3534024</ArticleId><ArticleId IdType="pubmed">23300938</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiasseu M, Alarcon-Martinez L, Belforte N, et al. . Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer&#x2019;s disease. Mol Neurodegener. 2017;12(1):58. doi:10.1186/s13024-017-0199-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0199-3</ArticleId><ArticleId IdType="pmc">PMC5543446</ArticleId><ArticleId IdType="pubmed">28774322</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Wang H, Li W, Cao X, Li C. Amyloid plaques in retina for diagnosis in Alzheimer&#x2019;s patients: a meta-analysis. Front Aging Neurosci. 2016;8:267. doi:10.3389/fnagi.2016.00267</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2016.00267</ArticleId><ArticleId IdType="pmc">PMC5102884</ArticleId><ArticleId IdType="pubmed">27891091</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Mattsson N, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Swedish BioFINDER Study Group . Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85(14):1240-1249. doi:10.1212/WNL.0000000000001991</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001991</ArticleId><ArticleId IdType="pmc">PMC4607601</ArticleId><ArticleId IdType="pubmed">26354982</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, McCue L, Jasielec MS, et al. . Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Ann Neurol. 2016;80(3):379-387. doi:10.1002/ana.24719</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24719</ArticleId><ArticleId IdType="pmc">PMC5016232</ArticleId><ArticleId IdType="pubmed">27398953</ArticleId></ArticleIdList></Reference><Reference><Citation>Forlenza OV, Radanovic M, Talib LL, et al. . Cerebrospinal fluid biomarkers in Alzheimer&#x2019;s disease: diagnostic accuracy and prediction of dementia. Alzheimers Dement (Amst). 2015;1(4):455-463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879480</ArticleId><ArticleId IdType="pubmed">27239524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2011;26(4):627-645. doi:10.3233/JAD-2011-110458</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110458</ArticleId><ArticleId IdType="pubmed">21694448</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30180184</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts.</ArticleTitle><Pagination><StartPage>e1002647</StartPage><MedlinePgn>e1002647</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002647</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1002647</ELocationID><Abstract><AbstractText Label="BACKGROUND">There are few data concerning the association between season and cognition and its neurobiological correlates in older persons-effects with important translational and therapeutic implications for the diagnosis and treatment of Alzheimer disease (AD). We aimed to measure these effects.</AbstractText><AbstractText Label="METHODS AND FINDINGS">We analyzed data from 3,353 participants from 3 observational community-based cohort studies of older persons (the Rush Memory and Aging Project [MAP], the Religious Orders Study [ROS], and the Minority Aging Research Study [MARS]) and 2 observational memory-clinic-based cohort studies (Centre de Neurologie Cognitive [CNC] study at Lariboisi&#xe8;re Hospital and the Sunnybrook Dementia Study [SDS]). We performed neuropsychological testing and, in subsets of participants, evaluated cerebrospinal fluid AD biomarkers, standardized structured autopsy measures, and/or prefrontal cortex gene expression by RNA sequencing. We examined the association between season and these variables using nested multiple linear and logistic regression models. There was a robust association between season and cognition that was replicated in multiple cohorts (amplitude = 0.14 SD [a measure of the magnitude of seasonal variation relative to overall variability; 95% CI 0.07-0.23], p = 0.007, in the combined MAP, ROS, and MARS cohorts; amplitude = 0.50 SD [95% CI 0.07-0.66], p = 0.017, in the SDS cohort). Average composite global cognitive function was higher in the summer and fall compared to winter and spring, with the difference equivalent in cognitive effect to 4.8 years' difference in age (95% CI 2.1-8.4, p = 0.002). Further, the odds of meeting criteria for mild cognitive impairment or dementia were higher in the winter and spring (odds ratio 1.31 [95% CI 1.10-1.57], p = 0.003). These results were robust against multiple potential confounders including depressive symptoms, sleep, physical activity, and thyroid status and persisted in cases with AD pathology. Moreover, season had a marked effect on cerebrospinal fluid A&#x3b2; 42 level (amplitude 0.30 SD [95% CI 0.10-0.64], p = 0.003), which peaked in the summer, and on the brain expression of 4 cognition-associated modules of co-expressed genes (m6: amplitude = 0.44 SD [95% CI 0.21-0.65], p = 0.0021; m13: amplitude = 0.46 SD [95% CI 0.27-0.76], p = 0.0009; m109: amplitude = 0.43 SD [95% CI 0.24-0.67], p = 0.0021; and m122: amplitude 0.46 SD [95% CI 0.20-0.71], p = 0.0012), which were in phase or anti-phase to the rhythms of cognition and which were in turn associated with binding sites for several seasonally rhythmic transcription factors including BCL11A, CTCF, EGR1, MEF2C, and THAP1. Limitations include the evaluation of each participant or sample once per annual cycle, reliance on self-report for measurement of environmental and behavioral factors, and potentially limited generalizability to individuals in equatorial regions or in the southern hemisphere.</AbstractText><AbstractText Label="CONCLUSIONS">Season has a clinically significant association with cognition and its neurobiological correlates in older adults with and without AD pathology. There may be value in increasing dementia-related clinical resources in the winter and early spring, when symptoms are likely to be most pronounced. Moreover, the persistence of robust seasonal plasticity in cognition and its neurobiological correlates, even in the context of concomitant AD pathology, suggests that targeting environmental or behavioral drivers of seasonal cognitive plasticity, or the key transcription factors and genes identified in this study as potentially mediating these effects, may allow us to substantially improve cognition in adults with and without AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Andrew S P</ForeName><Initials>ASP</Initials><Identifier Source="ORCID">0000-0003-2179-1553</Identifier><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaiteri</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0237-8758</Identifier><AffiliationInfo><Affiliation>Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohail</LastName><ForeName>Shahmir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swardfager</LastName><ForeName>Walter</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-0030-8908</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasaki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paquet</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre de Neurologie Cognitive, H&#xf4;pitaux Saint-Louis Lariboisi&#xe8;re Fernand-Widal, Assistance Publique-H&#xf4;pitaux de Paris, University of Paris Diderot, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U942, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuss</LastName><ForeName>Donald T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hugon</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre de Neurologie Cognitive, H&#xf4;pitaux Saint-Louis Lariboisi&#xe8;re Fernand-Widal, Assistance Publique-H&#xf4;pitaux de Paris, University of Paris Diderot, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U942, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>Aron S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG022018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078009</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG052488</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal&#x2019;s policy and the authors of this manuscript have the following competing interests: SEB has ad-hoc consultancies with the following: GE Healthcare, Boehringer Ingelheim, Novartis, Merck, Eli Lilly, Pfizer. Continuing medical education from: Novartis, Eisai, Medscape/Biogen, Eli Lilly. SEB receives grants to her institution from: Elan, Roche, GE Healthcare, Eli Lilly, Pfizer, Lundbeck, Transition Therapeutics, Biogen Idec, Novartis, Genentech, and Optina. CP is a consultant for FUJIRIBIO laboratory.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30180184</ArticleId><ArticleId IdType="pmc">PMC6122787</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1002647</ArticleId><ArticleId IdType="pii">PMEDICINE-D-18-01190</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry. 1984;41(1):72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">6581756</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens N, McGorry PD. Seasonality of symptom onset in first-episode schizophrenia. Psychol Med. 2003;33(1):163&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12537047</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer C, Muto V, Jaspar M, Kusse C, Lambot E, Chellappa SL, et al. Seasonality in human cognitive brain responses. Proc Natl Acad Sci U S A. 2016;113(11):3066&#x2013;71. 10.1073/pnas.1518129113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1518129113</ArticleId><ArticleId IdType="pmc">PMC4801294</ArticleId><ArticleId IdType="pubmed">26858432</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennen T, Martinussen M, Hansen BO, Hjemdal O. Arctic cognition: a study of cognitive performance in summer and winter at 69 degrees N. Appl Cogn Psychol. 1999;13(6):561&#x2013;80. 10.1002/(SICI)1099-0720(199912)13:6&lt;561::AID-ACP661&gt;3.0.CO;2-J</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1099-0720(199912)13:6&lt;561::AID-ACP661&gt;3.0.CO;2-J</ArticleId><ArticleId IdType="pubmed">11543349</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajajarvi E, Antila M, Kieseppa T, Lonnqvist J, Tuulio-Henriksson A, Partonen T. The effect of seasons and seasonal variation on neuropsychological test performance in patients with bipolar I disorder and their first-degree relatives. J Affect Disord. 2010;127(1&#x2013;3):58&#x2013;65. 10.1016/j.jad.2010.04.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2010.04.021</ArticleId><ArticleId IdType="pubmed">20466433</ArticleId></ArticleIdList></Reference><Reference><Citation>Afsar B, Kirkpantur A. Are there any seasonal changes of cognitive impairment, depression, sleep disorders and quality of life in hemodialysis patients? Gen Hosp Psychiatry. 2013;35(1):28&#x2013;32. 10.1016/j.genhosppsych.2012.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2012.08.007</ArticleId><ArticleId IdType="pubmed">23044242</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacny C, Kirk A, Morgan DG, Karunanayake C. Does day length affect cognitive performance in memory clinic patients? Can J Neurol Sci. 2011;38(3):461&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">21515507</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AS, Klein HU, Yu L, Chibnik LB, Ali S, Xu J, et al. Diurnal and seasonal molecular rhythms in human neocortex and their relation to Alzheimer&#x2019;s disease. Nat Commun. 2017;8:14931 10.1038/ncomms14931</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14931</ArticleId><ArticleId IdType="pmc">PMC5382268</ArticleId><ArticleId IdType="pubmed">28368004</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep fragmentation and the risk of incident Alzheimer&#x2019;s disease and cognitive decline in older persons. Sleep. 2013;36(7):1027&#x2013;32. 10.5665/sleep.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.2802</ArticleId><ArticleId IdType="pmc">PMC3669060</ArticleId><ArticleId IdType="pubmed">23814339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64(s1):S161&#x2013;89. 10.3233/JAD-179939</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Shah RC, Aggarwal NT, Bennett DA, Schneider JA. The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia. Curr Alzheimer Res. 2012;9(6):734&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409294</ArticleId><ArticleId IdType="pubmed">22471868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez J, McNeely AA, Scott CJM, Masellis M, Black SE, Alzheimer&#x2019;s disease neuroimaging I. white matter hyperintensity burden in elderly cohort studies: the Sunnybrook Dementia Study, Alzheimer&#x2019;s Disease Neuroimaging Initiative, and Three-City Study. Alzheimers Dement. 2016;12(2):203&#x2013;10. 10.1016/j.jalz.2015.06.1886</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.06.1886</ArticleId><ArticleId IdType="pubmed">26208292</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Beck TL, Bienias JL, Bennett DA. Terminal cognitive decline: accelerated loss of cognition in the last years of life. Psychosom Med. 2007;69(2):131&#x2013;7. 10.1097/PSY.0b013e31803130ae</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PSY.0b013e31803130ae</ArticleId><ArticleId IdType="pubmed">17327212</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Misch MR, Mitchell S, Francis PL, Sherborn K, Meradje K, McNeely AA, et al. Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography. Alzheimers Res Ther. 2014;6(9):71 10.1186/s13195-014-0071-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-014-0071-4</ArticleId><ArticleId IdType="pmc">PMC4256921</ArticleId><ArticleId IdType="pubmed">25484929</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattis S. Mental status examination for organic mental syndrome in the elderly patient In: Bellak L, Carasu TB, editors. Geriatirc psychiatry: a handbook for psychiatrists and primary care physicians. New York: Grune &amp; Stratton; 1976. pp. 77&#x2013;121.</Citation></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan EF, Ober BA. The California Verbal Learning Test. San Antonio: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale&#x2014;revised manual. San Antonio: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Kaplan EF, Fein D, Morris R, Delis D. The WAIS-R as a neuropsychological instrument. San Antonio: Psychological Corporation; 1991.</Citation></Reference><Reference><Citation>Heaton RK. Wisconsin Card Sorting Test manual. Odessa (FL): Psychological Assessment Resources; 1981.</Citation></Reference><Reference><Citation>Lezack MD. Neuropsychological assessment. New York: Oxford University Press; 1983.</Citation></Reference><Reference><Citation>Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK. Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment. 1999;6(2):147&#x2013;78. 10.1177/107319119900600204</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/107319119900600204</ArticleId><ArticleId IdType="pubmed">10335019</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL, Hamser K, Varney NR, Spreen O. contributions to neuropsychological assessment. New York: Oxford University Press; 1983.</Citation></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263&#x2013;9. 10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA. 2002;287(6):742&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11851541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837&#x2013;44. 10.1212/01.wnl.0000219668.47116.e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000219668.47116.e6</ArticleId><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer&#x2019;s disease. Neurology. 2003;60(2):246&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12552039</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Aging, Reagan Institute Working Group of Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x2019;s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18(4 Suppl):S1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer&#x2019;s disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol. 2006;5(5):406&#x2013;12. 10.1016/S1474-4422(06)70417-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(06)70417-3</ArticleId><ArticleId IdType="pubmed">16632311</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62(7):1148&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15079015</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke. 2011;42(3):722&#x2013;7. 10.1161/STROKEAHA.110.595082</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.110.595082</ArticleId><ArticleId IdType="pmc">PMC3042494</ArticleId><ArticleId IdType="pubmed">21212395</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin JZ, Yassour M, Adiconis X, Nusbaum C, Thompson DA, Friedman N, et al. Comprehensive comparative analysis of strand-specific RNA sequencing methods. Nat Methods. 2010;7(9):709&#x2013;15. 10.1038/nmeth.1491</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1491</ArticleId><ArticleId IdType="pmc">PMC3005310</ArticleId><ArticleId IdType="pubmed">20711195</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiconis X, Borges-Rivera D, Satija R, DeLuca DS, Busby MA, Berlin AM, et al. Comparative analysis of RNA sequencing methods for degraded or low-input samples. Nat Methods. 2013;10(7):623&#x2013;9. 10.1038/nmeth.2483</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2483</ArticleId><ArticleId IdType="pmc">PMC3821180</ArticleId><ArticleId IdType="pubmed">23685885</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25 10.1186/gb-2009-10-3-r25</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2009-10-3-r25</ArticleId><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118&#x2013;27. 10.1093/biostatistics/kxj037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxj037</ArticleId><ArticleId IdType="pubmed">16632515</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiteri C, Chen M, Szymanski B, Kuzmin K, Xie J, Lee C, et al. Identifying robust communities and multi-community nodes by combining top-down and bottom-up approaches to clustering. Sci Rep. 2015;5:16361 10.1038/srep16361</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep16361</ArticleId><ArticleId IdType="pmc">PMC4637843</ArticleId><ArticleId IdType="pubmed">26549511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, Gaiteri C, Sullivan SE, White CC, Tasaki S, Xu J, et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat Neurosci. 2018;21(6):811&#x2013;9. 10.1038/s41593-018-0154-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0154-9</ArticleId><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559 10.1186/1471-2105-9-559</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-559</ArticleId><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhuang J, Iyer S, Lin XY, Greven MC, Kim BH, et al. Factorbook.org: a Wiki-based database for transcription factor-binding data generated by the ENCODE consortium. Nucleic Acids Res. 2013;41(Database issue):D171&#x2013;6. 10.1093/nar/gks1221</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1221</ArticleId><ArticleId IdType="pmc">PMC3531197</ArticleId><ArticleId IdType="pubmed">23203885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhuang J, Iyer S, Lin X, Whitfield TW, Greven MC, et al. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res. 2012;22(9):1798&#x2013;812. 10.1101/gr.139105.112</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.139105.112</ArticleId><ArticleId IdType="pmc">PMC3431495</ArticleId><ArticleId IdType="pubmed">22955990</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C, et al. Architecture of the human regulatory network derived from ENCODE data. Nature. 2012;489(7414):91&#x2013;100. 10.1038/nature11245</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11245</ArticleId><ArticleId IdType="pmc">PMC4154057</ArticleId><ArticleId IdType="pubmed">22955619</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Berry-Kravis E, Arnold SE. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry. 2005;76(9):1194&#x2013;9. 10.1136/jnnp.2004.054445</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2004.054445</ArticleId><ArticleId IdType="pmc">PMC1739810</ArticleId><ArticleId IdType="pubmed">16107349</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, et al. Effects of age and amyloid deposition on Abeta dynamics in the human central nervous system. Arch Neurol. 2012;69(1):51&#x2013;8. 10.1001/archneurol.2011.235</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.235</ArticleId><ArticleId IdType="pmc">PMC3254706</ArticleId><ArticleId IdType="pubmed">21911660</ArticleId></ArticleIdList></Reference><Reference><Citation>Dopico XC, Evangelou M, Ferreira RC, Guo H, Pekalski ML, Smyth DJ, et al. Widespread seasonal gene expression reveals annual differences in human immunity and physiology. Nat Commun. 2015;6:7000 10.1038/ncomms8000</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8000</ArticleId><ArticleId IdType="pmc">PMC4432600</ArticleId><ArticleId IdType="pubmed">25965853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiteri C, Ding Y, French B, Tseng GC, Sibille E. Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders. Genes Brain Behav. 2014;13(1):13&#x2013;24. 10.1111/gbb.12106</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gbb.12106</ArticleId><ArticleId IdType="pmc">PMC3896950</ArticleId><ArticleId IdType="pubmed">24320616</ArticleId></ArticleIdList></Reference><Reference><Citation>Merikanto I, Lahti T, Castaneda AE, Tuulio-Henriksson A, Aalto-Setala T, Suvisaari J, et al. Influence of seasonal variation in mood and behavior on cognitive test performance among young adults. Nord J Psychiatry. 2012;66(5):303&#x2013;10. 10.3109/08039488.2011.633618</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08039488.2011.633618</ArticleId><ArticleId IdType="pubmed">22126305</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Kobayashi H, Nakayama E, Kakihana W. Seasonality in physical activity and walking of healthy older adults. J Physiol Anthropol. 2015;34:33 10.1186/s40101-015-0071-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40101-015-0071-5</ArticleId><ArticleId IdType="pmc">PMC4591564</ArticleId><ArticleId IdType="pubmed">26432340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yetish G, Kaplan H, Gurven M, Wood B, Pontzer H, Manger PR, et al. Natural sleep and its seasonal variations in three pre-industrial societies. Curr Biol. 2015;25(21):2862&#x2013;8. 10.1016/j.cub.2015.09.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2015.09.046</ArticleId><ArticleId IdType="pmc">PMC4720388</ArticleId><ArticleId IdType="pubmed">26480842</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahar DR, Froom P, Harari G, Yerushalmi N, Lubin F, Kristal-Boneh E. Changes in dietary intake account for seasonal changes in cardiovascular disease risk factors. Eur J Clin Nutr. 1999;53(5):395&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369496</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos SB, Rocha GP, Fernandez LL, de Padua AC, Reppold CT. Association of lower spiritual well-being, social support, self-esteem, subjective well-being, optimism and hope scores with mild cognitive impairment and mild dementia. Front Psychol. 2018;9:371 10.3389/fpsyg.2018.00371</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2018.00371</ArticleId><ArticleId IdType="pmc">PMC5891611</ArticleId><ArticleId IdType="pubmed">29666594</ArticleId></ArticleIdList></Reference><Reference><Citation>Hintzpeter B, Mensink GB, Thierfelder W, Muller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr. 2008;62(9):1079&#x2013;89. 10.1038/sj.ejcn.1602825</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejcn.1602825</ArticleId><ArticleId IdType="pubmed">17538533</ArticleId></ArticleIdList></Reference><Reference><Citation>Svartberg J, Jorde R, Sundsfjord J, Bonaa KH, Barrett-Connor E. Seasonal variation of testosterone and waist to hip ratio in men: the Tromso study. J Clin Endocrinol Metab. 2003;88(7):3099&#x2013;104. 10.1210/jc.2002-021878</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2002-021878</ArticleId><ArticleId IdType="pubmed">12843149</ArticleId></ArticleIdList></Reference><Reference><Citation>Morera AL, Abreu P. Seasonality of psychopathology and circannual melatonin rhythm. J Pineal Res. 2006;41(3):279&#x2013;83. 10.1111/j.1600-079X.2006.00365.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2006.00365.x</ArticleId><ArticleId IdType="pubmed">16948790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo N, Sekijima T, Kondo J, Takamatsu N, Tohya K, Ohtsu T. Circannual control of hibernation by HP complex in the brain. Cell. 2006;125(1):161&#x2013;72. 10.1016/j.cell.2006.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.03.017</ArticleId><ArticleId IdType="pubmed">16615897</ArticleId></ArticleIdList></Reference><Reference><Citation>Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol. 2010;67(2):217&#x2013;23. 10.1001/archneurol.2009.316</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.316</ArticleId><ArticleId IdType="pubmed">20142530</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, et al. A sensitive abeta oligomer assay discriminates Alzheimer&#x2019;s and aged control cerebrospinal fluid. J Neurosci. 2014;34(8):2884&#x2013;97. 10.1523/JNEUROSCI.1675-13.2014</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1675-13.2014</ArticleId><ArticleId IdType="pmc">PMC6608513</ArticleId><ArticleId IdType="pubmed">24553930</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018. March 1 10.1016/j.jalz.2018.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.01.010</ArticleId><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837&#x2013;42. 10.1038/nm1782</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30189209</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>925</StartPage><EndPage>940.e7</EndPage><MedlinePgn>925-940.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2018.07.039</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(18)30637-8</ELocationID><Abstract><AbstractText>Tau is the major constituent of neurofibrillary tangles in Alzheimer's disease (AD), but the mechanism underlying tau-associated neural damage remains unclear. Here, we show that tau can directly interact with nucleoporins of the nuclear pore complex (NPC) and affect their structural and functional integrity. Pathological tau impairs nuclear import and export in tau-overexpressing transgenic mice and in human AD brain tissue. Furthermore, the nucleoporin Nup98 accumulates in the cell bodies of some tangle-bearing neurons and can facilitate tau aggregation in&#xa0;vitro. These data support the hypothesis that tau can directly interact with NPC components, leading to their mislocalization and consequent disruption of NPC function. This raises the possibility that NPC dysfunction contributes to tau-induced neurotoxicity in AD and tauopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eftekharzadeh</LastName><ForeName>Bahareh</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daigle</LastName><ForeName>J Gavin</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapinos</LastName><ForeName>Larisa E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Biozentrum, University of Basel, Basel 4056, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coyne</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiantarelli</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlomagno</LastName><ForeName>Yari</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Sean J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaral</LastName><ForeName>Ana S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grima</LastName><ForeName>Jonathan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Rachel E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tepper</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeTure</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderburg</LastName><ForeName>Charles R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corjuc</LastName><ForeName>Bianca T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeVos</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Jose Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidensky</LastName><ForeName>Svetlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) and CAESAR Research Center, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvatella</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Barcelona 08028, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Roderick Y H</ForeName><Initials>RYH</Initials><AffiliationInfo><Affiliation>Biozentrum, University of Basel, Basel 4056, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegmann</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. Electronic address: jrothstein@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. Electronic address: bhyman@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS094239</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS085207</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS094489</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS099114</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089544</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100693</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS103360</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS099320</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2018 Sep 5;99(5):869-871. doi: 10.1016/j.neuron.2018.08.026.</RefSource><PMID Version="1">30189205</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2019 Jan 16;101(2):349. doi: 10.1016/j.neuron.2018.12.031.</RefSource><PMID Version="1">30653936</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Nup98</Keyword><Keyword MajorTopicYN="N">nuclear pore complex</Keyword><Keyword MajorTopicYN="N">nucleocytoplasmic transport</Keyword><Keyword MajorTopicYN="N">tauopathies</Keyword></KeywordList><CoiStatement>DECLARATION OF INTERESTS. The authors declare no competing interests. Dr. Eftekarzadeh is currently an employee of Biogen; Dr. Daigle is currently an employee of Abbvie.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30189209</ArticleId><ArticleId IdType="mid">NIHMS991142</ArticleId><ArticleId IdType="pmc">PMC6240334</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.07.039</ArticleId><ArticleId IdType="pii">S0896-6273(18)30637-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alber F, Dokudovskaya S, Veenhoff LM, Zhang W, Kipper J, Devos D, Suprapto A, Karni-Schmidt O, Williams R, Chait BT, et al. (2007). The molecular architecture of the nuclear pore complex. Nature 450, 695&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">18046406</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, and Dickson DW (2007). TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol 61, 435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Basel-Vanagaite L, Muncher L, Straussberg R, Pasmanik-Chor M, Yahav M, Rainshtein L, Walsh CA, Magal N, Taub E, Drasinover V, et al. (2006). Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis. Ann Neurol 60, 214&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">16786527</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins MB, Smith AM, Phillips EM, and Powers MA (2003). Complex formation among the RNA export proteins Nup98, Rae1/Gle2, and TAP. J Biol Chem 278, 20979&#x2013;20988.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637516</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Angelo MA, Raices M, Panowski SH, and Hetzer MW (2009). Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. Cell 136, 284&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805151</ArticleId><ArticleId IdType="pubmed">19167330</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasso M, and Pu RT (1998). Nuclear transport: run by Ran? Am J Hum Genet 63, 311&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377330</ArticleId><ArticleId IdType="pubmed">9683621</ArticleId></ArticleIdList></Reference><Reference><Citation>Denning DP, Patel SS, Uversky V, Fink AL, and Rexach M (2003). Disorder in the nuclear pore complex: the FG repeat regions of nucleoporins are natively unfolded. Proc Natl Acad Sci U S A 100, 2450&#x2013;2455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151361</ArticleId><ArticleId IdType="pubmed">12604785</ArticleId></ArticleIdList></Reference><Reference><Citation>Dultz E, Zanin E, Wurzenberger C, Braun M, Rabut G, Sironi L, and Ellenberg J (2008). Systematic kinetic analysis of mitotic dis- and reassembly of the nuclear pore in living cells. J Cell Biol 180, 857&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265396</ArticleId><ArticleId IdType="pubmed">18316408</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ, Hernandez F, Avila J, and Lucas JJ (2014). Huntington&#x2019;s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 20, 881&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pubmed">25038828</ArticleId></ArticleIdList></Reference><Reference><Citation>Floch AG, Palancade B, and Doye V (2014). Fifty years of nuclear pores and nucleocytoplasmic transport studies: multiple tools revealing complex rules. Methods Cell Biol 122, 1&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">24857723</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontoura BM, Blobel G, and Yaseen NR (2000). The nucleoporin Nup98 is a site for GDP/GTP exchange on ran and termination of karyopherin beta 2-mediated nuclear import. J Biol Chem 275, 31289&#x2013;31296.</Citation><ArticleIdList><ArticleId IdType="pubmed">10875935</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman SH, Spires-Jones T, Hyman BT, Growdon JH, and Frosch MP (2008). TARDNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol 67, 62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18091558</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, et al. (2015). GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525, 129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S, and Gorlich D (2007). A saturated FG-repeat hydrogel can reproduce the permeability properties of nuclear pore complexes. Cell 130, 512&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">17693259</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S, Richter RP, and Gorlich D (2006). FG-rich repeats of nuclear pore proteins form a three-dimensional meshwork with hydrogel-like properties. Science 314, 815&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082456</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Chillon-Marinas C, Goginashvili A, Atwal RS, Artates JW, Tabet R, Wheeler VC, Bang AG, Cleveland DW, and Lagier-Tourenne C (2017). Polyglutamine-Expanded Huntingtin Exacerbates Age-Related Disruption of Nuclear Integrity and Nucleocytoplasmic Transport. Neuron 94, 48&#x2013;57 e44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479704</ArticleId><ArticleId IdType="pubmed">28384474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW Jr., Morris JC, Growdon JH, and Hyman BT (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci 16, 4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, and Iqbal K (2008). Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15, 2321&#x2013;2328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656563</ArticleId><ArticleId IdType="pubmed">18855662</ArticleId></ArticleIdList></Reference><Reference><Citation>Grima JC, Daigle JG, Arbez N, Cunningham KC, Zhang K, Ochaba J, Geater C, Morozko E, Stocksdale J, Glatzer JC, et al. (2017). Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron 94, 93&#x2013;107 e106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595097</ArticleId><ArticleId IdType="pubmed">28384479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetzer M, Gruss OJ, and Mattaj IW (2002). The Ran GTPase as a marker of chromosome position in spindle formation and nuclear envelope assembly. Nature cell biology 4, E177&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105431</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinshaw JE, Carragher BO, and Milligan RA (1992). Architecture and design of the nuclear pore complex. Cell 69, 1133&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">1617726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S, Fujioka Y, Okada Y, Riku Y, Udagawa T, Honda D, Yokoi S, Endo K, Ikenaka K, Takagi S, et al. (2017). Altered Tau Isoform Ratio Caused by Loss of FUS and SFPQ Function Leads to FTLD-like Phenotypes. Cell Rep 18, 1118&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">28147269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, et al. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell 142, 387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto M, Asakawa H, Hiraoka Y, and Haraguchi T (2010). Nucleoporin Nup98: a gatekeeper in the eukaryotic kingdoms. Genes Cells 15, 661&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">20545767</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW 3rd, Sun S, Herdy JR, Bieri G, et al. (2015). Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci 18, 1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb HM, Folkmann AW, Belzil VV, Jao LE, Leblond CS, Girard SL, Daoud H, Noreau A, Rochefort D, Hince P, et al. (2015). Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Hum Mol Genet 24, 1363&#x2013;1373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321443</ArticleId><ArticleId IdType="pubmed">25343993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapinos LE, Schoch RL, Wagner RS, Schleicher KD, and Lim RY (2014). Karyopherin-centric control of nuclear pores based on molecular occupancy and kinetic analysis of multivalent binding with FG nucleoporins. Biophys J 106, 1751&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008817</ArticleId><ArticleId IdType="pubmed">24739174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke YD, Dramiga J, Schutz U, Kril JJ, Ittner LM, Schroder H, and Gotz J (2012). Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer&#x2019;s and Pick&#x2019;s disease. PLoS One 7, e35678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338448</ArticleId><ArticleId IdType="pubmed">22558197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley JB, Datta S, Snow CJ, Chatterjee M, Ni L, Spencer A, Yang CS, Cubenas-Potts C, Matunis MJ, and Paschal BM (2011). The defective nuclear lamina in Hutchinson-gilford progeria syndrome disrupts the nucleocytoplasmic Ran gradient and inhibits nuclear localization of Ubc9. Mol Cell Biol 31, 3378&#x2013;3395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147792</ArticleId><ArticleId IdType="pubmed">21670151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalczyk SW, Kapinos L, Blosser TR, Magalhaes T, van Nies P, Lim RY, and Dekker C (2011). Single-molecule transport across an individual biomimetic nuclear pore complex. Nat Nanotechnol 6, 433&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">21685911</ArticleId></ArticleIdList></Reference><Reference><Citation>Labokha AA, Gradmann S, Frey S, Hulsmann BB, Urlaub H, Baldus M, and Gorlich D (2013). Systematic analysis of barrier-forming FG hydrogels from Xenopus nuclear pore complexes. EMBO J 32, 204&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553378</ArticleId><ArticleId IdType="pubmed">23202855</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemke EA (2016). The Multiple Faces of Disordered Nucleoporins. J Mol Biol 428, 2011&#x2013;2024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611686</ArticleId><ArticleId IdType="pubmed">26791761</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenart P, Rabut G, Daigle N, Hand AR, Terasaki M, and Ellenberg J (2003). Nuclear envelope breakdown in starfish oocytes proceeds by partial NPC disassembly followed by a rapidly spreading fenestration of nuclear membranes. J Cell Biol 160, 1055&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172766</ArticleId><ArticleId IdType="pubmed">12654902</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Kumar Y, Zempel H, Mandelkow EM, Biernat J, and Mandelkow E (2011). Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J 30, 4825&#x2013;4837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243615</ArticleId><ArticleId IdType="pubmed">22009197</ArticleId></ArticleIdList></Reference><Reference><Citation>Loomis PA, Howard TH, Castleberry RP, and Binder LI (1990). Identification of nuclear tau isoforms in human neuroblastoma cells. Proc Natl Acad Sci U S A 87, 8422&#x2013;8426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54968</ArticleId><ArticleId IdType="pubmed">1700432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord CL, Timney BL, Rout MP, and Wente SR (2015). Altering nuclear pore complex function impacts longevity and mitochondrial function in S. cerevisiae. J Cell Biol 208, 729&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362458</ArticleId><ArticleId IdType="pubmed">25778920</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y, Yang TH, Kim HM, Drake D, Liu XS, et al. (2014). REST and stress resistance in ageing and Alzheimer&#x2019;s disease. Nature 507, 448&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110979</ArticleId><ArticleId IdType="pubmed">24670762</ArticleId></ArticleIdList></Reference><Reference><Citation>Matevossian A, and Akbarian S (2008). Neuronal nuclei isolation from human postmortem brain tissue. J Vis Exp.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233860</ArticleId><ArticleId IdType="pubmed">19078943</ArticleId></ArticleIdList></Reference><Reference><Citation>Maziuk B, Ballance HI, and Wolozin B (2017). Dysregulation of RNA Binding Protein Aggregation in Neurodegenerative Disorders. Front Mol Neurosci 10, 89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378767</ArticleId><ArticleId IdType="pubmed">28420962</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, Paquola ACM, Ku M, Hatch E, Bohnke L, Ladjevardi S, McGrath S, Campbell B, Lee H, Herdy JR, et al. (2015). Directly Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic Signatures and Reveal Age-Related Nucleocytoplasmic Defects. Cell Stem Cell 17, 705&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5929130</ArticleId><ArticleId IdType="pubmed">26456686</ArticleId></ArticleIdList></Reference><Reference><Citation>Milles S, and Lemke EA (2011). Single molecule study of the intrinsically disordered FG-repeat nucleoporin 153. Biophys J 101, 1710&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183753</ArticleId><ArticleId IdType="pubmed">21961597</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore MS, and Blobel G (1994). A G protein involved in nucleocytoplasmic transport: the role of Ran. Trends Biochem Sci 19, 211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">7519373</ArticleId></ArticleIdList></Reference><Reference><Citation>Obradovic Z, Peng K, Vucetic S, Radivojac P, Brown CJ, and Dunker AK (2003). Predicting intrinsic disorder from amino acid sequence. Proteins 53 Suppl 6, 566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">14579347</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng K, Vucetic S, Radivojac P, Brown CJ, Dunker AK, and Obradovic Z (2005). Optimizing long intrinsic disorder predictors with protein evolutionary information. J Bioinform Comput Biol 3, 35&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751111</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Frey S, Menzel A, Gorlich D, and Techert S (2012). Structural characterization of nanoscale meshworks within a nucleoporin FG hydrogel. Biomacromolecules 13, 1882&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pubmed">22571273</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers MA, Forbes DJ, Dahlberg JE, and Lund E (1997). The vertebrate GLFG nucleoporin, Nup98, is an essential component of multiple RNA export pathways. J Cell Biol 136, 241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2134807</ArticleId><ArticleId IdType="pubmed">9015297</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabut G, Doye V, and Ellenberg J (2004). Mapping the dynamic organization of the nuclear pore complex inside single living cells. Nat Cell Biol 6, 1114&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pubmed">15502822</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, and Gorlich D (2015). Nup98 FG domains from diverse species spontaneously phase-separate into particles with nuclear pore-like permselectivity. Elife 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4283134</ArticleId><ArticleId IdType="pubmed">25562883</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield LG, Miskiewicz HB, Tannenbaum LB, and Mirra SS (2006). Nuclear pore complex proteins in Alzheimer disease. J Neuropathol Exp Neurol 65, 45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410748</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow CJ, Dar A, Dutta A, Kehlenbach RH, and Paschal BM (2013). Defective nuclear import of Tpr in Progeria reflects the Ran sensitivity of large cargo transport. J Cell Biol 201, 541&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653351</ArticleId><ArticleId IdType="pubmed">23649804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S, et al. (2011). Nuclear tau, a key player in neuronal DNA protection. J Biol Chem 286, 4566&#x2013;4575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039398</ArticleId><ArticleId IdType="pubmed">21131359</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, Nicholls SB, Carlson GA, Pitstick R, Nobuhara CK, et al. (2015). Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#x2019;s disease brain. Nat Commun 6, 8490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E, and Mandelkow EM (2007). Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 27, 2896&#x2013;2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Timney BL, Raveh B, Mironska R, Trivedi JM, Kim SJ, Russel D, Wente SR, Sali A, and Rout MP (2016). Simple rules for passive diffusion through the nuclear pore complex. J Cell Biol 215, 57&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5057280</ArticleId><ArticleId IdType="pubmed">27697925</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, Apicco DJ, Youmans-Kidder K, Ash PEA, Cook C, Lummertz da Rocha E, Jansen-West K, Frame AA, Citro A, Leszyk JD, et al. (2016). Interaction of tau with the RNA-Binding Protein TIA1 Regulates tau Pathophysiology and Toxicity. Cell Rep 15, 1455&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325702</ArticleId><ArticleId IdType="pubmed">27160897</ArticleId></ArticleIdList></Reference><Reference><Citation>Violet M, Delattre L, Tardivel M, Sultan A, Chauderlier A, Caillierez R, Talahari S, Nesslany F, Lefebvre B, Bonnefoy E, et al. (2014). A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front Cell Neurosci 8, 84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957276</ArticleId><ArticleId IdType="pubmed">24672431</ArticleId></ArticleIdList></Reference><Reference><Citation>Vovk A, Gu C, Opferman MG, Kapinos LE, Lim RY, Coalson RD, Jasnow D, and Zilman A (2016). Simple biophysics underpins collective conformations of the intrinsically disordered proteins of the Nuclear Pore Complex. Elife 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4874778</ArticleId><ArticleId IdType="pubmed">27198189</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner RS, Kapinos LE, Marshall NJ, Stewart M, and Lim RY (2015). Promiscuous binding of Karyopherinbeta1 modulates FG nucleoporin barrier function and expedites NTF2 transport kinetics. Biophys J 108, 918&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336380</ArticleId><ArticleId IdType="pubmed">25692596</ArticleId></ArticleIdList></Reference><Reference><Citation>Weingarten MD, Lockwood AH, Hwo SY, and Kirschner MW (1975). A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72, 1858&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC432646</ArticleId><ArticleId IdType="pubmed">1057175</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis K (2003). Regulating access to the genome: nucleocytoplasmic transport throughout the cell cycle. Cell 112, 441&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">12600309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wente SR, and Rout MP (2010). The nuclear pore complex and nuclear transport. Cold Spring Harb Perspect Biol 2, a000562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944363</ArticleId><ArticleId IdType="pubmed">20630994</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, and Lee VM (2008). Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem 283, 13302&#x2013;13309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F, et al. (2018). Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell 173, 958&#x2013;971 e917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, et al. (2015). The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30185230</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans.</ArticleTitle><Pagination><StartPage>49</StartPage><MedlinePgn>49</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">49</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-018-0280-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">The R47H variant of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) significantly increases the risk for late onset Alzheimer's disease. Mouse models accurately reproducing phenotypes observed in Alzheimer' disease patients carrying the R47H coding variant are required to understand the TREM2 related dysfunctions responsible for the enhanced risk for late onset Alzheimer's disease.</AbstractText><AbstractText Label="METHODS">A CRISPR/Cas9-assisted gene targeting strategy was used to generate Trem2 R47H knock-in mice. Trem2 mRNA and protein levels as well as Trem2 splicing patterns were assessed in these mice, in iPSC-derived human microglia-like cells, and in human brains from Alzheimer's patients carrying the TREM2 R47H risk factor.</AbstractText><AbstractText Label="RESULTS">Two independent Trem2 R47H knock-in mouse models show reduced Trem2 mRNA and protein production. In both mouse models Trem2 haploinsufficiency was due to atypical splicing of mouse Trem2 R47H, which introduced a premature stop codon. Cellular splicing assays using minigene constructs demonstrate that the R47H variant induced abnormal splicing only occurs in mice but not in humans. TREM2 mRNA levels and splicing patterns were both normal in iPSC-derived human microglia-like cells and patient brains with the TREM2 R47H variant.</AbstractText><AbstractText Label="CONCLUSIONS">The Trem2 R47H variant activates a cryptic splice site that generates miss-spliced transcripts leading to Trem2 haploinsufficiency only in mice but not in humans. Since Trem2 R47H related phenotypes are mouse specific and do not occur in humans, humanized TREM2 R47H knock-in mice should be generated to study the cellular consequences caused by the human TREM2 R47H coding variant. Currently described phenotypes of Trem2 R47H knock-in mice can therefore not be translated to humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Xianyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Systemic Neuroscience, Ludwig- Maximilians- University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piers</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neuroinflammation, Cell Signalling Lab, University College London Institute of Neurology, WC1N 1PJ, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wefers</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Kaichuan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallach</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroinflammation, Cell Signalling Lab, University College London Institute of Neurology, WC1N 1PJ, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Wilbur</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Immunology and Pathology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology and Pathology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wurst</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technische Universit&#xe4;t M&#xfc;nchen-Weihenstephan, 85764, Neuherberg/Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pocock</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neuroinflammation, Cell Signalling Lab, University College London Institute of Neurology, WC1N 1PJ, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany. christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany. christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BB/M009513/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>No 115976</GrantID><Agency>Innovative Medicines Initiative 2 Joint Undertaking</Agency><Country>International</Country></Grant><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG051485</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HA1737/16-1</GrantID><Agency>Koselleck Project</Agency><Country>International</Country></Grant><Grant><GrantID>EXC 1010 SyNergy</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country>International</Country></Grant><Grant><GrantID>01EK1605C</GrantID><Agency>German Federal Ministry of Education and Research</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Human microglia</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Pre-mRNA splicing</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL: All mice were handled according to institutional guidelines approved by the animal welfare and use committee of the government of Upper Bavaria. Ethics committee from Ludwig-Maximilians- University and University College London approved this research project using human tissue. CONSENT FOR PUBLICATION: Consent for publication on using human tissue in this study is detailed in the Material Transfer Agreement (MTA) between organizations. COMPETING INTERESTS: C.H. collaborates with DENALI Therapeutics and received a speaker honorarium from Novartis and Roche. The other authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30185230</ArticleId><ArticleId IdType="pmc">PMC6126019</ArticleId><ArticleId IdType="doi">10.1186/s13024-018-0280-6</ArticleId><ArticleId IdType="pii">10.1186/s13024-018-0280-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sims R, Van Der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat Genet. [Internet] 2017;49:1373&#x2013;84. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/28714976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, Tan L, Chen Q, Tan MS, Zhou JS, Zhu XC, et al. A rare coding variant in TREM2 increases risk for Alzheimer&#x2019;s disease in Han Chinese. Neurobiol Aging [Internet]. Elsevier Inc. 2016;42:17.e1&#x2013;217.e3. Available from: 10.1016/j.neurobiolaging.2016.02.023.</Citation><ArticleIdList><ArticleId IdType="pubmed">27067662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. [Internet]. 2013;368:107&#x2013;16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23150908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med [Internet]. 2013;368:117&#x2013;27. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan G, White CC, Winn P a, Cimpean M, Replogle JM, Glick LR, et al. CD33 modulates TREM2: convergence of Alzheimer loci. Nat. Neurosci. [Internet]. 2015;2015. Available from: 10.1038/nn.4126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682915</ArticleId><ArticleId IdType="pubmed">26414614</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity [Internet]. Elsevier Inc.; 2017;47:566&#x2013;81.e9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1074761317303667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep [Internet] 2017;18:1186&#x2013;98. Available from: http://embor.embopress.org/lookup/doi/10.15252/embr.201743922.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201743922</ArticleId><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer&#x2019;s Disease Model. Cell [Internet]. Elsevier Inc.; 2015;160:1061&#x2013;71. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0092867415001270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SCC, Ulrich JD, Sergushichev A, Beatty WL, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer&#x2019;s Disease. Cell [Internet]. Elsevier Inc.; 2017;170:649&#x2013;63.e13. Available from: 10.1016/j.cell.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell [Internet]. Elsevier; 2017;169:1276&#x2013;90.e17. Available from: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, et al. The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J [Internet] 2017;36:1837&#x2013;53. Available from: http://emboj.embopress.org/lookup/doi/10.15252/embj.201796516.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201796516</ArticleId><ArticleId IdType="pmc">PMC5494459</ArticleId><ArticleId IdType="pubmed">28559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med [Internet] 2015;212:287&#x2013;95. Available from: http://www.jem.org/cgi/doi/10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, et al. TREM2 Haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron [Internet]. 2016;92:252&#x2013;64. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/27196974.</Citation><ArticleIdList><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. med. [Internet]. 2018;215:745&#x2013;60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29321225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Araque Caballero M&#xc1;, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer&#x2019;s disease occur after amyloid deposition and neuronal injury. Sci. Transl. Med. [Internet]. 2016;8:369ra178. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27974666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. [Internet]. 2016;jem.20151948. Available from: http://www.jem.org/lookup/doi/10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, et al. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol. [Internet]. 2015;129:429&#x2013;47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25631124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667728</ArticleId><ArticleId IdType="pubmed">25631124</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, et al. TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest. [Internet]. 2015;125:2161&#x2013;70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25893602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463196</ArticleId><ArticleId IdType="pubmed">25893602</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener. [Internet] 2017;12:1&#x2013;12. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/29037207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="pubmed">29037207</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl. Acad. Sci. U. S. A. [Internet]. 2017;114:11524&#x2013;9. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1710311114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, Liu C-C, Painter MM, Chen X-F, Verbeeck C, Zheng H, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem. [Internet] 2015;290:26043&#x2013;50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26374899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-Beta by microglia. Neuron. [Internet] 2016;91:328&#x2013;40. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/27477018.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wu X, Li X, Jiang L-L, Gui X, Liu Y, et al. TREM2 Is a Receptor for &#x3b2;-Amyloid that Mediates Microglial Function. Neuron [Internet]. 2018;97:1023&#x2013;31.e7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0896627318300564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudom A, Talreja S, Danao J, Bragg E, Kegel R, Min X, et al. Molecular basis for the loss-of-function effects of the Alzheimer&#x2019;s disease&#x2013;associated R47H variant of the immune receptor TREM2. J Biol Chem. [internet]. 2018;2:jbc.RA118.002352. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29794134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093241</ArticleId><ArticleId IdType="pubmed">29794134</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Su&#xe1;rez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. [Internet]. 2014;6:243ra86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24990881.</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng-hathaway PJ, Reed-geaghan EG, Jay TR, Casali BT, Bemiller SM, Puntambekar SS, et al. The T rem 2 R47H variant confers loss-of- function-like phenotypes in Alzheimer&#x2019; s disease. Mol Neurodegener. [Internet] 2018:1&#x2013;12. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/29859094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984804</ArticleId><ArticleId IdType="pubmed">29859094</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q, Danao J, Talreja S, Wen P, Yin J, Sun N, et al. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer&#x2019;s disease variant TREM2 R47H on murine myeloid cell function. J Biol Chem. [Internet]. 2018;jbc.RA118.001848. Available from: http://www.jbc.org/lookup/doi/10.1074/jbc.RA118.001848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.001848</ArticleId><ArticleId IdType="pmc">PMC6093249</ArticleId><ArticleId IdType="pubmed">29599291</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandl C, Ortiz O, R&#xf6;ttig B, Wefers B, Wurst W, K&#xfc;hn R. Creation of targeted genomic deletions using TALEN or CRISPR/Cas nuclease pairs in one-cell mouse embryos. FEBS Open Bio [Internet]. Federation of European Biochemical Societies; 2015;5:26&#x2013;35. Available from: 10.1016/j.fob.2014.11.009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4309836</ArticleId><ArticleId IdType="pubmed">25685662</ArticleId></ArticleIdList></Reference><Reference><Citation>Wefers B, Bashir S, Rossius J, Wurst W, K&#xfc;hn R. Gene editing in mouse zygotes using the CRISPR/Cas9 system. Methods [Internet]. Elsevier Inc. 2017;121&#x2013;122:55&#x2013;67. Available from: 10.1016/j.ymeth.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="pubmed">28263886</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeussler M, Sch&#xf6;nig K, Eckert H, Eschstruth A, Miann&#xe9; J, Renaud JB, et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. [Internet] 2016;17(1):148. Available from: 10.1186/s13059-016-1012-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934014</ArticleId><ArticleId IdType="pubmed">27380939</ArticleId></ArticleIdList></Reference><Reference><Citation>Marim FM, Silveira TN, Lima DS, Zamboni DS. A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. PLoS One. [Internet] 2010;5:1&#x2013;8. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/21179419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003694</ArticleId><ArticleId IdType="pubmed">21179419</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol. Med. [Internet] 2016;8:992&#x2013;1004. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/27402340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="pubmed">27402340</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, Vainchtein ID, Brouwer N, Boddeke EWGM, Eggen BJL. Isolation of microglia and immune infiltrates from mouse and primate central nervous system. Methods Mol Biol. [Internet] 2017;1559:333&#x2013;42. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/28063055.</Citation><ArticleIdList><ArticleId IdType="pubmed">28063055</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat methods [Internet]. 2011;8:409&#x2013;12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21460823.</Citation><ArticleIdList><ArticleId IdType="pubmed">21460823</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, et al. iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. Neuron. [Internet] 2017;94:278&#x2013;293.e9. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/28426964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wilgenburg B, Browne C, Vowles J, Cowley SA. Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. Covas DT, editor. PLoS One. [Internet] 2013;8:e71098. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23951090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3741356</ArticleId><ArticleId IdType="pubmed">23951090</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat Neurosci [Internet] 2014;17:131&#x2013;43. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4066672&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J, Li Y, Yuan B, Mitalipova M, Omer A, Corcoran S, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med.&#xa0;[Internet] 2016;22:1358&#x2013;67. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/27668937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenseler W, Sansom SN, Buchrieser J, Newey SE, Moore CS, Nicholls FJ, et al. A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response. Stem Cell Rep. [Internet] 2017;8:1727&#x2013;42. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/28591653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470330</ArticleId><ArticleId IdType="pubmed">28591653</ArticleId></ArticleIdList></Reference><Reference><Citation>CRAN - Package gplots [Internet]. Available from: https://cran.r-project.org/web/packages/gplots/index.html.</Citation></Reference><Reference><Citation>R package d3heatmap version 0.6.1.2. Comprehensive R Archive Network (CRAN). Available from: https://cran.r-project.org/web/packages/d3heatmap/index.html.</Citation></Reference><Reference><Citation>Bouchon A, Hern&#xe1;ndez-Munain C, Cella M, Colonna M. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med. [Internet] 2001;194:1111&#x2013;22. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2193511&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193511</ArticleId><ArticleId IdType="pubmed">11602640</ArticleId></ArticleIdList></Reference><Reference><Citation>Isken O, Maquat LE. Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function. Genes Dev.&#xa0;[Internet] 2007;21:1833&#x2013;56. Available from:&#xa0;https://www.ncbi.nlm.nih.gov/pubmed/17671086.</Citation><ArticleIdList><ArticleId IdType="pubmed">17671086</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. [Internet] 2017;37:637&#x2013;47. Available from: http://www.jneurosci.org/content/37/3/637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. [Internet]. 2016;213:667&#x2013;75. Available from: http://www.jem.org/lookup/doi/10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat. Rev. Neurosci. [Internet]. Nat Publ Group; 2016;17:201&#x2013;207. Available from: http://www.nature.com/doifinder/10.1038/nrn.2016.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.7</ArticleId><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Maquat LE. Nonsense-mediated mRNA decay in mammals. J Cell Sci. [Internet] 2005;118:1773&#x2013;6. Available from: http://jcs.biologists.org/cgi/doi/10.1242/jcs.01701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.01701</ArticleId><ArticleId IdType="pubmed">15860725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30190379</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>361</Volume><Issue>6406</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer's mouse model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaan8821</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aan8821</ELocationID><Abstract><AbstractText>Adult hippocampal neurogenesis (AHN) is impaired before the onset of Alzheimer's disease (AD) pathology. We found that exercise provided cognitive benefit to 5&#xd7;FAD mice, a mouse model of AD, by inducing AHN and elevating levels of brain-derived neurotrophic factor (BDNF). Neither stimulation of AHN alone, nor exercise, in the absence of increased AHN, ameliorated cognition. We successfully mimicked the beneficial effects of exercise on AD mice by genetically and pharmacologically inducing AHN in combination with elevating BDNF levels. Suppressing AHN later led to worsened cognitive performance and loss of preexisting dentate neurons. Thus, pharmacological mimetics of exercise, enhancing AHN and elevating BDNF levels, may improve cognition in AD. Furthermore, applied at early stages of AD, these mimetics may protect against subsequent neuronal cell death.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se Hoon</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-7905-4380</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bylykbashi</LastName><ForeName>Enjana</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3533-0192</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatila</LastName><ForeName>Zena K</ForeName><Initials>ZK</Initials><Identifier Source="ORCID">0000-0002-4383-6305</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Star W</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-2624-7365</Identifier><AffiliationInfo><Affiliation>Laboratoy of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulli</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1795-9897</Identifier><AffiliationInfo><Affiliation>Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemenson</LastName><ForeName>Gregory D</ForeName><Initials>GD</Initials><Identifier Source="ORCID">0000-0002-7704-8112</Identifier><AffiliationInfo><Affiliation>Laboratoy of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eunhee</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9297-2848</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rompala</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oram</LastName><ForeName>Mary K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-4693-2009</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asselin</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3598-5247</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronson</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7376-8622</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Can</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4340-5118</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Sean J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesinski</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Doo Yeon</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-6969-0340</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Praag</LastName><ForeName>Henriette</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5727-434X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Science, Charles E. Schmidt College of Medicine, and Brain Institute, Florida Atlantic University, Jupiter, FL 33458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spiegelman</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials><Identifier Source="ORCID">0000-0002-0938-4106</Identifier><AffiliationInfo><Affiliation>Laboratoy of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-7032-1454</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. tanzi@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG014713</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055784</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002227">Carbazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577593">FNDC5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005353">Fibronectins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C552520">P7C3 compound</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060508">Wnt3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C555508">Wnt3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577686">interleukin-6, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2018 Sep 7;361(6406):975-976. doi: 10.1126/science.aau8060.</RefSource><PMID Version="1">30190391</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002227" MajorTopicYN="N">Carbazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="Y">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005353" MajorTopicYN="N">Fibronectins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="Y">Neurogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010805" MajorTopicYN="N">Physical Conditioning, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060508" MajorTopicYN="N">Wnt3 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interest:</b> We declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30190379</ArticleId><ArticleId IdType="mid">NIHMS987544</ArticleId><ArticleId IdType="pmc">PMC6149542</ArticleId><ArticleId IdType="doi">10.1126/science.aan8821</ArticleId><ArticleId IdType="pii">361/6406/eaan8821</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE, Bertram L, Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: a genetic perspective. Cell 120, 545&#x2013;555 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS et al., Neurogenesis in the adult human hippocampus. Nat Med 4, 1313&#x2013;1317 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Y, Gage FH, Adult hippocampal neurogenesis and its role in Alzheimer&#x2019;s disease. Molecular neurodegeneration 6, 85&#x2013;93 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261815</ArticleId><ArticleId IdType="pubmed">22192775</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews L et al., Increased BMP6 levels in the brains of Alzheimer&#x2019;s disease patients and APP transgenic mice are accompanied by impaired neurogenesis. J Neurosci 30, 12252&#x2013;12262 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978735</ArticleId><ArticleId IdType="pubmed">20844121</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Nicola D et al., Temporal dynamics of hippocampal neurogenesis in chronic neurodegeneration. Brain 137, 2312&#x2013;2328 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107745</ArticleId><ArticleId IdType="pubmed">24941947</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K et al., Increased hippocampal neurogenesis in Alzheimer&#x2019;s disease. Proceedings of the National Academy of Sciences of the United States of America 101, 343&#x2013;347 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314187</ArticleId><ArticleId IdType="pubmed">14660786</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B et al., Failure of neuronal maturation in Alzheimer disease dentate gyrus. J Neuropathol Exp Neurol 67, 78&#x2013;84 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191920</ArticleId><ArticleId IdType="pubmed">18091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell MA, Geiger H, Van Zant GE, Lynn BC, Markesbery WR, Isolation of neural precursor cells from Alzheimer&#x2019;s disease and aged control postmortem brain. Neurobiology of aging 27, 909&#x2013;917 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">15979211</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK et al., Neurogenic abnormalities in Alzheimer&#x2019;s disease differ between stages of neurogenesis and are partly related to cholinergic pathology. Neurobiology of disease 47, 155&#x2013;162 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4075422</ArticleId><ArticleId IdType="pubmed">22504537</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H et al., Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O et al., Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120, 701&#x2013;713 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>Radak Z et al., Exercise plays a preventive role against Alzheimer&#x2019;s disease. J Alzheimers Dis 20, 777&#x2013;783 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20182027</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Kempermann G, Gage FH, Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nature neuroscience 2, 266&#x2013;270 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10195220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieper AA et al., Discovery of a proneurogenic, neuroprotective chemical. Cell 142, 39&#x2013;51 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930815</ArticleId><ArticleId IdType="pubmed">20603013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie DC et al., Wnt signalling regulates adult hippocampal neurogenesis. Nature 437, 1370&#x2013;1375 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16251967</ArticleId></ArticleIdList></Reference><Reference><Citation>Clelland CD et al., A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science 325, 210&#x2013;213 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997634</ArticleId><ArticleId IdType="pubmed">19590004</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuker L, Doeller CF, Fell J, Axmacher N, Human neuroimaging studies on the hippocampal CA3 region - integrating evidence for pattern separation and completion. Frontiers in cellular neuroscience 8, 64 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941178</ArticleId><ArticleId IdType="pubmed">24624058</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Ittner LM, Animal models of Alzheimer&#x2019;s disease and frontotemporal dementia. Nature reviews 9, 532&#x2013;544 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18568014</ArticleId></ArticleIdList></Reference><Reference><Citation>Meshi D et al., Hippocampal neurogenesis is not required for behavioral effects of environmental enrichment. Nature neuroscience 9, 729&#x2013;731 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16648847</ArticleId></ArticleIdList></Reference><Reference><Citation>Santarelli L et al., Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805&#x2013;809 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12907793</ArticleId></ArticleIdList></Reference><Reference><Citation>Garthe A, Behr J, Kempermann G, Adult-generated hippocampal neurons allow the flexible use of spatially precise learning strategies. PloS one 4, e5464 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674212</ArticleId><ArticleId IdType="pubmed">19421325</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch CE, Laping NJ, Morgan TE, Nichols NR, Pasinetti GM, TGF-beta 1 is an organizer of responses to neurodegeneration. Journal of cellular biochemistry 53, 314&#x2013;322 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8300749</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanders KC, Ren RF, Lippa CF, Transforming growth factor-betas in neurodegenerative disease. Progress in neurobiology 54, 71&#x2013;85 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9460794</ArticleId></ArticleIdList></Reference><Reference><Citation>Klassen HJ et al., Expression of cytokines by multipotent neural progenitor cells. Cytokine 22, 101&#x2013;106 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12849709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Ahlemeyer B, Bauerbach E, Krieglstein J, TGF-beta1 inhibits caspase-3 activation and neuronal apoptosis in rat hippocampal cultures. Neurochemistry international 38, 227&#x2013;235 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11099781</ArticleId></ArticleIdList></Reference><Reference><Citation>Battista D, Ferrari CC, Gage FH, Pitossi FJ, Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur J Neurosci 23, 83&#x2013;93 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16420418</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckwalter MS et al., Chronically increased transforming growth factor-beta1 strongly inhibits hippocampal neurogenesis in aged mice. Am J Pathol 169, 154&#x2013;164 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698757</ArticleId><ArticleId IdType="pubmed">16816369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy M et al., TGF-beta signalling in the adult neurogenic niche promotes stem cell quiescence as well as generation of new neurons. Journal of cellular and molecular medicine 18, 1444&#x2013;1459 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4124027</ArticleId><ArticleId IdType="pubmed">24779367</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachs FP et al., Transforming growth factor-beta1 is a negative modulator of adult neurogenesis. J Neuropathol Exp Neurol 65, 358&#x2013;370 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16691117</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH et al., A three-dimensional human neural cell culture model of Alzheimer&#x2019;s disease. Nature 515, 274&#x2013;278 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho J et al., Treadmill Running Reverses Cognitive Declines due to Alzheimer Disease. Medicine and science in sports and exercise 47, 1814&#x2013;1824 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25574797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Berchtold NC, Exercise: a behavioral intervention to enhance brain health and plasticity. Trends in neurosciences 25, 295&#x2013;301 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12086747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Berchtold NC, Christie LA, Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends in neurosciences 30, 464&#x2013;472 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17765329</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Martin M, Torres-Aleman I, Trejo JL, Growth factors as mediators of exercise actions on the brain. Neuromolecular Med 10, 99&#x2013;107 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18286390</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaynman SS, Ying Z, Yin D, Gomez-Pinilla F, Exercise differentially regulates synaptic proteins associated to the function of BDNF. Brain Res 1070, 124&#x2013;130 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16413508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrann CD et al., Exercise induces hippocampal BDNF through a PGC-1alpha/FNDC5 pathway. Cell metabolism 18, 649&#x2013;659 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3980968</ArticleId><ArticleId IdType="pubmed">24120943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamos JE, DeGennaro LJ, Drachman DA, Synaptic loss in Alzheimer&#x2019;s disease and other dementias. Neurology 39, 355&#x2013;361 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2927643</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, Wuu J, Mufson EJ, Fahnestock M, Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer&#x2019;s disease. Journal of neurochemistry 93, 1412&#x2013;1421 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15935057</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor DT, Coulson EJ, Dodd PR, Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis 21, 795&#x2013;811 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20634587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen P et al., In humans IL-6 is released from the brain during and after exercise and paralleled by enhanced IL-6 mRNA expression in the hippocampus of mice. Acta Physiol (Oxf) 201, 475&#x2013;482 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21083649</ArticleId></ArticleIdList></Reference><Reference><Citation>Baier PC, May U, Scheller J, Rose-John S, Schiffelholz T, Impaired hippocampus-dependent and -independent learning in IL-6 deficient mice. Behavioural brain research 200, 192&#x2013;196 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19378383</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen KK, Dempsey RJ, Vemuganti R, Adult interleukin-6 knockout mice show compromised neurogenesis. Neuroreport 22, 126&#x2013;130 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21266900</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson CA, Aoyama M, Harry GJ, Interleukin (IL)-1 and IL-6 regulation of neural progenitor cell proliferation with hippocampal injury: differential regulatory pathways in the subgranular zone (SGZ) of the adolescent and mature mouse brain. Brain, behavior, and immunity 25, 850&#x2013;862 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033445</ArticleId><ArticleId IdType="pubmed">20833246</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallieres L, Campbell IL, Gage FH, Sawchenko PE, Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci 22, 486&#x2013;492 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758670</ArticleId><ArticleId IdType="pubmed">11784794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yirmiya R, Goshen I, Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain, behavior, and immunity 25, 181&#x2013;213 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20970492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Deng W, Gage FH, Mechanisms and functional implications of adult neurogenesis. Cell 132, 645&#x2013;660 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18295581</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrieri D, van Praag H, Exercise-mimetic AICAR transiently benefits brain function. Oncotarget 6, 18293&#x2013;18313 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4621892</ArticleId><ArticleId IdType="pubmed">26286955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobilo T et al., AMPK agonist AICAR improves cognition and motor coordination in young and aged mice. Learn Mem 21, 119&#x2013;126 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895225</ArticleId><ArticleId IdType="pubmed">24443745</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong XP et al., Essential role of tau phosphorylation in adult hippocampal neurogenesis. Hippocampus 20, 1339&#x2013;1349 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19816983</ArticleId></ArticleIdList></Reference><Reference><Citation>Horder H et al., Midlife cardiovascular fitness and dementia: A 44-year longitudinal population study in women. Neurology 90, e1298&#x2013;e1305 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5894933</ArticleId><ArticleId IdType="pubmed">29540588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb SE et al., Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial. BMJ 361, k1675 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5953238</ArticleId><ArticleId IdType="pubmed">29769247</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Lozano A et al., Physical Activity and Alzheimer Disease: A Protective Association. Mayo Clinic proceedings 91, 999&#x2013;1020 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27492909</ArticleId></ArticleIdList></Reference><Reference><Citation>Briley D et al., Preserved neurogenesis in non-demented individuals with AD neuropathology. Scientific reports 6, 27812 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4906289</ArticleId><ArticleId IdType="pubmed">27298190</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH et al., Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 59, 568&#x2013;580 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489017</ArticleId><ArticleId IdType="pubmed">18760694</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Gundersen HJ, Unbiased stereological estimation of the number of neurons in the human hippocampus. The Journal of comparative neurology 296, 1&#x2013;22 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2358525</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30208380</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Preventing Cognitive Decline in Black Individuals With Mild Cognitive Impairment: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>1487</StartPage><EndPage>1493</EndPage><MedlinePgn>1487-1493</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.2513</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Mild cognitive impairment (MCI) is a transition state between normal cognitive aging and dementia that increases the risk for progressive cognitive decline. Preventing cognitive decline is a public health priority.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether behavioral activation prevents cognitive and functional decline over 2 years in black individuals with MCI.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Single-center, single-masked, attention-controlled randomized clinical trial. Participants were enrolled from June 21, 2011, to October 3, 2014, and follow-up ended December 13, 2016. Community-based recruitment and treatment of black individuals older than 65 years with amnestic MCI. Volunteer sample of 1390 persons with memory complaints were screened. Overall, 536 individuals had baseline assessment, and 315 (58.8%) were ineligible, most often owing to normal cognition (205 of 315 [65%]) or dementia (59 of 315 [18.7%]); 221 fully eligible participants were randomized. Analyses were intention to treat.</AbstractText><AbstractText Label="INTERVENTIONS">Participants were randomized to behavioral activation, which aimed to increase cognitive, physical, and social activity (111 [50.2%]), or supportive therapy, an attention control treatment (110 [49.8%]).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The prespecified primary outcome was a decline of 6 or more recalled words on the total recall score of the Hopkins Verbal Learning Test-Revised assessed at 6, 12, 18, and 24 months. The secondary outcome was functional decline.</AbstractText><AbstractText Label="RESULTS">Of 221 randomized participants (mean [SD] age, 75.8 [7.0] years, 175 women [79%]), 77 behavioral activation participants (69.4%) and 87 supportive therapy participants (79.1%) had 2-year outcome assessments. After baseline, behavioral activation participants engaged in significantly more cognitive activities than supportive therapy participants. The 2-year incidence of memory decline was 1.2% (95% CI, 0.2-6.4) for behavioral activation vs 9.3% (95% CI, 5.30-16.4) for supportive therapy (relative risk, 0.12; 95% CI, 0.02-0.74; P&#x2009;=&#x2009;.02). Behavioral activation was associated with stable everyday function, whereas supportive therapy was associated with decline (difference in slopes, 2.71; 95% CI, 0.12-5.30; P&#x2009;=&#x2009;.04). Rates of serious adverse events for behavioral activation and supportive therapy, respectively, were: falls (14 [13%] vs 28 [25%]), emergency department visits (24 [22%] vs 24 [22%]), hospitalizations (36 [32%] vs 31 [28%]), and deaths (7 [5%] vs 3 [4%]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Behavioral activation prevented cognitive and functional decline, but this finding requires further investigation. Black individuals have almost twice the rate of dementia as white individuals; behavioral activation may reduce this health disparity.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT01299766.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rovner</LastName><ForeName>Barry W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Psychiatry, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casten</LastName><ForeName>Robin J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Human Behavior, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hegel</LastName><ForeName>Mark T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leiby</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01299766</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG035025</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Transl Med. 2019 Jul;7(Suppl 3):S142. doi: 10.21037/atm.2019.06.19.</RefSource><PMID Version="1">31576349</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="Y">Black or African American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="N">Behavior Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072466" MajorTopicYN="N">Cognitive Remediation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="Y">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="Y">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30208380</ArticleId><ArticleId IdType="pmc">PMC6583200</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.2513</ArticleId><ArticleId IdType="pii">2698824</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Sommerlad A, Orgeta V, et al. . Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31363-6</ArticleId><ArticleId IdType="pubmed">28735855</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H-X, MacDonald SWS, Dekhtyar S, Fratiglioni L. Association of lifelong exposure to cognitive reserve-enhancing factors with dementia risk: A community-based cohort study. PLoS Med. 2017;14(3):e1002251. doi:10.1371/journal.pmed.1002251</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002251</ArticleId><ArticleId IdType="pmc">PMC5349652</ArticleId><ArticleId IdType="pubmed">28291786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane RL, Butler M, Fink HA, et al. . Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer&#x2019;s-type dementia. AHRQ Comparative Effectiveness Reviews. 2017. Report No.: 17-EHC008-EF.</Citation><ArticleIdList><ArticleId IdType="pubmed">28759193</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association 2010 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2010;6(2):158-194. doi:10.1016/j.jalz.2010.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.01.009</ArticleId><ArticleId IdType="pubmed">20298981</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, Besser LM, Crook JE, Kukull WA, Dickson DW. Neuropathologic differences by race from the National Alzheimer&#x2019;s Coordinating Center. Alzheimers Dement. 2016;12(6):669-677. doi:10.1016/j.jalz.2016.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.004</ArticleId><ArticleId IdType="pmc">PMC4903907</ArticleId><ArticleId IdType="pubmed">27094726</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Leurgans S, Aggarwal NT, et al. . Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528-534. doi:10.1212/WNL.0000000000001834</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001834</ArticleId><ArticleId IdType="pmc">PMC4540250</ArticleId><ArticleId IdType="pubmed">26180136</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavett BE, John SE, Gurnani AS, Bussell CA, Saurman JL. The role of Alzheimer&#x2019;s and cerebrovascular pathology in mediating the effects of age, race, and apolipoprotein E genotype on dementia severity in pathologically confirmed Alzheimer&#x2019;s disease. J Alzheimers Dis. 2016;49(2):531-545. doi:10.3233/JAD-150252</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150252</ArticleId><ArticleId IdType="pmc">PMC4858176</ArticleId><ArticleId IdType="pubmed">26444761</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. . The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE. Neurology. 2016;87(5):473-480. doi:10.1212/WNL.0000000000002914</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002914</ArticleId><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>Glymour MM, Manly JJ. Lifecourse social conditions and racial and ethnic patterns of cognitive aging. Neuropsychol Rev. 2008;18(3):223-254. doi:10.1007/s11065-008-9064-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11065-008-9064-z</ArticleId><ArticleId IdType="pubmed">18815889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BK, Glass TA, James BD, Bandeen-Roche K, Schwartz BS. Neighborhood psychosocial environment, apolipoprotein E genotype, and cognitive function in older adults. Arch Gen Psychiatry. 2011;68(3):314-321. doi:10.1001/archgenpsychiatry.2011.6</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.6</ArticleId><ArticleId IdType="pmc">PMC3328419</ArticleId><ArticleId IdType="pubmed">21383266</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper C, Tandy AR, Balamurali TBS, Livingston G. A systematic review and meta-analysis of ethnic differences in use of dementia treatment, care, and research. Am J Geriatr Psychiatry. 2010;18(3):193-203. doi:10.1097/JGP.0b013e3181bf9caf</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JGP.0b013e3181bf9caf</ArticleId><ArticleId IdType="pubmed">20224516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Cooke-Bailey JN, Reitz C, et al. ; Alzheimer Disease Genetics Consortium . Global and local ancestry in African-Americans: implications for Alzheimer&#x2019;s disease risk. Alzheimers Dement. 2016;12(3):233-243. doi:10.1016/j.jalz.2015.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.02.012</ArticleId><ArticleId IdType="pmc">PMC4681680</ArticleId><ArticleId IdType="pubmed">26092349</ArticleId></ArticleIdList></Reference><Reference><Citation>Federal Interagency Forum on Aging-Related Statistics  Older Americans 2012: key indicators of well-being. https://agingstats.gov/docs/PastReports/2012/OA2012.pdf. Washington, DC. Accessed July 31, 2018.</Citation></Reference><Reference><Citation>Benedict RHB, Brandt J. Manual: Hopkins verbal learning test-revised/Brief visuospatial memory test-revised. Lutz, FL: Psychological Assessment Resources; 1998.</Citation></Reference><Reference><Citation>Kanter JW, Manos RC, Bowe WM, Baruch DE, Busch AM, Rusch LC. What is behavioral activation? a review of the empirical literature. Clin Psychol Rev. 2010;30(6):608-620. doi:10.1016/j.cpr.2010.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpr.2010.04.001</ArticleId><ArticleId IdType="pubmed">20677369</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock IM. The health belief model and personal health behavior. Health Educ Monogr. 1974;2:354-466. doi:10.1177/109019817400200405</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/109019817400200405</ArticleId></ArticleIdList></Reference><Reference><Citation>Noavalis PN, Rojcewicz SJ, Peele R. Clinical Manual of Supportive Psychotherapy. Washington, DC: American Psychiatric Press; 1993.</Citation></Reference><Reference><Citation>Lucas JA, Ivnik RJ, Smith GE, et al. . Mayo&#x2019;s older African Americans normative studies: norms for Boston naming test, controlled oral word association, category fluency, animal naming, token test, WRAT-3 reading, trail making test, stroop test, and judgment of line orientation. Clin Neuropsychol. 2005;19(2):243-269. doi:10.1080/13854040590945337</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854040590945337</ArticleId><ArticleId IdType="pubmed">16019707</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, et al. . The Alzheimer&#x2019;s Disease Centers&#x2019; Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23(2):91-101. doi:10.1097/WAD.0b013e318191c7dd</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318191c7dd</ArticleId><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Unverzagt FW, Hall KS, Torke AM, et al. . Effects of age, education, and gender on CERAD neuropsychological test performance in an African-American sample. Clin Neuropsychol. 1996;10:180-190. doi:10.1080/13854049608406679</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854049608406679</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillenbaum GG, Heyman A, Huber MS, Ganguli M, Unverzagt FW. Performance of elderly African American and white community residents on the CERAD neuropsychological battery. J Int Neuropsychol Soc. 2001;7(4):502-509. doi:10.1017/S1355617701744062</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617701744062</ArticleId><ArticleId IdType="pubmed">11396552</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcopulos B, McLain C. Are our norms &#x201c;normal&#x201d;? a 4-year follow-up study of a biracial sample of rural elders with low education. Clin Neuropsychol. 2003;17(1):19-33. doi:10.1076/clin.17.1.19.15630</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/clin.17.1.19.15630</ArticleId><ArticleId IdType="pubmed">12854008</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AL, Rebok GW, Unverzagt FW, Willis SL, Brandt J. Word list memory predicts everyday function and problem-solving in the elderly: results from the ACTIVE cognitive intervention trial. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2011;18(2):129-146. doi:10.1080/13825585.2010.516814</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13825585.2010.516814</ArticleId><ArticleId IdType="pmc">PMC3265385</ArticleId><ArticleId IdType="pubmed">21069610</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomar JJ, Harvey PD, Bobes-Bascaran MT, Davies P, Goldberg TE. Development and cross-validation of the UPSA short form for the performance-based functional assessment of patients with mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry. 2011;19(11):915-922. doi:10.1097/JGP.0b013e3182011846</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JGP.0b013e3182011846</ArticleId><ArticleId IdType="pubmed">22024615</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33(8):783-795. doi:10.1097/00005650-199508000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199508000-00004</ArticleId><ArticleId IdType="pubmed">7637401</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotson VM, Schinka JA, Brown LM, Mortimer JA, Borenstein AR. Characteristics of the Florida cognitive activities scale in older African Americans. Assessment. 2008;15(1):72-77. doi:10.1177/1073191107307509</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073191107307509</ArticleId><ArticleId IdType="pubmed">18258733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturman MT, Morris MC, Mendes de Leon CF, Bienias JL, Wilson RS, Evans DA. Physical activity, cognitive activity, and cognitive decline in a biracial community population. Arch Neurol. 2005;62(11):1750-1754. doi:10.1001/archneur.62.11.1750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.11.1750</ArticleId><ArticleId IdType="pubmed">16286550</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Unverzagt FW, Hall KS, et al. . Mild cognitive impairment, incidence, progression, and reversion: findings from a community-based cohort of elderly African Americans. Am J Geriatr Psychiatry. 2014;22(7):670-681. doi:10.1016/j.jagp.2013.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2013.02.015</ArticleId><ArticleId IdType="pmc">PMC3842367</ArticleId><ArticleId IdType="pubmed">23831172</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HB, Richardson AK, Black BS, Shore AD, Kasper JD, Rabins PV. Race and cognitive decline among community-dwelling elders with mild cognitive impairment: findings from the Memory and Medical Care Study. Aging Ment Health. 2012;16(3):372-377. doi:10.1080/13607863.2011.609533</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13607863.2011.609533</ArticleId><ArticleId IdType="pmc">PMC3302954</ArticleId><ArticleId IdType="pubmed">21999809</ArticleId></ArticleIdList></Reference><Reference><Citation>Black SA, Rush RD. Cognitive and functional decline in adults aged 75 and older. J Am Geriatr Soc. 2002;50(12):1978-1986. doi:10.1046/j.1532-5415.2002.50609.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2002.50609.x</ArticleId><ArticleId IdType="pubmed">12473009</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadlen MF, Siscovick D, Fitzpatrick AL, Dulberg C, Kuller LH, Jackson S. Education, cognitive test scores, and black-white differences in dementia risk. J Am Geriatr Soc. 2006;54(6):898-905. doi:10.1111/j.1532-5415.2006.00747.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2006.00747.x</ArticleId><ArticleId IdType="pubmed">16776783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngandu T, Lehtisalo J, Solomon A, et al. . A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263. doi:10.1016/S0140-6736(15)60461-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)60461-5</ArticleId><ArticleId IdType="pubmed">25771249</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrieu S, Guyonnet S, Coley N, et al. ; MAPT Study Group . Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377-389. doi:10.1016/S1474-4422(17)30040-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30040-6</ArticleId><ArticleId IdType="pubmed">28359749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhetri JK, de Souto Barreto P, Cantet C, et al. . Effects of a 3-year multi-domain intervention with or without omega-3 supplementation on cognitive functions in older subjects with increased CAIDE dementia scores. J Alzheimers Dis. 2018;64(1):71-78. doi:10.3233/JAD-180209</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180209</ArticleId><ArticleId IdType="pubmed">29865075</ArticleId></ArticleIdList></Reference><Reference><Citation>Gates N, Fiatarone Singh MA, Sachdev PS, Valenzuela M. The effect of exercise training on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials. Am J Geriatr Psychiatry. 2013;21(11):1086-1097. doi:10.1016/j.jagp.2013.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2013.02.018</ArticleId><ArticleId IdType="pubmed">23831175</ArticleId></ArticleIdList></Reference><Reference><Citation>Stott J, Spector A. A review of the effectiveness of memory interventions in mild cognitive impairment (MCI). Int Psychogeriatr. 2011;23(4):526-538. doi:10.1017/S1041610210001973</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610210001973</ArticleId><ArticleId IdType="pubmed">20946704</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb FJ, Khubchandani J, Striley CW, Cottler LB. Black-white differences in willingness to participate and perceptions about health research: results from the population-based HealthStreet Study [published online March 30, 2018]. J Immigr Minor Health. doi:10.1007/s10903-018-0729-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10903-018-0729-2</ArticleId><ArticleId IdType="pmc">PMC6701178</ArticleId><ArticleId IdType="pubmed">29603088</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunbar-Jacob J, Holmes JL, Sereika S, et al. . Factors associated with attrition of African Americans during the recruitment phase of a clinical trial examining adherence among individuals with rheumatoid arthritis. Arthritis Rheum. 2004;51(3):422-428. doi:10.1002/art.20411</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20411</ArticleId><ArticleId IdType="pubmed">15188328</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30217935</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>14</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.</ArticleTitle><Pagination><StartPage>e1295</StartPage><EndPage>e1306</EndPage><MedlinePgn>e1295-e1306</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000006277</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To assess the onset, sequence, and rate of progression of comprehensive biomarker and clinical measures across the spectrum of Alzheimer disease (AD) using the Dominantly Inherited Alzheimer Network (DIAN) study and compare these to cross-sectional estimates.</AbstractText><AbstractText Label="METHODS">We conducted longitudinal clinical, cognitive, CSF, and neuroimaging assessments (mean of 2.7 [&#xb1;1.1] visits) in 217 DIAN participants. Linear mixed effects models were used to assess changes in each measure relative to individuals' estimated years to symptom onset and to compare mutation carriers and noncarriers.</AbstractText><AbstractText Label="RESULTS">Longitudinal &#x3b2;-amyloid measures changed first (starting 25 years before estimated symptom onset), followed by declines in measures of cortical metabolism (approximately 7-10 years later), then cognition and hippocampal atrophy (approximately 20 years later). There were significant differences in the estimates of CSF p-tau<sub>181</sub> and tau, with elevations from cross-sectional estimates preceding longitudinal estimates by over 10 years; further, longitudinal estimates identified a significant decline in CSF p-tau<sub>181</sub> near symptom onset as opposed to continued elevations.</AbstractText><AbstractText Label="CONCLUSION">These longitudinal estimates clarify the sequence and temporal dynamics of presymptomatic pathologic changes in autosomal dominant AD, information critical to a better understanding of the disease. The pattern of biomarker changes identified here also suggests that once &#x3b2;-amyloidosis begins, additional pathologies may begin to develop less than 10 years later, but more than 15 years before symptom onset, an important consideration for interventions meant to alter the disease course.</AbstractText><CopyrightInformation>&#xa9; 2018 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany. ericmcdade@wustl.edu batemanr@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guoqiao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paumier</LastName><ForeName>Katrina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allegri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noble</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of T&#xfc;bingen, Germany. ericmcdade@wustl.edu batemanr@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG053474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG046363</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG049087</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/M009106/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Fague</LastName><ForeName>M Scot</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30217935</ArticleId><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000006277</ArticleId><ArticleId IdType="pii">WNL.0000000000006277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills SM, Mallmann J, Santacruz AM, et al. . Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol 2013;169:737&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880800</ArticleId><ArticleId IdType="pubmed">24016464</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. . Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol 2015;72:316&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease: a longitudinal prospective study. Brain 1998;121:1631&#x2013;1639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762953</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, et al. . Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012;11:1048&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallon D, Rousseau S, Rovelet-Lecrux A, et al. . The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis 2012;30:847&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">22475797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Younkin SG, Pratico D, et al. . Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71:85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash DM, Ridgway GR, Liang Y, et al. . The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology 2013;81:1425&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806583</ArticleId><ArticleId IdType="pubmed">24049139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Schultz AP, Johnson K, et al. . Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology 2013;81:736&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776464</ArticleId><ArticleId IdType="pubmed">23884042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Liang LJ, Zhou Y, et al. . Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. Brain 2015;138:1036&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4963801</ArticleId><ArticleId IdType="pubmed">25688083</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology 2014;28:19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877741</ArticleId><ArticleId IdType="pubmed">24219606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013;80:1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, et al. . Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014;83:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014;6:228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JB, Fleisher AS, et al. . Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(suppl 3):321&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Aisen PS, Bateman RJ, et al. . Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin Invest 2012;2:975&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, et al. . The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model. Alzheimers Dement 2017;13:8&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TL, Blazey T, Jack CR Jr, et al. . Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci USA 2013;110:E4502&#x2013;E4509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, D'Angelo GM, Vlassenko AG, et al. . Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One 2013;8:e73377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Owen CJ, et al. . Quantitative amyloid imaging in autosomal dominant Alzheimer's disease: results from the DIAN study group. PLoS One 2016;11:e0152082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807073</ArticleId><ArticleId IdType="pubmed">27010959</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland WS, Devlin SJ, Grosse E. Regression by local fitting: methods, properties, and computational algorithms. J Econom 1988;37:87&#x2013;114.</Citation></Reference><Reference><Citation>Jack CR, Wiste HJ, Weigand SD, et al. . Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;81:1732&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. . Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain 2016;139:1226&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Sch&#xf6;ll M, Strandberg O, et al. . Earliest accumulation of &#x3b2;-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 2017;8:1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663717</ArticleId><ArticleId IdType="pubmed">29089479</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. . Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014;6:226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Cirrito JR, Stewart FR, et al. . In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 2011;31:13110&#x2013;13117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, et al. . Increased in vivo Amyloid-Beta 42 production, exchange, and irreversible loss in presenilin mutations carriers. Sci Transl Med 2013;5:189ra77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol 2013;126:659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutphen CLML, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM. Longitudinal decrease in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer disease. Alzheimers Dement 2018;14:869&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110083</ArticleId><ArticleId IdType="pubmed">29580670</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Knopman DS, et al. . Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 2014;82:1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013810</ArticleId><ArticleId IdType="pubmed">24706010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey TM, Su Y, et al. . Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol 2018;17:241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816717</ArticleId><ArticleId IdType="pubmed">29397305</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30232227</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>459</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaao5620</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aao5620</ELocationID><Abstract><AbstractText>&#x3b2;-Site APP (amyloid precursor protein) cleaving enzyme 1 (BACE1) is the &#x3b2;-secretase enzyme that initiates production of the toxic amyloid-&#x3b2; peptide that accumulates in the brains of patients with Alzheimer's disease (AD). Hence, BACE1 is a prime therapeutic target, and several BACE1 inhibitor drugs are currently being tested in clinical trials for AD. However, the safety of BACE1 inhibition is unclear. Germline BACE1 knockout mice have multiple neurological phenotypes, although these could arise from BACE1 deficiency during development. To address this question, we report that tamoxifen-inducible conditional BACE1 knockout mice in which the <i>Bace1</i> gene was ablated in the adult largely lacked the phenotypes observed in germline BACE1 knockout mice. However, one BACE1-null phenotype was induced after <i>Bace1</i> gene deletion in the adult mouse brain. This phenotype showed reduced length and disorganization of the hippocampal mossy fiber infrapyramidal bundle, the axonal pathway of dentate gyrus granule cells that is maintained by neurogenesis in the mouse brain. This defect in axonal organization correlated with reduced BACE1-mediated cleavage of the neural cell adhesion protein close homolog of L1 (CHL1), which has previously been associated with axon guidance. Although our results indicate that BACE1 inhibition in the adult mouse brain may avoid phenotypes associated with BACE1 deficiency during embryonic and postnatal development, they also suggest that BACE1 inhibitor drugs developed for treating AD may disrupt the organization of an axonal pathway in the hippocampus, an important structure for learning and memory.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ou-Yang</LastName><ForeName>Ming-Hsuan</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-1762-8123</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Jonathan E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-2259-4263</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomura</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8786-831X</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popovic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajapaksha</LastName><ForeName>Tharinda W</ForeName><Initials>TW</Initials><Identifier Source="ORCID">0000-0003-3238-2392</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Hongxin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contractor</LastName><ForeName>Anis</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5131-2536</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chetkovich</LastName><ForeName>Dane M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neurosciences, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tourtellotte</LastName><ForeName>Warren G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neurosciences, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1358-504X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. r-vassar@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS040748</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 NS046468</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K26 OD010945</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K26 RR026099</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022560</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30232227</ArticleId><ArticleId IdType="mid">NIHMS1604729</ArticleId><ArticleId IdType="pmc">PMC11017370</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aao5620</ArticleId><ArticleId IdType="pii">10/459/eaao5620</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE, The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2, (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475404</ArticleId><ArticleId IdType="pubmed">23028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J, The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL, Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235, 880&#x2013;884 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">2949367</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakaran G, Sisodia S, Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2, a006270 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M, Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735&#x2013;741 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME, Membrane-anchored aspartyl protease with Alzheimer&#x2019;s disease beta-secretase activity. Nature 402, 533&#x2013;537 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V, Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537&#x2013;540 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G, Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14, 419&#x2013;427 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J, Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America 97, 1456&#x2013;1460 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Barao S, Moechars D, Lichtenthaler SF, De Strooper B, BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer&#x2019;s Disease. Trends Neurosci 39, 158&#x2013;169 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26833257</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Vassar R, Targeting the beta secretase BACE1 for Alzheimer&#x2019;s disease therapy. The Lancet. Neurology 13, 319&#x2013;329 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086426</ArticleId><ArticleId IdType="pubmed">24556009</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Physiological Functions of the beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2. Front Mol Neurosci 10, 97 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395628</ArticleId><ArticleId IdType="pubmed">28469554</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R, Mice deficient in BACE1, the Alzheimer&#x2019;s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nature neuroscience 4, 231&#x2013;232 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC, BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nature neuroscience 4, 233&#x2013;234 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L, BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer&#x2019;s disease therapeutics. Human molecular genetics 10, 1317&#x2013;1324 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11406613</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D&#x2019;Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B, Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. The Journal of biological chemistry 280, 30797&#x2013;30806 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C, Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314, 664&#x2013;666 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R, Bace1 modulates myelination in the central and peripheral nervous system. Nature neuroscience 9, 1520&#x2013;1525 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG, Yan R, BACE1 deficiency causes altered neuronal activity and neurodegeneration. The Journal of neuroscience : the official journal of the Society for Neuroscience 30, 8819&#x2013;8829 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902368</ArticleId><ArticleId IdType="pubmed">20592204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt BD, Jaramillo TC, Chetkovich DM, Vassar R, BACE1&#x2212;/&#x2212; mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Molecular neurodegeneration 5, 31 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933677</ArticleId><ArticleId IdType="pubmed">20731874</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC, BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. The Journal of neuroscience : the official journal of the Society for Neuroscience 25, 11693&#x2013;11709 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF, Temporal memory deficits in Alzheimer&#x2019;s mouse models: rescue by genetic deletion of BACE1. The European journal of neuroscience 23, 251&#x2013;260 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16420434</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajapaksha TW, Eimer WA, Bozza TC, Vassar R, The Alzheimer&#x2019;s beta-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Molecular neurodegeneration 6, 88 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3269394</ArticleId><ArticleId IdType="pubmed">22204380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R, beta-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. The Journal of biological chemistry 287, 38408&#x2013;38425 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493884</ArticleId><ArticleId IdType="pubmed">22988240</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Rickenbacher GT, Rodriguez S, Moulia TW, Albers MW, The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Scientific reports 2, 231 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262176</ArticleId><ArticleId IdType="pubmed">22355745</ArticleId></ArticleIdList></Reference><Reference><Citation>Barao S, Gartner A, Leyva-Diaz E, Demyanenko G, Munck S, Vanhoutvin T, Zhou L, Schachner M, Lopez-Bendito G, Maness PF, De Strooper B, Antagonistic Effects of BACE1 and APH1B-gamma-Secretase Control Axonal Guidance by Regulating Growth Cone Collapse. Cell reports 12, 1367&#x2013;1376 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820248</ArticleId><ArticleId IdType="pubmed">26299962</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kovacs DM, Yan R, Wong PC, The beta-secretase enzyme BACE in health and Alzheimer&#x2019;s disease: regulation, cell biology, function, and therapeutic potential. The Journal of neuroscience : the official journal of the Society for Neuroscience 29, 12787&#x2013;12794 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Stepping closer to treating Alzheimer&#x2019;s disease patients with BACE1 inhibitor drugs. Transl Neurodegener 5, 13 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944430</ArticleId><ArticleId IdType="pubmed">27418961</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova E, Fehsenfeld S, Mantamadiotis T, Lemberger T, Greiner E, Stewart AF, Schutz G, A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis 31, 37&#x2013;42 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11668676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T, Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661&#x2013;665 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17251932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Barao S, Laga M, Bockstael K, Borgers M, Gijsen H, Annaert W, Moechars D, Mercken M, Gevaert K, De Strooper B, The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. The Journal of biological chemistry 287, 25927&#x2013;25940 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406677</ArticleId><ArticleId IdType="pubmed">22692213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, Volbracht C, Schepers U, Imhof A, Hoffmeister A, Haass C, Rossner S, Brase S, Lichtenthaler SF, Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. The EMBO journal 31, 3157&#x2013;3168 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3400020</ArticleId><ArticleId IdType="pubmed">22728825</ArticleId></ArticleIdList></Reference><Reference><Citation>Meakin PJ, Harper AJ, Hamilton DL, Gallagher J, McNeilly AD, Burgess LA, Vaanholt LM, Bannon KA, Latcham J, Hussain I, Speakman JR, Howlett DR, Ashford ML, Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J 441, 285&#x2013;296 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242510</ArticleId><ArticleId IdType="pubmed">21880018</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC, Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proceedings of the National Academy of Sciences of the United States of America 105, 5585&#x2013;5590 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Montag-Sallaz M, Schachner M, Montag D, Misguided axonal projections, neural cell adhesion molecule 180 mRNA upregulation, and altered behavior in mice deficient for the close homolog of L1. Mol Cell Biol 22, 7967&#x2013;7981 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134725</ArticleId><ArticleId IdType="pubmed">12391163</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyden A, Angenstein F, Sallaz M, Seidenbecher C, Montag D, Abnormal axonal guidance and brain anatomy in mouse mutants for the cell recognition molecules close homolog of L1 and NgCAM-related cell adhesion molecule. Neuroscience 155, 221&#x2013;233 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18588951</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Zhu LL, Zhao T, Wu LY, Wu KW, Schachner M, Xiao ZC, Fan M, CHL1 negatively regulates the proliferation and neuronal differentiation of neural progenitor cells through activation of the ERK1/2 MAPK pathway. Mol Cell Neurosci 46, 296&#x2013;307 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20933598</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakovcevski I, Siering J, Hargus G, Karl N, Hoelters L, Djogo N, Yin S, Zecevic N, Schachner M, Irintchev A, Close homologue of adhesion molecule L1 promotes survival of Purkinje and granule cells and granule cell migration during murine cerebellar development. J Comp Neurol 513, 496&#x2013;510 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19226508</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian N, Leshchyns&#x2019;ka I, Welch JH, Diakowski W, Yang H, Schachner M, Sytnyk V, Lipid raft-dependent endocytosis of close homolog of adhesion molecule L1 (CHL1) promotes neuritogenesis. The Journal of biological chemistry 287, 44447&#x2013;44463 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531758</ArticleId><ArticleId IdType="pubmed">23144456</ArticleId></ArticleIdList></Reference><Reference><Citation>Katic J, Loers G, Kleene R, Karl N, Schmidt C, Buck F, Zmijewski JW, Jakovcevski I, Preissner KT, Schachner M, Interaction of the cell adhesion molecule CHL1 with vitronectin, integrins, and the plasminogen activator inhibitor-2 promotes CHL1-induced neurite outgrowth and neuronal migration. The Journal of neuroscience : the official journal of the Society for Neuroscience 34, 14606&#x2013;14623 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608427</ArticleId><ArticleId IdType="pubmed">25355214</ArticleId></ArticleIdList></Reference><Reference><Citation>Demyanenko GP, Halberstadt AI, Rao RS, Maness PF, CHL1 cooperates with PAK1&#x2013;3 to regulate morphological differentiation of embryonic cortical neurons. Neuroscience 165, 107&#x2013;115 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791357</ArticleId><ArticleId IdType="pubmed">19819308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleene R, Chaudhary H, Karl N, Katic J, Kotarska A, Guitart K, Loers G, Schachner M, Interaction between CHL1 and serotonin receptor 2c regulates signal transduction and behavior in mice. J Cell Sci 128, 4642&#x2013;4652 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26527397</ArticleId></ArticleIdList></Reference><Reference><Citation>Demyanenko GP, Schachner M, Anton E, Schmid R, Feng G, Sanes J, Maness PF, Close homolog of L1 modulates area-specific neuronal positioning and dendrite orientation in the cerebral cortex. Neuron 44, 423&#x2013;437 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15504324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye H, Tan YL, Ponniah S, Takeda Y, Wang SQ, Schachner M, Watanabe K, Pallen CJ, Xiao ZC, Neural recognition molecules CHL1 and NB-3 regulate apical dendrite orientation in the neocortex via PTP alpha. The EMBO journal 27, 188&#x2013;200 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206121</ArticleId><ArticleId IdType="pubmed">18046458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, He W, Luo X, Tsubota KE, Yan R, BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway. Cell reports 4, 40&#x2013;49 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740554</ArticleId><ArticleId IdType="pubmed">23831026</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Shubert T, Zhao C, Gage FH, Exercise enhances learning and hippocampal neurogenesis in aged mice. The Journal of neuroscience : the official journal of the Society for Neuroscience 25, 8680&#x2013;8685 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360197</ArticleId><ArticleId IdType="pubmed">16177036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinno S, Decline in adult neurogenesis during aging follows a topographic pattern in the mouse hippocampus. J Comp Neurol 519, 451&#x2013;466 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21192078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R, The Alzheimer&#x2019;s beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta neuropathologica 126, 329&#x2013;352 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753469</ArticleId><ArticleId IdType="pubmed">23820808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O&#x2019;Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R, Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer&#x2019;s disease pathogenesis. The Journal of neuroscience : the official journal of the Society for Neuroscience 27, 3639&#x2013;3649 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner RL, Jang MH, Liu XB, Duan X, Sailor KA, Kim JY, Ge S, Jones EG, Ming GL, Song H, Cheng HJ, Development of hippocampal mossy fiber synaptic outputs by new neurons in the adult brain. Proceedings of the National Academy of Sciences of the United States of America 105, 14157&#x2013;14162 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544594</ArticleId><ArticleId IdType="pubmed">18780780</ArticleId></ArticleIdList></Reference><Reference><Citation>Toni N, Laplagne DA, Zhao C, Lombardi G, Ribak CE, Gage FH, Schinder AF, Neurons born in the adult dentate gyrus form functional synapses with target cells. Nature neuroscience 11, 901&#x2013;907 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572641</ArticleId><ArticleId IdType="pubmed">18622400</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves JT, Schafer ST, Gage FH, Adult Neurogenesis in the Hippocampus: From Stem Cells to Behavior. Cell 167, 897&#x2013;914 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27814520</ArticleId></ArticleIdList></Reference><Reference><Citation>Crusio WE, Schwegler H, Learning spatial orientation tasks in the radial-maze and structural variation in the hippocampus in inbred mice. Behav Brain Funct 1, 3 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1143776</ArticleId><ArticleId IdType="pubmed">15916698</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Song L, Laird F, Wong PC, Lee HK, BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. The Journal of neuroscience : the official journal of the Society for Neuroscience 28, 8677&#x2013;8681 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728626</ArticleId><ArticleId IdType="pubmed">18753368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Song L, Lee A, Laird F, Wong PC, Lee HK, Mossy fiber long-term potentiation deficits in BACE1 knock-outs can be rescued by activation of alpha7 nicotinic acetylcholine receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience 30, 13808&#x2013;13813 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137882</ArticleId><ArticleId IdType="pubmed">20943921</ArticleId></ArticleIdList></Reference><Reference><Citation>Imayoshi I, Sakamoto M, Ohtsuka T, Takao K, Miyakawa T, Yamaguchi M, Mori K, Ikeda T, Itohara S, Kageyama R, Roles of continuous neurogenesis in the structural and functional integrity of the adult forebrain. Nature neuroscience 11, 1153&#x2013;1161 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18758458</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R, Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. The Journal of neuroscience : the official journal of the Society for Neuroscience 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Das B, Hou H, He W, Yan R, BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. The Journal of experimental medicine, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839766</ArticleId><ArticleId IdType="pubmed">29444819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn HJ, Kuvelkar R, Li W, Mattson BA, Mei H, Palcza J, Scott JD, Tanen M, Troyer MD, Tseng JL, Stone JA, Parker EM, Forman MS, The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer&#x2019;s disease patients. Sci Transl Med 8, 363ra150 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27807285</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D, Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer&#x2019;s Disease. N Engl J Med 378, 1691&#x2013;1703 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776074</ArticleId><ArticleId IdType="pubmed">29719179</ArticleId></ArticleIdList></Reference><Reference><Citation>May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Martenyi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, Mergott DJ, The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. The Journal of neuroscience : the official journal of the Society for Neuroscience 35, 1199&#x2013;1210 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605527</ArticleId><ArticleId IdType="pubmed">25609634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto K, Matsuki S, Matsuguma K, Yoshihara T, Uchida N, Azuma F, Russell M, Hughes G, Haeberlein SB, Alexander RC, Eketjall S, Kugler AR, BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Abeta Peptides. J Clin Pharmacol, (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28618005</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Bostrom E, Westerlund I, Vial C, Buchholz BA, Possnert G, Mash DC, Druid H, Frisen J, Dynamics of hippocampal neurogenesis in adult humans. Cell 153, 1219&#x2013;1227 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394608</ArticleId><ArticleId IdType="pubmed">23746839</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura T, Oyamada Y, Fernandes HB, Remmers CL, Xu J, Meltzer HY, Contractor A, Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus. Neuropharmacology 100, 90&#x2013;97 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584174</ArticleId><ArticleId IdType="pubmed">25937215</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30232451</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>562</Volume><Issue>7728</Issue><PubDate><Year>2018</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline.</ArticleTitle><Pagination><StartPage>578</StartPage><EndPage>582</EndPage><MedlinePgn>578-582</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-018-0543-y</ELocationID><Abstract><AbstractText>Cellular senescence, which is characterized by an irreversible cell-cycle arrest<sup>1</sup> accompanied by a distinctive secretory phenotype<sup>2</sup>, can be induced through various intracellular and extracellular factors. Senescent cells that express the cell cycle inhibitory protein p16<sup>INK4A</sup> have been found to actively drive naturally occurring age-related tissue deterioration<sup>3,4</sup> and contribute to several diseases associated with ageing, including atherosclerosis<sup>5</sup> and osteoarthritis<sup>6</sup>. Various markers of senescence have been observed in patients with neurodegenerative diseases<sup>7-9</sup>; however, a role for senescent cells in the aetiology of these pathologies is unknown. Here we show a causal link between the accumulation of senescent cells and cognition-associated neuronal loss. We found that the MAPT<sup>P301S</sup>PS19 mouse model of tau-dependent neurodegenerative disease<sup>10</sup> accumulates p16<sup>INK4A</sup>-positive senescent astrocytes and microglia. Clearance of these cells as they arise using INK-ATTAC transgenic mice prevents gliosis, hyperphosphorylation of both soluble and insoluble tau leading to neurofibrillary tangle deposition, and degeneration of cortical and hippocampal neurons, thus preserving cognitive function. Pharmacological intervention with a first-generation senolytic modulates tau aggregation. Collectively, these results show that senescent cells have a role in the initiation and progression of tau-mediated disease, and suggest that targeting senescent cells may provide a therapeutic avenue for the treatment of these pathologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bussian</LastName><ForeName>Tyler J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Asef</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Charlton F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swenson</LastName><ForeName>Barbara L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Deursen</LastName><ForeName>Jan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Darren J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA. baker.darren@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA. baker.darren@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG053229</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>XKJ5VVK2WD</RegistryNumber><NameOfSubstance UI="C528561">navitoclax</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2018 Oct;562(7728):503-504. doi: 10.1038/d41586-018-06677-7.</RefSource><PMID Version="1">30349121</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016922" MajorTopicYN="Y">Cellular Senescence</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019941" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30232451</ArticleId><ArticleId IdType="mid">NIHMS1505435</ArticleId><ArticleId IdType="pmc">PMC6206507</ArticleId><ArticleId IdType="doi">10.1038/s41586-018-0543-y</ArticleId><ArticleId IdType="pii">10.1038/s41586-018-0543-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hayflick L &amp; Moorhead PS The serial cultivation of human diploid cell strains. Exp Cell Res 25, 585&#x2013;621 (1961).</Citation><ArticleIdList><ArticleId IdType="pubmed">13905658</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppe JP et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6, 2853&#x2013;2868 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592359</ArticleId><ArticleId IdType="pubmed">19053174</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184&#x2013;189 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845101</ArticleId><ArticleId IdType="pubmed">26840489</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232&#x2013;236 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468323</ArticleId><ArticleId IdType="pubmed">22048312</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs BG et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472&#x2013;477 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112585</ArticleId><ArticleId IdType="pubmed">27789842</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon OH et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med 23, 775&#x2013;781 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785239</ArticleId><ArticleId IdType="pubmed">28436958</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat R et al. Astrocyte senescence as a component of Alzheimer&#x2019;s disease. PLoS One 7, e45069 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3440417</ArticleId><ArticleId IdType="pubmed">22984612</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan FC, Hutchison ER, Eitan E &amp; Mattson MP Are there roles for brain cell senescence in aging and neurodegenerative disorders? Biogerontology 15, 643&#x2013;660 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264619</ArticleId><ArticleId IdType="pubmed">25305051</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo XG, Ding JQ &amp; Chen SD Microglia in the aging brain: relevance to neurodegeneration. Mol Neurodegener 5, 12 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852379</ArticleId><ArticleId IdType="pubmed">20334662</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs BG et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov, doi:10.1038/nrd.2017.116 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.116</ArticleId><ArticleId IdType="pmc">PMC5942225</ArticleId><ArticleId IdType="pubmed">28729727</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimri GP et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92, 9363&#x2013;9367 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40985</ArticleId><ArticleId IdType="pubmed">7568133</ArticleId></ArticleIdList></Reference><Reference><Citation>Stollewerk A, Klambt C &amp; Cantera R Electron microscopic analysis of Drosophila midline glia during embryogenesis and larval development using beta-galactosidase expression as endogenous cell marker. Microsc Res Tech 35, 294&#x2013;306 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8956276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming GL &amp; Song H Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70, 687&#x2013;702 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3106107</ArticleId><ArticleId IdType="pubmed">21609825</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenz EJ et al. Apoptosis of hippocampal pyramidal neurons is virus independent in a mouse model of acute neurovirulent picornavirus infection. Am J Pathol 175, 668&#x2013;684 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2716965</ArticleId><ArticleId IdType="pubmed">19608874</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 22, 78&#x2013;83 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762215</ArticleId><ArticleId IdType="pubmed">26657143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428&#x2013;435 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854923</ArticleId><ArticleId IdType="pubmed">26711051</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpel-Massler G et al. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nat Commun 8, 1067 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651864</ArticleId><ArticleId IdType="pubmed">29057925</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanary BE, Sammons NW, Nguyen C, Walker D &amp; Streit WJ Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res 10, 61&#x2013;74 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17378753</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A et al. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur J Neurosci 34, 3&#x2013;11 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21649759</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Braak H, Xue QS &amp; Bechmann I Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer&#x2019;s disease. Acta Neuropathol 118, 475&#x2013;485 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737117</ArticleId><ArticleId IdType="pubmed">19513731</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinta SJ et al. Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson&#x2019;s Disease. Cell Rep 22, 930&#x2013;940 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806534</ArticleId><ArticleId IdType="pubmed">29386135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper LH et al. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol Cell Biol 19, 764&#x2013;776 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC83933</ArticleId><ArticleId IdType="pubmed">9858599</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol 10, 825&#x2013;836 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2594014</ArticleId><ArticleId IdType="pubmed">18516091</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent JM, von dem Bussche N &amp; Lowenstein DH Prolonged seizures recruit caudal subventricular zone glial progenitors into the injured hippocampus. Hippocampus 16, 321&#x2013;328 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16435310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly PT, Cai F &amp; Song W Detection of neuritic plaques in Alzheimer&#x2019;s disease mouse model. J Vis Exp, doi:10.3791/2831 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2831</ArticleId><ArticleId IdType="pmc">PMC3197440</ArticleId><ArticleId IdType="pubmed">21841757</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KJ et al. Staging of Alzheimer&#x2019;s pathology in triple transgenic mice: a light and electron microscopic analysis. Int J Alzheimers Dis 2010, doi:10.4061/2010/780102 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2010/780102</ArticleId><ArticleId IdType="pmc">PMC2925282</ArticleId><ArticleId IdType="pubmed">20798886</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z et al. Age-related decline in BubR1 impairs adult hippocampal neurogenesis. Aging Cell 16, 598&#x2013;601 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5418205</ArticleId><ArticleId IdType="pubmed">28383136</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumamaru H et al. Liposomal clodronate selectively eliminates microglia from primary astrocyte cultures. J Neuroinflammation 9, 116, doi:10.1186/1742-2094-9-116 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-116</ArticleId><ArticleId IdType="pmc">PMC3419615</ArticleId><ArticleId IdType="pubmed">22651847</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon R et al. A simple magnetic separation method for high-yield isolation of pure primary microglia. J Neurosci Methods 194, 287&#x2013;296 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205446</ArticleId><ArticleId IdType="pubmed">21074565</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsay HJ et al. Amyloid beta peptide-mediated neurotoxicity is attenuated by the proliferating microglia more potently than by the quiescent phenotype. J Biomed Sci 20, 78 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870991</ArticleId><ArticleId IdType="pubmed">24152138</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CC, Hu S, Molitor TW, Shaskan EG &amp; Peterson PK Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 149, 2736&#x2013;2741 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1383325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G et al. Apoptosis and proinflammatory cytokine responses of primary mouse microglia and astrocytes induced by human H1N1 and avian H5N1 influenza viruses. Cell Mol Immunol 5, 113&#x2013;120 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4651245</ArticleId><ArticleId IdType="pubmed">18445341</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 676&#x2013;682 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung IY &amp; Benveniste EN Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol 144, 2999&#x2013;3007 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2109008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30232325</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A role for APP in Wnt signalling links synapse loss with &#x3b2;-amyloid production.</ArticleTitle><Pagination><StartPage>179</StartPage><MedlinePgn>179</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">179</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-018-0231-6</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD), the canonical Wnt inhibitor Dickkopf-1 (Dkk1) is induced by &#x3b2;-amyloid (A&#x3b2;) and shifts the balance from canonical towards non-canonical Wnt signalling. Canonical (Wnt-&#x3b2;-catenin) signalling promotes synapse stability, while non-canonical (Wnt-PCP) signalling favours synapse retraction; thus A&#x3b2;-driven synapse loss is mediated by Dkk1. Here we show that the Amyloid Precursor Protein (APP) co-activates both arms of Wnt signalling through physical interactions with Wnt co-receptors LRP6 and Vangl2, to bi-directionally modulate synapse stability. Furthermore, activation of non-canonical Wnt signalling enhances A&#x3b2; production, while activation of canonical signalling suppresses A&#x3b2; production. Together, these findings identify a pathogenic-positive feedback loop in which A&#x3b2; induces Dkk1 expression, thereby activating non-canonical Wnt signalling to promote synapse loss and drive further A&#x3b2; production. The Swedish familial AD variant of APP (APP<sub>Swe</sub>) more readily co-activates non-canonical, at the expense of canonical Wnt activity, indicating that its pathogenicity likely involves direct effects on synapses, in addition to increased A&#x3b2; production. Finally, we report that pharmacological inhibition of the A&#x3b2;-Dkk1-A&#x3b2; positive feedback loop with the drug fasudil can restore the balance between Wnt pathways, prevent dendritic spine withdrawal in vitro, and reduce A&#x3b2; load in vivo in mice with advanced amyloid pathology. These results clarify a relationship between A&#x3b2; accumulation and synapse loss and provide direction for the development of potential disease-modifying treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Christina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2838-8612</Identifier><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London, SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojo</LastName><ForeName>Ana I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Investigaci&#xf3;n Sanitaria La Paz (IdiPaz), Autonomous University of Madrid (UAM), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribe</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2854-2576</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broadstock</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London, SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Weiming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs, Geriatric Research Education and Clinical Center, Bedford, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morin</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs, Geriatric Research Education and Clinical Center, Bedford, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semenov</LastName><ForeName>Mikhail</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs, Geriatric Research Education and Clinical Center, Bedford, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baillie</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, G12 8QQ, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuadrado</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Investigaci&#xf3;n Sanitaria La Paz (IdiPaz), Autonomous University of Madrid (UAM), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Shawi</LastName><ForeName>Raya</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, Royal Free Campus, University College London, Rowland Hill Street, London, NW3 2PF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5007-6674</Identifier><AffiliationInfo><Affiliation>Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, Royal Free Campus, University College London, Rowland Hill Street, London, NW3 2PF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Killick</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8815-3436</Identifier><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London, SE5 9RT, UK. Richard.1.Killick@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/J007412/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M013944/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501126">DKK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C555475">LRP6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060488">Low Density Lipoprotein Receptor-Related Protein-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C468513">VANGL2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>84477-87-2</RegistryNumber><NameOfSubstance UI="D019307">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q0CH43PGXS</RegistryNumber><NameOfSubstance UI="C049347">fasudil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019307" MajorTopicYN="N">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060488" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060449" MajorTopicYN="Y">Wnt Signaling Pathway</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30232325</ArticleId><ArticleId IdType="pmc">PMC6145937</ArticleId><ArticleId IdType="doi">10.1038/s41398-018-0231-6</ArticleId><ArticleId IdType="pii">10.1038/s41398-018-0231-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kang J, et al. The precursor of Alzheimer&#x2019;s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733&#x2013;736. doi: 10.1038/325733a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/325733a0</ArticleId><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, et al. Early-onset Alzheimer&#x2019;s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991;353:844&#x2013;846. doi: 10.1038/353844a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/353844a0</ArticleId><ArticleId IdType="pubmed">1944558</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer&#x2019;s disease and its models. Neuroscience. 2013;251:51&#x2013;65. doi: 10.1016/j.neuroscience.2012.05.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2012.05.050</ArticleId><ArticleId IdType="pubmed">22687952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA. 1998;95:6448&#x2013;6453. doi: 10.1073/pnas.95.11.6448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6448</ArticleId><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat. Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstedt C, Caporaso GL, Thyberg J, Gandy SE, Greengard P. Identification of the Alzheimer beta/a4 amyloid precursor protein in clathrin-coated vesicles purified from Pc12 cells. J. Biol. Chem. 1993;268:608&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">8416966</ArticleId></ArticleIdList></Reference><Reference><Citation>Deyts C, Thinakaran G, Parent AT. APP receptor? to be or not to be. Trends Pharmacol. Sci. 2016;37:390&#x2013;411. doi: 10.1016/j.tips.2016.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2016.01.005</ArticleId><ArticleId IdType="pmc">PMC4846520</ArticleId><ArticleId IdType="pubmed">26837733</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldano, A. et al. The Drosophila homologue of the amyloid precursor protein is a conserved modulator of Wnt PCP signaling. PLoS Biol. 11, (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653798</ArticleId><ArticleId IdType="pubmed">23690751</ArticleId></ArticleIdList></Reference><Reference><Citation>Killick R, et al. Clusterin regulates beta-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol. Psychiatry. 2014;19:88&#x2013;98. doi: 10.1038/mp.2012.163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.163</ArticleId><ArticleId IdType="pmc">PMC3873038</ArticleId><ArticleId IdType="pubmed">23164821</ArticleId></ArticleIdList></Reference><Reference><Citation>Caricasole A, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer&#x2019;s brain. J. Neurosci. 2004;24:6021&#x2013;6027. doi: 10.1523/JNEUROSCI.1381-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1381-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729239</ArticleId><ArticleId IdType="pubmed">15229249</ArticleId></ArticleIdList></Reference><Reference><Citation>Purro SA, Dickins EM, Salinas PC. The secreted Wnt antagonist dickkopf-1 is required for amyloid beta-mediated synaptic loss. J. Neurosci. 2012;32:3492&#x2013;3498. doi: 10.1523/JNEUROSCI.4562-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4562-11.2012</ArticleId><ArticleId IdType="pmc">PMC6621056</ArticleId><ArticleId IdType="pubmed">22399772</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzo A, et al. Reversal of synapse degeneration by restoring wnt signaling in the adult hippocampus. Curr. Biol. 2016;26:2551&#x2013;2561. doi: 10.1016/j.cub.2016.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2016.07.024</ArticleId><ArticleId IdType="pmc">PMC5070786</ArticleId><ArticleId IdType="pubmed">27593374</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellers KJ, et al. Amyloid beta synaptotoxicity is Wnt-PCP dependent and blocked by fasudil. Alzheimers Dement. 2018;14:306&#x2013;317. doi: 10.1016/j.jalz.2017.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.09.008</ArticleId><ArticleId IdType="pmc">PMC5869054</ArticleId><ArticleId IdType="pubmed">29055813</ArticleId></ArticleIdList></Reference><Reference><Citation>Messeant J, et al. Wnt proteins contribute to neuromuscular junction formation through distinct signaling pathways. Development. 2017;144:1712&#x2013;1724. doi: 10.1242/dev.146167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.146167</ArticleId><ArticleId IdType="pubmed">28348167</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickins EM, Salinas PC. Wnts in action: from synapse formation to synaptic maintenance. Front. Cell Neurosci. 2013;7:162. doi: 10.3389/fncel.2013.00162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00162</ArticleId><ArticleId IdType="pmc">PMC3819050</ArticleId><ArticleId IdType="pubmed">24223536</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva CA, Vargas JY, Inestrosa NC. Wnts in adult brain: from synaptic plasticity to cognitive deficiencies. Front. Cell. Neurosci. 2013;7:224. doi: 10.3389/fncel.2013.00224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00224</ArticleId><ArticleId IdType="pmc">PMC3847898</ArticleId><ArticleId IdType="pubmed">24348327</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso SB, Inestrosa NC. WNT signaling in neuronal maturation and synaptogenesis. Front. Cell Neurosci. 2013;7:103. doi: 10.3389/fncel.2013.00103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00103</ArticleId><ArticleId IdType="pmc">PMC3701138</ArticleId><ArticleId IdType="pubmed">23847469</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakar S, et al. Evidence for opposing roles of Celsr3 and Vangl2 in glutamatergic synapse formation. Proc. Natl Acad. Sci. USA. 2017;114:E610&#x2013;E618. doi: 10.1073/pnas.1612062114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1612062114</ArticleId><ArticleId IdType="pmc">PMC5278468</ArticleId><ArticleId IdType="pubmed">28057866</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer&#x2019;s disease. Neuron. 2014;84:63&#x2013;77. doi: 10.1016/j.neuron.2014.08.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.08.048</ArticleId><ArticleId IdType="pmc">PMC4199382</ArticleId><ArticleId IdType="pubmed">25242217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamai K, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature. 2000;407:530&#x2013;535. doi: 10.1038/35035117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35035117</ArticleId><ArticleId IdType="pubmed">11029007</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbagallo, A. P. et al. Tyr(682) in the intracellular domain of APP regulates amyloidogenic APP processing in vivo. PLoS ONE5, (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982846</ArticleId><ArticleId IdType="pubmed">21103325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WJ, Goldstein JL, Brown MS. NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. J. Biol. Chem. 1990;265:3116&#x2013;3123.</Citation><ArticleIdList><ArticleId IdType="pubmed">1968060</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellers KJ, et al. Amyloid beta synaptotoxicity is Wnt-planar cell polarity dependent and blocked by fasudil. Alzheimers Dement. 2017;14:306&#x2013;317. doi: 10.1016/j.jalz.2017.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.09.008</ArticleId><ArticleId IdType="pmc">PMC5869054</ArticleId><ArticleId IdType="pubmed">29055813</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, et al. LTP and memory impairment caused by extracellular Abeta and Tau oligomers is APP-dependent. Elife. 2017;6:e26991. doi: 10.7554/eLife.26991.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.26991</ArticleId><ArticleId IdType="pmc">PMC5529106</ArticleId><ArticleId IdType="pubmed">28696204</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenov MV, Habas R, Macdonald BT, He X. SnapShot: noncanonical Wnt signaling pathways. Cell. 2007;131:1378. doi: 10.1016/j.cell.2007.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.12.011</ArticleId><ArticleId IdType="pubmed">18160045</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421. doi: 10.1016/S0896-6273(03)00434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501&#x2013;1508. doi: 10.1212/01.wnl.0000260698.46517.8f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000260698.46517.8f</ArticleId><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol. Aging. 2006;27:1372&#x2013;1384. doi: 10.1016/j.neurobiolaging.2005.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.09.012</ArticleId><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Boros BD, et al. Dendritic spines provide cognitive resilience against Alzheimer&#x2019;s disease. Ann. Neurol. 2017;82:602&#x2013;614. doi: 10.1002/ana.25049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25049</ArticleId><ArticleId IdType="pmc">PMC5744899</ArticleId><ArticleId IdType="pubmed">28921611</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenov MV, et al. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr. Biol. 2001;11:951&#x2013;961. doi: 10.1016/S0960-9822(01)00290-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(01)00290-1</ArticleId><ArticleId IdType="pubmed">11448771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 2001;3:683&#x2013;686. doi: 10.1038/35083081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35083081</ArticleId><ArticleId IdType="pubmed">11433302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzen A, et al. Rapid and direct transport of cell surface APP to the lysosome defines a novel selective pathway. Mol. Brain. 2010;3:11. doi: 10.1186/1756-6606-3-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-3-11</ArticleId><ArticleId IdType="pmc">PMC2868040</ArticleId><ArticleId IdType="pubmed">20409323</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu A, et al. Association of Dishevelled with the clathrin AP-2 adaptor is required for Frizzled endocytosis and planar cell polarity signaling. Dev. Cell. 2007;12:129&#x2013;141. doi: 10.1016/j.devcel.2006.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2006.10.015</ArticleId><ArticleId IdType="pmc">PMC2831292</ArticleId><ArticleId IdType="pubmed">17199046</ArticleId></ArticleIdList></Reference><Reference><Citation>Parr C, Mirzaei N, Christian M, Sastre M. Activation of the Wnt/beta-catenin pathway represses the transcription of the beta-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter. FASEB J. 2015;29:623&#x2013;635. doi: 10.1096/fj.14-253211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14-253211</ArticleId><ArticleId IdType="pubmed">25384422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan XZ, et al. Activation of NMDA receptors upregulates A disintegrin and metalloproteinase 10 via a Wnt/MAPK signaling pathway. J. Neurosci. 2012;32:3910&#x2013;3916. doi: 10.1523/JNEUROSCI.3916-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3916-11.2012</ArticleId><ArticleId IdType="pmc">PMC6703469</ArticleId><ArticleId IdType="pubmed">22423111</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay M, et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev. Cell. 2001;1:423&#x2013;434. doi: 10.1016/S1534-5807(01)00041-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1534-5807(01)00041-7</ArticleId><ArticleId IdType="pubmed">11702953</ArticleId></ArticleIdList></Reference><Reference><Citation>Seib DR, et al. Loss of dickkopf-1 restores neurogenesis in old age and counteracts cognitive decline. Cell Stem. Cell. 2013;12:204&#x2013;214. doi: 10.1016/j.stem.2012.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2012.11.010</ArticleId><ArticleId IdType="pubmed">23395445</ArticleId></ArticleIdList></Reference><Reference><Citation>Couch BA, DeMarco GJ, Gourley SL, Koleske AJ. Increased dendrite branching in AbetaPP/PS1 mice and elongation of dendrite arbors by fasudil administration. J. Alzheimers Dis. 2010;20:1003&#x2013;1008. doi: 10.3233/JAD-2010-091114.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-091114</ArticleId><ArticleId IdType="pmc">PMC3077946</ArticleId><ArticleId IdType="pubmed">20413901</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Chen X, Wang LY, Gao W, Zhu MJ. Rho kinase inhibitor fasudil protects against beta-amyloid-induced hippocampal neurodegeneration in rats. CNS Neurosci. Ther. 2013;19:603&#x2013;610. doi: 10.1111/cns.12116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12116</ArticleId><ArticleId IdType="pmc">PMC6493451</ArticleId><ArticleId IdType="pubmed">23638992</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science. 2003;302:1215&#x2013;1217. doi: 10.1126/science.1090154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1090154</ArticleId><ArticleId IdType="pubmed">14615541</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz JH, et al. Pharmacologic inhibition of ROCK2 suppresses amyloid-beta production in an Alzheimer&#x2019;s disease mouse model. J. Neurosci. 2013;33:19086&#x2013;19098. doi: 10.1523/JNEUROSCI.2508-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2508-13.2013</ArticleId><ArticleId IdType="pmc">PMC3850036</ArticleId><ArticleId IdType="pubmed">24305806</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentry EG, et al. Rho Kinase inhibition as a therapeutic for progressive supranuclear Palsy and corticobasal degeneration. J. Neurosci. 2016;36:1316&#x2013;1323. doi: 10.1523/JNEUROSCI.2336-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2336-15.2016</ArticleId><ArticleId IdType="pmc">PMC4728727</ArticleId><ArticleId IdType="pubmed">26818518</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanger SA, Mattheyses AL, Gentry EG, Herskowitz JH. ROCK1 and ROCK2 inhibition alters dendritic spine morphology in hippocampal neurons. Cell Logist. 2015;5:e1133266. doi: 10.1080/21592799.2015.1133266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21592799.2015.1133266</ArticleId><ArticleId IdType="pmc">PMC4820816</ArticleId><ArticleId IdType="pubmed">27054047</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller UC, Deller T, Korte M. Not just amyloid: physiological functions of the amyloid precursor protein family. Nat. Rev. Neurosci. 2017;18:281&#x2013;298. doi: 10.1038/nrn.2017.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2017.29</ArticleId><ArticleId IdType="pubmed">28360418</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosa LJ, et al. The physiological role of the amyloid precursor protein as an adhesion molecule in the developing nervous system. J. Neurochem. 2017;143:11&#x2013;29. doi: 10.1111/jnc.14122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14122</ArticleId><ArticleId IdType="pubmed">28677143</ArticleId></ArticleIdList></Reference><Reference><Citation>William Rebeck G, DTS. Pak. A mobile APP for sharing contacts on your cell: an editorial highlight for &#x2018;The physiological role of the Amyloid Precursor Protein (APP) as an adhesion molecule in the developing nervous system&#x2019; on doi: 10.1111/jnc.14122. J. Neurochem. 2017;143:9&#x2013;10. doi: 10.1111/jnc.14115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14115</ArticleId><ArticleId IdType="pubmed">28809040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C, Trzcinski O, Doering LC. Fluorescent labeling of dendritic spines in cell cultures with the carbocyanine dye &#x201c;DiI&#x201d;. Front. Neuroanat. 2014;8:30. doi: 10.3389/fnana.2014.00030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2014.00030</ArticleId><ArticleId IdType="pmc">PMC4023042</ArticleId><ArticleId IdType="pubmed">24847216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallaq R, et al. The Notch intracellular domain represses CRE-dependent transcription. Cell Signal. 2015;27:621&#x2013;629. doi: 10.1016/j.cellsig.2014.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2014.11.034</ArticleId><ArticleId IdType="pubmed">25479589</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalla K, et al. FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system. Mol. Psychiatry. 2017;23:1278&#x2013;1286. doi: 10.1038/mp.2017.138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.138</ArticleId><ArticleId IdType="pmc">PMC5984089</ArticleId><ArticleId IdType="pubmed">28727686</ArticleId></ArticleIdList></Reference><Reference><Citation>Causevic M, Farooq U, Lovestone S, Killick R. beta-Amyloid precursor protein and tau protein levels are differently regulated in human cerebellum compared to brain regions vulnerable to Alzheimer&#x2019;s type neurodegeneration. Neurosci. Lett. 2010;485:162&#x2013;166. doi: 10.1016/j.neulet.2010.08.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.08.088</ArticleId><ArticleId IdType="pubmed">20826196</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo AI, et al. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson&#x2019;s disease. Glia. 2010;58:588&#x2013;598. doi: 10.1002/glia.20947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20947</ArticleId><ArticleId IdType="pubmed">19908287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajares M, et al. Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy. 2016;12:1902&#x2013;1916. doi: 10.1080/15548627.2016.1208889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1208889</ArticleId><ArticleId IdType="pmc">PMC5079676</ArticleId><ArticleId IdType="pubmed">27427974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30248105</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.</ArticleTitle><Pagination><StartPage>e1002660</StartPage><MedlinePgn>e1002660</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002660</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1002660</ELocationID><Abstract><AbstractText Label="BACKGROUND">This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease.</AbstractText><AbstractText Label="METHODS AND FINDINGS">NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 April 2015. The study was conducted at 23 academic centres in nine European countries. Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine). Participants took a trial treatment capsule once a day after breakfast for 78 weeks. Participants were aged &gt;50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examination (SMMSE) score of &#x2265;12 and &lt;27. Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo. The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was 62% female. Baseline demographic and Alzheimer disease-specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4. The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465). Decline from baseline in ADAS-Cog 12 on placebo was 0.79 (95% CI, -0.07-1.64) at 13 weeks, 6.41 (5.33-7.49) at 52 weeks, and 9.63 (8.33-10.93) at 78 weeks and on nilvadipine was 0.88 (0.02-1.74) at 13 weeks, 5.75 (4.66-6.85) at 52 weeks, and 9.41 (8.09-10.73) at 78 weeks. Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia. Nilvadipine appeared to be safe and well tolerated. Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 versus 1,030), and serious adverse events (SAEs; 146 versus 101), were observed. There were 14 withdrawals because of AEs. Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid.</AbstractText><AbstractText Label="CONCLUSIONS">The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease.</AbstractText><AbstractText Label="TRIAL REGISTRATION">Clinicaltrials.gov NCT02017340, EudraCT number 2012-002764-27.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5012-2116</Identifier><AffiliationInfo><Affiliation>Mercer's Institute for Research on Ageing, St. James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Gerontology, Trinity College Dublin (TCD), Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segurado</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3547-6733</Identifier><AffiliationInfo><Affiliation>Centre for Support and Training in Analysis and Research (CSTAR), University College Dublin (UCD), Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Physiotherapy and Sport Science, University College Dublin (UCD), Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennelly</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Age Related Healthcare, Tallaght Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Gerontology, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olde Rikkert</LastName><ForeName>Marcel G M</ForeName><Initials>MGM</Initials><Identifier Source="ORCID">0000-0003-1397-1677</Identifier><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Radboudumc Alzheimer Center, Donders Institute of Medical Neurosciences, Radboudumc, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3071-2338</Identifier><AffiliationInfo><Affiliation>Division of Psychiatry, University College London and King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9880-9788</Identifier><AffiliationInfo><Affiliation>CHU Lille, Univ. Lille, DISTALZ Laboratory of Excellence, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;rjesson-Hanson</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2072-8010</Identifier><AffiliationInfo><Affiliation>Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucca</LastName><ForeName>Ugo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Laboratory of Geriatric Neuropsychiatry, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molloy</LastName><ForeName>D William</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7370-8630</Identifier><AffiliationInfo><Affiliation>University College Cork Centre for Gerontology and Rehabilitation, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coen</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mercer's Institute for Research on Ageing, St. James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riepe</LastName><ForeName>Matthias W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Geriatrics and Old Age Psychiatry, Psychiatry II, Ulm University at BKH G&#xfc;nzburg, G&#xfc;nzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xe1;lm&#xe1;n</LastName><ForeName>J&#xe1;nos</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenny</LastName><ForeName>Rose Anne</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Medical Gerontology, Trinity College Dublin (TCD), Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cregg</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Gerontology, Trinity College Dublin (TCD), Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Dwyer</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mercer's Institute for Research on Ageing, St. James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Cathal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health Research Institute, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mathematics Applications Consortium for Science and Industry (MACSI), Department of Mathematics and Statistics, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banzi</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breuilh</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CHU Lille, Univ. Lille, DISTALZ Laboratory of Excellence, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8560-1195</Identifier><AffiliationInfo><Affiliation>Centre for Support and Training in Analysis and Research (CSTAR), University College Dublin (UCD), Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Physiotherapy and Sport Science, University College Dublin (UCD), Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrix</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pentara Corporation, Salt Lake City, Utah, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaynor</LastName><ForeName>Siobhan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Medicine Ireland (MMI), Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikhi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Research Institute, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mathematics Applications Consortium for Science and Industry (MACSI), Department of Mathematics and Statistics, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taekema</LastName><ForeName>Diana G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Rijnstate Hospital, Arnhem, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemni</LastName><ForeName>Raffaello</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>IRCCS Don Gnocchi Foundation-University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>Flavio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9811-0897</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS AOU Polyclinic, Hospital San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franceschi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurology Department, Multimedica, Castellanza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centro San Giovanni di Dio-IRCCS Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanetti</LastName><ForeName>Orazio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centro San Giovanni di Dio-IRCCS Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konsta</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Aristotle University of Thessaloniki (AUTH), First Psychiatric Department, Papageorgiou General Hospital, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anastasios</LastName><ForeName>Orologas</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Ahepa University General Hospital of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nenopoulou</LastName><ForeName>Styliani</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9386-3694</Identifier><AffiliationInfo><Affiliation>Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki-Tagaraki</LastName><ForeName>Fani</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-2349-662X</Identifier><AffiliationInfo><Affiliation>Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pakaski</LastName><ForeName>Magdolna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dereeper</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centre Hospitalier de Calais, Calais, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Sayette</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Caen, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe9;n&#xe9;chal</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centre Hospitalier de Lens, Lens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavenu</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-7345-3295</Identifier><AffiliationInfo><Affiliation>Centre Hospitalier de B&#xe9;thune, B&#xe9;thune, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devendeville</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire d'Amiens, Amien, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calais</LastName><ForeName>Gauthier</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Groupement des H&#xf4;pitaux de l'Institut Catholique de Lille (GHICL), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crawford</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Archer Pharmaceuticals, Sarasota, Florida, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Roskamp Institute, Sarasota, Florida, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullan</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Archer Pharmaceuticals, Sarasota, Florida, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Roskamp Institute, Sarasota, Florida, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NILVAD Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02017340</AccessionNumber></AccessionNumberList></DataBank><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>2012-002764-27</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0214FUT37J</RegistryNumber><NameOfSubstance UI="C035100">nilvadipine</NameOfSubstance></Chemical><Chemical><RegistryNumber>I9ZF7L6G2L</RegistryNumber><NameOfSubstance UI="D009543">Nifedipine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009543" MajorTopicYN="N">Nifedipine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal's policy and the authors of this manuscript have the following competing interests: SH is a paid employee of Pentara Corporation, which received payment to verify the primary outcome analysis of this study, and is also a paid consultant for Acumen Pharmaceuticals, Affiris AG, Affirmativ Diagnostics PLLC, Alkahest, Allergan, Alzheon, Amylyx Pharmaceuticals, Apodemus, Avanir Pharmaceuticals, Banner Alzheimer's Institute, Biogen, Dr. Richard Isaacson, Gerson Lehrman Group, Grifols Shared Services North America, Ionis Pharmaceuticals, M3 Biotechnology, Neurotrope BioScience, Nutricia Research B.V., PhotoPharmics, Regenera Pharma, Roche (F. Hoffmann-La Roche--Switzerland), Toyama Chemical Co., and vTv Therapeutics; MM and FC are paid employees of Archer Pharmaceuticals, which owns patents for the use of nilvadipine in Alzheimer disease; MM, FC, SK, RS, and BL are named as inventors in a pending patent for the use of nilvadipine based on the results of this clinical trial. No other authors have declared competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30248105</ArticleId><ArticleId IdType="pmc">PMC6152871</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1002660</ArticleId><ArticleId IdType="pii">PMEDICINE-D-18-00761</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015. Feb; 29(2):113&#x2013;130. 10.1007/s40263-015-0230-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-015-0230-6</ArticleId><ArticleId IdType="pubmed">25700645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009. May 19; 72(20):1720&#x2013;1726 10.1212/01.wnl.0000345881.82856.d5</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000345881.82856.d5</ArticleId><ArticleId IdType="pmc">PMC2683736</ArticleId><ArticleId IdType="pubmed">19228583</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjar I, Brown L, Mack WJ, Chui H. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol. 2012. December; 69(12):1632&#x2013;1638. 10.1001/archneurol.2012.1010</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.1010</ArticleId><ArticleId IdType="pmc">PMC3608189</ArticleId><ArticleId IdType="pubmed">22964777</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, et al. Selective Antihypertensive Dihydropyridines Lower A&#x3b2; Accumulation by Targeting both the Production and the Clearance of A&#x3b2; across the Blood-Brain Barrier. Mol Med. 2011; 17:149&#x2013;162. 10.2119/molmed.2010.00180</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2010.00180</ArticleId><ArticleId IdType="pmc">PMC3060987</ArticleId><ArticleId IdType="pubmed">21170472</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyridine compounds facilitate the clearance of &#x3b2;-amyloid across the blood-brain barrier. Eur J Pharmacol. 2011; 659:124&#x2013;129. 10.1016/j.ejphar.2011.03.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2011.03.048</ArticleId><ArticleId IdType="pubmed">21497592</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Oiso Y, et al. Nilvadipine inhibits nuclear factor-kappa B-dependent transcription in hepatic cells. Clin Chim Acta. 2004; 350:151&#x2013;157. 10.1016/j.cccn.2004.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cccn.2004.07.012</ArticleId><ArticleId IdType="pubmed">15530472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagawa H, Nomura S, Ozaki Y, Nagahama M, Fukuhara S. Effects of nilvadipine on cytokine levels and soluble factors in collagen disease complicated with essential hypertension. Clin Exp Hypertens. 1999; 21:1177&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10513835</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Ait-Ghezala G, Bachmeier C, Laco G, Beaulieu-Abdelahad D, Lin Y, et al. The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-&#x3b2; production and Tau hyperphosphorylation. J Biol Chem. 2014; 289:33927&#x2013;33944. 10.1074/jbc.M114.608091</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.608091</ArticleId><ArticleId IdType="pmc">PMC4256331</ArticleId><ArticleId IdType="pubmed">25331948</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, et al. Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res. 2004; 999:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">14746921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanyu H, Hirao K, Shimizu S, Sato T, Kiuchi A, Iwamoto T. Nilvadipine prevents cognitive decline in patients with mild cognitive impairment. Int J Geriatr Psychiatry. 2007; 22:1264&#x2013;1266. 10.1002/gps.1851</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1851</ArticleId><ArticleId IdType="pubmed">18033677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennelly SP, Abdullah L, Paris D, Parish J, Mathura V, Mullan M, et al. Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry. 2011; 10:1038&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">21905098</ArticleId></ArticleIdList></Reference><Reference><Citation>Forette F, Seux ML, Staessen JA, Thijs L, Birkenh&#xe4;ger WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998; 352:1347&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">9802273</ArticleId></ArticleIdList></Reference><Reference><Citation>Forette F, Seux ML, Staessen JA, Thijs l, Babarskiene MR, Babeanu S, et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002; 162:2046&#x2013;2052.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasar S, Corratta M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: The Baltimore Longitudinal Study of Aging. Neurobiol Aging. 2005; 26:157&#x2013;163. 10.1016/j.neurobiolaging.2004.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.03.009</ArticleId><ArticleId IdType="pubmed">15582745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawlor B, Kennelly S, O'Dwyer S, Cregg F, Walsh C, Coen R, et al. NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. BMJ Open. 2014. October 9 10.1136/bmjopen-2014-006364</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2014-006364</ArticleId><ArticleId IdType="pmc">PMC4194801</ArticleId><ArticleId IdType="pubmed">25300460</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy W, Alemayehu E, Roberts RS. Reliability of a standardised Mini-Mental State Examination compared with traditional Mini-Mental State examination. Am J Psychiatry. 1991; 148:102&#x2013;105. 10.1176/ajp.148.1.102</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ajp.148.1.102</ArticleId><ArticleId IdType="pubmed">1984692</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141:1356&#x2013;1364. 10.1176/ajp.141.11.1356</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ajp.141.11.1356</ArticleId><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr. 1997; 9(Suppl 1):163&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447439</ArticleId></ArticleIdList></Reference><Reference><Citation>Meulenbroek O, O'Dwyer S, de Jong D, van Spijker G, Kennelly S, Cregg F, et al. European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. BMJ Open. 2016. July 19 10.1136/bmjopen-2016-011584</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-011584</ArticleId><ArticleId IdType="pmc">PMC4964180</ArticleId><ArticleId IdType="pubmed">27436668</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Cesari M, Liu F, Dong B, Vellas B. Effects of Diabetes Mellitus on Cognitive Decline in Patients with Alzheimer Disease: A Systematic Review. Can J Diabetes. 2017; 41:114&#x2013;119. 10.1016/j.jcjd.2016.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcjd.2016.07.003</ArticleId><ArticleId IdType="pubmed">27614804</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, Fox RC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010; 9:363&#x2013;372. 10.1016/S1474-4422(10)70043-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70043-0</ArticleId><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370:322&#x2013;333. 10.1056/NEJMoa1304839</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011. November 30 10.1126/scitranslmed.3002609</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002609</ArticleId><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="pubmed">22133718</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30254377</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse model.</ArticleTitle><Pagination><StartPage>3916</StartPage><MedlinePgn>3916</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3916</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-018-06449-x</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is an intractable progressive neurodegenerative disease characterized by cognitive decline and dementia. An inflammatory neurodegenerative pathway, involving Caspase-1 activation, is associated with human age-dependent cognitive impairment and several classical AD brain pathologies. Here, we show that the nontoxic and blood-brain barrier permeable small molecule Caspase-1 inhibitor VX-765 dose-dependently reverses episodic and spatial memory impairment, and hyperactivity in the J20 mouse model of AD. Cessation of VX-765 results in the reappearance of memory deficits in the mice after 1 month and recommencement of treatment re-establishes normal cognition. VX-765 prevents progressive amyloid beta peptide deposition, reverses brain inflammation, and normalizes synaptophysin protein levels in mouse hippocampus. Consistent with these findings, Caspase-1 null J20 mice are protected from episodic and spatial memory deficits, neuroinflammation and A&#x3b2; accumulation. These results provide in vivo proof of concept for Caspase-1 inhibition against AD cognitive deficits and pathologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4790-3034</Identifier><AffiliationInfo><Affiliation>Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. C&#xf4;te Ste-Catherine, Montreal, QC, H3T 1E2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, 845 Sherbrooke St West, Montreal, QC, H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>No&#xeb;l</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4405-3828</Identifier><AffiliationInfo><Affiliation>Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. C&#xf4;te Ste-Catherine, Montreal, QC, H3T 1E2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, 845 Sherbrooke St West, Montreal, QC, H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foveau</LastName><ForeName>B&#xe9;n&#xe9;dicte</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-1906-8892</Identifier><AffiliationInfo><Affiliation>Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. C&#xf4;te Ste-Catherine, Montreal, QC, H3T 1E2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynham</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9211-2733</Identifier><AffiliationInfo><Affiliation>Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. C&#xf4;te Ste-Catherine, Montreal, QC, H3T 1E2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, McGill University, 845 Sherbrooke St West, Montreal, QC, H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lecrux</LastName><ForeName>Clotilde</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3521-5266</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, 845 Sherbrooke St West, Montreal, QC, H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeBlanc</LastName><ForeName>Andr&#xe9;a C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0003-0418-3900</Identifier><AffiliationInfo><Affiliation>Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Ch. C&#xf4;te Ste-Catherine, Montreal, QC, H3T 1E2, Canada. andrea.leblanc@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, 845 Sherbrooke St West, Montreal, QC, H3A 0G4, Canada. andrea.leblanc@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, McGill University, 845 Sherbrooke St West, Montreal, QC, H3A 0G4, Canada. andrea.leblanc@mcgill.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-243413-BCA-CGAG-45097</GrantID><Agency>Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Sant&#xe9; du Canada)</Agency><Country>International</Country></Grant><Grant><GrantID>Project grant 153097</GrantID><Agency>Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Sant&#xe9; du Canada)</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061945">Caspase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062366">para-Aminobenzoates</NameOfSubstance></Chemical><Chemical><RegistryNumber>00OLE78529</RegistryNumber><NameOfSubstance UI="C520022">belnacasan</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.36</RegistryNumber><NameOfSubstance UI="D020170">Caspase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020170" MajorTopicYN="N">Caspase 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061945" MajorTopicYN="N">Caspase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062366" MajorTopicYN="N">para-Aminobenzoates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30254377</ArticleId><ArticleId IdType="pmc">PMC6156230</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-06449-x</ArticleId><ArticleId IdType="pii">10.1038/s41467-018-06449-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 2015;16:358&#x2013;372. doi: 10.1038/nrn3880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3880</ArticleId><ArticleId IdType="pubmed">25991443</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Qiaoqiao, Chowdhury Saba, Ma Rong, Le Kevin X., Hong Soyon, Caldarone Barbara J., Stevens Beth, Lemere Cynthia A. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Science Translational Medicine. 2017;9(392):eaaf6295. doi: 10.1126/scitranslmed.aaf6295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6295</ArticleId><ArticleId IdType="pmc">PMC6936623</ArticleId><ArticleId IdType="pubmed">28566429</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain. 2016;139:891&#x2013;907. doi: 10.1093/brain/awv379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv379</ArticleId><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, et al. Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-beta pathology. Brain. 2016;139:1265&#x2013;1281. doi: 10.1093/brain/aww016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww016</ArticleId><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;678. doi: 10.1038/nature11729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanopoulou K, Fragkouli A, Stylianopoulou F, Georgopoulos S. Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc. Natl. Acad. Sci. USA. 2010;107:20816&#x2013;20821. doi: 10.1073/pnas.1005888107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1005888107</ArticleId><ArticleId IdType="pmc">PMC2996412</ArticleId><ArticleId IdType="pubmed">21076037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauppinen Tiina M, Suh Sang, Higashi Youichirou, Berman Ari E, Escartin Carole, Won Seok, Wang Chao, Cho Seo-Hyun, Gan Li, Swanson Raymond A. Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid &#x3b2;. Journal of Neuroinflammation. 2011;8(1):152. doi: 10.1186/1742-2094-8-152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-152</ArticleId><ArticleId IdType="pmc">PMC3247192</ArticleId><ArticleId IdType="pubmed">22051244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716. doi: 10.1126/science.aad8373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Hernandez JI, et al. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer&#x2019;s disease through GSK3beta and secretases. Neurobiol. Aging. 2012;33:1816&#x2013;1828. doi: 10.1016/j.neurobiolaging.2011.09.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.09.040</ArticleId><ArticleId IdType="pubmed">22048123</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan MS, et al. Amyloid-beta induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer&#x2019;s disease. Cell Death Dis. 2014;5:e1382. doi: 10.1038/cddis.2014.348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.348</ArticleId><ArticleId IdType="pmc">PMC4454321</ArticleId><ArticleId IdType="pubmed">25144717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushal V, et al. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ. 2015;22:1676&#x2013;1686. doi: 10.1038/cdd.2015.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2015.16</ArticleId><ArticleId IdType="pmc">PMC4563782</ArticleId><ArticleId IdType="pubmed">25744023</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht S, Bogdanovic N, Ghetti B, Winblad B, LeBlanc AC. Caspase-6 activation in familial Alzheimer disease brains carrying amyloid precursor protein or presenilin I or presenilin II mutations. J. Neuropathol. Exp. Neurol. 2009;68:1282&#x2013;1293. doi: 10.1097/NEN.0b013e3181c1da10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181c1da10</ArticleId><ArticleId IdType="pmc">PMC3079356</ArticleId><ArticleId IdType="pubmed">19915487</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, et al. Active Caspase-6 and Caspase-6 cleaved Tau in neuropil threads, neuritic plaques and neurofibrillary tangles of Alzheimer&#x2019;s disease. Am. J. Pathol. 2004;165:523&#x2013;531. doi: 10.1016/S0002-9440(10)63317-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63317-2</ArticleId><ArticleId IdType="pmc">PMC1618555</ArticleId><ArticleId IdType="pubmed">15277226</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht S, et al. Activation of caspase-6 in aging and mild cognitive impairment. Am. J. Pathol. 2007;170:1200&#x2013;1209. doi: 10.2353/ajpath.2007.060974.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.060974</ArticleId><ArticleId IdType="pmc">PMC1829454</ArticleId><ArticleId IdType="pubmed">17392160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramcharitar J, Afonso VM, Albrecht S, Bennett DA, LeBlanc AC. Caspase-6 activity predicts lower episodic memory ability in aged individuals. Neurobiol. Aging. 2013;34:1815&#x2013;1824. doi: 10.1016/j.neurobiolaging.2013.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.01.007</ArticleId><ArticleId IdType="pmc">PMC3772349</ArticleId><ArticleId IdType="pubmed">23402898</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc AC, et al. Caspase-6 activity in the CA1 region of the hippocampus induces age-dependent memory impairment. Cell Death Differ. 2014;21:696&#x2013;706. doi: 10.1038/cdd.2013.194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2013.194</ArticleId><ArticleId IdType="pmc">PMC3978300</ArticleId><ArticleId IdType="pubmed">24413155</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O&#x2019;Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989. doi: 10.1038/nature07767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07767</ArticleId><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon DJ, et al. A caspase cascade regulating developmental axon degeneration. J. Neurosci. 2012;32:17540&#x2013;17553. doi: 10.1523/JNEUROSCI.3012-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3012-12.2012</ArticleId><ArticleId IdType="pmc">PMC3532512</ArticleId><ArticleId IdType="pubmed">23223278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivananthan S N, Lee A W, Goodyer C G, LeBlanc A C. Familial amyloid precursor protein mutants cause caspase-6-dependent but amyloid &#x3b2;-peptide-independent neuronal degeneration in primary human neuron cultures. Cell Death &amp; Disease. 2010;1(11):e100&#x2013;e100. doi: 10.1038/cddis.2010.74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2010.74</ArticleId><ArticleId IdType="pmc">PMC3032318</ArticleId><ArticleId IdType="pubmed">21368865</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaiman G, Petzke TL, Hammond J, LeBlanc AC. Targets of caspase-6 activity in human neurons and Alzheimer disease. Mol. Cell. Proteom. 2008;7:1541&#x2013;1555. doi: 10.1074/mcp.M800007-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M800007-MCP200</ArticleId><ArticleId IdType="pmc">PMC2500235</ArticleId><ArticleId IdType="pubmed">18487604</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc A. Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. J. Neurosci. 1995;15:7837&#x2013;7846. doi: 10.1523/JNEUROSCI.15-12-07837.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.15-12-07837.1995</ArticleId><ArticleId IdType="pmc">PMC6577962</ArticleId><ArticleId IdType="pubmed">8613723</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer&#x2019;s disease. J. Biol. Chem. 1999;274:23426&#x2013;23436. doi: 10.1074/jbc.274.33.23426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.33.23426</ArticleId><ArticleId IdType="pubmed">10438520</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L, Passer B, Tabaton M, Ganjei K, D&#x2019;Adamio L. Alternative, non-secretase processing of Alzheimer&#x2019;s b-amyloid precursor protein during apoptosis by caspase-6 and -8. J. Biol. Chem. 1999;274:21011&#x2013;21016. doi: 10.1074/jbc.274.30.21011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.30.21011</ArticleId><ArticleId IdType="pubmed">10409650</ArticleId></ArticleIdList></Reference><Reference><Citation>Halawani D, et al. Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer&#x2019;s disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation. J. Neurosci. 2010;30:6132&#x2013;6142. doi: 10.1523/JNEUROSCI.5874-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5874-09.2010</ArticleId><ArticleId IdType="pmc">PMC3187624</ArticleId><ArticleId IdType="pubmed">20427671</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer MB, et al. A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety. ChemMedChem. 2010;5:730&#x2013;738. doi: 10.1002/cmdc.200900531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.200900531</ArticleId><ArticleId IdType="pmc">PMC3062473</ArticleId><ArticleId IdType="pubmed">20229566</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer, M. B., Shen, M., Auld, D. S., Wells, J. A. &amp; Thomas, C. J. Probe Reports from the NIH Molecular Libraries Programhttp://www.ncbi.nlm.nih.gov/books/NBK56241/ (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21433368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannamaker W, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J. Pharmacol. Exp. Ther. 2007;321:509&#x2013;516. doi: 10.1124/jpet.106.111344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.106.111344</ArticleId><ArticleId IdType="pubmed">17289835</ArticleId></ArticleIdList></Reference><Reference><Citation>Doitsh G, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505:509&#x2013;514. doi: 10.1038/nature12940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12940</ArticleId><ArticleId IdType="pmc">PMC4047036</ArticleId><ArticleId IdType="pubmed">24356306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialer M, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI) Epilepsy Res. 2013;103:2&#x2013;30. doi: 10.1016/j.eplepsyres.2012.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eplepsyres.2012.10.001</ArticleId><ArticleId IdType="pubmed">23219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000;20:4050&#x2013;4058. doi: 10.1523/JNEUROSCI.20-11-04050.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-11-04050.2000</ArticleId><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer&#x2019;s disease are independent of caspase cleavage of the amyloid precursor protein. J. Neurosci. 2010;30:372&#x2013;381. doi: 10.1523/JNEUROSCI.5341-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5341-09.2010</ArticleId><ArticleId IdType="pmc">PMC3064502</ArticleId><ArticleId IdType="pubmed">20053918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright AL, et al. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer&#x2019;s disease. PLoS ONE. 2013;8:e59586. doi: 10.1371/journal.pone.0059586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0059586</ArticleId><ArticleId IdType="pmc">PMC3613362</ArticleId><ArticleId IdType="pubmed">23560052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res. 1998;57:1&#x2013;9. doi: 10.1016/S0169-328X(98)00040-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(98)00040-0</ArticleId><ArticleId IdType="pubmed">9630473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am. J. Pathol. 2010;177:311&#x2013;324. doi: 10.2353/ajpath.2010.090915.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.090915</ArticleId><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed JC, et al. Comparative analysis of apoptosis and inflammation genes of mice and humans. Genome Res. 2003;13:1376&#x2013;1388. doi: 10.1101/gr.1053803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1053803</ArticleId><ArticleId IdType="pmc">PMC403667</ArticleId><ArticleId IdType="pubmed">12819136</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, et al. Caspase-1 activation of caspase-6 in human apoptotic neurons. Cell Death Differ. 2006;13:285&#x2013;292. doi: 10.1038/sj.cdd.4401753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401753</ArticleId><ArticleId IdType="pubmed">16123779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramcharitar J, et al. Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer disease. J. Neuropathol. Exp. Neurol. 2013;72:824&#x2013;832. doi: 10.1097/NEN.0b013e3182a0a39f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3182a0a39f</ArticleId><ArticleId IdType="pmc">PMC3777607</ArticleId><ArticleId IdType="pubmed">23965742</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontillo A, Catamo E, Arosio B, Mari D, Crovella S. NALP1/NLRP1 genetic variants are associated with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2012;26:277&#x2013;281. doi: 10.1097/WAD.0b013e318231a8ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318231a8ac</ArticleId><ArticleId IdType="pubmed">21946017</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozueta A, et al. Genetic variation in caspase-1 as predictor of accelerated progression from mild cognitive impairment to Alzheimer&#x2019;s disease. J. Neurol. 2011;258:1538&#x2013;1539. doi: 10.1007/s00415-011-5935-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-5935-y</ArticleId><ArticleId IdType="pubmed">21311905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacoste B, Tong XK, Lahjouji K, Couture R, Hamel E. Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer&#x2019;s disease mice. J. Neuroinflamm. 2013;10:57. doi: 10.1186/1742-2094-10-57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-10-57</ArticleId><ArticleId IdType="pmc">PMC3710240</ArticleId><ArticleId IdType="pubmed">23642031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehgal N, et al. Withania somnifera reverses Alzheimer&#x2019;s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl. Acad. Sci. USA. 2012;109:3510&#x2013;3515. doi: 10.1073/pnas.1112209109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1112209109</ArticleId><ArticleId IdType="pmc">PMC3295277</ArticleId><ArticleId IdType="pubmed">22308347</ArticleId></ArticleIdList></Reference><Reference><Citation>Spilman P, et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer&#x2019;s model. Brain Res. 2014;1551:25&#x2013;44. doi: 10.1016/j.brainres.2013.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.12.029</ArticleId><ArticleId IdType="pmc">PMC4001856</ArticleId><ArticleId IdType="pubmed">24389031</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KA, et al. Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC study. Neurology. 2017;89:2262&#x2013;2270. doi: 10.1212/WNL.0000000000004688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004688</ArticleId><ArticleId IdType="pmc">PMC5705246</ArticleId><ArticleId IdType="pubmed">29093073</ArticleId></ArticleIdList></Reference><Reference><Citation>Luksch H, et al. Naturally occurring genetic variants of human caspase-1 differ considerably in structure and the ability to activate interleukin-1beta. Hum. Mutat. 2013;34:122&#x2013;131. doi: 10.1002/humu.22169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22169</ArticleId><ArticleId IdType="pubmed">22833538</ArticleId></ArticleIdList></Reference><Reference><Citation>Trompet S, et al. Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. Brain. 2008;131:1069&#x2013;1077. doi: 10.1093/brain/awn023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn023</ArticleId><ArticleId IdType="pubmed">18304957</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymann MC, et al. Human procaspase-1 variants with decreased enzymatic activity are associated with febrile episodes and may contribute to inflammation via RIP2 and NF-kappaB signaling. J. Immunol. 2014;192:4379&#x2013;4385. doi: 10.4049/jimmunol.1203524.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1203524</ArticleId><ArticleId IdType="pubmed">24706726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuida K, et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science. 1995;267:2000&#x2013;2003. doi: 10.1126/science.7535475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7535475</ArticleId><ArticleId IdType="pubmed">7535475</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 1987;147:229&#x2013;263. doi: 10.1111/j.1365-2818.1987.tb02837.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.1987.tb02837.x</ArticleId><ArticleId IdType="pubmed">3430576</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30297968</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>11</Issue><PubDate><Year>2018</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer's disease susceptibility.</ArticleTitle><Pagination><StartPage>1584</StartPage><EndPage>1592</EndPage><MedlinePgn>1584-1592</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-018-0238-1</ELocationID><Abstract><AbstractText>Here we use deep sequencing to identify sources of variation in mRNA splicing in the dorsolateral prefrontal cortex (DLPFC) of 450 subjects from two aging cohorts. Hundreds of aberrant pre-mRNA splicing events are reproducibly associated with Alzheimer's disease. We also generate a catalog of splicing quantitative trait loci (sQTL) effects: splicing of 3,006 genes is influenced by genetic variation. We report that altered splicing is the mechanism for the effects of the PICALM, CLU and PTK2B susceptibility alleles. Furthermore, we performed a transcriptome-wide association study and identified 21 genes with significant associations with Alzheimer's disease, many of which are found in known loci, whereas 8 are in novel loci. These results highlight the convergence of old and new genes associated with Alzheimer's disease in autophagy-lysosomal-related pathways. Overall, this study of the transcriptome of the aging brain provides evidence that dysregulation of mRNA splicing is a feature of Alzheimer's disease and is, in some cases, genetically driven.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Towfique</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9355-5704</Identifier><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yang I</ForeName><Initials>YI</Initials><Identifier Source="ORCID">0000-0002-0736-251X</Identifier><AffiliationInfo><Affiliation>Section of Genetic Medicine, University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Garrett</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humphrey</LastName><ForeName>Jack</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6274-6620</Identifier><AffiliationInfo><Affiliation>Genetics Institute, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9171-4962</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramdhani</LastName><ForeName>Satesh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying-Chih</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Ishaan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8934-9919</Identifier><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5860-2512</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James J. Peters VA Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadt</LastName><ForeName>Eric E</ForeName><Initials>EE</Initials><Identifier Source="ORCID">0000-0002-7892-8808</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young-Pearse</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafavi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sklar</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Broad Institute of MIT and Harvard, Cambridge, MA, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054005</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH057881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018522</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH084053</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH066392</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH080405</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH075916</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG055824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH097276</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH093725</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH085542</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Genet. 2018 Dec;19(12):738-739. doi: 10.1038/s41576-018-0064-4.</RefSource><PMID Version="1">30341439</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049490" MajorTopicYN="N">Systems Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018511" MajorTopicYN="N">Systems Integration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing financial interests. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30297968</ArticleId><ArticleId IdType="mid">NIHMS1504106</ArticleId><ArticleId IdType="pmc">PMC6354244</ArticleId><ArticleId IdType="doi">10.1038/s41588-018-0238-1</ArticleId><ArticleId IdType="pii">10.1038/s41588-018-0238-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang ET et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470&#x2013;6 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593745</ArticleId><ArticleId IdType="pubmed">18978772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornblihtt AR et al. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 14, 153&#x2013;65 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23385723</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa-Morais NL et al. The evolutionary landscape of alternative splicing in vertebrate species. Science 338, 1587&#x2013;93 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23258890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang GS &amp; Cooper TA Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8, 749&#x2013;61 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17726481</ArticleId></ArticleIdList></Reference><Reference><Citation>Dredge BK, Polydorides AD &amp; Darnell RB The splice of life: alternative splicing and neurological disease. Nat Rev Neurosci 2, 43&#x2013;50 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11253358</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN et al. Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. Nature 540, 423&#x2013;427 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102905</ArticleId><ArticleId IdType="pubmed">27919067</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351, 602&#x2013;11 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D et al. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet 21, 4094&#x2013;103 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428157</ArticleId><ArticleId IdType="pubmed">22723018</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein EM et al. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer&#x2019;s disease. J Biol Chem 270, 28257&#x2013;67 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7499323</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee L, Bussiere T, Buee-Scherrer V, Delacourte A &amp; Hof PR Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33, 95&#x2013;130 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenca GT et al. The Role of MAPT Haplotype H2 and Isoform 1N/4R in Parkinsonism of Older Adults. PLoS One 11, e0157452 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961370</ArticleId><ArticleId IdType="pubmed">27458716</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 110, 16562&#x2013;7 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799305</ArticleId><ArticleId IdType="pubmed">24023061</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquero-Garcia J et al. A new view of transcriptome complexity and regulation through the lens of local splicing variations. Elife 5, e11752 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801060</ArticleId><ArticleId IdType="pubmed">26829591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet 45, 1452&#x2013;8 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344, 519&#x2013;23 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910825</ArticleId><ArticleId IdType="pubmed">24786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer&#x2019;s disease susceptibility. Hum Mol Genet 23, 2729&#x2013;36 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990171</ArticleId><ArticleId IdType="pubmed">24381305</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z &amp; Wilson RS Overview and findings from the religious orders study. Curr Alzheimer Res 9, 628&#x2013;45 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Selected findings from the Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis 33 Suppl 1, S397&#x2013;403 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3434299</ArticleId><ArticleId IdType="pubmed">22647261</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat Neurosci 21, 811&#x2013;819 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YI et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat Genet 50, 151&#x2013;158 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742080</ArticleId><ArticleId IdType="pubmed">29229983</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YI et al. RNA splicing is a primary link between genetic variation and disease. Science 352, 600&#x2013;4 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5182069</ArticleId><ArticleId IdType="pubmed">27126046</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR et al. Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. Genome Res 21, 1572&#x2013;82 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202275</ArticleId><ArticleId IdType="pubmed">21846794</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchelmore C et al. NDRG2: a novel Alzheimer&#x2019;s disease associated protein. Neurobiol Dis 16, 48&#x2013;58 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15207261</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B &amp; Horvath S A General Framework for Weighted Gene Co-Expression Network Analysis. Statistical Applications in Genetics and Molecular Biology 4, Article 17 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M et al. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer&#x2019;s disease. Genome Med 8, 104 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088659</ArticleId><ArticleId IdType="pubmed">27799057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongen H, Buil A, Brown AA, Dermitzakis ET &amp; Delaneau O Fast and efficient QTL mapper for thousands of molecular phenotypes. Bioinformatics 32, 1479&#x2013;85 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4866519</ArticleId><ArticleId IdType="pubmed">26708335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein BE et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol 28, 1045&#x2013;8 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607281</ArticleId><ArticleId IdType="pubmed">20944595</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromer M et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci 19, 1442&#x2013;1453 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5083142</ArticleId><ArticleId IdType="pubmed">27668389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B et al. An xQTL map integrates the genetic architecture of the human brain&#x2019;s transcriptome and epigenome. Nat Neurosci 20, 1418&#x2013;1426 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolae DL et al. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 6, e1000888 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848547</ArticleId><ArticleId IdType="pubmed">20369019</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L et al. Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells. Cell 167, 1398&#x2013;1414 e24 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119954</ArticleId><ArticleId IdType="pubmed">27863251</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik M et al. CD33 Alzheimer&#x2019;s risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci 33, 13320&#x2013;5 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742922</ArticleId><ArticleId IdType="pubmed">23946390</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibley CR, Blazquez L &amp; Ule J Lessons from non-canonical splicing. Nat Rev Genet 17, 407&#x2013;21 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5154377</ArticleId><ArticleId IdType="pubmed">27240813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YC et al. CLIPdb: a CLIP-seq database for protein-RNA interactions. BMC Genomics 16, 51 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326514</ArticleId><ArticleId IdType="pubmed">25652745</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheckel C et al. Regulatory consequences of neuronal ELAV-like protein binding to coding and non-coding RNAs in human brain. Elife 5 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4798961</ArticleId><ArticleId IdType="pubmed">26894958</ArticleId></ArticleIdList></Reference><Reference><Citation>Borreca A, Gironi K, Amadoro G &amp; Ammassari-Teule M Opposite Dysregulation of Fragile-X Mental Retardation Protein and Heteronuclear Ribonucleoprotein C Protein Associates with Enhanced APP Translation in Alzheimer Disease. Mol Neurobiol 53, 3227&#x2013;3234 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26048669</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev A et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet 48, 245&#x2013;52 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4767558</ArticleId><ArticleId IdType="pubmed">26854917</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT et al. A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer&#x2019;s Disease. Cell Syst 4, 60&#x2013;72 e4 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269514</ArticleId><ArticleId IdType="pubmed">27989508</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, Erlich Y &amp; Pickrell JK Case-control association mapping by proxy using family history of disease. Nat Genet 49, 325&#x2013;331 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28092683</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev A et al. Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. Nat Genet 50, 538&#x2013;548 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942893</ArticleId><ArticleId IdType="pubmed">29632383</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet 44, 369&#x2013;75, S1&#x2013;3 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593158</ArticleId><ArticleId IdType="pubmed">22426310</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T et al. GeNets: a unified web platform for network-based genomic analyses. Nat Methods 15, 543&#x2013;546 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450090</ArticleId><ArticleId IdType="pubmed">29915188</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T et al. Alzheimer disease susceptibility loci: evidence for a protein network under natural selection. Am J Hum Genet 90, 720&#x2013;6 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322230</ArticleId><ArticleId IdType="pubmed">22482808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA New perspectives on lysosomes in ageing and neurodegenerative disease. Ageing Res Rev 32, 1 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27894596</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmett MJ et al. Histone deacetylase 3 prepares brown adipose tissue for acute thermogenic challenge. Nature 546, 544&#x2013;548 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5826652</ArticleId><ArticleId IdType="pubmed">28614293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Chang JC, Fan EY, Flajolet M &amp; Greengard P Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer&#x2019;s APP-CTF for terminal degradation via autophagy. Proc Natl Acad Sci U S A 110, 17071&#x2013;6 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3801056</ArticleId><ArticleId IdType="pubmed">24067654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925&#x2013;31 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet AL, Weintraub S, Mash DC &amp; Mesulam MM Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60, 729&#x2013;36 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12756137</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium GT Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648&#x2013;60 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science 343, 1246949 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064786</ArticleId><ArticleId IdType="pubmed">24604202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res 9, 646&#x2013;63 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559&#x2013;75 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson N, Price AL &amp; Reich D Population structure and eigenanalysis. PLoS Genet 2, e190 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1713260</ArticleId><ArticleId IdType="pubmed">17194218</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S et al. Next-generation genotype imputation service and methods. Nat Genet 48, 1284&#x2013;7 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy S et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet 48, 1279&#x2013;83 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388176</ArticleId><ArticleId IdType="pubmed">27548312</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B &amp; Dewey CN RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WE, Li C &amp; Rabinovic A Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118&#x2013;27 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16632515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman GE &amp; Schadt EE variancePartition: interpreting drivers of variation in complex gene expression studies. BMC Bioinformatics 17, 483 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123296</ArticleId><ArticleId IdType="pubmed">27884101</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Geijn B, McVicker G, Gilad Y &amp; Pritchard JK WASP: allele-specific software for robust molecular quantitative trait locus discovery. Nat Methods 12, 1061&#x2013;3 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626402</ArticleId><ArticleId IdType="pubmed">26366987</ArticleId></ArticleIdList></Reference><Reference><Citation>Degner JF et al. DNase I sensitivity QTLs are a major determinant of human expression variation. Nature 482, 390&#x2013;4 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501342</ArticleId><ArticleId IdType="pubmed">22307276</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Lee SH, Goddard ME &amp; Visscher PM GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 88, 76&#x2013;82 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014363</ArticleId><ArticleId IdType="pubmed">21167468</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD &amp; Tibshirani R Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100, 9440&#x2013;5 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Nica AC et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet 7, e1002003 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033383</ArticleId><ArticleId IdType="pubmed">21304890</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulietti M et al. SpliceAid-F: a database of human splicing factors and their RNA-binding sites. Nucleic Acids Res 41, D125&#x2013;31 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531144</ArticleId><ArticleId IdType="pubmed">23118479</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt EM et al. GREGOR: evaluating global enrichment of trait-associated variants in epigenomic features using a systematic, data-driven approach. Bioinformatics 31, 2601&#x2013;6 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612390</ArticleId><ArticleId IdType="pubmed">25886982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lage K et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol 25, 309&#x2013;16 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17344885</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30297807</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2018</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Integration of gene expression and brain-wide connectivity reveals the multiscale organization of mouse hippocampal networks.</ArticleTitle><Pagination><StartPage>1628</StartPage><EndPage>1643</EndPage><MedlinePgn>1628-1643</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-018-0241-y</ELocationID><Abstract><AbstractText>Understanding the organization of the hippocampus is fundamental to understanding brain function related to learning, memory, emotions, and diseases such as Alzheimer's disease. Physiological studies in humans and rodents have suggested that there is both structural and functional heterogeneity along the longitudinal axis of the hippocampus. However, the recent discovery of discrete gene expression domains in the mouse hippocampus has provided the opportunity to re-evaluate hippocampal connectivity. To integrate mouse hippocampal gene expression and connectivity, we mapped the distribution of distinct gene expression patterns in mouse hippocampus and subiculum to create the Hippocampus Gene Expression Atlas (HGEA). Notably, previously unknown subiculum gene expression patterns revealed a hidden laminar organization. Guided by the HGEA, we constructed the most detailed hippocampal connectome available using Mouse Connectome Project ( http://www.mouseconnectome.org ) tract tracing data. Our results define the hippocampus' multiscale network organization and elucidate each subnetwork's unique brain-wide connectivity patterns.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bienkowski</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-8231-8893</Identifier><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA. michael.bienkowski@ini.usc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowman</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Monica Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gou</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ard</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>Kaelan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Muye</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benavidez</LastName><ForeName>Nora L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Seita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu-Jaber</LastName><ForeName>Jaspar</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azam</LastName><ForeName>Sana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Darrick</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Nicholas N</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hintiryan</LastName><ForeName>Houri</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Hong-Wei</ForeName><Initials>HW</Initials><Identifier Source="ORCID">0000-0001-9972-3177</Identifier><AffiliationInfo><Affiliation>University of Southern California Stevens Neuroimaging and Informatics Institute, Center for Integrated Connectomics (CIC), Keck School of Medicine of University of Southern California, Los Angeles, CA, USA. hongwei.dong@ini.usc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA. hongwei.dong@ini.usc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, and Zilkha Neurogenetic Institute, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA. hongwei.dong@ini.usc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 MH114821</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC008983</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 MH114112</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA198932</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 MH107071</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH094360</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH114829</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063132" MajorTopicYN="Y">Connectome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Financial Interests. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30297807</ArticleId><ArticleId IdType="mid">NIHMS1504104</ArticleId><ArticleId IdType="pmc">PMC6398347</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0241-y</ArticleId><ArticleId IdType="pii">10.1038/s41593-018-0241-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fanselow MS &amp; Dong H-W Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 65, 7&#x2013;19 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822727</ArticleId><ArticleId IdType="pubmed">20152109</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruszak A &amp; Thuret S Why looking at the whole hippocampus is not enough&#x2014;a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer&#x2019;s disease diagnosis. Frontiers in Cellular Neuroscience 8 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978283</ArticleId><ArticleId IdType="pubmed">24744700</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser MB &amp; Moser EI Functional differentiation in the hippocampus. Hippocampus 8, 608&#x2013;619 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9882018</ArticleId></ArticleIdList></Reference><Reference><Citation>Poppenk J, Evensmoen HR, Moscovitch M &amp; Nadel L Long-axis specialization of the human hippocampus. Trends in cognitive sciences 17, 230&#x2013;240 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23597720</ArticleId></ArticleIdList></Reference><Reference><Citation>Risold P &amp; Swanson L Structural evidence for functional domains in the rat hippocampus. Science 272, 1484 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8633241</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson L &amp; Cowan W An autoradiographic study of the organization of the efferet connections of the hippocampal formation in the rat. Journal of Comparative Neurology 172, 49&#x2013;84 (1977).</Citation><ArticleIdList><ArticleId IdType="pubmed">65364</ArticleId></ArticleIdList></Reference><Reference><Citation>Strange BA, Witter MP, Lein ES &amp; Moser EI Functional organization of the hippocampal longitudinal axis. Nature Reviews Neuroscience 15, 655&#x2013;669 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25234264</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral DG Emerging principles of intrinsic hippocampal organization. Current opinion in neurobiology 3, 225&#x2013;229 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8390320</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H-W, Swanson LW, Chen L, Fanselow MS &amp; Toga AW Genomic&#x2013;anatomic evidence for distinct functional domains in hippocampal field CA1. Proceedings of the National Academy of Sciences 106, 11794&#x2013;11799 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710698</ArticleId><ArticleId IdType="pubmed">19561297</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson CL et al. Genomic anatomy of the hippocampus. Neuron 60, 1010&#x2013;1021 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19109908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A et al. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 347, 1138&#x2013;1142 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25700174</ArticleId></ArticleIdList></Reference><Reference><Citation>Cembrowski MS, Wang L, Sugino K, Shields BC &amp; Spruston N Hipposeq: a comprehensive RNA-seq database of gene expression in hippocampal principal neurons. eLife 5, e14997 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846374</ArticleId><ArticleId IdType="pubmed">27113915</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N et al. Div-Seq: Single-nucleus RNA-Seq reveals dynamics of rare adult newborn neurons. Science 353, 925&#x2013;928 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480621</ArticleId><ArticleId IdType="pubmed">27471252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES, Callaway EM, Albright TD &amp; Gage FH Redefining the boundaries of the hippocampal CA2 subfield in the mouse using gene expression and 3&#x2010;dimensional reconstruction. Journal of Comparative Neurology 485, 1&#x2013;10 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15776443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cembrowski MS &amp; Spruston N Integrating results across methodologies is essential for producing robust neuronal taxonomies. Neuron 94, 747&#x2013;751. e741 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28521129</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, Lubeck E, Zhou W &amp; Cai L In situ transcription profiling of single cells reveals spatial organization of cells in the mouse hippocampus. Neuron 92, 342&#x2013;357 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5087994</ArticleId><ArticleId IdType="pubmed">27764670</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, Lubeck E, Zhou W &amp; Cai L seqFISH accurately detects transcripts in single cells and reveals robust spatial organization in the hippocampus. Neuron 94, 752&#x2013;758. e751 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28521130</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingg B et al. Neural networks of the mouse neocortex. Cell 156, 1096&#x2013;1111 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169118</ArticleId><ArticleId IdType="pubmed">24581503</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SW et al. A mesoscale connectome of the mouse brain. Nature 508, 207 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5102064</ArticleId><ArticleId IdType="pubmed">24695228</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong HW The Allen reference atlas: A digital color brain atlas of the C57Bl/6J male mouse. (John Wiley &amp; Sons Inc, 2008).</Citation></Reference><Reference><Citation>Saunders A et al. A Single-Cell Atlas of Cell Types, States, and Other Transcriptional Patterns from Nine Regions of the Adult Mouse Brain. bioRxiv, 299081 (2018).</Citation></Reference><Reference><Citation>Scharfman HE The enigmatic mossy cell of the dentate gyrus. Nature reviews. Neuroscience 17, 562 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5369357</ArticleId><ArticleId IdType="pubmed">27466143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente de N&#xf3; R Studies on the structure of the cerebral cortex. II. Continuation of the study of the ammonic system. Journal f&#xfc;r Psychologie und Neurologie (1934).</Citation></Reference><Reference><Citation>Cui Z, Gerfen CR &amp; Young WS Hypothalamic and other connections with dorsal CA2 area of the mouse hippocampus. Journal of Comparative Neurology 521, 1844&#x2013;1866 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3798086</ArticleId><ArticleId IdType="pubmed">23172108</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek SM, Alexander GM &amp; Farris S Rediscovering area CA2: unique properties and functions. Nature Reviews Neuroscience 17, 89&#x2013;102 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4856153</ArticleId><ArticleId IdType="pubmed">26806628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohara K et al. Cell type-specific genetic and optogenetic tools reveal hippocampal CA2 circuits. Nature neuroscience 17, 269&#x2013;279 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004172</ArticleId><ArticleId IdType="pubmed">24336151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sik A, Penttonen M, Ylinen A &amp; Buzs&#xe1;ki G Hippocampal CA1 interneurons: an in vivo intracellular labeling study. The Journal of neuroscience 15, 6651&#x2013;6665 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577981</ArticleId><ArticleId IdType="pubmed">7472426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding SL Comparative anatomy of the prosubiculum, subiculum, presubiculum, postsubiculum, and parasubiculum in human, monkey, and rodent. Journal of Comparative Neurology 521, 4145&#x2013;4162 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23839777</ArticleId></ArticleIdList></Reference><Reference><Citation>Vann SD, Aggleton JP &amp; Maguire EA What does the retrosplenial cortex do? Nature Reviews Neuroscience 10, 792&#x2013;802 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19812579</ArticleId></ArticleIdList></Reference><Reference><Citation>Weible AP Remembering to attend: the anterior cingulate cortex and remote memory. Behavioural brain research 245, 63&#x2013;75 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23453992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura T et al. Engrams and circuits crucial for systems consolidation of a memory. Science 356, 73&#x2013;78 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5493329</ArticleId><ArticleId IdType="pubmed">28386011</ArticleId></ArticleIdList></Reference><Reference><Citation>Risold P &amp; Swanson L Connections of the rat lateral septal complex. Brain research reviews 24, 115&#x2013;195 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9385454</ArticleId></ArticleIdList></Reference><Reference><Citation>Cembrowski MS et al. Dissociable structural and functional hippocampal outputs via distinct subiculum cell classes. Cell 173, 1280&#x2013;1292. e1218 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29681453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier JL &amp; Tank DW A dedicated population for reward coding in the hippocampus. Neuron (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7023678</ArticleId><ArticleId IdType="pubmed">30008297</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keefe J &amp; Dostrovsky J The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely-moving rat. Brain research 34, 171&#x2013;175 (1971).</Citation><ArticleIdList><ArticleId IdType="pubmed">5124915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever C, Burton S, Jeewajee A, O&#x2019;Keefe J &amp; Burgess N Boundary vector cells in the subiculum of the hippocampal formation. The Journal of Neuroscience (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736390</ArticleId><ArticleId IdType="pubmed">19657030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafting T, Fyhn M, Molden S, Moser M-B &amp; Moser EI Microstructure of a spatial map in the entorhinal cortex. Nature 436, 801&#x2013;806 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15965463</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargolini F et al. Conjunctive representation of position, direction, and velocity in entorhinal cortex. Science 312, 758&#x2013;762 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16675704</ArticleId></ArticleIdList></Reference><Reference><Citation>Taube JS The head direction signal: origins and sensory-motor integration. Annu. Rev. Neurosci. 30, 181&#x2013;207 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17341158</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuyama T, Kitamura T, Roy DS, Itohara S &amp; Tonegawa S Ventral CA1 neurons store social memory. Science 353, 1536&#x2013;1541 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5493325</ArticleId><ArticleId IdType="pubmed">27708103</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitti FL &amp; Siegelbaum SA The hippocampal CA2 region is essential for social memory. Nature 508, 88&#x2013;92 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000264</ArticleId><ArticleId IdType="pubmed">24572357</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanselow MS &amp; Poulos AM The neuroscience of mammalian associative learning. Annu. Rev. Psychol. 56, 207&#x2013;234 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15709934</ArticleId></ArticleIdList></Reference><Reference><Citation>Tovote P, Fadok JP &amp; L&#xfc;thi A Neuronal circuits for fear and anxiety. Nature Reviews Neuroscience 16, 317&#x2013;331 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25991441</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson LW Cerebral hemisphere regulation of motivated behavior. Brain research 886, 113&#x2013;164 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11119693</ArticleId></ArticleIdList></Reference><Reference><Citation>Canteras NS, Pavesi E &amp; Carobrez AP Olfactory instruction for fear: neural system analysis. Frontiers in neuroscience 9 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526802</ArticleId><ArticleId IdType="pubmed">26300721</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross CT &amp; Canteras NS The many paths to fear. Nature Reviews Neuroscience 13, 651&#x2013;658 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22850830</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lima MAX, Baldo MVC &amp; Canteras NS A role for the anteromedial thalamic nucleus in the acquisition of contextual fear memory to predatory threats. Brain Structure and Function 222, 113&#x2013;129 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">26951288</ArticleId></ArticleIdList></Reference><Reference><Citation>Biag J et al. Cyto&#x2010;and chemoarchitecture of the hypothalamic paraventricular nucleus in the C57BL/6J male mouse: A study of immunostaining and multiple fluorescent tract tracing. Journal of Comparative Neurology 520, 6&#x2013;33 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104804</ArticleId><ArticleId IdType="pubmed">21674499</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson RH &amp; Swanson LW Structural characterization of a hypothalamic visceromotor pattern generator network. Brain Research Reviews 41, 153&#x2013;202 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12663080</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S &amp; Kirouac GJ Sources of inputs to the anterior and posterior aspects of the paraventricular nucleus of the thalamus. Brain Structure and Function 217, 257&#x2013;273 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22086160</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30297750</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-4349</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature chemistry</Title><ISOAbbreviation>Nat Chem</ISOAbbreviation></Journal><ArticleTitle>Inhibiting amyloid-&#x3b2; cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design.</ArticleTitle><Pagination><StartPage>1213</StartPage><EndPage>1221</EndPage><MedlinePgn>1213-1221</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41557-018-0147-z</ELocationID><Abstract><AbstractText>Inhibiting the interaction between amyloid-&#x3b2; (A&#x3b2;) and a neuronal cell surface receptor, LilrB2, has been suggested as a potential route for treating Alzheimer's disease. Supporting this approach, Alzheimer's-like symptoms are reduced in mouse models following genetic depletion of the LilrB2 homologue. In its pathogenic, oligomeric state, A&#x3b2; binds to LilrB2, triggering a pathway to synaptic loss. Here we identify the LilrB2 binding moieties of A&#x3b2; (<sup>16</sup>KLVFFA<sup>21</sup>) and identify its binding site on LilrB2 from a crystal structure of LilrB2 immunoglobulin domains D1D2 complexed to small molecules that mimic phenylalanine residues. In this structure, we observed two pockets that can accommodate the phenylalanine side chains of KLVFFA. These pockets were confirmed to be <sup>16</sup>KLVFFA<sup>21</sup> binding sites by mutagenesis. Rosetta docking revealed a plausible geometry for the A&#x3b2;-LilrB2 complex and assisted with the structure-guided selection of small molecule inhibitors. These molecules inhibit A&#x3b2;-LilrB2 interactions in vitro and on the cell surface and reduce A&#x3b2; cytotoxicity, which suggests these inhibitors are potential therapeutic leads against Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-4207-2697</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute and Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Woo Shik</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Molecular Biology Institute and Brain Research Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vuong</LastName><ForeName>Celine K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systems Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bethany</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Molecular Biology Institute and Brain Research Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Applied Mathematics, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Binsen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Molecular Biology Institute and Brain Research Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Kevin A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute and Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawaya</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0874-9043</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute and Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feigon</LastName><ForeName>Juli</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Douglas L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>David S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0003-2432-5419</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute and Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA. david@mbi.ucla.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3039-1877</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Molecular Biology Institute and Brain Research Institute, UCLA, Los Angeles, CA, USA. jianglin@ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 GM103403</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM114463</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054022</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR029205</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Chem</MedlineTA><NlmUniqueID>101499734</NlmUniqueID><ISSNLinking>1755-4330</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491341">LILRB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Chem. 2018 Dec;10(12):1267. doi: 10.1038/s41557-018-0182-9.</RefSource><PMID Version="1">30420778</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Financial Interests. DSE is an advisor and equity shareholder in ADDRx, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30297750</ArticleId><ArticleId IdType="mid">NIHMS1505109</ArticleId><ArticleId IdType="pmc">PMC6250578</ArticleId><ArticleId IdType="doi">10.1038/s41557-018-0147-z</ArticleId><ArticleId IdType="pii">10.1038/s41557-018-0147-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy JA &amp; Higgins GA Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science 256, 184&#x2013;5 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M, Sabatini BL &amp; Sudhof TC Synapses and Alzheimer&#x2019;s disease. Cold Spring Harb Perspect Biol 4(2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331702</ArticleId><ArticleId IdType="pubmed">22491782</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Alzheimer&#x2019;s disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 49, 215&#x2013;24 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">1692337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer&#x2019;s disease. Neuroscience 69, 757&#x2013;61 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8596645</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidler PM et al. Structure-based inhibitors of tau aggregation. Nat Chem 10, 170&#x2013;176 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784779</ArticleId><ArticleId IdType="pubmed">29359764</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE &amp; Bertram L Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: a genetic perspective. Cell 120, 545&#x2013;55 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Sleegers K &amp; Van Broeckhoven C Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 19, R4&#x2013;R11 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875058</ArticleId><ArticleId IdType="pubmed">20388643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP et al. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95, 6448&#x2013;53 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352&#x2013;7 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S et al. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 31, 6627&#x2013;38 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99&#x2013;102 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashe KH &amp; Zahs KR Probing the biology of Alzheimer&#x2019;s disease in mice. Neuron 66, 631&#x2013;45 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956420</ArticleId><ArticleId IdType="pubmed">20547123</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino V et al. Enhancing mitochondrial proteostasis reduces amyloid-beta proteotoxicity. Nature 552, 187&#x2013;193 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5730497</ArticleId><ArticleId IdType="pubmed">29211722</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu B et al. ER-associated degradation regulates Alzheimer&#x2019;s amyloid pathology and memory function by modulating gamma-secretase activity. Nat Commun 8, 1472 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684335</ArticleId><ArticleId IdType="pubmed">29133892</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng PN, Liu C, Zhao M, Eisenberg D &amp; Nowick JS Amyloid beta-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat Chem 4, 927&#x2013;33 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3481199</ArticleId><ArticleId IdType="pubmed">23089868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley Yat-Wah Man et al. Group 9 metal-based inhibitors of &#xdf;-amyloid (1&#x2013;40) fibrillation as potential therapeutic agents for Alzheimer&#x2019;s disease. Chemical Science 2, 917 (2011).</Citation></Reference><Reference><Citation>Ehrnhoefer DE et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15, 558&#x2013;66 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18511942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76, 173&#x2013;81 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>Evin G Future Therapeutics in Alzheimer&#x2019;s Disease: Development Status of BACE Inhibitors. BioDrugs 30, 173&#x2013;94 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27023706</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani Y et al. Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 32, 2037&#x2013;50 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621706</ArticleId><ArticleId IdType="pubmed">22323718</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Carranza DL, Guerrero-Munoz MJ &amp; Kayed R Immunotherapy for the treatment of Alzheimer&#x2019;s disease: amyloid-beta or tau, which is the right target? Immunotargets Ther 3, 19&#x2013;28 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918231</ArticleId><ArticleId IdType="pubmed">27471697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J et al. The antibody aducanumab reduces Abeta plaques in Alzheimer&#x2019;s disease. Nature 537, 50&#x2013;6 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW &amp; Strittmatter SM Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128&#x2013;32 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47&#x2013;52 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarosz-Griffiths HH, Noble E, Rushworth JV &amp; Hooper NM Amyloid-beta Receptors: The Good, the Bad, and the Prion Protein. J Biol Chem 291, 3174&#x2013;83 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751366</ArticleId><ArticleId IdType="pubmed">26719327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T et al. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer&#x2019;s model. Science 341, 1399&#x2013;404 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhrs T et al. 3D structure of Alzheimer&#x2019;s amyloid-beta(1&#x2013;42) fibrils. Proc Natl Acad Sci U S A 102, 17342&#x2013;7 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Colletier JP et al. Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci U S A 108, 16938&#x2013;43 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193189</ArticleId><ArticleId IdType="pubmed">21949245</ArticleId></ArticleIdList></Reference><Reference><Citation>Willcox BE et al. Crystal structure of LIR-2 (ILT4) at 1.8 A: differences from LIR-1 (ILT2) in regions implicated in the binding of the Human Cytomegalovirus class I MHC homolog UL18. BMC Struct Biol 2, 6 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130215</ArticleId><ArticleId IdType="pubmed">12390682</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveh B, London N, Zimmerman L &amp; Schueler-Furman O Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors. PLoS One 6, e18934 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084719</ArticleId><ArticleId IdType="pubmed">21572516</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroud JC, Liu C, Teng PK &amp; Eisenberg D Toxic fibrillar oligomers of amyloid-beta have cross-beta structure. Proc Natl Acad Sci U S A 109, 7717&#x2013;22 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356606</ArticleId><ArticleId IdType="pubmed">22547798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlman B &amp; Baker D Native protein sequences are close to optimal for their structures. Proc Natl Acad Sci U S A 97, 10383&#x2013;8 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27033</ArticleId><ArticleId IdType="pubmed">10984534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence MC &amp; Colman PM Shape complementarity at protein/protein interfaces. J Mol Biol 234, 946&#x2013;50 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8263940</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L et al. Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta. Elife 2, e00857 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3713518</ArticleId><ArticleId IdType="pubmed">23878726</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HC, Chang P, Dai XL &amp; Jiang ZF Protective effects of curcumin on amyloid-beta-induced neuronal oxidative damage. Neurochem Res 37, 1584&#x2013;97 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22476982</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y et al. Prolonged exposure of cortical neurons to oligomeric amyloid-beta impairs NMDA receptor function via NADPH oxidase-mediated ROS production: protective effect of green tea (&#x2212;)-epigallocatechin-3-gallate. ASN Neuro 3, e00050 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035478</ArticleId><ArticleId IdType="pubmed">21434871</ArticleId></ArticleIdList></Reference><Reference><Citation>Syken J, Grandpre T, Kanold PO &amp; Shatz CJ PirB restricts ocular-dominance plasticity in visual cortex. Science 313, 1795&#x2013;800 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16917027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gremer L et al. Fibril structure of amyloid-beta(1&#x2013;42) by cryo-electron microscopy. Science 358, 116&#x2013;119 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080689</ArticleId><ArticleId IdType="pubmed">28882996</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C et al. Out-of-register beta-sheets suggest a pathway to toxic amyloid aggregates. Proc Natl Acad Sci U S A 109, 20913&#x2013;8 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529048</ArticleId><ArticleId IdType="pubmed">23213214</ArticleId></ArticleIdList></Reference><Reference><Citation>Laganowsky A et al. Atomic view of a toxic amyloid small oligomer. Science 335, 1228&#x2013;31 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959867</ArticleId><ArticleId IdType="pubmed">22403391</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalivaeva NN, Belyaev ND, Kerridge C &amp; Turner AJ Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer&#x2019;s disease. Front Aging Neurosci 6, 235 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4166351</ArticleId><ArticleId IdType="pubmed">25278875</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespi GA, Hermans SJ, Parker MW &amp; Miles LA Molecular basis for mid-region amyloid-beta capture by leading Alzheimer&#x2019;s disease immunotherapies. Sci Rep 5, 9649 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549621</ArticleId><ArticleId IdType="pubmed">25880481</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott A &amp; Dolgin E Failed Alzheimer&#x2019;s trial does not kill leading theory of disease. Nature 540, 15&#x2013;16 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27905452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S et al. D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358, 381&#x2013;386 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856174</ArticleId><ArticleId IdType="pubmed">29051383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30646141</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Adolescent Cognitive Aptitudes and Later-in-Life Alzheimer Disease and Related Disorders.</ArticleTitle><Pagination><StartPage>e181726</StartPage><MedlinePgn>e181726</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e181726</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2018.1726</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Low early-life cognitive ability is a potential early marker of dementia risk in later life. Previous studies use only global measures of general intelligence and/or study this relationship in gender-specific samples. The contribution of early-life performance on specific cognitive abilities, such as language, reasoning, and visualization aptitudes, to indicating future dementia risk is unknown.</AbstractText><AbstractText Label="OBJECTIVES">To investigate the association between adolescent cognitive ability and Medicare-recorded Alzheimer disease and related disorders (ADRD) using both general and specific measures of cognitive ability and to explore these associations separately in men and women.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Population-based cohort study from the Project Talent-Medicare linked data set, a linkage of adolescent sociobehavioral data collected from high school students in 1960 to participants' 2012 to 2013 Medicare Claims and expenditures data. The association between adolescent cognitive ability and risk of ADRD in later life was assessed in a diverse sample of 43&#x202f;014 men and 42&#x202f;749 women aged 66 to 73 years using a series of logistic regressions stratified by sex, accounting for demographic characteristics, adolescent socioeconomic status, and regional effects. Data analysis was conducted from November 2017 to March 2018.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Presence of Medicare-reported ADRD.</AbstractText><AbstractText Label="RESULTS">Overall, 1239 men (2.9%) and 1416 women (3.3%) developed ADRD. Lower mechanical reasoning was associated with increased odds of ADRD in men (odds ratio, 1.17; 95% CI, 1.05-1.29), and lower memory for words in adolescence was associated with increased odds of ADRD in women (odds ratio, 1.16; 95% CI, 1.05-1.28). Lower performance on several other language, reasoning, visualization, and mathematic aptitudes in adolescence showed prominent, but weaker, associations with odds of ADRD.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This work contributes to the understanding of early-life origins of ADRD risk. The results suggest specific measures of cognitive ability may contribute to very early identification of at-risk subgroups who may benefit from prevention or intervention efforts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Alison R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>American Institutes for Research, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strombotne</LastName><ForeName>Kiersten L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>American Institutes for Research, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horner</LastName><ForeName>Elizabeth Mokyr</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>American Institutes for Research, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapham</LastName><ForeName>Susan J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>American Institutes for Research, Washington, DC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Netw Open. 2018 Sep 7;1(5):e181724. doi: 10.1001/jamanetworkopen.2018.1724.</RefSource><PMID Version="1">30646136</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004521" MajorTopicYN="N">Educational Measurement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30646141</ArticleId><ArticleId IdType="pmc">PMC6324501</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2018.1726</ArticleId><ArticleId IdType="pii">2701735</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization 
Dementia: fact sheet. http://www.who.int/mediacentre/factsheets/fs362/en/. Accessed December 15, 2017.</Citation></Reference><Reference><Citation>Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(1):-. doi:10.1097/01.wad.0000201854.62116.d7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wad.0000201854.62116.d7</ArticleId><ArticleId IdType="pubmed">16493239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res. 2012;9(6):628-645. doi:10.2174/156720512801322573</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322573</ArticleId><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Horner EM, Strombotne K, Huang A, Lapham S. Investigating the early life determinants of type-II diabetes using a Project Talent&#x2014;Medicare linked data-set. SSM Popul Health. 2018;4:189-196. doi:10.1016/j.ssmph.2018.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ssmph.2018.01.004</ArticleId><ArticleId IdType="pmc">PMC5976829</ArticleId><ArticleId IdType="pubmed">29854904</ArticleId></ArticleIdList></Reference><Reference><Citation>Strombotne K, Mokyr-Horner E, Walters E, Lapham S. Non-Credible Adolescent Survey Responses and Later-in-Life Alzheimer&#x2019;s Disease and Dementia. Washington, DC: American Institutes for Research; 2018.</Citation></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer&#x2019;s disease. Lancet Neurol. 2012;11(11):1006-1012. doi:10.1016/S1474-4422(12)70191-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70191-6</ArticleId><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer&#x2019;s disease in late life: findings from the Nun Study. JAMA. 1996;275(7):528-532. doi:10.1001/jama.1996.03530310034029</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1996.03530310034029</ArticleId><ArticleId IdType="pubmed">8606473</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstr&#xf6;m P, Nordstr&#xf6;m A, Eriksson M, Wahlund L-O, Gustafson Y. Risk factors in late adolescence for young-onset dementia in men: a nationwide cohort study. JAMA Intern Med. 2013;173(17):1612-1618. doi:10.1001/jamainternmed.2013.9079</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.9079</ArticleId><ArticleId IdType="pubmed">23939347</ArticleId></ArticleIdList></Reference><Reference><Citation>Osler M, Christensen GT, Garde E, Mortensen EL, Christensen K. Cognitive ability in young adulthood and risk of dementia in a cohort of Danish men, brothers, and twins. Alzheimers Dement. 2017;13(12):1355-1363. doi:10.1016/j.jalz.2017.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.04.003</ArticleId><ArticleId IdType="pubmed">28531378</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ TC, Hannah J, Batty GD, Booth CC, Deary IJ, Starr JM. Childhood cognitive ability and incident dementia: the 1932 Scottish mental survey cohort into their tenth decade. Epidemiology. 2017;28(3):361-364. doi:10.1097/EDE.0000000000000626</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000626</ArticleId><ArticleId IdType="pmc">PMC5381709</ArticleId><ArticleId IdType="pubmed">28151744</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekhtyar S, Wang H-X, Scott K, Goodman A, Koupil I, Herlitz A. A life-course study of cognitive reserve in dementia&#x2014;from childhood to old age. Am J Geriatr Psychiatry. 2015;23(9):885-896. doi:10.1016/j.jagp.2015.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2015.02.002</ArticleId><ArticleId IdType="pubmed">25746486</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Whiteman MC, Starr JM, Whalley LJ, Fox HC. The impact of childhood intelligence on later life: following up the Scottish mental surveys of 1932 and 1947. J Pers Soc Psychol. 2004;86(1):130-147. doi:10.1037/0022-3514.86.1.130</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0022-3514.86.1.130</ArticleId><ArticleId IdType="pubmed">14717632</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer&#x2019;s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48. doi:10.2147/CLEP.S37929</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37929</ArticleId><ArticleId IdType="pmc">PMC3891487</ArticleId><ArticleId IdType="pubmed">24470773</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Herlitz A, Fratiglioni L, Almkvist O, B&#xe4;ckman L. Cognitive predictors of incident Alzheimer&#x2019;s disease: a prospective longitudinal study. Neuropsychology. 1997;11(3):413-420. doi:10.1037/0894-4105.11.3.413</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0894-4105.11.3.413</ArticleId><ArticleId IdType="pubmed">9223145</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang AR, Strombotne KL, Achorn DL, Mokyr Horner E, Lapham S Methodology, generalizability, and research applications of the Project Talent-Medicare data linkage. Paper presented at: Population Association of America 2018 Annual Meeting; April 2018; Denver, CO.</Citation></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services 
What's Medicare?
https://www.medicare.gov/sign-up-change-plans/decide-how-to-get-medicare/whats-medicare/what-is-medicare.html. Accessed February 5, 2018.</Citation></Reference><Reference><Citation>Research Data Assistance Center(ResDAC) 
Identifying Medicare managed care beneficiaries from the master beneficiary summary or denominator files. https://www.resdac.org/resconnect/articles/114. Accessed February 5, 2018.</Citation></Reference><Reference><Citation>Wise LL, McLaughlin DH, Steel LL. The Project Talent Data Bank Handbook. Palo Alto, CA: American Institutes for Research; 1979.</Citation></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services 
Chronic condition data warehouse Medicare administrative data user guide. https://www.ccwdata.org/web/guest/user-documentation. Accessed October 25, 2017.</Citation></Reference><Reference><Citation>Taylor DH Jr, &#xd8;stbye T, Langa KM, Weir D, Plassman BL. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. J Alzheimers Dis. 2009;17(4):807-815. doi:10.3233/JAD-2009-1099</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1099</ArticleId><ArticleId IdType="pmc">PMC3697480</ArticleId><ArticleId IdType="pubmed">19542620</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services 
Mapping Medicare disparities. https://www.cms.gov/About-CMS/Agency-Information/OMH/OMH-Mapping-Medicare-Disparities.html. Accessed October 25, 2017.</Citation></Reference><Reference><Citation>Tang MX, Stern Y, Marder K, et al. . The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279(10):751-755. doi:10.1001/jama.279.10.751</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.279.10.751</ArticleId><ArticleId IdType="pubmed">9508150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M-X, Cross P, Andrews H, et al. . Incidence of AD in African-Americans, Caribbean hispanics, and caucasians in northern Manhattan. Neurology. 2001;56(1):49-56. doi:10.1212/WNL.56.1.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.1.49</ArticleId><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadlen MF, Siscovick D, Fitzpatrick AL, Dulberg C, Kuller LH, Jackson S. Education, cognitive test scores, and black-white differences in dementia risk. J Am Geriatr Soc. 2006;54(6):898-905. doi:10.1111/j.1532-5415.2006.00747.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2006.00747.x</ArticleId><ArticleId IdType="pubmed">16776783</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology. 2005;64(11):1853-1859. doi:10.1212/01.WNL.0000163773.21794.0B</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000163773.21794.0B</ArticleId><ArticleId IdType="pubmed">15955933</ArticleId></ArticleIdList></Reference><Reference><Citation>Howieson DB, Dame A, Camicioli R, Sexton G, Payami H, Kaye JA. Cognitive markers preceding Alzheimer&#x2019;s dementia in the healthy oldest old. J Am Geriatr Soc. 1997;45(5):584-589. doi:10.1111/j.1532-5415.1997.tb03091.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.1997.tb03091.x</ArticleId><ArticleId IdType="pubmed">9158579</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid NS, Taylor KI, Foldi NS, Berres M, Monsch AU. Neuropsychological signs of Alzheimer&#x2019;s disease 8 years prior to diagnosis. J Alzheimers Dis. 2013;34(2):537-546. doi:10.3233/JAD-121234</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-121234</ArticleId><ArticleId IdType="pubmed">23254631</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva D, Guerreiro M, Maroco J, et al. . Comparison of four verbal memory tests for the diagnosis and predictive value of mild cognitive impairment. Dement Geriatr Cogn Dis Extra. 2012;2(1):120-131. doi:10.1159/000336224</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000336224</ArticleId><ArticleId IdType="pmc">PMC3347876</ArticleId><ArticleId IdType="pubmed">22590473</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabert MH, Manly JJ, Liu X, et al. . Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry. 2006;63(8):916-924. doi:10.1001/archpsyc.63.8.916</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.8.916</ArticleId><ArticleId IdType="pubmed">16894068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherod MG, Griffith HR, Copeland J, et al. . Neurocognitive predictors of financial capacity across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer&#x2019;s disease. J Int Neuropsychol Soc. 2009;15(2):258-267. doi:10.1017/S1355617709090365</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617709090365</ArticleId><ArticleId IdType="pmc">PMC2838718</ArticleId><ArticleId IdType="pubmed">19203439</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt AL, Livingston RB, Galusha JM, Davis KM. Correlation between the Bicycle Drawing Task and neuropsychological variables in patients referred for a dementia evaluation. Percept Mot Skills. 2009;109(3):721-730. doi:10.2466/pms.109.3.721-730</Citation><ArticleIdList><ArticleId IdType="doi">10.2466/pms.109.3.721-730</ArticleId><ArticleId IdType="pubmed">20178271</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Beiser A, Wolf PA, Au R, White RF, D&#x2019;Agostino RB. The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000;57(6):808-813. doi:10.1001/archneur.57.6.808</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.6.808</ArticleId><ArticleId IdType="pubmed">10867777</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DH Jr, Fillenbaum GG, Ezell ME. The accuracy of Medicare claims data in identifying Alzheimer&#x2019;s disease. J Clin Epidemiol. 2002;55(9):929-937. doi:10.1016/S0895-4356(02)00452-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(02)00452-3</ArticleId><ArticleId IdType="pubmed">12393082</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifan A, Schelke M, Obeng-Aduasare Y, Isaacson R. Early life epidemiology of Alzheimer&#x2019;s disease: a critical review. Neuroepidemiology. 2015;45(4):237-254. doi:10.1159/000439568</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000439568</ArticleId><ArticleId IdType="pmc">PMC4679687</ArticleId><ArticleId IdType="pubmed">26501691</ArticleId></ArticleIdList></Reference><Reference><Citation>Whalley LJ, Deary IJ. Longitudinal cohort study of childhood IQ and survival up to age 76. BMJ. 2001;322(7290):819. doi:10.1136/bmj.322.7290.819</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.322.7290.819</ArticleId><ArticleId IdType="pmc">PMC30556</ArticleId><ArticleId IdType="pubmed">11290633</ArticleId></ArticleIdList></Reference><Reference><Citation>Flicker L. Modifiable lifestyle risk factors for Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;20(3):803-811. doi:10.3233/JAD-2010-091624</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-091624</ArticleId><ArticleId IdType="pubmed">20182016</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet Neurol. 2011;10(9):819-828. doi:10.1016/S1474-4422(11)70072-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70072-2</ArticleId><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean DC III, Jerskey BA, Chen K, et al. . Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 2014;71(1):11-22. doi:10.1001/jamaneurol.2013.4544</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4544</ArticleId><ArticleId IdType="pmc">PMC4056558</ArticleId><ArticleId IdType="pubmed">24276092</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P, Lerch JP, Pruessner JC, et al. . Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 2007;6(6):494-500. doi:10.1016/S1474-4422(07)70106-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70106-0</ArticleId><ArticleId IdType="pubmed">17509484</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, Borenstein AR, Gosche KM, Snowdon DA. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol. 2005;18(4):218-223. doi:10.1177/0891988705281869</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988705281869</ArticleId><ArticleId IdType="pmc">PMC1405917</ArticleId><ArticleId IdType="pubmed">16306243</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis SL, Tennstedt SL, Marsiske M, et al. ; ACTIVE Study Group . Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA. 2006;296(23):2805-2814. doi:10.1001/jama.296.23.2805</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.296.23.2805</ArticleId><ArticleId IdType="pmc">PMC2910591</ArticleId><ArticleId IdType="pubmed">17179457</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebok GW, Ball K, Guey LT, et al. . Ten-year effects of the ACTIVE cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc. 2014;62(1):16. doi:10.1111/jgs.12607</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.12607</ArticleId><ArticleId IdType="pmc">PMC4055506</ArticleId><ArticleId IdType="pubmed">24417410</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30318466</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4186</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Structure (London, England : 1993)</Title><ISOAbbreviation>Structure</ISOAbbreviation></Journal><ArticleTitle>Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody.</ArticleTitle><Pagination><StartPage>1626</StartPage><EndPage>1634.e4</EndPage><MedlinePgn>1626-1634.e4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.str.2018.08.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-2126(18)30326-5</ELocationID><Abstract><AbstractText>Aggregation of the hyperphosphorylated protein tau into neurofibrillary tangles and neuropil threads is a hallmark of Alzheimer disease (AD). Identification and characterization of the epitopes recognized by anti-tau antibodies might shed light on the molecular mechanisms of AD pathogenesis. Here we report on the biochemical and structural characterization of a&#xa0;tau-specific monoclonal antibody CBTAU-24.1, which was isolated from the human memory B cell repertoire. Immunohistochemical staining with CBTAU-24.1 specifically detects pathological tau structures in AD brain samples. The crystal structure of CBTAU-24.1 Fab with a phosphorylated tau peptide revealed recognition of a unique epitope (Ser235-Leu243) in the tau proline-rich domain. Interestingly, the antibody can bind tau regardless of phosphorylation state of its epitope region and also recognizes both monomeric and paired helical filament tau irrespective of phosphorylation status. This human anti-tau antibody and its unique epitope may aid in development of diagnostics and/or therapeutic AD strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Heng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Beijing Synchrotron Radiation Facility, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xueyong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, 3210 Merryfield Row, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadia</LastName><ForeName>Jehangir S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, 3210 Merryfield Row, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keogh</LastName><ForeName>Elissa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, 3210 Merryfield Row, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoozemans</LastName><ForeName>Jeroen J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam Neuroscience, VU University Medical Center, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siregar</LastName><ForeName>Berdien</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Archimedesweg 6, 2333 CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingan&#xe4;s</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Archimedesweg 6, 2333 CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoop</LastName><ForeName>Esther J M</ForeName><Initials>EJM</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Archimedesweg 6, 2333 CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goudsmit</LastName><ForeName>Jaap</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Archimedesweg 6, 2333 CN Leiden, the Netherlands; Department of Neurology, Amsterdam Neuroscience, Academic Medical Center, Meidreefberg 9, 1105 AZ Amsterdam, the Netherlands; Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apetri</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Archimedesweg 6, 2333 CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koudstaal</LastName><ForeName>Wouter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Archimedesweg 6, 2333 CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Ian A</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: wilson@scripps.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 GM103393</GrantID><Acronym>NIGMS NIH HHS</Acronym><Agency>National Institute of General Medical Sciences</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR001209</GrantID><Acronym>NCRR NIH HHS</Acronym><Agency>National Center for Research Resources</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Structure</MedlineTA><NlmUniqueID>101087697</NlmUniqueID><ISSNLinking>0969-2126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018985">Epitopes, B-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018985" MajorTopicYN="N">Epitopes, B-Lymphocyte</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">diagnostics</Keyword><Keyword MajorTopicYN="N">hyperphosphorylation</Keyword><Keyword MajorTopicYN="N">monoclonal antibody</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword><Keyword MajorTopicYN="N">x-ray crystallography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30318466</ArticleId><ArticleId IdType="doi">10.1016/j.str.2018.08.012</ArticleId><ArticleId IdType="pii">S0969-2126(18)30326-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30323343</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>11</Issue><PubDate><Year>2018</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature immunology</Title><ISOAbbreviation>Nat Immunol</ISOAbbreviation></Journal><ArticleTitle>Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.</ArticleTitle><Pagination><StartPage>1212</StartPage><EndPage>1223</EndPage><MedlinePgn>1212-1223</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41590-018-0232-x</ELocationID><Abstract><AbstractText>Activation of innate immunity and deposition of blood-derived fibrin in the central nervous system (CNS) occur in autoimmune and neurodegenerative diseases, including multiple sclerosis (MS) and Alzheimer's disease (AD). However, the mechanisms that link disruption of the blood-brain barrier (BBB) to neurodegeneration are poorly understood, and exploration of fibrin as a therapeutic target has been limited by its beneficial clotting functions. Here we report the generation of monoclonal antibody 5B8, targeted against the cryptic fibrin epitope &#x3b3;<sub>377-395</sub>, to selectively inhibit fibrin-induced inflammation and oxidative stress without interfering with clotting. 5B8 suppressed fibrin-induced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and the expression of proinflammatory genes. In animal models of MS and AD, 5B8 entered the CNS and bound to parenchymal fibrin, and its therapeutic administration reduced the activation of innate immunity and neurodegeneration. Thus, fibrin-targeting immunotherapy inhibited autoimmunity- and amyloid-driven neurotoxicity and might have clinical benefit without globally suppressing innate immunity or interfering with coagulation in diverse neurological diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Jae Kyu</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rafalski</LastName><ForeName>Victoria A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Franke</LastName><ForeName>Anke</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Ryan A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poda</LastName><ForeName>Suresh B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Lundbeck Research USA, Paramus, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rios Coronado</LastName><ForeName>Pamela E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Lars &#xd8;stergaard</ForeName><Initials>L&#xd8;</Initials><AffiliationInfo><Affiliation>H. Lundbeck A/S, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Veena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Lundbeck Research USA, Paramus, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baeten</LastName><ForeName>Kim M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikorski</LastName><ForeName>Shoana L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedard</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanspers</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardehle</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendiola</LastName><ForeName>Andrew S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davalos</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Justin P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-2164-4724</Identifier><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plastira</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2403-9973</Identifier><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Biology and Biochemistry, Medical University Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neonatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Samuel J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Small Molecule Discovery Center, Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Kenny K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Small Molecule Discovery Center, Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallenbeck</LastName><ForeName>Kenneth K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Small Molecule Discovery Center, Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syme</LastName><ForeName>Catriona</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakozaki</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellisman</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swanson</LastName><ForeName>Raymond A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-3664-5359</Identifier><AffiliationInfo><Affiliation>Neurology Service, San Francisco Veteran Affairs Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamvil</LastName><ForeName>Scott S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arkin</LastName><ForeName>Michelle R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Small Molecule Discovery Center, Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorn</LastName><ForeName>Stevin H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Lundbeck Research USA, Paramus, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pico</LastName><ForeName>Alexander R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavenhagen</LastName><ForeName>Jeffrey B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>H. Lundbeck A/S, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Lundbeck Research USA, Paramus, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akassoglou</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2632-1465</Identifier><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA. kakassoglou@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA. kakassoglou@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. kakassoglou@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS108159</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097976</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA082103</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS096920</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS052189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS081149</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK090382</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007175</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS082976</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI007334</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HD084387</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS092835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HD072222</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Immunol</MedlineTA><NlmUniqueID>100941354</NlmUniqueID><ISSNLinking>1529-2908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-32-5</RegistryNumber><NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Immunol. 2018 Nov;19(11):1149-1150. doi: 10.1038/s41590-018-0241-9.</RefSource><PMID Version="1">30323342</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests. The authors declare competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30323343</ArticleId><ArticleId IdType="mid">NIHMS1506142</ArticleId><ArticleId IdType="pmc">PMC6317891</ArticleId><ArticleId IdType="doi">10.1038/s41590-018-0232-x</ArticleId><ArticleId IdType="pii">10.1038/s41590-018-0232-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rivest S Regulation of innate immune responses in the brain. Nat Rev Immunol 9, 429&#x2013;439 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19461673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM &amp; Brown MA Innate immunity in the central nervous system. J Clin Invest 122, 1164&#x2013;1171 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314450</ArticleId><ArticleId IdType="pubmed">22466658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann H, van Horssen J &amp; Mahad D Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 8, 647&#x2013;656 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23007702</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuh C et al. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. Acta Neuropathol 128, 247&#x2013;266 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102830</ArticleId><ArticleId IdType="pubmed">24622774</ArticleId></ArticleIdList></Reference><Reference><Citation>Heppner FL, Ransohoff RM &amp; Becher B Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16, 358&#x2013;372 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25991443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann H Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer&#x2019;s disease. J Neural Transm 118, 747&#x2013;752 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21373761</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikic I et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 17, 495&#x2013;499 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21441916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitnis T &amp; Weiner HL CNS inflammation and neurodegeneration. J Clin Invest 127, 3577&#x2013;3587 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5617655</ArticleId><ArticleId IdType="pubmed">28872464</ArticleId></ArticleIdList></Reference><Reference><Citation>Frischer JM et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175&#x2013;1189 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677799</ArticleId><ArticleId IdType="pubmed">19339255</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Nelson AR, Betsholtz C &amp; Zlokovic BV Establishment and Dysfunction of the Blood-Brain Barrier. Cell 163, 1064&#x2013;1078 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655822</ArticleId><ArticleId IdType="pubmed">26590417</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MA, Ryu JK &amp; Akassoglou K Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci 19, 283&#x2013;301 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6743980</ArticleId><ArticleId IdType="pubmed">29618808</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D &amp; Akassoglou K Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 34, 43&#x2013;62 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22037947</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams RA et al. The fibrin-derived gamma377&#x2013;395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 204, 571&#x2013;582 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2137908</ArticleId><ArticleId IdType="pubmed">17339406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarova TP et al. Sequence gamma 377&#x2013;395(P2), but not gamma 190&#x2013;202(P1), is the binding site for the alpha MI-domain of integrin alpha M beta 2 in the gamma C-domain of fibrinogen. Biochemistry 42, 9365&#x2013;9373 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12899623</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 3, 1227 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514498</ArticleId><ArticleId IdType="pubmed">23187627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun 6, 8164 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4579523</ArticleId><ArticleId IdType="pubmed">26353940</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates RL et al. Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. Ann Neurol 82, 259&#x2013;270 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28719020</ArticleId></ArticleIdList></Reference><Reference><Citation>Marik C, Felts PA, Bauer J, Lassmann H &amp; Smith KJ Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130, 2800&#x2013;2815 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981817</ArticleId><ArticleId IdType="pubmed">17956913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee NJ et al. Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination. Brain 141, 1637&#x2013;1649 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972667</ArticleId><ArticleId IdType="pubmed">29688408</ArticleId></ArticleIdList></Reference><Reference><Citation>Strickland S Blood will out: vascular contributions to Alzheimer&#x2019;s disease. J Clin Invest 128, 556&#x2013;563 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785254</ArticleId><ArticleId IdType="pubmed">29388925</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan C &amp; Cunningham-Bussel A Beyond oxidative stress: an immunologist&#x2019;s guide to reactive oxygen species. Nat Rev Immunol 13, 349&#x2013;361 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4250048</ArticleId><ArticleId IdType="pubmed">23618831</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer MT et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135, 886&#x2013;899 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286337</ArticleId><ArticleId IdType="pubmed">22366799</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimohama S et al. Activation of NADPH oxidase in Alzheimer&#x2019;s disease brains. Biochem Biophys Res Commun 273, 5&#x2013;9 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10873554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma MW et al. NADPH oxidase in brain injury and neurodegenerative disorders. Mol Neurodegener 12, 7 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5240251</ArticleId><ArticleId IdType="pubmed">28095923</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslund-Vinding J, McBean G, Jaquet V &amp; Vilhardt F NADPH oxidases in oxidant production by microglia: activating receptors, pharmacology and association with disease. Br J Pharmacol 174, 1733&#x2013;1749 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446574</ArticleId><ArticleId IdType="pubmed">26750203</ArticleId></ArticleIdList></Reference><Reference><Citation>Han MH et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451, 1076&#x2013;1081 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18278032</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D et al. Early detection of thrombin activity in neuroinflammatory disease. Ann Neurol 75, 303&#x2013;308 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049631</ArticleId><ArticleId IdType="pubmed">24740641</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider L et al. Oxidative damage in multiple sclerosis lesions. Brain 134, 1914&#x2013;1924 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122372</ArticleId><ArticleId IdType="pubmed">21653539</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol 14, 388&#x2013;405 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST &amp; Scheff SW Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol 27, 457&#x2013;464 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoeb M &amp; Fang MC Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis 35, 312&#x2013;319 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888359</ArticleId><ArticleId IdType="pubmed">23479259</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocsai A et al. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat Immunol 7, 1326&#x2013;1333 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698344</ArticleId><ArticleId IdType="pubmed">17086186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedard K &amp; Krause KH The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87, 245&#x2013;313 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17237347</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR &amp; Colonna M Activating and inhibitory functions of DAP12. Nat Rev Immunol 7, 155&#x2013;161 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17220916</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L et al. Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci U S A 108, 5063&#x2013;5068 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064396</ArticleId><ArticleId IdType="pubmed">21383152</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clin Transl Sci 11, 147&#x2013;152 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866992</ArticleId><ArticleId IdType="pubmed">28767185</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 138, 761&#x2013;771 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339775</ArticleId><ArticleId IdType="pubmed">25595145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS et al. Interactive Associations of Vascular Risk and beta-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study. JAMA Neurol (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6143121</ArticleId><ArticleId IdType="pubmed">29799986</ArticleId></ArticleIdList></Reference><Reference><Citation>Miron VE et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16, 1211&#x2013;1218 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977045</ArticleId><ArticleId IdType="pubmed">23872599</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MA et al. Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular Damage. Neuron 96, 1003&#x2013;1012 e1007 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5851281</ArticleId><ArticleId IdType="pubmed">29103804</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka A, Belliveau MJ, Rosenberg PA &amp; Volpe JJ Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci 13, 1441&#x2013;1453 (1993).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576718</ArticleId><ArticleId IdType="pubmed">8096541</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 17, 131&#x2013;143 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B et al. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. Nat Neurosci 21, 541&#x2013;551 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629134</ArticleId><ArticleId IdType="pubmed">29507414</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D et al. High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity 48, 380&#x2013;395 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29426702</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh TT et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 9, 2020&#x2013;2033 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7649481</ArticleId></ArticleIdList></Reference><Reference><Citation>Flick MJ et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 113, 1596&#x2013;1606 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419487</ArticleId><ArticleId IdType="pubmed">15173886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lak M, Keihani M, Elahi F, Peyvandi F &amp; Mannucci PM Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 107, 204&#x2013;206 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10520042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugge TH et al. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87, 709&#x2013;719 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8929539</ArticleId></ArticleIdList></Reference><Reference><Citation>Akassoglou K, Yu W-M, Akpinar P &amp; Strickland S Fibrin inhibits peripheral nerve regeneration by arresting Schwann cell differentiation. Neuron 33, 861&#x2013;875 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11906694</ArticleId></ArticleIdList></Reference><Reference><Citation>Koseki-Kuno S, Yamakawa M, Dickneite G &amp; Ichinose A Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages. Blood 102, 4410&#x2013;4412 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12933578</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R &amp; Doolittle RF - cross-linking sites in human and bovine fibrin. Biochemistry 10, 4487&#x2013;4491 (1971).</Citation><ArticleIdList><ArticleId IdType="pubmed">5168975</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleman MM et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 124, 3590&#x2013;3600 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109540</ArticleId><ArticleId IdType="pubmed">24983320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20, 4106&#x2013;4114 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28, 41&#x2013;51 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson SH, Gallin JI &amp; Holland SM The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med 182, 751&#x2013;758 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192153</ArticleId><ArticleId IdType="pubmed">7650482</ArticleId></ArticleIdList></Reference><Reference><Citation>Saederup N et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 5, e13693 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965160</ArticleId><ArticleId IdType="pubmed">21060874</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen MR et al. Structural Basis for Simvastatin Competitive Antagonism of Complement Receptor 3. J Biol Chem 291, 16963&#x2013;16976 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016102</ArticleId><ArticleId IdType="pubmed">27339893</ArticleId></ArticleIdList></Reference><Reference><Citation>Abid MR, Spokes KC, Shih SC &amp; Aird WC NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem 282, 35373&#x2013;35385 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17908694</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 3, 1227 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514498</ArticleId><ArticleId IdType="pubmed">23187627</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61, 797&#x2013;805 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentleman RC et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5, R80 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545600</ArticleId><ArticleId IdType="pubmed">15461798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30323170</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference.</ArticleTitle><Pagination><StartPage>4273</StartPage><MedlinePgn>4273</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4273</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-018-05892-0</ELocationID><Abstract><AbstractText>The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treatment development, as study cohorts typically include multiple phenotypes on distinct disease trajectories. Here we introduce a machine-learning technique-Subtype and Stage Inference (SuStaIn)-able to uncover data-driven disease phenotypes with distinct temporal progression patterns, from widely available cross-sectional patient studies. Results from imaging studies in two neurodegenerative diseases reveal subgroups and their distinct trajectories of regional neurodegeneration. In genetic frontotemporal dementia, SuStaIn identifies genotypes from imaging alone, validating its ability to identify subtypes; further the technique reveals within-genotype heterogeneity. In Alzheimer's disease, SuStaIn uncovers three subtypes, uniquely characterising their temporal complexity. SuStaIn provides fine-grained patient stratification, which substantially enhances the ability to predict conversion between diagnostic categories over standard models that ignore subtype (p&#x2009;=&#x2009;7.18&#x2009;&#xd7;&#x2009;10<sup>-4</sup>) or temporal stage (p&#x2009;=&#x2009;3.96&#x2009;&#xd7;&#x2009;10<sup>-5</sup>). SuStaIn offers new promise for enabling disease subtype discovery and precision medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Alexandra L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-7772-781X</Identifier><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, WC1E 6BT, UK. alexandra.young@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University College London, London, WC1E 6BT, UK. alexandra.young@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinescu</LastName><ForeName>Razvan V</ForeName><Initials>RV</Initials><Identifier Source="ORCID">0000-0003-4042-8493</Identifier><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oxtoby</LastName><ForeName>Neil P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0003-0203-3909</Identifier><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocchetta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yong</LastName><ForeName>Keir</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Firth</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0001-7833-616X</Identifier><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>David L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0003-1491-1641</Identifier><AffiliationInfo><Affiliation>Leonard Wolfson Experimental Neurology Centre, UCL Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dick</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardoso</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1284-2558</Identifier><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, WC2R 2LS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Erasmus Medical Center, 3000 CA, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25121, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Dept. of Physiopathology and Transplantation, University of Milan, Centro Dino Ferrari, 20122, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via F. Sforza, 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, University of Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>Maria Carmela</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Centre for Research in Neurodegenerative Diseases, University of Toronto, ON, Toronto, M5T 0S8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>University of Cambridge, Department of Clinical Neurosciences, Cambridge, CB2 0SZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Karolinska Institutet, 171 77, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Istituto Neurologico Carlo Besta, 20133, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>University Hospitals and University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laforce</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0002-2031-490X</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Laval, Quebec, QC, G1V 0A6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Western Ontario, London, ON, N6A 3K7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendon&#xe7;a</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de Lisboa, 1649-028, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, 50121, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crutch</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ourselin</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Wolfson Experimental Neurology Centre, UCL Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, WC2R 2LS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-2059-024X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0003-2439-350X</Identifier><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Genetic FTD Initiative (GENFI)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UU_00024/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105597119</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J009482/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M023664/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00005/12</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008525/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M009106/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M009041/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M024873/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Andersson</LastName><ForeName>Christin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Archetti</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arighi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benussi</LastName><ForeName>Luisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Binetti</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cosseddu</LastName><ForeName>Maura</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fallstr&#xf6;m</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freedman</LastName><ForeName>Morris</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Giorgio G</ForeName><Initials>GG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gazzina</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grisoli</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jelic</LastName><ForeName>Vesna</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiskoot</LastName><ForeName>Lize</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keren</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Gemma</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maruta</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meeter</LastName><ForeName>Lieke</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Minkelen</LastName><ForeName>Rick</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xd6;ijerstedt</LastName><ForeName>Linn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panman</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pievani</LastName><ForeName>Michela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polito</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Premi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prioni</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redaelli</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giacomina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang-Wai</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thonberg</LastName><ForeName>Hakan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tiraboschi</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verdelho</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorensen</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lew</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fillit</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hefti</LastName><ForeName>Franz</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>Davie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>M Marcel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiminez</LastName><ForeName>Gus</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungeun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckholtz</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marylyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Raina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beccera</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teodoro</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>Colleen S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rountree</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dang</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliver</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockington</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Toledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greig</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerbone</LastName><ForeName>Brittany</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>Christina A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Terence Z</ForeName><Initials>TZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>Partha</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oates</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc-Adams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tingus</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel Hs</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek Robin</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirrel</LastName><ForeName>Sherye A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allard</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adeli</LastName><ForeName>Anahita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitzmiller</LastName><ForeName>Tamar J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasternak</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponto</LastName><ForeName>Laura L Boles</ForeName><Initials>LLB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neylan</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grafman</LastName><ForeName>Jordan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finley</LastName><ForeName>Shannon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedl</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleischman</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arfanakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massoglia</LastName><ForeName>Dino</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fruehling</LastName><ForeName>J Jay</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harding</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrie</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furst</LastName><ForeName>Ansgar J</ForeName><Initials>AJ</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30323170</ArticleId><ArticleId IdType="pmc">PMC6189176</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-05892-0</ArticleId><ArticleId IdType="pii">10.1038/s41467-018-05892-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rohrer JD, Rosen HJ. Neuroimaging in frontotemporal dementia. Int. Rev. Psychiatry. 2013;25:221&#x2013;229. doi: 10.3109/09540261.2013.778822.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09540261.2013.778822</ArticleId><ArticleId IdType="pubmed">23611351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekris LM, Yu CE, Bird TD, Tsuang DW. Review article: genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010;23:213&#x2013;227. doi: 10.1177/0891988710383571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988710383571</ArticleId><ArticleId IdType="pmc">PMC3044597</ArticleId><ArticleId IdType="pubmed">21045163</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, et al. Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics:a retrospective study. Lancet Neurol. 2011;10:785&#x2013;796. doi: 10.1016/S1474-4422(11)70156-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70156-9</ArticleId><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam Benjamin, Masellis Mario, Freedman Morris, Stuss Donald T, Black Sandra E. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. Alzheimer's Research &amp; Therapy. 2013;5(1):1. doi: 10.1186/alzrt155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt155</ArticleId><ArticleId IdType="pmc">PMC3580331</ArticleId><ArticleId IdType="pubmed">23302773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero R., Schmidt-Richberg A., Ledig C., Tong T., Wolz R., Rueckert D. Instantiated mixed effects modeling of Alzheimer's disease markers. NeuroImage. 2016;142:113&#x2013;125. doi: 10.1016/j.neuroimage.2016.06.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2016.06.049</ArticleId><ArticleId IdType="pubmed">27381077</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonteijn HM, et al. An event-based model for disease progression and its application in familial Alzheimer&#x2019;s disease and Huntington&#x2019;s disease. Neuroimage. 2012;60:1880&#x2013;1889. doi: 10.1016/j.neuroimage.2012.01.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.01.062</ArticleId><ArticleId IdType="pubmed">22281676</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL, et al. A data-driven model of biomarker changes in sporadic Alzheimer&#x2019;s disease. Brain. 2014;137:2564&#x2013;2577. doi: 10.1093/brain/awu176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu176</ArticleId><ArticleId IdType="pmc">PMC4132648</ArticleId><ArticleId IdType="pubmed">25012224</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, et al. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. 2014;10:S400&#x2013;S410. doi: 10.1016/j.jalz.2013.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.10.003</ArticleId><ArticleId IdType="pmc">PMC4169767</ArticleId><ArticleId IdType="pubmed">24656849</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedynak BM, et al. A computational neurodegenerative disease progression score: method and results with the Alzheimer&#x2019;s disease Neuroimaging Initiative cohort. Neuroimage. 2012;63:1478&#x2013;1486. doi: 10.1016/j.neuroimage.2012.07.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.07.059</ArticleId><ArticleId IdType="pmc">PMC3472161</ArticleId><ArticleId IdType="pubmed">22885136</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgel M, Prince JL, Wong DF, Resnick SM, Jedynak BM. A multivariate nonlinear mixed effects model for longitudinal image analysis: application to amyloid imaging. Neuroimage. 2016;134:658&#x2013;670. doi: 10.1016/j.neuroimage.2016.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2016.04.001</ArticleId><ArticleId IdType="pmc">PMC4912927</ArticleId><ArticleId IdType="pubmed">27095307</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC. Early role of vascular dysregulation on late-onset Alzheimer&#x2019;s disease based on multifactorial data-driven analysis. Nat. Commun. 2016;7:11934. doi: 10.1038/ncomms11934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11934</ArticleId><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="pubmed">27327500</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, et al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367. doi: 10.1016/S1474-4422(13)70044-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70044-9</ArticleId><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. Brain &#x3b2;-amyloid load approaches a plateau. Neurology. 2013;80:890&#x2013;896. doi: 10.1212/WNL.0b013e3182840bbe.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182840bbe</ArticleId><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxtoby, N. P. et al. in Bayesian and Graphical Models for Biomedical Imaging (eds Simpson, I., Arbel, T., Ribbens, A., Cardoso, M. J. &amp; Precup, D.) 8677, 85&#x2013;94 (Springer International Publishing, Berlin, 2014).</Citation></Reference><Reference><Citation>Whitwell JL, et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: A cluster analysis study. Brain. 2009;132:2932&#x2013;2946. doi: 10.1093/brain/awp232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp232</ArticleId><ArticleId IdType="pmc">PMC2768663</ArticleId><ArticleId IdType="pubmed">19762452</ArticleId></ArticleIdList></Reference><Reference><Citation>Nettiksimmons J, et al. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol. Aging. 2010;31:1419&#x2013;1428. doi: 10.1016/j.neurobiolaging.2010.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.04.025</ArticleId><ArticleId IdType="pmc">PMC2902683</ArticleId><ArticleId IdType="pubmed">20542598</ArticleId></ArticleIdList></Reference><Reference><Citation>Nettiksimmons J, DeCarli C, Landau S, Beckett L. Biological heterogeneity in ADNI amnestic mild cognitive impairment. Alzheimer&#x2019;s Dement. 2014;10:511&#x2013;521. doi: 10.1016/j.jalz.2013.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.09.003</ArticleId><ArticleId IdType="pmc">PMC4092059</ArticleId><ArticleId IdType="pubmed">24418061</ArticleId></ArticleIdList></Reference><Reference><Citation>Nettiksimmons J, et al. Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage. Psychol. Aging. 2013;28:191&#x2013;201. doi: 10.1037/a0031063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0031063</ArticleId><ArticleId IdType="pmc">PMC3751169</ArticleId><ArticleId IdType="pubmed">23527743</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh Y, et al. Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs. Neurology. 2014;83:1936&#x2013;1944. doi: 10.1212/WNL.0000000000001003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001003</ArticleId><ArticleId IdType="pmc">PMC4248459</ArticleId><ArticleId IdType="pubmed">25344382</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine AM, et al. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain. 2016;139:2261&#x2013;2274. doi: 10.1093/brain/aww142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww142</ArticleId><ArticleId IdType="pmc">PMC4958904</ArticleId><ArticleId IdType="pubmed">27324877</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang J, et al. Prediction of Alzheimer&#x2019;s disease pathophysiology based on cortical thickness patterns. Alzheimer&#x2019;s Dement. 2015;2:58&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879518</ArticleId><ArticleId IdType="pubmed">27239533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Xiuming, Mormino Elizabeth C., Sun Nanbo, Sperling Reisa A., Sabuncu Mert R., Yeo B. T. Thomas. Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer&#x2019;s disease. Proceedings of the National Academy of Sciences. 2016;113(42):E6535&#x2013;E6544. doi: 10.1073/pnas.1611073113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1611073113</ArticleId><ArticleId IdType="pmc">PMC5081632</ArticleId><ArticleId IdType="pubmed">27702899</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. 2012;135:794&#x2013;806. doi: 10.1093/brain/aws001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws001</ArticleId><ArticleId IdType="pmc">PMC3286334</ArticleId><ArticleId IdType="pubmed">22366795</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology. 2010;75:2204&#x2013;2211. doi: 10.1212/WNL.0b013e318202038c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318202038c</ArticleId><ArticleId IdType="pmc">PMC3013589</ArticleId><ArticleId IdType="pubmed">21172843</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology. 2010;75:2212&#x2013;2220. doi: 10.1212/WNL.0b013e31820203c2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31820203c2</ArticleId><ArticleId IdType="pmc">PMC3013590</ArticleId><ArticleId IdType="pubmed">21172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain. 2011;134:2565&#x2013;2581. doi: 10.1093/brain/awr198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr198</ArticleId><ArticleId IdType="pmc">PMC3170537</ArticleId><ArticleId IdType="pubmed">21908872</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer&#x2019;s disease: a case-control study. Lancet Neurol. 2012;11:868&#x2013;877. doi: 10.1016/S1474-4422(12)70200-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70200-4</ArticleId><ArticleId IdType="pmc">PMC3490201</ArticleId><ArticleId IdType="pubmed">22951070</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 2015;14:253&#x2013;262. doi: 10.1016/S1474-4422(14)70324-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features. Brain. 2012;135:736&#x2013;750. doi: 10.1093/brain/awr361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr361</ArticleId><ArticleId IdType="pmc">PMC3286330</ArticleId><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol. 2015;14:291&#x2013;301. doi: 10.1016/S1474-4422(14)70233-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70233-9</ArticleId><ArticleId IdType="pubmed">25638642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol. 2014;127:407&#x2013;418. doi: 10.1007/s00401-013-1239-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1239-x</ArticleId><ArticleId IdType="pmc">PMC4003885</ArticleId><ArticleId IdType="pubmed">24442578</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, et al. Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol. Aging. 2014;35:2421.e13&#x2013;2421.e17. doi: 10.1016/j.neurobiolaging.2014.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.04.016</ArticleId><ArticleId IdType="pmc">PMC4105839</ArticleId><ArticleId IdType="pubmed">24866401</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, et al. Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol. Neurodegener. 2014;9:38. doi: 10.1186/1750-1326-9-38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-38</ArticleId><ArticleId IdType="pmc">PMC4190282</ArticleId><ArticleId IdType="pubmed">25239657</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, et al. Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations. Neurology. 2009;73:1058&#x2013;1065. doi: 10.1212/WNL.0b013e3181b9c8b9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181b9c8b9</ArticleId><ArticleId IdType="pmc">PMC2754325</ArticleId><ArticleId IdType="pubmed">19786698</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73:1216&#x2013;1227. doi: 10.1016/j.neuron.2012.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.004</ArticleId><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73:1204&#x2013;1215. doi: 10.1016/j.neuron.2011.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.12.040</ArticleId><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL, et al. Multiple orderings of events in disease progression. Inf. Process. Med. Imaging. 2015;9123:711&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">26223048</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, J. &amp; Alexander, D. Advances in Neural Information Processing Systems 3104&#x2013;3112 (The MIT Press, Cambridge, MA, 2012).</Citation></Reference><Reference><Citation>Cardoso MJ, et al. Geodesic information flows. Med. Image Comput. Comput.-Assist. Interv. 2012;15:262&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">23286057</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann. Neurol. 2009;65:403&#x2013;413. doi: 10.1002/ana.21610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21610</ArticleId><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeratne Peter A., Young Alexandra L., Oxtoby Neil P., Marinescu Razvan V., Firth Nicholas C., Johnson Eileanoir B., Mohan Amrita, Sampaio Cristina, Scahill Rachael I., Tabrizi Sarah J., Alexander Daniel C. An image-based model of brain volume biomarker changes in Huntington's disease. Annals of Clinical and Translational Neurology. 2018;5(5):570&#x2013;582. doi: 10.1002/acn3.558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.558</ArticleId><ArticleId IdType="pmc">PMC5945962</ArticleId><ArticleId IdType="pubmed">29761120</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxtoby, N. P. et al. Data-driven models of dominantly-inherited Alzheimer&#x2019;s disease progression. Brain141,1529&#x2013;1544 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5920320</ArticleId><ArticleId IdType="pubmed">29579160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelman A, Hwang J, Vehtari A. Understanding predictive information criteria for Bayesian models. Stat. Comput. 2014;24:997&#x2013;1016. doi: 10.1007/s11222-013-9416-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11222-013-9416-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass RE, Raftery AE. Bayes factors. J. R. Stat. Soc. Ser. B. 1995;90:773&#x2013;795.</Citation></Reference><Reference><Citation>Bhattacharyya AK. On a measure of divergence between two statistical populations defined by their probability distributions. Sankhya Indian J. Stat. 1943;7:401&#x2013;406.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30323172</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>High prevalence of focal and multi-focal somatic genetic variants in the human brain.</ArticleTitle><Pagination><StartPage>4257</StartPage><MedlinePgn>4257</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4257</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-018-06331-w</ELocationID><Abstract><AbstractText>Somatic mutations during stem cell division are responsible for several cancers. In principle, a similar process could occur during the intense cell proliferation accompanying human brain development, leading to the accumulation of regionally distributed foci of mutations. Using dual platform &gt;5000-fold depth sequencing of 102 genes in 173 adult human brain samples, we detect and validate somatic mutations in 27 of 54 brains. Using a mathematical model of neurodevelopment and approximate Bayesian inference, we predict that macroscopic islands of pathologically mutated neurons are likely to be common in the general population. The detected mutation spectrum also includes DNMT3A and TET2 which are likely to have originated from blood cell lineages. Together, these findings establish developmental mutagenesis as a potential mechanism for neurodegenerative disorders, and provide a novel mechanism for the regional onset and focal pathology in sporadic cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keogh</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aryaman</LastName><ForeName>Juvid</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Mathematics, Imperial College London, London, SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Newcastle University, Campus for Aging and Vitality, Newcastle upon Tyne, NE4 5PL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Ameele</LastName><ForeName>Jelle</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coxhead</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Genetic Medicine, Central Parkway, Newcastle University, Newcastle Upon Tyne, NE1 3BZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Genetic Medicine, Central Parkway, Newcastle University, Newcastle Upon Tyne, NE1 3BZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bashton</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE1 7RU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Personalis Inc, 1330O'Brien Dr, Menlo Park, CA, 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Personalis Inc, 1330O'Brien Dr, Menlo Park, CA, 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Personalis Inc, 1330O'Brien Dr, Menlo Park, CA, 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haudenschild</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Personalis Inc, 1330O'Brien Dr, Menlo Park, CA, 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartha</LastName><ForeName>Gabor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Personalis Inc, 1330O'Brien Dr, Menlo Park, CA, 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Shujun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Personalis Inc, 1330O'Brien Dr, Menlo Park, CA, 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Chris M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Newcastle University, Campus for Aging and Vitality, Newcastle upon Tyne, NE4 5PL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Nick S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Mathematics, Imperial College London, London, SW7 2AZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EPSRC Centre for Mathematics of Precision Healthcare, Imperial College London, London, SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attems</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Newcastle University, Campus for Aging and Vitality, Newcastle upon Tyne, NE4 5PL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chinnery</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK. pfc25@cam.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0XY, UK. pfc25@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100540</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>101876/Z/13/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0502157</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0601943</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1501/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>212219/Z/18/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900652</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2019 Mar;34(3):321. doi: 10.1002/mds.27624.</RefSource><PMID Version="1">30675953</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002999" MajorTopicYN="N">Clone Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060005" MajorTopicYN="N">Genotyping Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30323172</ArticleId><ArticleId IdType="pmc">PMC6189186</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-06331-w</ArticleId><ArticleId IdType="pii">10.1038/s41467-018-06331-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001;2:492&#x2013;501. doi: 10.1038/35081564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35081564</ArticleId><ArticleId IdType="pubmed">11433374</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer&#x2019;s disease. Science. 2006;314:777&#x2013;781. doi: 10.1126/science.1132814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132814</ArticleId><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton A, Hardy J. The evolution of genetics: Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Neuron. 2016;90:1154&#x2013;1163. doi: 10.1016/j.neuron.2016.05.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.040</ArticleId><ArticleId IdType="pmc">PMC4936485</ArticleId><ArticleId IdType="pubmed">27311081</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Bras J, Hardy J. SnapShot: genetics of ALS and FTD. Cell. 2015;160:798 e791. doi: 10.1016/j.cell.2015.01.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.052</ArticleId><ArticleId IdType="pubmed">25679767</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 2010;11:301&#x2013;307. doi: 10.1038/nrm2873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2873</ArticleId><ArticleId IdType="pmc">PMC2892479</ArticleId><ArticleId IdType="pubmed">20308987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae T, et al. Different mutational rates and mechanisms in human cells at pregastrulation and neurogenesis. Science. 2018;359:550&#x2013;555. doi: 10.1126/science.aan8690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan8690</ArticleId><ArticleId IdType="pmc">PMC6311130</ArticleId><ArticleId IdType="pubmed">29217587</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodato MA, et al. Aging and neurodegeneration are associated with increased mutations in single human neurons. Science. 2018;359:555&#x2013;559. doi: 10.1126/science.aao4426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao4426</ArticleId><ArticleId IdType="pmc">PMC5831169</ArticleId><ArticleId IdType="pubmed">29217584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 2013;31:213&#x2013;219. doi: 10.1038/nbt.2514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2514</ArticleId><ArticleId IdType="pmc">PMC3833702</ArticleId><ArticleId IdType="pubmed">23396013</ArticleId></ArticleIdList></Reference><Reference><Citation>Koboldt DC, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22:568&#x2013;576. doi: 10.1101/gr.129684.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.129684.111</ArticleId><ArticleId IdType="pmc">PMC3290792</ArticleId><ArticleId IdType="pubmed">22300766</ArticleId></ArticleIdList></Reference><Reference><Citation>Koboldt DC, et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009;25:2283&#x2013;2285. doi: 10.1093/bioinformatics/btp373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp373</ArticleId><ArticleId IdType="pmc">PMC2734323</ArticleId><ArticleId IdType="pubmed">19542151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstung M, et al. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat. Commun. 2012;3:811. doi: 10.1038/ncomms1814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1814</ArticleId><ArticleId IdType="pubmed">22549840</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstung M, Papaemmanuil E, Campbell PJ. Subclonal variant calling with multiple samples and prior knowledge. Bioinformatics. 2014;30:1198&#x2013;1204. doi: 10.1093/bioinformatics/btt750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt750</ArticleId><ArticleId IdType="pmc">PMC3998123</ArticleId><ArticleId IdType="pubmed">24443148</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer GP. Mutagenesis at methylated CpG sequences. Curr. Top. Microbiol. Immunol. 2006;301:259&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">16570852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodato MA, et al. Somatic mutation in single human neurons tracks developmental and transcriptional history. Science. 2015;350:94&#x2013;98. doi: 10.1126/science.aab1785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab1785</ArticleId><ArticleId IdType="pmc">PMC4664477</ArticleId><ArticleId IdType="pubmed">26430121</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankar TS, Wastuwidyaningtyas BD, Dong Y, Lewis SA, Wang JD. The nature of mutations induced by replication-transcription collisions. Nature. 2016;535:178&#x2013;181. doi: 10.1038/nature18316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18316</ArticleId><ArticleId IdType="pmc">PMC4945378</ArticleId><ArticleId IdType="pubmed">27362223</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415&#x2013;421. doi: 10.1038/nature12477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12477</ArticleId><ArticleId IdType="pmc">PMC3776390</ArticleId><ArticleId IdType="pubmed">23945592</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansdorp PM. Immortal strands? Give me a break. Cell. 2007;129:1244&#x2013;1247. doi: 10.1016/j.cell.2007.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.06.017</ArticleId><ArticleId IdType="pubmed">17604711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan CY, Roth KA, Flavell RA, Rakic P. Mechanisms of programmed cell death in the developing brain. Trends Neurosci. 2000;23:291&#x2013;297. doi: 10.1016/S0166-2236(00)01581-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(00)01581-2</ArticleId><ArticleId IdType="pubmed">10856938</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppenheim RW. Cell death during development of the nervous system. Annu. Rev. Neurosci. 1991;14:453&#x2013;501. doi: 10.1146/annurev.ne.14.030191.002321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.ne.14.030191.002321</ArticleId><ArticleId IdType="pubmed">2031577</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc. Natl. Acad. Sci. USA. 2013;110:1999&#x2013;2004. doi: 10.1073/pnas.1221068110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1221068110</ArticleId><ArticleId IdType="pmc">PMC3568331</ArticleId><ArticleId IdType="pubmed">23345422</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenson PD, et al. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum. Genet. 2014;133:1&#x2013;9. doi: 10.1007/s00439-013-1358-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-013-1358-4</ArticleId><ArticleId IdType="pmc">PMC3898141</ArticleId><ArticleId IdType="pubmed">24077912</ArticleId></ArticleIdList></Reference><Reference><Citation>Roach JC, et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science. 2010;328:636&#x2013;639. doi: 10.1126/science.1186802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1186802</ArticleId><ArticleId IdType="pmc">PMC3037280</ArticleId><ArticleId IdType="pubmed">20220176</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J. Biol. Chem. 2009;284:3546&#x2013;3551. doi: 10.1074/jbc.M805627200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805627200</ArticleId><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference><Reference><Citation>McKerrell T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 2015;10:1239&#x2013;1245. doi: 10.1016/j.celrep.2015.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.02.005</ArticleId><ArticleId IdType="pmc">PMC4542313</ArticleId><ArticleId IdType="pubmed">25732814</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 2014;371:2488&#x2013;2498. doi: 10.1056/NEJMoa1408617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1408617</ArticleId><ArticleId IdType="pmc">PMC4306669</ArticleId><ArticleId IdType="pubmed">25426837</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat. Neurosci. 2017;20:136&#x2013;144. doi: 10.1038/nn.4475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4475</ArticleId><ArticleId IdType="pubmed">28092660</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates LR, Campbell PJ. Evolution of the cancer genome. Nat. Rev. Genet. 2012;13:795&#x2013;806. doi: 10.1038/nrg3317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3317</ArticleId><ArticleId IdType="pmc">PMC3666082</ArticleId><ArticleId IdType="pubmed">23044827</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306&#x2013;313. doi: 10.1038/nature10762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10762</ArticleId><ArticleId IdType="pmc">PMC3367003</ArticleId><ArticleId IdType="pubmed">22258609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortmann CA, et al. Effect of mutation order on myeloproliferative neoplasms. New Engl. J. Med. 2015;372:601&#x2013;612. doi: 10.1056/NEJMoa1412098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1412098</ArticleId><ArticleId IdType="pmc">PMC4660033</ArticleId><ArticleId IdType="pubmed">25671252</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpin J, et al. The ErbB2DeltaEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene. 2016;35:6053&#x2013;6064. doi: 10.1038/onc.2016.129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2016.129</ArticleId><ArticleId IdType="pmc">PMC5102823</ArticleId><ArticleId IdType="pubmed">27157621</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller Patricia A. J., Vousden Karen H. p53 mutations in cancer. Nature Cell Biology. 2013;15(1):2&#x2013;8. doi: 10.1038/ncb2641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2641</ArticleId><ArticleId IdType="pubmed">23263379</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulci Giulia, Ishii Nobuaki, Van Meir Erwin G. p53 and Brain Tumors: From Gene Mutations to Gene Therapy. Brain Pathology. 1998;8(4):599&#x2013;613. doi: 10.1111/j.1750-3639.1998.tb00187.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.1998.tb00187.x</ArticleId><ArticleId IdType="pmc">PMC8098259</ArticleId><ArticleId IdType="pubmed">9804370</ArticleId></ArticleIdList></Reference><Reference><Citation>Busque L, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 2012;44:1179&#x2013;1181. doi: 10.1038/ng.2413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2413</ArticleId><ArticleId IdType="pmc">PMC3483435</ArticleId><ArticleId IdType="pubmed">23001125</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen KD, et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 2015;29:910&#x2013;922. doi: 10.1101/gad.260174.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.260174.115</ArticleId><ArticleId IdType="pmc">PMC4421980</ArticleId><ArticleId IdType="pubmed">25886910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat. Rev. Cancer. 2015;15:152&#x2013;165. doi: 10.1038/nrc3895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3895</ArticleId><ArticleId IdType="pmc">PMC5814392</ArticleId><ArticleId IdType="pubmed">25693834</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Dumaop W, Galasko D, Desplats P. Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics. 2013;8:1030&#x2013;1038. doi: 10.4161/epi.25865.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/epi.25865</ArticleId><ArticleId IdType="pmc">PMC3891683</ArticleId><ArticleId IdType="pubmed">23907097</ArticleId></ArticleIdList></Reference><Reference><Citation>Monahan AJ, Warren M, Carvey PM. Neuroinflammation and peripheral immune infiltration in Parkinson&#x2019;s disease: an autoimmune hypothesis. Cell Transplant. 2008;17:363&#x2013;372. doi: 10.3727/096368908784423328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368908784423328</ArticleId><ArticleId IdType="pubmed">18522239</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology in Alzheimer&#x2019;s and Parkinson&#x2019;s disease: implications for drug therapy. Cell Transplant. 2007;16:285&#x2013;299. doi: 10.3727/000000007783464731.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/000000007783464731</ArticleId><ArticleId IdType="pubmed">17503739</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuster JJ, et al. Clonal hematopoiesis associated with Tet2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842&#x2013;847. doi: 10.1126/science.aag1381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag1381</ArticleId><ArticleId IdType="pmc">PMC5542057</ArticleId><ArticleId IdType="pubmed">28104796</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 2014;371:2477&#x2013;2487. doi: 10.1056/NEJMoa1409405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1409405</ArticleId><ArticleId IdType="pmc">PMC4290021</ArticleId><ArticleId IdType="pubmed">25426838</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Shattuck lecture&#x2014;neurodegenerative diseases and prions. N. Engl. J. Med. 2001;344:1516&#x2013;1526. doi: 10.1056/NEJM200105173442006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105173442006</ArticleId><ArticleId IdType="pubmed">11357156</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurd MD, Martorell P, Langa KM. Monetary costs of dementia in the United States. N. Engl. J. Med. 2013;369:489&#x2013;490. doi: 10.1056/NEJMc1305541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1305541</ArticleId><ArticleId IdType="pubmed">23902508</ArticleId></ArticleIdList></Reference><Reference><Citation>Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer&#x2019;s disease. Nature. 2016;539:187&#x2013;196. doi: 10.1038/nature20412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20412</ArticleId><ArticleId IdType="pubmed">27830780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandler M, et al. Pyroglutamylated amyloid-beta is associated with hyperphosphorylated tau and severity of Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;128:67&#x2013;79. doi: 10.1007/s00401-014-1296-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1296-9</ArticleId><ArticleId IdType="pubmed">24861310</ArticleId></ArticleIdList></Reference><Reference><Citation>Keogh MJ, et al. Exome sequencing in dementia with Lewy bodies. Transl. Psychiatry. 2016;6:e728. doi: 10.1038/tp.2015.220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2015.220</ArticleId><ArticleId IdType="pmc">PMC4872424</ArticleId><ArticleId IdType="pubmed">26836416</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomes Project C, et al. An integrated map of genetic variation from 1092 human genomes. Nature. 2012;491:56&#x2013;65. doi: 10.1038/nature11632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11632</ArticleId><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285&#x2013;291. doi: 10.1038/nature19057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19057</ArticleId><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. doi: 10.1093/nar/gkq603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq603</ArticleId><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JT, et al. Integrative genomics viewer. Nat. Biotechnol. 2011;29:24&#x2013;26. doi: 10.1038/nbt.1754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1754</ArticleId><ArticleId IdType="pmc">PMC3346182</ArticleId><ArticleId IdType="pubmed">21221095</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297&#x2013;1303. doi: 10.1101/gr.107524.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.107524.110</ArticleId><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011;43:491&#x2013;498. doi: 10.1038/ng.806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.806</ArticleId><ArticleId IdType="pmc">PMC3083463</ArticleId><ArticleId IdType="pubmed">21478889</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Auwera GA, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinform. 2013;43:11 10 11-33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243306</ArticleId><ArticleId IdType="pubmed">25431634</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007;81:559&#x2013;575. doi: 10.1086/519795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519795</ArticleId><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Keogh MJ, et al. Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. Genome Res. 2017;27:165&#x2013;173. doi: 10.1101/gr.210609.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.210609.116</ArticleId><ArticleId IdType="pmc">PMC5204341</ArticleId><ArticleId IdType="pubmed">28003435</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo FA, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J. Comp. Neurol. 2009;513:532&#x2013;541. doi: 10.1002/cne.21974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21974</ArticleId><ArticleId IdType="pubmed">19226510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30349106</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2018</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A histone acetylome-wide association study of Alzheimer's disease identifies disease-associated H3K27ac differences in the entorhinal cortex.</ArticleTitle><Pagination><StartPage>1618</StartPage><EndPage>1627</EndPage><MedlinePgn>1618-1627</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-018-0253-7</ELocationID><Abstract><AbstractText>We quantified genome-wide patterns of lysine H3K27 acetylation (H3K27ac) in entorhinal cortex samples from Alzheimer's disease (AD) cases and matched controls using chromatin immunoprecipitation and highly parallel sequencing. We observed widespread acetylomic variation associated with AD neuropathology, identifying 4,162 differential peaks (false discovery rate&#x2009;&lt;&#x2009;0.05) between AD cases and controls. Differentially acetylated peaks were enriched in disease-related biological pathways and included regions annotated to genes involved in the progression of amyloid-&#x3b2; and tau pathology (for example, APP, PSEN1, PSEN2, and MAPT), as well as regions containing variants associated with sporadic late-onset AD. Partitioned heritability analysis highlighted a highly significant enrichment of AD risk variants in entorhinal cortex H3K27ac peak regions. AD-associated variable H3K27ac was associated with transcriptional variation at proximal genes including CR1, GPR22, KMO, PIM3, PSEN1, and RGCC. In addition to identifying molecular pathways associated with AD neuropathology, we present a framework for genome-wide studies of histone modifications in complex disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marzi</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Blizard Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Szi Kay</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribarska</LastName><ForeName>Teodora</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannon</LastName><ForeName>Eilis</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Adam R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0001-6495-2711</Identifier><AffiliationInfo><Affiliation>University of Exeter Medical School, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pishva</LastName><ForeName>Ehsan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poschmann</LastName><ForeName>Jeremie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de Recherche en Transplantation et Immunologie, Inserm, Universit&#xe9; de Nantes, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1790-7376</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Sarraj</LastName><ForeName>Safa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5290-2151</Identifier><AffiliationInfo><Affiliation>UCL Cancer Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Essex, Colchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunnon</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schalkwyk</LastName><ForeName>Leonard C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>University of Essex, Colchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mill</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1115-3224</Identifier><AffiliationInfo><Affiliation>University of Exeter Medical School, University of Exeter, Exeter, UK. J.Mill@exeter.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L016397/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008924/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30349106</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0253-7</ArticleId><ArticleId IdType="pii">10.1038/s41593-018-0253-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30383090</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest.</ArticleTitle><Pagination><StartPage>64</StartPage><EndPage>71</EndPage><MedlinePgn>64-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.3223</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Prognostication of neurologic outcome after cardiac arrest is an important but challenging aspect of patient therapy management in critical care units.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether serum neurofilament light chain (NFL) levels can be used for prognostication of neurologic outcome after cardiac arrest.</AbstractText><AbstractText Label="DESIGN, SETTING AND PARTICIPANTS">Prospective clinical biobank study of data from the randomized Target Temperature Management After Cardiac Arrest trial, an international, multicenter study with 29 participating sites. Patients were included between November 11, 2010, and January 10, 2013. Serum NFL levels were analyzed between August 1 and August 23, 2017, after trial completion. A total of 782 unconscious patients with out-of-hospital cardiac arrest of presumed cardiac origin were eligible.</AbstractText><AbstractText Label="EXPOSURES">Serum NFL concentrations analyzed at 24, 48, and 72 hours after cardiac arrest with an ultrasensitive immunoassay.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Poor neurologic outcome at 6-month follow-up, defined according to the Cerebral Performance Category Scale as cerebral performance category 3 (severe cerebral disability), 4 (coma), or 5 (brain death).</AbstractText><AbstractText Label="RESULTS">Of 782 eligible patients, 65 patients (8.3%) were excluded because of issues with aliquoting, missing sampling, missing outcome, or transport problems of samples. Of the 717 patients included (91.7%), 580 were men (80.9%) and median (interquartile range [IQR]) age was 65 (56-73) years. A total of 360 patients (50.2%) had poor neurologic outcome at 6 months. Median (IQR) serum NFL level was significantly increased in the patients with poor outcome vs good outcome at 24 hours (1426 [299-3577] vs 37 [20-70] pg/mL), 48 hours (3240 [623-8271] vs 46 [26-101] pg/mL), and 72 hours (3344 [845-7838] vs 54 [30-122] pg/mL) (P&#x2009;&lt;&#x2009;.001 at all time points), with high overall performance (area under the curve, 0.94-0.95) and high sensitivities at high specificities (eg, 69% sensitivity with 98% specificity at 24 hours). Serum NFL levels had significantly greater performance than the other biochemical serum markers (ie, tau, neuron-specific enolase, and S100). At comparable specificities, serum NFL levels had greater sensitivity for poor outcome compared with routine electroencephalogram, somatosensory-evoked potentials, head computed tomography, and both pupillary and corneal reflexes (ranging from 29.2% to 49.0% greater for serum NFL level).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Findings from this study suggest that the serum NFL level is a highly predictive marker of long-term poor neurologic outcome at 24 hours after cardiac arrest and may be a useful complement to currently available neurologic prognostication methods.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moseby-Knappe</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Neurology, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Neurology, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Anesthesia and Intensive Care, Lund University, Helsingborg Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College of London Institute of Neurology, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dankiewicz</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Cardiology, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragancea</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Neurology, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friberg</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Anesthesia and Intensive Care, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lilja</LastName><ForeName>Gisela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Neurology, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Insel</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rylander</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westhall</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Clinical Neurophysiology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kjaergaard</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Cardiology, Rigshospitalet and Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wise</LastName><ForeName>Matt P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Adult Critical Care, University Hospital of Wales, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassager</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of Cardiology, Rigshospitalet and Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuiper</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Medical Center Leeuwarden, Leeuwarden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stammet</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Rescue Services, Luxembourg City, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanscher</LastName><ForeName>Michael C Jaeger</ForeName><Initials>MCJ</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Anaesthesia, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetterslev</LastName><ForeName>J&#xf8;rn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Copenhagen Trial Unit, Centre for Clinical Intervention Research Department, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erlinge</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Cardiology, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Janneke</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Academic Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellis</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Anesthesia and Intensive Care, Card. G. Panico Hospital Agency, Tricase, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cronberg</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Neurology, Lund University, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2020 Jul 1;77(7):907. doi: 10.1001/jamaneurol.2020.1261.</RefSource><PMID Version="1">32391869</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058687" MajorTopicYN="N">Out-of-Hospital Cardiac Arrest</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014015" MajorTopicYN="Y">Tissue Banks</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Zetterberg and Blennow are cofounders of Brain Biomarker Solutions in Gothenburg AB, a venture-based platform company at the University of Gothenburg. Dr Blennow has served as a paid consultant or served on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics. No other conflicts were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30383090</ArticleId><ArticleId IdType="pmc">PMC6440255</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.3223</ArticleId><ArticleId IdType="pii">2709115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Callaway CW, Donnino MW, Fink EL, et al. . Part 8: post-cardiac arrest care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18)(suppl 2):S465-S482. doi:10.1161/CIR.0000000000000262</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000262</ArticleId><ArticleId IdType="pmc">PMC4959439</ArticleId><ArticleId IdType="pubmed">26472996</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan JP, Cariou A. Post-resuscitation care: ERC&#x2013;ESICM guidelines 2015. Intensive Care Med. 2015;41(12):2204-2206. doi:10.1007/s00134-015-4094-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-4094-5</ArticleId><ArticleId IdType="pubmed">26464395</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossetti AO, Rabinstein AA, Oddo M. Neurological prognostication of outcome in patients in coma after cardiac arrest. Lancet Neurol. 2016;15(6):597-609. doi:10.1016/S1474-4422(16)00015-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00015-6</ArticleId><ArticleId IdType="pubmed">27017468</ArticleId></ArticleIdList></Reference><Reference><Citation>Stammet P, Collignon O, Hassager C, et al. ; TTM-Trial Investigators . Neuron-specific enolase as a predictor of death or poor neurological outcome after out-of-hospital cardiac arrest and targeted temperature management at 33&#xb0;C and 36&#xb0;C. J Am Coll Cardiol. 2015;65(19):2104-2114. doi:10.1016/j.jacc.2015.03.538</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.03.538</ArticleId><ArticleId IdType="pubmed">25975474</ArticleId></ArticleIdList></Reference><Reference><Citation>Stammet P, Dankiewicz J, Nielsen N, et al. ; Target Temperature Management After Out-of-Hospital Cardiac Arrest (TTM) trial investigators . Protein S100 as outcome predictor after out-of-hospital cardiac arrest and targeted temperature management at 33 &#xb0;C and 36 &#xb0;C. Crit Care. 2017;21(1):153. doi:10.1186/s13054-017-1729-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-017-1729-7</ArticleId><ArticleId IdType="pmc">PMC5477102</ArticleId><ArticleId IdType="pubmed">28629472</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P, Gren M, Liman V, et al. . Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep. 2016;6:36791. doi:10.1038/srep36791</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36791</ArticleId><ArticleId IdType="pmc">PMC5098187</ArticleId><ArticleId IdType="pubmed">27819296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Janelidze S, Hall S, et al. ; Swedish BioFINDER study . Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88(10):930-937. doi:10.1212/WNL.0000000000003680</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003680</ArticleId><ArticleId IdType="pmc">PMC5333515</ArticleId><ArticleId IdType="pubmed">28179466</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557-566. doi:10.1001/jamaneurol.2016.6117</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchis GM, Katan M, Barro C, et al. . Serum neurofilament light chain in patients with acute cerebrovascular events. Eur J Neurol. 2018;25(3):562-568. doi:10.1111/ene.13554</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13554</ArticleId><ArticleId IdType="pubmed">29281157</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M, Price RW, Andreasson U, et al. . Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135-140. doi:10.1016/j.ebiom.2015.11.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2015.11.036</ArticleId><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et al. . Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90(1):e22-e30. doi:10.1212/WNL.0000000000004761</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004761</ArticleId><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe9;n C, Ros&#xe9;n H, Andreasson U, et al. . Cerebrospinal fluid biomarkers in cardiac arrest survivors. Resuscitation. 2014;85(2):227-232. doi:10.1016/j.resuscitation.2013.10.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2013.10.032</ArticleId><ArticleId IdType="pubmed">24231570</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana OR, Schr&#xf6;der JW, Baukloh JK, et al. . Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. Int J Cardiol. 2013;168(2):1322-1327. doi:10.1016/j.ijcard.2012.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2012.12.016</ArticleId><ArticleId IdType="pubmed">23287695</ArticleId></ArticleIdList></Reference><Reference><Citation>Rundgren M, Friberg H, Cronberg T, Romner B, Petzold A. Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest. Crit Care. 2012;16(2):R45. doi:10.1186/cc11244</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc11244</ArticleId><ArticleId IdType="pmc">PMC3681370</ArticleId><ArticleId IdType="pubmed">22410303</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson DH, Rissin DM, Kan CW, et al. . The Simoa HD-1 Analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J Lab Autom. 2016;21(4):533-547. doi:10.1177/2211068215589580</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2211068215589580</ArticleId><ArticleId IdType="pubmed">26077162</ArticleId></ArticleIdList></Reference><Reference><Citation>Target Temperature Management After Cardiac Arrest. https://clinicaltrials.gov/ct2/show/NCT01020916. Accessed September 22, 2018.</Citation></Reference><Reference><Citation>Nielsen N, Wetterslev J, Cronberg T, et al. ; TTM Trial Investigators . Targeted temperature management at 33&#xb0;C versus 36&#xb0;C after cardiac arrest. N Engl J Med. 2013;369(23):2197-2206. doi:10.1056/NEJMoa1310519</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1310519</ArticleId><ArticleId IdType="pubmed">24237006</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen N, Wetterslev J, al-Subaie N, et al. . Target temperature management after out-of-hospital cardiac arrest: a randomized, parallel-group, assessor-blinded clinical trial&#x2014;rationale and design. Am Heart J. 2012;163(4):541-548. doi:10.1016/j.ahj.2012.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2012.01.013</ArticleId><ArticleId IdType="pubmed">22520518</ArticleId></ArticleIdList></Reference><Reference><Citation>Westhall E, Rossetti AO, van Rootselaar AF, et al. ; TTM Trial investigators . Standardized EEG interpretation accurately predicts prognosis after cardiac arrest. Neurology. 2016;86(16):1482-1490. doi:10.1212/WNL.0000000000002462</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002462</ArticleId><ArticleId IdType="pmc">PMC4836886</ArticleId><ArticleId IdType="pubmed">26865516</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragancea I, Horn J, Kuiper M, et al. ; TTM Trial Investigators . Neurological prognostication after cardiac arrest and targeted temperature management 33&#xb0;C versus 36&#xb0;C: results from a randomised controlled clinical trial. Resuscitation. 2015;93:164-170. doi:10.1016/j.resuscitation.2015.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2015.04.013</ArticleId><ArticleId IdType="pubmed">25921544</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossuyt PM, Reitsma JB, Bruns DE, et al. ; Standards for Reporting of Diagnostic Accuracy . Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ. 2003;326(7379):41-44. doi:10.1136/bmj.326.7379.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.326.7379.41</ArticleId><ArticleId IdType="pmc">PMC1124931</ArticleId><ArticleId IdType="pubmed">12511463</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Nielsen N, et al. . Serum tau and neurological outcome in cardiac arrest. Ann Neurol. 2017;82(5):665-675. doi:10.1002/ana.25067</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25067</ArticleId><ArticleId IdType="pmc">PMC5725735</ArticleId><ArticleId IdType="pubmed">28981963</ArticleId></ArticleIdList></Reference><Reference><Citation>Moseby-Knappe M, Pellis T, Dragancea I, et al. ; TTM Trial investigators . Head computed tomography for prognostication of poor outcome in comatose patients after cardiac arrest and targeted temperature management. Resuscitation. 2017;119:89-94. doi:10.1016/j.resuscitation.2017.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2017.06.027</ArticleId><ArticleId IdType="pubmed">28687281</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1(7905):480-484.</Citation><ArticleIdList><ArticleId IdType="pubmed">46957</ArticleId></ArticleIdList></Reference><Reference><Citation>Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham KP.
Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach
http://www.springer.com/us/book/9780387953649. Accessed April 12, 2017.</Citation></Reference><Reference><Citation>Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1-48.</Citation></Reference><Reference><Citation>Shahim P, Zetterberg H, Tegner Y, Blennow K. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology. 2017;88(19):1788-1794. doi:10.1212/WNL.0000000000003912</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003912</ArticleId><ArticleId IdType="pmc">PMC5419986</ArticleId><ArticleId IdType="pubmed">28404801</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30419087</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.</ArticleTitle><Pagination><StartPage>187</StartPage><EndPage>193</EndPage><MedlinePgn>187-193</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.3459</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Accumulating data suggest that elevated cerebrospinal fluid (CSF) neurofilament light (NfL) and neurogranin (Ng) levels are associated with cognitive decline and may be useful markers of neurodegeneration. However, to our knowledge, previous studies have not assessed these CSF markers in the community, evaluated them with regards to risk of mild cognitive impairment (MCI), or compared their prognostic value with CSF total tau (T-tau) or phosphorylated tau (P-tau).</AbstractText><AbstractText Label="OBJECTIVE">To determine (1) whether CSF NfL and Ng levels were associated with risk of MCI, (2) the effect size of these markers compared with CSF T-tau or P-tau for risk of MCI, and (3) whether CSF amyloid-&#x3b2; (A&#x3b2;42) modified these associations.</AbstractText><AbstractText Label="DESIGN, SETTING AND PARTICIPANTS">The analyses included 648 participants without cognitive impairment who were enrolled into the prospective population-based Mayo Clinic Study of Aging between January 2004 and December 2015 with available CSF data and at least 1 follow-up visit. Participants were followed up for a median of 3.8 years (interquartile range, 2.6-5.4 years). The CSF NfL and Ng levels were measured using an in-house sandwich enzyme-linked immunosorbent assay. The CSF A&#x3b2;42, T-tau, and P-tau levels were measured with automated electrochemiluminescence immunoassays. Cox proportional hazards models, with age as the timescale, were used to assess the association between CSF NfL, Ng, A&#x3b2;42, T-tau, or P-tau with risk of MCI after adjusting for sex, education, apolipoprotein E genotype, and the Charlson comorbidity index. To examine CSF A&#x3b2;42 as an effect modifier, it was categorized into tertiles; the bottom tertile was defined as having elevated brain amyloid.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Risk of MCI.</AbstractText><AbstractText Label="RESULTS">At baseline, the median age of the 648 participants without cognitive impairment was 72.3 years (range, 50.7-95.3 years) and 366 (56.5%) were men; 96 (14.8%) developed incident MCI. Compared with the bottom quartile, the top quartile of CSF NfL was associated with a 3.1-fold increased risk of MCI (hazard ratio, 3.13; 95% CI, 1.36-7.18) in multivariate models. Neither CSF T-tau, P-tau, nor Ng was associated with risk of MCI. There was no interaction between A&#x3b2;42 and CSF NfL for risk of MCI.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Elevated CSF NfL levels but not CSF T-tau, P-tau or Ng are a risk factor for MCI in a community population and are independent of brain amyloid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syrjanen</LastName><ForeName>Jeremy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the Institute of Neurology, University College London, Queen Square, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute at University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skoog</LastName><ForeName>Ingmar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waern</LastName><ForeName>Margda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Clinton E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Harten</LastName><ForeName>Argonde C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049704</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496649">NRGN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>132654-77-4</RegistryNumber><NameOfSubstance UI="D051579">Neurogranin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051579" MajorTopicYN="N">Neurogranin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Blennow has served as a consultant on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture&#x2013;based platform company at the University of Gothenburg. Dr Zetterberg has served on advisory boards for Eli Lilly, Roche Diagnostics, and Wave; has received travel grants from Teva; and is a cofounder of Brain Biomarker Solutions. Dr Skoog has been an advisor and speaker for Takeda. Dr Knopman serves on a data safety monitoring board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer Network study; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the Alzheimer&#x2019;s Disease Cooperative Study; and receives research support from the National Institutes of Health (NIH). Dr Jack has provided consulting services for Eli Lilly and receives research funding from the NIH (grants R01 AG011378, U01 HL096917, U01 AG024904, R01 AG041851, R01 AG037551, R01 AG043392, and U01 AG006786) and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr Petersen is a consultant for Roche Inc, Merck Inc, Biogen Inc, Genentech, Inc, and GE Healthcare. Dr Mielke served as a consultant to Eli Lilly and Lysosomal Therapeutics, Inc and receives research support from the NIH (grants R01 AG49704, P50 AG44170, U01 AG06786, and RF1 AG55151), the US Department of Defense (grant W81XWH-15-1), and unrestricted research grants from Biogen and Lundbeck.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30419087</ArticleId><ArticleId IdType="pmc">PMC6439969</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.3459</ArticleId><ArticleId IdType="pii">2712850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheltens P, Blennow K, Breteler MM, et al. . Alzheimer&#x2019;s disease. Lancet. 2016;388(10043):505-517. doi:10.1016/S0140-6736(15)01124-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)01124-1</ArticleId><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144. doi:10.1038/nrneurol.2010.4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.4</ArticleId><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Riederer P, O&#x2019;Bryant SE, et al. ; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut . Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2018;19(4):244-328. doi:10.1080/15622975.2017.1375556</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15622975.2017.1375556</ArticleId><ArticleId IdType="pmc">PMC5916324</ArticleId><ArticleId IdType="pubmed">29076399</ArticleId></ArticleIdList></Reference><Reference><Citation>Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003;987(1):25-31. doi:10.1016/S0006-8993(03)03219-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(03)03219-0</ArticleId><ArticleId IdType="pubmed">14499942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A. 1987;84(10):3472-3476. doi:10.1073/pnas.84.10.3472</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.84.10.3472</ArticleId><ArticleId IdType="pmc">PMC304893</ArticleId><ArticleId IdType="pubmed">3472217</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Skillb&#xe4;ck T, Mattsson N, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73(1):60-67. doi:10.1001/jamaneurol.2015.3037</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.3037</ArticleId><ArticleId IdType="pmc">PMC5624219</ArticleId><ArticleId IdType="pubmed">26524180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvartsberg H, Portelius E, Andreasson U, et al. . Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer&#x2019;s disease patients and healthy controls. Alzheimers Res Ther. 2015;7(1):40. doi:10.1186/s13195-015-0124-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0124-3</ArticleId><ArticleId IdType="pmc">PMC4487851</ArticleId><ArticleId IdType="pubmed">26136856</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Palmqvist S, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer&#x2019;s disease. EMBO Mol Med. 2016;8(10):1184-1196. doi:10.15252/emmm.201606540</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606540</ArticleId><ArticleId IdType="pmc">PMC5048367</ArticleId><ArticleId IdType="pubmed">27534871</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Westman E, Hansson O; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer&#x2019;s disease. Neurobiol Aging. 2017;58:14-29. doi:10.1016/j.neurobiolaging.2017.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.06.002</ArticleId><ArticleId IdType="pubmed">28692877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, Teunissen CE, Crimmins DL, et al. . Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015;72(11):1275-1280. doi:10.1001/jamaneurol.2015.1867</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1867</ArticleId><ArticleId IdType="pmc">PMC4694558</ArticleId><ArticleId IdType="pubmed">26366630</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington H, Paterson RW, Portelius E, et al. . Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829-835. doi:10.1212/WNL.0000000000002423</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002423</ArticleId><ArticleId IdType="pmc">PMC4793782</ArticleId><ArticleId IdType="pubmed">26826204</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Olsson B, H&#xf6;glund K, et al. . Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136(3):363-376. doi:10.1007/s00401-018-1851-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1851-x</ArticleId><ArticleId IdType="pmc">PMC6096740</ArticleId><ArticleId IdType="pubmed">29700597</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. . The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69. doi:10.1159/000115751</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000115751</ArticleId><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>St Sauver JL, Grossardt BR, Yawn BP, et al. . Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012;41(6):1614-1624. doi:10.1093/ije/dys195</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dys195</ArticleId><ArticleId IdType="pmc">PMC3535751</ArticleId><ArticleId IdType="pubmed">23159830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivnik RJ, Malec JF, Smith GE, et al. . Mayo&#x2019;s older Americans normative studies: updated AVLT norms for ages 56 to 97. Clin Neuropsychol. 1992;6(suppl):83-104. doi:10.1080/13854049208401880</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854049208401880</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194. doi:10.1111/j.1365-2796.2004.01388.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2004.01388.x</ArticleId><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>Gaetani L, H&#xf6;glund K, Parnetti L, et al. . A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther. 2018;10(1):8. doi:10.1186/s13195-018-0339-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0339-1</ArticleId><ArticleId IdType="pmc">PMC6389166</ArticleId><ArticleId IdType="pubmed">29370869</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Zetterberg H, Skillb&#xe4;ck T, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer&#x2019;s disease. Brain. 2015;138(pt 11):3373-3385. doi:10.1093/brain/awv267</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv267</ArticleId><ArticleId IdType="pmc">PMC4643642</ArticleId><ArticleId IdType="pubmed">26373605</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ III. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87(12):1202-1213. doi:10.1016/j.mayocp.2012.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2012.08.012</ArticleId><ArticleId IdType="pmc">PMC3541925</ArticleId><ArticleId IdType="pubmed">23199802</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of prognostic risk scores. Stat Methods Med Res. 2016;25(4):1692-1706. doi:10.1177/0962280213497434</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280213497434</ArticleId><ArticleId IdType="pmc">PMC3933449</ArticleId><ArticleId IdType="pubmed">23907781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H. Tauomics and kinetics in human neurons and biological fluids. Neuron. 2018;97(6):1202-1205. doi:10.1016/j.neuron.2018.02.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.030</ArticleId><ArticleId IdType="pubmed">29566788</ArticleId></ArticleIdList></Reference><Reference><Citation>Skillb&#xe4;ck T, Ros&#xe9;n C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol. 2014;71(4):476-483. doi:10.1001/jamaneurol.2013.6455</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6455</ArticleId><ArticleId IdType="pubmed">24566866</ArticleId></ArticleIdList></Reference><Reference><Citation>van Harten AC, Smits LL, Teunissen CE, et al. . Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. 2013;81(16):1409-1416. doi:10.1212/WNL.0b013e3182a8418b</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a8418b</ArticleId><ArticleId IdType="pubmed">24049134</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. . Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965. doi:10.1016/S1474-4422(13)70194-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70194-7</ArticleId><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonkwo OC, Alosco ML, Griffith HR, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol. 2010;67(6):688-696. doi:10.1001/archneurol.2010.118</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.118</ArticleId><ArticleId IdType="pmc">PMC2888499</ArticleId><ArticleId IdType="pubmed">20558388</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of &#x3b2;-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98-106. doi:10.1001/archgenpsychiatry.2011.155</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.155</ArticleId><ArticleId IdType="pubmed">22213792</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. . Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80(19):1784-1791. doi:10.1212/WNL.0b013e3182918ca6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182918ca6</ArticleId><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rossum IA, Vos SJ, Burns L, et al. . Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology. 2012;79(17):1809-1816. doi:10.1212/WNL.0b013e3182704056</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182704056</ArticleId><ArticleId IdType="pmc">PMC3475623</ArticleId><ArticleId IdType="pubmed">23019259</ArticleId></ArticleIdList></Reference><Reference><Citation>Headley A, De Leon-Benedetti A, Dong C, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Neurogranin as a predictor of memory and executive function decline in MCI patients. Neurology. 2018;90(10):e887-e895. doi:10.1212/WNL.0000000000005057</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005057</ArticleId><ArticleId IdType="pmc">PMC5863492</ArticleId><ArticleId IdType="pubmed">29429972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. ; Contributors . NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30464338</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>563</Volume><Issue>7733</Issue><PubDate><Year>2018</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Somatic APP gene recombination in Alzheimer's disease and normal neurons.</ArticleTitle><Pagination><StartPage>639</StartPage><EndPage>645</EndPage><MedlinePgn>639-645</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-018-0718-6</ELocationID><Abstract><AbstractText>The diversity and complexity of the human brain are widely assumed to be encoded within a constant genome. Somatic gene recombination, which changes germline DNA sequences to increase molecular diversity, could theoretically alter this code but has not been documented in the brain, to our knowledge. Here we describe recombination of the Alzheimer's disease-related gene APP, which encodes amyloid precursor protein, in human neurons, occurring mosaically as thousands of variant 'genomic cDNAs' (gencDNAs). gencDNAs lacked introns and ranged from full-length cDNA copies of expressed, brain-specific RNA splice variants to myriad smaller forms that contained intra-exonic junctions, insertions, deletions, and/or single nucleotide variations. DNA in situ hybridization identified gencDNAs within single neurons that were distinct from wild-type loci and absent from non-neuronal cells. Mechanistic studies supported neuronal 'retro-insertion' of RNA to produce gencDNAs; this process involved transcription, DNA breaks, reverse transcriptase activity, and age. Neurons from individuals with sporadic Alzheimer's disease showed increased gencDNA diversity, including eleven mutations known to be associated with familial Alzheimer's disease that were absent from healthy neurons. Neuronal gene recombination may allow 'recording' of neural activity for selective 'playback' of preferred gene variants whose expression bypasses splicing; this has implications for cellular diversity, learning and memory, plasticity, and diseases of the human brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ming-Hsiang</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddoway</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Gwendolyn E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Program, School of Medicine, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segota</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romanow</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Christine S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Program, School of Medicine, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Program, School of Medicine, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Jerold</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. jchun@sbpdiscovery.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007752</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.7</RegistryNumber><NameOfSubstance UI="D004259">DNA-Directed DNA Polymerase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2018 Nov;563(7733):631-632. doi: 10.1038/d41586-018-07334-9.</RefSource><PMID Version="1">30478369</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2019 Feb;566(7743):E6. doi: 10.1038/s41586-019-0905-0.</RefSource><PMID Version="1">30670873</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Exp Neurosci. 2019 May 16;13:1179069519849669. doi: 10.1177/1179069519849669.</RefSource><PMID Version="1">31205422</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Aug;584(7821):E20-E28. doi: 10.1038/s41586-020-2522-3.</RefSource><PMID Version="1">32814883</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004259" MajorTopicYN="N">DNA-Directed DNA Polymerase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011995" MajorTopicYN="Y">Recombination, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30464338</ArticleId><ArticleId IdType="mid">NIHMS1003498</ArticleId><ArticleId IdType="pmc">PMC6391999</ArticleId><ArticleId IdType="doi">10.1038/s41586-018-0718-6</ArticleId><ArticleId IdType="pii">10.1038/s41586-018-0718-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dreyer WJ, Gray WR &amp; Hood L The genetic, molecular and cellular basis of antibody formation: some facts and a unifying hypothesis. Cold Spring Harbor Symp. Quant. Biol 32, 353&#x2013;367 (1967).</Citation></Reference><Reference><Citation>Hozumi N &amp; Tonegawa S Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci U S A 73, 3628&#x2013;3632 (1976).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC431171</ArticleId><ArticleId IdType="pubmed">824647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun JJ, Schatz DG, Oettinger MA, Jaenisch R &amp; Baltimore D The recombination activating gene-1 (RAG-1) transcript is present in the murine central nervous system. Cell 64,189&#x2013;200 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1986864</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck L &amp; Axel R A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. Cell 65,175&#x2013;187 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1840504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q &amp; Maniatis T A striking organization of a large family of human neural caderhin-like cell adhesion genes. Cell 97, 779&#x2013;790 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10380929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori D, Millard SS, Wojtowicz WM &amp; Zipursky SL Dscam-mediated cell recognition regulates neural circuit formation. Annu Rev Cell Dev Biol 24, 597&#x2013;620, doi:10.1146/annurev.cellbio.24.110707.175250 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.24.110707.175250</ArticleId><ArticleId IdType="pmc">PMC2711549</ArticleId><ArticleId IdType="pubmed">18837673</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehen SK et al. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proc Natl Acad Sci US A 98,13361&#x2013;13366 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60876</ArticleId><ArticleId IdType="pubmed">11698687</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra JW et al. Neuronal DNA content variation (DCV) with regional and individual differences in the human brain. J Comp Neurol 518, 3981&#x2013;4000, doi:10.1002/cne.22436 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.22436</ArticleId><ArticleId IdType="pmc">PMC2932632</ArticleId><ArticleId IdType="pubmed">20737596</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehen SK et al. Constitutional aneuploidy in the normal human brain. J Neurosci 25, 2176&#x2013;2180 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726097</ArticleId><ArticleId IdType="pubmed">15745943</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell MJ et al. Mosaic copy number variation in human neurons. Science 342, 632&#x2013;637, doi:10.1126/science.1243472 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1243472</ArticleId><ArticleId IdType="pmc">PMC3975283</ArticleId><ArticleId IdType="pubmed">24179226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gole J et al. Massively parallel polymerase cloning and genome sequencing of single cells using nanoliter microwells. Nature biotechnology 31,1126&#x2013;1132, doi:10.1038/nbt.2720 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2720</ArticleId><ArticleId IdType="pmc">PMC3875318</ArticleId><ArticleId IdType="pubmed">24213699</ArticleId></ArticleIdList></Reference><Reference><Citation>Erwin JA et al. Ll-associated genomic regions are deleted in somatic cells of the healthy human brain. Nat Neurosci 19,1583&#x2013;1591, doi:10.1038/nn.4388 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4388</ArticleId><ArticleId IdType="pmc">PMC5127747</ArticleId><ArticleId IdType="pubmed">27618310</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazen JL et al. The Complete Genome Sequences, Unique Mutational Spectra, and Developmental Potency of Adult Neurons Revealed by Cloning. Neuron 89,1223&#x2013;1236, doi:10.1016/j.neuron.2016.02.004 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.02.004</ArticleId><ArticleId IdType="pmc">PMC4795965</ArticleId><ArticleId IdType="pubmed">26948891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodato MA et al. Somatic mutation in single human neurons tracks developmental and transcriptional history. Science 350, 94&#x2013;98, doi:10.1126/science.aab1785 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab1785</ArticleId><ArticleId IdType="pmc">PMC4664477</ArticleId><ArticleId IdType="pubmed">26430121</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson SE et al. Aneuploid cells are differentially susceptible to caspase-mediated death during embryonic cerebral cortical development. J Neurosci 32,16213&#x2013;16222, doi:10.1523/JNEUR0SCI.3706-12.2012 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUR0SCI.3706-12.2012</ArticleId><ArticleId IdType="pmc">PMC3614491</ArticleId><ArticleId IdType="pubmed">23152605</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushal D et al. Alteration of gene expression by chromosome loss in the postnatal mouse brain. J Neurosci 23, 5599&#x2013;5606 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741244</ArticleId><ArticleId IdType="pubmed">12843262</ArticleId></ArticleIdList></Reference><Reference><Citation>Evrony GD et al. Cell lineage analysis in human brain using endogenous retroelements. Neuron 85, 49&#x2013;59, doi:10.1016/j.neuron.2014.12.028 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.028</ArticleId><ArticleId IdType="pmc">PMC4299461</ArticleId><ArticleId IdType="pubmed">25569347</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushman DM et al. Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer&#x2019;s disease brains. Elife 4, doi:10.7554/eLife.05116 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.05116</ArticleId><ArticleId IdType="pmc">PMC4337608</ArticleId><ArticleId IdType="pubmed">25650802</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrell J, Farlow M, Ghetti B &amp; Benson MD A mutation in the amyloid precursor protein associated with hereditary Alzheimer&#x2019;s disease. Science 254, 97&#x2013;99 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1925564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M et al. A pathogenic mutation for probable Alzheimer&#x2019;s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1,345&#x2013;347, doi:10.1038/ng0892-345 (1992).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0892-345</ArticleId><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooli BV et al. Rare autosomal copy number variations in early-onset familial Alzheimer&#x2019;s disease. Mol Psychiatry 19, 676&#x2013;681, doi:10.1038/mp.2013.77 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.77</ArticleId><ArticleId IdType="pubmed">23752245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiseman FK et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci 16, 564&#x2013;574, doi:10.1038/nrn3983 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3983</ArticleId><ArticleId IdType="pmc">PMC4678594</ArticleId><ArticleId IdType="pubmed">26243569</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ &amp; Hardy J The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med 8, 595&#x2013;608, doi:10.15252/emmm.201606210 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X et al. Single-cell, genome-wide sequencing identifies clonal somatic copy-number variation in the human brain. Cell Rep 10, 645, doi:10.1016/j.celrep.2015.01.028 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.01.028</ArticleId><ArticleId IdType="pubmed">25832109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science 352, 1586&#x2013;1590, doi:10.1126/science.aaf1204 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1204</ArticleId><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawkins E &amp; Small DH Insights into the physiological function of the beta-amyloid precursor protein: beyond Alzheimer&#x2019;s disease. J Neurochem 129, 756&#x2013;769, doi:10.1111/jnc.12675 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12675</ArticleId><ArticleId IdType="pmc">PMC4314671</ArticleId><ArticleId IdType="pubmed">24517464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kujawa Steve, E. J, Eng Kevin, Hon Ting, Tseng Elizabeth, Wenger Aaron, Giorda Kristina, Wang Jiashi, &amp; Jarosz Mirna. A Method for the Identification of Variants in Alzheimer&#x2019;s Disease Candidate Genes and Transcripts Using Hybridization Capture Combined with Long-Read Sequencing. (2017).</Citation></Reference><Reference><Citation>The Alzheimer brain Iso-Seq dataset was generated by Pacific Biosciences, Menlo Park, California, and additional information about the sequencing and analysis
is provided at https://downloads.pacbcloud.com/public/dataset/Alzheimer_IsoSeq_2016/. The data used in the present study was retrieved from PacBio&#x2019;s online database at 
https://downloads.pacbcloud.com/public/dataset/Alzheimer_IsoSeq_2016/. (2016).</Citation></Reference><Reference><Citation>Roberts RJ, Carneiro MO &amp; Schatz MC The advantages of SMRT sequencing. Genome biology 14, 405, doi:10.1186/gb-2013-14-6-405 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2013-14-6-405</ArticleId><ArticleId IdType="pmc">PMC3953343</ArticleId><ArticleId IdType="pubmed">23822731</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid J et al. Real-time DNA sequencing from single polymerase molecules. Science 323, 133&#x2013;138, doi:10.1126/science.1162986 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1162986</ArticleId><ArticleId IdType="pubmed">19023044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L et al. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20, 4050&#x2013;4058 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming GL &amp; Song H Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70, 687&#x2013;702, doi:10.1016/j.neuron.2011.05.001 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.05.001</ArticleId><ArticleId IdType="pmc">PMC3106107</ArticleId><ArticleId IdType="pubmed">21609825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj RD et al. Neocortical neurogenesis in humans is restricted to development. Proc Natl Acad Sci U S A 103, 12564&#x2013;12568, doi:10.1073/pnas.0605177103 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605177103</ArticleId><ArticleId IdType="pmc">PMC1567918</ArticleId><ArticleId IdType="pubmed">16901981</ArticleId></ArticleIdList></Reference><Reference><Citation>Esnault C, Maestre J &amp; Heidmann T Human LINE retrotransposons generate processed pseudogenes. Nat Genet 24, 363&#x2013;367, doi:10.1038/74184 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/74184</ArticleId><ArticleId IdType="pubmed">10742098</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison PM, Zheng D, Zhang Z, Carriero N &amp; Gerstein M Transcribed processed pseudogenes in the human genome: an intermediate form of expressed retrosequence lacking protein-coding ability. Nucleic acids research 33, 2374&#x2013;2383, doi:10.1093/nar/gki531 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki531</ArticleId><ArticleId IdType="pmc">PMC1087782</ArticleId><ArticleId IdType="pubmed">15860774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyana-Sundaram S et al. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell 149, 1622&#x2013;1634, doi:10.1016/j.cell.2012.04.041 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.04.041</ArticleId><ArticleId IdType="pmc">PMC3597446</ArticleId><ArticleId IdType="pubmed">22726445</ArticleId></ArticleIdList></Reference><Reference><Citation>Muotri AR et al. Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. Nature 435, 903&#x2013;910, doi:10.1038/nature03663 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03663</ArticleId><ArticleId IdType="pubmed">15959507</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton KR et al. Ubiquitous L1 mosaicism in hippocampal neurons. Cell 161, 228&#x2013;239, doi:10.1016/j.cell.2015.03.026 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.03.026</ArticleId><ArticleId IdType="pmc">PMC4398972</ArticleId><ArticleId IdType="pubmed">25860606</ArticleId></ArticleIdList></Reference><Reference><Citation>Evrony GD, Lee E, Park PJ &amp; Walsh CA Resolving rates of mutation in the brain using single-neuron genomics. Elife 5, doi:10.7554/eLife.12966 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.12966</ArticleId><ArticleId IdType="pmc">PMC4805530</ArticleId><ArticleId IdType="pubmed">26901440</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston BD, Poiesz BJ &amp; Loeb LA Fidelity of HIV-1 reverse transcriptase. Science 242, 1168&#x2013;1171 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2460924</ArticleId></ArticleIdList></Reference><Reference><Citation>Madabhushi R et al. Activity-Induced DNA Breaks Govern the Expression of Neuronal Early-Response Genes. Cell 161, 1592&#x2013;1605, doi:10.1016/j.cell.2015.05.032 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.05.032</ArticleId><ArticleId IdType="pmc">PMC4886855</ArticleId><ArticleId IdType="pubmed">26052046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei PC et al. Long Neural Genes Harbor Recurrent DNA Break Clusters in Neural Stem/Progenitor Cells. Cell 164, 644&#x2013;655, doi:10.1016/j.cell.2015.12.039 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.039</ArticleId><ArticleId IdType="pmc">PMC4752721</ArticleId><ArticleId IdType="pubmed">26871630</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaschke AJ, Weiner JA &amp; Chun J Programmed cell death is a universal feature of embryonic and postnatal neuroproliferative regions throughout the central nervous system. J Comp Neurol 396, 39&#x2013;50 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9623886</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaschke AJ, Staley K &amp; Chun J Widespread programmed cell death in proliferative and postmitotic regions of the fetal cerebral cortex. Devehpm 122, 1165&#x2013;1174 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8620843</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberbielle E et al. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-beta. Nat Neurosci 16, 613&#x2013;621, doi:10.1038/nn.3356 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3356</ArticleId><ArticleId IdType="pmc">PMC3637871</ArticleId><ArticleId IdType="pubmed">23525040</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YA, Zhou B, Wernig M &amp; Sudhof TC ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion. Cell 168, 427&#x2013;441 e421, doi:10.1016/j.cell.2016.12.044 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.12.044</ArticleId><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A &amp; Vale RD RNA phase transitions in repeat expansion disorders. Nature 546, 243&#x2013;247, doi:10.1038/nature22386 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22386</ArticleId><ArticleId IdType="pmc">PMC5555642</ArticleId><ArticleId IdType="pubmed">28562589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H &amp; Koo EH The amyloid precursor protein: beyond amyloid. Molecular murodegemration 1,5, doi:10.1186/1750-1326-1-5 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-1-5</ArticleId><ArticleId IdType="pmc">PMC1538601</ArticleId><ArticleId IdType="pubmed">16930452</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori D et al. Robust discrimination between self and non-self neurites requires thousands of Dscaml isoforms. Nature 461, 644&#x2013;648, doi:10.1038/nature08431 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08431</ArticleId><ArticleId IdType="pmc">PMC2836808</ArticleId><ArticleId IdType="pubmed">19794492</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman-Karlsson MC, Meadows JP, Gavin CF, Hablitz JJ &amp; Sweatt JD Transcriptional and epigenetic regulation of Hebbian and non-Hebbian plasticity. Neurophamacology 80, 3&#x2013;17, doi:10.1016/j.neuropharm.2014.01.001 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2014.01.001</ArticleId><ArticleId IdType="pmc">PMC3984596</ArticleId><ArticleId IdType="pubmed">24418102</ArticleId></ArticleIdList></Reference><Reference><Citation>West AE &amp; Greenberg ME Neuronal activity-regulated gene transcription in synapse development and cognitive function. Cold Spring Harbor perspectives in biohgy 3, doi:10.1101/cshperspect.a005744 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a005744</ArticleId><ArticleId IdType="pmc">PMC3098681</ArticleId><ArticleId IdType="pubmed">21555405</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30482868</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e9712</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201809712</ELocationID><Abstract><AbstractText>Progranulin (PGRN) is predominantly expressed by microglia in the brain, and genetic and experimental evidence suggests a critical role in Alzheimer's disease (AD). We asked whether PGRN expression is changed in a disease severity-specific manner in AD We measured PGRN in cerebrospinal fluid (CSF) in two of the best-characterized AD patient cohorts, namely the Dominant Inherited Alzheimer's Disease Network (DIAN) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). In carriers of AD causing dominant mutations, cross-sectionally assessed CSF PGRN increased over the course of the disease and significantly differed from non-carriers 10&#xa0;years before the expected symptom onset. In late-onset AD, higher CSF PGRN was associated with more advanced disease stages and cognitive impairment. Higher CSF PGRN was associated with higher CSF soluble TREM2 (triggering receptor expressed on myeloid cells 2) only when there was underlying pathology, but not in controls. In conclusion, we demonstrate that, although CSF PGRN is not a diagnostic biomarker for AD, it may together with sTREM2 reflect microglial activation during the disease.</AbstractText><CopyrightInformation>&#xa9; 2018 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su&#xe1;rez-Calvet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2993-569X</Identifier><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany msuarez@barcelonabeta.org christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araque Caballero</LastName><ForeName>Miguel &#xc1;ngel</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morenas-Rodr&#xed;guez</LastName><ForeName>Estrella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Institut d'Investigacions Biom&#xe8;diques, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fellerer</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzmeier</LastName><ForeName>Nicolai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5811-8226</Identifier><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eren</LastName><ForeName>Erden</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Izmir International Biomedicine and Genome Institute Dokuz, Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Institute of Health Sciences, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deming</LastName><ForeName>Yuetiva</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7512-5703</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccio</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paumier</LastName><ForeName>Katrina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9045-1072</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Vic., Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany msuarez@barcelonabeta.org christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058922</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">progranulin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30482868</ArticleId><ArticleId IdType="pmc">PMC6284390</ArticleId><ArticleId IdType="doi">10.15252/emmm.201809712</ArticleId><ArticleId IdType="pii">emmm.201809712</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S et&#xa0;al (2010) Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol 177: 311&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC et&#xa0;al (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270&#x2013;279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering&#x2010;Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S et&#xa0;al (2006) Mutations in progranulin cause tau&#x2010;negative frontotemporal dementia linked to chromosome 17. Nature 442: 916&#x2013;919</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman A, Belcourt D, Bennett H, Lazure C, Solomon S (1990) Granulins, a novel class of peptide from leukocytes. Biochem Biophys Res Commun 173: 1161&#x2013;1168</Citation><ArticleIdList><ArticleId IdType="pubmed">2268320</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM et&#xa0;al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795&#x2013;804</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Berghoff M, Hochberg A, Schmid A, Schlegel J, Karrasch T, Kaps M, Sch&#xe4;ffler A (2016) Quantification and regulation of the adipokines resistin and progranulin in human cerebrospinal fluid. Eur J Clin Invest 46: 15&#x2013;26</Citation><ArticleIdList><ArticleId IdType="pubmed">26509463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari V, Palfree RG, Bateman A (1992) Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine&#x2010;rich granulin domains. Proc Natl Acad Sci USA 89: 1715&#x2013;1719</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48523</ArticleId><ArticleId IdType="pubmed">1542665</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Sleegers K, Engelborghs S, Maurer&#x2010;Stroh S, Gijselinck I, van der Zee J, Pickut BA, Van den Broeck M, Mattheijssens M, Peeters K et&#xa0;al (2008) Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71: 656&#x2013;664</Citation><ArticleIdList><ArticleId IdType="pubmed">18565828</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, Lammich S, Gijselinck I, Bittner T, Carlson AM, Sasse F et&#xa0;al (2011) Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci 31: 1885&#x2013;1894</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623716</ArticleId><ArticleId IdType="pubmed">21289198</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE et&#xa0;al (2015) Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 84: 508&#x2013;515</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336071</ArticleId><ArticleId IdType="pubmed">25568301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC, Srinivasan K, Friedman BA, Suto E, Modrusan Z, Lee WP, Kaminker JS, Hansen DV, Sheng M (2017) Progranulin deficiency causes impairment of autophagy and TDP&#x2010;43 accumulation. J Exp Med 214: 2611&#x2013;2628</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584112</ArticleId><ArticleId IdType="pubmed">28778989</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Wang Y (2016) TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17: 201&#x2013;207</Citation><ArticleIdList><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D et&#xa0;al (2012) Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 6: 502&#x2013;516</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Chakraverty S, Mayo K, Vallania FL, Mitra RD, Faber K, Williamson J, Bird T, Diaz&#x2010;Arrastia R, Foroud TM et&#xa0;al (2012) Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late&#x2010;onset Alzheimer's disease families. PLoS ONE 7: e31039</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ et&#xa0;al (2006) Null mutations in progranulin cause ubiquitin&#x2010;positive frontotemporal dementia linked to chromosome 17q21. Nature 442: 920&#x2013;924</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Brooks DJ, Edison P (2017) Suspected non&#x2010;Alzheimer's pathology &#x2013; Is it non&#x2010;Alzheimer's or non&#x2010;amyloid? Ageing Res Rev 36: 20&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">28235659</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel R, He Z, Carmichael KP, Halper J, Bateman A (2000) Cellular localization of gene expression for progranulin. J Histochem Cytochem 48: 999&#x2013;1009</Citation><ArticleIdList><ArticleId IdType="pubmed">10858277</ArticleId></ArticleIdList></Reference><Reference><Citation>De Riz M, Galimberti D, Fenoglio C, Piccio LM, Scalabrini D, Venturelli E, Pietroboni A, Piola M, Naismith RT, Parks BJ et&#xa0;al (2010) Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neurosci Lett 469: 234&#x2013;236</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893414</ArticleId><ArticleId IdType="pubmed">19963041</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R et&#xa0;al (2014) Longitudinal change in CSF biomarkers in autosomal&#x2010;dominant Alzheimer's disease. Sci Transl Med 6: 226ra30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Steinacker P, Volk AE, Weishaupt JH, Wollmer MA, Boxer A, Tumani H, Ludolph AC, Otto M (2016) Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. J Neural Transm 123: 289&#x2013;296</Citation><ArticleIdList><ArticleId IdType="pubmed">26659729</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenoglio C, Galimberti D, Cortini F, Kauwe JS, Cruchaga C, Venturelli E, Villa C, Serpente M, Scalabrini D, Mayo K et&#xa0;al (2009) Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. J Alzheimer's Dis 18: 603&#x2013;612</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842455</ArticleId><ArticleId IdType="pubmed">19625741</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, Diaz&#x2010;Ramirez G, Jiao J, Zhang Z, Huang EJ, Gao FB et&#xa0;al (2013) Dissociation of frontotemporal dementia&#x2010;related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci 33: 5352&#x2013;5361</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet&#x2010;Lecrux A, Boeve B, Petersen RC et&#xa0;al (2009) Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132: 583&#x2013;591</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664450</ArticleId><ArticleId IdType="pubmed">19158106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S et&#xa0;al (2002) Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33: 341&#x2013;355</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G (2008) Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71: 1235&#x2013;1239</Citation><ArticleIdList><ArticleId IdType="pubmed">18768919</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, Curtis SM, Mungas D, Crane PK, Alzheimer's Disease Neuroimaging Initiative (2012) A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with&#xa0;baseline mild cognitive impairment. Brain Imaging Behav 6: 517&#x2013;527</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Gispert JD, Su&#xe1;rez&#x2010;Calvet M, Mont&#xe9; GC, Tucholka A, Falcon C, Rojas S, Rami L, S&#xe1;nchez&#x2010;Valle R, Llad&#xf3; A, Kleinberger G et&#xa0;al (2016) Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's Dement 12: 1259&#x2013;1272</Citation><ArticleIdList><ArticleId IdType="pubmed">27423963</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, Janssens J, van der Zee J, Lang CM, Kremmer E et&#xa0;al (2014) Common pathobiochemical hallmarks of progranulin&#x2010;associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol 127: 845&#x2013;860</Citation><ArticleIdList><ArticleId IdType="pubmed">24619111</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tzl JK, Lang CM, Haass C, Capell A (2016) Impaired protein degradation in FTLD and related disorders. Ageing Res Rev 32: 122&#x2013;139</Citation><ArticleIdList><ArticleId IdType="pubmed">27166223</ArticleId></ArticleIdList></Reference><Reference><Citation>Habeck C, Risacher S, Lee GJ, Glymour MM, Mormino E, Mukherjee S, Kim S, Nho K, DeCarli C, Saykin AJ et&#xa0;al (2012) Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav 6: 568&#x2013;583</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532575</ArticleId><ArticleId IdType="pubmed">23179062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R et&#xa0;al (2018) CSF biomarkers of Alzheimer's disease concord with amyloid&#x2010;&#x3b2; PET and predict clinical progression: a study of fully automated immunoassays&#xa0;in BioFINDER and ADNI cohorts. Alzheimer's Dement 14: 1470&#x2013;1481</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss&#x2010;Coray T, Vitorica J, Ransohoff RM et&#xa0;al (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14: 388&#x2013;405</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Henjum K, Almdahl IS, &#xc5;rskog V, Minthon L, Hansson O, Fladby T, Nilsson LN (2016) Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res Ther 8: 17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848774</ArticleId><ArticleId IdType="pubmed">27121148</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, &#xd6;hrfelt A, Blennow K, Hardy J, Schott J et&#xa0;al (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener 11: 3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ, Taylor G, Deng Q, Kukar T (2017) Intracellular proteolysis of progranulin generates stable, lysosomal granulins that are haploinsufficient in patients with frontotemporal dementia caused by GRN mutations. eNeuro 4: ENEURO.0100&#x2010;17.2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562298</ArticleId><ArticleId IdType="pubmed">28828399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosokawa M, Arai T, Masuda&#x2010;Suzukake M, Kondo H, Matsuwaki T, Nishihara M, Hasegawa M, Akiyama H (2015) Progranulin reduction is associated with increased Tau phosphorylation in P301L Tau transgenic mice. J Neuropathol Exp Neurol 74: 158&#x2013;165</Citation><ArticleIdList><ArticleId IdType="pubmed">25575133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosokawa M, Tanaka Y, Arai T, Kondo H, Akiyama H, Hasegawa M (2018) Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice. Exp Anim 67: 63&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814315</ArticleId><ArticleId IdType="pubmed">28845019</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, Padukkavidana T, V&#xe6;gter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM (2010) Sortilin&#x2010;mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68: 654&#x2013;667</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990962</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId></ArticleIdList></Reference><Reference><Citation>Huchtemann T, K&#xf6;rtv&#xe9;lyessy P, Feistner H, Heinze HJ, Bittner D (2015) Progranulin levels in status epilepticus as a marker of neuronal recovery and neuroprotection. Epilepsy Behav 49: 170&#x2013;172</Citation><ArticleIdList><ArticleId IdType="pubmed">26211941</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ et&#xa0;al (2012) An operational approach to National Institute on Aging&#x2010;Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71: 765&#x2013;775</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS et&#xa0;al (2016a) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87: 539&#x2013;547</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Ch&#xe9;telat G, Dickson D, Fagan AM, Frisoni GB, Jagust W, Mormino EC, Petersen RC, Sperling RA et&#xa0;al (2016b) Suspected non&#x2010;Alzheimer disease pathophysiology &#x2014; concept and controversy. Nat Rev Neurol 12: 117&#x2013;124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4784257</ArticleId><ArticleId IdType="pubmed">26782335</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K et&#xa0;al (2017) Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's Dement 13: 205&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J et&#xa0;al (2018) NIA&#x2010;AA research framework: toward a biological definition of Alzheimer's disease. Alzheimer's Dement 14: 535&#x2013;562</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren&#x2010;Shaul H, Spinrad A, Weiner A, Matcovitch&#x2010;Natan O, Dvir&#x2010;Szternfeld R, Ulland TK, David E, Baruch K, Lara&#x2010;Astaiso D, Toth B et&#xa0;al (2017) A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169: 1276&#x2013;1290.e17</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura A, Takemura M, Saito K, Serrero G, Yoshikura N, Hayashi Y, Inuzuka T (2017) Increased cerebrospinal fluid progranulin correlates with interleukin&#x2010;6 in the acute phase of neuromyelitis optica spectrum disorder. J Neuroimmunol 305: 175&#x2013;181</Citation><ArticleIdList><ArticleId IdType="pubmed">28100408</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Capell A, Haass C, Van Broeckhoven C (2013) Mechanisms of granulin deficiency: lessons from cellular and animal models. Mol Neurobiol 47: 337&#x2013;360</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538123</ArticleId><ArticleId IdType="pubmed">23239020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Su&#xe1;rez&#x2010;Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger&#x2010;Weinzierl A, Mazaheri F et&#xa0;al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra86</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, Focke C, Deu&#xdf;ing M, Su&#xe1;rez&#x2010;Calvet M, Mazaheri F et&#xa0;al (2017) The FTD&#x2010;like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J 36: 1837&#x2013;1853</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494459</ArticleId><ArticleId IdType="pubmed">28559417</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rtv&#xe9;lyessy P, Gukasjan A, Sweeney&#x2010;Reed CM, Heinze HJ, Thurner L, Bittner DM (2015) Progranulin and amyloid&#x2010;&#x3b2; levels: relationship to neuropsychology in frontotemporal and Alzheimer's disease. J Alzheimer's Dis 46: 375&#x2013;380</Citation><ArticleIdList><ArticleId IdType="pubmed">25777512</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Fatimy RE, Beckers L, Loughlin EO, Xu Y, Greco DJ, Smith ST et&#xa0;al (2017) The TREM2&#x2010;APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47: 566&#x2013;581.e9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ (2011) Associations between cognitive, functional, and FDG&#x2010;PET measures of decline in AD and MCI. Neurobiol Aging 32: 1207&#x2013;1218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MJ, Chen TF, Cheng TW, Chiu MJ (2011) rs5848 variant of progranulin gene is a risk of Alzheimer's disease in the Taiwanese population. Neurodegener Dis 8: 216&#x2013;220</Citation><ArticleIdList><ArticleId IdType="pubmed">21212639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, Shang Y, Oldham MC, Martens LH, Gao F et&#xa0;al (2016) Progranulin deficiency promotes circuit&#x2010;specific synaptic pruning by microglia via complement activation. Cell 165: 921&#x2013;935</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D (2014) Neuroinflammation: the role and consequences. Neurosci Res 79: 1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">24144733</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, Min SW, Gan L, Finkbeiner S, Huang EJ et&#xa0;al (2012) Progranulin deficiency promotes neuroinflammation and neuron loss following toxin&#x2010;induced injury. J Clin Invest 122: 3955&#x2013;3959</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateo I, Gonz&#xe1;lez&#x2010;Aramburu I, Pozueta A, V&#xe1;zquez&#x2010;Higuera JL, Rodr&#xed;guez&#x2010;Rodr&#xed;guez E, S&#xe1;nchez&#x2010;Juan P, Calero M, Dobato JL, Infante J, Berciano J et&#xa0;al (2013) Reduced serum progranulin level might be associated with Parkinson's disease risk. Eur J Neurol 20: 1571&#x2013;1573</Citation><ArticleIdList><ArticleId IdType="pubmed">23398167</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Tr&#xfc;mbach D, Wurst W et&#xa0;al (2017) TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep 18: 1186&#x2013;1198</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R et&#xa0;al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263&#x2013;269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Patzke H, Loewen G, Dopper EG, Pijnenburg YA, van Minkelen R, van Swieten JC (2016) Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers. Dement Geriatr Cogn Dis Extra 6: 330&#x2013;340</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5040889</ArticleId><ArticleId IdType="pubmed">27703466</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH, Elia LP, Ward ME et&#xa0;al (2014) Progranulin protects against amyloid &#x3b2; deposition and toxicity in Alzheimer's disease mouse models. Nat Med 20: 1157&#x2013;1164</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4196723</ArticleId><ArticleId IdType="pubmed">25261995</ArticleId></ArticleIdList></Reference><Reference><Citation>Molgaard S, Demontis D, Nicholson AM, Finch NA, Petersen RC, Petersen CM, Rademakers R, Nykjaer A, Glerup S (2016) Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals. Exp Gerontol 84: 96&#x2013;100</Citation><ArticleIdList><ArticleId IdType="pubmed">27612602</ArticleId></ArticleIdList></Reference><Reference><Citation>Monserrate AE, Ryman DC, Ma S, Xiong C, Noble JM, Ringman JM, Morris JC, Danek A, M&#xfc;ller&#x2010;Sarnowski F, Clifford DB et&#xa0;al (2015) Factors associated with the onset and persistence of post&#x2010;lumbar puncture headache. JAMA Neurol 72: 325&#x2013;332</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364538</ArticleId><ArticleId IdType="pubmed">25622095</ArticleId></ArticleIdList></Reference><Reference><Citation>Morenas&#x2010;Rodr&#xed;guez E, Cervera&#x2010;Carles L, Vilaplana E, Alcolea D, Carmona&#x2010;Iragui M, Dols&#x2010;Icardo O, Ribosa&#x2010;Nogu&#xe9; R, Mu&#xf1;oz&#x2010;Llahuna L, Sala I, Bel&#xe9;n S&#xe1;nchez&#x2010;Saudin&#xf3;s M et&#xa0;al (2015) Progranulin protein levels in cerebrospinal fluid in primary neurodegenerative dementias. J Alzheimer's Dis 50: 539&#x2013;546</Citation><ArticleIdList><ArticleId IdType="pubmed">26682689</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43: 2412&#x2013;2414</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE et&#xa0;al (2012) Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. Clin Invest 2: 975&#x2013;984</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Naphade SB, Kigerl KA, Jakeman LB, Kostyk SK, Popovich PG, Kuret J (2010) Progranulin expression is upregulated after spinal contusion in mice. Acta Neuropathol 119: 123&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4290888</ArticleId><ArticleId IdType="pubmed">19946692</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM et&#xa0;al (2006) Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Finch NA, Thomas CS, Wojtas A, Rutherford NJ, Mielke MM, Roberts RO, Boeve BF, Knopman DS, Petersen RC et&#xa0;al (2014) Progranulin protein levels are differently regulated in plasma and CSF. Neurology 82: 1871&#x2013;1878</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105255</ArticleId><ArticleId IdType="pubmed">24771538</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereson S, Wils H, Kleinberger G, McGowan E, Vandewoestyne M, Van Broeck B, Joris G, Cuijt I, Deforce D, Hutton M et&#xa0;al (2009) Progranulin expression correlates with dense&#x2010;core amyloid plaque burden in Alzheimer disease mouse models. J Pathol 219: 173&#x2013;181</Citation><ArticleIdList><ArticleId IdType="pubmed">19557827</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW et&#xa0;al (2010) Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74: 201&#x2013;209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, Neal SJ, Orban PC, MacDonald JL, Hill AM, Lu G, Feldman HH, Mackenzie IR, Leavitt BR (2010) Progranulin expression in the developing and adult murine brain. J Comp Neurol 518: 3931&#x2013;3947</Citation><ArticleIdList><ArticleId IdType="pubmed">20737593</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, De Muynck L, Thu HN, Weynants B, Vanacker P, Dhondt J, Sleegers K, Schelhaas HJ, Verbeek M, Vandenberghe R et&#xa0;al (2010) Microglial upregulation of progranulin as a marker of motor neuron degeneration. J Neuropathol Exp Neurol 69: 1191&#x2013;1200</Citation><ArticleIdList><ArticleId IdType="pubmed">21107132</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del&#x2010;&#xc1;guila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131: 925&#x2013;933</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ, Crook RJ, Josephs KA et&#xa0;al (2008) Common variation in the miR&#x2010;659 binding&#x2010;site of GRN is a major risk factor for TDP43&#x2010;positive frontotemporal dementia. Hum Mol Genet 17: 3631&#x2013;3642</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581433</ArticleId><ArticleId IdType="pubmed">18723524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta&#x2010;Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB et&#xa0;al (2014) Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta&#x2010;analysis. Neurology 83: 253&#x2013;260</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber S, Debska&#x2010;Vielhaber G, Abdulla S, Machts J, Schreiber F, Kropf S, K&#xd6;rtvelyessy P, K&#xd6;rner S, Kollewe K, Petri S et&#xa0;al (2018) Peripheral nerve atrophy together with higher cerebrospinal fluid progranulin indicate axonal damage in amyotrophic lateral sclerosis. Muscle Nerve 57: 273&#x2013;278</Citation><ArticleIdList><ArticleId IdType="pubmed">28472860</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng J, Su L, Xu Z, Chen G (2014) Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer's disease. Gene 542: 141&#x2013;145</Citation><ArticleIdList><ArticleId IdType="pubmed">24680777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, Peeters K, Mattheijssens M, Cruts M, Vandenberghe R et&#xa0;al (2009) Serum biomarker for progranulin&#x2010;associated frontotemporal lobar degeneration. Ann Neurol 65: 603&#x2013;609</Citation><ArticleIdList><ArticleId IdType="pubmed">19288468</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF et&#xa0;al (2012) Strikingly different clinicopathological phenotypes determined by progranulin&#x2010;mutation dosage. Am J Hum Genet 90: 1102&#x2013;1107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M (2018) Humanized TREM2 mice reveal microglia&#x2010;intrinsic and &#x2010;extrinsic effects of R47H polymorphism. J Exp Med 215: 745&#x2013;760</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ et&#xa0;al (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280&#x2013;292</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Balota DA, Aschenbrenner AJ, Morris JC (2014) Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology 28: 19&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877741</ArticleId><ArticleId IdType="pubmed">24219606</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez&#x2010;Calvet M, Araque Caballero M&#xc1;, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C, Dominantly Inherited Alzheimer Network (2016a) Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8: 369ra178</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez&#x2010;Calvet M, Kleinberger G, Araque Caballero M&#xc1;, Brendel M, Rominger A, Alcolea D, Fortea J, Lle&#xf3; A, Blesa R, Gispert JD et&#xa0;al (2016b) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early&#x2010;stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8: 466&#x2013;476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh HS, Gelman BB, Lee SC (2014) Potential roles of microglial cell progranulin in HIV&#x2010;associated CNS pathologies and neurocognitive impairment. J Neuroimmune Pharmacol 9: 117&#x2013;132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930627</ArticleId><ArticleId IdType="pubmed">23959579</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, Strittmatter SM, Alzheimer's Disease Neuroimaging Initiative (2017) Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathol 133: 785&#x2013;807</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391267</ArticleId><ArticleId IdType="pubmed">28070672</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kampen JM, Kay DG (2017) Progranulin gene delivery reduces plaque burden and synaptic atrophy in a mouse model of Alzheimer's disease. PLoS ONE 12: e0182896</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570501</ArticleId><ArticleId IdType="pubmed">28837568</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercellino M, Grifoni S, Romagnolo A, Masera S, Mattioda A, Trebini C, Chiavazza C, Caligiana L, Capello E, Mancardi GL et&#xa0;al (2011) Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. Mult Scler J 17: 1194&#x2013;1201</Citation><ArticleIdList><ArticleId IdType="pubmed">21613335</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan J, M&#xe4;kinen P, Helisalmi S, Haapasalo A, Soininen H, Hiltunen M (2009) An association study between granulin gene polymorphisms and Alzheimer's disease in finnish population. Am J Med Genet Part B Neuropsychiatr Genet 150: 747&#x2013;750</Citation><ArticleIdList><ArticleId IdType="pubmed">19016491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH et&#xa0;al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160: 1061&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E et&#xa0;al (2012) The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimer's Dement 8: S1&#x2013;S68</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC et&#xa0;al (2017) Recent publications from the Alzheimer's disease neuroimaging initiative: reviewing progress toward improved AD clinical trials. Alzheimer's Dement 13: e1&#x2013;e85</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6818723</ArticleId><ArticleId IdType="pubmed">28342697</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Gillardon F, Deuschle C, Hobert MA, Jansen IE, Metzger FG, Heutink P, Gasser T, Maetzler W, Blauwendraat C et&#xa0;al (2017) Cerebrospinal fluid progranulin, but not serum progranulin, is reduced&#xa0;in GRN&#x2010;negative frontotemporal dementia. Neurodegener Dis 17: 83&#x2013;88</Citation><ArticleIdList><ArticleId IdType="pubmed">27760429</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemse EA, Durieux&#x2010;Lu S, van der Flier WM, Pijnenburg YA, de Jonge R, Teunissen CE (2016) Stability of progranulin under pre&#x2010;analytical conditions in serum and cerebrospinal fluid. J Alzheimers Dis 53: 107&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pubmed">27104901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Pereson S, Janssens J, Capell A, Van Dam D, Cuijt I, Joris G, De Deyn PP, Haass C et&#xa0;al (2012) Cellular ageing, increased mortality and FTLD&#x2010;TDP&#x2010;associated neuropathology in progranulin knockout mice. J Pathol 228: 67&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">22733568</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HM, Tan L, Wan Y, Tan MS, Zhang W, Zheng ZJ, Kong LL, Wang ZX, Jiang T, Tan L et&#xa0;al (2017) PGRN is associated with late&#x2010;onset Alzheimer's disease: a case&#x2010;control replication study and meta&#x2010;analysis. Mol Neurobiol 54: 1187&#x2013;1195</Citation><ArticleIdList><ArticleId IdType="pubmed">26820675</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF et&#xa0;al (2009) Exaggerated inflammation, impaired host defense, and neuropathology in progranulin&#x2010;deficient mice. J Exp Med 207: 117&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A (2010) Behavioral deficits and progressive neuropathology in progranulin&#x2010;deficient mice: a mouse model of frontotemporal dementia. FASEB J 24: 4639&#x2013;4647</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N et&#xa0;al (2014) An RNA&#x2010;sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34: 11929&#x2013;11947</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Xie G, Wang C, Zhang Z, Chen Q, Zhang L, Wu L, Wei Y, Ding H, Hang C et&#xa0;al (2015a) Decreased progranulin levels in patients and rats with subarachnoid hemorrhage: a potential role in inhibiting inflammation by suppressing neutrophil recruitment. J Neuroinflammation 12: 200</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4630923</ArticleId><ArticleId IdType="pubmed">26527034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, Sun Y, Hu F (2015b) Prosaposin facilitates sortilin&#x2010;independent lysosomal trafficking of progranulin. J Cell Biol 210: 991&#x2013;1002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576858</ArticleId><ArticleId IdType="pubmed">26370502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30510257</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia.</ArticleTitle><Pagination><StartPage>152</StartPage><EndPage>164</EndPage><MedlinePgn>152-164</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-018-0223-3</ELocationID><Abstract><AbstractText>Identifying the mechanisms through which genetic risk causes dementia is an imperative for new therapeutic development. Here, we apply a multistage, systems biology approach to elucidate the disease mechanisms in frontotemporal dementia. We identify two gene coexpression modules that are preserved in mice harboring mutations in MAPT, GRN and other dementia mutations on diverse genetic backgrounds. We bridge the species divide via integration with proteomic and transcriptomic data from the human brain to identify evolutionarily conserved, disease-relevant networks. We find that overexpression of miR-203, a hub of a putative regulatory microRNA (miRNA) module, recapitulates mRNA coexpression patterns associated with disease state and induces neuronal cell death, establishing this miRNA as a regulator of neurodegeneration. Using a database of drug-mediated gene expression changes, we identify small molecules that can normalize the disease-associated modules and validate this experimentally. Our results highlight the utility of an integrative, cross-species network approach to drug discovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Swarup</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-3762-2746</Identifier><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hinz</LastName><ForeName>Flora I</ForeName><Initials>FI</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rexach</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noguchi</LastName><ForeName>Ken-Ichi</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toyoshiba</LastName><ForeName>Hiroyoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oda</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirai</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center and Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Chialin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haggarty</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International Frontotemporal Dementia Genomics Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0002-7400-9097</Identifier><AffiliationInfo><Affiliation>The Penn FTD Center, Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>The Penn FTD Center, Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center and Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center and Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondou</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0003-2896-3450</Identifier><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. dhg@mednet.ucla.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. dhg@mednet.ucla.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA, USA. dhg@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100540</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105597119</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900652</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/7</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J009482/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UU_00005/12</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123192748</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>203249/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N012453/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R25 NS065723</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0502157</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0301152</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019143" MajorTopicYN="Y">Evolution, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Financial Interests. D.H.G. has received research funding from Takeda Pharmaceutical Company Limited. K.N., H.T., A.O., K.H. and S.K. are employees of Takeda Pharmaceutical Company Limited.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>Adaikalavan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nalls</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kwok</LastName><ForeName>John B J</ForeName><Initials>JBJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobson-Stone</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>William S</ForeName><Initials>WS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hodges</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piguet</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartley</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haan</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Agust&#xed;n</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boada</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Binetti</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benussi</LastName><ForeName>Luisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forloni</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albani</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serpente</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarim&#xf3;n</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blesa</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wald&#xf6;</LastName><ForeName>Maria Landqvist</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Christer</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R A</ForeName><Initials>IRA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek R</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mann</LastName><ForeName>David M A</ForeName><Initials>DMA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grafman</LastName><ForeName>Jordan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Attems</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Timothy D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKeith</LastName><ForeName>Ian G</ForeName><Initials>IG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaros</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pietrini</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huey</LastName><ForeName>Edward D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wassermann</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tierney</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baborie</LastName><ForeName>Atik</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pastor</LastName><ForeName>Pau</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortega-Cubero</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Razquin</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alonso</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perneczky</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diehl-Schmid</LastName><ForeName>Janine</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexopoulos</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurz</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainero</LastName><ForeName>Innocenzo</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubino</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinessi</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>George-Hyslop</LastName><ForeName>Peter St</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giacomina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giaccone</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlachetzki</LastName><ForeName>Johannes C M</ForeName><Initials>JCM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uphill</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pickering-Brown</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Momeni</LastName><ForeName>Parastoo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Zee</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruts</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cappa</LastName><ForeName>Stefano F</ForeName><Initials>SF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golfier</LastName><ForeName>V&#xe9;ronique</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vercelletto</LastName><ForeName>Martine</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bagnoli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piaceri</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nielsen</LastName><ForeName>J&#xf8;rgen E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hjermind</LastName><ForeName>Lena E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riemenschneider</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayhaus</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasparoni</LastName><ForeName>Gilles</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pichler</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ibach</LastName><ForeName>Bernd</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warren</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spillantini</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Huw R</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzu</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snowden</LastName><ForeName>Julie S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rollinson</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerhard</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruni</LastName><ForeName>Amalia C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maletta</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frangipane</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cupidi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernardi</LastName><ForeName>Livia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anfossi</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallo</LastName><ForeName>Maura</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conidi</LastName><ForeName>Maria Elena</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smirne</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Josephs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dopper</LastName><ForeName>Elise G P</ForeName><Initials>EGP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seelaar</LastName><ForeName>Harro</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande A L</ForeName><Initials>YAL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Logroscino</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capozzo</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novelli</LastName><ForeName>Valeria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puca</LastName><ForeName>Annibale A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franceschi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Postiglione</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milan</LastName><ForeName>Graziella</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kristiansen</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiang</LastName><ForeName>Huei-Hsin</ForeName><Initials>HH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rollin</LastName><ForeName>Adeline</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebouvier</LastName><ForeName>Thibaud</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapogiannis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30510257</ArticleId><ArticleId IdType="mid">NIHMS1507371</ArticleId><ArticleId IdType="pmc">PMC6602064</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0223-3</ArticleId><ArticleId IdType="pii">10.1038/s41591-018-0223-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hinz FI &amp; Geschwind DH Molecular Genetics of Neurodegenerative Dementias. Cold Spring Harb Perspect Biol 9, a023705 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378052</ArticleId><ArticleId IdType="pubmed">27940516</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Liu F &amp; Gong C-X Tau and neurodegenerative disease: the story so far. Nature Reviews Neurology 12, 15&#x2013;27 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26635213</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL et al. Alzheimer&#x2019;s disease. Nat Rev Dis Primers 1, 15056 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG Invited review: Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 41, 3&#x2013;23 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25495175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullane K &amp; Williams M Alzheimer&#x2019;s therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem. Pharmacol 85, 289&#x2013;305 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23178653</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary; (2013). doi:10.17226/13530</Citation><ArticleIdList><ArticleId IdType="doi">10.17226/13530</ArticleId><ArticleId IdType="pubmed">24049852</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Horvath S &amp; Geschwind DH Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Proc. Natl. Acad. Sci. U.S.A. 107, 12698&#x2013;12703 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906579</ArticleId><ArticleId IdType="pubmed">20616000</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H &amp; Kaddoumi A Effect of mouse strain as a background for Alzheimer&#x2019;s disease models on the clearance of amyloid-&#x3b2;. J Syst Integr Neurosci 2, 135&#x2013;140 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4963020</ArticleId><ArticleId IdType="pubmed">27478623</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitzner DS, Engler-Chiurazzi EB, Kotilinek LA, Ashe KH &amp; Reed MN Morris Water Maze Test: Optimization for Mouse Strain and Testing Environment. J Vis Exp e52706&#x2013;e52706 (2015). doi:10.3791/52706</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/52706</ArticleId><ArticleId IdType="pmc">PMC4545046</ArticleId><ArticleId IdType="pubmed">26132096</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM &amp; Green KN Animal models of Alzheimer disease. Cold Spring Harb Perspect Med 2, a006320&#x2013;a006320 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543097</ArticleId><ArticleId IdType="pubmed">23002015</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA &amp; Van Eldik LJ Using mice to model Alzheimer&#x2019;s dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 5, 88 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005958</ArticleId><ArticleId IdType="pubmed">24795750</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsten SL et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron 51, 549&#x2013;560 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16950154</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi T et al. Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice. Neuroscience Research 80, 76&#x2013;85 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24406748</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B &amp; Horvath S A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 4, Article17 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P &amp; Horvath S WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG &amp; Goedert M Tau protein pathology in neurodegenerative diseases. Trends in Neurosciences 21, 428&#x2013;433 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9786340</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Thu D, Waldvogel HJ, Faull RLM &amp; Luthi-Carter R Population-specific expression analysis (PSEA) reveals molecular changes in diseased brain. Nature Methods 8, 945&#x2013;947 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21983921</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Woltjer RL, Goodenbour JM, Horvath S &amp; Geschwind DH Genes and pathways underlying regional and cell type changes in Alzheimer&#x2019;s disease. Genome Med 5, 48 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706780</ArticleId><ArticleId IdType="pubmed">23705665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lage K et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nature Biotechnology 25, 309&#x2013;316 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17344885</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark C et al. BioGRID: a general repository for interaction datasets. Nucleic Acids Research 34, D535&#x2013;9 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347471</ArticleId><ArticleId IdType="pubmed">16381927</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 155, 1008&#x2013;1021 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934107</ArticleId><ArticleId IdType="pubmed">24267887</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN, Gandal MJ &amp; Geschwind DH Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat Rev Genet 16, 441&#x2013;458 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4699316</ArticleId><ArticleId IdType="pubmed">26149713</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray RZ, Wylie FG, Khromykh T, Hume DA &amp; Stow JL Syntaxin 6 and Vti1b form a novel SNARE complex, which is up-regulated in activated macrophages to facilitate exocytosis of tumor necrosis Factor-alpha. Journal of Biological Chemistry 280, 10478&#x2013;10483 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15640147</ArticleId></ArticleIdList></Reference><Reference><Citation>Gj&#xf8;rlund MD et al. Neuroligin-1 induces neurite outgrowth through interaction with neurexin-1&#x3b2; and activation of fibroblast growth factor receptor-1. The FASEB Journal 26, 4174&#x2013;4186 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22750515</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K-P et al. Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. Journal of Neuroscience 24, 10660&#x2013;10669 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730132</ArticleId><ArticleId IdType="pubmed">15564582</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski M et al. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. EMBO J 33, 2765&#x2013;2781 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282555</ArticleId><ArticleId IdType="pubmed">25319413</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessard CJ et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sj&#xf6;gren&#x2019;s syndrome. Nature Genetics 45, 1284&#x2013;1292 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867192</ArticleId><ArticleId IdType="pubmed">24097067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng ASL, Rademakers R &amp; Miller BL Frontotemporal dementia: a bridge between dementia and neuromuscular disease. Ann. N. Y. Acad. Sci 1338, 71&#x2013;93 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399703</ArticleId><ArticleId IdType="pubmed">25557955</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S et al. Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep. 17, 530&#x2013;551 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818780</ArticleId><ArticleId IdType="pubmed">26931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN et al. Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. Nature 540, 423&#x2013;427 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102905</ArticleId><ArticleId IdType="pubmed">27919067</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandal MJ et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science 359, 693&#x2013;697 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5898828</ArticleId><ArticleId IdType="pubmed">29439242</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J et al. Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nature Methods 9, 403&#x2013;409 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3420816</ArticleId><ArticleId IdType="pubmed">22388288</ArticleId></ArticleIdList></Reference><Reference><Citation>Menkes-Caspi N et al. Pathological tau disrupts ongoing network activity. Neuron 85, 959&#x2013;966 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25704951</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease (VostatAD01). ClinicalTrails Available at: (Accessed: 13 May 2018)</Citation></Reference><Reference><Citation>Zhang B et al. Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer&#x2019;s Disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>International Genomics of Alzheimer&#x2019;s Disease Consortium (IGAP). Convergent genetic and expression data implicate immunity in Alzheimer&#x2019;s disease. Alzheimers Dement 11, 658&#x2013;671 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672734</ArticleId><ArticleId IdType="pubmed">25533204</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan M et al. Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases. Mol. Syst. Biol 10, 743&#x2013;743 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299500</ArticleId><ArticleId IdType="pubmed">25080494</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolmetsch R &amp; Geschwind DH The human brain in a dish: the promise of iPSC-derived neurons. Cell 145, 831&#x2013;834 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691069</ArticleId><ArticleId IdType="pubmed">21663789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J Catastrophic cliffs: a partial suggestion for selective vulnerability in neurodegenerative diseases. Biochem. Soc. Trans 44, 659&#x2013;661 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27068985</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Verma S, Mantri S, Berman NE &amp; Sandhir R Targeting MicroRNAs in Prevention and Treatment of Neurodegenerative Disorders. Drug Dev. Res 76, 397&#x2013;418 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26359796</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen HLA et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med 368, 1685&#x2013;1694 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23534542</ArticleId></ArticleIdList></Reference><Reference><Citation>Young DD, Connelly CM, Grohmann C &amp; Deiters A Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc 132, 7976&#x2013;7981 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20527935</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M et al. Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci Data 3, 160089 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Methods References</Title><Reference><Citation>Schroeder A et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol 7, 3 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413964</ArticleId><ArticleId IdType="pubmed">16448564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wes PD et al. Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer&#x2019;s disease. PLoS ONE 9, e106050 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4143352</ArticleId><ArticleId IdType="pubmed">25153994</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K et al. Untangling the brain&#x2019;s neuroinflammatory and neurodegenerative transcriptional responses. Nat Comms 7, 11295 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844685</ArticleId><ArticleId IdType="pubmed">27097852</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. Journal of Biological Chemistry 276, 21562&#x2013;21570 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarin M et al. A Genome-wide Gene-Expression Analysis and Database in Transgenic Mice during Development of Amyloid or Tau Pathology. Cell Rep 10, 633&#x2013;644 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25620700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H et al. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell 165, 921&#x2013;935 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M et al. Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci Data 3, 160089 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea LG, Wang Z &amp; McElwee J Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer&#x2019;s Disease. Cell (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT et al. A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer&#x2019;s Disease. Cell Syst 4, 60&#x2013;72.e4 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269514</ArticleId><ArticleId IdType="pubmed">27989508</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nature Publishing Group 18, 1175&#x2013;1182 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L-C et al. A Conserved BDNF, Glutamate- and GABA-Enriched Gene Module Related to Human Depression Identified by Coexpression Meta-Analysis and DNA Variant Genome-Wide Association Studies. PLoS ONE 9, e90980 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946570</ArticleId><ArticleId IdType="pubmed">24608543</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromer M et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nature Publishing Group 19, 1442&#x2013;1453 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5083142</ArticleId><ArticleId IdType="pubmed">27668389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biology 14, R36 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053844</ArticleId><ArticleId IdType="pubmed">23618408</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078&#x2013;2079 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Pyl PT &amp; Huber W HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166&#x2013;169 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Conesa A et al. A survey of best practices for RNA-seq data analysis. Genome Biology 17, 13 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4728800</ArticleId><ArticleId IdType="pubmed">26813401</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN et al. Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. Nature 540, 423&#x2013;427 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102905</ArticleId><ArticleId IdType="pubmed">27919067</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ &amp; Smyth GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Risso D, Schwartz K, Sherlock G &amp; Dudoit S GC-content normalization for RNA-Seq data. BMC Bioinformatics 12, 480 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315510</ArticleId><ArticleId IdType="pubmed">22177264</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen KD, Irizarry RA &amp; Wu Z Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics 13, 204&#x2013;216 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297825</ArticleId><ArticleId IdType="pubmed">22285995</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedl&#xe4;nder MR, Mackowiak SD, Li N, Chen W &amp; Rajewsky N miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Research 40, 37&#x2013;52 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245920</ArticleId><ArticleId IdType="pubmed">21911355</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W &amp; Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P &amp; Horvath S WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A &amp; Horvath S Network neighborhood analysis with the multi-node topological overlap measure. Bioinformatics 23, 222&#x2013;231 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17110366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz M et al. Canonical genetic signatures of the adult human brain. Nature Publishing Group 18, 1832&#x2013;1844 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4700510</ArticleId><ArticleId IdType="pubmed">26571460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambon AC et al. GO-Elite: a flexible solution for pathway and ontology over-representation. Bioinformatics 28, 2209&#x2013;2210 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413395</ArticleId><ArticleId IdType="pubmed">22743224</ArticleId></ArticleIdList></Reference><Reference><Citation>Csardi G &amp; Nepusz T The igraph software package for complex network research. InterJournal (2006).</Citation></Reference><Reference><Citation>Zhang Y et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. Journal of Neuroscience 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Thu D, Waldvogel HJ, Faull RLM &amp; Luthi-Carter R Population-specific expression analysis (PSEA) reveals molecular changes in diseased brain. Nature Methods 8, 945&#x2013;947 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21983921</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Woltjer RL, Goodenbour JM, Horvath S &amp; Geschwind DH Genes and pathways underlying regional and cell type changes in Alzheimer&#x2019;s disease. Genome Med 5, 48 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706780</ArticleId><ArticleId IdType="pubmed">23705665</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Luo R, Oldham MC &amp; Horvath S Is my network module preserved and reproducible? PLoS Comput. Biol 7, e1001057 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024255</ArticleId><ArticleId IdType="pubmed">21283776</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivals I, Personnaz L, Taing L &amp; Potier M-C Enrichment or depletion of a GO category within a class of genes: which test? Bioinformatics 23, 401&#x2013;407 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17182697</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y &amp; Hochberg Y Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B &#x2026; (1995). doi:10.2307/2346101</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2346101</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimson A et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Molecular Cell 27, 91&#x2013;105 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800283</ArticleId><ArticleId IdType="pubmed">17612493</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossin EJ et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 7, e1001273 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020935</ArticleId><ArticleId IdType="pubmed">21249183</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark C et al. BioGRID: a general repository for interaction datasets. Nucleic Acids Research 34, D535&#x2013;9 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347471</ArticleId><ArticleId IdType="pubmed">16381927</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 155, 1008&#x2013;1021 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934107</ArticleId><ArticleId IdType="pubmed">24267887</ArticleId></ArticleIdList></Reference><Reference><Citation>Voineagu I et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 474, 380&#x2013;384 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607626</ArticleId><ArticleId IdType="pubmed">21614001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell Proteomics 13, 2513&#x2013;2526 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159666</ArticleId><ArticleId IdType="pubmed">24942700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929&#x2013;1935 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17008526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C, Fass DM, Folz-Donahue K, Macdonald ME &amp; Haggarty SJ Highly Expandable Human iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease Modeling and High-Throughput Screening. Curr Protoc Hum Genet 92, 21.8.1&#x2013;21.8.21 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293008</ArticleId><ArticleId IdType="pubmed">28075486</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep 2, 789&#x2013;798 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532907</ArticleId><ArticleId IdType="pubmed">23063362</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas MHU et al. MMP-9 and MMP-2 Contribute to Neuronal Cell Death in iPSC Models of Frontotemporal Dementia with MAPT Mutations. Stem Cell Reports 7, 316&#x2013;324 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032669</ArticleId><ArticleId IdType="pubmed">27594586</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30538104</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e99360</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/embj.201899360</ELocationID><Abstract><AbstractText>Accumulation of the protein tau characterises Alzheimer's disease and other tauopathies, including familial forms of frontotemporal dementia (FTD) that carry pathogenic tau mutations. Another hallmark feature of these diseases is the accumulation of dysfunctional mitochondria. Although disease-associated tau is known to impair several aspects of mitochondrial function, it is still unclear whether it also directly impinges on mitochondrial quality control, specifically Parkin-dependent mitophagy. Using the mito-QC mitophagy reporter, we found that both human wild-type (hTau) and FTD mutant tau (hP301L) inhibited mitophagy in neuroblastoma cells, by reducing mitochondrial translocation of Parkin. In the <i>Caenorhabditis elegans</i> nervous system, hTau expression reduced mitophagy, whereas hP301L expression completely inhibited it. These effects were not due to changes in the mitochondrial membrane potential or the cytoskeleton, as tau specifically impaired Parkin recruitment to defective mitochondria by sequestering it in the cytosol. This sequestration was mediated by aberrant interactions of Parkin with the projection domain of tau. As mitochondria are dysfunctional in neurodegenerative conditions, these data suggest a vicious cycle, with tau also inhibiting the degradation of damaged mitochondria.</AbstractText><CopyrightInformation>&#xa9; 2018 The Authors. Published under the terms of the CC BY NC ND 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummins</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4494-2345</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tweedie</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuryn</LastName><ForeName>Steven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3551-6790</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertran-Gonzalez</LastName><ForeName>Jesus</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3794-1782</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Decision Neuroscience Laboratory, School of Psychology, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;tz</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8501-7896</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia j.goetz@uq.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C111567">parkin protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063306" MajorTopicYN="Y">Mitophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C.&#xa0;elegans</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>12</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30538104</ArticleId><ArticleId IdType="pmc">PMC6356067</ArticleId><ArticleId IdType="doi">10.15252/embj.201899360</ArticleId><ArticleId IdType="pii">embj.201899360</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen GFG, Toth R, James J, Ganley IG (2013) Loss of iron triggers PINK1/Parkin&#x2010;independent mitophagy. EMBO Rep 14: 1127&#x2013;1135</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3981094</ArticleId><ArticleId IdType="pubmed">24176932</ArticleId></ArticleIdList></Reference><Reference><Citation>Amadoro G, Corsetti V, Florenzano F, Atlante A, Ciotti MT, Mongiardi MP, Bussani R, Nicolin V, Nori SL, Campanella M, Calissano P (2014) AD&#x2010;linked, toxic NH2 human tau affects the quality control of mitochondria in neurons. Neurobiol Dis 62: 489&#x2013;507</Citation><ArticleIdList><ArticleId IdType="pubmed">24411077</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloyannis SJ, Costa V, Michmizos D (2004) Mitochondrial alterations Alzheimer's disease. Am J Alzheimers Dis Other Demen 19: 89&#x2013;93</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10834007</ArticleId><ArticleId IdType="pubmed">15106389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodea L&#x2010;G, Eckert A, Ittner LM, Piguet O, G&#xf6;tz J (2016) Tau physiology and pathomechanisms in frontotemporal lobar degeneration. J Neurochem 138: 71&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094566</ArticleId><ArticleId IdType="pubmed">27306859</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S (1974) The genetics of Caenorhabditis elegans . Genetics 77: 71&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria,&#xa0;abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet 20: 4515&#x2013;4529</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3209824</ArticleId><ArticleId IdType="pubmed">21873260</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Dorn GW (2013) PINK1&#x2010;phosphorylated mitofusin 2 is a parkin receptor for culling damaged mitochondria. Science 340: 471&#x2013;475</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3774525</ArticleId><ArticleId IdType="pubmed">23620051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu CT, Bay&#x131;r H, Kagan VE (2014) LC3 binds externalized cardiolipin on injured mitochondria to signal mitophagy in neurons. Autophagy 10: 376&#x2013;378</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5396091</ArticleId><ArticleId IdType="pubmed">24351649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelissen T, Vilain S, Vints K, Gounko N, Verstreken P, Vandenberghe W (2018) Deficiency of parkin and PINK1 impairs age&#x2010;dependent mitophagy in Drosophila . eLife 7: e35878</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6008047</ArticleId><ArticleId IdType="pubmed">29809156</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummins N, G&#xf6;tz J (2017) Shedding light on mitophagy in neurons: what is the evidence for PINK1/Parkin mitophagy in&#xa0;vivo? Cell Mol Life Sci 75: 1151&#x2013;1162</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11105538</ArticleId><ArticleId IdType="pubmed">29085955</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC, Hauptmann S, Scherping I, Schuessel K, Keil U, Rizzu P, Ravid R, Dr&#xf6;se S, Brandt U, M&#xfc;ller WE, Eckert A, G&#xf6;tz J (2005) Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 280: 23802&#x2013;23814</Citation><ArticleIdList><ArticleId IdType="pubmed">15831501</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayanandan R, Van Slegtenhorst M, Mack TGA, Ko L, Yen S&#x2010;H, Leroy K, Brion J&#x2010;P, Anderton BH, Hutton M, Lovestone S (1999) Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett 446: 228&#x2013;232</Citation><ArticleIdList><ArticleId IdType="pubmed">10100846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding W&#x2010;X, Ni H&#x2010;M, Li M, Liao Y, Chen X, Stolz DB, Dorn GW, Yin X&#x2010;M (2010) Nix is critical to two distinct phases of mitophagy, reactive oxygen species&#x2010;mediated autophagy induction and parkin&#x2010;ubiquitin&#x2010;p62&#x2010;mediated mitochondrial priming. J Biol Chem 285: 27879&#x2013;27890</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2934655</ArticleId><ArticleId IdType="pubmed">20573959</ArticleId></ArticleIdList></Reference><Reference><Citation>Drew BG, Ribas V, Le JA, Henstridge DC, Phun J, Zhou Z, Soleymani T, Daraei P, Sitz D, Vergnes L, Wanagat J, Reue K, Febbraio MA, Hevener AL (2014) Hsp72 is a mitochondrial stress sensor critical for parkin action, oxidative metabolism, and insulin sensitivity in skeletal muscle. Diabetes 63: 1488&#x2013;1505</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994950</ArticleId><ArticleId IdType="pubmed">24379352</ArticleId></ArticleIdList></Reference><Reference><Citation>DuBoff B, G&#xf6;tz J, Feany MB (2012) Tau promotes neurodegeneration via Drp&#x2010;1 mislocalization in&#xa0;vivo . Neuron 75: 618&#x2013;632</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428596</ArticleId><ArticleId IdType="pubmed">22920254</ArticleId></ArticleIdList></Reference><Reference><Citation>DuBoff B, Feany M, G&#xf6;tz J (2013) Why size matters &#x2013; balancing mitochondrial dynamics in Alzheimer's disease. Trends Neurosci 36: 325&#x2013;335</Citation><ArticleIdList><ArticleId IdType="pubmed">23582339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E&#x2010;M, Mandelkow E (1998) Overexpression of tau protein inhibits kinesin&#x2010;dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 143: 777&#x2013;794</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148132</ArticleId><ArticleId IdType="pubmed">9813097</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert A, Nisbet R, Grimm A, G&#xf6;tz J (2014) March separate, strike together &#x2014; role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis 1842: 1258&#x2013;1266</Citation><ArticleIdList><ArticleId IdType="pubmed">24051203</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga TA, Elson&#x2010;Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB (2007) Abnormal bundling and accumulation of F&#x2010;actin mediates tau&#x2010;induced neuronal degeneration in&#xa0;vivo . Nat Cell Biol 9: 139&#x2013;148</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier&#x2010;Kemper A, Weissmann C, Golovyashkina N, Seb&#xf6;&#x2010;Lemke Z, Drewes G, Gerke V, Heinisch JJ, Brandt R (2011) The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2&#x2010;dependent manner. J Cell Biol 192: 647&#x2013;661</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044115</ArticleId><ArticleId IdType="pubmed">21339331</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler S, Holmstr&#xf6;m KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W (2010) PINK1/Parkin&#x2010;mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 12: 119&#x2013;131</Citation><ArticleIdList><ArticleId IdType="pubmed">20098416</ArticleId></ArticleIdList></Reference><Reference><Citation>Glauser L, Sonnay S, Stafa K, Moore DJ (2011) Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1. J Neurochem 118: 636&#x2013;645</Citation><ArticleIdList><ArticleId IdType="pubmed">21615408</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in transgenic mice expressing p301&#xa0;l tau. J Biol Chem 276: 529&#x2013;534</Citation><ArticleIdList><ArticleId IdType="pubmed">11013246</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Ittner LM (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9: 532&#x2013;544</Citation><ArticleIdList><ArticleId IdType="pubmed">18568014</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm A, Eckert A (2017) Brain aging and neurodegeneration: from a mitochondrial point of view. J Neurochem 143: 418&#x2013;431</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724505</ArticleId><ArticleId IdType="pubmed">28397282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, Zhukareva V, Vogelsberg&#x2010;Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD, Trojanowski JQ, Lee VM&#x2010;Y (1998) Mutation&#x2010;specific functional impairments in distinct tau isoforms of hereditary ftdp&#x2010;17. Science 282: 1914&#x2013;1917</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Li X&#x2010;C, Wang Z, Luo Y, Zhang X, Liu X&#x2010;P, Feng Q, Wang Q, Yue Z, Chen Z, Ye K, Wang J&#x2010;Z, Liu G&#x2010;P, Hu Y, Li X&#x2010;C, Wang Z, Luo Y, Zhang X, Liu X&#x2010;P, Feng Q et&#xa0;al (2016) Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin. Oncotarget 7: 17356&#x2013;17368</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4951217</ArticleId><ArticleId IdType="pubmed">26943044</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Alonso Adel C, Chen S, Chohan MO, El&#x2010;Akkad E, Gong C&#x2010;X, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke&#x2010;Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta Mol Basis Dis 1739: 198&#x2013;210</Citation><ArticleIdList><ArticleId IdType="pubmed">15615638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, Li KM, Gunning P, G&#xf6;tz J (2008) Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci USA 105: 15997&#x2013;16002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572931</ArticleId><ArticleId IdType="pubmed">18832465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, G&#xf6;tz J (2009) Phosphorylated Tau interacts with c&#x2010;Jun N&#x2010;terminal kinase&#x2010;interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem 284: 20909&#x2013;20916</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742856</ArticleId><ArticleId IdType="pubmed">19491104</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ (2010) Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol 191: 933&#x2013;942</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995166</ArticleId><ArticleId IdType="pubmed">21115803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA, Banerjee S, Youle RJ (2014) PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol 205: 143&#x2013;153</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003245</ArticleId><ArticleId IdType="pubmed">24751536</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, Koffie RM, Frosch MP, Hyman BT, Spires&#x2010;Jones TL (2011) Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol 179: 2071&#x2013;2082</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181340</ArticleId><ArticleId IdType="pubmed">21854751</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, Kimura Y, Tsuchiya H, Yoshihara H, Hirokawa T, Endo T, Fon EA, Trempe J&#x2010;F, Saeki Y, Tanaka K, Matsuda N (2014) Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510: 162&#x2013;166</Citation><ArticleIdList><ArticleId IdType="pubmed">24784582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD (2003) Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci USA 100: 9980&#x2013;9985</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187908</ArticleId><ArticleId IdType="pubmed">12872001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon K&#x2010;Y, Viollet B, Yoo OJ (2011) CCCP induces autophagy in an AMPK&#x2010;independent manner. Biochem Biophys Res Commun 416: 343&#x2013;348</Citation><ArticleIdList><ArticleId IdType="pubmed">22119190</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarou M, Sliter DA, Kane LA, Sarraf SA, Wang C, Burman JL, Sideris DP, Fogel AI, Youle RJ (2015) The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 524: 309&#x2013;314</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018156</ArticleId><ArticleId IdType="pubmed">26266977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JJ, Sanchez&#x2010;Martinez A, Zarate AM, Beninc&#xe1; C, Mayor U, Clague MJ, Whitworth AJ (2018) Basal mitophagy is widespread in Drosophila but minimally affected by loss of Pink1 or parkin. J Cell Biol 217: 1613&#x2013;1622</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5940313</ArticleId><ArticleId IdType="pubmed">29500189</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X&#x2010;C, Hu Y, Wang Z, Luo Y, Zhang Y, Liu X&#x2010;P, Feng Q, Wang Q, Ye K, Liu G&#x2010;P, Wang J&#x2010;Z (2016) Human wild&#x2010;type full&#x2010;length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins. Sci Rep 6: 24756</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4838862</ArticleId><ArticleId IdType="pubmed">27099072</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, G&#xf6;tz J (2017a) Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn&#x2010;mediated local protein translation. EMBO J 36: 3120&#x2013;3138</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666608</ArticleId><ArticleId IdType="pubmed">28864542</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, G&#xf6;tz J (2017b) Tau&#x2010;based therapies in neurodegeneration: opportunities and challenges. Nat Rev Drug Discov 16: 863</Citation><ArticleIdList><ArticleId IdType="pubmed">28983098</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Reddy PH (2012) Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 21: 2538&#x2013;2547</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3349426</ArticleId><ArticleId IdType="pubmed">22367970</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou Y, Saiki S, Kawajiri S, Sato F, Kimura M, Komatsu M, Hattori N, Tanaka K (2010) PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189: 211&#x2013;221</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856912</ArticleId><ArticleId IdType="pubmed">20404107</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumine H, Saito M, Shimoda&#x2010;Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa&#x2010;Hattori Y, Yokochi M, Kobayashi T, Igarashi S, Takano H, Sanpei K, Koike R, Mori H, Kondo T, Mizutani Y, Sch&#xe4;ffer AA, Yamamura Y, Nakamura S, Kuzuhara S, Tsuji S et&#xa0;al (1997) Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2&#x2010;27. Am J Hum Genet 60: 588&#x2013;596</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1712507</ArticleId><ArticleId IdType="pubmed">9042918</ArticleId></ArticleIdList></Reference><Reference><Citation>McWilliams TG, Prescott AR, Montava&#x2010;Garriga L, Ball G, Singh F, Barini E, Muqit MMK, Brooks SP, Ganley IG (2018) Basal mitophagy occurs independently of pink1 in mouse tissues of high metabolic demand. Cell Metab 27: 439&#x2013;449 e5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807059</ArticleId><ArticleId IdType="pubmed">29337137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mello CC, Kramer JM, Stinchcomb D, Ambros V (1991) Efficient gene transfer in C. elegans: extrachromosomal maintenance and integration of transforming sequences. EMBO J 10: 3959&#x2013;3970</Citation><ArticleIdList><ArticleId IdType="pmc">PMC453137</ArticleId><ArticleId IdType="pubmed">1935914</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DJ, West AB, Dikeman DA, Dawson VL, Dawson TM (2008) Parkin mediates the degradation&#x2010;independent ubiquitination of Hsp70. J Neurochem 105: 1806&#x2013;1819</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432938</ArticleId><ArticleId IdType="pubmed">18248624</ArticleId></ArticleIdList></Reference><Reference><Citation>Narendra DP, Jin SM, Tanaka A, Suen D&#x2010;F, Gautier CA, Shen J, Cookson MR, Youle RJ (2010) Pink1 is selectively stabilized on impaired mitochondria to activate parkin. PLoS Biol 8: e1000298</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811155</ArticleId><ArticleId IdType="pubmed">20126261</ArticleId></ArticleIdList></Reference><Reference><Citation>Palikaras K, Lionaki E, Tavernarakis N (2015) Coordination of mitophagy and mitochondrial biogenesis during ageing in C. elegans . Nature 521: 525&#x2013;528</Citation><ArticleIdList><ArticleId IdType="pubmed">25896323</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez MJ, Vergara&#x2010;Pulgar K, Jara C, Cabezas&#x2010;Opazo F, Quintanilla RA (2017) Caspase&#x2010;cleaved tau impairs mitochondrial dynamics in Alzheimer's disease. Mol Neurobiol 55: 1&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pubmed">28084594</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, Lucia MD, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13: 703&#x2013;714</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Dr&#xf6;se S, Brandt U, Savaskan E, Czech C, G&#xf6;tz J, Eckert A (2009) Amyloid&#x2010;&#x3b2; and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 106: 20057&#x2013;20062</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774257</ArticleId><ArticleId IdType="pubmed">19897719</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosado C, Mijaljica D, Hatzinisiriou I, Prescott M, Devenish RJ (2008) Rosella: a fluorescent pH&#x2010;biosensor for reporting vacuolar turnover of cytosol and organelles in yeast. Autophagy 4: 205&#x2013;213</Citation><ArticleIdList><ArticleId IdType="pubmed">18094608</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugarli EI, Langer T (2012) Mitochondrial quality control: a matter of life and death for neurons. EMBO J 31: 1336&#x2013;1349</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321185</ArticleId><ArticleId IdType="pubmed">22354038</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda&#x2010;Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J&#x2010;Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open&#x2010;source platform for biological&#x2010;image analysis. Nat Methods 9: 676&#x2013;682</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KL, Eckert A, Rhein V, Mai S, Haase W, Reichert AS, Jendrach M, M&#xfc;ller WE, Leuner K (2012) A new link to mitochondrial impairment in tauopathies. Mol Neurobiol 46: 205&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pubmed">22847631</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahpasand K, Uemura I, Saito T, Asano T, Hata K, Shibata K, Toyoshima Y, Hasegawa M, Hisanaga S&#x2010;I (2012) Regulation of mitochondrial transport and inter&#x2010;microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J Neurosci 32: 2430&#x2013;2441</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621814</ArticleId><ArticleId IdType="pubmed">22396417</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;derberg O, Leuchowius K&#x2010;J, Gullberg M, Jarvius M, Weibrecht I, Larsson L&#x2010;G, Landegren U (2008) Characterizing proteins and their interactions in cells and tissues using the in&#xa0;situ proximity ligation assay. Methods 45: 227&#x2013;232</Citation><ArticleIdList><ArticleId IdType="pubmed">18620061</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Brady ST (2015) Post&#x2010;translational modifications of tubulin: pathways to functional diversity of microtubules. Trends Cell Biol 25: 125&#x2013;136</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344850</ArticleId><ArticleId IdType="pubmed">25468068</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow E&#x2010;M (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156: 1051&#x2013;1063</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173473</ArticleId><ArticleId IdType="pubmed">11901170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka A, Cleland MM, Xu S, Narendra DP, Suen D&#x2010;F, Karbowski M, Youle RJ (2010) Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. J Cell Biol 191: 1367&#x2013;1380</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010068</ArticleId><ArticleId IdType="pubmed">21173115</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW (2001) Localization of a novel locus for autosomal recessive early&#x2010;onset parkinsonism, PARK6, on human chromosome 1p35&#x2010;p36. Am J Hum Genet 68: 895&#x2013;900</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1275643</ArticleId><ArticleId IdType="pubmed">11254447</ArticleId></ArticleIdList></Reference><Reference><Citation>Vives&#x2010;Bauza C, Zhou C, Huang Y, Cui M, de Vries RLA, Kim J, May J, Tocilescu MA, Liu W, Ko HS, Magrane J, Moore DJ, Dawson VL, Grailhe R, Dawson TM, Li C, Tieu K, Przedborski S (2010) PINK1&#x2010;dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA 107: 378&#x2013;383</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806779</ArticleId><ArticleId IdType="pubmed">19966284</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitworth AJ, Pallanck LJ (2017) PINK1/Parkin mitophagy and neurodegeneration&#x2014;what do we really know in&#xa0;vivo? Curr Opin Genet Dev 44: 47&#x2013;53</Citation><ArticleIdList><ArticleId IdType="pubmed">28213158</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Li C, G&#xf6;tz J (2015) Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule&#x2010;associated protein Tau to dendritic spines. Biochim Biophys Acta 1852: 913&#x2013;924</Citation><ArticleIdList><ArticleId IdType="pubmed">25558816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Sun X, Starovoytov V, Cai Q (2015) Parkin&#x2010;mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains. Hum Mol Genet 15: 2938&#x2013;2951</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4406302</ArticleId><ArticleId IdType="pubmed">25678552</ArticleId></ArticleIdList></Reference><Reference><Citation>Youle RJ, van der Bliek AM (2012) Mitochondrial fission, fusion, and stress. Science 337: 1062&#x2013;1065</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762028</ArticleId><ArticleId IdType="pubmed">22936770</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30597599</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>290</EndPage><MedlinePgn>284-290</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.25407</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; transmission has been described in patients both with and without iatrogenic Creutzfeldt-Jakob disease; however, there is little information regarding the clinical impact of this acquired amyloid-&#x3b2; pathology during life. Here, for the first time, we describe in detail the clinical and neuroimaging findings in 3 patients with early onset symptomatic amyloid-&#x3b2; cerebral amyloid angiopathy following childhood exposure to cadaveric dura (by neurosurgical grafting in 2 patients and tumor embolization in a third). Our observations provide further in vivo evidence that cerebral amyloid angiopathy might be caused by transmission of amyloid-&#x3b2; seeds (prions) present in cadaveric dura and have diagnostic relevance for younger patients presenting with suspected cerebral amyloid angiopathy. Ann Neurol 2019; 1-7 ANN NEUROL 2019;85:284-290.</AbstractText><CopyrightInformation>&#xa9; 2018 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Gargi</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0190-7782</Identifier><AffiliationInfo><Affiliation>Stroke Research Centre, Department of Brain Repair and Rehabilitation, University College London Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaunmuktane</LastName><ForeName>Zane</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Queen Square Institute of Neurology, London.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuropathology, National Hospital for Neurology and Neurosurgery, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alistair Lammie</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology, Cardiff University, Cardiff.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Barts and London School of Medicine and Dentistry, Queen Mary University of London and Royal London Hospital, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wani</LastName><ForeName>Mushtaq</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Morriston Hospital, Abertawe Bro Morgannwg University Health Board, Swansea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawhney</LastName><ForeName>Inder M S</ForeName><Initials>IMS</Initials><AffiliationInfo><Affiliation>Morriston Hospital, Abertawe Bro Morgannwg University Health Board, Swansea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houlden</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Queen Square Institute of Neurology, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Prion Clinic, National Hospital for Neurology and Neurosurgery, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, National Hospital for Neurology and Neurosurgery, London.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werring</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Stroke Research Centre, Department of Brain Repair and Rehabilitation, University College London Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R605/0717</GrantID><Acronym>DMT_</Acronym><Agency>The Dunhill Medical Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S01165X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1001253</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002102" MajorTopicYN="N">Cadaver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073116" MajorTopicYN="N">Cancer Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003399" MajorTopicYN="N">Craniotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004388" MajorTopicYN="N">Dura Mater</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="N">Embolization, Therapeutic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020786" MajorTopicYN="N">Hemangioma, Cavernous, Central Nervous System</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007049" MajorTopicYN="N">Iatrogenic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020288" MajorTopicYN="N">Papilloma, Choroid Plexus</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010307" MajorTopicYN="N">Parotid Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012887" MajorTopicYN="N">Skull Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Nothing to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30597599</ArticleId><ArticleId IdType="pmc">PMC6492172</ArticleId><ArticleId IdType="doi">10.1002/ana.25407</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jaunmuktane Z, Mead S, Ellis M, et al. Evidence for human transmission of amyloid&#x2010;beta pathology and cerebral amyloid angiopathy. Nature 2015;525:247&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">26354483</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontzek K, Lutz MI, Aguzzi A, et al. Amyloid&#x2010;beta pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt&#x2010;Jakob disease after dural grafting. Swiss Med Wkly 2016;146:w14287.</Citation><ArticleIdList><ArticleId IdType="pubmed">26812492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie DL, Adlard P, Peden AH, et al. Amyloid&#x2010;beta accumulation in the CNS in human growth hormone recipients in the UK. Acta Neuropathol 2017;134:221&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508038</ArticleId><ArticleId IdType="pubmed">28349199</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali I, Cohen ML, Haik S, et al. Iatrogenic Creutzfeldt&#x2010;Jakob disease with amyloid&#x2010;beta pathology: an international study. Acta Neuropathol Commun 2018;6:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759292</ArticleId><ArticleId IdType="pubmed">29310723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Lutz MI, Ricken G, et al. Dura mater is a potential source of Abeta seeds. Acta Neuropathol 2016;131:911&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865536</ArticleId><ArticleId IdType="pubmed">27016065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi T, Taniguchi Y, Sakai K, et al. Significant association of cadaveric dura mater grafting with subpial Abeta deposition and meningeal amyloid angiopathy. Acta Neuropathol 2016;132:313&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">27314593</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y, Imamura K, Iwai K, et al. Autopsied case of non&#x2010;plaque&#x2010;type dura mater graft&#x2010;associated Creutzfeldt&#x2010;Jakob disease presenting with extensive amyloid&#x2010;beta deposition. Neuropathology 2018;38:549&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">30084170</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z, Quaegebeur A, Taipa R, et al. Evidence of amyloid&#x2010;beta cerebral amyloid angiopathy transmission through neurosurgery. Acta Neuropathol 2018;135:671&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5904220</ArticleId><ArticleId IdType="pubmed">29450646</ArticleId></ArticleIdList></Reference><Reference><Citation>Herve D, Porche M, Cabrejo L, et al. Fatal Abeta cerebral amyloid angiopathy 4 decades after a dural graft at the age of 2 years. Acta Neuropathol 2018;135:801&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">29508058</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Pittman A, Adamson G, et al. Validation of next&#x2010;generation sequencing technologies in genetic diagnosis of dementia. Neurobiol Aging 2014;35:261&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">23998997</ArticleId></ArticleIdList></Reference><Reference><Citation>Corovic A, Kelly S, Markus HS. Cerebral amyloid angiopathy associated with inflammation: a systematic review of clinical and imaging features and outcome. Int J Stroke 2018;13:257&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">29134927</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvarani C, Morris JM, Giannini C, et al. Imaging findings of cerebral amyloid angiopathy, abeta&#x2010;related angiitis (ABRA), and cerebral amyloid angiopathy&#x2010;related inflammation: a single&#x2010;institution 25&#x2010;year experience. Medicine (Baltimore) 2016;95:e3613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4902405</ArticleId><ArticleId IdType="pubmed">27196463</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza F, Greenberg SM, Savoiardo M, et al. Anti&#x2010;amyloid beta autoantibodies in cerebral amyloid angiopathy&#x2010;related inflammation: implications for amyloid&#x2010;modifying therapies. Ann Neurol 2013;73:449&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">23625526</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR Jr, Black SE, et al. Amyloid&#x2010;related imaging abnormalities in amyloid&#x2010;modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693547</ArticleId><ArticleId IdType="pubmed">21784348</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee G, Alvares D, Bowen J, et al. Minimally symptomatic cerebral amyloid angiopathy&#x2010;related inflammation: three descriptive case reports. J Neurol Neurosurg Psychiatry 2019;90:113&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327917</ArticleId><ArticleId IdType="pubmed">29535144</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 2016;537:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson C, Estergard W, Oh J, et al. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 2011;7:396&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">21784350</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Hawkes CA, Kalaria RN, et al. White matter changes in dementia: role of impaired drainage of interstitial fluid. Brain Pathol 2015;25:63&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028907</ArticleId><ArticleId IdType="pubmed">25521178</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoine JC, Michel D, Bertholon P, et al. Creutzfeldt&#x2010;Jakob disease after extracranial dura mater embolization for a nasopharyngeal angiofibroma. Neurology 1997;48:1451&#x2013;1453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153491</ArticleId></ArticleIdList></Reference><Reference><Citation>Defebvre L, Destee A, Caron J, et al. Creutzfeldt&#x2010;Jakob disease after an embolization of intercostal arteries with cadaveric dura mater suggesting a systemic transmission of the prion agent. Neurology 1997;48:1470&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153501</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Obermuller U, Heilbronner G, et al. Peripherally applied Abeta&#x2010;containing inoculates induce cerebral beta&#x2010;amyloidosis. Science 2010;330:980&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature 2016;539:217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830781</ArticleId></ArticleIdList></Reference><Reference><Citation>
Public Health England
. Creutzfeldt&#x2010;Jakob disease (CJD) biannual update (February 2018). Accessed date: January 11, 2019. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/680709/hpr0518_CJD.pdf.</Citation></Reference><Reference><Citation>Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt&#x2010;Jakob disease at the millennium. Neurology 2000;55:1075&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071481</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooke FJ, Boyd A, Klug GM, et al. Lyodura use and the risk of iatrogenic Creutzfeldt&#x2010;Jakob disease in Australia. Med J Aust 2004;180:177&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">14960140</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudge P, Jaunmuktane Z, Adlard P, et al. Iatrogenic CJD due to pituitary&#x2010;derived growth hormone with genetically determined incubation times of up to 40 years. Brain 2015;138(pt 11):3386&#x2013;3399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4620512</ArticleId><ArticleId IdType="pubmed">26268531</ArticleId></ArticleIdList></Reference><Reference><Citation>Muayqil T, Gronseth G, Camicioli R. Evidence&#x2010;based guideline: diagnostic accuracy of CSF 14&#x2010;3&#x2010;3 protein in sporadic Creutzfeldt&#x2010;Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79:1499&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3525296</ArticleId><ArticleId IdType="pubmed">22993290</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet&#x2010;Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early&#x2010;onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006;129(pt 11):2977&#x2013;2983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet&#x2010;Lecrux A, Frebourg T, Tuominen H, et al. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007;78:1158&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117532</ArticleId><ArticleId IdType="pubmed">17442758</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrejo L, Guyant&#x2010;Marechal L, Laquerriere A, et al. Phenotype associated with APP duplication in five families. Brain 2006;129(pt 11):2966&#x2013;2976.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasuga K, Shimohata T, Nishimura A, et al. Identification of independent APP locus duplication in Japanese patients with early&#x2010;onset Alzheimer disease. J Neurol Neurosurg Psychiatry 2009;80:1050&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">19684239</ArticleId></ArticleIdList></Reference><Reference><Citation>Llado A, Grau&#x2010;Rivera O, Sanchez&#x2010;Valle R, et al. Large APP locus duplication in a sporadic case of cerebral haemorrhage. Neurogenetics 2014;15:145&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">24691562</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath CA, Barker RA, Esmonde TF, et al. Dura mater&#x2010;associated Creutzfeldt&#x2010;Jakob disease: experience from surveillance in the UK. J Neurol Neurosurg Psychiatry 2006;77:880&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117491</ArticleId><ArticleId IdType="pubmed">16627534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ae R, Hamaguchi T, Nakamura Y, et al. Update: Dura mater graft&#x2010;associated Creutzfeldt&#x2010;Jakob disease&#x2014;Japan, 1975&#x2010;2017. MMWR Morb Mortal Wkly Rep 2018;67:274&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5844283</ArticleId><ArticleId IdType="pubmed">29518068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama Y, Mineharu Y, Arawaka Y, et al. Cerebral amyloid angiopathy in a young man with a history of traumatic brain injury: a case report and review of the literature. Acta Neurochir (Wien) 2017;159:15&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">27812816</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30598546</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>565</Volume><Issue>7738</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structural basis of Notch recognition by human &#x3b3;-secretase.</ArticleTitle><Pagination><StartPage>192</StartPage><EndPage>197</EndPage><MedlinePgn>192-197</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-018-0813-8</ELocationID><Abstract><AbstractText>Aberrant cleavage of Notch by &#x3b3;-secretase leads to several types of cancer, but how &#x3b3;-secretase recognizes its substrate remains unknown. Here we report the cryo-electron microscopy structure of human &#x3b3;-secretase in complex with a Notch fragment at a resolution of 2.7&#xa0;&#xc5;. The transmembrane helix of Notch is surrounded by three transmembrane domains of PS1, and the carboxyl-terminal &#x3b2;-strand of the Notch fragment forms a &#x3b2;-sheet with two substrate-induced &#x3b2;-strands of PS1 on the intracellular side. Formation of the hybrid &#x3b2;-sheet is essential for substrate cleavage, which occurs at the carboxyl-terminal end of the Notch transmembrane helix. PS1 undergoes pronounced conformational rearrangement upon substrate binding. These features reveal the structural basis of Notch recognition and have implications for the recruitment of the amyloid precursor protein by &#x3b3;-secretase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Guanghui</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xuefei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Chuangye</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Jianlin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technology Center for Protein Sciences, Ministry of Education Key Laboratory of Protein Sciences, School of Life Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yigong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China. shi-lab@tsinghua.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, China. shi-lab@tsinghua.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30598546</ArticleId><ArticleId IdType="doi">10.1038/s41586-018-0813-8</ArticleId><ArticleId IdType="pii">10.1038/s41586-018-0813-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown, M. S., Ye, J., Rawson, R. B. &amp; Goldstein, J. L. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100, 391&#x2013;398 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80675-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawson, R. B. et al. Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. Mol. Cell 1, 47&#x2013;57 (1997).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(00)80006-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban, S., Lee, J. R. &amp; Freeman, M. Drosophila rhomboid-1 defines a family of putative intramembrane serine proteases. Cell 107, 173&#x2013;182 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(01)00525-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#x2019;s disease. Nature 375, 754&#x2013;760 (1995).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/375754a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihofen, A., Binns, K., Lemberg, M. K., Ashman, K. &amp; Martoglio, B. Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 296, 2215&#x2013;2218 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1070925</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolaridis, I. et al. Mechanism of farnesylated CAAX protein processing by the intramembrane protease Rce1. Nature 504, 301&#x2013;305 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. M. et al. Photoactivated &#x3b3;-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689&#x2013;694 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35015085</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. M. et al. Presenilin 1 is linked with &#x3b3;-secretase activity in the detergent solubilized state. Proc. Natl Acad. Sci. USA 97, 6138&#x2013;6143 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.110126897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly, W. T. et al. &#x3b3;-Secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl Acad. Sci. USA 100, 6382&#x2013;6387 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1037392100</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper, B. et al. A presenilin-1-dependent &#x3b3;-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518&#x2013;522 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19083</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper, B. et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387&#x2013;390 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/34910</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J. &amp; Younkin, S. G. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255, 728&#x2013;730 (1992).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1738847</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami, M. et al. &#x3b3;-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of &#x3b2;-carboxyl terminal fragment. J. Neurosci. 29, 13042&#x2013;13052 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2362-09.2009</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki, N. et al. An increased percentage of long amyloid &#x3b2; protein secreted by familial amyloid &#x3b2; protein precursor (&#x3b2;APP<sub>717</sub>) mutants. Science 264, 1336&#x2013;1340 (1994).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy, J. A. &amp; Higgins, G. A. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science 256, 184&#x2013;185 (1992).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Artavanis-Tsakonas, S., Rand, M. D. &amp; Lake, R. J. Notch signaling: cell fate control and signal integration in development. Science 284, 770&#x2013;776 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.284.5415.770</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl, G., Fitzgerald, K. &amp; Greenwald, I. Intrinsic activity of the Lin-12 and Notch intracellular domains in vivo. Cell 74, 331&#x2013;345 (1993).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90424-O</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan, R. &amp; Ilagan, M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216&#x2013;233 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.03.045</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269&#x2013;271 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1102160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, B. et al. &#x3b3;-Secretase gene mutations in familial acne inversa. Science 330, 1065 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1196284</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump, C. J., Johnson, D. S. &amp; Li, Y. M. Development and mechanism of &#x3b3;-secretase modulators for Alzheimer&#x2019;s disease. Biochemistry 52, 3197&#x2013;3216 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi400377p</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer&#x2019;s disease. N. Engl. J. Med. 369, 341&#x2013;350 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1210951</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolduc, D. M., Montagna, D. R., Seghers, M. C., Wolfe, M. S. &amp; Selkoe, D. J. The amyloid-beta forming tripeptide cleavage mechanism of &#x3b3;-secretase. eLife 5, e17578 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.17578</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper, B. &amp; Chavez Gutierrez, L. Learning by failing: ideas and concepts to tackle &#x3b3;-secretases in Alzheimer&#x2019;s disease and beyond. Annu. Rev. Pharmacol. Toxicol. 55, 419&#x2013;437 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010814-124309</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, D. S., Li, Y. M., Pettersson, M. &amp; St George-Hyslop, P. H. Structural and chemical biology of presenilin complexes. Cold Spring Harb. Perspect. Med. 7, a024067 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, P. et al. Three-dimensional structure of human &#x3b3;-secretase. Nature 512, 166&#x2013;170 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, L. et al. Structural basis of human &#x3b3;-secretase assembly. Proc. Natl Acad. Sci. USA 112, 6003&#x2013;6008 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1506242112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai, X. C. et al. An atomic structure of human &#x3b3;-secretase. Nature 525, 212&#x2013;217 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolduc, D. M., Montagna, D. R., Gu, Y., Selkoe, D. J. &amp; Wolfe, M. S. Nicastrin functions to sterically hinder &#x3b3;-secretase-substrate interactions driven by substrate transmembrane domain. Proc. Natl Acad. Sci. USA 113, E509&#x2013;E518 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1512952113</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe, M. S. et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and &#x3b3;-secretase activity. Nature 398, 513&#x2013;517 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai, X. C., Rajendra, E., Yang, G., Shi, Y. &amp; Scheres, S. H. Sampling the conformational space of the catalytic subunit of human &#x3b3;-secretase. eLife 4, e11182 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.11182</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagi-Niidome, S. et al. Cooperative roles of hydrophilic loop 1 and the C-terminus of presenilin 1 in the substrate-gating mechanism of &#x3b3;-secretase. J. Neurosci. 35, 2646&#x2013;2656 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3164-14.2015</ArticleId></ArticleIdList></Reference><Reference><Citation>Crescenzi, O. et al. Solution structure of the Alzheimer amyloid &#x3b2;-peptide (1&#x2013;42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur. J. Biochem. 269, 5642&#x2013;5648 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1432-1033.2002.03271.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Deatherage, C. L. et al. Structural and biochemical differences between the Notch and the amyloid precursor protein transmembrane domains. Sci. Adv. 3, e1602794 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.1602794</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadezhdin, K. D., Bocharova, O. V., Bocharov, E. V. &amp; Arseniev, A. S. Structural and dynamic study of the transmembrane domain of the amyloid precursor protein. Acta Naturae 3, 69&#x2013;76 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22649674</ArticleId><ArticleId IdType="pmc">3347594</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle, S. et al. Cholesterol-dependent &#x3b3;-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9, 11&#x2013;23 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2001.0470</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes, O., Paturi, S., Ye, W., Wolfe, M. S. &amp; Selkoe, D. J. Effects of membrane lipids on the activity and processivity of purified &#x3b3;-secretase. Biochemistry 51, 3565&#x2013;3575 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi300303g</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, L., Zhou, R., Yang, G. &amp; Shi, Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proc. Natl Acad. Sci. USA 114, E476&#x2013;E485 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1618657114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato, C., Takagi, S., Tomita, T. &amp; Iwatsubo, T. The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the &#x3b3;-secretase. J. Neurosci. 28, 6264&#x2013;6271 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1163-08.2008</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, L. et al. Structure of a site-2 protease family intramembrane metalloprotease. Science 318, 1608&#x2013;1612 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1150755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Z. et al. Structural analysis of a rhomboid family intramembrane protease reveals a gating mechanism for substrate entry. Nat. Struct. Mol. Biol. 13, 1084&#x2013;1091 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb1179</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker, R. P., Young, K., Feng, L., Shi, Y. &amp; Urban, S. Enzymatic analysis of a rhomboid intramembrane protease implicates transmembrane helix 5 as the lateral substrate gate. Proc. Natl Acad. Sci. USA 104, 8257&#x2013;8262 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0700814104</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinothkumar, K. R. et al. The structural basis for catalysis and substrate specificity of a rhomboid protease. EMBO J. 29, 3797&#x2013;3809 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoll, S. et al. Substrate binding and specificity of rhomboid intramembrane protease revealed by substrate&#x2013;peptide complex structures. EMBO J. 33, 2408&#x2013;2421 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201489367</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, S., Dickey, S. W. &amp; Urban, S. Crystal structures and inhibition kinetics reveal a two-stage catalytic mechanism with drug design implications for rhomboid proteolysis. Mol. Cell 61, 329&#x2013;340 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.12.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinothkumar, K. R., Pierrat, O. A., Large, J. M. &amp; Freeman, M. Structure of rhomboid protease in complex with &#x3b2;-lactam inhibitors defines the S2&#x2032; cavity. Structure 21, 1051&#x2013;1058 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2013.03.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Vosyka, O. et al. Activity-based probes for rhomboid proteases discovered in a mass spectrometry-based assay. Proc. Natl Acad. Sci. USA 110, 2472&#x2013;2477 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1215076110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei, J. &amp; Frank, J. Automated acquisition of cryo-electron micrographs for single particle reconstruction on an FEI Tecnai electron microscope. J. Struct. Biol. 150, 69&#x2013;80 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2005.01.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331&#x2013;332 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4193</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1&#x2013;12 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2015.11.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant, T. &amp; Grigorieff, N. Measuring the optimal exposure for single particle cryo-EM using a 2.6&#xa0;&#xc5; reconstruction of rotavirus VP6. eLife 4, e06980 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.06980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimanius, D., Forsberg, B. O., Scheres, S. H. &amp; Lindahl, E. Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. eLife 5,&#xa0;e18722 (2016).</Citation></Reference><Reference><Citation>Scheres, S. H. A Bayesian view on cryo-EM structure determination. J. Mol. Biol. 415, 406&#x2013;418 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.11.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519&#x2013;530 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2012.09.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres, S. H. Semi-automated selection of cryo-EM particles in RELION-1.3. J. Struct. Biol. 189, 114&#x2013;122 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2014.11.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartesaghi, A. et al. 2.2&#xa0;&#xc5; resolution cryo-EM structure of &#x3b2;-galactosidase in complex with a cell-permeant inhibitor. Science 348, 1147&#x2013;1151 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab1576</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, S. et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24&#x2013;35 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ultramic.2013.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213&#x2013;221 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909052925</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley, P. &amp; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D&#xa0;60, 2126&#x2013;2132 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444904019158</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D 58, 1948&#x2013;1954 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444902016657</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12&#x2013;21 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909042073</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb, B. &amp; Sali, A. Comparative protein structure modeling using MODELLER. Curr Protoc. Bioinformatics 5, 5&#x2013;6 (2010).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30602789</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>565</Volume><Issue>7740</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Cryo-EM structure of the human &#x3b1;1&#x3b2;3&#x3b3;2 GABA<sub>A</sub> receptor in a lipid bilayer.</ArticleTitle><Pagination><StartPage>516</StartPage><EndPage>520</EndPage><MedlinePgn>516-520</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-018-0833-4</ELocationID><Abstract><AbstractText>Type A &#x3b3;-aminobutyric acid (GABA<sub>A</sub>) receptors are pentameric ligand-gated ion channels and the main drivers of fast inhibitory neurotransmission in the vertebrate nervous system<sup>1,2</sup>. Their dysfunction is implicated in a range of neurological disorders, including depression, epilepsy and schizophrenia<sup>3,4</sup>. Among the numerous assemblies that are theoretically possible, the most prevalent in the brain are the &#x3b1;1&#x3b2;2/3&#x3b3;2 GABA<sub>A</sub> receptors<sup>5</sup>. The &#x3b2;3 subunit has an important role in maintaining inhibitory tone, and the expression of this subunit alone is sufficient to rescue inhibitory synaptic transmission in &#x3b2;1-&#x3b2;3 triple knockout neurons<sup>6</sup>. So far, efforts to generate accurate structural models for heteromeric GABA<sub>A</sub> receptors have been hampered by the use of engineered receptors and the presence of detergents<sup>7-9</sup>. Notably, some recent cryo-electron microscopy reconstructions have reported 'collapsed' conformations<sup>8,9</sup>; however, these disagree with the structure of the prototypical pentameric ligand-gated ion channel the Torpedo nicotinic acetylcholine receptor<sup>10,11</sup>, the large body of structural work on homologous homopentameric receptor variants<sup>12</sup> and the logic of an ion-channel architecture. Here we present a high-resolution cryo-electron microscopy structure of the full-length human &#x3b1;1&#x3b2;3&#x3b3;2L-a major synaptic GABA<sub>A</sub> receptor isoform-that is functionally reconstituted in lipid nanodiscs. The receptor is bound to a positive allosteric modulator 'megabody' and is in a desensitized conformation. Each GABA<sub>A</sub> receptor pentamer contains two phosphatidylinositol-4,5-bisphosphate molecules, the head groups of which occupy positively charged pockets in the intracellular juxtamembrane regions of &#x3b1;1 subunits. Beyond this level, the intracellular M3-M4 loops are largely disordered, possibly because interacting post-synaptic proteins are not present. This structure illustrates the molecular principles of heteromeric GABA<sub>A</sub> receptor organization and provides a reference framework for future mechanistic investigations of GABAergic signalling and pharmacology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laverty</LastName><ForeName>Duncan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK. dlaverty@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Rooma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ucha&#x144;ski</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masiulis</LastName><ForeName>Simonas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stec</LastName><ForeName>Wojciech J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malinauskas</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zivanov</LastName><ForeName>Jasenko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardon</LastName><ForeName>Els</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steyaert</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Keith W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. kwmiller@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aricescu</LastName><ForeName>A Radu</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK. radu@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. radu@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>A14414</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L009609/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1201/15</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 GM058448</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_EX_MR/L009609/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008051">Lipid Bilayers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019269">Phosphatidylinositol 4,5-Diphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2019 Jan;565(7740):436-438. doi: 10.1038/d41586-018-07843-7.</RefSource><PMID Version="1">30666053</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004553" MajorTopicYN="N">Electric Conductivity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008051" MajorTopicYN="N">Lipid Bilayers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019269" MajorTopicYN="N">Phosphatidylinositol 4,5-Diphosphate</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30602789</ArticleId><ArticleId IdType="mid">EMS80767</ArticleId><ArticleId IdType="pmc">PMC6364807</ArticleId><ArticleId IdType="doi">10.1038/s41586-018-0833-4</ArticleId><ArticleId IdType="pii">10.1038/s41586-018-0833-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sigel E, Steinmann ME. Structure, function, and modulation of GABAA receptors. J Biol Chem. 2012;287:40224&#x2013;40231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3504738</ArticleId><ArticleId IdType="pubmed">23038269</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen RW, Sieghart W. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology. 2009;56:141&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3525320</ArticleId><ArticleId IdType="pubmed">18760291</ArticleId></ArticleIdList></Reference><Reference><Citation>Braat S, Kooy RF. The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders. Neuron. 2015;86:1119&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">26050032</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald RL, Kang J-Q, Gallagher MJ. Mutations in GABAA receptor subunits associated with genetic epilepsies. J Physiol (Lond.) 2010;588:1861&#x2013;1869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901974</ArticleId><ArticleId IdType="pubmed">20308251</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritschy JM, Mohler H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J Comp Neurol. 1995;359:154&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557845</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen Q-A, Nicoll RA. The GABAA Receptor &#x3b2;; Subunit Is Required for Inhibitory Transmission. Neuron. 2018:1&#x2013;25. doi: 10.1016/j.neuron.2018.03.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.03.046</ArticleId><ArticleId IdType="pmc">PMC6089239</ArticleId><ArticleId IdType="pubmed">29706582</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller P, et al. Heteromeric GABAA receptor structures in positively-modulated active states. 2018 doi: 10.1101/338343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/338343</ArticleId></ArticleIdList></Reference><Reference><Citation>Phulera S, et al. Cryo-EM structure of the benzodiazepine-sensitive &#x3b1;1&#x3b2;1&#x3b3;2S tri-heteromeric GABAA receptor in complex with GABA. Elife. 2018;7:531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086659</ArticleId><ArticleId IdType="pubmed">30044221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, et al. Structure of a human synaptic GABAA receptor. Nature. 2018:1&#x2013;22. doi: 10.1038/s41586-018-0255-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0255-3</ArticleId><ArticleId IdType="pmc">PMC6220708</ArticleId><ArticleId IdType="pubmed">29950725</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature. 2003;423:949&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">12827192</ArticleId></ArticleIdList></Reference><Reference><Citation>Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4&#xc5; resolution. J Mol Biol. 2005;346:967&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">15701510</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemecz &#xc1;, Prevost MS, Menny A, Corringer P-J. Emerging Molecular Mechanisms of Signal Transduction in Pentameric Ligand-Gated Ion Channels. Neuron. 2016;90:452&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">27151638</ArticleId></ArticleIdList></Reference><Reference><Citation>Dostalova Z, et al. Human &#x3b1;1&#x3b2;3&#x3b3;2L gamma-aminobutyric acid type A receptors: High-level production and purification in a functional state. Protein Sci. 2014;23:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3926741</ArticleId><ArticleId IdType="pubmed">24288268</ArticleId></ArticleIdList></Reference><Reference><Citation>Masiulis S, Desai R, Ucha&#x144;ski T, Serna Martin S, Laverty D, Karia D, Malinauskas T, Zivanov J, Pardon E, Kotecha A, Steyaert J, et al. GABAA receptor signalling mechanisms revealed by structural pharmacology. Nature. 2018 This issue.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6370056</ArticleId><ArticleId IdType="pubmed">30602790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gielen M, Thomas P, Smart TG. The desensitization gate of inhibitory Cys-loop receptors. Nat Commun. 2015;6 6829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410641</ArticleId><ArticleId IdType="pubmed">25891813</ArticleId></ArticleIdList></Reference><Reference><Citation>Papke D, Grosman C. The role of intracellular linkers in gating and desensitization of human pentameric ligand-gated ion channels. J Neurosci. 2014;34:7238&#x2013;7252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028499</ArticleId><ArticleId IdType="pubmed">24849357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hille B, Dickson EJ, Kruse M, Vivas O, Suh B-C. Phosphoinositides regulate ion channels. Biochim Biophys Acta. 2015;1851:844&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364932</ArticleId><ArticleId IdType="pubmed">25241941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen SB, Tao X, MacKinnon R. Structural basis of PIP2 activation of the classical inward rectifier K+ channel Kir2.2. Nature. 2011;477:495&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3324908</ArticleId><ArticleId IdType="pubmed">21874019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennerick S, Taylor AA, Zorumski CF. Phosphatidylinositol 4,5-bisphosphate depletion fails to affect neurosteroid modulation of GABAA receptor function. Psychopharmacology (Berl.) 2014;231:3493&#x2013;3501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439103</ArticleId><ArticleId IdType="pubmed">24553581</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin J, Weiss DS. GABAA receptor needs two homologous domains of the beta-subunit for activation by GABA but not by pentobarbital. Nature. 1993;366:565&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504783</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibbs RE, Gouaux E. Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature. 2011;474:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160419</ArticleId><ArticleId IdType="pubmed">21572436</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller PS, Aricescu AR. Crystal structure of a human GABAA receptor. Nature. 2014;512:270&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4167603</ArticleId><ArticleId IdType="pubmed">24909990</ArticleId></ArticleIdList></Reference><Reference><Citation>Laverty D, et al. Crystal structures of a GABAA receptor chimera reveal new endogenous neurosteroid-binding sites. Nat Struct Mol Biol. 2017;24:977&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853794</ArticleId><ArticleId IdType="pubmed">28967882</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller PS, et al. Structural basis for GABAA receptor potentiation by neurosteroids. Nat Struct Mol Biol. 2017;24:986&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166781</ArticleId><ArticleId IdType="pubmed">28991263</ArticleId></ArticleIdList></Reference><Reference><Citation>Auerbach A, Akk G. Desensitization of mouse nicotinic acetylcholine receptor channels. A two-gate mechanism. J Gen Physiol. 1998;112:181&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525745</ArticleId><ArticleId IdType="pubmed">9689026</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali M, Akabas MH. The location of a closed channel gate in the GABAA receptor channel. J Gen Physiol. 2007;129:145&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2154354</ArticleId><ArticleId IdType="pubmed">17227918</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman SA, Miller KW. Mapping General Anesthetic Sites in Heteromeric &#x3b3;-Aminobutyric Acid Type A Receptors Reveals a Potential For Targeting Receptor Subtypes. Anesth Analg. 2016;123:1263&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5073028</ArticleId><ArticleId IdType="pubmed">27167687</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G-D, et al. Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. J Neurosci. 2006;26:11599&#x2013;11605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674783</ArticleId><ArticleId IdType="pubmed">17093081</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurd R, et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABAA receptor &#x3b2;3 subunit. FASEB J. 2003;17:250&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475885</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayakar SS, et al. Positive and Negative Allosteric Modulation of an &#x3b1;1&#x3b2;3&#x3b3;2 &#x3b3;-Aminobutyric Acid Type A (GABAA) Receptor by Binding to a Site in the Transmembrane Domain at the &#x3b3;+-&#x3b2;- Interface. J Biol Chem. 2015;290:23432&#x2013;23446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4645599</ArticleId><ArticleId IdType="pubmed">26229099</ArticleId></ArticleIdList></Reference><Reference><Citation>Tretter V, et al. Gephyrin, the enigmatic organizer at GABAergic synapses. Front Cell Neurosci. 2012;6:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351755</ArticleId><ArticleId IdType="pubmed">22615685</ArticleId></ArticleIdList></Reference><Reference><Citation>Unwin N. Segregation of lipids near acetylcholine-receptor channels imaged by cryo-EM. IUCrJ. 2017;4:393&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5571802</ArticleId><ArticleId IdType="pubmed">28875026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie TK, et al. Liposomes, Part F. Vol. 464. Elsevier; 2009. pp. 211&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Javaheri A, et al. Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. Nat Microbiol. 2016;2 16189.</Citation><ArticleIdList><ArticleId IdType="pubmed">27748768</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017;14:331&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K. Gctf: Real-time CTF determination and correction. J Struct Biol. 2016;193:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. A Bayesian view on cryo-EM structure determination. J Mol Biol. 2012;415:406&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314964</ArticleId><ArticleId IdType="pubmed">22100448</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilas JL, et al. MonoRes: Automatic and Accurate Estimation of Local Resolution for Electron Microscopy Maps. Structure. 2018;26:337&#x2013;344.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29395788</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Rosa-Trev&#xed;n JM, et al. Scipion: A software framework toward integration, reproducibility and validation in 3D electron microscopy. J Struct Biol. 2016;195:93&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">27108186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D Struct Biol. 2018;74:531&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis IW, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007;35:W375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1933162</ArticleId><ArticleId IdType="pubmed">17452350</ArticleId></ArticleIdList></Reference><Reference><Citation>Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372:774&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">17681537</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA. 2001;98:10037&#x2013;10041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC56910</ArticleId><ArticleId IdType="pubmed">11517324</ArticleId></ArticleIdList></Reference><Reference><Citation>McNicholas S, Potterton E, Wilson KS, Noble MEM. Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr D Biol Crystallogr. 2011;67:386&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069754</ArticleId><ArticleId IdType="pubmed">21460457</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurcik A, et al. CAVER Analyst 2.0: Analysis and Visualization of Channels and Tunnels in Protein Structures and Molecular Dynamics Trajectories. Bioinformatics. 2018;6:7597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6184705</ArticleId><ArticleId IdType="pubmed">29741570</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Dostalova Z, et al. High-level expression and purification of Cys-loop ligand-gated ion channels in a tetracycline-inducible stable mammalian cell line: GABAA and serotonin receptors. Protein Sci. 2010;19:1728&#x2013;1738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975136</ArticleId><ArticleId IdType="pubmed">20662008</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai R, et al. Contrasting actions of a convulsant barbiturate and its anticonvulsant enantiomer on the &#x3b1;1 &#x3b2;3 &#x3b3;2L GABAA receptor account for their in vivo effects. J Physiol (Lond.) 2015;593:4943&#x2013;4961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4650410</ArticleId><ArticleId IdType="pubmed">26378885</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman SA. A hydrophobic photolabel inhibits nicotinic acetylcholine receptors via open-channel block following a slow step. Biochemistry. 1999;38:14559&#x2013;14564.</Citation><ArticleIdList><ArticleId IdType="pubmed">10545178</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H, Low C-M, Moody OA, Jenkins A, Traynelis SF. Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases. Mol Pharmacol. 2015;88:203&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468639</ArticleId><ArticleId IdType="pubmed">25904555</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvill GL, et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology. 2014;82:1245&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001207</ArticleId><ArticleId IdType="pubmed">24623842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachance-Touchette P, et al. Novel &#x3b1;1 and &#x3b3;2 GABAA receptor subunit mutations in families with idiopathic generalized epilepsy. Eur J Neurosci. 2011;34:237&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">21714819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kash TL, Jenkins A, Kelley JC, Trudell JR, Harrison NL. Coupling of agonist binding to channel gating in the GABAA receptor. Nature. 2003;421:272&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">12529644</ArticleId></ArticleIdList></Reference><Reference><Citation>Epi4K Consortium et al. De novo mutations in epileptic encephalopathies. Nature. 2013;501:217&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773011</ArticleId><ArticleId IdType="pubmed">23934111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez CC, et al. GABAA Receptor Coupling Junction and Pore GABRB3 Mutations are Linked to Early-Onset Epileptic Encephalopathy. Sci Rep. 2017;7 15903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5698489</ArticleId><ArticleId IdType="pubmed">29162865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez CC, et al. Altered Channel Conductance States and Gating of GABAA Receptors by a Pore Mutation Linked to Dravet Syndrome. eNeuro. 2017;4 ENEURO.0251&#x2013;16.2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5301078</ArticleId><ArticleId IdType="pubmed">28197552</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip GMS, et al. A propofol binding site on mammalian GABAA receptors identified by photolabeling. Nat Chem Biol. 2013;9:715&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951778</ArticleId><ArticleId IdType="pubmed">24056400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30602790</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>565</Volume><Issue>7740</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>GABA<sub>A</sub> receptor signalling mechanisms revealed by structural pharmacology.</ArticleTitle><Pagination><StartPage>454</StartPage><EndPage>459</EndPage><MedlinePgn>454-459</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-018-0832-5</ELocationID><Abstract><AbstractText>Type-A &#x3b3;-aminobutyric (GABA<sub>A</sub>) receptors are ligand-gated chloride channels with a very rich pharmacology. Some of their modulators, including benzodiazepines and general anaesthetics, are among the most successful drugs in clinical use and are common substances of abuse. Without reliable structural data, the mechanistic basis for the pharmacological modulation of GABA<sub>A</sub> receptors remains largely unknown. Here we report several high-resolution cryo-electron microscopy structures in which the full-length human &#x3b1;1&#x3b2;3&#x3b3;2L GABA<sub>A</sub> receptor in lipid nanodiscs is bound to the channel-blocker picrotoxin, the competitive antagonist bicuculline, the agonist GABA (&#x3b3;-aminobutyric acid), and the classical benzodiazepines alprazolam and diazepam. We describe the binding modes and mechanistic effects of these ligands, the closed and desensitized states of the GABA<sub>A</sub> receptor gating cycle, and the basis for allosteric coupling between the extracellular, agonist-binding region and the transmembrane, pore-forming region. This work provides a structural framework in which to integrate previous physiology and pharmacology research and a rational basis for the development of GABA<sub>A</sub> receptor modulators.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masiulis</LastName><ForeName>Simonas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK. simonasm@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Rooma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ucha&#x144;ski</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serna Martin</LastName><ForeName>Itziar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laverty</LastName><ForeName>Duncan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karia</LastName><ForeName>Dimple</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malinauskas</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zivanov</LastName><ForeName>Jasenko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardon</LastName><ForeName>Els</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotecha</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Materials and Structural Analysis, Thermo Fisher Scientific, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steyaert</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Keith W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. kwmiller@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aricescu</LastName><ForeName>A Radu</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK. radu@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. radu@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L009609/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1201/15</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 GM058448</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_EX_MR/L009609/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018757">GABA Modulators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance></Chemical><Chemical><RegistryNumber>124-87-8</RegistryNumber><NameOfSubstance UI="D010852">Picrotoxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q3JTX2Q7TU</RegistryNumber><NameOfSubstance UI="D003975">Diazepam</NameOfSubstance></Chemical><Chemical><RegistryNumber>Y37615DVKC</RegistryNumber><NameOfSubstance UI="D001640">Bicuculline</NameOfSubstance></Chemical><Chemical><RegistryNumber>YU55MQ3IZY</RegistryNumber><NameOfSubstance UI="D000525">Alprazolam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2019 Jan;565(7740):436-438. doi: 10.1038/d41586-018-07843-7.</RefSource><PMID Version="1">30666053</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2019 Feb;566(7744):E8. doi: 10.1038/s41586-019-0929-5.</RefSource><PMID Version="1">30733619</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Transl Med. 2019 Jul;7(Suppl 3):S144. doi: 10.21037/atm.2019.06.23.</RefSource><PMID Version="1">31576351</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000525" MajorTopicYN="N">Alprazolam</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001640" MajorTopicYN="N">Bicuculline</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003975" MajorTopicYN="N">Diazepam</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018757" MajorTopicYN="N">GABA Modulators</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010852" MajorTopicYN="N">Picrotoxin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30602790</ArticleId><ArticleId IdType="mid">EMS80639</ArticleId><ArticleId IdType="pmc">PMC6370056</ArticleId><ArticleId IdType="doi">10.1038/s41586-018-0832-5</ArticleId><ArticleId IdType="pii">10.1038/s41586-018-0832-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sieghart W. Structure and pharmacology of gamma-aminobutyric acid A receptor subtypes. Pharmacol Rev. 1995;47:181&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">7568326</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard EA, et al. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev. 1998;50:291&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">9647870</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigel E, Steinmann ME. Structure, function, and modulation of GABAA receptors. J Biol Chem. 2012;287:40224&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3504738</ArticleId><ArticleId IdType="pubmed">23038269</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;hler H. GABAA receptors in central nervous system disease: anxiety, epilepsy and insomnia. J Recept Signal Transduct. 2006;26:731&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">17118808</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen RW. Analysis of &#x3b3;-aminobutyric acid (GABA) type A receptor subtypes using isosteric and allosteric ligands. Neurochem Res. 2014;39:1924&#x2013;1941.</Citation><ArticleIdList><ArticleId IdType="pubmed">25015397</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen RW. Allosteric ligands and their binding sites define &#x3b3;-aminobutyric acid (GABA) type A receptor subtypes. Adv Pharmacol. 2015;73:167&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">25637441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunkeler W. Benzodiazepines, the story of the antagonist flumazenil and of the partial agonist bretazenil. Chim Int J Chem. 1993;47:141&#x2013;147.</Citation></Reference><Reference><Citation>Squires RF, Brastrup C. Benzodiazepine receptors in rat brain. Nature. 1977;266:732&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">876354</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigel E, Mamalaki C, Barnard EA. Isolation of a GABA receptor from bovine brain using a benzodiazepine affinity column. FEBS Lett. 1982;147:45&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">6291997</ArticleId></ArticleIdList></Reference><Reference><Citation>Schofield PR, et al. Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family. Nature. 1987;328:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">3037384</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibbs RE, Gouaux E. Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature. 2011;474:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160419</ArticleId><ArticleId IdType="pubmed">21572436</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature. 2003;423:949&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">12827192</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller PS, Aricescu AR. Crystal structure of a human GABAA receptor. Nature. 2014;512:270&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4167603</ArticleId><ArticleId IdType="pubmed">24909990</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller PS, et al. Structural basis for GABAA receptor potentiation by neurosteroids. Nat Struct Mol Biol. 2017;24:986&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166781</ArticleId><ArticleId IdType="pubmed">28991263</ArticleId></ArticleIdList></Reference><Reference><Citation>Laverty D, et al. Crystal structures of a GABAA-receptor chimera reveal new endogenous neurosteroid-binding sites. Nat Struct Mol Biol. 2017;24:977&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853794</ArticleId><ArticleId IdType="pubmed">28967882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, et al. Structural basis of neurosteroid anesthetic action on GABAA receptors. Nat Commun. 2018;9 3972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6162318</ArticleId><ArticleId IdType="pubmed">30266951</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. Cryo-EM structure of the human &#x3b1;5&#x3b2;3 GABAA receptor. Cell Res. 2018;28:958&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123483</ArticleId><ArticleId IdType="pubmed">30140029</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, et al. Structure of a human synaptic GABAA receptor. Nature. 2018;559:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220708</ArticleId><ArticleId IdType="pubmed">29950725</ArticleId></ArticleIdList></Reference><Reference><Citation>Phulera S, et al. Cryo-EM structure of the benzodiazepine-sensitive &#x3b1;1&#x3b2;1&#x3b3;2S tri-heteromeric GABAA receptor in complex with GABA. Elife. 2018;7:e39383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086659</ArticleId><ArticleId IdType="pubmed">30044221</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller P, et al. Heteromeric GABAA receptor structures in positively-modulated active states. bioRxiv. 2018 doi: 10.1101/338343. 338343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/338343</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann SW, Baur R, Sigel E. Individual properties of the two functional agonist sites in GABAA receptors. J Neurosci. 2003;23:11158&#x2013;11166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741049</ArticleId><ArticleId IdType="pubmed">14657175</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan KR, Rudolph U, L&#xfc;scher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 2011;34:188&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020178</ArticleId><ArticleId IdType="pubmed">21353710</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoflach F, et al. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2. Mol Pharmacol. 1996;50:1253&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pubmed">8913357</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston GAR. Advantages of an antagonist: Bicuculline and other GABA antagonists. British Journal of Pharmacology. 2013;169:328&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651659</ArticleId><ArticleId IdType="pubmed">23425285</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishek BJ, Moss SJ, Smart TG. A functional comparison of the antagonist bicuculline and picrotoxin at recombinant GABAA receptors. Neuropharmacology. 1996;35:1289&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9014144</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman JD, Calvo DJ. Studies on the mechanisms of action of picrotoxin, quercetin and pregnanolone at the GABA rho 1 receptor. Br J Pharmacol. 2004;141:717&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574239</ArticleId><ArticleId IdType="pubmed">14732759</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X-J, Roberts D, Zhu G-N, Chang Y-C. Competitive antagonists facilitate the recovery from desensitization of &#x3b1;1&#x3b2;2&#x3b3;2 GABAA receptors expressed in Xenopus oocytes. Acta Pharmacol Sin. 2016;37:1020&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4973384</ArticleId><ArticleId IdType="pubmed">27374488</ArticleId></ArticleIdList></Reference><Reference><Citation>Dostalova Z, et al. Human &#x3b1;1&#x3b2;3&#x3b3;2L gamma-aminobutyric acid type A receptors: High-level production and purification in a functional state. Protein Sci. 2014;23:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3926741</ArticleId><ArticleId IdType="pubmed">24288268</ArticleId></ArticleIdList></Reference><Reference><Citation>Laverty D, et al. Structure of the human synaptic &#x3b1;1&#x3b2;2&#x3b3;2 GABAA receptor in a lipid bilayer. Nature. In this issue.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6364807</ArticleId><ArticleId IdType="pubmed">30602789</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Durkin KA, Casida JE. Structural model for gamma-aminobutyric acid receptor noncompetitive antagonist binding: widely diverse structures fit the same site. Proc Natl Acad Sci U S A. 2006;103:5185&#x2013;5190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458815</ArticleId><ArticleId IdType="pubmed">16537435</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Covey DF, Akabas MH. Interaction of picrotoxin with GABAA receptor channel-lining residues probed in cysteine mutants. Biophys J. 1995;69:1858&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1236419</ArticleId><ArticleId IdType="pubmed">8580329</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurley D, Amin J, Ross PC, Weiss DS, White G. Point mutations in the M2 region of the alpha, beta, or gamma subunit of the GABAA channel that abolish block by picrotoxin. Recept Channels. 1995;3:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">8589989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali M, Akabas MH. The location of a closed channel gate in the GABAA receptor channel. J Gen Physiol. 2007;129:145&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2154354</ArticleId><ArticleId IdType="pubmed">17227918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D-S, Mangin J-M, Moonen G, Rigo J-M, Legendre P. Mechanisms for picrotoxin block of 2 homomeric glycine receptors. J Biol Chem. 2006;281:3841&#x2013;3855.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344549</ArticleId></ArticleIdList></Reference><Reference><Citation>Unwin N. Nicotinic acetylcholine receptor and the structural basis of neuromuscular transmission: insights from Torpedo postsynaptic membranes. Q Rev Biophys. 2013;46:283&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820380</ArticleId><ArticleId IdType="pubmed">24050525</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian H, Pan Y, Zhu Y, Khalili P. Picrotoxin accelerates relaxation of GABAC receptors. Mol Pharmacol. 2004;67:470&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">15509715</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y, Weiss DS. Site-specific fluorescence reveals distinct structural changes with GABA receptor activation and antagonism. Nat Neurosci. 2002;5:1163&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pubmed">12368804</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AK, Ticku MK. Characterization of the picrotoxin site of GABAA receptors. Curr Protoc Pharmacol. 2001;8</Citation><ArticleIdList><ArticleId IdType="pubmed">22293961</ArticleId></ArticleIdList></Reference><Reference><Citation>Talwar S, Lynch JW. Phosphorylation mediated structural and functional changes in pentameric ligand-gated ion channels: Implications for drug discovery. Int J Biochem Cell Biol. 2014;53:218&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">24880089</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen RW. GABAA receptor: Positive and negative allosteric modulators. Neuropharmacology. 2018;136:10&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027637</ArticleId><ArticleId IdType="pubmed">29407219</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y, et al. Desensitization mechanism of GABA receptors revealed by single oocyte binding and receptor function. J Neurosci. 2002;22:7982&#x2013;7990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758118</ArticleId><ArticleId IdType="pubmed">12223551</ArticleId></ArticleIdList></Reference><Reference><Citation>Gielen M, Corringer P-J. The dual-gate model for pentameric ligand-gated ion channels activation and desensitization. J Physiol. 2018;596:1873&#x2013;1902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5978336</ArticleId><ArticleId IdType="pubmed">29484660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno S, Bracamontes J, Zorumski C, Weiss DS, Steinbach JH. Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABAA receptor. J Neurosci. 1997;17:625&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573228</ArticleId><ArticleId IdType="pubmed">8987785</ArticleId></ArticleIdList></Reference><Reference><Citation>Middendorp SJ, et al. Relative positioning of classical benzodiazepines to the &#x3b3;2 subunit of GABAA receptors. ACS Chem Biol. 2014;9:1846&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pubmed">24918742</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieland HA, L&#xfc;ddens H, Seeburg PH. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem. 1992;267:1426&#x2013;1429.</Citation><ArticleIdList><ArticleId IdType="pubmed">1346133</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2011;10:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375401</ArticleId><ArticleId IdType="pubmed">21799515</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman SA, Miller KW. Anesthetic sites and allosteric mechanisms of action on Cys-loop ligand-gated ion channels. Canadian Journal of Anesthesia. 2011;58:191&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108180</ArticleId><ArticleId IdType="pubmed">21213095</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters RJ, Hadley SH, Morris KDW, Amin J. Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nat Neurosci. 2000;3:1274&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher JL. A lysine residue in the &#x3b2;3 subunit contributes to the regulation of GABAA receptor activity by voltage. Mol Cell Neurosci. 2002;20:683&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">12213448</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud J-P, et al. Cryo-EM in drug discovery: achievements, limitations and prospects. Nat Rev Drug Discov. 2018;17:471&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">29880918</ArticleId></ArticleIdList></Reference><Reference><Citation>Einhauer A, Jungbauer A. The FLAG peptide, a versatile fusion tag for the purification of recombinant proteins. J Biochem Biophys Methods. 2001;49:455&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">11694294</ArticleId></ArticleIdList></Reference><Reference><Citation>Molday RS, MacKenzie D. Monoclonal antibodies to rhodopsin: characterization, cross-reactivity, and application as structural probes. Biochemistry. 1983;22:653&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">6188482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie TK, et al. Methods in enzymology. 2009;464:211&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4196316</ArticleId><ArticleId IdType="pubmed">19903557</ArticleId></ArticleIdList></Reference><Reference><Citation>Javaheri A, et al. Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. Nat Microbiol. 2017;2:16189.</Citation><ArticleIdList><ArticleId IdType="pubmed">27748768</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardon E, et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014;9:674&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297639</ArticleId><ArticleId IdType="pubmed">24577359</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife. 2018;7:e42166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, et al. MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nature Methods. 2017;14:331&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K. Gctf: Real-time CTF determination and correction. J Struct Biol. 2016;193:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. CryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ. 2019;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilas JL, et al. MonoRes: automatic and accurate estimation of local resolution for electron microscopy maps. Structure. 2018;26:337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">29395788</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF Chimera - A visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr Sect D Biol Crystallogr. 2010;66:486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr Sect D, Struct Biol. 2018;74:531&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, et al. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr Sect D Biol Crystallogr. 2010;66:12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, et al. New tools for the analysis and validation of cryo-EM maps and atomic models. Acta Crystallogr Sect D Struct Biol. 2018;74:814&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6130467</ArticleId><ArticleId IdType="pubmed">30198894</ArticleId></ArticleIdList></Reference><Reference><Citation>Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372:774&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">17681537</ArticleId></ArticleIdList></Reference><Reference><Citation>Smart OS, Neduvelil JG, Wang X, Wallace BA, Sansom MSP. HOLE: A program for the analysis of the pore dimensions of ion channel structural models. J Mol Graph. 1996;14:354&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">9195488</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman SA. A hydrophobic photolabel inhibits nicotinic acetylcholine receptors via open-channel block following a slow step. Biochemistry. 1999;38:14559&#x2013;14564.</Citation><ArticleIdList><ArticleId IdType="pubmed">10545178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30617257</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.</ArticleTitle><Pagination><StartPage>191</StartPage><EndPage>204</EndPage><MedlinePgn>191-204</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-018-0296-9</ELocationID><Abstract><AbstractText>Coding variants in the triggering receptor expressed on myeloid cells 2 (TREM2) are associated with late-onset Alzheimer's disease (AD). We demonstrate that amyloid plaque seeding is increased in the absence of functional Trem2. Increased seeding is accompanied by decreased microglial clustering around newly seeded plaques and reduced plaque-associated apolipoprotein E (ApoE). Reduced ApoE deposition in plaques is also observed in brains of AD patients carrying TREM2 coding variants. Proteomic analyses and microglia depletion experiments revealed microglia as one origin of plaque-associated ApoE. Longitudinal amyloid small animal positron emission tomography demonstrates accelerated amyloidogenesis in Trem2 loss-of-function mutants at early stages, which progressed at a lower rate with aging. These findings suggest that in the absence of functional Trem2, early amyloidogenesis is accelerated due to reduced phagocytic clearance of amyloid seeds despite reduced plaque-associated ApoE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parhizkar</LastName><ForeName>Samira</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5807-190X</Identifier><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arzberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deussing</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Focke</LastName><ForeName>Carola</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Monica</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8398-1814</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, and Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghasemigharagoz</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katzmarski</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical Center University of Freiburg, and Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krasemann</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women&#xb4;s Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, Garching, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monasor</LastName><ForeName>Laura Sebastian</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahirovic</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4403-9559</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettkus</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butovsky</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women&#xb4;s Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartenstein</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edbauer</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7186-4653</Identifier><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rominger</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ert&#xfc;rk</LastName><ForeName>Ali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5163-5100</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grathwohl</LastName><ForeName>Stefan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neher</LastName><ForeName>Jonas J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-1346-8924</Identifier><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, and Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Luehmann</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3661-2220</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical Center University of Freiburg, and Faculty of Medicine, University of Freiburg, Freiburg, Germany. melanie.meyer-luehmann@uniklinik-freiburg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany. christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany. christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088137</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054672</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051812</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Neurosci. 2024 Sep;27(9):1858-1859. doi: 10.1038/s41593-024-01752-x.</RefSource><PMID Version="1">39143410</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30617257</ArticleId><ArticleId IdType="mid">NIHMS1512778</ArticleId><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0296-9</ArticleId><ArticleId IdType="pii">10.1038/s41593-018-0296-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jucker M &amp; Walker LC Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45&#x2013;51 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313, 1781&#x2013;1784 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O &amp; Weiner HL Microglial signatures and their role in health and disease. Nat Rev Neurosci 19, 622&#x2013;635 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255106</ArticleId><ArticleId IdType="pubmed">30206328</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM &amp; Colonna M The identity and function of microglia in neurodegeneration. Nat Immunol 19, 1048&#x2013;1058 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30250185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Colonna M &amp; Holtzman DM Elucidating the Role of TREM2 in Alzheimer&#x2019;s Disease. Neuron 94, 237&#x2013;248 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med 368, 107&#x2013;116 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer&#x2019;s Disease. Cell 170, 649&#x2013;663 e613 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, et al. The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J 36, 1837&#x2013;1853 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494459</ArticleId><ArticleId IdType="pubmed">28559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6, 243ra286 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 17, 131&#x2013;143 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, et al. ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron 96, 1024&#x2013;1032 e1023 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948105</ArticleId><ArticleId IdType="pubmed">29216449</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, et al. Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of beta-amyloidosis. Neuron 96, 1013&#x2013;1023 e1014 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728673</ArticleId><ArticleId IdType="pubmed">29216448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB Jr., Das S &amp; Potter H Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 92&#x2013;94 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest 128, 2144&#x2013;2155 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919821</ArticleId><ArticleId IdType="pubmed">29600961</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer&#x2019;s Disease. J Neurosci 37, 637&#x2013;647 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213, 667&#x2013;675 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med 212, 287&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane MD, et al. Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci 20, 3606&#x2013;3611 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772682</ArticleId><ArticleId IdType="pubmed">10804202</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7, 940&#x2013;946 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177, 3520&#x2013;3524 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol 70, 78&#x2013;84 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. Altered microglial response to Abeta plaques in APPPS1&#x2013;21 mice heterozygous for TREM2. Mol Neurodegener 9, 20 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel M, et al. Increase of TREM2 during Aging of an Alzheimer&#x2019;s Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. Front Aging Neurosci 9, 8 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5282474</ArticleId><ArticleId IdType="pubmed">28197095</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickens AM, et al. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med 55, 466&#x2013;472 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24516258</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtman IR, et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta Neuropathol Commun 3, 31 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489356</ArticleId><ArticleId IdType="pubmed">26001565</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, et al. Formation and maintenance of Alzheimer&#x2019;s disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 12, 1361&#x2013;1363 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Heppner FL, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 11, 146&#x2013;152 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15665833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat Genet 49, 1373&#x2013;1384 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med 215, 1047&#x2013;1058 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng-Hathaway PJ, et al. The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer&#x2019;s disease. Mol Neurodegener 13, 29 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984804</ArticleId><ArticleId IdType="pubmed">29859094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavisse S, et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci 32, 10809&#x2013;10818 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621018</ArticleId><ArticleId IdType="pubmed">22875916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau WF, et al. Exploration of the impact of stereochemistry on the identification of the novel translocator protein PET imaging agent [(18)F]GE-180. Nucl Med Biol 42, 711&#x2013;719 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26072270</ArticleId></ArticleIdList></Reference><Reference><Citation>Feeney C, et al. Kinetic analysis of the translocator protein positron emission tomography ligand [(18)F]GE-180 in the human brain. Eur J Nucl Med Mol Imaging 43, 2201&#x2013;2210 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047949</ArticleId><ArticleId IdType="pubmed">27349244</ArticleId></ArticleIdList></Reference><Reference><Citation>Vomacka L, et al. TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Res 7, 89 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5693838</ArticleId><ArticleId IdType="pubmed">29150726</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutin H, et al. 18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. Eur J Nucl Med Mol Imaging 42, 503&#x2013;511 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25351507</ArticleId></ArticleIdList></Reference><Reference><Citation>James ML, et al. [(18)F]GE-180 PET Detects Reduced Microglia Activation After LM11A-31 Therapy in a Mouse Model of Alzheimer&#x2019;s Disease. Theranostics 7, 1422&#x2013;1436 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5436503</ArticleId><ArticleId IdType="pubmed">28529627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC &amp; Sheng M TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron 91, 328&#x2013;340 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis 9, 305&#x2013;318 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Mormino E &amp; Johnson K The evolution of preclinical Alzheimer&#x2019;s disease: implications for prevention trials. Neuron 84, 608&#x2013;622 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285623</ArticleId><ArticleId IdType="pubmed">25442939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler-Waldkirch S, et al. Seed-induced Abeta deposition is modulated by microglia under environmental enrichment in a mouse model of Alzheimer&#x2019;s disease. EMBO J 37, 167&#x2013;182 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5770788</ArticleId><ArticleId IdType="pubmed">29229786</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 215, 745&#x2013;760 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer&#x2019;s disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8, 369ra178 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer&#x2019;s disease. Nature 537, 50&#x2013;56 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Hamilton RL, Styren GC &amp; Klunk WE X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer&#x2019;s disease pathology. J Histochem Cytochem 48, 1223&#x2013;1232 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10950879</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel M, et al. Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study. J Nucl Med 57, 954&#x2013;960 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26912428</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhoff F, et al. Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [(18)F]-Florbetaben PET Quantitation in Alzheimer&#x2019;s Model Mice. Front Neurosci 10, 45 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4770021</ArticleId><ArticleId IdType="pubmed">26973442</ArticleId></ArticleIdList></Reference><Reference><Citation>Deussing M, et al. Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [(18)F]GE180 PET quantification. NeuroImage 165, 83&#x2013;91 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28988133</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 283, 677&#x2013;683 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17962197</ArticleId></ArticleIdList></Reference><Reference><Citation>Daria A, et al. Young microglia restore amyloid plaque clearance of aged microglia. EMBO J 36, 583&#x2013;603 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5331757</ArticleId><ArticleId IdType="pubmed">28007893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski JR, Zougman A, Nagaraj N &amp; Mann M Universal sample preparation method for proteome analysis. Nat Methods 6, 359&#x2013;362 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19377485</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappsilber J, Mann M &amp; Ishihama Y Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2, 1896&#x2013;1906 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17703201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruderer R, Bernhardt OM, Gandhi T &amp; Reiter L High-precision iRT prediction in the targeted analysis of data-independent acquisition and its impact on identification and quantitation. Proteomics 16, 2246&#x2013;2256 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094550</ArticleId><ArticleId IdType="pubmed">27213465</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 13, 2513&#x2013;2526 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159666</ArticleId><ArticleId IdType="pubmed">24942700</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30615028</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.</ArticleTitle><Pagination><StartPage>264</StartPage><EndPage>273</EndPage><MedlinePgn>264-273</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.4249</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Racial differences in molecular biomarkers for Alzheimer disease may suggest race-dependent biological mechanisms.</AbstractText><AbstractText Label="OBJECTIVE">To ascertain whether there are racial disparities in molecular biomarkers for Alzheimer disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">A total of 1255 participants (173 African Americans) were enrolled from January 1, 2004, through December 31, 2015, in longitudinal studies at the Knight Alzheimer Disease Research Center at Washington University and completed a magnetic resonance imaging study of the brain and/or positron emission tomography of the brain with Pittsburgh compound B (radioligand for aggregated amyloid-&#x3b2;) and/or cerebrospinal fluid (CSF) assays for the concentrations of amyloid-&#x3b2;42, total tau, and phosphorylated tau181. Independent cross-sectional analyses were conducted from April 22, 2016, to August 27, 2018, for each biomarker modality with an analysis of variance or analysis of covariance including age, sex, educational level, race, apolipoprotein E (APOE) &#x3b5;4 allele status, and clinical status (normal cognition or dementia). All biomarker assessments were conducted without knowledge of the clinical status of the participants.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcomes were hippocampal volumes adjusted for differences in intracranial volumes, global cerebral amyloid burden as transformed into standardized uptake value ratios (partial volume corrected), and CSF concentrations of amyloid-&#x3b2;42, total tau, and phosphorylated tau181.</AbstractText><AbstractText Label="RESULTS">Of the 1255 participants (707 women and 548 men; mean [SD] age, 70.8 [9.9] years), 116 of 173 African American participants (67.1%) and 724 of 1082 non-Hispanic white participants (66.9%) had normal cognition. There were no racial differences in the frequency of cerebral ischemic lesions noted on results of brain magnetic resonance imaging, mean cortical standardized uptake value ratios for Pittsburgh compound B, or for amyloid-&#x3b2;42 concentrations in CSF. However, in individuals with a reported family history of dementia, mean (SE) total hippocampal volumes were lower for African American participants than for white participants (6418.26 [138.97] vs 6990.50 [44.10] mm3). Mean (SE) CSF concentrations of total tau were lower in African American participants than in white participants (293.65 [34.61] vs 443.28 [18.20] pg/mL; P&#x2009;&lt;&#x2009;.001), as were mean (SE) concentrations of phosphorylated tau181 (53.18 [4.91] vs 70.73 [2.46] pg/mL; P&#x2009;&lt;&#x2009;.001). There was a significant race by APOE &#x3b5;4 interaction for both CSF total tau and phosphorylated tau181 such that only APOE &#x3b5;4-positive participants showed the racial differences.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The results of this study suggest that analyses of molecular biomarkers of Alzheimer disease should adjust for race. The lower CSF concentrations of total tau and phosphorylated tau181 in African American individuals appear to reflect a significant race by APOE &#x3b5;4 interaction, suggesting a differential effect of this Alzheimer risk variant in African American individuals compared with white individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCue</LastName><ForeName>Lena M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moulder</LastName><ForeName>Krista L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG053474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG053426</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2019 Mar 1;76(3):251-253. doi: 10.1001/jamaneurol.2018.3444.</RefSource><PMID Version="1">30615027</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30615028</ArticleId><ArticleId IdType="pmc">PMC6439726</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.4249</ArticleId><ArticleId IdType="pii">2719700</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schoenberg BS, Anderson DW, Haerer AF. Severe dementia: prevalence and clinical features in a biracial US population. Arch Neurol. 1985;42(8):740-743. doi:10.1001/archneur.1985.04210090004002</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1985.04210090004002</ArticleId><ArticleId IdType="pubmed">4026605</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Cross P, Andrews H, et al. . Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56(1):49-56. doi:10.1212/WNL.56.1.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.1.49</ArticleId><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Go R, et al. ; MIRAGE Study Group . Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287(3):329-336. doi:10.1001/jama.287.3.329</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.287.3.329</ArticleId><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14&#xa0;years. Alzheimers Dement. 2016;12(3):216-224. doi:10.1016/j.jalz.2015.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.12.007</ArticleId><ArticleId IdType="pmc">PMC4969071</ArticleId><ArticleId IdType="pubmed">26874595</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillenbaum GG, Heyman A, Huber MS, et al. . The prevalence and 3-year incidence of dementia in older black and white community residents. J Clin Epidemiol. 1998;51(7):587-595. doi:10.1016/S0895-4356(98)00024-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(98)00024-9</ArticleId><ArticleId IdType="pubmed">9674666</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AL, Kuller LH, Ives DG, et al. . Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc. 2004;52(2):195-204. doi:10.1111/j.1532-5415.2004.52058.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2004.52058.x</ArticleId><ArticleId IdType="pubmed">14728627</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, Besser LM, Crook JE, Kukull WA, Dickson DW. Neuropathologic differences by race from the National Alzheimer&#x2019;s Coordinating Center. Alzheimers Dement. 2016;12(6):669-677. doi:10.1016/j.jalz.2016.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.004</ArticleId><ArticleId IdType="pmc">PMC4903907</ArticleId><ArticleId IdType="pubmed">27094726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins CH, Grant EA, Schmitt SE, McKeel DW, Morris JC. The neuropathology of Alzheimer disease in African American and white individuals. Arch Neurol. 2006;63(1):87-90. doi:10.1001/archneur.63.1.87</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.1.87</ArticleId><ArticleId IdType="pubmed">16401740</ArticleId></ArticleIdList></Reference><Reference><Citation>Riudavets MA, Rubio A, Cox C, Rudow G, Fowler D, Troncoso JC. The prevalence of Alzheimer neuropathologic lesions is similar in blacks and whites. J Neuropathol Exp Neurol. 2006;65(12):1143-1148. doi:10.1097/01.jnen.0000248548.20799.a3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000248548.20799.a3</ArticleId><ArticleId IdType="pubmed">17146288</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickman AM, Schupf N, Manly JJ, et al. . Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol. 2008;65(8):1053-1061. doi:10.1001/archneur.65.8.1053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.8.1053</ArticleId><ArticleId IdType="pmc">PMC2692286</ArticleId><ArticleId IdType="pubmed">18695055</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Reed BR, Jagust W, Martinez O, Ortega M, Mungas D. Brain behavior relationships among African Americans, whites, and Hispanics. Alzheimer Dis Assoc Disord. 2008;22(4):382-391. doi:10.1097/WAD.0b013e318185e7fe</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318185e7fe</ArticleId><ArticleId IdType="pmc">PMC2743876</ArticleId><ArticleId IdType="pubmed">19068502</ArticleId></ArticleIdList></Reference><Reference><Citation>Manly JJ, Touradji P, Tang MX, Stern Y. Literacy and memory decline among ethnically diverse elders. J Clin Exp Neuropsychol. 2003;25(5):680-690. doi:10.1076/jcen.25.5.680.14579</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/jcen.25.5.680.14579</ArticleId><ArticleId IdType="pubmed">12815505</ArticleId></ArticleIdList></Reference><Reference><Citation>Szanton SL, Rifkind JM, Mohanty JG, et al. . Racial discrimination is associated with a measure of red blood cell oxidative stress: a potential pathway for racial health disparities. Int J Behav Med. 2012;19(4):489-495. doi:10.1007/s12529-011-9188-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12529-011-9188-z</ArticleId><ArticleId IdType="pmc">PMC3496810</ArticleId><ArticleId IdType="pubmed">21913047</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Falvey C, Harris TB, et al. ; Health ABC Study . Effect of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. BMJ. 2013;347:f7051. doi:10.1136/bmj.f7051</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.f7051</ArticleId><ArticleId IdType="pmc">PMC3898154</ArticleId><ArticleId IdType="pubmed">24355614</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Bennett DA. Alzheimer&#x2019;s disease in African Americans: risk factors and challenges for the future. Health Aff (Millwood). 2014;33(4):580-586. doi:10.1377/hlthaff.2013.1353</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2013.1353</ArticleId><ArticleId IdType="pmc">PMC4084964</ArticleId><ArticleId IdType="pubmed">24711318</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Census Bureau  QuickFacts: population estimates, July 1, 2017. 
https://www.census.gov/quickfacts/fact/table/US/PST045217#PST045217. Accessed November 21, 2018.</Citation></Reference><Reference><Citation>Honig LS, Vellas B, Woodward M, et al. . Trial of solanezumab for mild dementia due to Alzheimer&#x2019;s disease. N Engl J Med. 2018;378(4):321-330. doi:10.1056/NEJMoa1705971</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1705971</ArticleId><ArticleId IdType="pubmed">29365294</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Alzheimer&#x2019;s Coordinating Center (NACC) 
https://www.alz.washington.edu/. Accessed November 21, 2018.</Citation></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. . The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE. Neurology. 2016;87(5):473-480. doi:10.1212/WNL.0000000000002914</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002914</ArticleId><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonough IM. Beta-amyloid and cortical thickness reveal racial disparities in preclinical Alzheimer&#x2019;s disease. Neuroimage Clin. 2017;16:659-667. doi:10.1016/j.nicl.2017.09.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.09.014</ArticleId><ArticleId IdType="pmc">PMC5984571</ArticleId><ArticleId IdType="pubmed">29868439</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell JC, Watts KD, Parker MW, et al. . Race modifies the relationship between cognition and Alzheimer&#x2019;s disease cerebrospinal fluid biomarkers. Alzheimers Res Ther. 2017;9(1):88. doi:10.1186/s13195-017-0315-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0315-1</ArticleId><ArticleId IdType="pmc">PMC5668981</ArticleId><ArticleId IdType="pubmed">29096697</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolz R, Schwarz AJ, Gray KR, Yu P, Hill DL; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology. 2016;87(12):1235-1241. doi:10.1212/WNL.0000000000003126</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003126</ArticleId><ArticleId IdType="pmc">PMC5035986</ArticleId><ArticleId IdType="pubmed">27558378</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble JM, Manly JJ, Schupf N, Tang MX, Luchsinger JA. Type 2 diabetes and ethnic disparities in cognitive impairment. Ethn Dis. 2012;22(1):38-44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398739</ArticleId><ArticleId IdType="pubmed">22774307</ArticleId></ArticleIdList></Reference><Reference><Citation>Data USA. St Louis, MO-IL metro area. https://datausa.io/profile/geo/st.-louis-mo-il-metro-area/#intro. Accessed November 21, 2018.</Citation></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. . The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210-216. doi:10.1097/01.wad.0000213865.09806.92</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wad.0000213865.09806.92</ArticleId><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, et al. . The Alzheimer&#x2019;s Disease Centers&#x2019; Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23(2):91-101. doi:10.1097/WAD.0b013e318191c7dd</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318191c7dd</ArticleId><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414. doi:10.1212/WNL.43.11.2412-a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.11.2412-a</ArticleId><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. . Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59(3):512-519. doi:10.1002/ana.20730</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20730</ArticleId><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B. FreeSurfer. Neuroimage. 2012;62(2):774-781. doi:10.1016/j.neuroimage.2012.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.01.021</ArticleId><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, et al. . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968-980. doi:10.1016/j.neuroimage.2006.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.021</ArticleId><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Head D, Parker J, et al. . A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23(2):724-738. doi:10.1016/j.neuroimage.2004.06.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2004.06.018</ArticleId><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Goncharova I, Sullivan MP, et al. . MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer&#x2019;s disease. Neurobiol Aging. 2001;22(5):747-754. doi:10.1016/S0197-4580(01)00271-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00271-8</ArticleId><ArticleId IdType="pubmed">11705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey T, Su Y, et al. . Longitudinal &#x3b2;-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol. 2016;73(10):1192-1200. doi:10.1001/jamaneurol.2016.2642</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.2642</ArticleId><ArticleId IdType="pmc">PMC5237381</ArticleId><ArticleId IdType="pubmed">27548756</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. doi:10.1002/ana.20009</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20009</ArticleId><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, D&#x2019;Angelo GM, Vlassenko AG, et al. . Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One. 2013;8(11):e73377. doi:10.1371/journal.pone.0073377</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0073377</ArticleId><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904-911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Kauwe JS, Mayo K, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer&#x2019;s disease. PLoS Genet. 2010;6(9):e1001101. doi:10.1371/journal.pgen.1001101</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1001101</ArticleId><ArticleId IdType="pmc">PMC2940763</ArticleId><ArticleId IdType="pubmed">20862329</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Sutphen CL, Teunissen C, et al. . Upward drift in cerebrospinal fluid amyloid &#x3b2; 42 assay values for more than 10 years. Alzheimers Dement. 2018;14(1):62-70. doi:10.1016/j.jalz.2017.06.2264</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2264</ArticleId><ArticleId IdType="pmc">PMC5750131</ArticleId><ArticleId IdType="pubmed">28710906</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Flores S, Hornbeck RC, et al. . Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. Neuroimage Clin. 2018;19:406-416. doi:10.1016/j.nicl.2018.04.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2018.04.022</ArticleId><ArticleId IdType="pmc">PMC6051499</ArticleId><ArticleId IdType="pubmed">30035025</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer RP, Sekar P, Osborne J, et al. . Racial/ethnic variation of APOE alleles for lobar intracerebral hemorrhage. Neurology. 2018;91(5):e410-e420. doi:10.1212/WNL.0000000000005908</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005908</ArticleId><ArticleId IdType="pmc">PMC6093767</ArticleId><ArticleId IdType="pubmed">29959260</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523-527. doi:10.1038/nature24016</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x2018;Mini-mental state&#x2019;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Osuntokun BO, Sahota A, Ogunniyi AO, et al. . Lack of an association between apolipoprotein E epsilon 4 and Alzheimer&#x2019;s disease in elderly Nigerians. Ann Neurol. 1995;38(3):463-465. doi:10.1002/ana.410380319</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380319</ArticleId><ArticleId IdType="pubmed">7668835</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestre G, Ottman R, Stern Y, et al. . Apolipoprotein E and Alzheimer&#x2019;s disease: ethnic variation in genotypic risks. Ann Neurol. 1995;37(2):254-259. doi:10.1002/ana.410370217</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410370217</ArticleId><ArticleId IdType="pubmed">7847867</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Jun G, Naj A, et al. ; Alzheimer Disease Genetics Consortium . Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E &#x3f5;4, and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013;309(14):1483-1492. doi:10.1001/jama.2013.2973</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.2973</ArticleId><ArticleId IdType="pmc">PMC3667653</ArticleId><ArticleId IdType="pubmed">23571587</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue MW, Schu M, Vardarajan BN, et al. ; Alzheimer Disease Genetics Consortium . Two rare AKAP9 variants are associated with Alzheimer&#x2019;s disease in African Americans. Alzheimers Dement. 2014;10(6):609-618. doi:10.1016/j.jalz.2014.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.06.010</ArticleId><ArticleId IdType="pmc">PMC4253055</ArticleId><ArticleId IdType="pubmed">25172201</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, Carrasquillo MM, Benitez BA, et al. . TREM2 is associated with increased risk for Alzheimer&#x2019;s disease in African Americans. Mol Neurodegener. 2015;10:19. doi:10.1186/s13024-015-0016-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0016-9</ArticleId><ArticleId IdType="pmc">PMC4426167</ArticleId><ArticleId IdType="pubmed">25886450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mez J, Chung J, Jun G, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium . Two novel loci, COBL and SLC10A2, for Alzheimer&#x2019;s disease in African Americans. Alzheimers Dement. 2017;13(2):119-129. doi:10.1016/j.jalz.2016.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.09.002</ArticleId><ArticleId IdType="pmc">PMC5318231</ArticleId><ArticleId IdType="pubmed">27770636</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30617256</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.</ArticleTitle><Pagination><StartPage>404</StartPage><EndPage>413</EndPage><MedlinePgn>404-413</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-018-0311-9</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is highly heritable and recent studies have identified over 20 disease-associated genomic loci. Yet these only explain a small proportion of the genetic variance, indicating that undiscovered loci remain. Here, we performed a large genome-wide association study of clinically diagnosed AD and AD-by-proxy (71,880 cases, 383,378 controls). AD-by-proxy, based on parental diagnoses, showed strong genetic correlation with AD (r<sub>g</sub>&#x2009;=&#x2009;0.81). Meta-analysis identified 29 risk loci, implicating 215 potential causative genes. Associated genes are strongly expressed in immune-related tissues and cell types (spleen, liver, and microglia). Gene-set analyses indicate biological mechanisms involved in lipid-related processes and degradation of amyloid precursor proteins. We show strong genetic correlations with multiple health-related outcomes, and Mendelian randomization results suggest a protective effect of cognitive ability on AD risk. These results are a step forward in identifying the genetic factors that contribute to AD risk and add novel insights into the neurobiology of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jansen</LastName><ForeName>Iris E</ForeName><Initials>IE</Initials><Identifier Source="ORCID">0000-0003-1901-8131</Identifier><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Savage</LastName><ForeName>Jeanne E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-2034-8341</Identifier><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Kyoko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryois</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Dylan M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Stacy</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7726-5152</Identifier><AffiliationInfo><Affiliation>deCODE Genetics/Amgen, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sealock</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Graduate Program, Vanderbilt University, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlsson</LastName><ForeName>Ida K</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Gerontology and Aging Research Network-J&#xf6;nk&#xf6;ping (ARN-J), School of Health and Welfare, J&#xf6;nk&#xf6;ping University, J&#xf6;nk&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe4;gg</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2452-1500</Identifier><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Athanasiu</LastName><ForeName>Lavinia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NORMENT, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voyle</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proitsi</LastName><ForeName>Petroula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2553-6974</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witoelar</LastName><ForeName>Aree</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NORMENT, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stringer</LastName><ForeName>Sven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3115-8532</Identifier><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Age-Related Diseases, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almdahl</LastName><ForeName>Ina S</ForeName><Initials>IS</Initials><Identifier Source="ORCID">0000-0001-6070-4921</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AHUS Campus, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry of Old Age, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, University of Troms&#xf8;, Troms&#xf8;, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergh</LastName><ForeName>Sverre</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, T&#xf8;nsberg, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Old Age Psychiatry Research, Innlandet Hospital Trust, Ottestad, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bettella</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NORMENT, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjornsson</LastName><ForeName>Sigurbjorn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe6;khus</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, T&#xf8;nsberg, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Department, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe5;then</LastName><ForeName>Geir</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3224-7983</Identifier><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, St Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Leeuw</LastName><ForeName>Christiaan</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1076-9828</Identifier><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desikan</LastName><ForeName>Rahul S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>Srdjan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8140-8061</Identifier><AffiliationInfo><Affiliation>NORMENT, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumitrescu</LastName><ForeName>Logan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory &amp; Alzheimer's Center, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fladby</LastName><ForeName>Tormod</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AHUS Campus, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohman</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-3377-7014</Identifier><AffiliationInfo><Affiliation>Vanderbilt Memory &amp; Alzheimer's Center, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Palmi V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiddle</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-4350-7437</Identifier><AffiliationInfo><Affiliation>MRC Biostatistics Unit, Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rongve</LastName><ForeName>Arvid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Research and Innovation, Helse Fonna, Haugesund, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saltvedt</LastName><ForeName>Ingvild</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sando</LastName><ForeName>Sigrid B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, St Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selb&#xe6;k</LastName><ForeName>Geir</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, T&#xf8;nsberg, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health and Society, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoai</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disorders, Institute of Neurology, UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skene</LastName><ForeName>Nathan G</ForeName><Initials>NG</Initials><Identifier Source="ORCID">0000-0002-6807-3180</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snaedal</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stordal</LastName><ForeName>Eystein</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2443-7923</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Namsos Hospital, Namsos, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulstein</LastName><ForeName>Ingun D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Memory Clinic, Geriatric Department, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yunpeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>NORMENT, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Linda R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, St Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disorders, Institute of Neurology, UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hjerling-Leffler</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4539-1776</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4224-9245</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Informatics Research, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK London, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Lea K</ForeName><Initials>LK</Initials><Identifier Source="ORCID">0000-0001-5143-2282</Identifier><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Hreinn</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>deCODE Genetics/Amgen, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Kari</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1676-864X</Identifier><AffiliationInfo><Affiliation>deCODE Genetics/Amgen, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Nancy L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ripke</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charit&#xe9;-Universit&#xe4;tsmedizin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0002-4461-3568</Identifier><AffiliationInfo><Affiliation>NORMENT, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Posthuma</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7582-2365</Identifier><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands. d.posthuma@vu.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands. d.posthuma@vu.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17214</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>T32 GM080178</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>EP-C-14-005</GrantID><Acronym>EPA</Acronym><Agency>EPA</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/P021573/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 MH109536</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG059716</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049164</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Genet. 2020 Mar;52(3):354. doi: 10.1038/s41588-019-0573-x.</RefSource><PMID Version="1">32029921</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests Statement. The authors report the following potentially competing financial
interests. P.F.S.: Lundbeck (advisory committee), Pfizer (Scientific Advisory
Board member), and Roche (grant recipient, speaker reimbursement). J.H.L.:
Cartana (Scientific Advisor) and Roche (grant recipient). O.A.A.: Lundbeck
(speaker&#x2019;s honorarium). St.St., H.S., and K.S. are employees of deCODE
Genetics/Amgen. J.H. is a cograntee of Cytox from Innovate UK (UK Department of
Business). D.A. has received research support and/or honoraria from
Astra-Zeneca, Lundbeck, Novartis Pharmaceuticals, and GE Health, and serves as a
paid consultant for Lundbeck, Eisai, Heptares, and Axovant. All other authors
declare no financial interests or potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30617256</ArticleId><ArticleId IdType="mid">NIHMS1031924</ArticleId><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="doi">10.1038/s41588-018-0311-9</ArticleId><ArticleId IdType="pii">10.1038/s41588-018-0311-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association 2013; 9(1): 63&#x2013;75.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006; 63(2): 168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset Alzheimer&#x2019;s disease revisited. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association 2016; 12(6): 733&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">27016693</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet 2013; 45(12): 1452&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature 1991; 349(6311): 704&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#x2019;s disease. Nature 1995; 375(6534): 754&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Froelich S, Sorbi S, et al. Alzheimer&#x2019;s disease associated with mutations in presenilin 2 is rare and variably penetrant. Human molecular genetics 1996; 5(7): 985&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8817335</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer&#x2019;s disease: an appraisal for the development of therapeutics. Nature reviews Drug discovery 2011; 10(9): 698&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. The New England journal of medicine 2013; 368(2): 107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S, Stefansson H, Jonsson T, et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer&#x2019;s disease. Nature genetics 2015; 47(5): 445&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature reviews Neurology 2013; 9(2): 106&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, Erlich Y, Pickrell JK. Case-control association mapping by proxy using family history of disease. Nat Genet 2017; 49(3): 325&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28092683</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, Harris SE, Zhang Q, et al. GWAS on family history of Alzheimer&#x2019;s disease. Transl Psychiatry 2018; 8: 99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet 2015; 47(3): 291&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bakker PIW, Ferreira MAR, Jia X, Neale BM, Raychaudhuri S, Voight BF. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genet 2008; 17(R2): R122&#x2013;R8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782358</ArticleId><ArticleId IdType="pubmed">18852200</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med 2013; 368(2): 117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Schork AJ, Wang Y, et al. Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. Circulation 2015; 131(23): 2061&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4677995</ArticleId><ArticleId IdType="pubmed">25862742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nature genetics 2017; 49(9): 1373&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson DF, Helgason H, Gudjonsson SA, et al. Large-scale whole-genome sequencing of the Icelandic population. Nature genetics 2015; 47(5): 435&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">25807286</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinthorsdottir V, Thorleifsson G, Sulem P, et al. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nature genetics 2014; 46(3): 294&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24464100</ArticleId></ArticleIdList></Reference><Reference><Citation>Euesden J, Lewis CM, O&#x2019;Reilly PF. PRSice: Polygenic Risk Score software. Bioinformatics 2015; 31(9): 1466&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410663</ArticleId><ArticleId IdType="pubmed">25550326</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Myers AJ, Huentelman M, Hardy J. Polygenic risk score analysis of pathologically confirmed Alzheimer disease. Annals of Neurology 2017; 82(2): 311&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599118</ArticleId><ArticleId IdType="pubmed">28727176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M, Witten DM, Jain P, O&#x2019;Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nature genetics 2014; 46(3): 310&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511(7510): 421&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112379</ArticleId><ArticleId IdType="pubmed">25056061</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK, Bulik-Sullivan B, Gusev A, et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nature genetics 2015; 47(11): 1228&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626285</ArticleId><ArticleId IdType="pubmed">26414678</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nature communications 2017; 8(1): 1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705698</ArticleId><ArticleId IdType="pubmed">29184056</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerberg L, Hallstrom BM, Oksvold P, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Molecular &amp; Cellular Proteomics : MCP 2014; 13(2): 397&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916642</ArticleId><ArticleId IdType="pubmed">24309898</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurses MS, Ural MN, Gulec MA, Akyol O, Akyol S. Pathophysiological Function of ADAMTS Enzymes on Molecular Mechanism of Alzheimer&#x2019;s Disease. Aging and disease 2016; 7(4): 479&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4963191</ArticleId><ArticleId IdType="pubmed">27493839</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh J, Choi SH, Romano DM, et al. ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. Neuron 2013; 80(2): 385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105199</ArticleId><ArticleId IdType="pubmed">24055016</ArticleId></ArticleIdList></Reference><Reference><Citation>Dries DR, Yu G. Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer&#x2019;s disease. Current Alzheimer research 2008; 5(2): 132&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474811</ArticleId><ArticleId IdType="pubmed">18393798</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitriu A, Golji J, Labadorf AT, et al. Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease. BMC medical genomics 2016; 9: 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4722694</ArticleId><ArticleId IdType="pubmed">26793951</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol 2015; 11(4): e1004219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>Expansion of the Gene Ontology knowledgebase and resources. Nucleic acids research 2017; 45(D1): D331&#x2013;d8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210579</ArticleId><ArticleId IdType="pubmed">27899567</ArticleId></ArticleIdList></Reference><Reference><Citation>Anttila V, Bulik-Sullivan B, Finucane HK, et al. Analysis of shared heritability in common disorders of the brain. Science 2018; 360(6395).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097237</ArticleId><ArticleId IdType="pubmed">29930110</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage JE, Jansen PR, Stringer S, et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat Genet 2018; 50(7): 9129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6411041</ArticleId><ArticleId IdType="pubmed">29942086</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Zheng Z, Zhang F, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nature communications 2018; 9(1): 224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5768719</ArticleId><ArticleId IdType="pubmed">29335400</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene NG, Grant SG. Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment. Frontiers in neuroscience 2016; 10: 16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730103</ArticleId><ArticleId IdType="pubmed">26858593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Rivest S. Lipid metabolism and neuroinflammation in Alzheimer&#x2019;s disease: a role for liver X receptors. Endocrine reviews 2012; 33(5): 715&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">22766509</ArticleId></ArticleIdList></Reference><Reference><Citation>Loewendorf A, Fonteh A, Mg H, Me C. Inflammation in Alzheimer&#x2019;s Disease: Cross-talk between Lipids and Innate Immune Cells of the Brain; 2015.</Citation></Reference><Reference><Citation>Stern Y Cognitive reserve in ageing and Alzheimer&#x2019;s disease. The Lancet Neurology 2012; 11(11): 1006&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Satizabal C, Beiser AS, Seshadri S. Incidence of Dementia over Three Decades in the Framingham Heart Study. The New England journal of medicine 2016; 375(1): 93&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6374770</ArticleId><ArticleId IdType="pubmed">27406362</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams HH, Hibar DP, Chouraki V, et al. Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature neuroscience 2016; 19(12): 1569&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5227112</ArticleId><ArticleId IdType="pubmed">27694991</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikram MA, Fornage M, Smith AV, et al. Common variants at 6q22 and 17q21 are associated with intracranial volume. Nature genetics 2012; 44(5): 539&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618290</ArticleId><ArticleId IdType="pubmed">22504418</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves AB, Mortimer JA, Larson EB, Wenzlow A, Bowen JD, McCormick WC. Head circumference as a measure of cognitive reserve. Association with severity of impairment in Alzheimer&#x2019;s disease. The British journal of psychiatry : the journal of mental science 1996; 169(1): 86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8818374</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott RD, White LR, Ross GW, et al. Height as a marker of childhood development and late-life cognitive function: the Honolulu-Asia Aging Study. Pediatrics 1998; 102(3 Pt 1): 602&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9738183</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuffrida ML, Tomasello F, Caraci F, Chiechio S, Nicoletti F, Copani A. Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer&#x2019;s disease. Molecular neurobiology 2012; 46(3): 605&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">22886436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience 2015; 4: 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. Nature genetics 2015; 47(11): 1236&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4797329</ArticleId><ArticleId IdType="pubmed">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Ferreira T, Morris AP, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet 2012; 44(4): 369&#x2013;75, s1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593158</ArticleId><ArticleId IdType="pubmed">22426310</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S, Francis P, Kloszewska I, et al. AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer&#x2019;s disease. Annals of the New York Academy of Sciences 2009; 1180: 36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">19906259</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC bioinformatics 2011; 12: 77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic acids research 2010; 38(16): e164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome research 2012; 22(9): 1790&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431494</ArticleId><ArticleId IdType="pubmed">22955989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nature methods 2012; 9(3): 215&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577932</ArticleId><ArticleId IdType="pubmed">22373907</ArticleId></ArticleIdList></Reference><Reference><Citation>Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015; 518(7539): 317&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="pubmed">25693563</ArticleId></ArticleIdList></Reference><Reference><Citation>Amendola LM, Dorschner MO, Robertson PD, et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome research 2015; 25(3): 305&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352885</ArticleId><ArticleId IdType="pubmed">25637381</ArticleId></ArticleIdList></Reference><Reference><Citation>Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science (New York, NY) 2015; 348(6235): 648&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nature genetics 2013; 45(10): 1238&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991562</ArticleId><ArticleId IdType="pubmed">24013639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhernakova DV, Deelen P, Vermaat M, et al. Identification of context-dependent expression quantitative trait loci in whole blood. Nature genetics 2017; 49(1): 139&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">27918533</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt AD, Hu M, Jung I, et al. A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. Cell reports 2016; 17(8): 2042&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5478386</ArticleId><ArticleId IdType="pubmed">27851967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy A, Trabzuni D, Guelfi S, et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. Nature neuroscience 2014; 17(10): 1418&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4208299</ArticleId><ArticleId IdType="pubmed">25174004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromer M, Roussos P, Sieberts SK, et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nature neuroscience 2016; 19(11): 1442&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5083142</ArticleId><ArticleId IdType="pubmed">27668389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B, White CC, Klein HU, et al. An xQTL map integrates the genetic architecture of the human brain&#x2019;s transcriptome and epigenome. Nature neuroscience 2017; 20(10): 1418&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005; 102(43): 15545&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N, Avraham-Davidi I, Basu A, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nature methods 2017; 14(10): 955&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30635412</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>116</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R).</ArticleTitle><Pagination><StartPage>1686</StartPage><EndPage>1691</EndPage><MedlinePgn>1686-1691</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1812155116</ELocationID><Abstract><AbstractText>While neuroinflammation is an evolving concept and the cells involved and their functions are being defined, microglia are understood to be a key cellular mediator of brain injury and repair. The ability to measure microglial activity specifically and noninvasively would be a boon to the study of neuroinflammation, which is involved in a wide variety of neuropsychiatric disorders including traumatic brain injury, demyelinating disease, Alzheimer's disease (AD), and Parkinson's disease, among others. We have developed [<sup>11</sup>C]CPPC [5-cyano-<i>N</i>-(4-(4-[<sup>11</sup>C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide], a positron-emitting, high-affinity ligand that is specific for the macrophage colony-stimulating factor 1 receptor (CSF1R), the expression of which is essentially restricted to microglia within brain. [<sup>11</sup>C]CPPC demonstrates high and specific brain uptake in a murine and nonhuman primate lipopolysaccharide model of neuroinflammation. It also shows specific and elevated uptake in a murine model of AD, experimental allergic encephalomyelitis murine model of demyelination and in postmortem brain tissue of patients with AD. Radiation dosimetry in mice indicated [<sup>11</sup>C]CPPC to be safe for future human studies. [<sup>11</sup>C]CPPC can be synthesized in sufficient radiochemical yield, purity, and specific radioactivity and possesses binding specificity in relevant models that indicate potential for human PET imaging of CSF1R and the microglial component of neuroinflammation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horti</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; ahorti1@jhmi.edu mpomper@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naik</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foss</LastName><ForeName>Catherine A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minn</LastName><ForeName>Il</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misheneva</LastName><ForeName>Varia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuchuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., West Point, PA 19486.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>William B</ForeName><Initials>WB</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yunkou</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaCourse</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Hye-Hyun</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Hwanhee</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesniak</LastName><ForeName>Wojciech G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valentine</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletnikova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabresi</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-7776-6472</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savonenko</LastName><ForeName>Alena V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dannals</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletnikov</LastName><ForeName>Mikhail V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomper</LastName><ForeName>Martin G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; ahorti1@jhmi.edu mpomper@jhmi.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS041435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB024495</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 AG054802</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG054802</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000622186">CSF1R protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016187">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>81627-83-0</RegistryNumber><NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011323" MajorTopicYN="N">Primates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016187" MajorTopicYN="N">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CSF1R</Keyword><Keyword MajorTopicYN="N">DAM</Keyword><Keyword MajorTopicYN="N">[11C]CPPC</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">positron-emission tomography</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30635412</ArticleId><ArticleId IdType="pmc">PMC6358677</ArticleId><ArticleId IdType="doi">10.1073/pnas.1812155116</ArticleId><ArticleId IdType="pii">1812155116</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masgrau R, Guaza C, Ransohoff RM, Galea E. Should we stop saying &#x2018;glia&#x2019; and &#x2018;neuroinflammation&#x2019;? Trends Mol Med. 2017;23:486&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">28499701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronel C, et al. Molecular targets for PET imaging of activated microglia: The current situation and future expectations. Int J Mol Sci. 2017;18:E802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412386</ArticleId><ArticleId IdType="pubmed">28398245</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen B, Vugts DJ, Windhorst AD, Mach RH. PET imaging of microglial activation-beyond targeting TSPO. Molecules. 2018;23:607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6017265</ArticleId><ArticleId IdType="pubmed">29518005</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Barres BA, Bennett ML. Microglia: Scapegoat, saboteur, or something else? Science. 2013;339:156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431634</ArticleId><ArticleId IdType="pubmed">23307732</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, et al. Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer&#x2019;s disease and amyotrophic lateral sclerosis. Brain Res. 1994;639:171&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">7514086</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyraud F, Cousin S, Italiano A. CSF-1R inhibitor development: Current clinical status. Curr Oncol Rep. 2017;19:70.</Citation><ArticleIdList><ArticleId IdType="pubmed">28875266</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V, Gokhan &#x15e;, Nandi S, Mehler MF, Stanley ER. Emerging roles for CSF-1 receptor and its ligands in the nervous system. Trends Neurosci. 2016;39:378&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4884457</ArticleId><ArticleId IdType="pubmed">27083478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Tang TM, Lue LF. Studies on colony stimulating factor receptor-1 and ligands colony stimulating factor-1 and interleukin-34 in Alzheimer&#x2019;s disease brains and human microglia. Front Aging Neurosci. 2017;9:244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552759</ArticleId><ArticleId IdType="pubmed">28848420</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AM, et al. M-CSF increases proliferation and phagocytosis while modulating receptor and transcription factor expression in adult human microglia. J Neuroinflammation. 2013;10:85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3729740</ArticleId><ArticleId IdType="pubmed">23866312</ArticleId></ArticleIdList></Reference><Reference><Citation>Palle P, Monaghan KL, Milne SM, Wan ECK. Cytokine signaling in multiple sclerosis and its therapeutic applications. Med Sci (Basel) 2017;5:E0023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753652</ArticleId><ArticleId IdType="pubmed">29099039</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Gamal MI, et al. Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors. J Med Chem. 2018;61:5450&#x2013;5466.</Citation><ArticleIdList><ArticleId IdType="pubmed">29293000</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, et al. Inflammatory repertoire of Alzheimer&#x2019;s disease and nondemented elderly microglia in vitro. Glia. 2001;35:72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11424194</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy GM, Jr, Zhao F, Yang L, Cordell B. Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer&#x2019;s disease. Am J Pathol. 2000;157:895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885684</ArticleId><ArticleId IdType="pubmed">10980129</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, et al. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer&#x2019;s disease. Nature. 1997;389:689&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">9338779</ArticleId></ArticleIdList></Reference><Reference><Citation>Boissonneault V, et al. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer&#x2019;s disease. Brain. 2009;132:1078&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">19151372</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, et al. Disease-associated microglia: A universal immune sensor of neurodegeneration. Cell. 2018;173:1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Raivich G, et al. Regulation of MCSF receptors on microglia in the normal and injured mouse central nervous system: A quantitative immunofluorescence study using confocal laser microscopy. J Comp Neurol. 1998;395:342&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596528</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Morin C, Ayrignac X, Ellie E, Tournier-Lasserve E, Labauge P. CSF1R-related leukoencephalopathy mimicking primary progressive multiple sclerosis. J Neurol. 2016;263:1864&#x2013;1865.</Citation><ArticleIdList><ArticleId IdType="pubmed">27314966</ArticleId></ArticleIdList></Reference><Reference><Citation>Alterman RL, Stanley ER. Colony stimulating factor-1 expression in human glioma. Mol Chem Neuropathol. 1994;21:177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">8086034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentz MR, et al. Exploring the relationship of macrophage colony-stimulating factor levels on neuroaxonal metabolism and cognition during chronic human immunodeficiency virus infection. J Neurovirol. 2010;16:368&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164773</ArticleId><ArticleId IdType="pubmed">20839921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Gauthier V, Schirrmacher R. 5-(4-((4-[(18)F]Fluorobenzyl)oxy)-3-methoxybenzyl)pyrimidine-2,4-diamine: A selective dual inhibitor for potential PET imaging of Trk/CSF-1R. Bioorg Med Chem Lett. 2014;24:4784&#x2013;4790.</Citation><ArticleIdList><ArticleId IdType="pubmed">25257201</ArticleId></ArticleIdList></Reference><Reference><Citation>Illig CR, et al. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. Bioorg Med Chem Lett. 2008;18:1642&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">18242992</ArticleId></ArticleIdList></Reference><Reference><Citation>Krauser JA, et al. Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite. Xenobiotica. 2015;45:107&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">25180976</ArticleId></ArticleIdList></Reference><Reference><Citation>DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203524</ArticleId><ArticleId IdType="pubmed">22039576</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnikova T, et al. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci. 2013;33:3765&#x2013;3779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711622</ArticleId><ArticleId IdType="pubmed">23447589</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobos N, et al. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimers Dis. 2012;28:905&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">22112548</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55:453&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871685</ArticleId><ArticleId IdType="pubmed">17203472</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MV, et al. Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J Neuroimmunol. 2008;199:83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">18582952</ArticleId></ArticleIdList></Reference><Reference><Citation>Catorce MN, Gevorkian G. LPS-induced murine neuroinflammation model: Main features and suitability for pre-clinical assessment of nutraceuticals. Curr Neuropharmacol. 2016;14:155&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825946</ArticleId><ArticleId IdType="pubmed">26639457</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi S, et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev Biol. 2012;367:100&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388946</ArticleId><ArticleId IdType="pubmed">22542597</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson MD, et al. CSF-1 deficiency in mice results in abnormal brain development. Development. 1996;122:2661&#x2013;2672.</Citation><ArticleIdList><ArticleId IdType="pubmed">8787741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SC, et al. Macrophage colony-stimulating factor in human fetal astrocytes and microglia. Differential regulation by cytokines and lipopolysaccharide, and modulation of class II MHC on microglia. J Immunol. 1993;150:594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">8419491</ArticleId></ArticleIdList></Reference><Reference><Citation>Aid S, Parikh N, Palumbo S, Bosetti F. Neuronal overexpression of cyclooxygenase-2 does not alter the neuroinflammatory response during brain innate immune activation. Neurosci Lett. 2010;478:113&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891071</ArticleId><ArticleId IdType="pubmed">20451580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickens AM, et al. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med. 2014;55:466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">24516258</ArticleId></ArticleIdList></Reference><Reference><Citation>5. Federal Register &#xa7;361.1 (2018), pp 21378&#x2013;21381.</Citation></Reference><Reference><Citation>Hannestad J, et al. Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates. Neuroimage. 2012;63:232&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699786</ArticleId><ArticleId IdType="pubmed">22776451</ArticleId></ArticleIdList></Reference><Reference><Citation>Heppner FL, Ransohoff RM, Becher B. Immune attack: The role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991443</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, El Khoury J. TREM2 and the neuroimmunology of Alzheimer&#x2019;s disease. Biochem Pharmacol. 2014;88:495&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972304</ArticleId><ArticleId IdType="pubmed">24355566</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30630874</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>363</Volume><Issue>6428</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Recognition of the amyloid precursor protein by human &#x3b3;-secretase.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaw0930</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aaw0930</ELocationID><Abstract><AbstractText>Cleavage of amyloid precursor protein (APP) by the intramembrane protease &#x3b3;-secretase is linked to Alzheimer's disease (AD). We report an atomic structure of human &#x3b3;-secretase in complex with a transmembrane (TM) APP fragment at 2.6-angstrom resolution. The TM helix of APP closely interacts with five surrounding TMs of PS1 (the catalytic subunit of &#x3b3;-secretase). A hybrid &#x3b2; sheet, which is formed by a &#x3b2; strand from APP and two &#x3b2; strands from PS1, guides &#x3b3;-secretase to the scissile peptide bond of APP between its TM and &#x3b2; strand. Residues at the interface between PS1 and APP are heavily targeted by recurring mutations from AD patients. This structure, together with that of &#x3b3;-secretase bound to Notch, reveal contrasting features of substrate binding, which may be applied toward the design of substrate-specific inhibitors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Rui</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0782-4761</Identifier><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Guanghui</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6835-1611</Identifier><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xuefei</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-7135-0954</Identifier><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Biology, Westlake Institute for Advanced Study, Westlake University, 18 Shilongshan Road, Xihu District, Hangzhou 310024, Zhejiang Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Sciences, Westlake University, 18 Shilongshan Road, Xihu District, Hangzhou 310024, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Jianlin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9384-8742</Identifier><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technology Center for Protein Sciences, Ministry of Education Key Laboratory of Protein Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yigong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2030-168X</Identifier><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China. shi-lab@tsinghua.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biology, Westlake Institute for Advanced Study, Westlake University, 18 Shilongshan Road, Xihu District, Hangzhou 310024, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2019 Feb 15;363(6428):690-691. doi: 10.1126/science.aaw5547.</RefSource><PMID Version="1">30765551</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020134" MajorTopicYN="Y">Catalytic Domain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072756" MajorTopicYN="N">Protein Conformation, alpha-Helical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072757" MajorTopicYN="N">Protein Conformation, beta-Strand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="Y">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30630874</ArticleId><ArticleId IdType="doi">10.1126/science.aaw0930</ArticleId><ArticleId IdType="pii">science.aaw0930</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30626715</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>474</Issue><PubDate><Year>2019</Year><Month>Jan</Month><Day>09</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaau6550</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aau6550</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD), deposition of insoluble amyloid-&#x3b2; (A&#x3b2;) is followed by intracellular aggregation of tau in the neocortex and subsequent neuronal cell loss, synaptic loss, brain atrophy, and cognitive impairment. By the time even the earliest clinical symptoms are detectable, A&#x3b2; accumulation is close to reaching its peak and neocortical tau pathology is frequently already present. The period in which AD pathology is accumulating in the absence of cognitive symptoms represents a clinically relevant time window for therapeutic intervention. Sleep is increasingly recognized as a potential marker for AD pathology and future risk of cognitive impairment. Previous studies in animal models and humans have associated decreased non-rapid eye movement (NREM) sleep slow wave activity (SWA) with A&#x3b2; deposition. In this study, we analyzed cognitive performance, brain imaging, and cerebrospinal fluid (CSF) AD biomarkers in participants enrolled in longitudinal studies of aging. In addition, we monitored their sleep using a single-channel electroencephalography (EEG) device worn on the forehead. After adjusting for multiple covariates such as age and sex, we found that NREM SWA showed an inverse relationship with AD pathology, particularly tauopathy, and that this association was most evident at the lowest frequencies of NREM SWA. Given that our study participants were predominantly cognitively normal, this suggested that changes in NREM SWA, especially at 1 to 2 Hz, might be able to discriminate tau pathology and cognitive impairment either before or at the earliest stages of symptomatic AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lucey</LastName><ForeName>Brendan P</ForeName><Initials>BP</Initials><Identifier Source="ORCID">0000-0001-5400-825X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. luceyb@wustl.edu holtzman@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>Austin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9192-111X</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landsness</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toedebusch</LastName><ForeName>Cristina D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLeland</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaza</LastName><ForeName>Aiad M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCue</LastName><ForeName>Lena</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9869-6736</Identifier><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><Identifier Source="ORCID">0000-0002-8114-0552</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. luceyb@wustl.edu holtzman@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054567</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG052550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76 AG054863</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB009352</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS098577</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002346</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 EB021955</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR000450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Mar;15(3):126-127. doi: 10.1038/s41582-019-0140-1.</RefSource><PMID Version="1">30700823</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Sci Transl Med. 2020 Jan 8;12(525):eaba5187. doi: 10.1126/scitranslmed.aba5187.</RefSource><PMID Version="1">31915302</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005133" MajorTopicYN="N">Eye Movements</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077310" MajorTopicYN="N">Sleep, Slow-Wave</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: BPL, AM, ECL, CDT, JSM, AMZ, LM, and CX: No competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30626715</ArticleId><ArticleId IdType="mid">NIHMS1004823</ArticleId><ArticleId IdType="pmc">PMC6342564</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aau6550</ArticleId><ArticleId IdType="pii">11/474/eaau6550</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med 367, 795&#x2013;804 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ, Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol 9, 119&#x2013;128 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price JL, Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer&#x2019;s disease. J Molec Neurosci 17, 101&#x2013;118 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Amyloid-beta-42 in humans. Ann Neurol 59, 512&#x2013;519 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM, Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343&#x2013;349 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn J, Leverenz J, Brodey M, Schellenberg G, Kaye J, Raskind M, Zhang J, Peskind E, Montine T, CSF tau/amyloid-beta(42) ratio for increased risk of mild cognitive impairment. Neurology 69, 631&#x2013;639 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L, Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228&#x2013;234 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC, Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol 45, 358&#x2013;368 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH, Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; Dementia 7, 280&#x2013;292 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y-E, Lucey BP, Holtzman DM, Sleep and Alzheimer disease pathology-a bidirectional relationship. Nat Rev Neurol 10, 115&#x2013;119 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979317</ArticleId><ArticleId IdType="pubmed">24366271</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Bateman RJ, Amyloid-&#x3b2; diurnal pattern: possible role of sleep in Alzheimer&#x2019;s disease pathogenesis. Neurobiol Aging 35, S29&#x2013;S34 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24910393</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM, Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science 354, 1004&#x2013;1008 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5219881</ArticleId><ArticleId IdType="pubmed">27885006</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldemichael DA, Grossberg GT, Circadian rhythm disturbances in patients with Alzheimer&#x2019;s disease. Int J Alzheimers Dis, 716453 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939436</ArticleId><ArticleId IdType="pubmed">20862344</ArticleId></ArticleIdList></Reference><Reference><Citation>McCurry SM, Logsdon RG, Teri L, Gibbons LE, Kukull WA, Bowen JD, McCormick WC, Larson EB, Characteristics of sleep disturbance in community-dwelling Alzheimer&#x2019;s disease patients. J Geriatr Psychiatry Neurol 12, 53&#x2013;59 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10483925</ArticleId></ArticleIdList></Reference><Reference><Citation>Tworoger SS, Lee S, Schernhammer ES, Grodstein F, The association of self-reported sleep duration, difficulty sleeping, and snoring with cognitive function in older women. Alzheimer Dis Assoc Disord 20, 41&#x2013;48 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16493235</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Gamaldo AA, An Y, Wu MN, Simonsick EM, Bilgel M, Zhou Y, Wong DF, Ferrucci L, Resnick SM, Self-reported sleep and &#x3b2;-amyloid deposition in community-dwelling older adults. JAMA Neurol 70, 1537&#x2013;1543 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918480</ArticleId><ArticleId IdType="pubmed">24145859</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho DZ, Louis EKS, Knopman DS, Boeve BF, Lowe VJ, Roberts RO, Mielke MM, Przybelski SA, Machulda MM, Petersen RC, Jack CR, Vemuri P, Association of excessive daytime sleepiness with longitudinal &#x3b2;-amyloid accumulation in elderly persons without dementia. JAMA Neurol, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885188</ArticleId><ArticleId IdType="pubmed">29532057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y-E, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley S, Morris JC, Holtzman DM, Sleep quality and preclinical Alzheimer&#x2019;s disease. JAMA Neurol 70, 587&#x2013;593 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Laffan AM, Harrison SL, Redline S, Spira AP, Ensrud KE, Ancoli-Israel S, Stone KL, Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 306, 613&#x2013;619 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600944</ArticleId><ArticleId IdType="pubmed">21828324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancoli-Israel S, Palmer BW, Cooke JR, Corey-Bloom J, Fiorentino L, Natarajan L, Liu L, Ayalon L, He F, Loredo JS, Cognitive effects of treating obstructive sleep apnea in Alzheimer&#x2019;s disease: a randomized controlled study. J Am Geriatr Soc 56, 2076&#x2013;2081 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585146</ArticleId><ArticleId IdType="pubmed">18795985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke JR, Ayalon L, Palmer BW, Loredo JS, Corey-Bloom J, Natarajan L, Liu L, Ancoli-Israel S, Sustained use of CPAP slows deterioration of cognition, sleep, and mood in patients with Alzheimer&#x2019;s disease and obstructive sleep apnea: a preliminary study. J Clin Sleep Med 5, 305&#x2013;309 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725246</ArticleId><ArticleId IdType="pubmed">19968005</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Y, Blackwell T, Stone KL, Hoang TD, Redline S, Yaffe K, Periodic limb movements in sleep are associated with greater cognitive decline in older men without dementia. Sleep 39, 1807&#x2013;1810 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5020362</ArticleId><ArticleId IdType="pubmed">27568800</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J-E, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM, Amyloid-&#x3b2; dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005&#x2013;1007 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju Y-E, Kasten T, Morris JC, Mintun M, Duntley S, Bateman RJ, Effects of age and amyloid deposition on A&#x3b2; dynamics in the human central nervous system. Arch Neurol 69, 51&#x2013;58 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254706</ArticleId><ArticleId IdType="pubmed">21911660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Gonzales C, Das U, Li J, Siemers ER, Slemmon JR, Bateman RJ, Huang Y, Fox GB, Claassen JA, Slats D, Verbeek MM, Tong G, Soares H, Savage MJ, Kennedy M, Forman M, Sj&#xf6;gren M, Margolin R, Chen X, Farlow MR, Dean RA, Waring JF, An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-&#x3b2; concentrations collected by lumbar puncture and indwelling lumbar catheter. Alzheimers Res Ther 7, 53 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518529</ArticleId><ArticleId IdType="pubmed">26225140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Mawuenyega KG, Patterson BW, Elbert DL, Ovod V, Kasten T, Morris JC, Bateman RJ, Associations Between &#x3b2;-Amyloid Kinetics and the &#x3b2;-Amyloid Diurnal Pattern in the Central Nervous System. JAMA Neurol 74, 207&#x2013;215 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305432</ArticleId><ArticleId IdType="pubmed">27992627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee J-M, Holtzman DM, Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci 14, 750&#x2013;756 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang J-E, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM, Endocytosis is required for synaptic activity-dependent release of Amyloid-beta in vivo. Neuron 58, 42&#x2013;51 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM, Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron 48, 913&#x2013;922 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR, Opposing synaptic regulation of Amyloid-beta metabolism by NMDA receptors in vivo. J Neurosci 31, 11328&#x2013;11337 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329800</ArticleId><ArticleId IdType="pubmed">21813692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R, APP processing and synaptic function. Neuron 37, 925&#x2013;937 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y-ES, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM, Claassen JA, Holtzman DM, Slow wave sleep disruption increases cerebrospinal fluid amyloid-&#x3b2; levels. Brain 140, 2104&#x2013;2111 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790144</ArticleId><ArticleId IdType="pubmed">28899014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Hicks TJ, McLeland JS, Toedebusch CD, Boyd J, Elbert DL, Patterson BW, Baty J, Morris JC, Ovod V, Mawuenyega KG, Bateman RJ, Effect of sleep on overnight CSF amyloid-&#x3b2; kinetics. Ann Neurol 83, 197&#x2013;204 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876097</ArticleId><ArticleId IdType="pubmed">29220873</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O&#x2019;Donnell J, Christensen DJ, Nicholson C, Illiff JJ, Takano T, Deane R, Nedergaard M, Sleep drives metabolite clearance from the adult brain. Science 342, 373&#x2013;377 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM, Disruption of the sleep-wake cycle and diurnal fluctuation of amyloid-&#x3b2; in mice with Alzheimer&#x2019;s disease pathology. Sci Transl Med 4, 150ra122 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Mahan TE, Robinson GO, Rocha A, Holtzman DM, Altered sleep and EEG power in the P301S tau transgenic mouse model. Ann Clin Transl Neurol 4, 180&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338139</ArticleId><ArticleId IdType="pubmed">28275652</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Rao V, Lu B, Saletin JM, Lindquist JR, Ancoli-Israel S, Jagust W, Walker MP, Prefrontal atrophy, disrupted NREM slow waves and impaired hippocampal-dependent memory in aging. Nat Neurosci 16, 357&#x2013;364 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286370</ArticleId><ArticleId IdType="pubmed">23354332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Marks SM, Vogel JW, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP, &#x3b2;-amyloid deposition in the human brain disrupts NREM slow wave sleep and associated hippocampus-dependent long-term memory. Nat Neurosci 18, 1051&#x2013;1057 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482795</ArticleId><ArticleId IdType="pubmed">26030850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Holtzman DM, How amyloid, sleep, and memory connect. Nat Neurosci 18, 933&#x2013;934 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4770804</ArticleId><ArticleId IdType="pubmed">26108720</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, The clinical dementia rating (CDR): current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, Miller JP, Storandt M, Duchek J, Morris JC, Rubin EH, Burke WJ, Coben LA, Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. Ann Neurol 23, 477&#x2013;484 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TL, Raichle M, Koudelis D, Butler T, Hornbeck R, Pulizos C, Knight ADRC Research Imaging (KARI) Methods and Definitions DR14 v1.1. (Washington University in St Louis, St Louis, MO, 2018).</Citation></Reference><Reference><Citation>Su Y, D&#x2019;Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, Blazey TM, Christensen JJ, Vora S, Morris JC, Mintun MA, Benzinger TL, Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE 8, e73377 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, Gordon BA, Su Y, Christensen J, Friedrichsen K, Jackson K, Hornbeck R, Balota DA, Cairns NJ, Morris JC, Ances BM, Benzinger TL, AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. Neuroimage 161, 171&#x2013;178 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696044</ArticleId><ArticleId IdType="pubmed">28756238</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TL, Holtzman DM, Morris JC, Fagan AM, Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 1&#x2013;10 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119652</ArticleId><ArticleId IdType="pubmed">29501462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Campbell I, Feinberg I, Internight reliability and benchmark values for computer analyses of non-rapid eye movement (NREM) and REM EEG in normal young adult and elderly subjects. Clin Neurophysiol 112, 1540&#x2013;1552 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11459695</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Sowers M, Buysse DJ, Consens F, Kravitz HM, Matthews KA, Owens JF, Gold EB, Hall M, Sources of variability in epidemiological studies of sleep using repeated nights of in-home polysomnography: SWAN sleep study. J Clin Sleep Med 8, 87&#x2013;96 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266336</ArticleId><ArticleId IdType="pubmed">22334814</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda N, Honma H, Kohsaka M, Kobayashi R, Sakakibara S, Kohsaka S, Koyama T, Gender difference of slow wave sleep in middle aged and elderly subjects. Psychiatry Clin Neurosci 53, 151&#x2013;153 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10459675</ArticleId></ArticleIdList></Reference><Reference><Citation>Cauter EV, Leproult R, Plat L, Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA 284, 861&#x2013;868 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10938176</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R, Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79, 110&#x2013;119 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, Gomez-Isla T, Hyman BT, Schultz A, Vasdev N, Johnson KA, Dickerson BC, Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol 74, 427&#x2013;436 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470368</ArticleId><ArticleId IdType="pubmed">28241163</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, Ances BM, Tau and A&#x3b2; imaging, CSFmeasures, and cognition in Alzheimer&#x2019;s disease. Sci Transl Med 8, 338&#x2013;366 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher KE, Koscik RL, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Sager MA, Asthana S, Johnson SC, Benca RM, Bendlin BB, Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology 89, 445&#x2013;453 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539733</ArticleId><ArticleId IdType="pubmed">28679595</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H, CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain 129, 3035&#x2013;3041 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>(Advanced Brain Monitoring).</Citation></Reference><Reference><Citation>Lucey BP, McLeland JS, Toedebusch CD, Boyd J, Morris JC, Landsness EC, Yamada K, Holtzman DM, Comparison of a single-channel EEG sleep study to polysomnography. J Sleep Res 25, 625&#x2013;635 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5135638</ArticleId><ArticleId IdType="pubmed">27252090</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinoy ED, Frey DJ, Kaslovsky DN, Meyer FG, Wright KP, Age-related changes in slow wave activity rise time and NREM sleep EEG with and without zolpidem in healthy young and older adults. Sleep Med 15, 1037&#x2013;1045 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4615697</ArticleId><ArticleId IdType="pubmed">24980066</ArticleId></ArticleIdList></Reference><Reference><Citation>C. Iber, The AASM Manual for Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications: version 2.1. (American Academy of Sleep Medicine, Westchester, IL, 2014).</Citation></Reference><Reference><Citation>Landsness EC, Crupi D, Hulse BK, Peterson MJ, Huber R, Ansari H, Coen M, Cirelli C, Benca RM, Ghilardi MF, Tononi G, Sleep-dependent improvement in visuomotor learning: a causal role for slow waves. Sleep 32, 1273&#x2013;1284 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753806</ArticleId><ArticleId IdType="pubmed">19848357</ArticleId></ArticleIdList></Reference><Reference><Citation>Landsness EC, Goldstein MR, Peterson MJ, Tononi G, Benca RM, Antidepressant effects of selective slow wave sleep deprivation in major depression: a high-density EEG investigation. J Psychiat Res 45, 1019&#x2013;1026 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119746</ArticleId><ArticleId IdType="pubmed">21397252</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, FreeSurfer. Neuroimage 62, 774&#x2013;781 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, Raichle ME, Hornbeck RC, Aldea P, Morris JC, Benzinger TL, Quantitative amyloid imaging using image-derived arterial input function. PLoS ONE 10, e0122920 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388540</ArticleId><ArticleId IdType="pubmed">25849581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC, Correction for partial volume effects in PET: Principle and Validation. J Nucl Med 39, 904&#x2013;911 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T, Zetterberg H, Teunissen CE, Ostlund RE, Militello M, Andreasson U, Hubeek I, Gibson D, Chu DC, Eichenlaub U, Heiss P, Kobold U, Leinenbach A, Madin K, Manuilova E, Rabe C, Blennow K, Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1&#x2013;42) in human cerebrospinal fluid. Alzheimers Dement 12, 517&#x2013;526 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26555316</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG, Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42, 377&#x2013;381 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedeker D, in Encyclopedia of statistics in behavioral science, Everitt BS, Howell DC, Eds. (John Wiley &amp; Sons, Ltd, Chichester, 2005), pp. 729&#x2013;738.</Citation></Reference><Reference><Citation>R Foundation for Statistical Computing, R. C. Team, Ed. (Vienna, Austria, 2013).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30630900</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>363</Volume><Issue>6423</Issue><PubDate><Year>2019</Year><Month>Jan</Month><Day>11</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Secreted amyloid-&#x3b2; precursor protein functions as a GABA<sub>B</sub>R1a ligand to modulate synaptic transmission.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaao4827</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aao4827</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; precursor protein (APP) is central to the pathogenesis of Alzheimer's disease, yet its physiological function remains unresolved. Accumulating evidence suggests that APP has a synaptic function mediated by an unidentified receptor for secreted APP (sAPP). Here we show that the sAPP extension domain directly bound the sushi 1 domain specific to the &#x3b3;-aminobutyric acid type B receptor subunit 1a (GABA<sub>B</sub>R1a). sAPP-GABA<sub>B</sub>R1a binding suppressed synaptic transmission and enhanced short-term facilitation in mouse hippocampal synapses via inhibition of synaptic vesicle release. A 17-amino acid peptide corresponding to the GABA<sub>B</sub>R1a binding region within APP suppressed in vivo spontaneous neuronal activity in the hippocampus of anesthetized Thy1-GCaMP6s mice. Our findings identify GABA<sub>B</sub>R1a as a synaptic receptor for sAPP and reveal a physiological role for sAPP in regulating GABA<sub>B</sub>R1a function to modulate synaptic transmission.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>Heather C</ForeName><Initials>HC</Initials><Identifier Source="ORCID">0000-0002-5818-4338</Identifier><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Malmazet</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neuro-Electronics Research Flanders, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreurs</LastName><ForeName>An</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5407-7933</Identifier><AffiliationInfo><Affiliation>Brain &amp; Cognition, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frere</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6819-2211</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Molle</LastName><ForeName>Inge</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-0114-9379</Identifier><AffiliationInfo><Affiliation>VIB-VUB Structural Biology Research Center, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volkov</LastName><ForeName>Alexander N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>VIB-VUB Structural Biology Research Center, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jean Jeener NMR Centre, VUB, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creemers</LastName><ForeName>Eline</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9675-8195</Identifier><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vertkin</LastName><ForeName>Irena</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-9395-7968</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nys</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranaivoson</LastName><ForeName>Fanomezana M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Child Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comoletti</LastName><ForeName>Davide</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2081-6376</Identifier><AffiliationInfo><Affiliation>Child Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Cell Biology, Robert Wood Johnson Medical School, Rutgers University, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savas</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remaut</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>VIB-VUB Structural Biology Research Center, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balschun</LastName><ForeName>Detlef</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0065-0188</Identifier><AffiliationInfo><Affiliation>Brain &amp; Cognition, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wierda</LastName><ForeName>Keimpe D</ForeName><Initials>KD</Initials><Identifier Source="ORCID">0000-0002-8784-9490</Identifier><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slutsky</LastName><ForeName>Inna</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-0700-2266</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrow</LastName><ForeName>Karl</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1409-096X</Identifier><AffiliationInfo><Affiliation>Neuro-Electronics Research Flanders, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>imec, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven, Belgium. bart.destrooper@kuleuven.vib.be joris.dewit@kuleuven.vib.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK-Dementia Research Institute at University College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Joris</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1120-1089</Identifier><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven, Belgium. bart.destrooper@kuleuven.vib.be joris.dewit@kuleuven.vib.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>311083</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>R01 AG061787</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546266">Gabrb1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486298">Srpx protein, mouse</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2019 Jan 11;363(6423):123-124. doi: 10.1126/science.aaw0636.</RefSource><PMID Version="1">30630916</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2019 Mar;20(3):129. doi: 10.1038/s41583-019-0136-2.</RefSource><PMID Version="1">30733610</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2019 Feb 20;101(4):557-559. doi: 10.1016/j.neuron.2019.01.058.</RefSource><PMID Version="1">30790537</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="Y">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="Y">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> EP 16180433.1 &#x201c;Therapeutic agents for neurological and psychiatric disorders&#x201d;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30630900</ArticleId><ArticleId IdType="mid">NIHMS1009544</ArticleId><ArticleId IdType="pmc">PMC6366617</ArticleId><ArticleId IdType="doi">10.1126/science.aao4827</ArticleId><ArticleId IdType="pii">363/6423/eaao4827</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldgaber D, Lerman M, McBride OW, Saffiotti U, Gajdusek DC, Characterization and Chromosomal Localization of a cDNA Encoding Brain Amyloid of Alzheimer&#x2019;s Disease. Science. 235, 877&#x2013;880 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3810169</ArticleId></ArticleIdList></Reference><Reference><Citation>Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM, Molecular Cloning and Characterization of a cDNA Encoding the Cerebrovascular and the Neuritic Plaque Amyloid Peptides. Proc. Natl. Acad. Sci. 84, 4190&#x2013;4194 (1987).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305050</ArticleId><ArticleId IdType="pubmed">3035574</ArticleId></ArticleIdList></Reference><Reference><Citation>N. R. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 235 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">2949367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J et al., The precursor of Alzheimer&#x2019;s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325 (1987), pp. 733&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakaran G, Sisodia S, Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2 (2012), doi:10.1101/cshperspect.a006270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006270</ArticleId><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M et al., &#x3b7;-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature. 526, 443&#x2013;447 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570618</ArticleId><ArticleId IdType="pubmed">26322584</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson GR et al., Age-related cognitive deficits, impaired long-term potentiation and reduction in synpatic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience. 90, 1&#x2013;13 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook GR et al., Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology. 38, 349&#x2013;359 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10219973</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyan S-H et al., Amyloid precursor protein (APP) regulates synaptic structure and function. Mol. Cell. Neurosci. 51, 43&#x2013;52 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538857</ArticleId><ArticleId IdType="pubmed">22884903</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzjohn SM et al., Similar levels of long-term potentiation in amyloid precursor protein - null and wild-type mice in the CA1 region of picrotoxin treated slices. Neurosci. Lett. 288, 9&#x2013;12 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10869803</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Wang Z, Wang B, Justice NJ, Zheng H, Amyloid Precursor Protein Regulates Ca v 1 . 2 L-type Calcium Channel Levels and Function to Influence GABAergic Short-Term Plasticity. Neuroscience. 29, 15660&#x2013;15668 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833283</ArticleId><ArticleId IdType="pubmed">20016080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B et al., The Amyloid Precursor Protein Controls Adult Hippocampal Neurogenesis through GABAergic Interneurons. J Neurosci. 34, 13314&#x2013;13325 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4180470</ArticleId><ArticleId IdType="pubmed">25274811</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Wang J, Jiang J, Zheng X, Justice NJ, APP modulates KCC2 expression and function in hippocampal GABAergic inhibition, 1&#x2013;26 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5224924</ArticleId><ArticleId IdType="pubmed">28054918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mockett BG, Richter M, Abraham WC, M&#xfc;ller UC, Therapeutic Potential of Secreted Amyloid Precursor Protein APPs&#x3b1;. Front. Mol. Neurosci. 10, 30 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293819</ArticleId><ArticleId IdType="pubmed">28223920</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller UC, Deller T, Korte M, Not just amyloid&#x202f;: physiological functions of the amyloid precursor protein family. Nat. Rev. Neurosci. (2017), doi:10.1038/nrn.2017.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2017.29</ArticleId><ArticleId IdType="pubmed">28360418</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, Barger SW, Blalock EM, Mattson MP, Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature. 379 (1996), pp. 74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">8538744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida A, Furukawa K, Keller JN, Mattson MP, Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices. Neuroreport. 8, 2133&#x2013;7 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9243598</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor CJ et al., Endogenous secreted amyloid precursor protein-&#x3b1; regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol. Dis. 31, 250&#x2013;260 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18585048</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong M et al., Secreted amyloid precursor protein-alpha can restore novel object location memory and hippocampal LTP in aged rats. Neurobiol. Learn. Mem. 138, 291&#x2013;299 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27521248</ArticleId></ArticleIdList></Reference><Reference><Citation>Weyer SW et al., Comparative analysis of single and combined APP/APLP knockouts reveals reduced spine density in APP-KO mice that is prevented by APPs&#x3b1; expression. Acta Neuropathol. Commun. 2, 36 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023627</ArticleId><ArticleId IdType="pubmed">24684730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring S et al., The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J. Neurosci. 27, 7817&#x2013;7826 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672885</ArticleId><ArticleId IdType="pubmed">17634375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hick M et al., Acute function of secreted amyloid precursor protein fragment APPs&#x3b1; in synaptic plasticity. Acta Neuropathol. 129, 21&#x2013;37 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25432317</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitoh T et al., Secreted form of amyloid-beta protein precursor is involved in the growth regulation of fibroblasts. Cell. 58, 615&#x2013;622 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2475254</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhard C, Borgers M, David G, De Strooper B, Soluble amyloid-&#x3b2; precursor protein binds its cell surface receptor in a cooperative fashion with glypican and syndecan proteoglycans. J. Cell Sci. 126, 4856&#x2013;61 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23986479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm BG et al., Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science. 344, 1023&#x2013;8 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24876496</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas JN et al., Ecto-Fc MS identifies ligand-receptor interactions through extracellular domain Fc fusion protein baits and shotgun proteomic analysis. Nat. Protoc. 9, 2061&#x2013;2074 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384169</ArticleId><ArticleId IdType="pubmed">25101821</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk J et al., Modular composition and dynamics of native GABAB receptors identified by high-resolution proteomics. Nat. Neurosci. 19 (2015), doi:10.1038/nn.4198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4198</ArticleId><ArticleId IdType="pubmed">26691831</ArticleId></ArticleIdList></Reference><Reference><Citation>Gassmann M, Bettler B, Regulation of neuronal GABAB receptor functions by subunit composition. Nat. Rev. Neurosci. 13, 380&#x2013;394 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22595784</ArticleId></ArticleIdList></Reference><Reference><Citation>Pin J-P, Bettler B, Organization and functions of mGlu and GABAB receptor complexes. Nature. 540, 60&#x2013;68 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27905440</ArticleId></ArticleIdList></Reference><Reference><Citation>Coburger I et al., Analysis of the overall structure of the multi-domain amyloid precursor protein (APP). PLoS One. 8, 1&#x2013;12 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3852973</ArticleId><ArticleId IdType="pubmed">24324731</ArticleId></ArticleIdList></Reference><Reference><Citation>Shariati SAM, De Strooper B, Redundancy and divergence in the amyloid precursor protein family. FEBS Lett. 587, 2036&#x2013;2045 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23707420</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigot R et al., Differential Compartmentalization and Distinct Functions of GABAB Receptor Variants. Neuron. 50, 589&#x2013;601 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531664</ArticleId><ArticleId IdType="pubmed">16701209</ArticleId></ArticleIdList></Reference><Reference><Citation>Biermann B et al., The Sushi domains of GABAB receptors function as axonal targeting signals. J. Neurosci. 30, 1385&#x2013;94 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633810</ArticleId><ArticleId IdType="pubmed">20107064</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmeier PC, Kaupmann K, Urwyler S, Roles of GABAB receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release. J. Neural Transm. 115, 1401&#x2013;1411 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18665320</ArticleId></ArticleIdList></Reference><Reference><Citation>Wierda KDB, S&#xf8;rensen JB, Innervation by a GABAergic neuron depresses spontaneous release in glutamatergic neurons and unveils the clamping phenotype of synaptotagmin-1. J. Neurosci. 34, 2100&#x2013;10 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608537</ArticleId><ArticleId IdType="pubmed">24501351</ArticleId></ArticleIdList></Reference><Reference><Citation>Scanziani M, Capogna M, G&#xe4;hwiler BH, Thompson SM, Presynaptic inhibition of miniature excitatory synaptic currents by baclofen and adenosine in the hippocampus. Neuron. 9, 919&#x2013;927 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1358131</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyadomi M, Iyadomi I, Kumamoto E, Tomokuni K, Yoshimura M, Presynaptic inhibition by baclofen of miniature EPSCs and IPSCs in substantia gelatinosa neurons of the adult rat spinal dorsal horn. Pain. 85, 385&#x2013;393 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10781911</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrbacher J, Jarolimek W, a Lewen U Misgeld, GABAB receptor-mediated inhibition of spontaneous inhibitory synaptic currents in rat midbrain culture. J. Physiol. 500 ( Pt 3, 739&#x2013;49 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1159421</ArticleId><ArticleId IdType="pubmed">9161988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich D, Bettler B, GABAB receptors: synaptic functions and mechanisms of diversity. Curr. Opin. Neurobiol. 17, 298&#x2013;303 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17433877</ArticleId></ArticleIdList></Reference><Reference><Citation>Blein S et al., Structural analysis of the complement control protein (CCP) modules of GABAB receptor 1a: Only one of the two CCP modules is compactly folded. J. Biol. Chem. 279, 48292&#x2013;48306 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15304491</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Farber S. a, Growdon JH, Wurtman RJ, Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc. Natl. Acad. Sci. U. S. A. 90, 5191&#x2013;5193 (1993).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46681</ArticleId><ArticleId IdType="pubmed">8506366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F et al., APP Processing and Synaptic Function. Neuron. 37, 925&#x2013;937 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Vertkin I et al., GABAB receptor deficiency causes failure of neuronal homeostasis in hippocampal networks. Proc. Natl. Acad. Sci. U. S. A. 112, E3291&#x2013;3299 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485096</ArticleId><ArticleId IdType="pubmed">26056260</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L, Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 17, 777&#x2013;792 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8162106</ArticleId><ArticleId IdType="pubmed">27829687</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y et al., Implications of GABAergic Neurotransmission in Alzheimer&#x2019;s Disease. Front. Aging Neurosci. 8, 1&#x2013;12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4763334</ArticleId><ArticleId IdType="pubmed">26941642</ArticleId></ArticleIdList></Reference><Reference><Citation>Froestl W et al., SGS742: The first GABAB receptor antagonist in clinical trials. Biochem. Pharmacol. 68, 1479&#x2013;1487 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15451390</ArticleId></ArticleIdList></Reference><Reference><Citation>Helm KA et al., GABAB receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus. Neuropharmacology. 48, 956&#x2013;964 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15857622</ArticleId></ArticleIdList></Reference><Reference><Citation>Born HA et al., Genetic Suppression of Transgenic APP Rescues Hypersynchronous Network Activity in a Mouse Model of Alzeimer&#x2019;s Disease. J. Neurosci. 34, 3826&#x2013;3840 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951689</ArticleId><ArticleId IdType="pubmed">24623762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettler B, Kaupmann K, Mosbacher J, Gassmann M, Structure M, Molecular Structure and Physiological Functions of GABA B Receptors. Fisiol Rev. 84, 835&#x2013;867 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15269338</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster JD, Kitchen I, Bettler B, Chen Y, GABAB receptor subtypes differentially modulate synaptic inhibition in the dentate gyrus to enhance granule cell output. Br. J. Pharmacol. 168, 1808&#x2013;1819 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623052</ArticleId><ArticleId IdType="pubmed">23186302</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips GR et al., The presynaptic particle web: Ultrastructure, composition, dissolution, and reconstitution. Neuron. 32, 63&#x2013;77 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11604139</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Umans L, Van Leuven F, Van Den Berghe H, Study of the synthesis and secretion of normal and artificial mutants of murine amyloid precursor protein (APP): Cleavage of APP occurs in a late compartment of the default secretion pathway. J. Cell Biol. 121, 295&#x2013;304 (1993).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200101</ArticleId><ArticleId IdType="pubmed">8468348</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C et al., ??-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. FEBS J. 277, 1503&#x2013;1518 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847843</ArticleId><ArticleId IdType="pubmed">20163459</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit J et al., LRRTM2 Interacts with Neurexin1 and Regulates Excitatory Synapse Formation. Neuron. 64, 799&#x2013;806 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829666</ArticleId><ArticleId IdType="pubmed">20064388</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas JN et al., The Sorting Receptor SorCS1 Regulates Trafficking of Neurexin and AMPA Receptors. Neuron. 87, 764&#x2013;780 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692362</ArticleId><ArticleId IdType="pubmed">26291160</ArticleId></ArticleIdList></Reference><Reference><Citation>a J. Link et al., Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol. 17, 676&#x2013;682 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10404161</ArticleId></ArticleIdList></Reference><Reference><Citation>Washburn MP, Wolters D, Yates JR, Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19, 242&#x2013;7 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11231557</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas JN, Toyama BH, Xu T, Yates JR, Hetzer MW, Extremely Long-Lived Nuclear Pore Proteins in the Rat Brain. Science (80-. ). 335, 942&#x2013;942 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296478</ArticleId><ArticleId IdType="pubmed">22300851</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, Elias JE, Thoreen CC, Licklider LJ, Gygi SP, Evaluation of Multidimensional Chromatography Coupled with Tandem Mass Spectrometry ( LC / LC - MS / MS ) for Large-Scale Protein Analysis&#x202f;: The Yeast Proteome. J. Proteome Res. 2, 43&#x2013;50 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12643542</ArticleId></ArticleIdList></Reference><Reference><Citation>D. Cociorva, D. L. Tabb, J. R. Yates, in Current Protocols in Bioinformatics, Andreas, D, Baxevanis, Eds. (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18428785</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabb DL, McDonald WH, Yates JR, DTASelect and Contrast: Tools for Assembling and Comparing Protein Identifications from Shotgun Proteomics. J. Proteome Res. 1, 21&#x2013;26 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811961</ArticleId><ArticleId IdType="pubmed">12643522</ArticleId></ArticleIdList></Reference><Reference><Citation>JK E, AL M, JR Y., An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom. 5, 976&#x2013;89 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">24226387</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S et al., Mice with Combined Gene Knock-outs Reveal Essential and Partially Redundant Functions of Amyloid Precursor Protein Family Members. J. Neurosci. 20, 7951&#x2013;7963 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramov E et al., Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 12, 1567&#x2013;1576 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19935655</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Delaglio F; Grzesiek S; Vuister GW; Zhu G; Pfeifer J; Bax, NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR. 6, 277&#x2013;293 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8520220</ArticleId></ArticleIdList></Reference><Reference><Citation>E. D. Vranken WF; Boucher W; Stevens TJ; Fogh RH; Pajon A; Llinas M; Ulrich EL; Markley JL; Ionides J; Laue, The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins. 59, 687&#x2013;696 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15815974</ArticleId></ArticleIdList></Reference><Reference><Citation>R. W. Cheung MS; Maguire ML; Stevens TJ; Broadhurst, DANGLE: a Bayesian inferential method for predicting protein backbone dihedral angles and secondary structure. J. Magn. Reson. 202, 223&#x2013;233 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20015671</ArticleId></ArticleIdList></Reference><Reference><Citation>L. G&#xfc;ntert, P; Buchner, Combined automated NOE assignment and structure calculation with CYANA. J. Biomol. NMR. 62, 453&#x2013;471 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25801209</ArticleId></ArticleIdList></Reference><Reference><Citation>G. L. Br&#xfc;nger AT; Adams PD; Clore GM; DeLano WL; Gros P; Grosse-Kunsteleve RW; Jiang J-S; Kuszewski J; Nilges M; Pannu NS; Read RJ; Rice LM; Simonson T; Warren, Crystallography and NMR system (CNS): a new software suite for macromolecular structure determination. Acta Cryst. Ser. D. 54, 901&#x2013;921 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9757107</ArticleId></ArticleIdList></Reference><Reference><Citation>W. M.P., The Transferred NOE In: Webb GA (eds) Modern Magnetic Resonance. Springer, Dordrecht: (2008).</Citation></Reference><Reference><Citation>G. M. Schwieters, CD; Kuszewski J; Tjandra N; Clore, The Xplor-NIH NMR molecular structure determination package. J. Magn. Reson. 160, 66&#x2013;7r (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12565051</ArticleId></ArticleIdList></Reference><Reference><Citation>Dana H et al., Thy1-GCaMP6 transgenic mice for neuronal population imaging in vivo. PLoS One. 9 (2014), doi:10.1371/journal.pone.0108697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0108697</ArticleId><ArticleId IdType="pmc">PMC4177405</ArticleId><ArticleId IdType="pubmed">25250714</ArticleId></ArticleIdList></Reference><Reference><Citation>Pologruto TA, Sabatini BL, Svoboda K, ScanImage: Flexible software for operating laser scanning microscopes. Biomed. Eng. Online. 2, 1&#x2013;9 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC161784</ArticleId><ArticleId IdType="pubmed">12801419</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zkan E et al., An extracellular interactome of immunoglobulin and LRR proteins reveals receptor-ligand networks. Cell. 154 (2013), doi:10.1016/j.cell.2013.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.06.006</ArticleId><ArticleId IdType="pmc">PMC3756661</ArticleId><ArticleId IdType="pubmed">23827685</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton van der Merwe P, Neil Barclay A, Transient intercellular adhesion: the importance of weak protein-protein interactions. Trends Biochem. Sci. 19, 354&#x2013;358 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7985226</ArticleId></ArticleIdList></Reference><Reference><Citation>Blein S et al., Structural analysis of the complement control protein (CCP) modules of GABAB receptor 1a: Only one of the two CCP modules is compactly folded. J. Biol. Chem. 279, 48292&#x2013;48306 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15304491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30643288</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.</ArticleTitle><Pagination><StartPage>270</StartPage><EndPage>276</EndPage><MedlinePgn>270-276</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-018-0297-y</ELocationID><Abstract><AbstractText>Vascular contributions to cognitive impairment are increasingly recognized<sup>1-5</sup> as shown by neuropathological<sup>6,7</sup>, neuroimaging<sup>4,8-11</sup>, and cerebrospinal fluid biomarker<sup>4,12</sup> studies. Moreover, small vessel disease of the brain has been estimated to contribute to approximately 50% of all dementias worldwide, including those caused by Alzheimer's disease (AD)<sup>3,4,13</sup>. Vascular changes in AD have been typically attributed to the vasoactive and/or vasculotoxic effects of amyloid-&#x3b2; (A&#x3b2;)<sup>3,11,14</sup>, and more recently tau<sup>15</sup>. Animal studies suggest that A&#x3b2; and tau lead to blood vessel abnormalities and blood-brain barrier (BBB) breakdown<sup>14-16</sup>. Although neurovascular dysfunction<sup>3,11</sup> and BBB breakdown develop early in AD<sup>1,4,5,8-10,12,13</sup>, how they relate to changes in the AD classical biomarkers A&#x3b2; and tau, which also develop before dementia<sup>17</sup>, remains unknown. To address this question, we studied brain capillary damage using a novel cerebrospinal fluid biomarker of BBB-associated capillary mural cell pericyte, soluble platelet-derived growth factor receptor-&#x3b2;<sup>8,18</sup>, and regional BBB permeability using dynamic contrast-enhanced magnetic resonance imaging<sup>8-10</sup>. Our data show that individuals with early cognitive dysfunction develop brain capillary damage and BBB breakdown in the hippocampus irrespective of Alzheimer's A&#x3b2; and/or tau biomarker changes, suggesting that BBB breakdown is an early biomarker of human cognitive dysfunction independent of A&#x3b2; and tau.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nation</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Melanie D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0001-9009-6488</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montagne</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Abhay P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Orazio</LastName><ForeName>Lina M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pachicano</LastName><ForeName>Maricarmen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepehrband</LastName><ForeName>Farshid</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4483-5961</Identifier><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Amy R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buennagel</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Huntington Medical Research Institutes, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Huntington Medical Research Institutes, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><Identifier Source="ORCID">0000-0002-8114-0552</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Hope Center for Neurodegenerative Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>The Hope Center for Neurodegenerative Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>The Hope Center for Neurodegenerative Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials><Identifier Source="ORCID">0000-0002-6802-8232</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. zlokovic@usc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. zlokovic@usc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS090904</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100459</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054434</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG055034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG058780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG052350</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG058780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020797">Receptor, Platelet-Derived Growth Factor beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2019 Feb;25(2):201-203. doi: 10.1038/s41591-019-0348-z.</RefSource><PMID Version="1">30728536</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020797" MajorTopicYN="N">Receptor, Platelet-Derived Growth Factor beta</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>COMPETING INTERESTS STATEMENT: The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30643288</ArticleId><ArticleId IdType="mid">NIHMS1511919</ArticleId><ArticleId IdType="pmc">PMC6367058</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0297-y</ArticleId><ArticleId IdType="pii">10.1038/s41591-018-0297-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Snyder HM et al. Vascular contributions to cognitive impairment and dementia including Alzheimer&#x2019;s disease. Alzheimers Dement. J. Alzheimers Assoc 11, 710&#x2013;717 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731036</ArticleId><ArticleId IdType="pubmed">25510382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF et al. Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. JAMA 317, 1443&#x2013;1450 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="pubmed">28399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron 96, 17&#x2013;42 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657612</ArticleId><ArticleId IdType="pubmed">28957666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Sagare AP &amp; Zlokovic BV Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol 14, 133&#x2013;150 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat. Rev. Neurosci 12, 723&#x2013;738 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA &amp; Schneider JA Relation of cerebral vessel disease to Alzheimer&#x2019;s disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol. 15, 934&#x2013;943 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969105</ArticleId><ArticleId IdType="pubmed">27312738</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer&#x2019;s Coordinating Centre. Brain J. Neurol 136, 2697&#x2013;2706 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858112</ArticleId><ArticleId IdType="pubmed">23842566</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296&#x2013;302 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350773</ArticleId><ArticleId IdType="pubmed">25611508</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Haar HJ et al. Neurovascular unit impairment in early Alzheimer&#x2019;s disease measured with magnetic resonance imaging. Neurobiol. Aging 45, 190&#x2013;196 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27459939</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Haar HJ et al. Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease. Radiology 281, 527&#x2013;535 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27243267</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisler K, Nelson AR, Montagne A &amp; Zlokovic BV Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat. Rev. Neurosci 18, 419&#x2013;434 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759779</ArticleId><ArticleId IdType="pubmed">28515434</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y et al. Early role of vascular dysregulation on late-onset Alzheimer&#x2019;s disease based on multifactorial data-driven analysis. Nat. Commun 7, 11934 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="pubmed">27327500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardlaw JM et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 12, 822&#x2013;838 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714437</ArticleId><ArticleId IdType="pubmed">23867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, Zhao Z &amp; Zlokovic BV Alzheimer&#x2019;s disease: A matter of blood-brain barrier dysfunction? J. Exp. Med 214, 3151&#x2013;3169 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679168</ArticleId><ArticleId IdType="pubmed">29061693</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RE et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A 115, E1289&#x2013;E1298 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819390</ArticleId><ArticleId IdType="pubmed">29358399</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair LJ et al. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol. Commun 3, 8 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4353464</ArticleId><ArticleId IdType="pubmed">25775028</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. J. Alzheimers Assoc 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, Sweeney MD, Makshanoff J &amp; Zlokovic BV Shedding of soluble platelet-derived growth factor receptor-&#x3b2; from human brain pericytes. Neurosci. Lett 607, 97&#x2013;101 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631673</ArticleId><ArticleId IdType="pubmed">26407747</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan C et al. Diagnostic Values of Cerebrospinal Fluid T-Tau and A&#x3b2;&#x2084;&#x2082; using Meso Scale Discovery Assays for Alzheimer&#x2019;s Disease. J. Alzheimers Dis. JAD 45, 709&#x2013;719 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517668</ArticleId><ArticleId IdType="pubmed">25613100</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80, 1784&#x2013;1791 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J. Alzheimers Dis. JAD 42, 275&#x2013;289 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133291</ArticleId><ArticleId IdType="pubmed">24844687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68, 409&#x2013;427 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindahl P, Johansson BR, Lev&#xe9;en P &amp; Betsholtz C Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242&#x2013;245 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9211853</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Bell RD &amp; Zlokovic BV Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol. Neurodegener 5, 32 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936891</ArticleId><ArticleId IdType="pubmed">20738866</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandewijck M et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475&#x2013;480 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29443965</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost A et al. Brain and Retinal Pericytes: Origin, Function and Role. Front. Cell. Neurosci 10, 20 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740376</ArticleId><ArticleId IdType="pubmed">26869887</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelson K, Swendeman S, Saftig P &amp; Blobel CP Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent cross-talk between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling pathways. J. Biol. Chem 285, 25024&#x2013;25032 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2915738</ArticleId><ArticleId IdType="pubmed">20529858</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Sagare AP &amp; Zlokovic BV Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer&#x2019;s disease. J Cereb Blood Flow Metab 35, 1055&#x2013;1068 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4640280</ArticleId><ArticleId IdType="pubmed">25899298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin A, Blennow K &amp; Rosengren L Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype. Alzheimer Dis. Assoc. Disord 13 Suppl 3, S102&#x2013;105 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10609688</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA &amp; Barres BA Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468, 562&#x2013;566 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A et al. Pericytes regulate the blood-brain barrier. Nature 468, 557&#x2013;561 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Spellman T et al. Hippocampal-prefrontal input supports spatial encoding in working memory. Nature 522, 309&#x2013;314 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505751</ArticleId><ArticleId IdType="pubmed">26053122</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z et al. Dynamic ErbB4 Activity in Hippocampal-Prefrontal Synchrony and Top-Down Attention in Rodents. Neuron 98, 380&#x2013;393.e4 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909841</ArticleId><ArticleId IdType="pubmed">29628188</ArticleId></ArticleIdList></Reference><Reference><Citation>Croxson PL et al. Quantitative investigation of connections of the prefrontal cortex in the human and macaque using probabilistic diffusion tractography. J. Neurosci. Off. J. Soc. Neurosci 25, 8854&#x2013;8866 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725599</ArticleId><ArticleId IdType="pubmed">16192375</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Shea A, Cohen RA, Porges EC, Nissim NR &amp; Woods AJ Cognitive Aging and the Hippocampus in Older Adults. Front. Aging Neurosci 8, 298 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5143675</ArticleId><ArticleId IdType="pubmed">28008314</ArticleId></ArticleIdList></Reference><Reference><Citation>Glikmann-Johnston Y, Oren N, Hendler T &amp; Shapira-Lichter I Distinct functional connectivity of the hippocampus during semantic and phonemic fluency. Neuropsychologia 69, 39&#x2013;49 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25619848</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Aranda C et al. Neuroanatomical correlates of verbal fluency in early Alzheimer&#x2019;s disease and normal aging. Brain Lang. 155&#x2013;156, 24&#x2013;35 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27062691</ArticleId></ArticleIdList></Reference><Reference><Citation>Grahn JA, Parkinson JA &amp; Owen AM The cognitive functions of the caudate nucleus. Prog. Neurobiol 86, 141&#x2013;155 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18824075</ArticleId></ArticleIdList></Reference><Reference><Citation>Provost J-S, Hanganu A &amp; Monchi O Neuroimaging studies of the striatum in cognition Part I: healthy individuals. Front. Syst. Neurosci 9, 140 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596942</ArticleId><ArticleId IdType="pubmed">26500513</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DA The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer&#x2019;s disease. Alzheimers Dement. J. Alzheimers Assoc 10, 372&#x2013;380 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24589433</ArticleId></ArticleIdList></Reference><Reference><Citation>Jak AJ et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry 17, 368&#x2013;375 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743175</ArticleId><ArticleId IdType="pubmed">19390294</ArticleId></ArticleIdList></Reference><Reference><Citation>Jak AJ et al. Neuropsychological Criteria for Mild Cognitive Impairment and Dementia Risk in the Framingham Heart Study. J. Int. Neuropsychol. Soc. JINS 22, 937&#x2013;943 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5045758</ArticleId><ArticleId IdType="pubmed">27029348</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis D, Kramer J, Kaplan E &amp; Ober B California Verbal Learning Test. (PsychCorp, 2000).</Citation></Reference><Reference><Citation>Nation DA et al. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer&#x2019;s disease. J. Alzheimers Dis. JAD 30, 595&#x2013;603 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370943</ArticleId><ArticleId IdType="pubmed">22451309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangen KJ et al. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer&#x2019;s disease. Alzheimers Dement. J. Alzheimers Assoc 11, 394&#x2013;403.e1 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287462</ArticleId><ArticleId IdType="pubmed">25022538</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;ltt&#xe4; M et al. Evaluating amyloid-&#x3b2; oligomers in cerebrospinal fluid as a biomarker for Alzheimer&#x2019;s disease. PloS One 8, e66381 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682966</ArticleId><ArticleId IdType="pubmed">23799095</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta U et al. Tau oligomers in cerebrospinal fluid in Alzheimer&#x2019;s disease. Ann. Clin. Transl. Neurol 4, 226&#x2013;235 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5376754</ArticleId><ArticleId IdType="pubmed">28382304</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeek MM, Otte-H&#xf6;ller I, Wesseling P, Ruiter DJ &amp; de Waal RM Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta 1. Am. J. Pathol 144, 372&#x2013;382 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887139</ArticleId><ArticleId IdType="pubmed">8311120</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes SR et al. ROCKETSHIP: a flexible and modular software tool for the planning, processing and analysis of dynamic MRI studies. BMC Med. Imaging 15, 19 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466867</ArticleId><ArticleId IdType="pubmed">26076957</ArticleId></ArticleIdList></Reference><Reference><Citation>Patlak CS &amp; Blasberg RG Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab 5, 584&#x2013;590 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">4055928</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B FreeSurfer. NeuroImage 62, 774&#x2013;781 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341&#x2013;355 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 31, 968&#x2013;980 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B &amp; Dale AM Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A 97, 11050&#x2013;11055 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27146</ArticleId><ArticleId IdType="pubmed">10984517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Sereno MI, Tootell RB &amp; Dale AM High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum. Brain Mapp 8, 272&#x2013;284 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873338</ArticleId><ArticleId IdType="pubmed">10619420</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinov I et al. Neuroimaging study designs, computational analyses and data provenance using the LONI pipeline. PloS One 5, (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946935</ArticleId><ArticleId IdType="pubmed">20927408</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepehrband F et al. Neuroanatomical morphometric characterization of sex differences in youth using statistical learning. NeuroImage 172, 217&#x2013;227 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5967879</ArticleId><ArticleId IdType="pubmed">29414494</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PloS One 8, e73377 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA et al. Longitudinal &#x3b2;-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. JAMA Neurol. 73, 1192&#x2013;1200 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237381</ArticleId><ArticleId IdType="pubmed">27548756</ArticleId></ArticleIdList></Reference><Reference><Citation>Glickman ME, Rao SR &amp; Schultz MR False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J. Clin. Epidemiol 67, 850&#x2013;857 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24831050</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30650353</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia.</ArticleTitle><Pagination><StartPage>582</StartPage><EndPage>593.e5</EndPage><MedlinePgn>582-593.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2018.12.085</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(18)32045-X</ELocationID><Abstract><AbstractText>The neuronal microtubule-associated protein tau, MAPT, is central to the pathogenesis of many dementias. Autosomal-dominant mutations in MAPT cause inherited frontotemporal dementia (FTD), but the underlying pathogenic mechanisms are unclear. Using human stem cell models of FTD due to MAPT mutations, we find that tau becomes hyperphosphorylated and mislocalizes to cell bodies and dendrites in cortical neurons, recapitulating a key early event in FTD. Mislocalized tau in the cell body leads to abnormal microtubule movements in FTD-MAPT neurons that grossly deform the nuclear membrane. This results in defective nucleocytoplasmic transport, which is corrected by microtubule depolymerization. Neurons in the post-mortem human FTD-MAPT cortex have a high incidence of nuclear invaginations, indicating that tau-mediated nuclear membrane dysfunction is an important pathogenic process in FTD. Defects in nucleocytoplasmic transport in FTD point to important commonalities in the pathogenic mechanisms of tau-mediated dementias and ALS-FTD due to TDP-43 and C9orf72 mutations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paonessa</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QN, UK; Alzheimer's Research UK Stem Cell Research Centre, University of Cambridge, CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Lewis D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QN, UK; Alzheimer's Research UK Stem Cell Research Centre, University of Cambridge, CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanki</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QN, UK; Alzheimer's Research UK Stem Cell Research Centre, University of Cambridge, CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larrieu</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wray</LastName><ForeName>Selina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livesey</LastName><ForeName>Frederick J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QN, UK; Alzheimer's Research UK Stem Cell Research Centre, University of Cambridge, CB2 1QN, UK; UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK. Electronic address: r.livesey@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>11224</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>206242/Z/17/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>86609</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>18796</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L016397/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>WT101052MA</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009685" MajorTopicYN="N">Nuclear Envelope</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">MAPT</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">human neurons</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">microtubule dynamics</Keyword><Keyword MajorTopicYN="N">nuclear membrane</Keyword><Keyword MajorTopicYN="N">nucleocytoplasmic transport</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30650353</ArticleId><ArticleId IdType="pmc">PMC6335264</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.12.085</ArticleId><ArticleId IdType="pii">S2211-1247(18)32045-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akhmanova A., Steinmetz M.O. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Nat. Rev. Mol. Cell Biol. 2008;9:309&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322465</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso Adel.C., Mederlyova A., Novak M., Grundke-Iqbal I., Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J.&#xa0;Biol. Chem. 2004;279:34873&#x2013;34881.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190058</ArticleId></ArticleIdList></Reference><Reference><Citation>Applegate K.T., Besson S., Matov A., Bagonis M.H., Jaqaman K., Danuser G. plusTipTracker: quantitative image analysis software for the measurement of microtubule dynamics. J.&#xa0;Struct. Biol. 2011;176:168&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3298692</ArticleId><ArticleId IdType="pubmed">21821130</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C., Lee V.M.-Y., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat. Rev. Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292:1552&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottanelli F., Kromann E.B., Allgeyer E.S., Erdmann R.S., Wood Baguley S., Sirinakis G., Schepartz A., Baddeley D., Toomre D.K., Rothman J.E., Bewersdorf J. Two-colour live-cell nanoscale imaging of intracellular targets. Nat. Commun. 2016;7:10778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4785223</ArticleId><ArticleId IdType="pubmed">26940217</ArticleId></ArticleIdList></Reference><Reference><Citation>Broers J.L.V., Ramaekers F.C.S., Bonne G., Yaou R.B., Hutchison C.J. Nuclear lamins: laminopathies and their role in premature ageing. Physiol. Rev. 2006;86:967&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">16816143</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke B., Stewart C.L. The nuclear lamins: flexibility in function. Nat. Rev. Mol. Cell Biol. 2013;14:13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23212477</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero B., Wang Y., Diaz A., Tasset I., Juste Y.R., Stiller B., Mandelkow E.-M., Mandelkow E., Cuervo A.M. Interplay of pathogenic forms of human tau with different autophagic pathways. Aging Cell. 2018;17:e12692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5770880</ArticleId><ArticleId IdType="pubmed">29024336</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell B.C., Collins F.S. Human laminopathies: nuclei gone genetically awry. Nat. Rev. Genet. 2006;7:940&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">17139325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang W., Worman H.J., Gundersen G.G. Accessorizing and anchoring the LINC complex for multifunctionality. J.&#xa0;Cell Biol. 2015;208:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284225</ArticleId><ArticleId IdType="pubmed">25559183</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C.-C., Zhang Y., Umoh M.E., Vaughan S.W., Lorenzini I., Liu F., Sayegh M., Donlin-Asp P.G., Chen Y.H., Duong D.M. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci. 2018;21:228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp M., Liu Q., Roux K., Rattner J.B., Shanahan C., Burke B., Stahl P.D., Hodzic D. Coupling of the nucleus and cytoplasm: role of the LINC complex. J.&#xa0;Cell Biol. 2006;172:41&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063530</ArticleId><ArticleId IdType="pubmed">16380439</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza I., Poorkaj P., Hong M., Nochlin D., Lee V.M., Bird T.D., Schellenberg G.D. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. U S A. 1999;96:5598&#x2013;5603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21906</ArticleId><ArticleId IdType="pubmed">10318930</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R., Ross J.L., Goldman Y.E., Holzbaur E.L.F. Differential regulation of dynein and kinesin motor proteins by tau. Science. 2008;319:1086&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekharzadeh B., Daigle J.G., Kapinos L.E., Coyne A., Schiantarelli J., Carlomagno Y., Cook C., Miller S.J., Dujardin S., Amaral A.S. Tau protein disrupts nucleocytoplasmic transport in Alzheimer&#x2019;s disease. Neuron. 2018;99:925&#x2013;940.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240334</ArticleId><ArticleId IdType="pubmed">30189209</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick A.W.P., Falcon B., He S., Murzin A.G., Murshudov G., Garringer H.J., Crowther R.A., Ghetti B., Goedert M., Scheres S.H.W. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature. 2017;547:185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Lu Y., Lopez-Gonzalez R., Kim N.C., Almeida S., Lee K.-H., Badders N., Valentine M., Miller B.L., Wong P.C. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B. Alzheimer&#x2019;s disease: An acquired neurodegenerative laminopathy. Nucleus. 2016;7:275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4991240</ArticleId><ArticleId IdType="pubmed">27167528</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Bardai F.H., Feany M.B. Lamin dysfunction mediates neurodegeneration in tauopathies. Curr. Biol. 2016;26:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713335</ArticleId><ArticleId IdType="pubmed">26725200</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H., Hussaini S.A., Wegmann S., Profaci C., Daniels J.D., Herman M., Emrani S., Figueroa H.Y., Hyman B.T., Davies P., Duff K.E. 3D visualization of the temporal and spatial spread of tau pathology reveals extensive sites of tau accumulation associated with neuronal loss and recognition memory deficit in aged tau transgenic mice. PLoS ONE. 2016;11:e0159463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4965059</ArticleId><ArticleId IdType="pubmed">27466814</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerace L., Huber M.D. Nuclear lamina at the crossroads of the cytoplasm and nucleus. J.&#xa0;Struct. Biol. 2012;177:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261324</ArticleId><ArticleId IdType="pubmed">22126840</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Ghetti B., Spillantini M.G. Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a006254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281593</ArticleId><ArticleId IdType="pubmed">22355793</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J., Probst A., Spillantini M.G., Sch&#xe4;fer T., Jakes R., B&#xfc;rki K., Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 1995;14:1304&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398215</ArticleId><ArticleId IdType="pubmed">7729409</ArticleId></ArticleIdList></Reference><Reference><Citation>Grima J.C., Daigle J.G., Arbez N., Cunningham K.C., Zhang K., Ochaba J., Geater C., Morozko E., Stocksdale J., Glatzer J.C. Mutant Huntingtin disrupts the nuclear pore complex. Neuron. 2017;94:93&#x2013;107.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595097</ArticleId><ArticleId IdType="pubmed">28384479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Vega A., Braun M., Scharrel L., Jahnel M., Wegmann S., Hyman B.T., Alberti S., Diez S., Hyman A.A. Local nucleation of microtubule bundles through tubulin concentration into a condensed tau phase. Cell Rep. 2017;20:2304&#x2013;2312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828996</ArticleId><ArticleId IdType="pubmed">28877466</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.-L. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A., Mertens J., Boeynaems S., Bogaert E., Chai N., Yamada S.B., Paul J.W., 3rd, Sun S., Herdy J.R., Bieri G. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015;18:1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadavath H., Hofele R.V., Biernat J., Kumar S., Tepper K., Urlaub H., Mandelkow E., Zweckstetter M. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc. Natl. Acad. Sci. U S A. 2015;112:7501&#x2013;7506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4475932</ArticleId><ArticleId IdType="pubmed">26034266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley J.B., Datta S., Snow C.J., Chatterjee M., Ni L., Spencer A., Yang C.-S., Cube&#xf1;as-Potts C., Matunis M.J., Paschal B.M. The defective nuclear lamina in Hutchinson-Gilford progeria syndrome disrupts the nucleocytoplasmic Ran gradient and inhibits nuclear localization of Ubc9. Mol. Cell. Biol. 2011;31:3378&#x2013;3395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147792</ArticleId><ArticleId IdType="pubmed">21670151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowall N.W., Kosik K.S. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer&#x2019;s disease. Ann. Neurol. 1987;22:639&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">3122646</ArticleId></ArticleIdList></Reference><Reference><Citation>Larrieu D., Britton S., Demir M., Rodriguez R., Jackson S.P. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science. 2014;344:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246063</ArticleId><ArticleId IdType="pubmed">24786082</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J., Yue Z. Neuronal aggregates: formation, clearance, and spreading. Dev. Cell. 2015;32:491&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376477</ArticleId><ArticleId IdType="pubmed">25710535</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Lee I.-W., Jo Y.-J., Namgoong S., Kim N.-H. Depletion of the LINC complex disrupts cytoskeleton dynamics and meiotic resumption in mouse oocytes. Sci. Rep. 2016;6:20408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740751</ArticleId><ArticleId IdType="pubmed">26842404</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J., Paquola A.C.M., Ku M., Hatch E., B&#xf6;hnke L., Ladjevardi S., McGrath S., Campbell B., Lee H., Herdy J.R. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell. 2015;17:705&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5929130</ArticleId><ArticleId IdType="pubmed">26456686</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberdoerffer P., Sinclair D.A. The role of nuclear architecture in genomic instability and ageing. Nat. Rev. Mol. Cell Biol. 2007;8:692&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">17700626</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor M.N., Fox N.C., Mummery C.J., Schott J.M., Warren J.D. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9:793&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947856</ArticleId><ArticleId IdType="pubmed">20650401</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 2012;9:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Shammas S.L., Garcia G.A., Kumar S., Kjaergaard M., Horrocks M.H., Shivji N., Mandelkow E., Knowles T.P.J., Mandelkow E., Klenerman D. A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nat. Commun. 2015;6:7025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4421837</ArticleId><ArticleId IdType="pubmed">25926130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield L.G., Miskiewicz H.B., Tannenbaum L.B., Mirra S.S. Nuclear pore complex proteins in Alzheimer disease. J.&#xa0;Neuropathol. Exp. Neurol. 2006;65:45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410748</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Kirwan P., Livesey F.J. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat. Protoc. 2012;7:1836&#x2013;1846.</Citation><ArticleIdList><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Kirwan P., Smith J., Robinson H.P.C., Livesey F.J. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci. 2012;15:477&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3882590</ArticleId><ArticleId IdType="pubmed">22306606</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow C.J., Dar A., Dutta A., Kehlenbach R.H., Paschal B.M. Defective nuclear import of Tpr in Progeria reflects the Ran sensitivity of large cargo transport. J.&#xa0;Cell Biol. 2013;201:541&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653351</ArticleId><ArticleId IdType="pubmed">23649804</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito T., Preza E., Mahoney C.J., Set&#xf3;-Salvia N., Ryan N.S., Morris H.R., Arber C., Devine M.J., Houlden H., Warner T.T. Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10&#xa0;+ 16 splice-site mutation in MAPT. Hum. Mol. Genet. 2015;24:5260&#x2013;5269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550814</ArticleId><ArticleId IdType="pubmed">26136155</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E., Mandelkow E.-M. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J.&#xa0;Neurosci. 2007;27:2896&#x2013;2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinczek B., Ebneth A., Mandelkow E.M., Mandelkow E. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J.&#xa0;Cell Sci. 1999;112:2355&#x2013;2367.</Citation><ArticleIdList><ArticleId IdType="pubmed">10381391</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M., Barghorn S., Biernat J., Mandelkow E.-M., Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim. Biophys. Acta. 2005;1739:158&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Mandelkow E. Tau in physiology and pathology. Nat. Rev. Neurosci. 2016;17:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.-Z., Xia Y.-Y., Grundke-Iqbal I., Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J.&#xa0;Alzheimers Dis. 2013;33(Suppl 1):S123&#x2013;S139.</Citation><ArticleIdList><ArticleId IdType="pubmed">22710920</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster M., Witkin K.L., Cohen-Fix O. Sizing up the nucleus: nuclear shape, size and nuclear-envelope assembly. J.&#xa0;Cell Sci. 2009;122:1477&#x2013;1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680097</ArticleId><ArticleId IdType="pubmed">19420234</ArticleId></ArticleIdList></Reference><Reference><Citation>Witman G.B., Cleveland D.W., Weingarten M.D., Kirschner M.W. Tubulin requires tau for growth onto microtubule initiating sites. Proc. Natl. Acad. Sci. U S A. 1976;73:4070&#x2013;4074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC431332</ArticleId><ArticleId IdType="pubmed">1069293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H., Mandelkow E.-M. Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer disease and hereditary spastic paraplegia. Mol. Neurodegener. 2015;10:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687341</ArticleId><ArticleId IdType="pubmed">26691836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.-J., Gendron T.F., Grima J.C., Sasaguri H., Jansen-West K., Xu Y.-F., Katzman R.B., Gass J., Murray M.E., Shinohara M. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 2016;19:668&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Daigle J.G., Cunningham K.M., Coyne A.N., Ruan K., Grima J.C., Bowen K.E., Wadhwa H., Yang P., Rigo F. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173:958&#x2013;971.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30664784</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.</ArticleTitle><Pagination><StartPage>277</StartPage><EndPage>283</EndPage><MedlinePgn>277-283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-018-0304-3</ELocationID><Abstract><AbstractText>Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly Inherited Alzheimer Network and ultrasensitive immunoassay technology to demonstrate that NfL levels in the cerebrospinal fluid (n&#x2009;=&#x2009;187) and serum (n&#x2009;=&#x2009;405) are correlated with one another and are elevated at the presymptomatic stages of familial Alzheimer's disease. Longitudinal, within-person analysis of serum NfL dynamics (n&#x2009;=&#x2009;196) confirmed this elevation and further revealed that the rate of change of serum NfL could discriminate mutation carriers from non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels (that is, 16.2 versus 6.8 years before the estimated symptom onset). Serum NfL rate of change peaked in participants converting from the presymptomatic to the symptomatic stage and was associated with cortical thinning assessed by magnetic resonance imaging, but less so with amyloid-&#x3b2; deposition or glucose metabolism (assessed by positron emission tomography). Serum NfL was predictive for both the rate of cortical thinning and cognitive changes assessed by the Mini-Mental State Examination and Logical Memory test. Thus, NfL dynamics in serum predict disease progression and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer's disease, which supports its potential utility as a clinically useful biomarker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Preische</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, and Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Department of Radiology, and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apel</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, and Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhle</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, and Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barro</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xe4;ber</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuder-Buletta</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaFougere</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, and Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xf6;glein</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Neurodegeneration Division, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medical Health and Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-2967-9662</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegeneration, Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Indiana Alzheimer Disease Center and Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine at USC, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noble</LastName><ForeName>James M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-0648-6702</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><Identifier Source="ORCID">0000-0002-8114-0552</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Department of Radiology, and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Department of Radiology, and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Department of Radiology, and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guoqiao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Department of Radiology, and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Department of Radiology, and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Department of Radiology, and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-2109-2955</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Department of Radiology, and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9045-1072</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany. mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, and Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, T&#xfc;bingen, Germany. mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG053474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS098577</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2019 Feb;25(2):201-203. doi: 10.1038/s41591-019-0348-z.</RefSource><PMID Version="1">30728536</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuroscientist. 2019 Oct;25(5):385. doi: 10.1177/1073858419868688.</RefSource><PMID Version="1">31554494</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Transl Med. 2019 Jul;7(Suppl 3):S133. doi: 10.21037/atm.2019.05.81.</RefSource><PMID Version="1">31576340</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. A.M.G. has consulted for Cognition Therapeutics, Biogen, GlaxoSmithKline, Illumina, Eisai, AbbVie, and Pfizer and served on the Scientific Advisory Board for Denali Therapeutics. A.M.F. is a member of the Scientific Advisory Boards for AbbVie, Genentech and Roche Diagnostics and provides consultation for Araclon/Grifols and DiamiR.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Allegri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amtashar</LastName><ForeName>Fatima</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodge</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandon</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buck</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chea</LastName><ForeName>Sochenda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chrem</LastName><ForeName>Patricio</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cinco</LastName><ForeName>Jake</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clifford</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Mello</LastName><ForeName>Mirelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donahue</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Douglas</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edigo</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Marty</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrar</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flynn</LastName><ForeName>Gigi</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujii</LastName><ForeName>Hisako</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gant</LastName><ForeName>Cortaiga</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardener</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gurney</LastName><ForeName>Jenny</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirohara</LastName><ForeName>Mie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hornbeck</LastName><ForeName>Russ</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiBari</LastName><ForeName>Siri Houeland</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Snezana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerome</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasuga</LastName><ForeName>Kensaku</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawarabayashi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klunk</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuder-Buletta</LastName><ForeName>Elke</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Jae-Hong</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcus</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Neal Scott</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maue-Dreyfus</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montoya</LastName><ForeName>Lucy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mori</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagamatsu</LastName><ForeName>Akem</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neimeyer</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roh</LastName><ForeName>Jee Hoon</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimada</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shiroto</LastName><ForeName>Tomoyo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoji</LastName><ForeName>Mikio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sohrabi</LastName><ForeName>Hamid</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sparks</LastName><ForeName>Paige</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kazushi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swisher</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taddei</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfsberger</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiong</ForeName><Initials>X</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30664784</ArticleId><ArticleId IdType="mid">NIHMS1008079</ArticleId><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId><ArticleId IdType="pii">10.1038/s41591-018-0304-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med 367, 795&#x2013;804 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer&#x2019;s disease: a longitudinal study. Lancet Neurol 17, 241&#x2013;250 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816717</ArticleId><ArticleId IdType="pubmed">29397305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Karlawish J &amp; Johnson KA Preclinical Alzheimer disease: the challenges ahead. Nat. Rev. Neurol 9, 54&#x2013;58 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643203</ArticleId><ArticleId IdType="pubmed">23183885</ArticleId></ArticleIdList></Reference><Reference><Citation>Fandos N et al. Plasma amyloid &#x3b2; 42/40 ratios as biomarkers for amyloid &#x3b2; cerebral deposition in cognitively normal individuals. Alzheimers Dement. (Amst) 8, 179&#x2013;187 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602863</ArticleId><ArticleId IdType="pubmed">28948206</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H &amp; Blennow K Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 74, 557&#x2013;566 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A et al. High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature 554, 249&#x2013;254 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V et al. Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13, 841&#x2013;849 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PSJ et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 89, 2167&#x2013;2175 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696646</ArticleId><ArticleId IdType="pubmed">29070659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 14, 989&#x2013;997 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold A Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci 233, 183&#x2013;198 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15896809</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlaepfer WW &amp; Lynch RG Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system. J. Cell Biol 74, 241&#x2013;250 (1977).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2109861</ArticleId><ArticleId IdType="pubmed">326799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56&#x2013;66 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Barro C et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141, 2382&#x2013;2391 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29860296</ArticleId></ArticleIdList></Reference><Reference><Citation>Brureau A et al. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol. Dis 104, 73&#x2013;84 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28392472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult. Scler 22, 1550&#x2013;1559 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26754800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W et al. Plasma neurofilament light chain levels in Alzheimer&#x2019;s disease. Neurosci. Lett 650, 60&#x2013;64 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28428015</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin. Investig. (Lond) 2, 975&#x2013;984 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulder KL et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res. Ther 5, 48 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978584</ArticleId><ArticleId IdType="pubmed">24131566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253&#x2013;260 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen K et al. The future of blood-based biomarkers for Alzheimer&#x2019;s disease. Alzheimers Dement 10, 115&#x2013;131 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4128378</ArticleId><ArticleId IdType="pubmed">23850333</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91, e1295&#x2013;e1306 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutphen CL et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer&#x2019;s disease. Alzheimers Dement 14, 869&#x2013;879 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110083</ArticleId><ArticleId IdType="pubmed">29580670</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TLS et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA 110, E4502&#x2013;E4509 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer&#x2019;s disease pathophysiology (SNAP) or Alzheimer&#x2019;s disease pathology: a longitudinal study. Lancet Neurol 15, 1044&#x2013;1053 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27450471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr. &amp; Holtzman DM Biomarker modeling of Alzheimer&#x2019;s disease. Neuron 80, 1347&#x2013;1358 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84, 2247&#x2013;2257 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann. Clin. Transl. Neurol 3, 216&#x2013;225 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774256</ArticleId><ArticleId IdType="pubmed">27042681</ArticleId></ArticleIdList></Reference><Reference><Citation>Norgren N, Karlsson JE, Rosengren L &amp; Stigbrand T Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid. Hybridomics 21, 53&#x2013;59 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11991817</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne LM et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington&#x2019;s disease: a retrospective cohort analysis. Lancet Neurol 16, 601&#x2013;609 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5507767</ArticleId><ArticleId IdType="pubmed">28601473</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M &amp; De Strooper B The amyloid cascade hypothesis for Alzheimer&#x2019;s disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov 10, 698&#x2013;712 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci. Transl. Med 6, 226ra230 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnunen KM et al. Presymptomatic atrophy in autosomal dominant Alzheimer&#x2019;s disease: a serial magnetic resonance imaging study. Alzheimers Dement 14, 43&#x2013;53 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5751893</ArticleId><ArticleId IdType="pubmed">28738187</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci. Rep 6, 36791 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5098187</ArticleId><ArticleId IdType="pubmed">27819296</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M &amp; Walker LC Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci 21, 1341&#x2013;1349 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375686</ArticleId><ArticleId IdType="pubmed">30258241</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ et al. Autosomal-dominant Alzheimera&#x2019;s disease: a review and proposal for the prevention of Alzheimera&#x2019;s disease. Alzheimers Res. Ther 3, 1 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ et al. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology 35, 390&#x2013;400 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521391</ArticleId><ArticleId IdType="pubmed">25964057</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M et al. Neurological manifestations of autosomal dominant familial Alzheimer&#x2019;s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol 15, 1317&#x2013;1325 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5116769</ArticleId><ArticleId IdType="pubmed">27777020</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas JB et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol 71, 1111&#x2013;1122 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240274</ArticleId><ArticleId IdType="pubmed">25069482</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE &amp; McHugh PR &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 12, 189&#x2013;198 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D Wechsler Memory Scale-Revised: Manual (The Psychological Corporation, San Antonio, 1987).</Citation></Reference><Reference><Citation>Kuhle J et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult. Scler 19, 1597&#x2013;1603 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23529999</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto G et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol 81, 857&#x2013;870 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519945</ArticleId><ArticleId IdType="pubmed">28512753</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter B
et al.
Stan: a probabilistic programming language.
J. Stat. Softw
https://www.jstatsoft.org/article/view/v076i01 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9788645</ArticleId><ArticleId IdType="pubmed">36568334</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelman A, Lee D &amp; Guo J Stan: a probabilistic programming language for Bayesian inference and optimization. J. Educ. Behav. Stat 40, 530&#x2013;543 (2015).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30663607</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project.</ArticleTitle><Pagination><StartPage>177</StartPage><EndPage>184</EndPage><MedlinePgn>177-184</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(18)30371-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(18)30371-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Some people with substantial Alzheimer's disease pathology at autopsy had shown few characteristic clinical symptoms or signs of the disease, whereas others with little Alzheimer's disease pathology have been diagnosed with Alzheimer's dementia. We aimed to examine whether frailty, which is associated with both age and dementia, moderates the relationship between Alzheimer's disease pathology and Alzheimer's dementia.</AbstractText><AbstractText Label="METHODS">We did a cross-sectional analysis of data from participants of the Rush Memory and Aging Project, a clinical-pathological cohort study of older adults (older than 59 years) without known dementia at baseline, living in Illinois, USA. Participants in the cohort study underwent annual neuropsychological and clinical evaluations. In the present cross-sectional analysis, we included those participants who did not have any form of dementia or who had Alzheimer's dementia at the time of their last clinical assessment and who had died and for whom complete autopsy data were available. Alzheimer's disease pathology was quantified by a summary measure of neurofibrillary tangles and neuritic and diffuse plaques. Clinical diagnosis of Alzheimer's dementia was based on clinician consensus. Frailty was operationalised retrospectively using health variable information obtained at each clincial evaluation using the deficit accumulation approach (41-item frailty index). Logistic regression and moderation modelling were used to assess relationships between Alzheimer's disease pathology, frailty, and Alzheimer's dementia. All analyses were adjusted for age, sex, and education.</AbstractText><AbstractText Label="FINDINGS">Up to data cutoff (Jan 20, 2017), we included 456 participants (mean age at death 89&#xb7;7 years [SD 6&#xb7;1]; 316 [69%] women). 242 (53%) had a diagnosis of possible or probable Alzheimer's dementia at their last clinical assessment. Frailty (odds ratio 1&#xb7;76, 95% CI 1&#xb7;54-2&#xb7;02; p&lt;0&#xb7;0001) and Alzheimer's disease pathology (4&#xb7;81, 3&#xb7;31-7&#xb7;01; p&lt;0&#xb7;0001) were independently associated with Alzheimer's dementia, after adjusting for age, sex, and education. When frailty was added to the model for the relationship between Alzheimer's disease pathology and Alzheimer's dementia, model fit improved (p&lt;0&#xb7;0001). There was a significant interaction between frailty and Alzheimer's disease pathology (odds ratio 0&#xb7;73, 95% CI 0&#xb7;57-0&#xb7;94; p<sub>interaction</sub>=0&#xb7;015). People with an increased frailty score had a weakened direct link between Alzheimer's disease pathology and Alzheimer's dementia; that is, people with a low amount of frailty were better able to tolerate Alzheimer's disease pathology, whereas those with higher amounts of frailty were more likely both to have more Alzheimer's disease pathology and for it to be expressed as dementia.</AbstractText><AbstractText Label="INTERPRETATION">The degree of frailty among people of the same age modifies the association between Alzheimer's disease pathology and Alzheimer's dementia. That frailty is related to both odds of Alzheimer's dementia and disease expression has implications for clinical management, since individuals with even a low level of Alzheimer's disease pathology might be at risk for dementia if they have high amounts of frailty. Further research should assess how frailty and cognition change over time to better elucidate this complex relationship.</AbstractText><AbstractText Label="FUNDING">None.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Lindsay M K</ForeName><Initials>LMK</Initials><AffiliationInfo><Affiliation>Geriatric Medicine Research, Centre for Health Care of the Elderly, Nova Scotia Health Authority, Halifax, NS, Canada; Department of Medicine, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theou</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Geriatric Medicine Research, Centre for Health Care of the Elderly, Nova Scotia Health Authority, Halifax, NS, Canada; Department of Medicine, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godin</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Geriatric Medicine Research, Centre for Health Care of the Elderly, Nova Scotia Health Authority, Halifax, NS, Canada; Department of Medicine, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrew</LastName><ForeName>Melissa K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Geriatric Medicine Research, Centre for Health Care of the Elderly, Nova Scotia Health Authority, Halifax, NS, Canada; Department of Medicine, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rockwood</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Geriatric Medicine Research, Centre for Health Care of the Elderly, Nova Scotia Health Authority, Halifax, NS, Canada; Department of Medicine, Dalhousie University, Halifax, NS, Canada. Electronic address: kenneth.rockwood@dal.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2019 Feb;18(2):133-134. doi: 10.1016/S1474-4422(18)30446-0.</RefSource><PMID Version="1">30663601</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2019 Mar;18(3):e2. doi: 10.1016/S1474-4422(19)30036-5.</RefSource><PMID Version="1">30784561</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2019 Mar;25(3):358. doi: 10.1038/s41591-019-0399-1.</RefSource><PMID Version="1">30842666</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016330" MajorTopicYN="N">Frail Elderly</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073496" MajorTopicYN="N">Frailty</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30663607</ArticleId><ArticleId IdType="mid">NIHMS1849980</ArticleId><ArticleId IdType="pmc">PMC11062500</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(18)30371-5</ArticleId><ArticleId IdType="pii">S1474-4422(18)30371-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. J. Alzheimers Assoc. 7, 280&#x2013;292 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Searle SD &amp; Rockwood K. Frailty and the risk of cognitive impairment. Alzheimers Res. Ther 7, (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4523015</ArticleId><ArticleId IdType="pubmed">26240611</ArticleId></ArticleIdList></Reference><Reference><Citation>Clegg A, Young J, Iliffe S, Rikkert MO &amp; Rockwood K. Frailty in elderly people. The Lancet 381, 752&#x2013;762 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098658</ArticleId><ArticleId IdType="pubmed">23395245</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LP et al. Frailty in Older Adults Evidence for a Phenotype. J. Gerontol. A. Biol. Sci. Med. Sci. 56, M146&#x2013;M157 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11253156</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitnitski AB, Mogilner AJ &amp; Rockwood K. Accumulation of Deficits as a Proxy Measure of Aging. Sci. World J. 1, 323&#x2013;336 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6084020</ArticleId><ArticleId IdType="pubmed">12806071</ArticleId></ArticleIdList></Reference><Reference><Citation>Canevelli M et al. External Validity of Randomized Controlled Trials on Alzheimer&#x2019;s Disease: The Biases of Frailty and Biological Aging. Front. Neurol. 8, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5712065</ArticleId><ArticleId IdType="pubmed">29230192</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X, Mitnitski A &amp; Rockwood K. Nontraditional risk factors combine to predict Alzheimer disease and dementia. Neurology 77, 227&#x2013;234 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136058</ArticleId><ArticleId IdType="pubmed">21753161</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X, Mitnitski A &amp; Rockwood K. Age-related deficit accumulation and the risk of late-life dementia. Alzheimer&#x2019;s Res Ther 6, 54 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4212514</ArticleId><ArticleId IdType="pubmed">25356088</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Schneider JA, Leurgans S &amp; Bennett DA. Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology 71, 499&#x2013;504 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676981</ArticleId><ArticleId IdType="pubmed">18695161</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G et al. Clinical diagnosis of Alzheimer&#x2019;s disease Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 34, 939&#x2013;939 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Overview and Findings from the Rush Memory and Aging Project. Curr. Alzheimer Res. 9, 646&#x2013;663 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Boyle PA, Wilson RS, Tang Y &amp; Bennett DA. Frailty is Associated With Incident Alzheimer&#x2019;s Disease and Cognitive Decline in the Elderly: Psychosom. Med. 69, 483&#x2013;489 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17556640</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS et al. Brain Pathology Contributes to Simultaneous Change in Physical Frailty and Cognition in Old Age. J. Gerontol. A. Biol. Sci. Med. Sci. 69, 1536&#x2013;1544 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4296120</ArticleId><ArticleId IdType="pubmed">25136002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Decision rules guiding the clinical diagnosis of Alzheimer&#x2019;s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology 27, 169&#x2013;176 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>Searle SD, Mitnitski A, Gahbauer EA, Gill TM &amp; Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 8, 24 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573877</ArticleId><ArticleId IdType="pubmed">18826625</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer&#x2019;s disease. Neurology 60, 246&#x2013;252 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L et al. TOMM40&#x2019;523 variant and cognitive decline in older persons with APOE &#x3b5;3/3 genotype. Neurology 88, 661&#x2013;668 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5317377</ArticleId><ArticleId IdType="pubmed">28108637</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover M, Rotermann M, Sanmartin C &amp; Bernier J. Validation of an index to estimate the prevalence of frailty among community-dwelling seniors. Health Rep. 24, 10&#x2013;17 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24258362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes AF Introduction to Mediation, Moderation, and Conditional Process Analysis, Second Edition: A Regression-Based Approach. (Guilford Publications, 2017).</Citation></Reference><Reference><Citation>Bennett DA, Schneider JA, Tang Y, Arnold SE &amp; Wilson RS. The effect of social networks on the relation between Alzheimer&#x2019;s disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol. 5, 406&#x2013;412 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16632311</ArticleId></ArticleIdList></Reference><Reference><Citation>Canevelli M, Cesari M &amp; van Kan GA. Frailty and cognitive decline: how do they relate? Curr. Opin. Clin. Nutr. Metab. Care 18, 43&#x2013;50 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25405314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace LMK, Theou O, Andrew MK &amp; Rockwood K. Relationship between frailty and Alzheimer&#x2019;s disease biomarkers: a scoping review. Alzheimers Dement. Diagn. Assess. Dis. Monit. Accept. Feb 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6072899</ArticleId><ArticleId IdType="pubmed">30094326</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM et al. Age, neuropathology, and dementia. N. Engl. J. Med. 360, 2302&#x2013;2309 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen HJ et al. Atrial structure, function and arrhythmogenesis in aged and frail mice. Sci. Rep. 7, 44336 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349540</ArticleId><ArticleId IdType="pubmed">28290548</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson DA, Savva GM &amp; Kenny RA. Frailty and cognitive impairment&#x2014;A review of the evidence and causal mechanisms. Ageing Res. Rev. 12, 840&#x2013;851 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23831959</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F et al. Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. J. Alzheimers Dis. JAD 62, 993&#x2013;1012 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870024</ArticleId><ArticleId IdType="pubmed">29562543</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong JJ et al. Changes in Frailty Predict Changes in Cognition in Older Men: The Honolulu-Asia Aging Study. J. Alzheimers Dis. JAD 53, 1003&#x2013;1013 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5469372</ArticleId><ArticleId IdType="pubmed">27314525</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann. Neurol. 83, 74&#x2013;83 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876116</ArticleId><ArticleId IdType="pubmed">29244218</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I et al. Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. J. Neuropathol. Exp. Neurol. 65, 740&#x2013;757 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16896308</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards M &amp; Brayne C. What do we mean by Alzheimer&#x2019;s disease? BMJ 341, c4670 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20940218</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30679382</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>363</Volume><Issue>6429</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.</ArticleTitle><Pagination><StartPage>880</StartPage><EndPage>884</EndPage><MedlinePgn>880-884</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aav2546</ELocationID><Abstract><AbstractText>The sleep-wake cycle regulates interstitial fluid (ISF) and cerebrospinal fluid (CSF) levels of &#x3b2;-amyloid (A&#x3b2;) that accumulates in Alzheimer's disease (AD). Furthermore, chronic sleep deprivation (SD) increases A&#x3b2; plaques. However, tau, not A&#x3b2;, accumulation appears to drive AD neurodegeneration. We tested whether ISF/CSF tau and tau seeding and spreading were influenced by the sleep-wake cycle and SD. Mouse ISF tau was increased ~90% during normal wakefulness versus sleep and ~100% during SD. Human CSF tau also increased more than 50% during SD. In a tau seeding-and-spreading model, chronic SD increased tau pathology spreading. Chemogenetically driven wakefulness in mice also significantly increased both ISF A&#x3b2; and tau. Thus, the sleep-wake cycle regulates ISF tau, and SD increases ISF and CSF tau as well as tau pathology spreading.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Holth</LastName><ForeName>Jerrah K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0001-5930-6555</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fritschi</LastName><ForeName>Sarah K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0003-4665-7203</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chanung</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6418-3809</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Nigel P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0002-8494-0635</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Emory Epilepsy Center, Emory University, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Neuroscience, Emory University, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0001-9811-7490</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0003-3980-9221</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7912-2016</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geerling</LastName><ForeName>Joel C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-9956-4006</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuller</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Division of Sleep Medicine, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucey</LastName><ForeName>Brendan P</ForeName><Initials>BP</Initials><Identifier Source="ORCID">0000-0001-5400-825X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA. holtzman@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS073613</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS103161</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG047999</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS092652</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS105929</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS089381</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002346</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76 AG054863</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR000450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2019 Feb 22;363(6429):813-814. doi: 10.1126/science.aaw5583.</RefSource><PMID Version="1">30792288</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="N">Wakefulness</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>: D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali, Genentech, and Proclara. D.M.H. consults for AbbVie. None of the authors report competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30679382</ArticleId><ArticleId IdType="mid">NIHMS1011179</ArticleId><ArticleId IdType="pmc">PMC6410369</ArticleId><ArticleId IdType="doi">10.1126/science.aav2546</ArticleId><ArticleId IdType="pii">science.aav2546</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spillantini MG, Goedert M, Tau pathology and neurodegeneration. Lancet neurology 12, 609&#x2013;622 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A et al., Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain 140, 3286&#x2013;3300 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F et al., Transmission and spreading of tauopathy in transgenic mouse brain. Nature cell biology 11, 909&#x2013;913 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI, Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11, 155&#x2013;159 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M et al., Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. The Journal of neuroscience: the official journal of the Society for Neuroscience 33, 1024&#x2013;1037 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A et al., Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L et al., Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP, Physiological release of endogenous tau is stimulated by neuronal activity. EMBO reports 14, 389&#x2013;394 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K et al., Neuronal activity regulates extracellular tau in vivo. The Journal of experimental medicine 211, 387&#x2013;393 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW et al., Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci 19, 1085&#x2013;1092 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, Tononi G, Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nat Neurosci 11, 200&#x2013;208 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18204445</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW et al., Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 14, 750&#x2013;756 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Uehara T, Sumiyoshi T, Itoh H, Kurata K, Lactate production and neurotransmitters; evidence from microdialysis studies. Pharmacol Biochem Behav 90, 273&#x2013;281 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18502489</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH et al., Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of beta-Amyloid in Mice with Alzheimer&#x2019;s Disease Pathology. Sci Transl Med 4, 150ra122 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE et al., Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005&#x2013;1007 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP et al., Effect of sleep on overnight cerebrospinal fluid amyloid beta kinetics. Ann Neurol 83, 197&#x2013;204 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876097</ArticleId><ArticleId IdType="pubmed">29220873</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Iwatsubo T, Extracellular &#x3b1;-synuclein levels are regulated by neuronal activity. Mol Neurodegener 13, 9 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822605</ArticleId><ArticleId IdType="pubmed">29467003</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K et al., Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo. Neuron 80, 402&#x2013;414 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA et al., Tau impairs neural circuits, dominating amyloid-&#x3b2; effects, in Alzheimer models in vivo. Nat Neurosci 22, 57&#x2013;64 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560629</ArticleId><ArticleId IdType="pubmed">30559471</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen NP et al., Supramammillary glutamate neurons are a key node of the arousal system. Nat Commun 8, 1405 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5680228</ArticleId><ArticleId IdType="pubmed">29123082</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL et al., Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159&#x2013;170 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K et al., Analysis of in vivo turnover of tau in a mouse model of tauopathy. Molecular neurodegeneration 10, 55 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4621881</ArticleId><ArticleId IdType="pubmed">26502977</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C et al., Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98, 861&#x2013;864 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192252</ArticleId><ArticleId IdType="pubmed">29772204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K et al., Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci Transl Med 9, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5727571</ArticleId><ArticleId IdType="pubmed">28424326</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L et al., Sleep drives metabolite clearance from the adult brain. Science 342, 373&#x2013;377 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y et al., Chronic Sleep Disruption Advances the Temporal Progression of Tauopathy in P301S Mutant Mice. J Neurosci 38, 10255&#x2013;10270 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6262148</ArticleId><ArticleId IdType="pubmed">30322903</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K et al., In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice. Journal of Neuroscience. 31, 13110&#x2013;13117 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR et al., In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. Journal of Neuroscience. 23, 8844&#x2013;8853 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Macauley SL et al., Hyperglycemia modulates extracellular amyloid-&#x3b2; concentrations and neuronal activity in vivo. J. Clin. Invest 125, 2463&#x2013;2467 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4497756</ArticleId><ArticleId IdType="pubmed">25938784</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BW et al., Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol. 78, 439&#x2013;453 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado RB, Hip&#xf3;lide DC, Benedito-Silva AA, Tufik S, Sleep deprivation induced by modified multiple platform technique: quantification of sleep loss and recovery. Brain Res. 1004, 45&#x2013;51 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15033418</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30686764</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-&#x3b2; in iPSC-Derived Alzheimer's Disease Neurons.</ArticleTitle><Pagination><StartPage>363</StartPage><EndPage>375.e9</EndPage><MedlinePgn>363-375.e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2018.12.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(18)30603-9</ELocationID><Abstract><AbstractText>Genetic, epidemiologic, and biochemical evidence suggests that predisposition to Alzheimer's disease (AD) may arise from altered cholesterol metabolism, although the molecular pathways that may link cholesterol to AD phenotypes are only partially understood. Here, we perform a phenotypic screen for pTau accumulation in AD-patient iPSC-derived neurons and identify cholesteryl esters (CE), the storage product of excess cholesterol, as upstream regulators of Tau early during AD development. Using isogenic induced pluripotent stem cell (iPSC) lines carrying mutations in the cholesterol-binding domain of APP or APP null alleles, we found that while CE also regulate A&#x3b2; secretion, the effects of CE on Tau and A&#x3b2; are mediated by independent pathways. Efficacy and toxicity screening in iPSC-derived astrocytes and neurons showed that allosteric activation of CYP46A1 lowers CE specifically in neurons and is well tolerated by astrocytes. These data reveal that CE independently regulate Tau and A&#x3b2; and identify a druggable CYP46A1-CE-Tau axis in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Kant</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan 1087, 1081 HV Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langness</LastName><ForeName>Vanessa F</ForeName><Initials>VF</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>Cheryl M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Lauren K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leestemaker</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Oncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steenvoorden</LastName><ForeName>Evelyne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rynearson</LastName><ForeName>Kevin D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brouwers</LastName><ForeName>Jos F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University Yalelaan 2, 3584 CM Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helms</LastName><ForeName>J Bernd</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University Yalelaan 2, 3584 CM Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovaa</LastName><ForeName>Huib</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Oncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giera</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA; Research Biologist, VA San Diego Healthcare System, La Jolla, CA 92161, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bang</LastName><ForeName>Anne G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LSB</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA. Electronic address: lgoldstein@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG048083</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2019 Mar 7;24(3):347-349. doi: 10.1016/j.stem.2019.02.003.</RefSource><PMID Version="1">30849361</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">CYP46A1 Tau</Keyword><Keyword MajorTopicYN="N">amyloid beta</Keyword><Keyword MajorTopicYN="N">cholesterol metabolism</Keyword><Keyword MajorTopicYN="N">cholesteryl esters</Keyword><Keyword MajorTopicYN="N">disease modeling</Keyword><Keyword MajorTopicYN="N">drug screening</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cells</Keyword><Keyword MajorTopicYN="N">lipids</Keyword><Keyword MajorTopicYN="N">proteostasis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30686764</ArticleId><ArticleId IdType="pmc">PMC6414424</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2018.12.013</ArticleId><ArticleId IdType="pii">S1934-5909(18)30603-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson K.W., Mast N., Hudgens J.W., Lin J.B., Turko I.V., Pikuleva I.A. Mapping of the allosteric site in cholesterol hydroxylase CYP46A1 for efavirenz, a drug that stimulates enzyme activity. J.&#xa0;Biol. Chem. 2016;291:11876&#x2013;11886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4882454</ArticleId><ArticleId IdType="pubmed">27056331</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova N., Blas-Garcia A., Galindo M.J., Esplugues J.V. Efavirenz: what is known about the cellular mechanisms responsible for its adverse effects. Eur. J. Pharmacol. 2017;812:163&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">28690189</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrese E.L., Saudale F.Z., Soulages J.L. Lipid droplets as signaling platforms linking metabolic and cellular functions. Lipid Insights. 2014;7:7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161058</ArticleId><ArticleId IdType="pubmed">25221429</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett P.J., Song Y., Van Horn W.D., Hustedt E.J., Schafer J.M., Hadziselimovic A., Beel A.J., Sanders C.R. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science. 2012;336:1168&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528355</ArticleId><ArticleId IdType="pubmed">22654059</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkers C.R., van Leeuwen F.W.B., Groothuis T.A., Peperzak V., van Tilburg E.W., Borst J., Neefjes J.J., Ovaa H. Profiling proteasome activity in tissue with fluorescent probes. Mol. Pharm. 2007;4:739&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">17708652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem-Bergman L., Lindh J.D., Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br. J. Clin. Pharmacol. 2011;72:164&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3141200</ArticleId><ArticleId IdType="pubmed">21223360</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M., Grigoriadis N., Lourbopoulos A., Touloumi O., Rosenmann D., Abramsky O., Rosenmann H. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J.&#xa0;Neuropathol. Exp. Neurol. 2009;68:314&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">19225406</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownjohn P.W., Smith J., Portelius E., Serneels L., Kvartsberg H., De Strooper B., Blennow K., Zetterberg H., Livesey F.J. Phenotypic screening identifies modulators of amyloid precursor protein processing in human stem cell models of Alzheimer&#x2019;s disease. Stem Cell Reports. 2017;8:870&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390098</ArticleId><ArticleId IdType="pubmed">28285880</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R., Hofmann-Kiefer K., McCulloch C., Ptok U., Heun R. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59:627&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196665</ArticleId></ArticleIdList></Reference><Reference><Citation>Burlot M.-A., Braudeau J., Michaelsen-Preusse K., Potier B., Ayciriex S., Varin J., Gautier B., Djelti F., Audrain M., Dauphinot L. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Hum. Mol. Genet. 2015;24:5965&#x2013;5976.</Citation><ArticleIdList><ArticleId IdType="pubmed">26358780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan R.B., Oliveira T.G., Cortes E.P., Honig L.S., Duff K.E., Small S.A., Wenk M.R., Shui G., Di Paolo G. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J.&#xa0;Biol. Chem. 2012;287:2678&#x2013;2688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268426</ArticleId><ArticleId IdType="pubmed">22134919</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.H., Kim Y.H., Hebisch M., Sliwinski C., Lee S., D&#x2019;Avanzo C., Chen H., Hooli B., Asselin C., Muffat J. A three-dimensional human neural cell culture model of Alzheimer&#x2019;s disease. Nature. 2014;515:274&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Antonio M., Woodruff G., Nathanson J.L., D&#x2019;Antonio-Chronowska A., Arias A., Matsui H., Williams R., Herrera C., Reyna S.M., Yeo G.W. High-throughput and cost-effective characterization of induced pluripotent stem cells. Stem Cell Reports. 2017;8:1101&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390243</ArticleId><ArticleId IdType="pubmed">28410643</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong A., Schuurman K.G., Rodenko B., Ovaa H., Berkers C.R. Fluorescence-based proteasome activity profiling. Methods Mol. Biol. 2012;803:183&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">22065226</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paolo G., Kim T.-W. Linking lipids to Alzheimer&#x2019;s disease: cholesterol and beyond. Nat. Rev. Neurosci. 2011;12:284&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321383</ArticleId><ArticleId IdType="pubmed">21448224</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey C.A., Ash P., Klosak N., Lee W.C., Petrucelli L., Hutton M., Eckman C.B. Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol. Neurodegener. 2006;1:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1570347</ArticleId><ArticleId IdType="pubmed">16930453</ArticleId></ArticleIdList></Reference><Reference><Citation>Djelti F., Braudeau J., Hudry E., Dhenain M., Varin J., Bi&#xe8;che I., Marquer C., Chali F., Ayciriex S., Auzeil N. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer&#x2019;s disease. Brain. 2015;138:2383&#x2013;2398.</Citation><ArticleIdList><ArticleId IdType="pubmed">26141492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J.&#xa0;Cell Biol. 2003;160:113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley P. Lipids in Alzheimer&#x2019;s disease: a century-old story. Biochim. Biophys. Acta. 2010;1801:750&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">20471492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong L.K., Yang M.M., Dos Santos Chaves R., Reyna S.M., Langness V.F., Woodruff G., Roberts E.A., Young J.E., Goldstein L.S.B. Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-&#x3b2; clearance in human astrocytes. J.&#xa0;Biol. Chem. 2018;293:11341&#x2013;11357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6065173</ArticleId><ArticleId IdType="pubmed">29858247</ArticleId></ArticleIdList></Reference><Reference><Citation>Giera M., Pl&#xf6;ssl F., Bracher F. Fast and easy in&#xa0;vitro screening assay for cholesterol biosynthesis inhibitors in the post-squalene pathway. Steroids. 2007;72:633&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">17583759</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore A., Li Z., Fung H.-L., Young J.E., Agarwal S., Antosiewicz-Bourget J., Canto I., Giorgetti A., Israel M.A., Kiskinis E. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011;471:63&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074107</ArticleId><ArticleId IdType="pubmed">21368825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton L.K., Dufresne M., Jopp&#xe9; S.E., Petryszyn S., Aumont A., Calon F., Barnab&#xe9;-Heider F., Furtos A., Parent M., Chaurand P., Fernandes K.J.L. Aberrant lipid metabolism in the forebrain niche suppresses adult neural stem cell proliferation in an animal model of Alzheimer&#x2019;s disease. Cell Stem Cell. 2015;17:397&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26321199</ArticleId></ArticleIdList></Reference><Reference><Citation>Han D.H., Na H.-K., Choi W.H., Lee J.H., Kim Y.K., Won C., Lee S.-H., Kim K.P., Kuret J., Min D.-H., Lee M.J. Direct cellular delivery of human proteasomes to delay tau aggregation. Nat. Commun. 2014;5:5633.</Citation><ArticleIdList><ArticleId IdType="pubmed">25476420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutter-Paier B., Huttunen H.J., Puglielli L., Eckman C.B., Kim D.Y., Hofmeister A., Moir R.D., Domnitz S.B., Frosch M.P., Windisch M., Kovacs D.M. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer&#x2019;s disease. Neuron. 2004;44:227&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473963</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttunen H.J., Peach C., Bhattacharyya R., Barren C., Pettingell W., Hutter-Paier B., Windisch M., Berezovska O., Kovacs D.M. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J. 2009;23:3819&#x2013;3828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775008</ArticleId><ArticleId IdType="pubmed">19625658</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttunen H.J., Havas D., Peach C., Barren C., Duller S., Xia W., Frosch M.P., Hutter-Paier B., Windisch M., Kovacs D.M. The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J.&#xa0;Neuropathol. Exp. Neurol. 2010;69:777&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918281</ArticleId><ArticleId IdType="pubmed">20613640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat. Rev. Mol. Cell Biol. 2008;9:125&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">18216769</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamisuki S., Mao Q., Abu-Elheiga L., Gu Z., Kugimiya A., Kwon Y., Shinohara T., Kawazoe Y., Sato S., Asakura K. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 2009;16:882&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">19716478</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasinska J.M., Hayden M.R. Cholesterol metabolism in Huntington disease. Nat. Rev. Neurol. 2011;7:561&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">21894212</ArticleId></ArticleIdList></Reference><Reference><Citation>Keck S., Nitsch R., Grune T., Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer&#x2019;s disease. J.&#xa0;Neurochem. 2003;85:115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12641733</ArticleId></ArticleIdList></Reference><Reference><Citation>Keembiyehetty C.N., Krzeslak A., Love D.C., Hanover J.A. A lipid-droplet-targeted O-GlcNAcase isoform is a key regulator of the proteasome. J.&#xa0;Cell Sci. 2011;124:2851&#x2013;2860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3148132</ArticleId><ArticleId IdType="pubmed">21807949</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer&#x2019;s disease. J.&#xa0;Neurochem. 2000;75:436&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T., Imamura K., Funayama M., Tsukita K., Miyake M., Ohta A., Woltjen K., Nakagawa M., Asada T., Arai T. iPSC-based compound screening and in&#xa0;vitro trials identify a synergistic anti-amyloid &#x3b2; combination for Alzheimer&#x2019;s disease. Cell Rep. 2017;21:2304&#x2013;2312.</Citation><ArticleIdList><ArticleId IdType="pubmed">29166618</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.T., Sliskovic D.R., Picard J.A., Roth B.D., Wierenga W., Hicks J.L., Bousley R.F., Hamelehle K.L., Homan R., Speyer C. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J.&#xa0;Med. Chem. 1996;39:5031&#x2013;5034.</Citation><ArticleIdList><ArticleId IdType="pubmed">8978833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.J., Lee J.H., Rubinsztein D.C. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog. Neurobiol. 2013;105:49&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">23528736</ArticleId></ArticleIdList></Reference><Reference><Citation>Leestemaker Y., de Jong A., Witting K.F., Penning R., Schuurman K., Rodenko B., Zaal E.A., van de Kooij B., Laufer S., Heck A.J.R. Proteasome activation by small molecules. Cell Chem. Biol. 2017;24:725&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552582</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-C., Liu C.-C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokireddy S., Kukushkin N.V., Goldberg A.L. cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc. Natl. Acad. Sci. USA. 2015;112:E7176&#x2013;E7185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702992</ArticleId><ArticleId IdType="pubmed">26669444</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna-Mu&#xf1;oz J., Ch&#xe1;vez-Mac&#xed;as L., Garc&#xed;a-Sierra F., Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer&#x2019;s disease. J.&#xa0;Alzheimers Dis. 2007;12:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">18198423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mast N., Anderson K.W., Johnson K.M., Phan T.T.N., Guengerich F.P., Pikuleva I.A. In&#xa0;vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds. J.&#xa0;Biol. Chem. 2017;292:12934&#x2013;12946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546033</ArticleId><ArticleId IdType="pubmed">28642370</ArticleId></ArticleIdList></Reference><Reference><Citation>Mast N., Saadane A., Valencia-Olvera A., Constans J., Maxfield E., Arakawa H., Li Y., Landreth G., Pikuleva I.A. Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer&#x2019;s disease. Neuropharmacology. 2017;123:465&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546235</ArticleId><ArticleId IdType="pubmed">28655608</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrick S.E., Demoise D.C., Lee V.M. Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A. J.&#xa0;Biol. Chem. 1996;271:5589&#x2013;5594.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621419</ArticleId></ArticleIdList></Reference><Reference><Citation>Michikawa M., Fan Q.W., Isobe I., Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J.&#xa0;Neurochem. 2000;74:1008&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693931</ArticleId></ArticleIdList></Reference><Reference><Citation>Minagawa H., Gong J.-S., Jung C.-G., Watanabe A., Lund-Katz S., Phillips M.C., Saito H., Michikawa M. Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture. J.&#xa0;Neurosci. Res. 2009;87:2498&#x2013;2508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065888</ArticleId><ArticleId IdType="pubmed">19326444</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S., Evans L.D.B., Andersson T., Portelius E., Smith J., Dias T.B., Saurat N., McGlade A., Kirwan P., Blennow K. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 2015;11:689&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431668</ArticleId><ArticleId IdType="pubmed">25921538</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutinho M., Nunes M.J., Rodrigues E. Cholesterol 24-hydroxylase: brain cholesterol metabolism and beyond. Biochim. Biophys. Acta. 2016;1861(12 Pt A):1911&#x2013;1920.</Citation><ArticleIdList><ArticleId IdType="pubmed">27663182</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller C., Binder U., Bracher F., Giera M. Antifungal drug testing by combining minimal inhibitory concentration testing with target identification by gas chromatography-mass spectrometry. Nat. Protoc. 2017;12:947&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">28384139</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore C.R., Rice H.C., Srikanth P., Callahan D.G., Shin T., Benjamin L.N.P., Walsh D.M., Selkoe D.J., Young-Pearse T.L. The familial Alzheimer&#x2019;s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum. Mol. Genet. 2014;23:3523&#x2013;3536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049307</ArticleId><ArticleId IdType="pubmed">24524897</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N., Clelland C.L., Emrani S., Kukushkin N.V., Yu W.H., Goldberg A.L., Duff K.E. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat. Med. 2016;22:46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787271</ArticleId><ArticleId IdType="pubmed">26692334</ArticleId></ArticleIdList></Reference><Reference><Citation>Naldini L., Bl&#xf6;mer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In&#xa0;vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">8602510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochalek A., Mihalik B., Avci H.X., Chandrasekaran A., T&#xe9;gl&#xe1;si A., Bock I., Giudice M.L., T&#xe1;ncos Z., Moln&#xe1;r K., L&#xe1;szl&#xf3; L. Neurons derived from sporadic Alzheimer&#x2019;s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation. Alzheimers Res. Ther. 2017;9:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5709977</ArticleId><ArticleId IdType="pubmed">29191219</ArticleId></ArticleIdList></Reference><Reference><Citation>Pani A., Dess&#xec; S., Diaz G., La Colla P., Abete C., Mulas C., Angius F., Cannas M.D., Orru C.D., Cocco P.L. Altered cholesterol ester cycle in skin fibroblasts from patients with Alzheimer&#x2019;s disease. J.&#xa0;Alzheimers Dis. 2009;18:829&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">19749436</ArticleId></ArticleIdList></Reference><Reference><Citation>Parrales A., Ranjan A., Iyer S.V., Padhye S., Weir S.J., Roy A., Iwakuma T. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat. Cell Biol. 2016;18:1233&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340314</ArticleId><ArticleId IdType="pubmed">27775703</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L., Konopka G., Pack-Chung E., Ingano L.A., Berezovska O., Hyman B.T., Chang T.Y., Tanzi R.E., Kovacs D.M. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 2001;3:905&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584272</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L., Tanzi R.E., Kovacs D.M. Alzheimer&#x2019;s disease: the cholesterol connection. Nat. Neurosci. 2003;6:345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12658281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran K.V., Margolis S.S. A mammalian nervous-system-specific plasma membrane proteasome complex that modulates neuronal function. Nat. Struct. Mol. Biol. 2017;24:419&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5383508</ArticleId><ArticleId IdType="pubmed">28287632</ArticleId></ArticleIdList></Reference><Reference><Citation>Riekse R.G., Li G., Petrie E.C., Leverenz J.B., Vavrek D., Vuletic S., Albers J.J., Montine T.J., Lee V.M.-Y., Lee M. Effect of statins on Alzheimer&#x2019;s disease biomarkers in cerebrospinal fluid. J.&#xa0;Alzheimers Dis. 2006;10:399&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">17183151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharpe L.J., Cook E.C.L., Zelcer N., Brown A.J. The UPS and downs of cholesterol homeostasis. Trends Biochem. Sci. 2014;39:527&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">25220377</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepardson N.E., Shankar G.M., Selkoe D.J. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch. Neurol. 2011;68:1385&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248784</ArticleId><ArticleId IdType="pubmed">22084122</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepardson N.E., Shankar G.M., Selkoe D.J. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 2011;68:1239&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3211071</ArticleId><ArticleId IdType="pubmed">21987540</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Kirwan P., Smith J., MacLean G., Orkin S.H., Livesey F.J. A human stem cell model of early Alzheimer&#x2019;s disease pathology in Down syndrome. Sci. Transl. Med. 2012;4:124ra29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129935</ArticleId><ArticleId IdType="pubmed">22344463</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Inoue H., Wu J.C., Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat. Rev. Drug Discov. 2017;16:115&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416143</ArticleId><ArticleId IdType="pubmed">27980341</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya Y., Niu Z., Bryleva E.Y., Harris B.T., Murphy S.R., Kheirollah A., Bowen Z.D., Chang C.C.Y., Chang T.-Y. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer&#x2019;s disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiol. Aging. 2015;36:2248&#x2013;2259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457653</ArticleId><ArticleId IdType="pubmed">25930235</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer&#x2019;s disease: a dual pathway hypothesis. Neuron. 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajima Y., Ishikawa M., Maekawa K., Murayama M., Senoo Y., Nishimaki-Mogami T., Nakanishi H., Ikeda K., Arita M., Taguchi R. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer&#x2019;s disease. Lipids Health Dis. 2013;12:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668217</ArticleId><ArticleId IdType="pubmed">23659495</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Najm R., Xu Q., Jeong D.-E., Walker D., Balestra M.E., Yoon S.Y., Yuan H., Li G., Miller Z.A. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med. 2018;24:647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="pubmed">29632371</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie H., Litersky J.M., Hartigan J.A., Jope R.S., Johnson G.V. The interrelationship between selective tau phosphorylation and microtubule association. Brain Res. 1998;798:173&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">9666118</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D.-S., Stavrides P., Saito M., Kumar A., Rodriguez-Navarro J.A., Pawlik M., Huo C., Walkley S.U., Saito M., Cuervo A.M., Nixon R.A. Defective macroautophagic turnover of brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting lysosomal proteolytic deficits. Brain. 2014;137:3300&#x2013;3318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240291</ArticleId><ArticleId IdType="pubmed">25270989</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J.E., Boulanger-Weill J., Williams D.A., Woodruff G., Buen F., Revilla A.C., Herrera C., Israel M.A., Yuan S.H., Edland S.D., Goldstein L.S.B. Elucidating molecular phenotypes caused by the SORL1 Alzheimer&#x2019;s disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell. 2015;16:373&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388804</ArticleId><ArticleId IdType="pubmed">25772071</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J.E., Fong L.K., Frankowski H., Petsko G.A., Small S.A., Goldstein L.S.B. Stabilizing the retromer complex in a human stem cell model of Alzheimer&#x2019;s disease reduces TAU phosphorylation independently of amyloid precursor protein. Stem Cell Reports. 2018;10:1046&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919412</ArticleId><ArticleId IdType="pubmed">29503090</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S.H., Martin J., Elia J., Flippin J., Paramban R.I., Hefferan M.P., Vidal J.G., Mu Y., Killian R.L., Israel M.A. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS ONE. 2011;6:e17540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047583</ArticleId><ArticleId IdType="pubmed">21407814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zissimopoulos J.M., Barthold D., Brinton R.D., Joyce G. Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol. 2017;74:225&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5646357</ArticleId><ArticleId IdType="pubmed">27942728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30689776</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.</ArticleTitle><Pagination><StartPage>460</StartPage><EndPage>470</EndPage><MedlinePgn>460-470</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awy327</ELocationID><Abstract><AbstractText>Mounting evidence indicates that the polygenic basis of late-onset Alzheimer's disease can be harnessed to identify individuals at greatest risk for cognitive decline. We have previously developed and validated a polygenic hazard score comprising of 31 single nucleotide polymorphisms for predicting Alzheimer's disease dementia age of onset. In this study, we examined whether polygenic hazard scores are associated with: (i) regional tracer uptake using amyloid PET; (ii) regional volume loss using longitudinal MRI; (iii) post-mortem regional amyloid-&#x3b2; protein and tau associated neurofibrillary tangles; and (iv) four common non-Alzheimer's pathologies. Even after accounting for APOE, we found a strong association between polygenic hazard scores and amyloid PET standard uptake volume ratio with the largest effects within frontal cortical regions in 980 older individuals across the disease spectrum, and longitudinal MRI volume loss within the entorhinal cortex in 607 older individuals across the disease spectrum. We also found that higher polygenic hazard scores were associated with greater rates of cognitive and clinical decline in 632 non-demented older individuals, even after controlling for APOE status, frontal amyloid PET and entorhinal cortex volume. In addition, the combined model that included polygenic hazard scores, frontal amyloid PET and entorhinal cortex volume resulted in a better fit compared to a model with only imaging markers. Neuropathologically, we found that polygenic hazard scores were associated with regional post-mortem amyloid load and neuronal neurofibrillary tangles, even after accounting for APOE, validating our imaging findings. Lastly, polygenic hazard scores were associated with Lewy body and cerebrovascular pathology. Beyond APOE, we show that in living subjects, polygenic hazard scores were associated with amyloid deposition and neurodegeneration in susceptible brain regions. Polygenic hazard scores may also be useful for the identification of individuals at the highest risk for developing multi-aetiological dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Chin Hong</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Division of Psychology, Nanyang Technological University, 48 Nanyang Avenue, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonham</LastName><ForeName>Luke W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Chun Chieh</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Cognitive Science, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, 300 Pasteur Dr, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugrue</LastName><ForeName>Leo P</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broce</LastName><ForeName>Iris J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, 550 16th Street, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Francisco, 982 Mission St, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, 204 N Broad St, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauppi</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, 8929 University Center, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Linda K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, 8929 University Center, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, 1959 NE Pacific St, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosun</LastName><ForeName>Duygu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, 15 Parkman St, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, 1750 W Harrison St, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, 15 Parkman St, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>NORMENT Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Boks 1072 Blindern, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Cognitive Science, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, 8929 University Center, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desikan</LastName><ForeName>Rahul S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020412" MajorTopicYN="N">Multifactorial Inheritance</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30689776</ArticleId><ArticleId IdType="pmc">PMC6351776</ArticleId><ArticleId IdType="doi">10.1093/brain/awy327</ArticleId><ArticleId IdType="pii">5300061</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aiken LS, West SG. Multiple regression: testing and interpreting interactions. Thousand Oaks, CA, US: Sage Publications, Inc.; 1991.</Citation></Reference><Reference><Citation>Alzheimer&#x2019;s Association. Alzheimer&#x2019;s disease facts and figures. Alzheimers Demen 2017; 12: 459&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr Alzheimer Res 2012a; 9: 628&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush memory and aging project. Curr Alzheimer Res 2012b; 9: 646&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious orders study and rush memory and aging project. J Alzheimers Dis 2018; 64: S161&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Broce IJ, Tan CH, Fan CC, Jansen I, Savage JE, Witoelar A et al. . Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. Acta Neuropathol 2018; 1&#x2013;18. doi: 10.1007/s00401-018-1928-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358498</ArticleId><ArticleId IdType="pubmed">30413934</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouraki V, Reitz C, Maury F, Bis JC, Bellenguez C, Yu L et al. . Evaluation of a genetic risk score to improve risk prediction for Alzheimer&#x2019;s disease. J Alzheimers Dis 2016; 53: 921&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036102</ArticleId><ArticleId IdType="pubmed">27340842</ArticleId></ArticleIdList></Reference><Reference><Citation>Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA et al. . Alzheimer&#x2019;s Disease-Related Dementias Summit 2016: national research priorities. Neurology 2017; 89: 2381&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719928</ArticleId><ArticleId IdType="pubmed">29117955</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A et al. . Development and assessment of a composite score for memory in the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012; 6: 502&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Cabral HJ, Fischl B, Guttmann CR, Blacker D, Hyman BT et al. . Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease. AJNR Am J Neuroradiol 2009; 30: 532&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656417</ArticleId><ArticleId IdType="pubmed">19112067</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples A et al. . Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLoS Med 2017; 14: e1002258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360219</ArticleId><ArticleId IdType="pubmed">28323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Schork AJ, Wang Y, Thompson WK, Dehghan A, Ridker PM et al. . Polygenic overlap between C-reactive protein, plasma lipids, and Alzheimer disease. Circulation 2015; 131: 2061&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4677995</ArticleId><ArticleId IdType="pubmed">25862742</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D et al. . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006; 31: 968&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Jones L. Genomic profiling and diagnostic biomarkers in Alzheimer&#x2019;s disease. Lancet Neurol 2017; 16: 582&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">28721917</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E et al. . Common polygenic variation enhances risk prediction for Alzheimer&#x2019;s disease. Brain 2015; 138: 3673&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006219</ArticleId><ArticleId IdType="pubmed">26490334</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Myers AJ, Huentelman M, Hardy J. Polygenic risk score analysis of pathologically confirmed Alzheimer disease. Ann Neurol 2017; 82: 311&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599118</ArticleId><ArticleId IdType="pubmed">28727176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge T, Sabuncu MR, Smoller JW, Sperling RA, Mormino EC. Dissociable influences of APOE e4 and polygenic risk of AD dementia on amyloid and cognition. Neurology 2018; 90: 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5931806</ArticleId><ArticleId IdType="pubmed">29592889</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P et al. . A composite score for executive functioning, validated in Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012; 6: 517&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Godert M. Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: the prion concept in relation to assembled A&#x3b2;, tau, and &#x3b1;-synuclein. Science 2015; 349: 1255555.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250687</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci 1996; 16: 4491&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Tholen S, Yousefi BH, Alexopoulos P, F&#xf6;rschler A, F&#xf6;rstl H et al. . Progression of cerebral amyloid load is associated with the apolipoprotein E &#x25b;4 genotype in Alzheimer&#x2019;s disease. Biol Psychiatry 2010; 68: 879&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045041</ArticleId><ArticleId IdType="pubmed">20598287</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hernandez DG et al. . Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson&#x2019;s and Alzheimer&#x2019;s diseases. Neurobiol Aging 2016; 38: 214.e7&#x2013;e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759606</ArticleId><ArticleId IdType="pubmed">26643944</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Brendel M, Grimmer T, Rominger A, Yakushev I. Predicting regional pattern of longitudinal &#x3b2;-amyloid accumulation by baseline PET. J Nul Med 2017; 58: 639&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373505</ArticleId><ArticleId IdType="pubmed">27754901</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, Mahmood Z, Lau EP, Karacozoff AM, Burggren AC, Small GW et al. . An Alzheimer&#x2019;s disease genetic risk score predicts longitudinal thinning of hippocampal complex subregions in healthy older adults. eNeuro 2016; 3 pii: ENEURO.0098&#x2013;16.2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945997</ArticleId><ArticleId IdType="pubmed">27482534</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM. Subregional neuroanatomical change as a biomarker for Alzheimer&#x2019;s disease. Proc Natl Acad Sci 2009; 106: 20954&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791580</ArticleId><ArticleId IdType="pubmed">19996185</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Dale AM. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Medical Image Analysis 2011; 15: 489&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115407</ArticleId><ArticleId IdType="pubmed">21388857</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX et al. . Neuropathological and genetic correlates of survival and dementia onset in synnucleinopathies: a retrospective analysis. Lancet Neurol 2017; 16: 55&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181646</ArticleId><ArticleId IdType="pubmed">27979356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al. . NIA-AA research-framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement 2018; 14: 535&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM et al. . Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1192&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauppi K, Fan CC, McEvoy LK, Holland D, Tan CH, Chen CH et al. . Combining polygenic hazard score with volumetric MRI and cognitive measures improves prediction of progression from mild cognitive impairment to Alzheimer&#x2019;s disease. Front Neurosci 2018; 12: 260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5937163</ArticleId><ArticleId IdType="pubmed">29760643</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeus B, Theuns J, VanBroeckhoven C. The genetics of dementia with Lewy bodies: what are we missing? Arch Neurol 2012; 69: 1113&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22635379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW et al. . Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology 2016; 5: 481&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970660</ArticleId><ArticleId IdType="pubmed">27385740</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabuncu MR, Buckner RL, Smoller JW, Lee PH, Fischl B, Sperling RA. The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. Cereb Cortex. 2012; 22: 2653&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464416</ArticleId><ArticleId IdType="pubmed">22169231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CH, Desikan RS. Interpreting Alzheimer&#x2019;s disease polygenic scores. Ann Neurol. 2018; 83: 443&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29394507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CH, Fan CC, Mormino EC, Sugrue LP, Broce IJ, Hess CP et al. . Polygenic hazard score: an enrichment marker for Alzheimer&#x2019;s associated amyloid and tau deposition. Acta Neuropathol 2018; 135: 85&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5758038</ArticleId><ArticleId IdType="pubmed">29177679</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CH, Hyman BT, Tan JJX, Hess CP, Dillon WP, Schellenberg GD et al. . Polygenic hazard scores in preclinical Alzheimer disease. Ann Neurol 2017; 82: 484&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5758043</ArticleId><ArticleId IdType="pubmed">28940650</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaker AA, Weinberg BD, Dillon WP, Hess CP, Cabral HJ, Fleischman DA et al. . Entorhinal cortex: antemortem cortical thickness and postmortem neurofibrillary tangles and amyloid pathology. AJNR Am J Neuroradiol 2017; 38: 961&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433913</ArticleId><ArticleId IdType="pubmed">28279988</ArticleId></ArticleIdList></Reference><Reference><Citation>Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nav Rev Genet 2018; 19: 581&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">29789686</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen GW, Hyman BT, Damasio AR. Entorhinal cortex pathology in Alzheimer&#x2019;s disease. Hippocampus 1991; 1: 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669339</ArticleId></ArticleIdList></Reference><Reference><Citation>Voyle N, Patel H, Folarin A, Newhouse S, Johnstone C, Visser PJ et al. . Genetic risk as a marker of amyloid-b and tau burden in cerebrospinal fluid. J Alzheimers Dis 2017; 55: 1417&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181674</ArticleId><ArticleId IdType="pubmed">27834776</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30688979</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>321</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>12</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>553</StartPage><EndPage>561</EndPage><MedlinePgn>553-561</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2018.21442</ELocationID><Abstract><AbstractText Label="IMPORTANCE">There are currently no proven treatments to reduce the risk of mild cognitive impairment and dementia.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the effect of intensive blood pressure control on risk of dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Randomized clinical trial conducted at 102 sites in the United States and Puerto Rico among adults aged 50 years or older with hypertension but without diabetes or history of stroke. Randomization began on November 8, 2010. The trial was stopped early for benefit on its primary outcome (a composite of cardiovascular events) and all-cause mortality on August 20, 2015. The final date for follow-up of cognitive outcomes was July 22, 2018.</AbstractText><AbstractText Label="INTERVENTIONS">Participants were randomized to a systolic blood pressure goal of either less than 120 mm Hg (intensive treatment group; n&#x2009;=&#x2009;4678) or less than 140 mm Hg (standard treatment group; n&#x2009;=&#x2009;4683).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary cognitive outcome was occurrence of adjudicated probable dementia. Secondary cognitive outcomes included adjudicated mild cognitive impairment and a composite outcome of mild cognitive impairment or probable dementia.</AbstractText><AbstractText Label="RESULTS">Among 9361 randomized participants (mean age, 67.9 years; 3332 women [35.6%]), 8563 (91.5%) completed at least 1 follow-up cognitive assessment. The median intervention period was 3.34 years. During a total median follow-up of 5.11 years, adjudicated probable dementia occurred in 149 participants in the intensive treatment group vs 176 in the standard treatment group (7.2 vs 8.6 cases per 1000 person-years; hazard ratio [HR], 0.83; 95% CI, 0.67-1.04). Intensive BP control significantly reduced the risk of mild cognitive impairment (14.6 vs 18.3 cases per 1000 person-years; HR, 0.81; 95% CI, 0.69-0.95) and the combined rate of mild cognitive impairment or probable dementia (20.2 vs 24.1 cases per 1000 person-years; HR, 0.85; 95% CI, 0.74-0.97).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Among ambulatory adults with hypertension, treating to a systolic blood pressure goal of less than 120 mm Hg compared with a goal of less than 140 mm Hg did not result in a significant reduction in the risk of probable dementia. Because of early study termination and fewer than expected cases of dementia, the study may have been underpowered for this end point.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT01206062.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>SPRINT MIND Investigators for the SPRINT Research Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajewski</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auchus</LastName><ForeName>Alexander P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryan</LastName><ForeName>R Nick</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chelune</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah School of Medicine, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Alfred K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Maryjo L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coker</LastName><ForeName>Laura H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cushman</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutler</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davatzikos</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desiderio</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erus</LastName><ForeName>Guray</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fine</LastName><ForeName>Larry J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Clinical Applications and Prevention Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaussoin</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Darrin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Meng-Kang</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Karen C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimmel</LastName><ForeName>Paul L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Disorders, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Manjula Kurella</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Stanford University School of Medicine; Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Neuroepidemiology Section, Intramural Research Program, National Institute on Aging, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Cora E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martindale-Adams</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moy</LastName><ForeName>Claudia S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasrallah</LastName><ForeName>Ilya M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Linda O</ForeName><Initials>LO</Initials><AffiliationInfo><Affiliation>Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oparil</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Mahboob</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Louis Stokes Cleveland Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rapp</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reboussin</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocco</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Section of Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Bonnie C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Still</LastName><ForeName>Carolyn H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Supiano</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of Utah School of Medicine, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Joni K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadley</LastName><ForeName>Virginia G</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Daniel E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whelton</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Valerie M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolard</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Jackson T</ForeName><Initials>JT</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Division of Nephrology and Hypertension, Department of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Clinton B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01206062</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002548</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001064</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA AG007480</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001427</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2019 Feb 12;321(6):548-549. doi: 10.1001/jama.2019.0008.</RefSource><PMID Version="1">30688980</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2019 May 21;92(21):1017-1018. doi: 10.1212/WNL.0000000000007543.</RefSource><PMID Version="1">31019101</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2019 Jul 9;322(2):169-170. doi: 10.1001/jama.2019.5840.</RefSource><PMID Version="1">31287515</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Williamson, Pajewski, Chelune, Crowe, Cushman, Lerner, Lewis, Lewis, Oparil, Rahman, Reboussin, Rocco, Supiano, Wadley, Weiner, and C. B. Wright reported receipt of research support from the National Institutes of Health (NIH). Dr Williamson reported that his institution received funding from Biogen (unrelated to this study). Dr Cushman reported receipt of grants from Lilly and personal fees from Sanofi Pharmaceuticals and uncompensated consulting for Novartis Pharmaceuticals and Takeda Pharmaceuticals. Dr Oparil reported receipt of personal fees from Actelion Clinical Research Inc, Boehringer Ingelheim/Lilly, Lundbeck, Novo Nordisk Inc, 98point6 Inc, George Clinical Pty Ltd, Idorsia Pharmaceuticals, Pfizer Inc, and ROX Medical Inc and grant support from Actelion Clinical Research Inc, George Clinical Pty Ltd, Idorsia Pharmaceuticals, and Novartis. Dr Oparil also reported being the editor-in-chief of <i>Current Hypertension Reports </i>(until December 2020), published by Springer Science Business Media LLC, for which she receives an annual stipend of $5000. Dr Sink reported being a full-time employee of Wake Forest School of Medicine during the conduct of this study and since becoming a full-time employee of Genentech. Dr C. B. Wright reported royalties from UpToDate.com for 2 chapters on vascular dementia. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30688979</ArticleId><ArticleId IdType="mid">NIHMS1016144</ArticleId><ArticleId IdType="pmc">PMC6439590</ArticleId><ArticleId IdType="doi">10.1001/jama.2018.21442</ArticleId><ArticleId IdType="pii">2723256</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75. doi:10.1016/j.jalz.2012.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.007</ArticleId><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, et al. . Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58(3):397-405. doi:10.1001/archneur.58.3.397</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.58.3.397</ArticleId><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, et al. . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYP.0000000000000066</ArticleId><ArticleId IdType="pubmed">29133354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, H&#xe4;nninen T, et al. . Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56(12):1683-1689. doi:10.1212/WNL.56.12.1683</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.12.1683</ArticleId><ArticleId IdType="pubmed">11425934</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487-499. doi:10.1016/S1474-4422(05)70141-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70141-1</ArticleId><ArticleId IdType="pubmed">16033691</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204. doi:10.1212/01.wnl.0000271090.28148.24</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000271090.28148.24</ArticleId><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Schnaider-Beeri M, Schmeidler J, et al. . Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol. 2008;65(9):1211-1217. doi:10.1001/archneur.65.9.1211</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.9.1211</ArticleId><ArticleId IdType="pmc">PMC3071251</ArticleId><ArticleId IdType="pubmed">18779425</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C; Medical Research Council Cognitive Function and Ageing Study . Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302-2309. doi:10.1056/NEJMoa0806142</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0806142</ArticleId><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouch L, Cestac P, Hanon O, et al. . Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29(2):113-130. doi:10.1007/s40263-015-0230-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-015-0230-6</ArticleId><ArticleId IdType="pubmed">25700645</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Torres RV, Davey A. Clinical trials of blood pressure lowering and antihypertensive medication: is cognitive measurement state-of-the-art? Am J Hypertens. 2018;31(6):631-642. doi:10.1093/ajh/hpy033</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpy033</ArticleId><ArticleId IdType="pmc">PMC5946865</ArticleId><ArticleId IdType="pubmed">29481592</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson SE, Read S, Berg S, Johansson B, Melander A, Lindblad U. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res. 2007;19(1):41-47. doi:10.1007/BF03325209</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03325209</ArticleId><ArticleId IdType="pubmed">17332720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossello E, Pieraccioli M, Nesti N, et al. . Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med. 2015;175(4):578-585. doi:10.1001/jamainternmed.2014.8164</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2014.8164</ArticleId><ArticleId IdType="pubmed">25730775</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JT Jr, Williamson JD, Whelton PK, et al. ; SPRINT Research Group . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1511939</ArticleId><ArticleId IdType="pmc">PMC4689591</ArticleId><ArticleId IdType="pubmed">26551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Supiano MA, Applegate WB, et al. ; SPRINT Research Group . Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged &#x2265;75 years: a randomized clinical trial. JAMA. 2016;315(24):2673-2682. doi:10.1001/jama.2016.7050</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.7050</ArticleId><ArticleId IdType="pmc">PMC4988796</ArticleId><ArticleId IdType="pubmed">27195814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosius WT, Sink KM, Foy CG, et al. ; SPRINT Study Research Group . The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532-546. doi:10.1177/1740774514537404</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774514537404</ArticleId><ArticleId IdType="pmc">PMC4156910</ArticleId><ArticleId IdType="pubmed">24902920</ArticleId></ArticleIdList></Reference><Reference><Citation>Chobanian AV, Bakris GL, Black HR, et al. ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee . The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572. doi:10.1001/jama.289.19.2560</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.19.2560</ArticleId><ArticleId IdType="pubmed">12748199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? a meta-analysis. Lancet. 2005;366(9496):1545-1553. doi:10.1016/S0140-6736(05)67573-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)67573-3</ArticleId><ArticleId IdType="pubmed">16257341</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al. . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale. 4th ed San Antonio, TX: Pearson; 2008.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale. 4th ed San Antonio, TX: Pearson; 2009.</Citation></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37(3):323-329. doi:10.1093/geronj/37.3.323</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/37.3.323</ArticleId><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaussoin SA, Espeland MA, Absher J, Howard BV, Jones BM, Rapp SR. Ascertaining dementia-related outcomes for deceased or proxy-dependent participants: an overview of the Women&#x2019;s Health Initiative Memory Study supplemental case ascertainment protocol. Int J Geriatr Psychiatry. 2012;27(2):205-214. doi:10.1002/gps.2714</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2714</ArticleId><ArticleId IdType="pmc">PMC4381429</ArticleId><ArticleId IdType="pubmed">21416508</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh K, Breitner JCS, Magruder-Habib K. Detection of dementia in the elderly using telephone screening of cognitive status. Neuropsychiatry Neuropsychol Behav Neurol. 1993;6:103-110.</Citation></Reference><Reference><Citation>Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ. A validation study of the Dementia Questionnaire. Arch Neurol. 1994;51(9):901-906. doi:10.1001/archneur.1994.00540210073015</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1994.00540210073015</ArticleId><ArticleId IdType="pubmed">8080390</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlowitz DR, Foy CG, Kazis LE, et al. ; SPRINT Research Group . Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J Med. 2017;377(8):733-744. doi:10.1056/NEJMoa1611179</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1611179</ArticleId><ArticleId IdType="pmc">PMC5706112</ArticleId><ArticleId IdType="pubmed">28834483</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Evans GW, Shorr RI, et al. . Syncope, hypotension, and falls in the treatment of hypertension: results from the randomized clinical Systolic Blood Pressure Intervention Trial. J Am Geriatr Soc. 2018;66(4):679-686. doi:10.1111/jgs.15236</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15236</ArticleId><ArticleId IdType="pmc">PMC8045467</ArticleId><ArticleId IdType="pubmed">29601076</ArticleId></ArticleIdList></Reference><Reference><Citation>Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526. doi:10.1093/biomet/81.3.515</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/81.3.515</ArticleId></ArticleIdList></Reference><Reference><Citation>Delord M, Genin E. Multiple imputation for competing risks regression with interval-censored data. J Stat Comput Simul. 2016;86(11):2217-2228. doi:10.1080/00949655.2015.1106543</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00949655.2015.1106543</ArticleId></ArticleIdList></Reference><Reference><Citation>Staessen JA, Fagard R, Thijs L, et al. ; Systolic Hypertension in Europe Trial Investigators . Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350(9080):757-764. doi:10.1016/S0140-6736(97)05381-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(97)05381-6</ArticleId><ArticleId IdType="pubmed">9297994</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group . The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157-2172. doi:10.1097/01.hjh.0000194120.42722.ac</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.hjh.0000194120.42722.ac</ArticleId><ArticleId IdType="pubmed">16269957</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckett NS, Peters R, Fletcher AE, et al. ; HYVET Study Group . Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898. doi:10.1056/NEJMoa0801369</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0801369</ArticleId><ArticleId IdType="pubmed">18378519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogihara T, Saruta T, Rakugi H, et al. ; Valsartan in Elderly Isolated Systolic Hypertension Study Group . Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56(2):196-202. doi:10.1161/HYPERTENSIONAHA.109.146035</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.146035</ArticleId><ArticleId IdType="pubmed">20530299</ArticleId></ArticleIdList></Reference><Reference><Citation>Saper CB. How low can you go? Ann Neurol. 2015;78(5):665-666. doi:10.1002/ana.24530</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24530</ArticleId><ArticleId IdType="pubmed">26395548</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Lopez O, Armstrong MJ, et al. . Mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126-135. doi:10.1212/WNL.0000000000004826</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004826</ArticleId><ArticleId IdType="pmc">PMC5772157</ArticleId><ArticleId IdType="pubmed">29282327</ArticleId></ArticleIdList></Reference><Reference><Citation>Forette F, Seux M-L, Staessen JA, et al. ; Systolic Hypertension in Europe Investigators . The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046-2052. doi:10.1001/archinte.162.18.2046</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.162.18.2046</ArticleId><ArticleId IdType="pubmed">12374512</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Beckett N, Forette F, et al. ; HYVET Investigators . Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-689. doi:10.1016/S1474-4422(08)70143-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70143-1</ArticleId><ArticleId IdType="pubmed">18614402</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Launer LJ, Bryan RN, et al. ; Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators . Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174(3):324-333. doi:10.1001/jamainternmed.2013.13656</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.13656</ArticleId><ArticleId IdType="pmc">PMC4423790</ArticleId><ArticleId IdType="pubmed">24493100</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>